


**CUMULATIVE
SUPPLEMENT 12
DECEMBER 2017**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

37th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2017

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

37th EDITION

**Cumulative Supplement 12
December 2017**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	vii
1.5 Availability of the Edition	viii
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend	x
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

37th EDITION

**CUMULATIVE SUPPLEMENT 12
December 2017**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 37th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
JAI PHARMA LTD (JAI PHARMA LTD)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
TG UNITED LABS LLC (TG UNITED LABS)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following

explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-

counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a

particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2016</u>	<u>MAR 2017</u>	<u>JUN 2017</u>	<u>SEP 2017</u>	<u>DEC 2017</u>
DRUG PRODUCTS	18130	18391	18711	19012	19294
LISTED SINGLE	2646	2688	2708	2721	2758
SOURCE	(14.6%)	(14.6%)	(14.5%)	(14.3%)	(14.3%)
MULTISOURCE	15484	15703	16003	16291	16536
	(85.4%)	(85.4%)	(85.5%)	(85.7%)	(85.7%)
THERAPEUTICALLY	15335	15581	15882	16180	16431
EQUIVALENT	(84.7%)	(84.7%)	(84.9%)	(85.1%)	(85.2%)
NOT THERAPEUTICALLY	129	122	121	111	105
EQUIVALENT	(0.7%)	(0.7%)	(0.6%)	(0.6%)	(0.5%)
EXCEPTIONS ¹	73	73	73	73	73
	(0.4%)	(0.4%)	(0.4%)	(0.4%)	(0.4%)
NEW MOLECULAR	7	14	17	14	25
ENTITIES APPROVED					
NUMBER OF	1051	1053	1050	1054	1075
APPLICANTS					

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code

for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

****Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE

TABLET; ORAL						
ABACAVIR SULFATE						
AB	CIPLA LTD	EQ 300MG BASE	A078119	001	Nov 21, 2017	Nov NEWA

ABACAVIR SULFATE; LAMIVUDINE

TABLET; ORAL						
ABACAVIR SULFATE AND LAMIVUDINE						
AB	AUROBINDO PHARMA LTD	EQ 600MG BASE; 300MG	A206151	001	Mar 28, 2017	Mar NEWA
AB	CIPLA LTD	EQ 600MG BASE; 300MG	A091144	001	Mar 28, 2017	Mar NEWA
AB	LUPIN LTD	EQ 600MG BASE; 300MG	A204990	001	Mar 28, 2017	Mar NEWA

ABALOPARATIDE

SOLUTION; SUBCUTANEOUS						
TYMLOS						
+	RADIUS HEALTH INC	3.12MG/1.56ML (2MG/ML)	N208743	001	Apr 28, 2017	Apr NEWA

ABEMACICLIB

TABLET; ORAL						
VERZENIO						
+	ELI LILLY AND CO	50MG	N208716	001	Sep 28, 2017	Sep NEWA
+		100MG	N208716	002	Sep 28, 2017	Sep NEWA
+		150MG	N208716	003	Sep 28, 2017	Sep NEWA
+		200MG	N208716	004	Sep 28, 2017	Sep NEWA

ABIRATERONE ACETATE

TABLET; ORAL						
ZYTIGA						
+	JANSSEN BIOTECH	500MG	N202379	002	Apr 14, 2017	May NEWA

ACALABRUTINIB

CAPSULE; ORAL						
CALQUENCE						
+	ACERTA PHARMA BV	100MG	N210259	001	Oct 31, 2017	Oct NEWA
+	ASTRAZENECA	100MG	N210259	001	Oct 31, 2017	Nov CAHN

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL						
ACAMPROSATE CALCIUM						
AB	ZYDUS PHARMS USA INC	333MG	A205995	001	May 26, 2017	May NEWA

ACETAMINOPHEN

SOLUTION; IV (INFUSION)						
ACETAMINOPHEN						
AP	CUSTOPHARM INC	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	Jan CAHN

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL						
BUTALBITAL AND ACETAMINOPHEN						
>A>	MIKART INC	300MG; 50MG	A207313	001	Dec 27, 2017	Dec NEWA
TABLET; ORAL						
BUTALBITAL AND ACETAMINOPHEN						
AA	TEDOR PHARMA INC	300MG; 50MG	A207635	001	Jun 05, 2017	May NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL						
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE						
>D>	AB	!	NEXGEN PHARMA	300MG; 50MG; 40MG	A040885	001 Nov 16, 2009 Dec CTEC
>A>	AA	!		300MG; 50MG; 40MG	A040885	001 Nov 16, 2009 Dec CTEC
	AB		TEDOR PHARMA INC	300MG; 50MG; 40MG	A206615	001 Aug 04, 2017 Jul NEWA
TABLET; ORAL						
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE						
	AA		ACTAVIS LABS UT INC	325MG; 50MG; 40MG	A088616	001 Nov 09, 1984 Apr CTNA
>D>	AA		MALLINCKRODT INC	325MG; 50MG; 40MG	A087804	001 Jan 24, 1985 Dec CAHN
	AA			325MG; 50MG; 40MG	A087804	001 Jan 24, 1985 Mar CAHN
		@	NOVAST LABS LTD	325MG; 50MG; 40MG	A040864	001 Dec 01, 2008 Sep CAHN
>A>	AA		SPECGX LLC	325MG; 50MG; 40MG	A087804	001 Jan 24, 1985 Dec CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

@ HIKMA INTL PHARMS 325MG;50MG;40MG;30MG

A075618 001 Mar 23, 2001 Nov DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ ALLIED PHARMA INC 120MG/5ML;12MG/5ML

A086366 001

Jul CAHN

>D> AA WOCKHARDT 120MG/5ML;12MG/5ML

A087006 001

Dec CAHN

>A> AA WOCKHARDT BIO AG 120MG/5ML;12MG/5ML

A087006 001

Dec CAHN

SUSPENSION;ORAL

CAPITAL AND CODEINE

@ VALEANT PHARMS LLC 120MG/5ML;12MG/5ML

A086024 001

Aug DISC

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ ANDA REPOSITORY 300MG;15MG

A089673 002 Feb 10, 1988

Nov CMS1

@ 300MG;30MG

A089673 003 Feb 10, 1988

Nov CMS1

@ 300MG;60MG

A089673 001 Feb 10, 1988

Sep CAHN

>D> AA ! MALLINCKRODT INC 300MG;15MG

A040419 001 May 31, 2001

Dec CAHN

>D> AA 300MG;30MG

A040419 002 May 31, 2001

Dec CAHN

>D> AA 300MG;60MG

A040419 003 May 31, 2001

Dec CAHN

>A> AA ! SPECGX LLC 300MG;15MG

A040419 001 May 31, 2001

Dec CAHN

>A> AA 300MG;30MG

A040419 002 May 31, 2001

Dec CAHN

>A> AA 300MG;60MG

A040419 003 May 31, 2001

Dec CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

ZYFREL

@ CYPRESS PHARM INC 325MG/15ML;7.5MG/15ML

A090468 001 Apr 14, 2016 Nov DISC

TABLET;ORAL

ANEXSIA 5/325

>D> AA MALLINCKRODT 325MG;5MG

A040409 001 Oct 20, 2000

Dec CAHN

>A> AA SPECGX LLC 325MG;5MG

A040409 001 Oct 20, 2000

Dec CAHN

ANEXSIA 7.5/325

>D> AA MALLINCKRODT 325MG;7.5MG

A040405 001 Sep 08, 2000

Dec CAHN

>A> AA SPECGX LLC 325MG;7.5MG

A040405 001 Sep 08, 2000

Dec CAHN

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA ABHAI LLC 300MG;5MG

A209036 001 Jun 21, 2017

Jun NEWA

AA 300MG;7.5MG

A209036 002 Jun 21, 2017

Jun NEWA

AA 300MG;10MG

A209036 003 Jun 21, 2017

Jun NEWA

AA 325MG;5MG

A209037 001 Jun 21, 2017

Jun NEWA

AA 325MG;7.5MG

A209037 002 Jun 21, 2017

Jun NEWA

AA 325MG;10MG

A209037 003 Jun 21, 2017

Jun NEWA

AA AMNEAL PHARMS NY 300MG;5MG

A206869 001 Jun 23, 2017

Jun NEWA

AA LANNETT HOLDINGS INC 300MG;5MG

A207171 001 Jun 20, 2017

Jun NEWA

AA 300MG;7.5MG

A207171 002 Jun 20, 2017

Jun NEWA

AA 300MG;10MG

A207171 003 Jun 20, 2017

Jun NEWA

AA 325MG;5MG

A207172 001 Jun 22, 2017

Jun NEWA

AA 325MG;7.5MG

A207172 002 Jun 22, 2017

Jun NEWA

AA 325MG;10MG

A207172 003 Jun 22, 2017

Jun NEWA

>D> AA MALLINCKRODT 325MG;10MG

A040400 001 Jul 26, 2000

Dec CAHN

>D> AA MALLINCKRODT INC 300MG;5MG

A206718 001 Mar 31, 2017

Dec CAHN

AA 300MG;5MG

A206718 001 Mar 31, 2017

Mar NEWA

>D> AA 300MG;7.5MG

A206718 002 Mar 31, 2017

Dec CAHN

AA 300MG;10MG

A206718 002 Mar 31, 2017

Mar NEWA

>D> AA 300MG;10MG

A206718 003 Mar 31, 2017

Dec CAHN

AA 300MG;10MG

A206718 003 Mar 31, 2017

Mar NEWA

AA ! MIKART 300MG;7.5MG

A040658 002 Mar 24, 2006

May CHRS

AA 300MG;7.5MG

A040658 002 Mar 24, 2006

Apr CMS1

AA ! 300MG;10MG

A040658 003 Jun 23, 2004

May CHRS

AA 300MG;10MG

A040658 003 Jun 23, 2004

Apr CMS1

>A> AA SPECGX LLC 300MG;5MG

A206718 001 Mar 31, 2017

Dec CAHN

>A> AA 300MG;7.5MG

A206718 002 Mar 31, 2017

Dec CAHN

>A> AA 300MG;10MG

A206718 003 Mar 31, 2017

Dec CAHN

>A> AA 325MG;10MG

A040400 001 Jul 26, 2000

Dec CAHN

AA UPSHER-SMITH LABS 325MG;5MG

A206484 001 Mar 24, 2017

Jun CAHN

AA 325MG;5MG

A206484 001 Mar 24, 2017

Mar NEWA

AA 325MG;7.5MG

A206484 002 Mar 24, 2017

Jun CAHN

AA 325MG;7.5MG

A206484 002 Mar 24, 2017

Mar NEWA

AA 325MG;10MG

A206484 003 Mar 24, 2017

Jun CAHN

AA 325MG;10MG

A206484 003 Mar 24, 2017

Mar NEWA

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	WES PHARMA INC	325MG;5MG	A210211	001	Oct 30, 2017	Oct NEWA
AA		325MG;7.5MG	A210211	002	Oct 30, 2017	Oct NEWA
AA		325MG;10MG	A210211	003	Oct 30, 2017	Oct NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

>D> AA	! MALLINCKRODT INC	325MG/5ML;5MG/5ML	A 040680	001	Sep 29, 2006	Dec CAHN
>A> AA	! SPECGX LLC	325MG/5ML;5MG/5ML	A 040680	001	Sep 29, 2006	Dec CAHN

TABLET;ORAL

OXYCET

>D> AA	MALLINCKRODT	325MG;5MG	A 087463	001	Dec 07, 1983	Dec CAHN
>A> AA	SPECGX LLC	325MG;5MG	A 087463	001	Dec 07, 1983	Dec CAHN

OXYCODONE AND ACETAMINOPHEN

AA	AMNEAL PHARMS	325MG;5MG	A 040777	001	Nov 27, 2007	May CAHN
AA	ASCENT PHARMS INC	325MG;2.5MG	A207419	001	Mar 22, 2017	Mar NEWA
AA		325MG;5MG	A207419	002	Mar 22, 2017	Mar NEWA
AA		325MG;7.5MG	A207419	003	Mar 22, 2017	Mar NEWA
AA		325MG;10MG	A207419	004	Mar 22, 2017	Mar NEWA
AA	CHEMO RESEARCH SL	325MG;5MG	A207574	001	Dec 13, 2016	Nov CAHN
AA	LANNETT HOLDINGS INC	325MG;5MG	A207333	001	Sep 25, 2017	Sep NEWA
AA		325MG;10MG	A207333	002	Sep 25, 2017	Sep NEWA
>D> AA	MALLINCKRODT	325MG;7.5MG	A 040545	001	Jun 30, 2004	Dec CAHN
>D> AA		325MG;10MG	A 040545	002	Jun 30, 2004	Dec CAHN
>A> AA	NESHER PHARMS	325MG;2.5MG	A210079	001	Dec 28, 2017	Dec NEWA
>A> AA		325MG;5MG	A210079	002	Dec 28, 2017	Dec NEWA
>A> AA		325MG;7.5MG	A210079	003	Dec 28, 2017	Dec NEWA
>A> AA		325MG;10MG	A210079	004	Dec 28, 2017	Dec NEWA
AA	NOVEL LABS INC	325MG;2.5MG	A204407	001	Feb 24, 2017	Feb NEWA
AA		325MG;5MG	A204407	002	Feb 24, 2017	Feb NEWA
AA		325MG;7.5MG	A204407	003	Feb 24, 2017	Feb NEWA
AA		325MG;10MG	A204407	004	Feb 24, 2017	Feb NEWA
>A> AA	SPECGX LLC	325MG;7.5MG	A 040545	001	Jun 30, 2004	Dec CAHN
>A> AA		325MG;10MG	A 040545	002	Jun 30, 2004	Dec CAHN

PERCOCET

AA	! VINTAGE PHARMS LLC	325MG;7.5MG	A 040330	003	Nov 23, 2001	Jan CMS1
AA	!	325MG;10MG	A 040330	004	Nov 23, 2001	Jan CMS1

TABLET, EXTENDED RELEASE;ORAL

XARTEMIS XR

+ @	MALLINCKRODT INC	325MG;7.5MG	N204031	001	Mar 11, 2014	Aug DISC
-----	------------------	-------------	---------	-----	--------------	----------

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	ALKEM LABS LTD	325MG;37.5MG	A202076	001	Mar 30, 2012	Nov CAHN
AB	APOGEE PHARMA	325MG;37.5MG	A202076	001	Mar 30, 2012	Sep CAHN
AB	AUROBINDO PHARMA LTD	325MG;37.5MG	A207152	001	Mar 22, 2017	Mar NEWA
@	CSPC OUYI PHARM CO	325MG;37.5MG	A076914	001	Jul 26, 2006	Oct CAHN
AB	MACLEODS PHARMS LTD	325MG;37.5MG	A206885	001	May 02, 2017	Apr NEWA

ACETAZOLAMIDE

TABLET;ORAL

ACETAZOLAMIDE

AB	STRIDES PHARMA	125MG	A209734	001	Nov 20, 2017	Nov NEWA
AB		250MG	A209734	002	Nov 20, 2017	Nov NEWA
AB	SUN PHARM INDUSTRIES	125MG	A089753	002	Jun 22, 1988	Jul CMS1

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

AP	PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A205358	001	Jun 20, 2017	Jun NEWA
----	----------------------	--------------------	---------	-----	--------------	----------

ACETIC ACID, GLACIAL

SOLUTION;IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT	ICU MEDICAL INC	250MG/100ML	N017656	001		Feb CAHN
----	-----------------	-------------	---------	-----	--	----------

SOLUTION/DROPS;OTIC

ACETIC ACID

>D> AT	! WOCHARDT	2%	A 040166	001	Jul 26, 1996	Dec CAHN
>A> AT	! WOCHARDT BIO AG	2%	A 040166	001	Jul 26, 1996	Dec CAHN

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS;OTIC

ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE

@ BAUSCH AND LOMB 2%;0.79%

A040063 001 Feb 25, 1994 Oct DISC

ACETOHEXAMIDE

TABLET;ORAL

ACETOHEXAMIDE

@ WATSON LABS TEVA 250MG

A071893 001 Nov 25, 1987 May CAHN

@ 500MG

A071894 001 Nov 25, 1987 May CAHN

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

AP SAGENT PHARMS 6GM/30ML (200MG/ML)

A091684 001 Oct 31, 2017 Oct NEWA

ACITRETIN

CAPSULE;ORAL

ACITRETIN

@ MYLAN PHARMS INC 17.5MG

A203707 001 Sep 10, 2015 Oct DISC

@ 22.5MG

A203707 002 Sep 10, 2015 Oct DISC

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL

SEMPREX-D

+! AUXILIUM PHARMS LLC 8MG;60MG

N019806 001 Mar 25, 1994 May CAHN

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

AB ! APOTEX INC 200MG

A075677 001 Sep 28, 2005 Oct CHRS

AB BOSCOGEN 200MG

A075090 001 Jan 26, 1999 May CAHN

AB CARLSBAD TECHNOLOGY 200MG

A206261 001 Aug 16, 2017 Aug NEWA

@ CHARTWELL MOLECULES 200MG

A074872 001 Apr 22, 1997 Jan CAHN

@ MYLAN 200MG

A074727 001 Apr 22, 1997 Jun DISC

ZOVIRAX

AB + MYLAN PHARMS INC 200MG

N018828 001 Jan 25, 1985 Oct CHRS

OINTMENT;TOPICAL

ACYCLOVIR

AB G AND W LABS INC 5%

A205591 001 Nov 13, 2017 Oct NEWA

AB GLENMARK PHARMS LTD 5%

A205510 001 Jul 31, 2017 Jul NEWA

AB TOLMAR 5%

A206437 001 Jul 31, 2017 Jul NEWA

SUSPENSION;ORAL

ZOVIRAX

AB +! MYLAN PHARMS INC 200MG/5ML

N019909 001 Dec 22, 1989 Jan CAHN

TABLET;BUCCAL

SITAVIG

+! EPI HLTH 50MG

N203791 001 Apr 12, 2013 Jun CAHN

TABLET;ORAL

ACYCLOVIR

@ CHARTWELL MOLECULES 400MG

A074834 001 Apr 24, 1997 Jan CAHN

@ 800MG

A074834 002 Apr 24, 1997 Jan CAHN

AB HERITAGE PHARMS INC 400MG

A074891 001 Oct 31, 1997 Apr CMFD

AB 800MG

A074891 002 Oct 31, 1997 Apr CMFD

AB MYLAN PHARMS INC 400MG

A075211 001 Sep 28, 1998 Mar CAHN

AB 800MG

A075211 002 Sep 28, 1998 Mar CAHN

ZOVIRAX

AB + MYLAN PHARMS INC 400MG

N020089 001 Apr 30, 1991 Jan CAHN

AB +! 800MG

N020089 002 Apr 30, 1991 Jan CAHN

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR SODIUM

@ ATHENEX INC EQ 500MG BASE/VIAL

A074596 002 Apr 22, 1997 Mar CAHN

@ EQ 1GM BASE/VIAL

A074596 001 Apr 22, 1997 Mar CAHN

>D> AP ! HIKMA PHARMS EQ 1GM BASE/VIAL

A205771 002 Feb 29, 2016 Mar CTEC

>A> AP MYLAN LABS LTD EQ 500MG BASE/VIAL

A203927 001 Mar 29, 2017 Dec DISC

>A> @ EQ 500MG BASE/VIAL

A203927 001 Mar 29, 2017 Dec DISC

AP EQ 500MG BASE/VIAL

A203927 001 Mar 29, 2017 Mar NEWA

>D> AP EQ 1GM BASE/VIAL

A203927 002 Mar 29, 2017 Dec DISC

>A> @ EQ 1GM BASE/VIAL

A203927 002 Mar 29, 2017 Dec DISC

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

AP		EQ 1GM BASE/VIAL	A203927	002	Mar 29, 2017	Mar	NEWA
AP	ZYDUS PHARMS USA INC	EQ 500MG BASE/VIAL	A206606	001	Jun 13, 2017	May	NEWA
AP		EQ 1GM BASE/VIAL	A206606	002	Jun 13, 2017	May	NEWA

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

AP	WEST-WARD PHARMS INT	3MG/ML	A076404	001	Jun 16, 2004	Jan	CAHN
AP		3MG/ML	A076500	001	Jun 16, 2004	Jan	CAHN
	@	3MG/ML	A076501	001	Jun 16, 2004	Jan	CAHN

SOLUTION; IV (INFUSION)

ADENOSINE

AP	AUROBINDO PHARMA LTD	60MG/20ML (3MG/ML)	A205331	001	Nov 02, 2017	Oct	NEWA
AP		90MG/30ML (3MG/ML)	A205331	002	Nov 02, 2017	Oct	NEWA
AP	FRESENIUS KABI USA	60MG/20ML (3MG/ML)	A077897	001	Nov 27, 2017	Nov	NEWA
AP		90MG/30ML (3MG/ML)	A077897	002	Nov 27, 2017	Nov	NEWA

ALBENDAZOLE

TABLET; ORAL

ALBENZA

+	IMPAX LABS INC	200MG	N020666	001	Jun 11, 1996	Jun	CAHN
---	----------------	-------	---------	-----	--------------	-----	------

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

PROVENTIL-HFA

BX	+	3M DRUG DELIVERY	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996	May	CAHN
----	---	------------------	--------------------	---------	-----	--------------	-----	------

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN	AUROBINDO PHARMA LTD	EQ 0.083% BASE	A206224	001	Oct 17, 2017	Oct	NEWA
AN	SUN PHARMA GLOBAL	EQ 0.083% BASE	A207857	001	Jul 21, 2017	Jul	NEWA

TABLET; ORAL

ALBUTEROL SULFATE

>A>	@	FOSUN PHARMA	EQ 2MG BASE	A072151	001	Dec 05, 1989	Dec	CAHN
>A>	@		EQ 4MG BASE	A072152	001	Dec 05, 1989	Dec	CAHN
>D>	@	SANDOZ	EQ 2MG BASE	A072151	001	Dec 05, 1989	Dec	CAHN
>D>	@		EQ 4MG BASE	A072152	001	Dec 05, 1989	Dec	CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AN	SUN PHARMA GLOBAL	EQ 0.083% BASE; 0.017%	A207875	001	Aug 07, 2017	Nov	CMS1
AN		EQ 0.083% BASE; 0.17%	A207875	001	Aug 07, 2017	Jul	NEWA
AN	WATSON LABS TEVA	EQ 0.083% BASE; 0.017%	A077063	001	Dec 31, 2007	Feb	CAHN

ALENDRONATE SODIUM

SOLUTION; ORAL

FOSAMAX

+	@	MERCK	EQ 70MG BASE/75ML	N021575	001	Sep 17, 2003	Sep	CRLD
---	---	-------	-------------------	---------	-----	--------------	-----	------

TABLET; ORAL

ALENDRONATE SODIUM

@ UPSHER-SMITH LABS

EQ 5MG BASE

A075871 001 Apr 22, 2009 Jun CAHN

@ EQ 10MG BASE

A075871 002 Apr 22, 2009 Jun CAHN

@ EQ 35MG BASE

A075871 004 Apr 22, 2009 Jun CAHN

@ EQ 40MG BASE

A075871 003 Apr 22, 2009 Jun CAHN

@ EQ 70MG BASE

A075871 005 Apr 22, 2009 Jun CAHN

ALISKIREN HEMIFUMARATE

CAPSULE, PELLET; ORAL

TEKTURNA

+	NODEN PHARMA	EQ 37.5MG BASE	N210709	001	Nov 14, 2017	Nov	NEWA
---	--------------	----------------	---------	-----	--------------	-----	------

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB	SUN PHARM INDUSTRIES	100MG	A071450	002	Jan 09, 1987	Nov	CMS1
AB	ZYDUS PHARMS USA INC	100MG	A210117	001	Oct 12, 2017	Oct	NEWA
AB		300MG	A210117	002	Oct 12, 2017	Oct	NEWA

ZYLOPRIM

AB	+	CASPER PHARMA LLC	100MG	N016084	001		Jul	CAHN
AB	+		300MG	N016084	002		Jul	CAHN

ALLOPURINOL; LESINURAD

TABLET; ORAL

DUZALLO

+	ARDEA BIOSCIENCES	200MG; 200MG	N209203	001	Aug 18, 2017	Aug NEWA
+	!	300MG; 200MG	N209203	002	Aug 18, 2017	Aug NEWA
+	IRONWOOD PHARMS INC	200MG; 200MG	N209203	001	Aug 18, 2017	Sep CAHN
+	!	300MG; 200MG	N209203	002	Aug 18, 2017	Sep CAHN

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

AB	AMNEAL PHARMS	EQ 0.5MG BASE	A206647	001	Dec 22, 2016	May CAHN
AB		EQ 1MG BASE	A206647	002	Dec 22, 2016	May CAHN

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

+	SANDOZ INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N021163	001	May 18, 2000	May CAHN
---	------------	---	---------	-----	--------------	----------

INJECTABLE; IV (INFUSION)

INFUVITE ADULT

+	SANDOZ INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML	N021559	001	Jun 16, 2003	May CAHN
---	------------	--	---------	-----	--------------	----------

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB	ACTAVIS ELIZABETH	0.25MG	A074342	001	Oct 31, 1993	Apr CAHN
AB		0.5MG	A074342	002	Oct 31, 1993	Apr CAHN
AB		1MG	A074342	003	Oct 31, 1993	Apr CAHN
AB		2MG	A074342	004	Oct 31, 1993	Apr CAHN
	@ MYLAN PHARMS INC	0.25MG	A074046	001	Oct 19, 1993	Nov DISC
	@	0.5MG	A074046	002	Oct 19, 1993	Nov DISC
	@	1MG	A074046	003	Oct 19, 1993	Nov DISC
	@	2MG	A074046	004	May 07, 1997	Nov DISC

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB	AUROBINDO PHARMA LTD	0.5MG	A090871	001	Jun 07, 2011	Jan CAHN
AB		1MG	A090871	002	Jun 07, 2011	Jan CAHN
AB		2MG	A090871	003	Jun 07, 2011	Jan CAHN
AB		3MG	A090871	004	Jun 07, 2011	Jan CAHN
	@ MYLAN	0.5MG	A077391	002	Jan 26, 2006	Nov DISC
	@	1MG	A077391	003	Jan 26, 2006	Nov DISC
	@	2MG	A077391	004	Jan 26, 2006	Nov DISC
	@	3MG	A077391	001	Jan 26, 2006	Nov DISC

TABLET, ORALLY DISINTEGRATING; ORAL

ALPRAZOLAM

AB	ACTAVIS ELIZABETH	0.25MG	A078561	001	Mar 16, 2010	Sep CAHN
AB		0.5MG	A078561	002	Mar 16, 2010	Sep CAHN
AB		1MG	A078561	003	Mar 16, 2010	Sep CAHN
AB		2MG	A078561	004	Mar 16, 2010	Sep CAHN

ALPROSTADIL

INJECTABLE; INJECTION

EDEX

	@ AUXILIUM PHARMS LLC	0.005MG/VIAL	N020649	001	Jun 12, 1997	May CAHN
AP	+	0.01MG/VIAL	N020649	002	Jun 12, 1997	May CAHN
	+	0.01MG/VIAL	N020649	005	Jul 30, 1998	May CAHN
AP	+	0.02MG/VIAL	N020649	003	Jun 12, 1997	May CAHN
	+	0.02MG/VIAL	N020649	006	Jul 30, 1998	May CAHN
AP	+	0.04MG/VIAL	N020649	004	Jun 12, 1997	May CAHN
	+	0.04MG/VIAL	N020649	007	Jul 30, 1998	May CAHN

SUPPOSITORY; URETHRAL

MUSE

+	MYLAN SPECIALITY LP	0.125MG	N020700	001	Nov 19, 1996	Mar CAHN
+		0.25MG	N020700	002	Nov 19, 1996	Mar CAHN

SUPPOSITORY; URETHRAL
MUSE

+	!	0.5MG	N020700	003	Nov 19, 1996	Mar	CAHN
+	!	1MG	N020700	004	Nov 19, 1996	Mar	CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	100MG	A208966	001	Jun 21, 2017	Jun	NEWA
AB		HERITAGE PHARMA	100MG	A209171	001	Jun 12, 2017	May	NEWA
AB		LANNETT HOLDINGS INC	100MG	A209221	001	Jun 15, 2017	May	NEWA
AB		STRIDES PHARMA	100MG	A209047	001	Jun 07, 2017	May	NEWA
AB		USL PHARMA	100MG	A070589	001	Aug 05, 1986	Jun	CAHN

CAPSULE, EXTENDED RELEASE; ORAL

GOCOVRI

+		ADAMAS PHARMA	EQ 68.5MG BASE	N208944	001	Aug 24, 2017	Aug	NEWA
+	!		EQ 137MG BASE	N208944	002	Aug 24, 2017	Aug	NEWA

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

AA	!	CMP PHARMA INC	50MG/5ML	A075819	001	Sep 11, 2002	Apr	CAHN
AA	!	PHARM ASSOC	50MG/5ML	A074509	001	Jul 17, 1995	May	CAHN
>D> AA	!	WOCKHARDT	50MG/5ML	A075060	001	Dec 24, 1998	Dec	CAHN
>A> AA	!	WOCKHARDT BIO AG	50MG/5ML	A075060	001	Dec 24, 1998	Dec	CAHN

SYMMETREL

+	@	ENDO PHARMS	50MG/5ML	N016023	002		Jan	CRLD
---	---	-------------	----------	---------	-----	--	-----	------

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

AB		NEWGEN PHARMS LLC	100MG	A207571	001	Jan 31, 2017	Jan	NEWA
AB		STRIDES PHARMA	100MG	A209035	001	Jun 09, 2017	May	NEWA
AB	!	USL PHARMA	100MG	A076186	001	Dec 16, 2002	Jun	CAHN

AMCINONIDE

CREAM; TOPICAL

CYCLOCORT

+	@	ASTELLAS	0.025%	N018116	001		Jun	CRLD
+	@		0.1%	N018116	002		Jun	CRLD

LOTION; TOPICAL

CYCLOCORT

+	@	ASTELLAS	0.1%	N019729	001	Jun 13, 1988	Jun	CRLD
---	---	----------	------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

CYCLOCORT

+	@	ASTELLAS	0.1%	N018498	001		Jun	CRLD
---	---	----------	------	---------	-----	--	-----	------

AMIFOSTINE

INJECTABLE; INJECTION

AMIFOSTINE

AP		MYLAN LABS LTD	500MG/VIAL	A204363	001	Jul 17, 2017	Jul	NEWA
AP		SUN PHARMA GLOBAL	500MG/VIAL	A077126	001	Mar 14, 2008	Apr	CAHN

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

AB		WINDLAS HLTHCARE	5MG	A204180	001	Aug 07, 2015	Jul	CAHN
----	--	------------------	-----	---------	-----	--------------	-----	------

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>A>	@	FOSUN PHARMA	EQ 5MG ANHYDROUS; 50MG	A073357	001	Nov 27, 1991	Dec	CAHN
>D>	@	SANDOZ	EQ 5MG ANHYDROUS; 50MG	A073357	001	Nov 27, 1991	Dec	CAHN

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN 10%

		ICU MEDICAL INC	10% (10GM/100ML)	N017673	003		Feb	CAHN
--	--	-----------------	------------------	---------	-----	--	-----	------

AMINOSYN 10% (PH6)

		ICU MEDICAL INC	10% (10GM/100ML)	N017673	008	Nov 18, 1985	Feb	CAHN
--	--	-----------------	------------------	---------	-----	--------------	-----	------

AMINOSYN 3.5%

		ICU MEDICAL INC	3.5% (3.5GM/100ML)	N017789	004		Feb	CAHN
--	--	-----------------	--------------------	---------	-----	--	-----	------

AMINOSYN 5%

		ICU MEDICAL INC	5% (5GM/100ML)	N017673	001		Feb	CAHN
--	--	-----------------	----------------	---------	-----	--	-----	------

INJECTABLE; INJECTION

AMINOSYN 7%

ICU MEDICAL INC	7% (7GM/100ML)	N017673	002		Feb CAHN
-----------------	----------------	---------	-----	--	----------

AMINOSYN 7% (PH6)

ICU MEDICAL INC	7% (7GM/100ML)	N017673	006	Nov 18, 1985	Feb CAHN
-----------------	----------------	---------	-----	--------------	----------

AMINOSYN 8.5%

ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673	004		Feb CAHN
-----------------	--------------------	---------	-----	--	----------

AMINOSYN 8.5% (PH6)

ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673	007	Nov 18, 1985	Feb CAHN
-----------------	--------------------	---------	-----	--------------	----------

AMINOSYN II 10%

ICU MEDICAL INC	10% (10GM/100ML)	N019438	005	Apr 03, 1986	Feb CAHN
-----------------	------------------	---------	-----	--------------	----------

AMINOSYN II 10% IN PLASTIC CONTAINER

ICU MEDICAL INC	10% (10GM/100ML)	N020015	001	Dec 19, 1991	Feb CAHN
-----------------	------------------	---------	-----	--------------	----------

AMINOSYN II 15% IN PLASTIC CONTAINER

ICU MEDICAL INC	15% (15GM/100ML)	N020041	001	Dec 19, 1991	Feb CAHN
-----------------	------------------	---------	-----	--------------	----------

AMINOSYN II 3.5%

@ ICU MEDICAL INC	3.5% (3.5GM/100ML)	N019438	001	Apr 03, 1986	Feb CAHN
-------------------	--------------------	---------	-----	--------------	----------

AMINOSYN II 5%

@ ICU MEDICAL INC	5% (5GM/100ML)	N019438	002	Apr 03, 1986	Feb CAHN
-------------------	----------------	---------	-----	--------------	----------

AMINOSYN II 7%

ICU MEDICAL INC	7% (7GM/100ML)	N019438	003	Apr 03, 1986	Feb CAHN
-----------------	----------------	---------	-----	--------------	----------

AMINOSYN II 8.5%

ICU MEDICAL INC	8.5% (8.5GM/100ML)	N019438	004	Apr 03, 1986	Feb CAHN
-----------------	--------------------	---------	-----	--------------	----------

AMINOSYN-HBC 7%

ICU MEDICAL INC	7% (7GM/100ML)	N019374	001	Jul 12, 1985	Feb CAHN
-----------------	----------------	---------	-----	--------------	----------

AMINOSYN-HF 8%

ICU MEDICAL INC	8% (8GM/100ML)	A020345	001	Apr 04, 1996	Jun CAHN
-----------------	----------------	---------	-----	--------------	----------

AMINOSYN-PF 10%

ICU MEDICAL INC	10% (10GM/100ML)	N019492	002	Oct 17, 1986	Feb CAHN
-----------------	------------------	---------	-----	--------------	----------

AMINOSYN-PF 7%

ICU MEDICAL INC	7% (7GM/100ML)	N019398	001	Sep 06, 1985	Feb CAHN
-----------------	----------------	---------	-----	--------------	----------

AMINOSYN-RF 5.2%

ICU MEDICAL INC	5.2% (5.2GM/100ML)	N018429	001		Apr CAHN
-----------------	--------------------	---------	-----	--	----------

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

ICU MEDICAL INC	3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML; 234MG/100ML	N017789	003		Feb CAHN
-----------------	--	---------	-----	--	----------

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

@ ICU MEDICAL INC	3.5%; 21MG/100ML; 128MG/100ML; 234MG/100ML	N017789	005		Feb CAHN
-------------------	--	---------	-----	--	----------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

ICU MEDICAL INC	10%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 410MG/100ML	N019437	004	Apr 03, 1986	Apr CAHN
-----------------	--	---------	-----	--------------	----------

AMINOSYN II 7% W/ ELECTROLYTES

@ ICU MEDICAL INC	7%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 410MG/100ML	N019437	006	Apr 03, 1986	Apr CAHN
-------------------	---	---------	-----	--------------	----------

AMINOSYN II 8.5% W/ ELECTROLYTES

ICU MEDICAL INC	8.5%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 410MG/100ML	N019437	005	Apr 03, 1986	Apr CAHN
-----------------	---	---------	-----	--------------	----------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M

@ ICU MEDICAL INC	3.5%; 30MG/100ML; 97MG/100ML; 120MG/100ML; 49MG/100ML	N019437	007	Apr 03, 1986	Apr CAHN
-------------------	---	---------	-----	--------------	----------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES

ICU MEDICAL INC	7%; 102MG/100ML; 522MG/100ML; 410MG/100ML	N017789	002		Feb CAHN
-----------------	---	---------	-----	--	----------

AMINOSYN 8.5% W/ ELECTROLYTES

ICU MEDICAL INC	8.5%; 102MG/100ML; 522MG/100ML; 410MG/100ML	N017673	005		Feb CAHN
-----------------	---	---------	-----	--	----------

AMINOLEVULINIC ACID HYDROCHLORIDEFOR SOLUTION; ORAL
GLEOLAN

+! NXDC 1.5GM/VIAL

N208630 001 Jun 06, 2017 Jun NEWA

AMIODARONE HYDROCHLORIDEINJECTABLE; INJECTION
AMIODARONE HYDROCHLORIDE

AP AUROBINDO PHARMA LTD 50MG/ML

A204550 001 Oct 25, 2017 Oct NEWA

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

>A> AB MAYNE PHARMA INC 100MG

A075389 002 Dec 28, 2017 Dec NEWA

AB 200MG

A075389 001 Jan 25, 2001 Jan CAHN

>A> AB 400MG

A075389 003 Dec 28, 2017 Dec NEWA

@ MYLAN 200MG

A075188 001 Feb 24, 1999 Mar DISC

AB ! SANDOZ 200MG

A075315 001 Dec 23, 1998 Mar CHRS

AB TARO PHARM 100MG

A075424 002 Dec 18, 2002 Mar CAHN

AB 200MG

A075424 001 Mar 30, 2001 Mar CAHN

300MG

A076362 002 Dec 02, 2003 Mar CAHN

AB 400MG

A076362 001 Nov 29, 2002 Mar CAHN

PACERONE

AB UPSHER-SMITH LABS 100MG

A075135 002 Apr 12, 2005 Jun CAHN

AB 200MG

A075135 001 Apr 30, 1998 Jun CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB ZYDUS PHARMS USA INC 10MG

A210086 001 Oct 06, 2017 Sep NEWA

AB 25MG

A210086 002 Oct 06, 2017 Sep NEWA

AB 50MG

A210086 003 Oct 06, 2017 Sep NEWA

AB 75MG

A210086 004 Oct 06, 2017 Sep NEWA

AB 100MG

A210086 005 Oct 06, 2017 Sep NEWA

AB 150MG

A210086 006 Oct 06, 2017 Sep NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

@ ANDA REPOSITORY EQ 12.5MG BASE; 5MG

A070765 001 Dec 10, 1986 Sep CAHN

@ EQ 25MG BASE; 10MG

A070766 001 Dec 10, 1986 Sep CAHN

@ WATSON LABS TEVA EQ 12.5MG BASE; 5MG

A072052 001 Dec 16, 1988 May CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

>A> @ FOSUN PHARMA EQ 2.5MG BASE

A076859 001 Sep 10, 2007 Dec CAHN

>A> @ EQ 5MG BASE

A076859 002 Sep 10, 2007 Dec CAHN

>A> @ EQ 10MG BASE

A076859 003 Sep 10, 2007 Dec CAHN

AB MYLAN PHARMS INC EQ 2.5MG BASE

A076418 001 Oct 03, 2005 Mar CAHN

@ EQ 2.5MG BASE

A078224 001 Feb 27, 2008 May DISC

AB EQ 5MG BASE

A076418 002 Oct 03, 2005 Mar CAHN

@ EQ 5MG BASE

A078224 002 Feb 27, 2008 May DISC

AB EQ 10MG BASE

A076418 003 Oct 03, 2005 Mar CAHN

@ EQ 10MG BASE

A078224 003 Feb 27, 2008 May DISC

>D> @ SANDOZ EQ 2.5MG BASE

A076859 001 Sep 10, 2007 Dec CAHN

@ EQ 5MG BASE

A076859 002 Sep 10, 2007 Dec CAHN

>D> @ EQ 10MG BASE

A076859 003 Sep 10, 2007 Dec CAHN

@ SOVEREIGN PHARMS EQ 2.5MG BASE

A204900 001 Jul 23, 2015 Sep DISC

@ EQ 5MG BASE

A204900 002 Jul 23, 2015 Sep DISC

@ EQ 10MG BASE

A204900 003 Jul 23, 2015 Sep DISC

AB UPSHER-SMITH LABS EQ 2.5MG BASE

A077759 001 Jul 09, 2007 Jun CAHN

AB EQ 5MG BASE

A077759 002 Jul 09, 2007 Jun CAHN

AB EQ 10MG BASE

A077759 003 Jul 09, 2007 Jun CAHN

AB VIVIMED GLOBAL EQ 2.5MG BASE

A077516 001 Jul 11, 2007 Aug CAHN

AB EQ 5MG BASE

A077516 002 Jul 11, 2007 Aug CAHN

AB EQ 10MG BASE

A077516 003 Jul 11, 2007 Aug CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

>A>	AB	AUROBINDO PHARMA LTD	5MG;12.5MG;160MG	A206180	001	Dec 19, 2017	Dec NEWA
>A>	AB		5MG;25MG;160MG	A206180	002	Dec 19, 2017	Dec NEWA
>A>	AB		10MG;12.5MG;160MG	A206180	003	Dec 19, 2017	Dec NEWA
>A>	AB		10MG;25MG;160MG	A206180	004	Dec 19, 2017	Dec NEWA
>A>	AB		10MG;25MG;320MG	A206180	005	Dec 19, 2017	Dec NEWA

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB	ALEMBIC PHARMS LTD	EQ 5MG BASE;20MG	A207073	001	Jul 17, 2017	Jul NEWA
AB		EQ 5MG BASE;40MG	A207073	002	Jul 17, 2017	Jul NEWA
AB		EQ 10MG BASE;20MG	A207073	003	Jul 17, 2017	Jul NEWA
AB		EQ 10MG BASE;40MG	A207073	004	Jul 17, 2017	Jul NEWA
AB	ALKEM LABS LTD	EQ 5MG BASE;20MG	A209042	001	Aug 14, 2017	Jul NEWA
AB		EQ 5MG BASE;40MG	A209042	002	Aug 14, 2017	Jul NEWA
AB		EQ 10MG BASE;20MG	A209042	003	Aug 14, 2017	Jul NEWA
AB		EQ 10MG BASE;40MG	A209042	004	Aug 14, 2017	Jul NEWA
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE;20MG	A206906	001	May 15, 2017	May NEWA
AB		EQ 5MG BASE;40MG	A206906	002	May 15, 2017	May NEWA
AB		EQ 10MG BASE;20MG	A206906	003	May 15, 2017	May NEWA
AB		EQ 10MG BASE;40MG	A206906	004	May 15, 2017	May NEWA
AB	GLENMARK PHARMS LTD	EQ 5MG BASE;20MG	A207807	001	Jul 05, 2017	Jun NEWA
AB		EQ 5MG BASE;40MG	A207807	002	Jul 05, 2017	Jun NEWA
AB		EQ 10MG BASE;20MG	A207807	003	Jul 05, 2017	Jun NEWA
AB		EQ 10MG BASE;40MG	A207807	004	Jul 05, 2017	Jun NEWA
AB	JUBILANT GENERICS	EQ 5MG BASE;20MG	A207450	001	May 15, 2017	May NEWA
AB		EQ 5MG BASE;40MG	A207450	002	May 15, 2017	May NEWA
AB		EQ 10MG BASE;20MG	A207450	003	May 15, 2017	May NEWA
AB		EQ 10MG BASE;40MG	A207450	004	May 15, 2017	May NEWA
AB	MICRO LABS	EQ 5MG BASE;20MG	A207435	001	Nov 02, 2017	Oct NEWA
AB		EQ 5MG BASE;40MG	A207435	002	Nov 02, 2017	Oct NEWA
AB		EQ 10MG BASE;20MG	A207435	003	Nov 02, 2017	Oct NEWA
AB		EQ 10MG BASE;40MG	A207435	004	Nov 02, 2017	Oct NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE;20MG	A202933	001	Nov 25, 2016	Apr CAHN
AB		EQ 5MG BASE;40MG	A202933	002	Nov 25, 2016	Apr CAHN
AB		EQ 10MG BASE;20MG	A202933	003	Nov 25, 2016	Apr CAHN
AB		EQ 10MG BASE;40MG	A202933	004	Nov 25, 2016	Apr CAHN
AB	ZYDUS PHARMS USA INC	EQ 5MG BASE;20MG	A207771	001	Sep 22, 2017	Sep NEWA
AB		EQ 5MG BASE;40MG	A207771	002	Sep 22, 2017	Sep NEWA
AB		EQ 10MG BASE;20MG	A207771	003	Sep 22, 2017	Sep NEWA
AB		EQ 10MG BASE;40MG	A207771	004	Sep 22, 2017	Sep NEWA

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL

PRESTALIA

>A>	+	MARINA BIOTECH	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Dec CAHN
>A>	+		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Dec CAHN
>A>	+	!	EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Dec CAHN
>D>	+	SYMPLMED PHARMS LLC	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Dec CAHN
>D>	+		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Dec CAHN
>D>	+	!	EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Dec CAHN

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP	GEN HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A207025	001	Feb 03, 2016	May CAHN
----	----------	------------------------------------	---------	-----	--------------	----------

AMMONIUM LACTATE

LOTION;TOPICAL

LAC-HYDRIN

+	@	RANBAXY	EQ 12% BASE	N019155	001	Apr 24, 1985	Jan CRLD
---	---	---------	-------------	---------	-----	--------------	----------

AMOXAPINE

TABLET;ORAL

AMOXAPINE

@	UPSHER-SMITH LABS	25MG	A072943	001	Jun 28, 1991	Jun CAHN
@		50MG	A072944	001	Jun 28, 1991	Jun CAHN
@		100MG	A072878	001	Jun 28, 1991	Jun CAHN
@		150MG	A072879	001	Jun 28, 1991	Jun CAHN

TABLET;ORAL

AMOXAPINE

@	WATSON PHARMS TEVA	25MG	A072418	001	May 11, 1989	Feb CAHN
@		50MG	A072419	001	May 11, 1989	Feb CAHN
@		100MG	A072420	001	May 11, 1989	Feb CAHN
@		150MG	A072421	001	May 11, 1989	Feb CAHN

AMOXICILLIN

FOR SUSPENSION;ORAL

AMOXICILLIN

>D>	AB	WOCKHARDT	400MG/5ML	A065319	002	Jun 18, 2007	Dec CAHN
>A>	AB	WOCKHARDT BIO AG	400MG/5ML	A065319	002	Jun 18, 2007	Dec CAHN
		AMOXIL					
+	@	DR REDDYS LABS INC	200MG/5ML	N050760	001	Apr 15, 1999	Sep CRLD
	@		200MG/5ML	N050760	001	Apr 15, 1999	Feb DISC
+	@		400MG/5ML	N050760	002	Apr 15, 1999	Sep CRLD
	@		400MG/5ML	N050760	002	Apr 15, 1999	Feb DISC

TABLET, CHEWABLE;ORAL

AMOXICILLIN

		TEVA	125MG	A064013	002	Sep 11, 1995	Feb CTEC
!			250MG	A064013	001	Dec 22, 1992	Feb CTEC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>D>	AB	WOCKHARDT	250MG/5ML;EQ 62.5MG BASE/5ML	A065431	001	Nov 25, 2008	Dec CAHN
>A>	AB	WOCKHARDT BIO AG	250MG/5ML;EQ 62.5MG BASE/5ML	A065431	001	Nov 25, 2008	Dec CAHN
>A>	AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065420	001	Dec 02, 2013	Dec CAHN
>D>	AB	WOCKHARDT EU OPERATN	600MG/5ML;EQ 42.9MG BASE/5ML	A065420	001	Dec 02, 2013	Dec CAHN
		AUGMENTIN '125'					
+		DR REDDYS LABS INC	125MG/5ML;EQ 31.25MG BASE/5ML	N050575	001	Aug 06, 1984	Nov CTEC
		AUGMENTIN '200'					
+	@	DR REDDYS LABS INC	200MG/5ML;EQ 28.5MG BASE/5ML	N050725	001	May 31, 1996	Feb DISC
	@		AUGMENTIN '400'				
+	@	DR REDDYS LABS INC	400MG/5ML;EQ 57MG BASE/5ML	N050725	002	May 31, 1996	Feb DISC
	@		AUGMENTIN ES-600				
+	@	DR REDDYS LABS INC	600MG/5ML;EQ 42.9MG BASE/5ML	N050755	001	Jun 22, 2001	Feb DISC

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	!	SANDOZ	250MG;EQ 125MG BASE	A065189	001	Aug 23, 2005	Feb CHRS
AB	!		875MG;EQ 125MG BASE	A065063	001	Mar 14, 2002	Oct CHRS
AB	!	SANDOZ INC	500MG;EQ 125MG BASE	A065117	001	Nov 27, 2002	Feb CHRS
		AUGMENTIN '875'					
AB	+	DR REDDYS LABS INC	875MG;EQ 125MG BASE	N050720	001	Feb 13, 1996	Oct CHRS
		TABLET, CHEWABLE;ORAL					
		AMOXICILLIN AND CLAVULANATE POTASSIUM					
		TEVA	200MG;EQ 28.5MG BASE	A065205	001	Feb 09, 2005	Feb CTEC
	!		400MG;EQ 57MG BASE	A065205	002	Feb 09, 2005	Feb CTEC
		AUGMENTIN '200'					
+	@	DR REDDYS LABS INC	200MG;EQ 28.5MG BASE	N050726	001	May 31, 1996	Feb DISC
	@		AUGMENTIN '400'				
+	@	DR REDDYS LABS INC	400MG;EQ 57MG BASE	N050726	002	May 31, 1996	Feb DISC

AMPHETAMINE

SUSPENSION, EXTENDED RELEASE;ORAL

ADZENYS ER

+	!	NEOS THERAPS INC	EQ 1.25MG BASE/ML	N204325	001	Sep 15, 2017	Sep NEWA
---	---	------------------	-------------------	---------	-----	--------------	----------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

MYDAYIS

+		SHIRE DEV LLC	3.125MG;3.125MG;3.125MG;3.125MG	N022063	001	Jun 20, 2017	Jun NEWA
+			6.25MG;6.25MG;6.25MG;6.25MG	N022063	002	Jun 20, 2017	Jun NEWA
+			9.375MG;9.375MG;9.375MG;9.375MG	N022063	003	Jun 20, 2017	Jun NEWA
+			12.5MG;12.5MG;12.5MG;12.5MG	N022063	004	Jun 20, 2017	Jun NEWA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		ALVOGEN MALTA	1.25MG;1.25MG;1.25MG;1.25MG	A207388	001	Jul 28, 2017	Jul NEWA
AB			1.875MG;1.875MG;1.875MG;1.875MG	A207388	002	Jul 28, 2017	Jul NEWA
AB			2.5MG;2.5MG;2.5MG;2.5MG	A207388	003	Jul 28, 2017	Jul NEWA
AB			3.125MG;3.125MG;3.125MG;3.125MG	A207388	004	Jul 28, 2017	Jul NEWA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		3.75MG;3.75MG;3.75MG;3.75MG	A207388	005	Jul 28, 2017	Jul NEWA
AB		5MG;5MG;5MG;5MG	A207388	006	Jul 28, 2017	Jul NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A207388	007	Jul 28, 2017	Jul NEWA
AB	EPIC PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A040444	001	Jun 19, 2002	May CAHN
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040444	005	Nov 03, 2014	May CAHN
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040444	002	Jun 19, 2002	May CAHN
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040444	006	Nov 03, 2014	May CAHN
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040444	007	Nov 03, 2014	May CAHN
AB		5MG;5MG;5MG;5MG	A040444	003	Jun 19, 2002	May CAHN
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040444	004	Jun 19, 2002	May CAHN
>D> AB	MALLINCKRODT INC	1.25MG;1.25MG;1.25MG;1.25MG	A040440	001	Oct 07, 2003	Dec CAHN
>D> AB		1.875MG;1.875MG;1.875MG;1.875MG	A040440	002	Oct 07, 2003	Dec CAHN
>D> AB		2.5MG;2.5MG;2.5MG;2.5MG	A040440	003	Oct 07, 2003	Dec CAHN
>D> AB		3.125MG;3.125MG;3.125MG;3.125MG	A040440	004	Oct 07, 2003	Dec CAHN
>D> AB		3.75MG;3.75MG;3.75MG;3.75MG	A040440	005	Oct 07, 2003	Dec CAHN
>D> AB		5MG;5MG;5MG;5MG	A040440	006	Oct 07, 2003	Dec CAHN
>D> AB		7.5MG;7.5MG;7.5MG;7.5MG	A040440	007	Oct 07, 2003	Dec CAHN
AB	NESHER PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A207340	001	Oct 31, 2017	Oct NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A207340	002	Oct 31, 2017	Oct NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A207340	003	Oct 31, 2017	Oct NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A207340	004	Oct 31, 2017	Oct NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A207340	005	Oct 31, 2017	Oct NEWA
AB		5MG;5MG;5MG;5MG	A207340	006	Oct 31, 2017	Oct NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A207340	007	Oct 31, 2017	Oct NEWA
>A> AB	SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A040440	001	Oct 07, 2003	Dec CAHN
>A> AB		1.875MG;1.875MG;1.875MG;1.875MG	A040440	002	Oct 07, 2003	Dec CAHN
>A> AB		2.5MG;2.5MG;2.5MG;2.5MG	A040440	003	Oct 07, 2003	Dec CAHN
>A> AB		3.125MG;3.125MG;3.125MG;3.125MG	A040440	004	Oct 07, 2003	Dec CAHN
>A> AB		3.75MG;3.75MG;3.75MG;3.75MG	A040440	005	Oct 07, 2003	Dec CAHN
>A> AB		5MG;5MG;5MG;5MG	A040440	006	Oct 07, 2003	Dec CAHN
>A> AB		7.5MG;7.5MG;7.5MG;7.5MG	A040440	007	Oct 07, 2003	Dec CAHN
>A> AB	SUNRISE PHARM INC	1.25MG;1.25MG;1.25MG;1.25MG	A209799	001	Dec 28, 2017	Dec NEWA
>A> AB		1.875MG;1.875MG;1.875MG;1.875MG	A209799	002	Dec 28, 2017	Dec NEWA
>A> AB		2.5MG;2.5MG;2.5MG;2.5MG	A209799	003	Dec 28, 2017	Dec NEWA
>A> AB		3.125MG;3.125MG;3.125MG;3.125MG	A209799	004	Dec 28, 2017	Dec NEWA
>A> AB		3.75MG;3.75MG;3.75MG;3.75MG	A209799	005	Dec 28, 2017	Dec NEWA
>A> AB		5MG;5MG;5MG;5MG	A209799	006	Dec 28, 2017	Dec NEWA
>A> AB		7.5MG;7.5MG;7.5MG;7.5MG	A209799	007	Dec 28, 2017	Dec NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX;INJECTION

ABELCET

+!	LEADIANT BIOSCI INC	5MG/ML	N050724	001	Nov 20, 1995	Nov CAHN
----	---------------------	--------	---------	-----	--------------	----------

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

	@ HANFORD GC	EQ 125MG BASE/VIAL	A062772	005	Apr 15, 1993	Oct CMS1
AP		EQ 250MG BASE/VIAL	A062772	006	Apr 15, 1993	Oct CMS1
AP		EQ 500MG BASE/VIAL	A062772	007	Apr 15, 1993	Oct CMS1
	@	EQ 500MG BASE/VIAL	A062772	008	Apr 15, 1993	Oct CMS1
	@	EQ 1GM BASE/VIAL	A062772	002	Apr 15, 1993	Oct CMS1
AP		EQ 2GM BASE/VIAL	A062772	003	Apr 15, 1993	Oct CMS1
	@	EQ 2GM BASE/VIAL	A062772	004	Apr 15, 1993	Oct CMS1
	@ WEST-WARD PHARMS INT	EQ 125MG BASE/VIAL	A062692	001	Jun 24, 1986	Jan CAHN
	@	EQ 250MG BASE/VIAL	A062692	002	Jun 24, 1986	Jan CAHN
	@	EQ 500MG BASE/VIAL	A062692	003	Jun 24, 1986	Jan CAHN
	@	EQ 1GM BASE/VIAL	A062692	004	Jun 24, 1986	Jan CAHN
	@	EQ 2GM BASE/VIAL	A062692	005	Jun 24, 1986	Jan CAHN
	@	EQ 10GM BASE/VIAL	A062692	006	Jun 24, 1986	Jan CAHN
	PENBRITIN-S					
+	@ WYETH AYERST	EQ 125MG BASE/VIAL	N050072	001		Jun CRLD
+	@	EQ 250MG BASE/VIAL	N050072	002		Jun CRLD
+	@	EQ 500MG BASE/VIAL	N050072	003		Jun CRLD
+	@	EQ 1GM BASE/VIAL	N050072	004		Jun CRLD
+	@	EQ 2GM BASE/VIAL	N050072	005		Jun CRLD
+	@	EQ 4GM BASE/VIAL	N050072	006		Jun CRLD

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP	ANTIBIOTICE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A201406	001	Dec 07, 2015	Jul CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A201406	002	Dec 07, 2015	Jul CAHN
AP	WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074	001	Mar 19, 2002	Jan CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074	002	Mar 19, 2002	Jan CAHN
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065076	001	Mar 19, 2002	Jan CAHN

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

ANAGRELIDE HYDROCHLORIDE

	@ MYLAN PHARMS INC	EQ 0.5MG BASE	A076811	001	Apr 18, 2005	May DISC
AB		EQ 0.5MG BASE	A076811	001	Apr 18, 2005	Mar CAHN
	@	EQ 0.5MG BASE	A077613	001	Jun 27, 2006	May DISC
	@	EQ 1MG BASE	A076811	002	Apr 18, 2005	May DISC
AB		EQ 1MG BASE	A076811	002	Apr 18, 2005	Mar CAHN
	@	EQ 1MG BASE	A077613	002	Jun 27, 2006	May DISC
AB	TORRENT PHARMS LTD	EQ 0.5MG BASE	A209151	001	Jun 30, 2017	Jun NEWA
AB		EQ 1MG BASE	A209151	002	Jun 30, 2017	Jun NEWA
	@ UPSHER-SMITH LABS	EQ 0.5MG BASE	A076683	001	Apr 18, 2005	Jun CAHN
	@	EQ 1MG BASE	A076683	002	Apr 18, 2005	Jun CAHN

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

	@ SUN PHARM INDS LTD	1MG	A091177	001	Jul 15, 2011	Sep DISC
	@ WATSON LABS TEVA	1MG	A078984	001	Jun 28, 2010	May CAHN
	ARIMIDEX					
AB	+! ASTRAZENECA PHARMS	1MG	N020541	001	Dec 27, 1995	May CAHN

>A> ANGIOTENSIN II

>A> SOLUTION; IV (INFUSION)

>A> GIAPREZA

>A>	+! LA JOLLA PHARM CO	2.5MG/ML (2.5MG/ML)	N209360	001	Dec 21, 2017	Dec NEWA
>A>	+!	5MG/2ML (2.5MG/ML)	N209360	002	Dec 21, 2017	Dec NEWA

APREPITANT

CAPSULE; ORAL

APREPITANT

AB	GLENMARK PHARMS LTD	40MG	A207777	001	Oct 12, 2017	Oct NEWA
AB		80MG	A207777	002	Oct 12, 2017	Oct NEWA
AB		125MG	A207777	003	Oct 12, 2017	Oct NEWA
	EMULSION; IV (INFUSION)					
	CINVANTI					
	+! HERON THERAPS INC	130MG/18ML (7.2MG/ML)	N209296	001	Nov 09, 2017	Nov NEWA

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

	+! HIKMA PHARM CO LTD	50MG/50ML (1MG/ML)	N203049	002	Sep 30, 2016	Feb NEWA
AP	+! NOVARTIS PHARMS CORP	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000	Jun CAHN
	INJECTABLE; IV (INFUSION)					
	ARGATROBAN IN SODIUM CHLORIDE					
AP	GLAND PHARMA LTD	125MG/125ML (1MG/ML)	A205570	001	May 22, 2017	May NEWA
AP	+! SANDOZ	125MG/125ML (1MG/ML)	N022485	001	May 09, 2011	May CFTG

ARIPIPRAZOLE

TABLET; ORAL

ABILIFY MYCITE KIT

	+ OTSUKA PHARM CO LTD	2MG	N207202	001	Nov 13, 2017	Nov NEWA
	+!	5MG	N207202	002	Nov 13, 2017	Nov NEWA
	+	10MG	N207202	003	Nov 13, 2017	Nov NEWA
	+	15MG	N207202	004	Nov 13, 2017	Nov NEWA
	+	20MG	N207202	005	Nov 13, 2017	Nov NEWA
	+	30MG	N207202	006	Nov 13, 2017	Nov NEWA
	ARIPIPRAZOLE					
AB	ORCHID HLTHCARE	2MG	A202683	001	May 23, 2017	May NEWA
AB		5MG	A202683	002	May 23, 2017	May NEWA

TABLET;ORAL
ARIPIPIRAZOLE

AB		10MG	A202683	003	May 23, 2017	May NEWA
AB		15MG	A202683	004	May 23, 2017	May NEWA
AB		20MG	A202683	005	May 23, 2017	May NEWA
AB		30MG	A202683	006	May 23, 2017	May NEWA
AB	PRINSTON INC	2MG	A205363	001	Dec 04, 2017	Nov NEWA
AB		5MG	A205363	002	Dec 04, 2017	Nov NEWA
AB		10MG	A205363	003	Dec 04, 2017	Nov NEWA
AB		15MG	A205363	004	Dec 04, 2017	Nov NEWA
AB		20MG	A205363	005	Dec 04, 2017	Nov NEWA
AB		30MG	A205363	006	Dec 04, 2017	Nov NEWA
AB	SANTOS BIOTECH	2MG	A091279	001	Jan 09, 2017	May CAHN
AB		5MG	A091279	002	Jan 09, 2017	May CAHN
AB		10MG	A091279	003	Jan 09, 2017	May CAHN
AB		15MG	A091279	004	Jan 09, 2017	May CAHN
AB		20MG	A091279	005	Jan 09, 2017	May CAHN
AB		30MG	A091279	006	Jan 09, 2017	May CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
ARIPIPIRAZOLE

AB	! ALEMBIC PHARMS LTD	10MG	A202102	001	Apr 28, 2015	Nov CTEC
AB		15MG	A202102	002	Apr 28, 2015	Nov CTEC
AB	ORCHID HLTHCARE	10MG	A202547	001	Dec 11, 2017	Nov NEWA
AB		15MG	A202547	002	Dec 11, 2017	Nov NEWA

ARIPIPIRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ARISTADA

+	ALKERMES INC	1064MG/3.9ML (272.82MG/ML)	N207533	004	Jun 05, 2017	Jun NEWA
---	--------------	----------------------------	---------	-----	--------------	----------

ARMODAFINIL

TABLET;ORAL
ARMODAFINIL

	NATCO PHARMA LTD	100MG	A202768	004	Sep 28, 2017	Sep NEWA
AB		200MG	A202768	005	Sep 28, 2017	Sep NEWA

ARSENIC TRIOXIDE

INJECTABLE;INJECTION
TRISENOX

+	! CEPHALON	2MG/ML	N021248	002	Oct 13, 2017	Oct NEWA
---	------------	--------	---------	-----	--------------	----------

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION
SEPTOCAINE

AP	! DEPROCO	4%;EQ 0.0085MG BASE/1.7ML (4%;EQ 0.005MG BASE/ML)	N022010	001	Mar 30, 2006	Jun CFTG
	ULTACAN					
AP	HANSAMED INC	4%;EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	A201751	001	Jul 11, 2017	Jun NEWA
	ULTACAN FORTE					
AP	HANSAMED INC	4%;EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	A201750	001	Jul 11, 2017	Jun NEWA

ASCORBIC ACID

SOLUTION;IV (INFUSION)
ASCOR

+	! MCGUFF	25,000MG/50ML (500MG/ML)	N209112	001	Oct 02, 2017	Oct NEWA
---	----------	--------------------------	---------	-----	--------------	----------

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE;IV (INFUSION)
INFUVITE PEDIATRIC

+	! SANDOZ INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	001	Feb 21, 2001	May CAHN
	INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)					
+	! SANDOZ INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021646	001	Jan 29, 2004	May CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 ADULT

@	HOSPIRA	10MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG	N008809	004	Aug 08, 1985	Nov	CTNA
		/ML; 20					
+	@	IU/ML; 0.04MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/ML; 0.3MG/ML; 330 UNITS/ML; 1	N008809	006	Sep 09, 2004	Nov	CTNA
		20MG/ML; 0.006MG/ML; 0.05MCG/ML; 1.5MG/ML; 0.0005MG/ML; 0.06MG/ML; 4MG/ML; 0.6MG/ML; 0.36MG/ML; 0.6MG/ML; 0.1MG/ML; 1MG/ML					
+	@	20MG/ML; 0.006MG/ML; 0.05MCG/ML; 1.5MG	N008809	006	Sep 09, 2004	Aug	DISC
		G/ML; 0.0005MG/ML; 0.06MG/ML; 4MG/ML; 0.6MG/ML; 0.36MG/ML; 0.6MG/ML; 0.1MG/ML; 1MG/ML					

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 ADULT

@	HOSPIRA	20MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG	N008809	005	Apr 22, 2004	Nov	CTNA
		/ML; 20					
		IU/ML; 0.6MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/ML; 0.6MG/ML; 330 UNITS/ML; 1					

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

FIORINAL

+	@	ALLERGAN SALES LLC	325MG; 50MG; 40MG	N017534	003	Apr 16, 1986	Jan	CRLD
---	---	--------------------	-------------------	---------	-----	--------------	-----	------

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB		NOVAST LABS LTD	325MG; 200MG	A040832	001	Jan 07, 2010	Sep	CAHN
----	--	-----------------	--------------	---------	-----	--------------	-----	------

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

ASPIRIN AND DIPYRIDAMOLE

AB		AMNEAL PHARMS	25MG; 200MG	A206392	001	Mar 08, 2016	May	CAHN
AB		IMPAX LABS INC	25MG; 200MG	A206964	001	Jan 18, 2017	Jan	NEWA
AB		PAR PHARM INC	25MG; 200MG	A207944	001	Jan 18, 2017	Jan	NEWA
AB		SANDOZ INC	25MG; 200MG	A206739	001	Jan 18, 2017	Jan	NEWA
AB		ZYDUS PHARMS USA INC	25MG; 200MG	A206753	001	Aug 29, 2017	Aug	NEWA

ASPIRIN; MEPROBAMATE

TABLET; ORAL

EQUAGESIC

@	SUN PHARM INDUSTRIES	325MG; 200MG	N011702	003	Dec 29, 1983	Oct	CAHN
---	----------------------	--------------	---------	-----	--------------	-----	------

ATENOLOL

TABLET; ORAL

ATENOLOL

AB		UNIQUE PHARM LABS	25MG	A077443	001	Sep 13, 2006	Aug	CAHN
AB			50MG	A077443	002	Sep 13, 2006	Aug	CAHN
AB			100MG	A077443	003	Sep 13, 2006	Aug	CAHN
	@	WATSON LABS TEVA	100MG	A073353	001	Dec 27, 1991	May	CAHN

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

AB		SUN PHARM INDUSTRIES	50MG; 25MG	A073582	002	Apr 29, 1993	Nov	CMS1
----	--	----------------------	------------	---------	-----	--------------	-----	------

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

AB		APOTEX INC	10MG	A078983	001	May 30, 2017	May	NEWA
AB			18MG	A078983	002	May 30, 2017	May	NEWA
AB			25MG	A078983	003	May 30, 2017	May	NEWA
AB			40MG	A078983	004	May 30, 2017	May	NEWA
AB			60MG	A078983	005	May 30, 2017	May	NEWA
AB			80MG	A078983	006	May 30, 2017	May	NEWA
AB			100MG	A078983	007	May 30, 2017	May	NEWA

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	10MG	A079016	001	May 30, 2017	May NEWA
AB		18MG	A079016	002	May 30, 2017	May NEWA
AB		25MG	A079016	003	May 30, 2017	May NEWA
AB		40MG	A079016	004	May 30, 2017	May NEWA
AB		60MG	A079016	005	May 30, 2017	May NEWA
AB		80MG	A079016	006	May 30, 2017	May NEWA
AB		100MG	A079016	007	May 30, 2017	May NEWA
AB	GLENMARK PHARMS LTD	10MG	A079019	001	May 30, 2017	May NEWA
AB		18MG	A079019	002	May 30, 2017	May NEWA
AB		25MG	A079019	003	May 30, 2017	May NEWA
AB		40MG	A079019	004	May 30, 2017	May NEWA
AB		60MG	A079019	005	May 30, 2017	May NEWA
AB		80MG	A079019	006	May 30, 2017	May NEWA
AB		100MG	A079019	007	May 30, 2017	May NEWA
AB	TEVA PHARMS USA	10MG	A079022	001	May 30, 2017	May NEWA
AB		18MG	A079022	002	May 30, 2017	May NEWA
AB		25MG	A079022	003	May 30, 2017	May NEWA
AB		40MG	A079022	004	May 30, 2017	May NEWA
AB		60MG	A079022	005	May 30, 2017	May NEWA
AB		80MG	A079022	006	May 30, 2017	May NEWA
AB		100MG	A079022	007	May 30, 2017	May NEWA
STRATTERA						
AB	+ LILLY	10MG	N021411	002	Nov 26, 2002	May CFTG
AB	+	18MG	N021411	003	Nov 26, 2002	May CFTG
AB	+	25MG	N021411	004	Nov 26, 2002	May CFTG
AB	+	40MG	N021411	005	Nov 26, 2002	May CFTG
AB	+!	60MG	N021411	006	Nov 26, 2002	May CFTG
AB	+	80MG	N021411	007	Feb 14, 2005	May CFTG
AB	+	100MG	N021411	008	Feb 14, 2005	May CFTG

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	TEVA PHARMS USA	EQ 10MG BASE	A205300	001	Mar 27, 2017	Mar NEWA
AB		EQ 20MG BASE	A205300	002	Mar 27, 2017	Mar NEWA
AB		EQ 40MG BASE	A205300	003	Mar 27, 2017	Mar NEWA
AB		EQ 80MG BASE	A205300	004	Mar 27, 2017	Mar NEWA

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

	WATSON LABS TEVA	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Apr NEWA
		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Apr NEWA
		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Apr NEWA
!		EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Apr NEWA

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

AB	APOTEX INC	750MG/5ML	A209750	001	Oct 11, 2017	Oct NEWA
AB	PADDOCK LLC	750MG/5ML	A207833	001	Apr 28, 2017	Apr NEWA

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

AP	MYLAN LABS LTD	10MG/ML	A206096	001	Jun 22, 2017	Jun NEWA
	@ WATSON PHARMS TEVA	10MG/ML	A074945	001	Jul 28, 1998	Feb CAHN
ATRACURIUM BESYLATE PRESERVATIVE FREE						
AP	MYLAN LABS LTD	10MG/ML	A206001	001	Apr 07, 2017	Mar NEWA
TRACRIUM						
+	@ HOSPIRA	10MG/ML	N018831	002	Jun 20, 1985	Apr CMS1
TRACRIUM PRESERVATIVE FREE						
+	@ HOSPIRA	10MG/ML	N018831	001	Nov 23, 1983	Apr CMS1

ATROPINE SULFATE

SOLUTION;INTRAVENOUS

ATROPINE SULFATE LIFESHIELD ABBOJECT SYRINGE

+	!	HOSPIRA	0.5MG/5ML (0.1MG/ML)	N021146	004	Aug 17, 2017	Aug NEWA
+	!		1MG/10ML (0.1MG/ML)	N021146	005	Aug 17, 2017	Aug NEWA

SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, ENDOTRACHEAL
 ATROPINE SULFATE ANSYR PLASTIC SYRINGE

+!	HOSPIRA	0.25MG/5ML (0.05MG/ML)	N021146	002	Jul 09, 2001	Aug CDFR
+!		0.5MG/5ML (0.1MG/ML)	N021146	001	Jul 09, 2001	Aug CDFR
+!		1MG/10ML (0.1MG/ML)	N021146	003	Jul 09, 2001	Aug NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

!	WEST-WARD PHARMS INT	0.025MG/5ML;2.5MG/5ML	A087708	001	May 03, 1982	Nov CTEC
---	----------------------	-----------------------	---------	-----	--------------	----------

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	ANI PHARMS INC	0.025MG;2.5MG	A086727	001		Jun CMFD
----	----------------	---------------	---------	-----	--	----------

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

ENLON-PLUS

+	@ MYLAN INSTITUTIONAL	0.14MG/ML;10MG/ML	N019678	001	Nov 06, 1991	Nov DISC
---	-----------------------	-------------------	---------	-----	--------------	----------

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE;INTRAMUSCULAR

ATNAA

>D>	@ US ARMY	2.1MG/0.7ML;600MG/0.7ML	N021175	001	Jan 17, 2002	Dec CPOT
-----	-----------	-------------------------	---------	-----	--------------	----------

>A>	@	2.1MG/0.7ML;600MG/2ML	N021175	001	Jan 17, 2002	Dec CPOT
-----	---	-----------------------	---------	-----	--------------	----------

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;IV (INFUSION)

AVYCAZ

+	! CEREXA	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	May CAHN
---	----------	------------------------	---------	-----	--------------	----------

AZACITIDINE

POWDER;IV (INFUSION), SUBCUTANEOUS

AZACITIDINE

AP	ACTAVIS LLC	100MG/VIAL	N208216	001	Apr 29, 2016	Mar CTEC
----	-------------	------------	---------	-----	--------------	----------

AP	DR REDDYS LABS LTD	100MG/VIAL	A201537	001	Sep 16, 2013	Mar CDFR
----	--------------------	------------	---------	-----	--------------	----------

AP	MYLAN INSTITUTIONAL	100MG/VIAL	A204949	001	Apr 28, 2016	Mar CDFR
----	---------------------	------------	---------	-----	--------------	----------

AP	NATCO PHARMA LTD	100MG/VIAL	A207234	001	Jun 23, 2017	Jun NEWA
----	------------------	------------	---------	-----	--------------	----------

AP	SHILPA MEDICARE	100MG/VIAL	A207518	001	Sep 29, 2016	Mar CDFR
----	-----------------	------------	---------	-----	--------------	----------

VIDAZA

AP	+! CELGENE	100MG/VIAL	N050794	001	May 19, 2004	Mar CDFR
----	------------	------------	---------	-----	--------------	----------

AZATHIOPRINE SODIUM

INJECTABLE;INJECTION

IMURAN

+	@ CASPER PHARMA LLC	EQ 100MG BASE/VIAL	N017391	001		Jul CAHN
---	---------------------	--------------------	---------	-----	--	----------

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AZELASTINE HYDROCHLORIDE

>D>	AT	SANDOZ INC	0.05%	A202305	001	May 31, 2012	Dec CHRS
-----	----	------------	-------	---------	-----	--------------	----------

>A>	AT	!	0.05%	A202305	001	May 31, 2012	Dec CHRS
-----	----	---	-------	---------	-----	--------------	----------

	AT		0.05%	A202305	001	May 31, 2012	Feb CAHN
--	----	--	-------	---------	-----	--------------	----------

>D> OPTIVAR

>D>	AT	+! MYLAN SPECIALITY LP	0.05%	N021127	001	May 22, 2000	Dec DISC
-----	----	------------------------	-------	---------	-----	--------------	----------

>A>		+ @	0.05%	N021127	001	May 22, 2000	Dec DISC
-----	--	-----	-------	---------	-----	--------------	----------

	AT	+!	0.05%	N021127	001	May 22, 2000	Mar CAHN
--	----	----	-------	---------	-----	--------------	----------

SPRAY, METERED;NASAL

ASTELIN

AB	+!	MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N020114	001	Nov 01, 1996	Mar CAHN
----	----	---------------------	-----------------------	---------	-----	--------------	----------

ASTEPRO

	@	MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N022203	001	Oct 15, 2008	Mar CAHN
--	---	---------------------	-----------------------	---------	-----	--------------	----------

AB	+!		EQ 0.1876MG BASE/SPRAY	N022203	002	Aug 31, 2009	Mar CAHN
----	----	--	------------------------	---------	-----	--------------	----------

AZELASTINE HYDROCHLORIDE

AB		ALKEM LABS LTD	EQ 0.125MG BASE/SPRAY	A208156	001	Aug 18, 2017	Aug NEWA
----	--	----------------	-----------------------	---------	-----	--------------	----------

AB		AMNEAL PHARMS LLC	EQ 0.125MG BASE/SPRAY	A204660	001	Aug 28, 2017	Aug NEWA
----	--	-------------------	-----------------------	---------	-----	--------------	----------

>A>	AB		EQ 0.1876MG BASE/SPRAY	A208199	001	Dec 15, 2017	Dec NEWA
-----	----	--	------------------------	---------	-----	--------------	----------

AB		BRECKENRIDGE PHARM	EQ 0.125MG BASE/SPRAY	A090176	001	Jul 28, 2015	Feb CAHN
----	--	--------------------	-----------------------	---------	-----	--------------	----------

AB		UPSHER-SMITH LABS	EQ 0.125MG BASE/SPRAY	A202609	001	Mar 17, 2017	Jun CAHN
----	--	-------------------	-----------------------	---------	-----	--------------	----------

AB			EQ 0.125MG BASE/SPRAY	A202609	001	Mar 17, 2017	Mar NEWA
----	--	--	-----------------------	---------	-----	--------------	----------

AB		WEST-WARD PHARMS INT	EQ 0.1876MG BASE/SPRAY	A207243	001	Sep 22, 2017	Sep NEWA
----	--	----------------------	------------------------	---------	-----	--------------	----------

AB		ZYDUS PHARMS USA INC	EQ 0.125MG BASE/SPRAY	A091409	001	Aug 14, 2017	Jul NEWA
----	--	----------------------	-----------------------	---------	-----	--------------	----------

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB	APOTEX INC	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	A207712	001	Apr 28, 2017	Apr NEWA
	DYMISTA					
AB	+! MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236	001	May 01, 2012	Apr CFTG
	+!	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236	001	May 01, 2012	Mar CAHN

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB	LUPIN LTD	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	Aug CTEC
AB		EQ 200MG BASE/5ML	A065488	002	May 15, 2015	Aug CTEC
	INJECTABLE;INJECTION					
	AZITHROMYCIN					
	@ CSPC OUYI PHARM CO	EQ 500MG BASE/VIAL	A065265	001	Jan 18, 2007	Oct CAHN
AP	MYLAN LABS LTD	EQ 500MG BASE/VIAL	A204732	001	Jan 26, 2017	Jan NEWA
	TABLET;ORAL					
	AZITHROMYCIN					
	@ MYLAN	EQ 250MG BASE	A065365	001	May 30, 2007	Jun DISC
	@	EQ 500MG BASE	A065366	001	May 30, 2007	May DISC
	ZITHROMAX					
AB	+ PFIZER	EQ 250MG BASE	N050711	001	Jul 18, 1996	Apr CRLD
AB	+	EQ 500MG BASE	N050784	001	May 24, 2002	Apr CRLD

BACITRACIN

INJECTABLE;INJECTION

BACITRACIN

AP	AKORN	50,000 UNITS/VIAL	A206719	001	Oct 20, 2017	Oct NEWA
----	-------	-------------------	---------	-----	--------------	----------

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;TOPICAL

CORTISPORIN

+!	MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	N050168	002	May 04, 1984	Feb CAHN
----	----------------	--	---------	-----	--------------	----------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT	PERRIGO CO TENNESSEE	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764	002		Nov CPOT
	NEOSPORIN					
AT	+ CASPER PHARMA LLC	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050417	001		Apr CMFD

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

AP	EMERALD INTL LTD	0.05MG/ML	A091193	001	May 03, 2016	Mar CAHN
AP		0.5MG/ML	A091193	002	May 03, 2016	Mar CAHN
AP		2MG/ML	A091193	003	May 03, 2016	Mar CAHN
	GABLOFEN					
+!	MALLINCKRODT INC	1MG/ML	N022462	004	Jun 22, 2012	Mar CRLD
AP	PIRAMAL CRITICAL	0.05MG/ML	N022462	001	Nov 19, 2010	Apr CAHN
AP		0.5MG/ML	N022462	002	Nov 19, 2010	Apr CAHN
+!		1MG/ML	N022462	004	Jun 22, 2012	Apr CAHN
AP		2MG/ML	N022462	003	Nov 19, 2010	Apr CAHN

TABLET;ORAL

BACLOFEN

	@ MYLAN	10MG	A077181	001	Jul 29, 2005	May DISC
AB	OXFORD PHARMS	10MG	A077088	002	Oct 31, 2007	Apr CMS1
	RUBICON RES PVT LTD	5MG	A209102	001	Nov 28, 2017	Nov NEWA
AB		10MG	A209102	002	Nov 28, 2017	Nov NEWA
AB		20MG	A209102	003	Nov 28, 2017	Nov NEWA
AB	SUN PHARM INDS INC	10MG	A077862	001	Aug 14, 2006	Nov CMS1
AB	USL PHARMA	10MG	A074584	001	Aug 19, 1996	Jun CAHN
AB		20MG	A074584	002	Aug 19, 1996	Jun CAHN
>A>	VINTAGE PHARMS	10MG	A077068	002	Aug 30, 2005	Dec CMS1

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

AB	WEST-WARD PHARMS INT	750MG	A077806	001	Dec 28, 2007	Jul CTEC
BX		750MG	A077806	001	Dec 28, 2007	Apr CTEC

BARIUM SULFATE

FOR SUSPENSION;ORAL

E-Z-CAT DRY

+	@ BRACCO	40% (9GM/POUCH)	N208036	003	Jan 03, 2017	Nov DISC
+	!	40% (9GM/POUCH)	N208036	003	Jan 03, 2017	Aug NEWA
	E-Z-HD					
+	!	BRACCO	98%	(334GM/BOTTLE)	N208036	001 Jan 11, 2016 Apr CPOT
	E-Z-PAQUE					
+	!	BRACCO	96%	(169GM/BOTTLE)	N208036	002 Apr 07, 2017 Apr NEWA
	SUSPENSION;ORAL					
	LIQUID E-Z-PAQUE					
+	!	BRACCO	60%	(213GM/355ML)	N208143	003 Mar 01, 2017 Mar NEWA
	READI-CAT 2 SMOOTHIES					
+	!	BRACCO	2%	(9GM/450ML)	N208143	002 Jan 15, 2016 Nov CHRS
	TAGITOL V					
+	!	BRACCO	40%	(8GM/20ML)	N208143	005 Aug 04, 2017 Aug NEWA
	VARIBAR NECTAR					
+	!	BRACCO	40%	(96GM/240ML)	N208143	004 Jul 07, 2017 Jul NEWA

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED;INHALATION

QVAR REDIHALER

+	NORTON WATERFORD	0.04MG/INH	N207921	001	Aug 03, 2017	Aug NEWA
+	!	0.08MG/INH	N207921	002	Aug 03, 2017	Aug NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB	AMNEAL PHARMS	5MG	A076820	001	Feb 03, 2006	Apr CAHN
AB		10MG	A076820	002	Feb 03, 2006	Apr CAHN
AB		20MG	A076820	003	Feb 03, 2006	Apr CAHN
AB		40MG	A076820	004	Feb 03, 2006	Apr CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

LOTENSIN HCT

+	@ US PHARMS HOLDINGS I	5MG;6.25MG	N020033	001	May 19, 1992	May DISC
---	------------------------	------------	---------	-----	--------------	----------

BENDROFLUMETHIAZIDE; NADOLOL

TABLET;ORAL

CORZIDE

AB	+	KING PHARMS LLC	5MG;40MG	N018647	001	May 25, 1983	Mar CAHN
AB	+	!	5MG;80MG	N018647	002	May 25, 1983	Mar CAHN
		NADOLOL AND BENDROFLUMETHIAZIDE					
		@ MYLAN	5MG;40MG	A078688	001	Feb 15, 2008	Nov DISC
		@	5MG;80MG	A078688	002	Feb 15, 2008	Nov DISC

>A> BENOXINATE HYDROCHLORIDE; FLUORESCHEIN SODIUM

>A> SOLUTION/DROPS;OPHTHALMIC

>A> ALTAFLUOR BENOX

>A>	+	!	ALTAIRE PHARMS INC	0.4%;0.25%	N208582	001	Dec 14, 2017	Dec NEWA
-----	---	---	--------------------	------------	---------	-----	--------------	----------

BENZNIDAZOLE

TABLET;ORAL

BENZNIDAZOLE

+	CHEMO RESEARCH SL	12.5MG	N209570	001	Aug 29, 2017	Aug NEWA
+	!	100MG	N209570	002	Aug 29, 2017	Aug NEWA

BENZONATATE

CAPSULE;ORAL

TESSALON

AA	+	PFIZER	100MG	N011210	001		Apr CRLD
----	---	--------	-------	---------	-----	--	----------

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

>A>	AB	TARO	5%;1.2%	A206218	001	Dec 15, 2017	Dec NEWA
	AB	TOLMAR	5%;EQ 1% BASE	A204087	001	Jun 27, 2017	Jun NEWA

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

BENZPHETAMINE HYDROCHLORIDE

	AA	ANDA REPOSITORY	50MG	A040578	001	Apr 17, 2006	Sep CAHN
		@ EPIC PHARMA LLC	50MG	A040714	001	Oct 29, 2007	May CAHN
>D>	AA	MALLINCKRODT INC	50MG	A040773	001	Apr 25, 2007	Dec CAHN
>A>	AA	SPECGX LLC	50MG	A040773	001	Apr 25, 2007	Dec CAHN
	AA	TWI PHARMS INC	50MG	A040578	001	Apr 17, 2006	Mar CAHN

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

		@ ANDA REPOSITORY	1MG	A081264	001	Jan 23, 1992	Sep CAHN
		@	2MG	A081265	001	Jan 23, 1992	Sep CAHN
	AA	EPIC PHARMA LLC	0.5MG	A072264	001	Feb 27, 1989	May CAHN
	AA		1MG	A072265	001	Feb 27, 1989	May CAHN
	AA		2MG	A072266	001	Feb 27, 1989	May CAHN
		OXFORD PHARMS	0.5MG	A040706	002	Feb 14, 2008	May CMS1
			1MG	A040706	003	Feb 14, 2008	May CMS1
	AA	! UPSHER-SMITH LABS	0.5MG	A040103	001	Dec 12, 1996	Feb CAHN
	AA	!	1MG	A040103	002	Dec 12, 1996	Feb CAHN
	AA	!	2MG	A040103	003	Dec 12, 1996	Feb CAHN
	AA	! USL PHARMA	0.5MG	A040103	001	Dec 12, 1996	Jun CAHN
	AA	!	1MG	A040103	002	Dec 12, 1996	Jun CAHN
	AA	!	2MG	A040103	003	Dec 12, 1996	Jun CAHN

BETAINE HYDROCHLORIDE

FOR SOLUTION;ORAL

CYSTADANE

	+	ORPHAN EUROPE	1GM/SCOOPFUL	N020576	001	Oct 25, 1996	Jul CAHN
--	---	---------------	--------------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

AB	!	FOUGERA PHARMS INC	EQ 0.05% BASE	A070275	001	Aug 12, 1985	Jan CAHN
		@ TARO	EQ 0.05% BASE	A074272	001	Sep 30, 1994	Apr CAHN
		DIPROSONE					
	+	@ SCHERING	EQ 0.05% BASE	N017781	001		Jan CRLD

OINTMENT;TOPICAL

BETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS INC	EQ 0.05% BASE	N019141	001	Sep 04, 1984	Aug CAHN
AB		TARO	EQ 0.05% BASE	A074271	001	Sep 15, 1994	Apr CAHN

OINTMENT, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		TELLIGENT PHARMA INC	EQ 0.05% BASE	A206118	001	Nov 09, 2017	Oct NEWA
----	--	----------------------	---------------	---------	-----	--------------	----------

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

BETAMETHASONE VALERATE

AB		PERRIGO UK FINCO	0.12%	A078337	001	Nov 26, 2012	Apr CAHN
AB		RICONPHARMA LLC	0.12%	A207144	001	May 24, 2017	May NEWA
AB		TARO PHARM	0.12%	A208204	001	May 24, 2017	May NEWA

LUXIQ

AB	+	MYLAN PHARMS INC	0.12%	N020934	001	Feb 28, 1999	Jan CAHN
----	---	------------------	-------	---------	-----	--------------	----------

CREAM;TOPICAL

BETAMETHASONE VALERATE

AB	+	FOUGERA PHARMS INC	EQ 0.1% BASE	N018861	001	Aug 31, 1983	Aug CAHN
----	---	--------------------	--------------	---------	-----	--------------	----------

LOTION;TOPICAL

BETAMETHASONE VALERATE

AB	+	FOUGERA PHARMS INC	EQ 0.1% BASE	N018866	001	Aug 31, 1983	Aug CAHN
----	---	--------------------	--------------	---------	-----	--------------	----------

OINTMENT;TOPICAL

BETAMETHASONE VALERATE

AB	+	FOUGERA PHARMS INC	EQ 0.1% BASE	N018865	001	Aug 31, 1983	Aug CAHN
----	---	--------------------	--------------	---------	-----	--------------	----------

BETAXOLOL HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
BETAXOLOL HYDROCHLORIDE

AT	MEDIMETRIKS PHARMS	EQ 0.5% BASE	A 075630	001	Apr 12, 2001	Sep CAHN
AT	TELIGENT	EQ 0.5% BASE	A 075630	001	Apr 12, 2001	Apr CAHN

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

AA	ECI PHARMS LLC	5MG	A 040725	001	Oct 26, 2007	Sep CAHN
AA		10MG	A 040726	001	Oct 26, 2007	Sep CAHN
AA		25MG	A 040727	001	Oct 26, 2007	Sep CAHN
AA		50MG	A 040728	001	Oct 26, 2007	Sep CAHN
	@ IMPAX LABS	5MG	A 040721	001	Nov 01, 2006	Jan CMS1
	@	10MG	A 040721	002	Nov 01, 2006	Jan CMS1
	@	25MG	A 040721	003	Nov 01, 2016	Jan CMS1
AA	LANNETT HOLDINGS INC	5MG	A 040677	002	Mar 27, 2008	May CMS1
AA		10MG	A 040677	003	Mar 27, 2008	May CMS1
AA		25MG	A 040677	004	Mar 27, 2008	May CMS1
AA	UPSHER-SMITH LABS	5MG	A 040633	001	Jun 01, 2005	Jun CAHN
AA		10MG	A 040634	001	Jun 01, 2005	Jun CAHN
AA		25MG	A 040635	001	Jun 01, 2005	Jun CAHN
AA		50MG	A 040636	001	Jun 01, 2005	Jun CAHN

BETRIXABAN

CAPSULE;ORAL

BEVYXXA

+	PORTOLA PHARMS INC	40MG	N 208383	001	Jun 23, 2017	Jun NEWA
+	!	80MG	N 208383	002	Jun 23, 2017	Jun NEWA

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB	SANTOS BIOTECH	50MG	A 091011	001	Jun 10, 2015	May CAHN
AB	WATSON LABS TEVA	50MG	A 078634	001	Aug 28, 2009	May CAHN
	CASODEX					
AB	+! ASTRAZENECA PHARMS	50MG	N 020498	001	Oct 04, 1995	May CAHN

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

AT	SANDOZ INC	0.03%	A 202565	001	May 05, 2015	Mar CAHN
----	------------	-------	----------	-----	--------------	----------

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL

HELIDAC

+	@ CASPER PHARMA LLC	262.4MG,N/A,N/A;N/A,250MG,N/A;N/A, N/A,500MG	N 050719	001	Aug 15, 1996	Jul CAHN
---	---------------------	--	----------	-----	--------------	----------

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

	@ ANDA REPOSITORY	5MG	A 075474	001	Oct 25, 2002	Sep CAHN
	@	10MG	A 075474	002	Oct 25, 2002	Sep CAHN
AB	ORIT LABS LLC	5MG	A 204891	001	Jan 11, 2017	Jan NEWA
AB		10MG	A 204891	002	Jan 11, 2017	Jan NEWA

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

	@ WATSON LABS TEVA	2.5MG;6.25MG	A 075469	001	Sep 25, 2000	May CAHN
	@	5MG;6.25MG	A 075469	002	Sep 25, 2000	May CAHN
	@	10MG;6.25MG	A 075469	003	Sep 25, 2000	May CAHN
	ZIAC					
AB	+ TEVA BRANDED PHARM	2.5MG;6.25MG	N 020186	003	Mar 26, 1993	Jan CAHN
AB	+	5MG;6.25MG	N 020186	001	Mar 26, 1993	Jan CAHN
AB	+	10MG;6.25MG	N 020186	002	Mar 26, 1993	Jan CAHN

BIVALIRUDIN

INJECTABLE; INTRAVENOUS
BIVALIRUDIN

AP	ACCORD HLTHCARE	250MG/VIAL	A206551	001	Nov 22, 2017	Nov	NEWA
AP	APOTEX INC	250MG/VIAL	A204876	001	Jul 06, 2017	Jun	NEWA
AP	DR REDDYS LABS LTD	250MG/VIAL	A201577	001	May 26, 2017	May	NEWA
>A>	SOLUTION; IV (INFUSION)						
>A>	BIVALIRUDIN IN 0.9% SODIUM CHLORIDE						
>A>	+! CELERITY PHARMS	250MG/50ML (5MG/ML)	N208374	001	Dec 21, 2017	Dec	NEWA
>A>	+!	500MG/100ML (5MG/ML)	N208374	002	Dec 21, 2017	Dec	NEWA

BORTEZOMIB

POWDER; INTRAVENOUS
BORTEZOMIB

FRESENIUS KABI USA	3.5MG/VIAL	N205004	001	Nov 06, 2017	Nov	NEWA
--------------------	------------	---------	-----	--------------	-----	------

BOSENTAN

TABLET, FOR SUSPENSION; ORAL
TRACLEER

+! ACTELION PHARMS	32MG	N209279	001	Sep 05, 2017	Sep	NEWA
--------------------	------	---------	-----	--------------	-----	------

BOSUTINIB MONOHYDRATE

TABLET; ORAL
BOSULIF

+ PF PRISM CV	EQ 400MG BASE	N203341	003	Oct 27, 2017	Oct	NEWA
---------------	---------------	---------	-----	--------------	-----	------

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE

@ WEST-WARD PHARMS INT	50MG/ML	A070545	001	May 14, 1986	Jan	CAHN
------------------------	---------	---------	-----	--------------	-----	------

BREXPIRAZOLE

TABLET; ORAL
REXULTI

+! OTSUKA PHARM CO LTD	2MG	N205422	004	Jul 10, 2015	Aug	CHRS
+	4MG	N205422	006	Jul 10, 2015	Aug	CHRS

BRIGATINIB

TABLET; ORAL
ALUNBRIG

+ ARIAD	30MG	N208772	001	Apr 28, 2017	Apr	NEWA
+!	90MG	N208772	002	Apr 28, 2017	Apr	NEWA
+	180MG	N208772	003	Oct 02, 2017	Oct	NEWA

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC
BRIMONIDINE TARTRATE

AT	SANDOZ INC	0.2%	A076254	001	Sep 16, 2003	Feb	CAHN
AT		0.2%	A078075	001	Jan 30, 2008	Mar	CAHN
	QOLIANA						
AT	SANDOZ INC	0.15%	N021764	001	May 22, 2006	Mar	CAHN

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
BROMFENAC SODIUM

AT1	AMRING PHARMS	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Mar	CAHN
AT1	! APOTEX INC	EQ 0.09% ACID	A202435	001	Jun 19, 2014	Feb	CHRS
AT2	! HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Mar	CHRS

BROMPHENIRAMINE MALEATE

TABLET; ORAL
BROMPHENIRAMINE MALEATE

@ UPSHER-SMITH LABS	4MG	A083215	001		Jun	CAHN
---------------------	-----	---------	-----	--	-----	------

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

	BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE						
AA	TARO PHARM	2MG/5ML; 10MG/5ML; 30MG/5ML	A205112	001	Feb 27, 2017	Feb	NEWA

BUDESONIDECAPSULE; ORAL
BUDESONIDE

AB	AMNEAL PHARMS	3MG	A206200	001	Jul 31, 2017	Jul NEWA
AB	APPCO PHARMA LLC	3MG	A207367	001	Apr 07, 2017	Mar NEWA
AB	SCIECURE PHARMA INC	3MG	A209041	001	Sep 28, 2017	Sep NEWA
AB	ZYDUS PHARMS USA INC	3MG	A206134	001	May 04, 2017	Apr NEWA

SUSPENSION; INHALATION
BUDESONIDE

AN	CIPLA LTD	0.25MG/2ML	A205710	001	Nov 16, 2017	Oct NEWA
AN		0.5MG/2ML	A205710	002	Nov 16, 2017	Oct NEWA
AN		1MG/2ML	A205710	003	Nov 16, 2017	Oct NEWA

BUMETANIDEINJECTABLE; INJECTION
BUMETANIDE

AP	! ATHENEX INC	0.25MG/ML	A074441	001	Jan 27, 1995	Mar CAHN
AP	WEST-WARD PHARMS INT	0.25MG/ML	A079196	001	Apr 30, 2008	Jan CAHN

BUMEX

+ @ VALIDUS PHARMS 0.25MG/ML

N018226 001 Feb 28, 1983 Jun CAHN

TABLET; ORAL

BUMETANIDE

AB	AMNEAL PHARMS CO	0.5MG	A209724	001	Oct 18, 2017	Oct NEWA
AB		1MG	A209724	002	Oct 18, 2017	Oct NEWA
AB		2MG	A209724	003	Oct 18, 2017	Oct NEWA

BUMEX

AB	+ VALIDUS PHARMS	0.5MG	N018225	002	Feb 28, 1983	Jun CAHN
AB	+	1MG	N018225	001	Feb 28, 1983	Jun CAHN
AB	+	2MG	N018225	003	Jun 14, 1985	Jun CAHN

BUPIVACAINE HYDROCHLORIDEINJECTABLE; SPINAL
BUPIVACAINE HYDROCHLORIDE

AP	BAXTER HLTHCARE CORP	0.75%	A207266	001	Jul 25, 2016	Aug CAHN
----	----------------------	-------	---------	-----	--------------	----------

BUPRENORPHINESOLUTION, EXTENDED RELEASE; SUBCUTANEOUS
SUBLOCADE

+	INDIVIOR INC	100MG/0.5ML (100MG/0.5ML)	N209819	001	Nov 29, 2017	Nov NEWA
+	!	300MG/1.5ML (200MG/ML)	N209819	002	Nov 29, 2017	Nov NEWA

BUPRENORPHINE HYDROCHLORIDEFILM; BUCCAL
BELBUCA

+	BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015	Jan CAHN
+		EQ 0.15MG BASE	N207932	002	Oct 23, 2015	Jan CAHN
+		EQ 0.3MG BASE	N207932	003	Oct 23, 2015	Jan CAHN
+		EQ 0.45MG BASE	N207932	004	Oct 23, 2015	Jan CAHN
+		EQ 0.6MG BASE	N207932	005	Oct 23, 2015	Jan CAHN
+		EQ 0.75MG BASE	N207932	006	Oct 23, 2015	Jan CAHN
+	!	EQ 0.9MG BASE	N207932	007	Oct 23, 2015	Jan CAHN

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB	RHODES PHARMS	EQ 2MG BASE	A207276	001	Mar 27, 2017	Mar NEWA
AB		EQ 8MG BASE	A207276	002	Mar 27, 2017	Mar NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	AMNEAL PHARMS	EQ 8MG BASE; EQ 2MG BASE	A203136	002	Feb 22, 2013	May CAHN	
>A>	AB	MALLINCKRODT INC	EQ 2MG BASE; EQ 0.5MG BASE	A207000	001	Dec 13, 2017	Dec NEWA
>A>	AB		EQ 8MG BASE; EQ 2MG BASE	A207000	002	Dec 13, 2017	Dec NEWA
>A>	AB	SPECGX LLC	EQ 2MG BASE; EQ 0.5MG BASE	A207000	001	Dec 13, 2017	Dec CAHN
>A>	AB		EQ 8MG BASE; EQ 2MG BASE	A207000	002	Dec 13, 2017	Dec CAHN

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	AMNEAL PHARMS	EQ 2MG BASE; EQ 0.5MG BASE	A203136	001	Feb 22, 2013	May CAHN
	ZUBSOLV					
+	OREXO US INC	EQ 5.7MG BASE; EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jan CHRS
+	!	EQ 11.4MG BASE; EQ 2.9MG BASE	N204242	004	Dec 11, 2014	Jan CHRS

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

AB	INVAGEN PHARMS	75MG	A207389	001	Sep 18, 2017	Sep NEWA
AB		100MG	A207389	002	Sep 18, 2017	Sep NEWA
	WELLBUTRIN					
	+ @ GLAXOSMITHKLINE	50MG	N018644	001	Dec 30, 1985	Sep CRLD
	+ @	75MG	N018644	002	Dec 30, 1985	Sep CRLD
	+ @	100MG	N018644	003	Dec 30, 1985	Sep CRLD
	TABLET, EXTENDED RELEASE; ORAL					
	BUPROPION HYDROCHLORIDE					
AB3	ANBISON LAB CO LTD	150MG	A207224	001	Jun 30, 2017	Jun NEWA
AB3		300MG	A207224	002	Jun 30, 2017	Jun NEWA
AB3	JUBILANT GENERICS	150MG	A207459	001	Jun 30, 2017	Jun NEWA
AB3		300MG	A207459	002	Jun 30, 2017	Jun NEWA
AB3	LUPIN LTD	150MG	A090693	001	Apr 06, 2017	Mar NEWA
AB3		300MG	A090693	002	Apr 06, 2017	Mar NEWA
AB3	SCIEGEN PHARMS INC	150MG	A207479	001	Apr 12, 2017	Mar NEWA
AB3		300MG	A207479	002	Apr 12, 2017	Mar NEWA
AB3	SINOTHERAPEUTICS INC	150MG	A208652	001	Aug 21, 2017	Aug NEWA
AB3		300MG	A208652	002	Aug 21, 2017	Aug NEWA
AB2	TECH ORGANIZED	150MG	A206122	001	Aug 17, 2016	Sep CAHN
AB3	TWI PHARMS INC	150MG	A210081	001	Nov 03, 2017	Oct NEWA
AB3		300MG	A210081	002	Nov 03, 2017	Oct NEWA
	FORFIVO XL					
	+! ALVOGEN	450MG	N022497	001	Nov 10, 2011	Jan CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	5MG	A208829	001	May 24, 2017	May NEWA
AB		7.5MG	A208829	002	May 24, 2017	May NEWA
AB		10MG	A208829	003	May 24, 2017	May NEWA
AB		15MG	A208829	004	May 24, 2017	May NEWA
AB		30MG	A208829	005	May 24, 2017	May NEWA
	@ MYLAN	5MG	A075467	001	Feb 28, 2002	Jun DISC
	@	10MG	A075467	003	Feb 28, 2002	Jun DISC
	@	15MG	A075467	004	Feb 28, 2002	Jun DISC
AB	STRIDES PHARMA	5MG	A202330	001	Aug 25, 2014	Apr CAHN
AB		7.5MG	A202330	005	Feb 17, 2017	Sep NEWA
AB		10MG	A202330	002	Aug 25, 2014	Apr CAHN
AB		15MG	A202330	003	Aug 25, 2014	Apr CAHN
AB		30MG	A202330	004	Aug 25, 2014	Apr CAHN

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

AP	ACTAVIS LLC	6MG/ML	A205139	001	Dec 08, 2017	Nov NEWA
>A> AP	AMNEAL PHARMS CO	6MG/ML	A209580	001	Dec 18, 2017	Dec NEWA
AP	PHARMASCIENCE INC	6MG/ML	A207050	001	Mar 24, 2017	Mar NEWA
AP	SANDOZ INC	6MG/ML	A205106	001	Jul 07, 2017	Jun NEWA
	MYLERAN					
AP	ASPEN GLOBAL INC	6MG/ML	A208536	001	Nov 20, 2017	Nov NEWA

BUTABARBITAL SODIUM

TABLET; ORAL

BUTISOL SODIUM

	@ MYLAN SPECIALITY LP	15MG	N000793	002		Mar CAHN
	+!	30MG	N000793	004		Mar CAHN
	@	50MG	N000793	003		Mar CAHN
	@	100MG	N000793	005		Mar CAHN

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

	@ BAXTER HLTHCARE CORP	2MG/ML	A075697	001	Oct 23, 2001	Aug CAHN
	BUTORPHANOL TARTRATE PRESERVATIVE FREE					
	@ BAXTER HLTHCARE CORP	1MG/ML	A075695	001	Oct 23, 2001	Aug CAHN
	@	2MG/ML	A075695	002	Oct 23, 2001	Aug CAHN
AP	WEST-WARD PHARMS INT	1MG/ML	A075045	001	Aug 12, 1998	Jan CAHN
AP		2MG/ML	A075045	002	Aug 12, 1998	Jan CAHN

CAFFEINE CITRATESOLUTION;INTRAVENOUS
CAFFEINE CITRATE

>A> AP	MICRO LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A207400	001	Dec 14, 2017	Dec NEWA
--------	------------	------------------------------------	---------	-----	--------------	----------

CALCIPOTRIENEAEROSOL, FOAM;TOPICAL
SORILUX

+! MAYNE PHARMA 0.005%

N022563 001 Oct 06, 2010 Jan CAHN

OINTMENT;TOPICAL
CALCIPOTRIENE

! GLENMARK PHARMS INC 0.005%

A090633 001 Mar 24, 2010 May CAHN

SOLUTION;TOPICAL
CALCIPOTRIENE

>A> AT	NOVEL LABS INC	0.005%	A207163	001	Dec 26, 2017	Dec NEWA
--------	----------------	--------	---------	-----	--------------	----------

CALCITONIN SALMONSPRAY, METERED;NASAL
CALCITONIN-SALMON

AB ! APOTEX INC 200 IU/SPRAY

A076396 001 Nov 17, 2008 Apr CHRS

MIACALCIN

+ @ MYLAN IRELAND LTD 200 IU/SPRAY

N020313 002 Aug 17, 1995 Apr DISC

CALCITONIN SALMON RECOMBINANTSPRAY, METERED;NASAL
FORTICAL

@ UPSHER-SMITH LABS 200 IU/SPRAY

N021406 001 Aug 12, 2005 Jun CAHN

CALCITRIOLCAPSULE;ORAL
CALCITRIOL

AB AMNEAL PHARMS 0.25MCG

A203289 002 Jun 14, 2017 May NEWA

AB 0.5MCG

A203289 001 Jun 14, 2017 May NEWA

INJECTABLE;INJECTION
CALCIJEX

+ @ ABBVIE 0.001MG/ML

N018874 001 Sep 25, 1986 May CRLD

+ @ 0.002MG/ML

N018874 002 Sep 25, 1986 May CRLD

CALCITRIOL

! AKORN 0.001MG/ML

A078066 001 Jan 29, 2008 May CHRS

CALCIUM ACETATECAPSULE;ORAL
CALCIUM ACETATE

AB CHARTWELL RX 667MG

A091312 001 Jun 01, 2012 Mar CAHN

TABLET;ORAL

CALCIUM ACETATE

AB ! PADDOCK LLC 667MG

A091561 001 Apr 13, 2011 Apr CHRS

ELIPHOS

AB CYPRESS PHARM 667MG

A078502 001 Nov 25, 2008 Apr CHRS

CALCIUM CHLORIDEINJECTABLE;INJECTION
CALCIUM CHLORIDE 10%

AP LUITPOLD PHARMS INC 100MG/ML

A209088 001 Jul 27, 2017 Jul NEWA

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

AP +! HOSPIRA 100MG/ML

N021117 001 Jan 28, 2000 Jul CFTG

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

@ HOSPIRA 33MG/100ML;5GM/100ML;30MG/100ML;86 0MG/100ML N018254 001

Aug DISC

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

B BRAUN 33MG/100ML;5GM/100ML;30MG/100ML;86 0MG/100ML N020000 001 Apr 17, 1992 Aug CTEC

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

>D>	AP	ICU MEDICAL INC	20MG/100ML;5GM/100ML;30MG/100ML;60	N017608	001			Dec	CRLD
			00MG/100ML;310MG/100ML						
>A>	AP	+	20MG/100ML;5GM/100ML;30MG/100ML;60	N017608	001			Dec	CRLD
			00MG/100ML;310MG/100ML						
	AP		20MG/100ML;5GM/100ML;30MG/100ML;60	N017608	001			Feb	CAHN
			00MG/100ML;310MG/100ML						
		POTASSIUM CHLORIDE 10MEQ	IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
	@	ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;6	N019685	005	Oct 17, 1988		Feb	CAHN
			00MG/100ML;310MG/100ML						
	@		20MG/100ML;5GM/100ML;179MG/100ML;6	N019685	006	Oct 17, 1988		Feb	CAHN
			00MG/100ML;310MG/100ML						
		POTASSIUM CHLORIDE 15MEQ	IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
	@	ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;6	N019685	007	Oct 17, 1988		Feb	CAHN
			00MG/100ML;310MG/100ML						
		POTASSIUM CHLORIDE 20MEQ	IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
	AP	ICU MEDICAL INC	20MG/100ML;5GM/100ML;179MG/100ML;6	N019685	002	Oct 17, 1988		Feb	CAHN
			00MG/100ML;310MG/100ML						
	AP		20MG/100ML;5GM/100ML;328MG/100ML;6	N019685	008	Oct 17, 1988		Feb	CAHN
			00MG/100ML;310MG/100ML						
		POTASSIUM CHLORIDE 30MEQ	IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
	@	ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;6	N019685	003	Oct 17, 1988		Feb	CAHN
			00MG/100ML;310MG/100ML						
		POTASSIUM CHLORIDE 40MEQ	IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
	AP	ICU MEDICAL INC	20MG/100ML;5GM/100ML;328MG/100ML;6	N019685	004	Oct 17, 1988		Feb	CAHN
			00MG/100ML;310MG/100ML						
		POTASSIUM CHLORIDE 5MEQ	IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
	@	ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;6	N019685	001	Oct 17, 1988		Feb	CAHN
			00MG/100ML;310MG/100ML						

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

RINGER'S IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	33MG/100ML;30MG/100ML;860MG/100ML	N018251	001				Feb	CAHN
		SOLUTION;IRRIGATION							
		RINGER'S IN PLASTIC CONTAINER							
AT	ICU MEDICAL INC	33MG/100ML;30MG/100ML;860MG/100ML	N017635	001				Feb	CAHN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	20MG/100ML;30MG/100ML;600MG/100ML;	N017641	001				Feb	CAHN
		310MG/100ML							
		SOLUTION;IRRIGATION							
		LACTATED RINGER'S IN PLASTIC CONTAINER							
AT	+	ICU MEDICAL INC	20MG/100ML;30MG/100ML;600MG/100ML;	N019416	001	Jan 17, 1986		Feb	CAHN
			310MG/100ML						

CALCIUM GLUCONATE

SOLUTION;IV (INFUSION)

CALCIUM GLUCONATE

+	!	FRESENIUS KABI USA	1GM/10ML (100MG/ML)	N208418	001	Jun 15, 2017		Jun	NEWA
+	!		5GM/50ML (100MG/ML)	N208418	002	Jun 15, 2017		Jun	NEWA
+	!		10GM/100ML (100MG/ML)	N208418	003	Jun 15, 2017		Jun	NEWA

CANDESARTAN CILEXETIL

TABLET;ORAL

CANDESARTAN CILEXETIL

AB	ALEMBIC PHARMS LTD	32MG	A209119	001	Jun 20, 2017		Jun	NEWA
AB	ZYDUS PHARMS USA INC	4MG	A091390	001	Aug 23, 2017		Aug	NEWA
AB		8MG	A091390	002	Aug 23, 2017		Aug	NEWA
AB		16MG	A091390	003	Aug 23, 2017		Aug	NEWA
AB		32MG	A091390	004	Aug 23, 2017		Aug	NEWA

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB	MYLAN PHARMS INC	16MG;12.5MG	A090704	001	Dec 04, 2012		May	CAHN
AB		32MG;12.5MG	A090704	002	Dec 04, 2012		May	CAHN
AB		32MG;25MG	A090704	003	Dec 04, 2012		May	CAHN
AB	ZYDUS PHARMS USA INC	16MG;12.5MG	A203466	001	Nov 27, 2017		Nov	NEWA

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB		32MG;12.5MG	A203466	002	Nov 27, 2017	Nov NEWA
AB		32MG;25MG	A203466	003	Nov 27, 2017	Nov NEWA

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB	ALKEM LABS LTD	150MG	A207652	001	Nov 24, 2017	Nov NEWA
AB		500MG	A207652	002	Nov 24, 2017	Nov NEWA
AB	AMNEAL PHARMS	150MG	A204741	001	Feb 28, 2017	Feb NEWA
AB		500MG	A204741	002	Feb 28, 2017	Feb NEWA

CAPREOMYCIN SULFATE

INJECTABLE;INJECTION

CAPASTAT SULFATE

AP	+! AKORN	EQ 1GM BASE/VIAL	N050095	001		Nov CFTG
----	----------	------------------	---------	-----	--	----------

CAPREOMYCIN SULFATE

AP	MYLAN LABS LTD	EQ 1GM BASE/VIAL	A202634	001	Nov 27, 2017	Nov NEWA
----	----------------	------------------	---------	-----	--------------	----------

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

	@ BOSCOGEN	12.5MG	A074677	004	May 30, 1997	May CAHN
	@	25MG	A074677	002	May 30, 1997	May CAHN
	@	50MG	A074677	001	May 30, 1997	May CAHN
	@	100MG	A074677	003	May 30, 1997	May CAHN
>A>	@ FOSUN PHARMA	12.5MG	A074363	001	Nov 09, 1995	Dec CAHN
>A>	@	25MG	A074363	002	Nov 09, 1995	Dec CAHN
>A>	@	50MG	A074363	003	Nov 09, 1995	Dec CAHN
>A>	@	100MG	A074363	004	Nov 09, 1995	Dec CAHN
AB	MYLAN PHARMS INC	12.5MG	A074434	001	Feb 13, 1996	Mar CAHN
AB		25MG	A074434	002	Feb 13, 1996	Mar CAHN
AB		50MG	A074434	003	Feb 13, 1996	Mar CAHN
AB	!	100MG	A074434	004	Feb 13, 1996	Mar CAHN
>D>	@ SANDOZ	12.5MG	A074363	001	Nov 09, 1995	Dec CAHN
>D>	@	25MG	A074363	002	Nov 09, 1995	Dec CAHN
>D>	@	50MG	A074363	003	Nov 09, 1995	Dec CAHN
>D>	@	100MG	A074363	004	Nov 09, 1995	Dec CAHN
>D> AB	WOCKHARDT	12.5MG	A074532	001	Mar 28, 1997	Dec CAHN
>D> AB		25MG	A074532	002	Mar 28, 1997	Dec CAHN
>D> AB		50MG	A074532	003	Mar 28, 1997	Dec CAHN
>D> AB		100MG	A074532	004	Mar 28, 1997	Dec CAHN
>A> AB	WOCKHARDT LTD	12.5MG	A074532	001	Mar 28, 1997	Dec CAHN
>A> AB		25MG	A074532	002	Mar 28, 1997	Dec CAHN
>A> AB		50MG	A074532	003	Mar 28, 1997	Dec CAHN
>A> AB		100MG	A074532	004	Mar 28, 1997	Dec CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

EQUETRO

+	VALIDUS PHARMS	100MG	N021710	001	Dec 10, 2004	Jun CAHN
+		200MG	N021710	002	Dec 10, 2004	Jun CAHN
+!		300MG	N021710	003	Dec 10, 2004	Jun CAHN

SOLUTION;IV (INFUSION)

CARNEXIV

+	LUNDBECK PHARMS LLC	200MG/20ML (10MG/ML)	N206030	001	Oct 07, 2016	Jan CAHN
---	---------------------	----------------------	---------	-----	--------------	----------

SUSPENSION;ORAL

CARBAMAZEPINE

>D> AB	WOCKHARDT	100MG/5ML	A075714	001	Jun 05, 2002	Dec CAHN
>A> AB	WOCKHARDT BIO AG	100MG/5ML	A075714	001	Jun 05, 2002	Dec CAHN
	TERIL					
AB	TARO PHARM	100MG/5ML	A076729	001	Sep 20, 2004	Mar CAHN

CARBIDOPA

TABLET;ORAL

CARBIDOPA

AB	NOVEL LABS INC	25MG	A204763	001	Oct 20, 2017	Oct NEWA
----	----------------	------	---------	-----	--------------	----------

CARBOPLATININJECTABLE; INJECTION
CARBOPLATIN

@ WATSON LABS TEVA	50MG/VIAL	A076162	001	Oct 14, 2004	May CAHN
@	150MG/VIAL	A076162	002	Oct 14, 2004	May CAHN
@	450MG/VIAL	A076162	003	Oct 14, 2004	May CAHN

INJECTABLE; IV (INFUSION)
CARBOPLATIN

AP	ACCORD HLTHCARE	50MG/5ML (10MG/ML)	A206775	001	Feb 09, 2017	Jan NEWA
AP		150MG/15ML (10MG/ML)	A206775	002	Feb 09, 2017	Jan NEWA
AP		450MG/45ML (10MG/ML)	A206775	003	Feb 09, 2017	Jan NEWA
AP		600MG/60ML (10MG/ML)	A206775	004	Feb 09, 2017	Jan NEWA
AP	GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A207324	001	Feb 15, 2017	Jan NEWA
AP		150MG/15ML (10MG/ML)	A207324	002	Feb 15, 2017	Jan NEWA
AP		450MG/45ML (10MG/ML)	A207324	003	Feb 15, 2017	Jan NEWA
AP		600MG/60ML (10MG/ML)	A207324	004	Feb 15, 2017	Jan NEWA
AP	INGENUS PHARMS LLC	50MG/5ML (10MG/ML)	A208487	001	Apr 26, 2017	Apr NEWA
AP		150MG/15ML (10MG/ML)	A208487	002	Apr 26, 2017	Apr NEWA
AP		450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	Apr NEWA
AP		600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	Apr NEWA

CARISOPRODOLCAPSULE; ORAL
SOMA

@ MYLAN SPECIALITY LP	250MG	N011792	003		Mar CAHN
-----------------------	-------	---------	-----	--	----------

TABLET; ORAL

CARISOPRODOL

AA	@ EPIC PHARMA LLC	350MG	A040397	001	Sep 21, 2000	May CAHN
AB	HIKMA INTL PHARMS	350MG	A040124	001	Jan 24, 1996	Apr CMFD
AB	NOSTRUM LABS INC	250MG	A207237	001	May 11, 2017	Apr NEWA

SOMA

AB	+! MYLAN SPECIALITY LP	250MG	N011792	004	Sep 13, 2007	Mar CAHN
AA	+	350MG	N011792	001		Mar CAHN

CARTEOLOL HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
CARTEOLOL HYDROCHLORIDE

AT	! SANDOZ INC	1%	A075476	001	Jan 03, 2000	May CHRS
AT		1%	A075476	001	Jan 03, 2000	Mar CAHN
	OCUPRESS					
	+ @ NOVARTIS	1%	N019972	001	May 23, 1990	May DISC

CARVEDILOL

TABLET; ORAL

CARVEDILOL

@ PLIVA HRVATSKA DOO	3.125MG	A078240	001	Oct 30, 2007	Jul DISC
@	6.25MG	A078240	002	Oct 30, 2007	Jul DISC
@	12.5MG	A078240	003	Oct 30, 2007	Jul DISC
@	25MG	A078240	004	Oct 30, 2007	Jul DISC

CARVEDILOL PHOSPHATECAPSULE, EXTENDED RELEASE; ORAL
CARVEDILOL PHOSPHATE

AB	SUN PHARM INDUSTRIES	10MG	A090132	001	Oct 25, 2017	Oct NEWA
AB		20MG	A090132	002	Oct 25, 2017	Oct NEWA
AB		40MG	A090132	003	Oct 25, 2017	Oct NEWA
AB		80MG	A090132	004	Oct 25, 2017	Oct NEWA
	COREG CR					
AB	+ SMITHKLINE BEECHAM	10MG	N022012	001	Oct 20, 2006	Oct CFTG
AB	+	20MG	N022012	002	Oct 20, 2006	Oct CFTG
AB	+!	40MG	N022012	003	Oct 20, 2006	Oct CFTG
AB	+	80MG	N022012	004	Oct 20, 2006	Oct CFTG

CASPOFUNGIN ACETATEPOWDER; IV (INFUSION)
CANCIDAS

AP	+! MERCK	50MG/VIAL	N021227	001	Jan 26, 2001	Mar CDFR
AP	+!	70MG/VIAL	N021227	002	Jan 26, 2001	Mar CDFR
	CASPOFUNGIN ACETATE					
AP	GLAND PHARMA LTD	50MG/VIAL	A207092	001	Sep 29, 2017	Sep NEWA
AP		70MG/VIAL	A207092	002	Sep 29, 2017	Sep NEWA

POWDER;IV (INFUSION)
CASPOFUNGIN ACETATE

AP	MYLAN LABS LTD	50MG/VIAL	A207650	001	Sep 29, 2017	Sep NEWA
AP		70MG/VIAL	A207650	002	Sep 29, 2017	Sep NEWA

CEFACLOXFOR SUSPENSION;ORAL
CEFACLOX

	YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065412	001	Feb 17, 2012	Nov CTEC
		EQ 187MG BASE/5ML	A065412	002	Feb 17, 2012	Nov CTEC
		EQ 250MG BASE/5ML	A065412	003	Feb 17, 2012	Nov CTEC
!		EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012	Nov CTEC

CEFADROXIL/CEFADROXIL HEMIHYDRATECAPSULE;ORAL
CEFADROXIL

AB	CSPC OUYI PHARM CO	EQ 500MG BASE	A205072	001	Jul 28, 2017	Jul NEWA
>D> AB	SANDOZ	EQ 500MG BASE	A062291	001		Dec DISC
>A>	@	EQ 500MG BASE	A062291	001		Dec DISC

CEFAZOLIN SODIUMINJECTABLE;INJECTION
CEFAZOLIN SODIUM

!	ACS DOBFAR	EQ 20GM BASE/VIAL	A065306	002	Aug 18, 2014	Oct CHRS
@	FACTA FARMA	EQ 10GM BASE/VIAL	A063209	001	Dec 27, 1991	Oct DISC
@		EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Oct DISC

CEFDINIRCAPSULE;ORAL
OMNICEF

+	@ ABBVIE	300MG	N050739	001	Dec 04, 1997	Jan CRLD
---	----------	-------	---------	-----	--------------	----------

FOR SUSPENSION;ORAL
OMNICEF

+	@ ABBVIE	125MG/5ML	N050749	001	Dec 04, 1997	Jan CRLD
+	@	250MG/5ML	N050749	002	Jul 29, 2004	Jan CRLD

CEFIXIMEFOR SUSPENSION;ORAL
CEFIXIME

AB	BELCHER PHARMS LLC	100MG/5ML	A206938	001	Feb 06, 2017	Jan NEWA
AB		200MG/5ML	A206938	002	Feb 06, 2017	Jan NEWA
AB		500MG/5ML	A206939	001	Feb 06, 2017	Jan NEWA
AB	SANDOZ INC	100MG/5ML	A206144	001	Nov 17, 2017	Nov NEWA
AB		200MG/5ML	A206144	002	Nov 17, 2017	Nov NEWA
	SUPRAX					
AB	+! LUPIN LTD	500MG/5ML	N202091	001	Feb 20, 2013	Jan CFTG

CEFOTAXIME SODIUMINJECTABLE;INJECTION
CLAFORAN

@	SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A062659	001	Jan 13, 1987	Aug DISC
@		EQ 2GM BASE/VIAL	A062659	002	Jan 13, 1987	Aug DISC

CEFOTETAN DISODIUMINJECTABLE;INJECTION
CEFOTAN

AP	+ TELIGENT	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Apr CAHN
AP	+	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Apr CAHN
	@	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Apr CAHN
	CEFOTAN IN PLASTIC CONTAINER					
	@ TELIGENT	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Apr CAHN
	@	EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Apr CAHN

CEFOXITIN SODIUMINJECTABLE;INJECTION
CEFOXITIN

AP	WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL	A065051	001	Sep 11, 2000	Jan CAHN
AP		EQ 2GM BASE/VIAL	A065051	002	Sep 11, 2000	Jan CAHN
AP		EQ 10GM BASE/VIAL	A065050	001	Sep 11, 2000	Jan CAHN
	MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
+	@ MERCK	EQ 20MG BASE/ML	N050581	003	Sep 20, 1984	Sep CRLD
+	@	EQ 40MG BASE/ML	N050581	004	Sep 20, 1984	Sep CRLD

INJECTABLE;INJECTION

MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ @ MERCK	EQ 20MG BASE/ML	N050581	002	Sep 20, 1984	Sep CRLD
+ @	EQ 40MG BASE/ML	N050581	001	Sep 20, 1984	Sep CRLD

CEFPROZIL

TABLET;ORAL

CEFPROZIL

AB	AUROBINDO PHARMA LTD	250MG	A065340	001	May 24, 2007	Jan CAHN
AB		500MG	A065340	002	May 24, 2007	Jan CAHN

CEFTAZIDIME

INJECTABLE;INJECTION

FORTAZ

AP	+	TELIGENT	500MG/VIAL	N050578	001	Jul 19, 1985	Apr CAHN
AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Apr CAHN
AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Apr CAHN
AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Apr CAHN

CEFTAZIDIME SODIUM

INJECTABLE;INJECTION

FORTAZ IN PLASTIC CONTAINER

@ TELIGENT	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	May CAHN
+	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	May CAHN
+	EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	May CAHN

CEFTRIAZONE SODIUM

INJECTABLE;INJECTION

CEFTRIAZONE SODIUM

AP	HIKMA FARMACEUTICA	EQ 10GM BASE/VIAL	A090701	001	Oct 04, 2017	Sep NEWA
AP	SAGENT PHARMS	EQ 10GM BASE/VIAL	A091117	001	Jan 20, 2017	Jan NEWA
	ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER					
	+ @ HOFFMANN LA ROCHE	EQ 10MG BASE/ML	N050624	001	Feb 11, 1987	Jan CRLD
	+ @	EQ 20MG BASE/ML	N050624	002	Feb 11, 1987	Jan CRLD
	+ @	EQ 40MG BASE/ML	N050624	003	Feb 11, 1987	Jan CRLD

CEFUROXIME AXETIL

TABLET;ORAL

CEFUROXIME AXETIL

AB	AUROBINDO PHARMA LTD	EQ 125MG BASE	A065308	001	Mar 29, 2006	Jan CAHN
AB		EQ 250MG BASE	A065308	002	Mar 29, 2006	Jan CAHN
AB		EQ 500MG BASE	A065308	003	Mar 29, 2006	Jan CAHN

CEFUROXIME SODIUM

INJECTABLE;INJECTION

CEFUROXIME SODIUM

AP	ACS DOBFAR SPA	EQ 1.5GM BASE/VIAL	A064125	002	May 30, 1997	Sep CAHN	
AP		EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Sep CAHN	
	ZINACEF						
AP	+	TELIGENT	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	May CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	May CAHN
	ZINACEF IN PLASTIC CONTAINER						
	@ TELIGENT	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	May CAHN	
	+	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	May CAHN	
	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS						
	CEFUROXIME SODIUM						
AB	ACS DOBFAR SPA	EQ 750MG BASE/VIAL	A064125	001	May 30, 1997	Sep CAHN	
	ZINACEF						
AB	+	TELIGENT	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	May CAHN

CELECOXIB

CAPSULE;ORAL

CELECOXIB

AB	JUBILANT GENERICS	50MG	A207061	001	Apr 04, 2017	Mar NEWA
AB		100MG	A207061	002	Apr 04, 2017	Mar NEWA
AB		200MG	A207061	003	Apr 04, 2017	Mar NEWA
AB		400MG	A207061	004	Apr 04, 2017	Mar NEWA

CEPHALEXINCAPSULE;ORAL
CEPHALEXIN

AB	AUROBINDO PHARMA LTD	EQ 250MG BASE	A065253	001	Nov 16, 2005	Jan CAHN
AB		EQ 500MG BASE	A065253	002	Nov 16, 2005	Jan CAHN

FOR SUSPENSION;ORAL
CEPHALEXIN

AB	YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065336	001	Jul 25, 2007	Aug CMFD
AB		EQ 250MG BASE/5ML	A065336	002	Jul 25, 2007	Aug CMFD

CEPHAPIRIN SODIUMINJECTABLE;INJECTION
CEPHAPIRIN SODIUM

@	WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062720	001	Jul 02, 1987	Jan CAHN
@		EQ 1GM BASE/VIAL	A062720	002	Jul 02, 1987	Jan CAHN
@		EQ 2GM BASE/VIAL	A062720	003	Jul 02, 1987	Jan CAHN
@		EQ 20GM BASE/VIAL	A062720	004	Jul 02, 1987	Jan CAHN

CETIRIZINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
ZERVIAE

+	!	EYEVANCE PHARMS	EQ 0.24% BASE	N208694	001	May 30, 2017	Oct CAHN
+	!	NICOX OPHTHALMICS	EQ 0.24% BASE	N208694	001	May 30, 2017	May NEWA

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

AA	ALLIED PHARMA INC	5MG/5ML	A090191	001	Nov 12, 2009	Apr CAHN
----	-------------------	---------	---------	-----	--------------	----------

CEVIMELINE HYDROCHLORIDECAPSULE;ORAL
CEVIMELINE HYDROCHLORIDE

AB	RISING PHARMS INC	30MG	A203775	001	Jun 04, 2014	May CAHN
----	-------------------	------	---------	-----	--------------	----------

CHENODIOLTABLET;ORAL
CHENIX

+	@	LEADIANT BIOSCI INC	250MG	N018513	002	Jul 28, 1983	Feb CAHN
---	---	---------------------	-------	---------	-----	--------------	----------

CHLORAMPHENICOL SODIUM SUCCINATEINJECTABLE;INJECTION
CHLOROMYCETIN

+	@	PARKEDALE	EQ 1GM BASE/VIAL	N050155	001		Mar CRLD
---	---	-----------	------------------	---------	-----	--	----------

CHLORDIAZEPOXIDE HYDROCHLORIDECAPSULE;ORAL
CHLORDIAZEPOXIDE HYDROCHLORIDE

@	UPSHER-SMITH LABS	5MG	A084678	001		Jun CAHN
@		5MG	A084919	001		Aug CAHN
@		10MG	A084041	001		Jun CAHN
@		10MG	A084920	001		Aug CAHN
@		25MG	A084679	002		Jun CAHN
@		25MG	A084823	001		Aug CAHN

CHLORHEXIDINE GLUCONATESOLUTION;DENTAL
CHLORHEXIDINE GLUCONATE

>D>	AT	WOCKHARDT	0.12%	A075006	001	Mar 03, 2004	Dec CAHN
>A>	AT	WOCKHARDT BIO AG	0.12%	A075006	001	Mar 03, 2004	Dec CAHN
		PERIOGARD					
	AT	COLGATE PALMOLIVE CO	0.12%	A073695	001	Jan 14, 1994	May CAHN

CHLOROPROCAINE HYDROCHLORIDESOLUTION;INTRATHECAL
CLOROTEKAL

>A>	+	B BRAUN MEDICAL INC	50MG/5ML (10MG/ML)	N208791	001	Sep 26, 2017	Dec CAHN
>D>	+	SINTETICA SA	50MG/5ML (10MG/ML)	N208791	001	Sep 26, 2017	Dec CAHN
	+		50MG/5ML (10MG/ML)	N208791	001	Sep 26, 2017	Sep NEWA

CHLOROQUINE PHOSPHATE

TABLET; ORAL						
ARALEN						
	+ @ SANOFI AVENTIS US	EQ 300MG BASE	N006002	001		Sep DISC
CHLOROQUINE PHOSPHATE						
AA	! NATCO PHARMA LTD	EQ 300MG BASE	A090612	001	Jan 21, 2011	Sep CHRS

CHLOROTHIAZIDE

TABLET; ORAL						
CHLOROTHIAZIDE						
	! MYLAN	250MG	A084217	002		Sep CMS1

CHLORPHENESIN CARBAMATE

TABLET; ORAL						
MAOLATE						
	@ PAMLAB LLC	400MG	N014217	002		Mar CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL						
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE						
AA	ACELLA PHARMS LLC	4MG/5ML; 5MG/5ML	A206891	001	Jun 09, 2017	May NEWA
	@ TRIS PHARMA INC	4MG/5ML; 5MG/5ML	A206438	001	Jan 27, 2015	Sep DISC

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL						
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE						
AA	BIO-PHARM INC	4MG/5ML; 5MG/5ML; 60MG/5ML	A206660	001	May 15, 2017	May NEWA
	@ TRIS PHARMA INC	4MG/5ML; 5MG/5ML; 60MG/5ML	A203838	001	Nov 26, 2014	Sep DISC

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL						
CHLORPROMAZINE HYDROCHLORIDE						
	USL PHARMA	10MG	A083386	001		Jun CAHN
		10MG	A083386	001		May CTEC
	!	25MG	A084112	001		Jun CAHN
	!	25MG	A084112	001		May CHRS
		50MG	A084113	001		Jun CAHN
		50MG	A084113	001		May CTEC
	!	100MG	A084114	001		Jun CAHN
	!	100MG	A084114	001		May CHRS
		200MG	A084115	001		Jun CAHN
		200MG	A084115	001		May CTEC
THORAZINE						
	@ GLAXOSMITHKLINE	10MG	N009149	002		May CRLD
	@	25MG	N009149	007		May CRLD
	@	50MG	N009149	013		May CRLD
	@	100MG	N009149	018		May CRLD
	@	200MG	N009149	020		May CRLD

CHLORPROPAMIDE

TABLET; ORAL						
CHLORPROPAMIDE						
	@ ANI PHARMS INC	250MG	A087353	001		Jan CAHN
	@ WATSON LABS TEVA	250MG	A088826	001	Sep 26, 1984	May CAHN
GLUCAMIDE						
AB	ANI PHARMS INC	250MG	A088641	001	Oct 11, 1984	Jul CMFD

CHLORTHALIDONE

TABLET; ORAL						
CHLORTHALIDONE						
AB	RICONPHARMA LLC	25MG	A206904	001	Mar 30, 2017	Mar NEWA
AB		50MG	A206904	002	Mar 30, 2017	Mar NEWA

CHOLESTYRAMINE

POWDER; ORAL						
CHOLESTYRAMINE LIGHT						
AB	ZYDUS PHARMS USA INC	EQ 4GM RESIN/SCOOPFUL	A202902	001	Apr 25, 2017	Aug CTNA
AB		EQ 4GM RESIN/SCOOPFUL	A202902	001	Apr 25, 2017	Apr NEWA
PREVALITE						
AB	UPSHER-SMITH LABS	EQ 4GM RESIN/PACKET	A073263	001	Feb 22, 1996	Jun CAHN
AB		EQ 4GM RESIN/SCOOPFUL	A073263	002	Oct 30, 1997	Jun CAHN

CHOLINE C-11INJECTABLE;INTRAVENOUS
CHOLINE C-11

AP	UCSF RODIOPHARM	4-33.1mCi/ML	A208444	001	Nov 20, 2017	Nov NEWA
	UNIV TX MD ANDERSON	4-100mCi/ML	A205690	001	Oct 29, 2015	Jul CPOT

CHOLINE FENOFIBRATECAPSULE, DELAYED RELEASE;ORAL
FENOFIBRIC ACID

AB	ALEMBIC PHARMS LTD	EQ 45MG FENOFIBRIC ACID	A208705	001	May 12, 2017	May NEWA
AB		EQ 135MG FENOFIBRIC ACID	A208705	002	May 12, 2017	May NEWA

CICLESONIDEAEROSOL, METERED;INHALATION
ALVESCO

+	ASTRAZENECA PHARMS	0.08MG/INH	N021658	002	Jan 10, 2008	Jul CAHN
+		0.16MG/INH	N021658	003	Jan 10, 2008	Jul CAHN

AEROSOL, METERED;NASAL
ZETONNA

+	ASTRAZENECA PHARMS	0.037MG/INH	N202129	001	Jan 20, 2012	Jul CAHN
---	--------------------	-------------	---------	-----	--------------	----------

SPRAY, METERED;NASAL
OMNARIS

+	ASTRAZENECA PHARMS	0.05MG/INH	N022004	001	Oct 20, 2006	Jul CAHN
---	--------------------	------------	---------	-----	--------------	----------

CICLOPIROXCREAM;TOPICAL
CICLOPIROX

AB	PERRIGO NEW YORK	0.77%	A077364	001	Mar 03, 2006	Apr CAHN
----	------------------	-------	---------	-----	--------------	----------

GEL;TOPICAL
CICLOPIROX

AB	+	CNTY LINE PHARMS	0.77%	N020519	001	Jul 21, 1997	Sep CTNA
----	---	------------------	-------	---------	-----	--------------	----------

SHAMPOO;TOPICAL
CICLOPIROX

AT	PERRIGO CO	1%	A078594	001	Feb 16, 2010	Apr CAHN
----	------------	----	---------	-----	--------------	----------

CILOSTAZOLTABLET;ORAL
CILOSTAZOL

AB	CHARTWELL RX	50MG	A077722	001	Sep 24, 2012	Sep CAHN
----	--------------	------	---------	-----	--------------	----------

AB		100MG	A077831	001	Sep 24, 2012	Sep CAHN
----	--	-------	---------	-----	--------------	----------

@	EPIC PHARMA LLC	50MG	A077150	001	Mar 11, 2005	May CAHN
---	-----------------	------	---------	-----	--------------	----------

@		100MG	A077022	001	Nov 23, 2004	May CAHN
---	--	-------	---------	-----	--------------	----------

@	MYLAN	50MG	A077323	002	Apr 20, 2006	May DISC
---	-------	------	---------	-----	--------------	----------

@		100MG	A077323	001	Apr 20, 2006	May DISC
---	--	-------	---------	-----	--------------	----------

@	MYLAN PHARMS INC	50MG	A077019	001	Nov 23, 2004	Mar DISC
---	------------------	------	---------	-----	--------------	----------

@		100MG	A077019	002	Nov 23, 2004	Mar DISC
---	--	-------	---------	-----	--------------	----------

@	PLIVA HRVATSKA DOO	50MG	A077898	001	Oct 29, 2007	Mar DISC
---	--------------------	------	---------	-----	--------------	----------

@		100MG	A077898	002	Oct 29, 2007	Mar DISC
---	--	-------	---------	-----	--------------	----------

PLETAL

+	@ OTSUKA	50MG	N020863	001	Jan 15, 1999	Jan CRLD
---	----------	------	---------	-----	--------------	----------

+	@	100MG	N020863	002	Jan 15, 1999	Jan CRLD
---	---	-------	---------	-----	--------------	----------

CIMETIDINETABLET;ORAL
CIMETIDINE

@	CHARTWELL MOLECULES	200MG	A074281	001	May 17, 1994	Jan CAHN
---	---------------------	-------	---------	-----	--------------	----------

@		300MG	A074281	002	May 17, 1994	Jan CAHN
---	--	-------	---------	-----	--------------	----------

@		400MG	A074281	003	May 17, 1994	Jan CAHN
---	--	-------	---------	-----	--------------	----------

@		800MG	A074329	001	May 17, 1994	Jan CAHN
---	--	-------	---------	-----	--------------	----------

>A>	@	FOSUN PHARMA	200MG	A074100	001	Jan 31, 1995	Dec CAHN
-----	---	--------------	-------	---------	-----	--------------	----------

>A>	@		300MG	A074100	002	Jan 31, 1995	Dec CAHN
-----	---	--	-------	---------	-----	--------------	----------

>A>	@		400MG	A074100	003	Jan 31, 1995	Dec CAHN
-----	---	--	-------	---------	-----	--------------	----------

>A>	@		800MG	A074100	004	Jan 31, 1995	Dec CAHN
-----	---	--	-------	---------	-----	--------------	----------

>D>	@	SANDOZ	200MG	A074100	001	Jan 31, 1995	Dec CAHN
-----	---	--------	-------	---------	-----	--------------	----------

>D>	@		300MG	A074100	002	Jan 31, 1995	Dec CAHN
-----	---	--	-------	---------	-----	--------------	----------

>D>	@		400MG	A074100	003	Jan 31, 1995	Dec CAHN
-----	---	--	-------	---------	-----	--------------	----------

>D>	@		800MG	A074100	004	Jan 31, 1995	Dec CAHN
-----	---	--	-------	---------	-----	--------------	----------

@	SANDOZ INC	200MG	A074250	001	Jun 29, 1995	Mar CAHN
---	------------	-------	---------	-----	--------------	----------

@		300MG	A074250	002	Jun 29, 1995	Mar CAHN
---	--	-------	---------	-----	--------------	----------

@		400MG	A074250	003	Jun 29, 1995	Mar CAHN
---	--	-------	---------	-----	--------------	----------

@		800MG	A074250	004	Jun 29, 1995	Mar CAHN
---	--	-------	---------	-----	--------------	----------

TABLET;ORAL

CIMETIDINE

@ UPSHER-SMITH LABS	200MG	A074506	001	Jan 24, 1996	Jun CAHN
@	300MG	A074506	002	Jan 24, 1996	Jun CAHN
@	400MG	A074506	003	Jan 24, 1996	Jun CAHN
@	800MG	A074506	004	Jan 24, 1996	Jun CAHN

CIMETIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CIMETIDINE HYDROCHLORIDE

DAVA PHARMS INC	EQ 300MG BASE/2ML	A074428	001	Apr 25, 1996	Nov CTEC
-----------------	-------------------	---------	-----	--------------	----------

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

AA	PHARM ASSOC	EQ 300MG BASE/5ML	A074553	001	Jan 27, 1997	May CAHN
>D> AA	WOCKHARDT	EQ 300MG BASE/5ML	A074757	001	Oct 17, 1997	Dec CAHN
>A> AA	WOCKHARDT BIO AG	EQ 300MG BASE/5ML	A074757	001	Oct 17, 1997	Dec CAHN

CIPROFLOXACIN

INJECTABLE;INJECTION

CIPRO

+ @ BAYER HLTHCARE	400MG/40ML (10MG/ML)	N019847	001	Dec 26, 1990	Feb DISC
+ @	200MG/20ML (10MG/ML)	N019847	002	Dec 26, 1990	Feb DISC
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER					
+ @ BAYER HLTHCARE	200MG/100ML	N019857	001	Dec 26, 1990	Feb DISC
+ @	400MG/200ML	N019857	002	Dec 26, 1990	Feb DISC

CIPROFLOXACIN

AP	!	BAXTER HLTHCARE CORP	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Aug CAHN
AP	!		400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Aug CAHN
AP	!	CLARIS	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Feb CHRS
AP	!		400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Feb CHRS
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP		BAXTER HLTHCARE CORP	200MG/100ML	A078024	001	Mar 18, 2008	Aug CAHN
AP			400MG/200ML	A078024	002	Mar 18, 2008	Aug CAHN
AP	!	HOSPIRA	200MG/100ML	A077753	001	Mar 18, 2008	Feb CHRS
AP	!		400MG/200ML	A077753	002	Mar 18, 2008	Feb CHRS

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

@ AMRING PHARMS	EQ 0.3% BASE	A078598	001	Jan 16, 2008	Oct DISC	
AT	EQ 0.3% BASE	A078598	001	Jan 16, 2008	Mar CAHN	
AT	TELIGENT	EQ 0.3% BASE	A076754	001	Jun 09, 2004	Apr CAHN

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

@ MYLAN	EQ 250MG BASE	A075685	002	Jun 09, 2004	Aug DISC	
@	EQ 500MG BASE	A075685	003	Jun 09, 2004	Aug DISC	
@	EQ 750MG BASE	A075685	001	Jun 09, 2004	Aug DISC	
AB	TARO PHARM	EQ 100MG BASE	A076912	001	Feb 18, 2005	Mar CAHN
AB		EQ 250MG BASE	A076912	002	Oct 06, 2004	Mar CAHN
AB		EQ 500MG BASE	A076912	003	Oct 06, 2004	Mar CAHN
AB		EQ 750MG BASE	A076912	004	Oct 06, 2004	Mar CAHN
AB	UNIQUE PHARM LABS	EQ 250MG BASE	A076639	001	Sep 10, 2004	Aug CAHN
AB		EQ 500MG BASE	A076639	002	Sep 10, 2004	Aug CAHN
AB		EQ 750MG BASE	A076639	003	Sep 10, 2004	Aug CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205873	001	Jun 16, 2017	Jun NEWA
AP	JIANGSU HENGRUI MED	EQ 2MG BASE/ML	A209334	001	Aug 30, 2017	Aug NEWA
CISATRACURIUM BESYLATE PRESERVATIVE FREE						
AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205872	001	Jun 16, 2017	Jun NEWA
AP		EQ 10MG BASE/ML	A205872	002	Jun 16, 2017	Jun NEWA
AP	JIANGSU HENGRUI MED	EQ 2MG BASE/ML	A204960	001	Jan 27, 2017	Jan NEWA
AP		EQ 10MG BASE/ML	A204960	002	Sep 19, 2017	Nov CAIN

CISATRACURIUM BESYLATE PRESERVATIVE FREE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP	JIANGSU HENGRUI MED	EQ 10MG BASE/ML	A204960	002	Sep 19, 2017	Sep NEWA
----	---------------------	-----------------	---------	-----	--------------	----------

CISPLATIN

INJECTABLE; INJECTION							
CISPLATIN							
AP	GLAND PHARMA LTD	1MG/ML	A207323	001	Mar 17, 2017	Mar	NEWA
AP	+ HQ SPCLT PHARMA	1MG/ML	N018057	004	Nov 08, 1988	Mar	CRLD
PLATINOL							
	+ @ HQ SPCLT PHARMA	10MG/VIAL	N018057	001			Mar CRLD
	+ @	50MG/VIAL	N018057	002			Mar CRLD
PLATINOL-AQ							
	+ @ HQ SPCLT PHARMA	0.5MG/ML	N018057	003	Jul 18, 1984	Mar	CRLD

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL							
CITALOPRAM HYDROBROMIDE							
	@ MYLAN PHARMS INC	EQ 10MG BASE	A077668	001	Feb 28, 2007	Mar	DISC
	@	EQ 20MG BASE	A077668	002	Feb 28, 2007	Mar	DISC
	@	EQ 40MG BASE	A077668	003	Feb 28, 2007	Mar	DISC
SOLUTION; ORAL							
CITALOPRAM HYDROBROMIDE							
AA	AUROBINDO PHARMA LTD	EQ 10MG BASE/5ML	A077812	001	Aug 28, 2006	Jan	CAHN
TABLET; ORAL							
CITALOPRAM HYDROBROMIDE							
	@ EPIC PHARMA LLC	EQ 10MG BASE	A077036	001	Oct 28, 2004	May	CAHN
	@	EQ 20MG BASE	A077036	002	Oct 28, 2004	May	CAHN
	@	EQ 40MG BASE	A077036	003	Oct 28, 2004	May	CAHN
	@ MYLAN	EQ 10MG BASE	A077039	001	Feb 03, 2005	Jun	DISC
	@	EQ 20MG BASE	A077039	002	Feb 03, 2005	Jun	DISC
	@	EQ 40MG BASE	A077039	003	Feb 03, 2005	Jun	DISC
	@ MYLAN PHARMS INC	EQ 10MG BASE	A077037	001	Nov 05, 2004	May	DISC
	@	EQ 20MG BASE	A077037	002	Nov 05, 2004	May	DISC
	@	EQ 40MG BASE	A077037	003	Nov 05, 2004	May	DISC

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION; ORAL							
PREPOPIK							
+	FERRING PHARMS INC	12GM/PACKET; 3.5GM/PACKET; 10MG/PACK ET	N202535	001	Jul 16, 2012	Mar	CAHN
SOLUTION; ORAL							
CLENPIQ							
+	FERRING PHARMS INC	12GM/160ML; 3.5GM/160ML; 10MG/160ML	N209589	001	Nov 28, 2017	Nov	NEWA

CLARITHROMYCIN

TABLET; ORAL							
CLARITHROMYCIN							
	@ MYLAN	250MG	A065195	001	Mar 11, 2005	May	DISC
	@	500MG	A065195	002	Mar 11, 2005	May	DISC

CLEMASTINE FUMARATE

TABLET; ORAL							
CLEMASTINE FUMARATE							
	@ SANDOZ	2.68MG	A073459	001	Oct 31, 1993	Feb	DISC
!	TEVA	2.68MG	A073283	001	Jan 31, 1992	Feb	CTEC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL							
CLINDAMYCIN HYDROCHLORIDE							
AB	EPIC PHARMA LLC	EQ 150MG BASE	A065194	001	Mar 22, 2004	May	CAHN
AB		EQ 300MG BASE	A065194	002	Mar 22, 2004	May	CAHN
AB	LANNETT	EQ 75MG BASE	A065243	002	Aug 12, 2005	Aug	CMS1
	@ MYLAN PHARMS INC	EQ 75MG BASE	A091225	001	May 31, 2011	May	DISC
	@	EQ 150MG BASE	A091225	002	May 31, 2011	May	DISC
	@	EQ 300MG BASE	A091225	003	May 31, 2011	May	DISC
CLINDAMYCIN HYDROCLHORIDE							
AB	LANNETT	EQ 150MG BASE	A065243	003	Aug 12, 2005	Aug	CMS1

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL							
CLINDAMYCIN PALMITATE HYDROCHLORIDE							
AA	INVAGEN PHARMS	EQ 75MG BASE/5ML	A206958	001	May 05, 2017	Apr	NEWA
AA	ORIT LABS LLC	EQ 75MG BASE/5ML	A206958	001	May 05, 2017	Jun	CAHN
AA	PADDOCK LLC	EQ 75MG BASE/5ML	A090902	001	Jul 07, 2010	Apr	CAHN

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL							
EVOCLIN							
AT	+	MYLAN PHARMS INC	1%	N050801	001	Oct 22, 2004	Jan CAHN
INJECTABLE;INJECTION							
CLINDAMYCIN PHOSPHATE							
AP		MYLAN LABS LTD	EQ 150MG BASE/ML	A204748	001	Oct 10, 2017	Sep NEWA
AP			EQ 150MG BASE/ML	A204749	001	Oct 10, 2017	Sep NEWA
AP		SAGENT PHARMS	EQ 150MG BASE/ML	A090109	001	Sep 30, 2011	Apr CAHN
AP		WEST-WARD PHARMS INT	EQ 150MG BASE/ML	A065206	001	Sep 24, 2004	Jan CAHN
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER							
AP		BAXTER HLTHCARE CORP	EQ 6MG BASE/ML	A208084	001	Jun 28, 2017	Jul CAHN
AP			EQ 12MG BASE/ML	A208084	002	Jun 28, 2017	Jul CAHN
AP			EQ 18MG BASE/ML	A208084	003	Jun 28, 2017	Jul CAHN
AP		CELERITY PHARMS	EQ 6MG BASE/ML	A208084	001	Jun 28, 2017	Jun NEWA
AP			EQ 12MG BASE/ML	A208084	002	Jun 28, 2017	Jun NEWA
AP			EQ 18MG BASE/ML	A208084	003	Jun 28, 2017	Jun NEWA
SOLUTION;IV (INFUSION)							
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE							
+	!	BAXTER HLTHCARE CORP	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)	N208083	001	Apr 20, 2017	May CAHN
+	!		EQ 600MG BASE/50ML (EQ 12MG BASE/ML)	N208083	002	Apr 20, 2017	May CAHN
+	!		EQ 900MG BASE/50ML (EQ 18MG BASE/ML)	N208083	003	Apr 20, 2017	May CAHN
+	!	CELERITY PHARMS	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)	N208083	001	Apr 20, 2017	Apr NEWA
+	!		EQ 600MG BASE/50ML (EQ 12MG BASE/ML)	N208083	002	Apr 20, 2017	Apr NEWA
+	!		EQ 900MG BASE/50ML (EQ 18MG BASE/ML)	N208083	003	Apr 20, 2017	Apr NEWA
SOLUTION;TOPICAL							
CLINDAMYCIN PHOSPHATE							
AT		FOUGERA PHARMS INC	EQ 1% BASE	A064159	001	Jun 05, 1997	Jan CAHN
		@ NOVAST LABS LTD	EQ 1% BASE	A064108	001	Sep 27, 1996	Sep CAHN
SWAB;TOPICAL							
CLINDETS							
AT		PERRIGO CO	EQ 1% BASE	A064136	001	Sep 30, 1996	Apr CAHN

CLOBAZAM

SUSPENSION;ORAL							
ONFI							
+	!	LUNDBECK PHARMS LLC	2.5MG/ML	N203993	001	Dec 14, 2012	Jan CAHN
TABLET;ORAL							
ONFI							
		@ LUNDBECK PHARMS LLC	5MG	N202067	001	Oct 21, 2011	Jan CAHN
+			10MG	N202067	002	Oct 21, 2011	Jan CAHN
+	!		20MG	N202067	003	Oct 21, 2011	Jan CAHN

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL							
CLOBETASOL PROPIONATE							
AB1		INGENUS PHARMS LLC	0.05%	A206805	001	Jul 31, 2017	Jul NEWA
OLUX							
AB1	+	MYLAN PHARMS INC	0.05%	N021142	001	May 26, 2000	Jan CAHN
OLUX E							
AB2	+	MYLAN PHARMS INC	0.05%	N022013	001	Jan 12, 2007	Jan CAHN
CREAM;TOPICAL							
CLOBETASOL PROPIONATE							
AB1		FOUGERA PHARMS INC	0.05%	A074392	001	Sep 30, 1996	Jan CAHN
AB1		MYLAN PHARMS INC	0.05%	A075338	001	Feb 09, 2001	May CMFD
		@	0.05%	A075338	001	Feb 09, 2001	Jan CAHN
AB1		TARO	0.05%	A074249	001	Jul 08, 1996	Apr CAHN
CLOBETASOL PROPIONATE (EMOLLIENT)							
		@ NOVAST LABS LTD	0.05%	A075733	001	Aug 22, 2001	Sep CAHN
AB2		TELIGENT PHARMA INC	0.05%	A209411	001	Aug 21, 2017	Aug NEWA
IMPOYZ							
+	!	PROMIUS PHARMA LLC	0.025%	N209483	001	Nov 28, 2017	Nov NEWA
GEL;TOPICAL							
CLOBETASOL PROPIONATE							
AB		PERRIGO CO	0.05%	A075027	001	Oct 31, 1997	Apr CAHN
AB		TARO	0.05%	A075279	001	May 28, 1999	Apr CAHN

GEL;TOPICAL							
CLOBETASOL PROPIONATE							
AB	TELIGENT PHARMA INC	0.05%	A208881	001	Mar 06, 2017	Feb	NEWA
LOTION;TOPICAL							
CLOBETASOL PROPIONATE							
AB	LUPIN LTD	0.05%	A209147	001	Sep 22, 2017	Sep	NEWA
OINTMENT;TOPICAL							
CLOBETASOL PROPIONATE							
AB	GLENMARK PHARMS	0.05%	A208933	001	Mar 20, 2017	Mar	NEWA
AB	MYLAN PHARMS INC	0.05%	A075057	001	Aug 12, 1998	Nov	CTEC
AB1		0.05%	A075057	001	Aug 12, 1998	May	CMFD
	@	0.05%	A075057	001	Aug 12, 1998	Jan	CAHN
AB	TARO	0.05%	A074248	001	Jul 12, 1996	Apr	CAHN
AB	ZYDUS PHARMS USA INC	0.05%	A210199	001	Oct 27, 2017	Oct	NEWA
TEMOVATE							
	+ @ FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Jan	CRLD
SHAMPOO;TOPICAL							
CLOBETASOL PROPIONATE							
AB	HI-TECH PHARMACAL	0.05%	A209871	001	Oct 27, 2017	Oct	NEWA
SOLUTION;TOPICAL							
CLOBETASOL PROPIONATE							
AT	MACLEODS PHARMS LTD	0.05%	A209361	001	Oct 25, 2017	Oct	NEWA
AT	TARO	0.05%	A075224	001	Nov 16, 1998	Apr	CAHN
>D> AT	WOCKHARDT	0.05%	A075205	001	Nov 13, 1998	Dec	CAHN
>A> AT	WOCKHARDT BIO AG	0.05%	A075205	001	Nov 13, 1998	Dec	CAHN
SPRAY;TOPICAL							
CLOBETASOL PROPIONATE							
AT	AKORN	0.05%	A207218	001	Apr 28, 2017	Apr	NEWA
AT	ZYDUS PHARMS USA INC	0.05%	A206378	001	Feb 16, 2017	Feb	NEWA
<u>CLOFARABINE</u>							
INJECTABLE;IV (INFUSION)							
CLOFARABINE							
AP	ABON PHARMS LLC	20MG/20ML (1MG/ML)	A204029	001	May 09, 2017	Apr	NEWA
AP	AMNEAL PHARMS CO	20MG/20ML (1MG/ML)	A208857	001	Nov 06, 2017	Oct	NEWA
AP	DR REDDYS LABS LTD	20MG/20ML (1MG/ML)	A205375	001	Nov 06, 2017	Oct	NEWA
AP	MSN LABS PVT LTD	20MG/20ML (1MG/ML)	A209775	001	Dec 06, 2017	Nov	NEWA
AP	MYLAN LABS LTD	20MG/20ML (1MG/ML)	A208860	001	Nov 06, 2017	Oct	NEWA
CLOLAR							
AP	+! GENZYME	20MG/20ML (1MG/ML)	N021673	001	Dec 28, 2004	Apr	CFTG
<u>CLOFAZIMINE</u>							
CAPSULE;ORAL							
LAMPRENE							
	+ @ NOVARTIS	50MG	N019500	002	Dec 15, 1986	Aug	DISC
<u>CLOFIBRATE</u>							
CAPSULE;ORAL							
CLOFIBRATE							
	@ USL PHARMA	500MG	A070531	001	Jun 16, 1986	Jun	CAHN
<u>CLOMIPRAMINE HYDROCHLORIDE</u>							
CAPSULE;ORAL							
ANAFRANIL							
>D> AB	+! MALLINCKRODT LLC	25MG	N019906	001	Dec 29, 1989	Dec	CAHN
>D> AB	+	50MG	N019906	002	Dec 29, 1989	Dec	CAHN
>D> AB	+	75MG	N019906	003	Dec 29, 1989	Dec	CAHN
>A> AB	+! SPECGX LLC	25MG	N019906	001	Dec 29, 1989	Dec	CAHN
>A> AB	+	50MG	N019906	002	Dec 29, 1989	Dec	CAHN
>A> AB	+	75MG	N019906	003	Dec 29, 1989	Dec	CAHN
CLOMIPRAMINE HYDROCHLORIDE							
AB	SANDOZ	25MG	A074953	001	Jun 25, 1997	Feb	CMFD
AB		50MG	A074953	002	Jun 25, 1997	Feb	CMFD
AB		75MG	A074953	003	Jun 25, 1997	Feb	CMFD
>A> AB	ZYDUS PHARMS USA INC	25MG	A208961	001	Dec 27, 2017	Dec	NEWA
>A> AB		50MG	A208961	002	Dec 27, 2017	Dec	NEWA
>A> AB		75MG	A208961	003	Dec 27, 2017	Dec	NEWA

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

	@ MYLAN PHARMS INC	0.5MG	A074940	001	Oct 30, 1997	Mar DISC
	@	1MG	A074940	002	Oct 30, 1997	Mar DISC
	@	2MG	A074940	003	Oct 30, 1997	Mar DISC
AB	PRINSTON INC	0.5MG	A077856	001	Jun 28, 2006	Feb CAHN
AB		1MG	A077856	002	Jun 28, 2006	Feb CAHN
AB		2MG	A077856	003	Jun 28, 2006	Feb CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

	CHARTWELL MOLECULES	0.1MG	A071785	002	Apr 05, 1988	Jul CMS1
		0.2MG	A071785	003	Apr 05, 1988	Jul CMS1
	@	0.3MG	A071785	001	Apr 05, 1988	Feb CAHN
AB	PRINSTON INC	0.1MG	A077901	001	Mar 09, 2007	Feb CAHN
AB		0.2MG	A077901	002	Mar 09, 2007	Feb CAHN
AB		0.3MG	A077901	003	Mar 09, 2007	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB2	ACTAVIS ELIZABETH	0.1MG	A202792	001	May 15, 2015	Apr CAHN
AB1		0.1MG	A203320	001	May 15, 2015	Apr CAHN
	@	0.2MG	A202792	002	May 15, 2015	Apr CAHN
	@	0.2MG	A203320	002	May 15, 2015	Apr CAHN
AB1	AJANTA PHARMA LTD	0.1MG	A209686	001	Nov 20, 2017	Nov NEWA
AB1	AMNEAL PHARMS NY	0.1MG	A210052	001	Nov 20, 2017	Nov NEWA
AB1	LUPIN LTD	0.1MG	A209285	001	Oct 23, 2017	Oct NEWA
AB1	XIAMEN LP PHARM CO	0.1MG	A209757	001	Nov 20, 2017	Nov NEWA

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB	ACME LABS	EQ 75MG BASE	A078004	001	May 17, 2012	Jul CAHN
AB	ALLIED PHARMA INC	EQ 75MG BASE	A078004	001	May 17, 2012	Mar CAHN
AB	CSPC OUYI PHARM CO	EQ 75MG BASE	A204359	001	Feb 02, 2017	Jan NEWA

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

	AUROLIFE PHARMA LLC	3.75MG	A072112	002	Aug 11, 2017	Aug CMS1
		7.5MG	A072112	003	Aug 11, 2017	Aug CMS1

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

	@ SUN PHARM INDS LTD	3.75MG	A076911	001	Sep 29, 2004	Oct DISC
	@	7.5MG	A076911	002	Sep 29, 2004	Oct DISC
	@	15MG	A076911	003	Sep 29, 2004	Oct DISC
AB	TARO PHARM	3.75MG	A075731	003	Apr 27, 2000	Mar CAHN
AB		7.5MG	A075731	002	Apr 27, 2000	Mar CAHN
AB		15MG	A075731	001	Apr 27, 2000	Mar CAHN

CLOTTRIMAZOLE

SOLUTION;TOPICAL

CLOTTRIMAZOLE

AT	! TARO	1%	A074580	001	Jul 29, 1996	Apr CAHN
	LOTTRIMIN					
	+ @ SCHERING PLOUGH	1%	N017613	001		Jul CRLD

CLOZAPINE

SUSPENSION;ORAL

VERSACLOZ

+	! TASMAN PHARMA	50MG/ML	N203479	001	Feb 06, 2013	Sep CAHN
---	-----------------	---------	---------	-----	--------------	----------

TABLET;ORAL

CLOZAPINE

AB	MAYNE PHARMA	50MG	A203807	003	Aug 22, 2017	Aug NEWA
AB		200MG	A203807	004	Aug 22, 2017	Aug NEWA
AB	SUN PHARM INDS INC	200MG	A075713	004	Nov 07, 2017	Oct NEWA
AB	ZYDUS PHARMS USA INC	25MG	A209480	001	Dec 06, 2017	Nov NEWA
AB		50MG	A209480	002	Dec 06, 2017	Nov NEWA
AB		100MG	A209480	003	Dec 06, 2017	Nov NEWA
AB		200MG	A209480	004	Dec 06, 2017	Nov NEWA

>A>		<u>COCAINE HYDROCHLORIDE</u>					
>A>		SOLUTION;NASAL					
>A>		GOPRELTO					
>A>		+!	GENUS LIFESCIENCES 4%	N209963	001	Dec 14, 2017	Dec NEWA
		<u>CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE</u>					
		SYRUP;ORAL					
		PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE					
		@ PHARM ASSOC	10MG/5ML;6.25MG/5ML	A089647	001	Dec 22, 1988	May CAHN
>D>	AA	WOCKHARDT	10MG/5ML;6.25MG/5ML	A088875	001	Dec 17, 1984	Dec CAHN
>A>	AA	WOCKHARDT BIO AG	10MG/5ML;6.25MG/5ML	A088875	001	Dec 17, 1984	Dec CAHN
		<u>CODEINE SULFATE</u>					
		SOLUTION;ORAL					
		CODEINE SULFATE					
		@ WEST-WARD PHARMS INT	30MG/5ML	N202245	001	Jun 30, 2011	Jan CAHN
		TABLET;ORAL					
		CODEINE SULFATE					
AB	+	WEST-WARD PHARMS INT	15MG	N022402	001	Jul 16, 2009	Jan CAHN
AB	+		30MG	N022402	002	Jul 16, 2009	Jan CAHN
AB	+		60MG	N022402	003	Jul 16, 2009	Jan CAHN
		<u>COLESTIPOL HYDROCHLORIDE</u>					
		GRANULE;ORAL					
		COLESTID					
AB	+	PHARMACIA UPJOHN	5GM/SCOOPFUL	N017563	003	Sep 22, 1995	Nov CAHN
AB	+		5GM/PACKET	N017563	004	Sep 22, 1995	Nov CAHN
		FLAVORED COLESTID					
		+ PHARMACIA UPJOHN	5GM/PACKET	N017563	001		Nov CAHN
		+	5GM/SCOOPFUL	N017563	002		Nov CAHN
		TABLET;ORAL					
		COLESTID					
AB	+	PHARMACIA UPJOHN	1GM	N020222	001	Jul 19, 1994	Nov CAHN
		<u>COPANLISIB DIHYDROCHLORIDE</u>					
		POWDER;IV (INFUSION)					
		ALIQOPA					
		+!	BAYER HEALTHCARE 60MG/VIAL	N209936	001	Sep 14, 2017	Sep NEWA
		<u>COPPER</u>					
		INTRAUTERINE DEVICE;INTRAUTERINE					
		PARAGARD T 380A					
		+!	COOPERSURGICAL 309MG/COPPER	N018680	001	Nov 15, 1984	Nov CAHN
		<u>CORTICOTROPIN</u>					
		INJECTABLE;INJECTION					
		PURIFIED CORTROPHIN GEL					
		@ ANI PHARMS INC	40 UNITS/ML	N008975	001		May CAHN
		@	80 UNITS/ML	N008975	002		May CAHN
		<u>CORTICOTROPIN-ZINC HYDROXIDE</u>					
		INJECTABLE;INJECTION					
		CORTROPHIN-ZINC					
		@ ANI PHARMS INC	40 UNITS/ML	N009854	001		May CAHN
		<u>COSYNTROPIN</u>					
		SOLUTION;INTRAVENOUS					
		COSYNTROPIN					
		@ SANDOZ INC	0.25MG/ML (0.25MG/ML)	N022028	001	Feb 21, 2008	May CAHN
		<u>CROMOLYN SODIUM</u>					
		CONCENTRATE;ORAL					
		CROMOLYN SODIUM					
AA		AILEX PHARMS LLC	100MG/5ML	A209264	001	Oct 16, 2017	Oct NEWA
AA		RISING PHARMS INC	100MG/5ML	A202583	001	Oct 27, 2011	Oct CAHN
		GASTROCROM					
AA	+	MYLAN SPECIALITY LP	100MG/5ML	N020479	001	Feb 29, 1996	Mar CAHN
		SOLUTION;INHALATION					
		CROMOLYN SODIUM					
AN		AILEX PHARMS LLC	10MG/ML	A209453	001	Oct 16, 2017	Oct NEWA

SOLUTION; INHALATION									
CROMOLYN SODIUM									
	@ BAUSCH AND LOMB	10MG/ML		A075585	001	Dec 21, 2000	Jul	DISC	
AN		10MG/ML		A075585	001	Dec 21, 2000	Feb	CAHN	
>D>	AN	WOCKHARDT	10MG/ML	A075346	001	Oct 25, 1999	Dec	CAHN	
>A>	AN	WOCKHARDT BIO AG	10MG/ML	A075346	001	Oct 25, 1999	Dec	CAHN	
INTAL									
	+ @ KING PHARMS LLC	10MG/ML		N018596	001	May 28, 1982	Sep	CRLD	
	@	10MG/ML		N018596	001	May 28, 1982	May	CAHN	
SOLUTION/DROPS; OPHTHALMIC									
CROLOM									
	@ BAUSCH AND LOMB	4%		A074443	001	Jan 30, 1995	Oct	DISC	
<u>CYANOCOBALAMIN</u>									
INJECTABLE; INJECTION									
CYANOCOBALAMIN									
AP	MYLAN LABS LTD	1MG/ML		A204829	001	Jun 05, 2017	May	NEWA	
DODEX									
	@ ACCORD HLTHCARE	1MG/ML		A083022	001		Jun	CAHN	
<u>CYCLOBENZAPRINE HYDROCHLORIDE</u>									
TABLET; ORAL									
CYCLOBENZAPRINE HYDROCHLORIDE									
AB	JUBILANT CADISTA	7.5MG		A077563	003	Aug 25, 2017	Aug	NEWA	
AB	OXFORD PHARMS	5MG		A077209	002	Feb 03, 2006	May	CMS1	
AB	PRINSTON INC	5MG		A077797	001	Feb 28, 2007	Feb	CAHN	
AB		10MG		A077797	002	Feb 28, 2007	Feb	CAHN	
AB	RUBICON RES PVT LTD	5MG		A208170	001	May 31, 2017	May	NEWA	
AB		7.5MG		A208170	002	May 31, 2017	May	NEWA	
AB		10MG		A208170	003	May 31, 2017	May	NEWA	
	@ UPSHER-SMITH LABS	5MG		A072854	002	Feb 03, 2006	Jun	CAHN	
	@	10MG		A072854	001	Nov 19, 1991	Jun	CAHN	
<u>CYCLOPHOSPHAMIDE</u>									
CAPSULE; ORAL									
CYCLOPHOSPHAMIDE									
	+ WEST-WARD PHARMS INT	25MG		N203856	001	Sep 16, 2013	Jan	CAHN	
	+!	50MG		N203856	002	Sep 16, 2013	Jan	CAHN	
INJECTABLE; INJECTION									
CYTOXAN (LYOPHILIZED)									
	+ @ BAXTER HLTHCARE	500MG/VIAL		N012142	003		Feb	CRLD	
	+ @	1GM/VIAL		N012142	004	Aug 30, 1982	Feb	CRLD	
	+ @	2GM/VIAL		N012142	005	Aug 30, 1982	Feb	CRLD	
<u>CYCLOSPORINE</u>									
SOLUTION; ORAL									
CYCLOSPORINE									
>D>	AB2	WOCKHARDT	100MG/ML	A065133	001	Sep 17, 2004	Dec	CAHN	
>A>	AB2	WOCKHARDT BIO AG	100MG/ML	A065133	001	Sep 17, 2004	Dec	CAHN	
<u>CYPROHEPTADINE HYDROCHLORIDE</u>									
SYRUP; ORAL									
CYPROHEPTADINE HYDROCHLORIDE									
AA	BIO-PHARM INC	2MG/5ML		A204823	001	Dec 27, 2016	Sep	CAHN	
AA	SILARX PHARMS INC	2MG/5ML		A203191	001	Jul 13, 2017	Jul	NEWA	
PERIACTIN									
	+ @ MERCK	2MG/5ML		N013220	002		Jan	CRLD	
TABLET; ORAL									
CYPROHEPTADINE HYDROCHLORIDE									
AA	AILEX PHARMS LLC	4MG		A207555	001	Jan 31, 2017	Sep	CAHN	
AA	APNAR PHARMA LP	4MG		A207555	001	Jan 31, 2017	Jan	NEWA	
>A>	AA	COREPHARMA	4MG	A040537	001	Sep 30, 2003	Dec	CAHN	
>D>	AA	IMPAX LABS INC	4MG	A040537	001	Sep 30, 2003	Dec	CAHN	
AA		4MG		A040537	001	Sep 30, 2003	Feb	CAHN	
AA	SANTOS BIOTECH	4MG		A040644	001	May 30, 2006	May	CAHN	
AA	ZYDUS PHARMS USA INC	4MG		A208938	001	May 19, 2017	May	NEWA	

CYSTEAMINE BITARTRATECAPSULE, DELAYED RELEASE;ORAL
PROCYSBI

+	HORIZON PHARMA USA	EQ 25MG BASE	N203389	001	Apr 30, 2013	Mar CAHN
+	!	EQ 75MG BASE	N203389	002	Apr 30, 2013	Mar CAHN

CYSTEAMINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
CYSTARAN

+	!	LEADIANT BIOSCI INC	EQ 0.44% BASE	N200740	001	Oct 02, 2012	Feb CAHN
---	---	---------------------	---------------	---------	-----	--------------	----------

CYTARABINEINJECTABLE;INJECTION
CYTARABINE

AP		HONG KONG	20MG/ML	A206190	001	Nov 09, 2017	Nov CAHN
AP		MYLAN LABS LTD	20MG/ML	A200915	001	Dec 13, 2011	Mar CAHN
AP		SAGENT PHARMS	20MG/ML	A206190	001	Nov 09, 2017	Oct NEWA
		WEST-WARD PHARMS INT	100MG/VIAL	A071471	001	Aug 02, 1989	Mar CTEC
	!		500MG/VIAL	A071472	001	Aug 02, 1989	Mar CHRS
	!		1GM/VIAL	A074245	001	Aug 31, 1994	Mar CHRS
	!		2GM/VIAL	A074245	002	Aug 31, 1994	Mar CHRS
		CYTOSAR-U					
	@	TEVA PHARMS USA	100MG/VIAL	A075206	001	Dec 30, 1998	Mar DISC
	@		500MG/VIAL	A075206	002	Dec 30, 1998	Mar DISC
	@		1GM/VIAL	A075206	004	Dec 30, 1998	Mar DISC
	@		2GM/VIAL	A075206	003	Dec 30, 1998	Mar DISC

CYTARABINE; DAUNORUBICINPOWDER;INTRAVENOUS
VYXEOS

+	!	CELATOR PHARMS	100MG;44MG	N209401	001	Aug 03, 2017	Aug NEWA
---	---	----------------	------------	---------	-----	--------------	----------

POWDER;IV (INFUSION)
VYXEOS

+	!	CELATOR PHARMS	100MG;44MG	N209401	001	Aug 03, 2017	Nov CDFR
---	---	----------------	------------	---------	-----	--------------	----------

DACARBAZINEINJECTABLE;INJECTION
DACARBAZINE

	!	FRESENIUS KABI USA	100MG/VIAL	A075371	001	Aug 27, 1999	Nov CTEC
AP	!		100MG/VIAL	A075371	001	Aug 27, 1999	Feb CHRS
AP	!		200MG/VIAL	A075371	002	Aug 27, 1999	Feb CHRS
		DTIC-DOME					
+	@	BAYER HLTHCARE	100MG/VIAL	N017575	001		Apr DISC
+	@		200MG/VIAL	N017575	002		Apr DISC

DACTINOMYCININJECTABLE;INJECTION
DACTINOMYCIN

AP		MYLAN LABS LTD	0.5MG/VIAL	A203385	001	Nov 09, 2017	Oct NEWA
----	--	----------------	------------	---------	-----	--------------	----------

DALBAVANCIN HYDROCHLORIDEPOWDER;IV (INFUSION)
DALVANCE

+	!	ALLERGAN SALES LLC	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	Aug CAHN
---	---	--------------------	--------------------	---------	-----	--------------	----------

DALFAMPRIDINETABLET, EXTENDED RELEASE;ORAL
AMPYRA

AB	+	!	ACORDA	10MG	N022250	001	Jan 22, 2010	Jan CFTG
			DALFAMPRIDINE					
AB			ACTAVIS LABS FL INC	10MG	A206836	001	Jan 23, 2017	Jan NEWA
AB			AUROBINDO PHARMA LTD	10MG	A206811	001	Jan 23, 2017	Jan NEWA

DANTROLENE SODIUMINJECTABLE;INJECTION
DANTROLENE SODIUM

AP		HIKMA PHARMS	20MG/VIAL	A204762	001	Jun 19, 2017	Jun NEWA
----	--	--------------	-----------	---------	-----	--------------	----------

DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
XIGDUO XR

+	ASTRAZENECA AB	EQ 2.5MG BASE; 1GM	N205649	005	Jul 28, 2017	Jul NEWA
---	----------------	--------------------	---------	-----	--------------	----------

DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL
QTERN

+	ASTRAZENECA AB	EQ 10MG BASE; EQ 5MG BASE	N209091	001	Feb 27, 2017	Feb NEWA
---	----------------	---------------------------	---------	-----	--------------	----------

DAPSONE

GEL; TOPICAL
ACZONE

AB	+	ALLERGAN	5%	N021794	001	Jul 07, 2005	Oct CFTG
----	---	----------	----	---------	-----	--------------	----------

DAPSONE

AB		TARO	5%	A209506	001	Oct 16, 2017	Oct NEWA
----	--	------	----	---------	-----	--------------	----------

TABLET; ORAL
DAPSONE

AB		ACTAVIS LLC	25MG	A204380	001	Mar 23, 2017	Mar NEWA
----	--	-------------	------	---------	-----	--------------	----------

AB			100MG	A204380	002	Mar 23, 2017	Mar NEWA
----	--	--	-------	---------	-----	--------------	----------

AB		NOVITIUM PHARMA	25MG	A206505	001	Dec 01, 2016	Oct CAHN
----	--	-----------------	------	---------	-----	--------------	----------

AB			100MG	A206505	002	Dec 01, 2016	Oct CAHN
----	--	--	-------	---------	-----	--------------	----------

AB		VIRTUS PHARMS	25MG	A204074	001	May 10, 2016	Sep CAHN
----	--	---------------	------	---------	-----	--------------	----------

AB			100MG	A204074	002	May 10, 2016	Sep CAHN
----	--	--	-------	---------	-----	--------------	----------

DAPTOMYCIN

POWDER; INTRAVENOUS
DAPTOMYCIN

+	SAGENT PHARMS	350MG/VIAL	N208385	001	Sep 12, 2017	Sep NEWA
---	---------------	------------	---------	-----	--------------	----------

POWDER; IV (INFUSION)
DAPTOMYCIN

+	SAGENT PHARMS	350MG/VIAL	N208385	001	Sep 12, 2017	Nov CDFR
---	---------------	------------	---------	-----	--------------	----------

+	XELLIA PHARMS APS	350MG/VIAL	N209949	001	Oct 20, 2017	Oct NEWA
---	-------------------	------------	---------	-----	--------------	----------

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL
DARIFENACIN

AB		MACLEODS PHARMS LTD	EQ 7.5MG BASE	A207302	001	Jul 28, 2017	Jul NEWA
----	--	---------------------	---------------	---------	-----	--------------	----------

AB			EQ 15MG BASE	A207302	002	Jul 28, 2017	Jul NEWA
----	--	--	--------------	---------	-----	--------------	----------

DARIFENACIN HYDROBROMIDE

AB		ALEMBIC PHARMS LTD	EQ 7.5MG BASE	A207681	001	Dec 08, 2017	Nov NEWA
----	--	--------------------	---------------	---------	-----	--------------	----------

AB			EQ 15MG BASE	A207681	002	Dec 08, 2017	Nov NEWA
----	--	--	--------------	---------	-----	--------------	----------

DARUNAVIR ETHANOLATE

TABLET; ORAL
DARUNAVIR ETHANOLATE

AB		TEVA PHARMS USA	EQ 600MG BASE	A202118	001	Nov 21, 2017	Nov NEWA
----	--	-----------------	---------------	---------	-----	--------------	----------

PREZISTA

AB	+	JANSSEN PRODS	EQ 600MG BASE	N021976	002	Feb 25, 2008	Nov CFTG
----	---	---------------	---------------	---------	-----	--------------	----------

DECITABINE

INJECTABLE; INTRAVENOUS
DECITABINE

AP		ACCORD HLTHCARE	50MG/VIAL	A203475	001	Feb 27, 2017	Feb NEWA
----	--	-----------------	-----------	---------	-----	--------------	----------

AP		CHEMI SPA	50MG/VIAL	A206033	001	Sep 22, 2017	Sep NEWA
----	--	-----------	-----------	---------	-----	--------------	----------

AP		CIPLA LTD	50MG/VIAL	A208601	001	Nov 16, 2017	Nov NEWA
----	--	-----------	-----------	---------	-----	--------------	----------

AP		PHARMASCIENCE INC	50MG/VIAL	A204607	001	May 31, 2017	May NEWA
----	--	-------------------	-----------	---------	-----	--------------	----------

DEFERASIROX

GRANULE; ORAL
JADENU SPRINKLE

+	NOVARTIS PHARMS CORP	90MG	N207968	001	May 18, 2017	May NEWA
---	----------------------	------	---------	-----	--------------	----------

+		180MG	N207968	002	May 18, 2017	May NEWA
---	--	-------	---------	-----	--------------	----------

+		360MG	N207968	003	May 18, 2017	May NEWA
---	--	-------	---------	-----	--------------	----------

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION
DEFEROXAMINE MESYLATE

AP	GLAND PHARMA LTD	500MG/VIAL	A207384	001	Sep 29, 2017	Sep NEWA
AP		2GM/VIAL	A207384	002	Sep 29, 2017	Sep NEWA

DEFLAZACORT

SUSPENSION; ORAL
EMFLAZA

+	MARATHON PHARMS LLC	22.75MG/ML	N208685	001	Feb 09, 2017	Feb NEWA
+	PTC THERAP	22.75MG/ML	N208685	001	Feb 09, 2017	Apr CAHN

TABLET; ORAL
EMFLAZA

+	MARATHON PHARMS LLC	6MG	N208684	001	Feb 09, 2017	Feb NEWA
+		18MG	N208684	002	Feb 09, 2017	Feb NEWA
+		30MG	N208684	003	Feb 09, 2017	Feb NEWA
+		36MG	N208684	004	Feb 09, 2017	Feb NEWA
+	PTC THERAP	6MG	N208684	001	Feb 09, 2017	Apr CAHN
+		18MG	N208684	002	Feb 09, 2017	Apr CAHN
+		30MG	N208684	003	Feb 09, 2017	Apr CAHN
+		36MG	N208684	004	Feb 09, 2017	Apr CAHN

DELAFLOXACIN MEGLUMINE

POWDER; IV (INFUSION)
BAXDELA

+	MELINTA	EQ 300MG BASE/VIAL	N208611	001	Jun 19, 2017	Nov CAHN
+	MELINTA THERAPS INC	EQ 300MG BASE/VIAL	N208611	001	Jun 19, 2017	Jun NEWA

TABLET; ORAL
BAXDELA

+	MELINTA	EQ 450MG BASE	N208610	001	Jun 19, 2017	Nov CAHN
+	MELINTA THERAPS INC	EQ 450MG BASE	N208610	001	Jun 19, 2017	Jun NEWA

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

>A>	AB	COREPHARMA	10MG	A205153	001	Oct 28, 2016	Dec CAHN
>A>	AB		25MG	A205153	002	Oct 28, 2016	Dec CAHN
>A>	AB		50MG	A205153	003	Oct 28, 2016	Dec CAHN
>A>	AB		75MG	A205153	004	Oct 28, 2016	Dec CAHN
>A>	AB		100MG	A205153	005	Oct 28, 2016	Dec CAHN
>A>	AB		150MG	A205153	006	Oct 28, 2016	Dec CAHN
>D>	AB	IMPAX LABS INC	10MG	A205153	001	Oct 28, 2016	Dec CAHN
	AB		10MG	A205153	001	Oct 28, 2016	Feb CAHN
>D>	AB		25MG	A205153	002	Oct 28, 2016	Dec CAHN
	AB		25MG	A205153	002	Oct 28, 2016	Feb CAHN
>D>	AB		50MG	A205153	003	Oct 28, 2016	Dec CAHN
	AB		50MG	A205153	003	Oct 28, 2016	Feb CAHN
>D>	AB		75MG	A205153	004	Oct 28, 2016	Dec CAHN
	AB		75MG	A205153	004	Oct 28, 2016	Feb CAHN
>D>	AB		100MG	A205153	005	Oct 28, 2016	Dec CAHN
	AB		100MG	A205153	005	Oct 28, 2016	Feb CAHN
>D>	AB		150MG	A205153	006	Oct 28, 2016	Dec CAHN
	AB		150MG	A205153	006	Oct 28, 2016	Feb CAHN
>A>	AB	INGENUS PHARMS LLC	10MG	A204963	001	Dec 26, 2017	Dec NEWA
>A>	AB		25MG	A204963	002	Dec 26, 2017	Dec NEWA
>A>	AB		50MG	A204963	003	Dec 26, 2017	Dec NEWA
>A>	AB		75MG	A204963	004	Dec 26, 2017	Dec NEWA
>A>	AB		100MG	A204963	005	Dec 26, 2017	Dec NEWA
>A>	AB		150MG	A204963	006	Dec 26, 2017	Dec NEWA

DESMETHYL PIROXICAM

CAPSULE; ORAL
PIROXICAM

	SUN PHARM INDUSTRIES	10MG	A073536	002	Jan 23, 2008	Mar CMS1
--	----------------------	------	---------	-----	--------------	----------

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION
DESMOPRESSIN ACETATE

	@ HOSPIRA	0.004MG/ML	A075220	001	Aug 28, 2000	Jul DISC
AP	SAGENT PHARMS	0.004MG/ML	A204695	001	Aug 22, 2017	Aug NEWA
AP		0.004MG/ML	A204751	001	Aug 22, 2017	Aug NEWA

	INJECTABLE;INJECTION								
	DESMOPRESSIN ACETATE								
	@ TEVA PHARMS USA	0.004MG/ML	A074888	001	Oct 15, 1997	Jul	DISC		
	SPRAY, METERED;NASAL								
	DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)								
AB	ZYDUS PHARMS USA INC	0.01MG/SPRAY	A091345	001	Oct 03, 2017	Sep	NEWA		
	NOCTIVA								
+	AVADEL SPEC LT	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Oct	CAHN		
+	!	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Oct	CAHN		
+	SERENITY PHARMS LLC	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Mar	NEWA		
+	!	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Mar	NEWA		
	STIMATE								
	@ FERRING PHARMS INC	0.15MG/SPRAY	N020355	001	Mar 07, 1994	Jun	CAHN		
	STIMATE (NEEDS NO REFRIGERATION)								
+	!	FERRING PHARMS INC	0.15MG/SPRAY	N020355	002	Oct 24, 2007	Jun	CAHN	
	TABLET;ORAL								
	DESMOPRESSIN ACETATE								
AB	HERITAGE PHARMA	0.1MG	A207880	001	May 26, 2017	May	NEWA		
AB		0.1MG	A207880	001	May 26, 2017	May	CAHN		
AB		0.2MG	A207880	002	May 26, 2017	May	NEWA		
AB		0.2MG	A207880	002	May 26, 2017	May	CAHN		
	<u>DESOGESTREL; ETHINYL ESTRADIOL</u>								
	TABLET;ORAL-28								
	DESOGESTREL AND ETHINYL ESTRADIOL								
AB	ACCORD HLTHCARE	0.15MG,N/A;0.02MG,0.01MG	A209170	001	Jun 05, 2017	May	NEWA		
AB	AUROBINDO PHARMA LTD	0.15MG,N/A;0.02MG,0.01MG	A206853	001	Mar 22, 2017	Mar	NEWA		
	ISIBLOOM								
AB	LABS LEON FARMA	0.15MG;0.03MG	A202789	001	Aug 12, 2015	Nov	CAHN		
	KALLIGA								
AB	AUROBINDO PHARMA LTD	0.15MG;0.03MG	A207081	001	May 17, 2017	May	NEWA		
	VOLNEA								
AB	LABS LEON FARMA	0.15MG,N/A;0.02MG,0.01MG	A202689	001	Sep 09, 2016	Nov	CAHN		
	<u>DESONIDE</u>								
	CREAM;TOPICAL								
	DESONIDE								
AB	GLENMARK PHARMS	0.05%	A209729	001	Jul 24, 2017	Jul	NEWA		
	LOTION;TOPICAL								
	DESONIDE								
AB	GLENMARK PHARMS	0.05%	A209494	001	Sep 26, 2017	Sep	NEWA		
AB	TELIGENT PHARMA INC	0.05%	A207855	001	Sep 28, 2017	Sep	NEWA		
	OINTMENT;TOPICAL								
	DESONIDE								
AB	GLENMARK PHARMS LTD	0.05%	A209996	001	Sep 15, 2017	Sep	NEWA		
AB	HI-TECH PHARMACAL	0.05%	A208836	001	Mar 27, 2017	Mar	NEWA		
	<u>DESOXIMETASONE</u>								
	CREAM;TOPICAL								
	TOPICORT								
AB	! TARO	0.05%	A073210	001	Nov 30, 1990	Apr	CAHN		
AB	!	0.25%	A073193	001	Nov 30, 1990	Apr	CAHN		
+	@	0.25%	N017856	001		May	CAHN		
	TOPICORT LP								
+	@ TARO	0.05%	N018309	001		May	CAHN		
	GEL;TOPICAL								
	DESOXIMETASONE								
AB	RISING PHARMS INC	0.05%	A204675	001	Aug 12, 2016	May	CAHN		
	TOPICORT								
AB	! TARO	0.05%	A074904	001	Jul 14, 1998	Apr	CAHN		
+	@	0.05%	N018586	001	Mar 29, 1982	May	CAHN		
+	@ TARO PHARMS NORTH	0.05%	N018586	001	Mar 29, 1982	Jan	CRLD		
	OINTMENT;TOPICAL								
	DESOXIMETASONE								
AB	RISING PHARMS INC	0.25%	A204272	001	Nov 30, 2016	May	CAHN		
AB	ZYDUS PHARMS USA INC	0.25%	A205206	001	Sep 19, 2017	Sep	NEWA		
	TOPICORT								
AB	+	!	TARO	0.05%	N018594	001	Jan 17, 1985	May	CAHN
AB	!	0.25%	A074286	001	Jun 07, 1996	Apr	CAHN		
+	@	0.25%	N018763	001	Sep 30, 1983	May	CAHN		

SPRAY; TOPICAL
 DESOXIMETASONE

AT	PERRIGO ISRAEL	0.25%	A206441	001	Jan 20, 2017	Jan NEWA
----	----------------	-------	---------	-----	--------------	----------

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL
 DESVENLAFAXINE SUCCINATE

AB	ACTAVIS LABS FL	EQ 25MG BASE	A204065	001	Jul 29, 2016	May CAHN
AB		EQ 50MG BASE	A204065	002	Jul 29, 2016	May CAHN
AB		EQ 100MG BASE	A204065	003	Jul 29, 2016	May CAHN
AB	WEST-WARD PHARMS INT	EQ 25MG BASE	A204082	002	Aug 28, 2017	Aug NEWA
AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A204020	001	Oct 11, 2017	Sep NEWA
AB		EQ 100MG BASE	A204020	002	Oct 11, 2017	Sep NEWA

DEUTETRABENAZINE

TABLET; ORAL
 AUSTEDO

+	TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017	Apr NEWA
+		9MG	N208082	002	Apr 03, 2017	Apr NEWA
+	!	12MG	N208082	003	Apr 03, 2017	Apr NEWA

DEXAMETHASONE

ELIXIR; ORAL
 DEXAMETHASONE

>A>	AA	WOCKHARDT BIO AG	0.5MG/5ML	A088254	001	Jul 27, 1983	Dec CAHN
>D>	AA	WOCKHARDT EU OPERATN	0.5MG/5ML	A088254	001	Jul 27, 1983	Dec CAHN

TABLET; ORAL

DEXAMETHASONE

AB	LARKEN LABS INC	1.5MG	A201270	001	Jul 17, 2017	Jul NEWA
BP	PAR PHARM	6MG	A088481	001	Nov 28, 1983	May CHRS
	@ UPSHER SMITH	0.75MG	A087534	001		Jun CAHN
	@	1.5MG	A087533	001		Jun CAHN
BP	XSPIRE PHARMA	1.5MG	A088237	001	Apr 28, 1983	Aug CAHN
BP		1.5MG	A088237	001	Apr 28, 1983	Jul CAHN
	HEXADROL					
	@ ASPEN GLOBAL INC	0.5MG	N012675	004		Oct CAHN
	@	0.75MG	N012675	007		Oct CAHN
	@	1.5MG	N012675	009		Oct CAHN
	@	4MG	N012675	010		Oct CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP	WEST-WARD PHARMS INT	EQ 4MG PHOSPHATE/ML	A084282	001		Aug CMFD
----	----------------------	---------------------	---------	-----	--	----------

SOLUTION/DROPS; OPHTHALMIC, OTIC

DEXAMETHASONE SODIUM PHOSPHATE

AT	!	SANDOZ INC	EQ 0.1% PHOSPHATE	A088771	001	Jan 16, 1985	Feb CAHN
----	---	------------	-------------------	---------	-----	--------------	----------

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

MAXITROL

AT		SANDOZ INC	0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A062341	001	May 22, 1984	Feb CAHN
----	--	------------	---	---------	-----	--------------	----------

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

DEXCHLORPHENIRAMINE MALEATE

>D>	!	WOCKHARDT	2MG/5ML	A088251	001	Mar 23, 1984	Dec CAHN
>A>	!	WOCKHARDT BIO AG	2MG/5ML	A088251	001	Mar 23, 1984	Dec CAHN

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL

DEXILANT

AB	+	TAKEDA PHARMS USA	60MG	N022287	002	Jan 30, 2009	Apr CFTG
----	---	-------------------	------	---------	-----	--------------	----------

DEXLANSOPRAZOLE

AB		PAR PHARM INC	60MG	A202294	001	Apr 19, 2017	Apr NEWA
----	--	---------------	------	---------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE; ORAL

DEXILANT SOLUTAB

+	@	TAKEDA PHARMS USA	30MG	N208056	001	Jan 26, 2016	Aug DISC
---	---	-------------------	------	---------	-----	--------------	----------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP	ACCORD HLTHCARE	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204023	001	Feb 09, 2016	Mar	CAHN
AP	JIANGSU HENGRUI MED	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A209065	001	Sep 19, 2017	Sep	NEWA
AP	LUITPOLD PHARMS INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203773	001	May 12, 2017	May	CAHN
AP	PHARMAFORCE	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203773	001	May 12, 2017	May	NEWA
AP	TEVA PHARMS USA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205272	001	Nov 28, 2017	Nov	NEWA
AP	WEST-WARD PHARMS INT	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205046	001	Apr 26, 2017	Apr	NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	IMPAX LABS INC	25MG	A203614	001	Jul 05, 2017	Jun	NEWA
AB		35MG	A203614	002	Jul 05, 2017	Jun	NEWA
AB	TEVA PHARMS USA	25MG	A202731	001	Jul 05, 2017	Jun	NEWA
AB		35MG	A202731	004	Jul 05, 2017	Jun	NEWA

TABLET; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	LANNETT CO INC	2.5MG	A209468	001	Sep 25, 2017	Sep	NEWA
AB		5MG	A209468	002	Sep 25, 2017	Sep	NEWA
AB		10MG	A209468	003	Sep 25, 2017	Sep	NEWA
AB	RHODES PHARMS	2.5MG	A208756	001	Nov 20, 2017	Nov	NEWA
AB		5MG	A208756	002	Nov 20, 2017	Nov	NEWA
AB		10MG	A208756	003	Nov 20, 2017	Nov	NEWA

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

AB	+ IMPAX LABS INC	5MG	N017078	001		Aug	CAHN
AB	+	10MG	N017078	002		Aug	CAHN
AB	+!	15MG	N017078	003		Aug	CAHN

DEXTROAMPHETAMINE SULFATE

>D>	AB	MALLINCKRODT	5MG	A076353	001	May 06, 2003	Dec	CAHN
>D>	AB		10MG	A076353	002	May 06, 2003	Dec	CAHN
>D>	AB		15MG	A076353	003	May 06, 2003	Dec	CAHN
	AB	NESHER PHARMS	5MG	A209111	001	Jun 27, 2017	Jun	NEWA
	AB		10MG	A209111	002	Jun 27, 2017	Jun	NEWA
	AB		15MG	A209111	003	Jun 27, 2017	Jun	NEWA
>A>	AB	SPECGX LLC	5MG	A076353	001	May 06, 2003	Dec	CAHN
>A>	AB		10MG	A076353	002	May 06, 2003	Dec	CAHN
>A>	AB		15MG	A076353	003	May 06, 2003	Dec	CAHN
	AB	VINTAGE PHARMS	5MG	A205673	001	Oct 31, 2017	Oct	NEWA
	AB		10MG	A205673	002	Oct 31, 2017	Oct	NEWA
	AB		15MG	A205673	003	Oct 31, 2017	Oct	NEWA

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

	@	EPIC PHARMA LLC	5MG	A090652	001	Mar 07, 2014	May	CAHN
	@		10MG	A090652	002	Mar 07, 2014	May	CAHN
>D>	AA	MALLINCKRODT	5MG	A040436	001	Jan 29, 2002	Dec	CAHN
>D>	AA		10MG	A040436	002	Jan 29, 2002	Dec	CAHN
>A>	AA	SPECGX LLC	5MG	A040436	001	Jan 29, 2002	Dec	CAHN
>A>	AA		10MG	A040436	002	Jan 29, 2002	Dec	CAHN
	AA	SUNRISE PHARM INC	5MG	A210059	001	Oct 18, 2017	Oct	NEWA
	AA		10MG	A210059	002	Oct 18, 2017	Oct	NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE W/ DEXTROMETHORPHAN

>D>	AA	WOCKHARDT	15MG/5ML; 6.25MG/5ML	A088864	001	Jan 04, 1985	Dec	CAHN
>A>	AA	WOCKHARDT BIO AG	15MG/5ML; 6.25MG/5ML	A088864	001	Jan 04, 1985	Dec	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE; ORAL

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE						
AB	ACTAVIS ELIZABETH	20MG;10MG	A202934	001	Oct 10, 2017	Sep NEWA
NUDEXTA						
AB	+! AVANIR PHARMS	20MG;10MG	N021879	001	Oct 29, 2010	Sep CFTG

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER						
AP	+! ICU MEDICAL INC	10GM/100ML	N018080	001		Feb CAHN
DEXTROSE 20% IN PLASTIC CONTAINER						
AP	+! ICU MEDICAL INC	20GM/100ML	N018564	001	Mar 23, 1982	Feb CAHN
DEXTROSE 30% IN PLASTIC CONTAINER						
AP	+! ICU MEDICAL INC	30GM/100ML	N019345	001	Jan 26, 1985	Feb CAHN
DEXTROSE 40% IN PLASTIC CONTAINER						
AP	+! ICU MEDICAL INC	40GM/100ML	N018562	001	Mar 23, 1982	May CAHN
DEXTROSE 5% IN PLASTIC CONTAINER						
AP	+! ICU MEDICAL INC	50MG/ML	N016367	002		Feb CAHN
DEXTROSE 50% IN PLASTIC CONTAINER						
AP	+! ICU MEDICAL INC	50GM/100ML	N018563	001	Mar 23, 1982	Feb CAHN
	@	50GM/100ML	N019894	001	Dec 26, 1989	Jun CAHN
DEXTROSE 60% IN PLASTIC CONTAINER						
	+! BAXTER HLTHCARE	60GM/100ML	N017521	005	Mar 26, 1982	Nov CTEC
DEXTROSE 70% IN PLASTIC CONTAINER						
AP	+! ICU MEDICAL INC	70GM/100ML	N018561	001	Mar 23, 1982	Apr CAHN
AP	+!	70GM/100ML	N019893	001	Dec 26, 1989	Feb CAHN

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER						
	ICU MEDICAL INC	5GM/100ML; 21MG/100ML; 128MG/100ML; 2	N017610	001		Feb CAHN
		34MG/100ML				

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER						
	ICU MEDICAL INC	5GM/100ML; 30MG/100ML; 141MG/100ML; 1	N019513	001	May 08, 1986	Feb CAHN
		5MG/100ML; 260MG/100ML; 25MG/100ML				

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER						
	@ B BRAUN	5GM/100ML; 30MG/100ML; 97MG/100ML; 22	N019844	001	Jun 10, 1993	Aug DISC
		0MG/100ML; 140MG/100ML				

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER						
	ICU MEDICAL INC	5GM/100ML; 30MG/100ML; 37MG/100ML; 22	N017609	001		Feb CAHN
		2MG/100ML; 526MG/100ML; 502MG/100ML				

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER						
	+ BAXTER HLTHCARE	5GM/100ML; 75MG/100ML	N017634	004		Sep CRLD
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER						
AP	+ BAXTER HLTHCARE	5GM/100ML; 150MG/100ML	N017634	001		Sep CRLD
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER						
AP	+ BAXTER HLTHCARE	5GM/100ML; 224MG/100ML	N017634	003		Sep CRLD
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER						
AP	+ BAXTER HLTHCARE	5GM/100ML; 300MG/100ML	N017634	002		Sep CRLD
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER						
	ICU MEDICAL INC	5GM/100ML; 149MG/100ML	N018371	001		Apr CAHN
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	ICU MEDICAL INC	5GM/100ML; 224MG/100ML	N018371	003		Apr CAHN
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER						
	ICU MEDICAL INC	5GM/100ML; 298MG/100ML	N018371	002		Apr CAHN

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN

5GM/100ML; 150MG/100ML; 130MG/100ML;
280MG/100ML; 91MG/100ML

N019870 001 Jun 10, 1993 Aug DISC

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

>D>		ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 225MG/100ML	N018365	002	Jul 05, 1983	Dec	CRLD
>A>	+		5GM/100ML; 74.5MG/100ML; 225MG/100ML	N018365	002	Jul 05, 1983	Dec	CRLD
			5GM/100ML; 74.5MG/100ML; 225MG/100ML	N018365	002	Jul 05, 1983	Feb	CAHN
>D>			5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	006	Mar 28, 1988	Dec	CRLD
>A>	+		5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	006	Mar 28, 1988	Dec	CRLD
			5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	006	Mar 28, 1988	Feb	CAHN
		POTASSIUM CHLORIDE 10MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.3% IN PLASTIC CONTAINER				
		ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 300MG/100ML	N018876	001	Jan 17, 1986	Jun	CAHN
			5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	006	Mar 28, 1988	Jun	CAHN
		POTASSIUM CHLORIDE 10MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.45% IN PLASTIC CONTAINER				
AP		ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 450MG/100ML	N018362	005	Mar 28, 1988	Feb	CAHN
AP			5GM/100ML; 74.5MG/100ML; 450MG/100ML	N018362	009	Jul 05, 1983	Feb	CAHN
		POTASSIUM CHLORIDE 10MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.9% IN PLASTIC CONTAINER				
AP		ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 900MG/100ML	N019691	002	Mar 24, 1988	Apr	CAHN
AP			5GM/100ML; 149MG/100ML; 900MG/100ML	N019691	004	Mar 24, 1988	Apr	CAHN
		POTASSIUM CHLORIDE 15MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.225% IN PLASTIC CONTAINER				
		ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 225MG/100ML	N018365	008	Mar 28, 1988	Feb	CAHN
		POTASSIUM CHLORIDE 15MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.3% IN PLASTIC CONTAINER				
		ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 300MG/100ML	N018876	007	Mar 28, 1988	Jun	CAHN
		POTASSIUM CHLORIDE 15MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.45% IN PLASTIC CONTAINER				
AP		ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 450MG/100ML	N018362	006	Mar 28, 1988	Feb	CAHN
		POTASSIUM CHLORIDE 15MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.9% IN PLASTIC CONTAINER				
AP		ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 900MG/100ML	N019691	006	Mar 24, 1988	Apr	CAHN
		POTASSIUM CHLORIDE 20MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.225% IN PLASTIC CONTAINER				
>D>		ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	001		Dec	CRLD
>A>	+		5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	001		Dec	CRLD
			5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	001		Feb	CAHN
>D>			5GM/100ML; 298MG/100ML; 225MG/100ML	N018365	009	Mar 28, 1988	Dec	CRLD
>A>	+		5GM/100ML; 298MG/100ML; 225MG/100ML	N018365	009	Mar 28, 1988	Dec	CRLD
			5GM/100ML; 298MG/100ML; 225MG/100ML	N018365	009	Mar 28, 1988	Feb	CAHN
		POTASSIUM CHLORIDE 20MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.3% IN PLASTIC CONTAINER				
		ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 300MG/100ML	N018876	008	Mar 28, 1988	Jun	CAHN
		POTASSIUM CHLORIDE 20MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.45% IN PLASTIC CONTAINER				
AP		ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 450MG/100ML	N018362	010	Jul 05, 1983	Feb	CAHN
AP			5GM/100ML; 298MG/100ML; 450MG/100ML	N018362	007	Mar 28, 1988	Feb	CAHN
		POTASSIUM CHLORIDE 20MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.9% IN PLASTIC CONTAINER				
AP		ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 900MG/100ML	N019691	005	Mar 24, 1988	Apr	CAHN
AP			5GM/100ML; 298MG/100ML; 900MG/100ML	N019691	008	Mar 24, 1988	Apr	CAHN
		POTASSIUM CHLORIDE 20MEQ	IN DEXTROSE 5% IN SODIUM CHLORIDE	0.3% IN PLASTIC CONTAINER				
		ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	002	Jan 17, 1986	Jun	CAHN
		POTASSIUM CHLORIDE 30MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.225% IN PLASTIC CONTAINER				
		ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 225MG/100ML	N018365	003	Jul 05, 1983	Feb	CAHN
		POTASSIUM CHLORIDE 30MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.3% IN PLASTIC CONTAINER				
		ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 300MG/100ML	N018876	003	Jan 17, 1986	Jun	CAHN
		POTASSIUM CHLORIDE 30MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.45% IN PLASTIC CONTAINER				
AP		ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 450MG/100ML	N018362	002		Feb	CAHN
		POTASSIUM CHLORIDE 30MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.9% IN PLASTIC CONTAINER				
AP		ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 900MG/100ML	N019691	007	Mar 24, 1988	Apr	CAHN
		POTASSIUM CHLORIDE 40MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.225% IN PLASTIC CONTAINER				
		ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 225MG/100ML	N018365	004	Jul 05, 1983	Feb	CAHN
		POTASSIUM CHLORIDE 40MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.3% IN PLASTIC CONTAINER				
		ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 300MG/100ML	N018876	004	Mar 28, 1988	Jun	CAHN
		POTASSIUM CHLORIDE 40MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.45% IN PLASTIC CONTAINER				
AP		ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 450MG/100ML	N018362	003		Feb	CAHN
		POTASSIUM CHLORIDE 40MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.9% IN PLASTIC CONTAINER				
AP		ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 900MG/100ML	N019691	009	Mar 24, 1988	Apr	CAHN
		POTASSIUM CHLORIDE 5MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.225% IN PLASTIC CONTAINER				
		ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 225MG/100ML	N018365	005	Mar 28, 1988	Feb	CAHN
			5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	007	Mar 28, 1988	Feb	CAHN
		POTASSIUM CHLORIDE 5MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.3% IN PLASTIC CONTAINER				
		ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 300MG/100ML	N018876	005	Mar 28, 1988	Jun	CAHN
			5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	009	Mar 28, 1988	Jun	CAHN

INJECTABLE;INJECTION									
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER									
AP	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	008	Mar 28, 1988	Feb	CAHN		
AP		5GM/100ML;149MG/100ML;450MG/100ML	N018362	004	Mar 28, 1988	Feb	CAHN		
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER									
AP	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691	001	Mar 24, 1988	Apr	CAHN		
AP		5GM/100ML;149MG/100ML;900MG/100ML	N019691	003	Mar 24, 1988	Apr	CAHN		
<u>DEXTROSE; SODIUM CHLORIDE</u>									
INJECTABLE;INJECTION									
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER									
	B BRAUN	10GM/100ML;900MG/100ML	N019631	015	Feb 24, 1988	Aug	CTEC		
	@ BAXTER HLTHCARE	10GM/100ML;900MG/100ML	N016696	001		Nov	DISC		
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER									
+	ICU MEDICAL INC	5GM/100ML;225MG/100ML	N017606	001		Feb	CAHN		
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER									
+	ICU MEDICAL INC	5GM/100ML;300MG/100ML	N017799	001		Feb	CAHN		
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER									
AP	ICU MEDICAL INC	5GM/100ML;450MG/100ML	N017607	001		Feb	CAHN		
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER									
AP	+	ICU MEDICAL INC	5GM/100ML;900MG/100ML	N017585	001	Aug	CRLD		
AP		5GM/100ML;900MG/100ML	N017585	001		Feb	CAHN		
<u>DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM</u>									
INJECTABLE;INJECTION									
MD-76R									
+	@ LIEBEL-FLARSHEIM	66%;10%	N019292	001	Sep 29, 1989	Aug	DISC		
	RENOGRAFIN-76								
+	BRACCO	66%;10%	N010040	001		Aug	CTEC		
<u>DIAZEPAM</u>									
TABLET;ORAL									
DIAZEPAM									
	@ UPSHER-SMITH LABS	2MG	A070302	001	Dec 20, 1985	Jun	CAHN		
	@	5MG	A070303	001	Dec 20, 1985	Jun	CAHN		
	@	10MG	A070304	001	Dec 20, 1985	Jun	CAHN		
	@ VIRTUS PHARMS	2MG	A070462	001	Feb 25, 1986	Feb	CAHN		
	@	5MG	A070463	001	Feb 25, 1986	Feb	CAHN		
	@	10MG	A070464	001	Feb 25, 1986	Feb	CAHN		
<u>DICHLORPHENAMIDE</u>									
TABLET;ORAL									
KEVEYIS									
+	STRONGBRIDGE US	50MG	N011366	002	Aug 07, 2015	Aug	CRLD		
<u>DICLOFENAC POTASSIUM</u>									
TABLET;ORAL									
DICLOFENAC POTASSIUM									
	@ WATSON LABS TEVA	50MG	A075152	001	Nov 27, 1998	May	CAHN		
<u>DICLOFENAC SODIUM</u>									
SOLUTION;TOPICAL									
DICLOFENAC SODIUM									
AT	ANDA REPOSITORY	1.5%	A202393	001	Nov 24, 2014	Sep	CAHN		
AT	!	APOTEX INC	1.5%	A202027	001	May 27, 2014	Jul	CHRS	
AT	RICONPHARMA LLC	1.5%	A206715	001	Aug 07, 2017	Jul	NEWA		
AT	TWI PHARMS INC	1.5%	A202393	001	Nov 24, 2014	Mar	CAHN		
PENNSAID									
+	HORIZON PHARMA	2%	N204623	001	Jan 16, 2014	Oct	CTEC		
AT	+	2%	N204623	001	Jan 16, 2014	May	CFTG		
SOLUTION/DROPS;OPHTHALMIC									
DICLOFENAC SODIUM									
AT	SANDOZ INC	0.1%	A078031	001	Feb 06, 2008	Feb	CAHN		
TABLET, DELAYED RELEASE;ORAL									
DICLOFENAC SODIUM									
	@ ALLIED PHARMA INC	50MG	A074986	001	Feb 26, 1999	Apr	CAHN		
	@	75MG	A074986	002	Feb 26, 1999	Apr	CAHN		
AB	UNIQUE PHARM LABS	25MG	A090066	001	Dec 01, 2010	Aug	CAHN		
AB		50MG	A090066	002	Dec 01, 2010	Aug	CAHN		
AB		75MG	A077863	003	Jun 08, 2007	Aug	CAHN		

TABLET, EXTENDED RELEASE;ORAL						
DICLOFENAC SODIUM						
AB	@ ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002	Apr DISC
	! DEXCEL LTD	100MG	A076201	001	Nov 06, 2002	Apr CHRS
	VOLTAREN-XR					
	+ @ NOVARTIS	100MG	N020254	001	Mar 08, 1996	Jul CRLD
<u>DICLOFENAC SODIUM; MISOPROSTOL</u>						
TABLET, DELAYED RELEASE;ORAL						
DICLOFENAC SODIUM AND MISOPROSTOL						
AB	EAGLE PHARMS	50MG;0.2MG	A200540	001	Mar 14, 2014	Jan CAHN
AB		75MG;0.2MG	A200540	002	Mar 14, 2014	Jan CAHN
AB	EXELA HOLDINGS	50MG;0.2MG	A200540	001	Mar 14, 2014	Mar CAHN
AB		75MG;0.2MG	A200540	002	Mar 14, 2014	Mar CAHN
<u>DICYCLOMINE HYDROCHLORIDE</u>						
INJECTABLE;INJECTION						
DICYCLOMINE HYDROCHLORIDE						
AP	LUITPOLD PHARMS INC	10MG/ML	A208353	001	Feb 17, 2017	Feb NEWA
<u>DIDANOSINE</u>						
CAPSULE, DELAYED REL PELLETS;ORAL						
DIDANOSINE						
	@ MYLAN PHARMS INC	125MG	A090788	001	Apr 08, 2010	May DISC
	@	200MG	A090788	002	Apr 08, 2010	May DISC
	@	250MG	A090788	003	Apr 08, 2010	May DISC
	@	400MG	A090788	004	Apr 08, 2010	May DISC
FOR SOLUTION;ORAL						
DIDANOSINE						
	@ AUROBINDO PHARMA	10MG/ML	A078112	001	Mar 08, 2007	Jul DISC
VIDEX						
	+! BRISTOL-MYERS SQUIBB	10MG/ML	N020156	001	Oct 09, 1991	Jul CTEC
TABLET, FOR SUSPENSION;ORAL						
DIDANOSINE						
	@ AUROBINDO	100MG	A077275	001	Aug 14, 2012	Jul DISC
	@	150MG	A077275	002	Aug 14, 2012	Jul DISC
	@	200MG	A077275	003	Aug 14, 2012	Jul DISC
<u>DIENOGEST; ESTRADIOL VALERATE</u>						
TABLET;ORAL						
NATAZIA						
	+! BAYER HLTHCARE	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M G, N/A	N022252	001	May 06, 2010	Apr CTEC
<u>DIETHYLPROPION HYDROCHLORIDE</u>						
TABLET;ORAL						
DIETHYLPROPION HYDROCHLORIDE						
	@ EPIC PHARMA LLC	25MG	A040828	001	Nov 05, 2008	May CAHN
<u>DIFLORASONE DIACETATE</u>						
CREAM;TOPICAL						
PSORCON						
	+ @ TARO PHARMS NORTH	0.05%	N020205	001	Nov 20, 1992	Sep CRLD
OINTMENT;TOPICAL						
DIFLORASONE DIACETATE						
AB	RICONPHARMA LLC	0.05%	A207440	001	Feb 27, 2017	Feb NEWA
AB	! TARO	0.05%	A075331	001	May 14, 1999	Apr CAHN
PSORCON						
	+ @ PHARMACIA AND UPJOHN	0.05%	N019260	001	Aug 28, 1985	Mar CRLD
<u>DIFLUNISAL</u>						
TABLET;ORAL						
DIFLUNISAL						
	@ ALLIED PHARMA INC	250MG	A073562	001	Nov 27, 1992	Jul CAHN
	@	500MG	A073563	001	Nov 27, 1992	Jul CAHN
AB	ZYDUS PHARMS USA INC	500MG	A203547	001	Jun 16, 2017	Jun NEWA

DIGOXIN

ELIXIR;ORAL

DIGOXIN

+! WEST-WARD PHARMS INT 0.05MG/ML

N021648 001 Aug 26, 2004 Jan CAHN

INJECTABLE;INJECTION

DIGOXIN

AP SANDOZ INC 0.25MG/ML

A040481 001 Aug 21, 2003 Mar CAHN

AP WEST-WARD PHARMS INT 0.25MG/ML

A083391 001 Jul CAHN

LANOXIN

AP +! COVIS PHARMA BV 0.25MG/ML

N009330 002 May CAHN

LANOXIN PEDIATRIC

+! COVIS PHARMA BV 0.1MG/ML

N009330 004 May CAHN

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION

DIHYDROERGOTAMINE MESYLATE

AP HIKMA PHARMS 1MG/ML

A206621 001 Sep 15, 2017 Sep NEWA

AP WEST-WARD PHARMS INT 1MG/ML

A040453 001 Jun 09, 2003 Jan CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB3 SUN PHARM INDS LTD 120MG

A203023 001 Jun 08, 2017 May NEWA

AB3 180MG

A203023 002 Jun 08, 2017 May NEWA

AB3 240MG

A203023 003 Jun 08, 2017 May NEWA

AB3 300MG

A203023 004 Jun 08, 2017 May NEWA

AB3 360MG

A203023 005 Jun 08, 2017 May NEWA

AB3 ZYDUS PHARMS USA INC 120MG

A206534 001 Aug 08, 2017 Jul NEWA

AB4 120MG

A206641 001 Aug 11, 2017 Jul NEWA

AB3 180MG

A206534 002 Aug 08, 2017 Jul NEWA

AB4 180MG

A206641 002 Aug 11, 2017 Jul NEWA

AB3 240MG

A206534 003 Aug 08, 2017 Jul NEWA

AB4 240MG

A206641 003 Aug 11, 2017 Jul NEWA

AB3 300MG

A206534 004 Aug 08, 2017 Jul NEWA

AB4 300MG

A206641 004 Aug 11, 2017 Jul NEWA

AB3 360MG

A206534 005 Aug 08, 2017 Jul NEWA

AB4 360MG

A206641 005 Aug 11, 2017 Jul NEWA

AB4 420MG

A206641 006 Aug 11, 2017 Jul NEWA

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

AP ! ATHENEX INC 5MG/ML

A074617 001 Feb 28, 1996 Mar CAHN

AP WEST-WARD PHARMS INT 5MG/ML

A078538 001 Dec 17, 2008 Jan CAHN

TABLET;ORAL

DILTIAZEM HYDROCHLORIDE

@ CHARTWELL MOLECULES 30MG

A074093 001 Nov 05, 1992 Feb CAHN

@ 60MG

A074093 002 Nov 05, 1992 Feb CAHN

@ 90MG

A074093 003 Nov 05, 1992 Feb CAHN

@ 120MG

A074093 004 Nov 05, 1992 Feb CAHN

DIMENHYDRINATE

INJECTABLE;INJECTION

DIMENHYDRINATE

@ WATSON LABS TEVA 50MG/ML

A080615 001 May CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR;ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

! PHARM ASSOC 12.5MG/5ML

A087513 001 Feb 10, 1982 May CAHN

INJECTABLE;INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

@ WATSON LABS TEVA 10MG/ML

A080873 001 May CAHN

@ 50MG/ML

A080873 002 May CAHN

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

@ WATSON LABS TEVA 50MG/ML

A080873 003 May CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION
DIPYRIDAMOLE

AP	!	ATHENEX INC	5MG/ML	A074939	001	Apr 13, 1998	Mar CAHN
----	---	-------------	--------	---------	-----	--------------	----------

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL
DISOPYRAMIDE PHOSPHATE

AB		MAYNE PHARMA	EQ 150MG BASE	A070173	002	May 31, 1985	Sep CMS1
----	--	--------------	---------------	---------	-----	--------------	----------

CAPSULE, EXTENDED RELEASE; ORAL
NORPACE CR

+	!	GD SEARLE LLC	EQ 150MG BASE	N018655	002	Jul 20, 1982	Nov CTEC
---	---	---------------	---------------	---------	-----	--------------	----------

DISULFIRAM

TABLET; ORAL
DISULFIRAM

AB		CHARTWELL MOLECULES	250MG	A091563	001	Dec 31, 2012	Jan CAHN
----	--	---------------------	-------	---------	-----	--------------	----------

AB			500MG	A091563	002	Dec 31, 2012	Jan CAHN
----	--	--	-------	---------	-----	--------------	----------

		@ WATSON LABS TEVA	500MG	A086890	001		May CAHN
--	--	--------------------	-------	---------	-----	--	----------

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL
DIVALPROEX SODIUM

AB		PRINSTON INC	EQ 125MG VALPROIC ACID	A090210	001	Nov 30, 2009	Feb CAHN
----	--	--------------	------------------------	---------	-----	--------------	----------

AB			EQ 250MG VALPROIC ACID	A090210	002	Nov 30, 2009	Feb CAHN
----	--	--	------------------------	---------	-----	--------------	----------

AB			EQ 500MG VALPROIC ACID	A090210	003	Nov 30, 2009	Feb CAHN
----	--	--	------------------------	---------	-----	--------------	----------

AB		UPSHER-SMITH LABS	EQ 125MG VALPROIC ACID	A078182	001	Jul 29, 2008	Jun CAHN
----	--	-------------------	------------------------	---------	-----	--------------	----------

AB			EQ 250MG VALPROIC ACID	A078182	002	Jul 29, 2008	Jun CAHN
----	--	--	------------------------	---------	-----	--------------	----------

AB			EQ 500MG VALPROIC ACID	A078182	003	Jul 29, 2008	Jun CAHN
----	--	--	------------------------	---------	-----	--------------	----------

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTREX

+		@ LILLY	EQ 12.5MG BASE/ML	N017820	002		Aug CRLD
---	--	---------	-------------------	---------	-----	--	----------

DOCETAXEL

INJECTABLE; INJECTION
DOCEFREZ

+		@ SUN PHARMA GLOBAL	20MG/VIAL	N022534	001	May 03, 2011	Aug DISC
---	--	---------------------	-----------	---------	-----	--------------	----------

+		@	80MG/VIAL	N022534	002	May 03, 2011	Aug DISC
---	--	---	-----------	---------	-----	--------------	----------

DOCETAXEL

AP		ACTAVIS LLC	20MG/ML (20MG/ML)	N203551	001	Apr 12, 2013	Feb CAHN
----	--	-------------	-------------------	---------	-----	--------------	----------

AP			80MG/4ML (20MG/ML)	N203551	002	Apr 12, 2013	Feb CAHN
----	--	--	--------------------	---------	-----	--------------	----------

140MG/7ML (20MG/ML)

AP		DFB ONCOLOGY LTD	20MG/ML (20MG/ML)	A206177	001	Jan 20, 2017	Jan NEWA
----	--	------------------	-------------------	---------	-----	--------------	----------

AP			80MG/4ML (20MG/ML)	A206177	002	Jan 20, 2017	Jan NEWA
----	--	--	--------------------	---------	-----	--------------	----------

200MG/10ML (20MG/ML)

+		@ HOSPIRA INC	120MG/6ML (20MG/ML)	N022234	006	Jun 23, 2016	Aug DISC
---	--	---------------	---------------------	---------	-----	--------------	----------

+			160MG/8ML (20MG/ML)	N022234	007	Jan 24, 2017	Jan NEWA
---	--	--	---------------------	---------	-----	--------------	----------

AP		INGENUS PHARMS LLC	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017	Aug NEWA
----	--	--------------------	--------------------	---------	-----	--------------	----------

AP			80MG/8ML (10MG/ML)	A207563	002	Aug 31, 2017	Aug NEWA
----	--	--	--------------------	---------	-----	--------------	----------

AP			160MG/16ML (10MG/ML)	A207563	003	Aug 31, 2017	Aug NEWA
----	--	--	----------------------	---------	-----	--------------	----------

AP		JIANGSU HENGRUI MED	20MG/ML (20MG/ML)	A207252	001	Aug 09, 2017	Jul NEWA
----	--	---------------------	-------------------	---------	-----	--------------	----------

!			40MG/ML	A203170	001	Feb 15, 2017	Jan NEWA
---	--	--	---------	---------	-----	--------------	----------

AP			80MG/4ML (20MG/ML)	A207252	002	Aug 09, 2017	Jul NEWA
----	--	--	--------------------	---------	-----	--------------	----------

AP			160MG/8ML (20MG/ML)	A207252	003	Aug 09, 2017	Jul NEWA
----	--	--	---------------------	---------	-----	--------------	----------

		@ PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014	Jan DISC
--	--	---------------	--------------------	---------	-----	--------------	----------

		@	80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014	Jan DISC
--	--	---	--------------------	---------	-----	--------------	----------

		@	130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014	Jan DISC
--	--	---	----------------------	---------	-----	--------------	----------

		@	200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014	Jan DISC
--	--	---	----------------------	---------	-----	--------------	----------

DOFETILIDE

CAPSULE; ORAL
DOFETILIDE

AB		MAYNE PHARMA INC	0.125MG	A207058	001	Jun 06, 2016	Feb CAHN
----	--	------------------	---------	---------	-----	--------------	----------

AB			0.25MG	A207058	002	Jun 06, 2016	Feb CAHN
----	--	--	--------	---------	-----	--------------	----------

AB			0.5MG	A207058	003	Jun 06, 2016	Feb CAHN
----	--	--	-------	---------	-----	--------------	----------

DOLASETRON MESYLATEINJECTABLE; INJECTION
ANZEMET

+ @ US PHARM HOLDINGS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997	Oct DISC
+ @	100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997	Oct DISC

TABLET; ORAL
ANZEMET

+ @ US PHARM HOLDINGS	50MG	N020623	001	Sep 11, 1997	Oct DISC
+ @	100MG	N020623	002	Sep 11, 1997	Oct DISC

DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDETABLET; ORAL
JULUCA

+! VIIV HLTHCARE	EQ 50MG BASE; EQ 25MG BASE	N210192	001	Nov 21, 2017	Nov NEWA
------------------	----------------------------	---------	-----	--------------	----------

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB	ACI HEALTHCARE LTD	5MG	A078662	001	May 31, 2011	Jun CAHN
AB		10MG	A078662	002	May 31, 2011	Jun CAHN
AB	ALLIED PHARMA INC	5MG	A078662	001	May 31, 2011	Mar CAHN
AB		10MG	A078662	002	May 31, 2011	Mar CAHN
AB	CADILA PHARMS LTD	5MG	A204609	001	Sep 19, 2017	Sep NEWA
AB		10MG	A204609	002	Sep 19, 2017	Sep NEWA
AB	VIVIMED GLOBAL	5MG	A090551	001	May 31, 2011	Aug CAHN
AB		10MG	A090551	002	May 31, 2011	Aug CAHN
AB	ZHEJIANG HISUN PHARM	23MG	A202410	001	Mar 24, 2017	Mar NEWA
AB	ZYDUS PHARMS USA INC	23MG	A203162	001	Aug 31, 2017	Aug NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

AB	AMNEAL PHARMS	10MG; 14MG	A208328	001	Jan 27, 2017	Jan NEWA
AB		10MG; 28MG	A208328	002	Jan 27, 2017	Jan NEWA
	NAMZARIC					
AB	+ FOREST LABS LLC	10MG; 14MG	N206439	001	Dec 23, 2014	Jan CFTG
AB	+!	10MG; 28MG	N206439	002	Dec 23, 2014	Jan CFTG

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

!	LUITPOLD	160MG/ML	A070826	001	Feb 11, 1987	Nov CTEC
@	TELIGENT	40MG/ML	N018656	001	Jun 28, 1983	May CAHN

DORIPENEM

INJECTABLE; IV (INFUSION)

DORIBAX

+ @ SHIONOGI INC	250MG/VIAL	N022106	002	Oct 05, 2010	Sep DISC
+ @	500MG/VIAL	N022106	001	Oct 12, 2007	Sep DISC

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT	SANDOZ INC	EQ 2% BASE	A078748	001	Nov 06, 2008	Mar CAHN
AT		EQ 2% BASE	A078981	001	Apr 13, 2009	Feb CAHN
	@ ZAMBON SPA	EQ 2% BASE	A091034	001	Dec 04, 2013	Nov DISC
AT		EQ 2% BASE	A091034	001	Dec 04, 2013	Sep CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT	SANDOZ INC	EQ 2% BASE; EQ 0.5% BASE	A090604	001	Nov 18, 2009	Mar CAHN
AT	ZAMBON SPA	EQ 2% BASE; EQ 0.5% BASE	A091180	001	Dec 04, 2013	Sep CAHN

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOXAPRAM HYDROCHLORIDE

AP	ATHENEX INC	20MG/ML	A076266	001	Jan 10, 2003	Mar CAHN
----	-------------	---------	---------	-----	--------------	----------

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

>A>	@ FOSUN PHARMA	EQ 1MG BASE	A075646	001	Oct 18, 2000	Dec CAHN
>A>	@	EQ 2MG BASE	A075646	002	Oct 18, 2000	Dec CAHN
>A>	@	EQ 4MG BASE	A075646	003	Oct 18, 2000	Dec CAHN
>A>	@	EQ 8MG BASE	A075646	004	Oct 18, 2000	Dec CAHN
>D>	@ SANDOZ	EQ 1MG BASE	A075646	001	Oct 18, 2000	Dec CAHN
>D>	@	EQ 2MG BASE	A075646	002	Oct 18, 2000	Dec CAHN
>D>	@	EQ 4MG BASE	A075646	003	Oct 18, 2000	Dec CAHN
>D>	@	EQ 8MG BASE	A075646	004	Oct 18, 2000	Dec CAHN
AB	ZYDUS PHARMS USA INC	EQ 1MG BASE	A208719	001	Jul 07, 2017	Jun NEWA
AB		EQ 2MG BASE	A208719	002	Jul 07, 2017	Jun NEWA
AB		EQ 4MG BASE	A208719	003	Jul 07, 2017	Jun NEWA
AB		EQ 8MG BASE	A208719	004	Jul 07, 2017	Jun NEWA

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB	AMNEAL PHARMS CO	EQ 10MG BASE	A207482	001	Jun 28, 2017	Jun NEWA
AB		EQ 25MG BASE	A207482	002	Jun 28, 2017	Jun NEWA
AB		EQ 50MG BASE	A207482	003	Jun 28, 2017	Jun NEWA
AB		EQ 75MG BASE	A207482	004	Jun 28, 2017	Jun NEWA
AB		EQ 100MG BASE	A207482	005	Jun 28, 2017	Jun NEWA
	@ WATSON LABS TEVA	EQ 50MG BASE	A072987	001	Mar 29, 1991	May CAHN

CONCENTRATE;ORAL

DOXEPIN HYDROCHLORIDE

>D> AA	WOCKHARDT	EQ 10MG BASE/ML	A071918	001	Jul 20, 1988	Dec CAHN
>A> AA	WOCKHARDT BIO AG	EQ 10MG BASE/ML	A071918	001	Jul 20, 1988	Dec CAHN

CREAM;TOPICAL

ZONALON

+!	MYLAN PHARMS INC	5%	N020126	001	Apr 01, 1994	Jan CAHN
----	------------------	----	---------	-----	--------------	----------

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

@	MYLAN PHARMS INC	EQ 3MG BASE	A202337	001	Jan 20, 2016	Nov DISC
@		EQ 6MG BASE	A202337	002	Jan 20, 2016	Nov DISC

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP	AMNEAL PHARMS CO	2MCG/ML (2MCG/ML)	A208974	001	May 24, 2017	May NEWA
AP		4MCG/2ML (2MCG/ML)	A208974	002	May 24, 2017	May NEWA
AP		4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017	May NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	AMNEAL PHARMS CO	20MG/VIAL	A208888	001	Feb 17, 2017	Feb NEWA
AP		50MG/VIAL	A208888	002	Feb 17, 2017	Feb NEWA
AP	GLAND PHARMA LTD	2MG/ML	A209825	001	Aug 11, 2017	Jul NEWA

INJECTABLE, LIPOSOMAL;INJECTION

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB	DR REDDYS LABS LTD	20MG/10ML (2MG/ML)	A208657	001	May 15, 2017	May NEWA
AB		50MG/25ML (2MG/ML)	A208657	002	May 15, 2017	May NEWA

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB	ALEMBIC PHARMS LTD	EQ 75MG BASE	A209165	001	Jul 28, 2017	Jul NEWA
AB		EQ 100MG BASE	A209165	002	Jul 28, 2017	Jul NEWA
AB	MAYNE PHARMA INC	EQ 50MG BASE	A209396	001	Sep 29, 2017	Sep NEWA
AB		EQ 75MG BASE	A209396	002	Sep 29, 2017	Sep NEWA
AB		EQ 100MG BASE	A209396	003	Sep 29, 2017	Sep NEWA

TABLET;ORAL

DOXYCYCLINE

AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A209582	001	Sep 28, 2017	Sep NEWA
AB		EQ 75MG BASE	A209582	002	Sep 28, 2017	Sep NEWA
AB		EQ 100MG BASE	A209582	003	Sep 28, 2017	Sep NEWA
AB		EQ 150MG BASE	A209582	004	Sep 28, 2017	Sep NEWA

DOXYCYCLINE HYCLATE

		CAPSULE;ORAL							
		PERIOSTAT							
		+ @ COLLAGENEX	EQ 20MG BASE	N050744	001	Sep 30, 1998	Nov	CDFR	
		CAPSULE, DELAYED RELEASE;ORAL							
		DOXYCYCLINE HYCLATE							
		@ MEDICIS	EQ 75MG BASE	A065281	001	Dec 21, 2005	Jul	DISC	
		@	EQ 100MG BASE	A065281	002	Dec 21, 2005	Jul	DISC	
		INJECTABLE;INJECTION							
		DOXY 200							
AP	!	FRESENIUS KABI USA	EQ 200MG BASE/VIAL	A062475	002	Dec 09, 1983	Nov	CTEC	
		DOXYCYCLINE							
AP		ZYDUS PHARMS USA INC	EQ 100MG BASE/VIAL	A207757	001	Sep 28, 2017	Sep	NEWA	
AP			EQ 200MG BASE/VIAL	A207757	002	Sep 28, 2017	Sep	NEWA	
		VIBRAMYCIN							
		+ @ PFIZER	EQ 100MG BASE/VIAL	N050442	002		Jan	CRLD	
		+ @	EQ 200MG BASE/VIAL	N050442	001		Jan	CRLD	
		TABLET;ORAL							
		ACTICLATE							
AB	+	AQUA PHARMS LLC	EQ 75MG BASE	N205931	001	Jul 25, 2014	Jun	CFTG	
AB	+	!	EQ 150MG BASE	N205931	002	Jul 25, 2014	Jun	CFTG	
		DOXYCYCLINE HYCLATE							
AB		AMNEAL PHARMS CO	EQ 75MG BASE	A209372	001	Oct 06, 2017	Sep	NEWA	
AB			EQ 150MG BASE	A209372	002	Oct 06, 2017	Sep	NEWA	
		CARIBE HOLDINGS	EQ 50MG BASE	A062269	003		Mar	CMFD	
		@	EQ 50MG BASE	A062269	003		Jan	CAHN	
AB			EQ 100MG BASE	A062269	002	Nov 08, 1982	Jan	CAHN	
		@ EPIC PHARMA LLC	EQ 20MG BASE	A065182	001	May 13, 2005	May	CAHN	
AB		LUPIN LTD	EQ 75MG BASE	A208818	001	Sep 27, 2017	Sep	NEWA	
AB			EQ 150MG BASE	A208818	002	Sep 27, 2017	Sep	NEWA	
AB		MAYNE PHARMA INC	EQ 75MG BASE	A208765	001	Jun 14, 2017	May	NEWA	
AB			EQ 150MG BASE	A208765	002	Jun 14, 2017	May	NEWA	
AB		NOVEL LABS INC	EQ 100MG BASE	A207558	001	Sep 06, 2017	Aug	NEWA	
AB		ZYDUS PHARMS USA INC	EQ 100MG BASE	A207773	001	Oct 30, 2017	Oct	NEWA	
		TABLET, DELAYED RELEASE;ORAL							
		DORYX MPC							
>D>	+	MAYNE PHARMA	EQ 60MG BASE	N050795	007	May 20, 2016	Dec	DISC	
>A>	+	@	EQ 60MG BASE	N050795	007	May 20, 2016	Dec	DISC	

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

		TABLET, DELAYED RELEASE;ORAL							
		DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE							
AB		PAR PHARM INC	10MG;10MG	A208518	001	Dec 06, 2017	Nov	NEWA	

DRONABINOL

		SOLUTION;ORAL							
		SYNDROS							
	+	!	INSYS DEV CO INC	5MG/ML	N205525	001	Mar 23, 2017	Mar	NEWA

DROPERIDOL

		INJECTABLE;INJECTION							
		DROPERIDOL							
>A>	AP		EUROHLTH INTL SARL	2.5MG/ML	A208197	001	Dec 14, 2017	Dec	NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

		TABLET;ORAL							
		DROSPIRENONE AND ETHINYL ESTRADIOL							
>A>	AB		CYNDEA PHARMA	3MG;0.02MG	A209423	001	Dec 22, 2017	Dec	NEWA
	AB		PII	3MG;0.02MG	A203291	001	Jul 18, 2017	Jul	NEWA
		LORYNA							
AB			LABS LEON FARMA	3MG;0.02MG	A079221	001	Mar 28, 2011	Nov	CAHN
		TABLET;ORAL-28							
		SYEDA							
AB			LABS LEON FARMA	3MG;0.03MG	A090114	001	Mar 28, 2011	Nov	CAHN

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET;ORAL

TYDEMY

AB	LUPIN LTD	3MG,N/A;0.03MG,N/A;0.451MG,0.451MG	A205948	001	Dec 12, 2017	Nov NEWA
----	-----------	------------------------------------	---------	-----	--------------	----------

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A204815	001	Mar 23, 2017	Mar NEWA
AB		EQ 30MG BASE	A204815	002	Mar 23, 2017	Mar NEWA
AB		EQ 60MG BASE	A204815	003	Mar 23, 2017	Mar NEWA
AB	PRINSTON INC	EQ 20MG BASE	A206653	001	May 18, 2017	May NEWA
AB		EQ 30MG BASE	A206653	002	May 18, 2017	May NEWA
AB		EQ 60MG BASE	A206653	003	May 18, 2017	May NEWA
AB	ZYDUS HLTHCARE	EQ 20MG BASE	A090739	001	Jan 08, 2014	Apr CAHN
AB		EQ 30MG BASE	A090739	002	Jan 08, 2014	Apr CAHN
AB		EQ 60MG BASE	A090739	003	Jan 08, 2014	Apr CAHN

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

AB	AMNEAL PHARMS	0.5MG	A203118	001	Nov 20, 2015	May CAHN
AB	HAUPT PHARMA	0.5MG	A207935	001	Oct 13, 2017	Oct NEWA
AB	HUMANWELL PURACAP	0.5MG	A209909	001	Nov 21, 2017	Nov NEWA
AB	MARKSANS PHARMA	0.5MG	A204376	001	Apr 07, 2017	Mar NEWA
AB	ZYDUS PHARMS USA INC	0.5MG	A204373	001	Oct 04, 2017	Sep NEWA

DYPHYLLINE

TABLET;ORAL

LUFYLLIN

	@ MYLAN SPECIALITY LP	200MG	A084566	001		Mar CAHN
	@	400MG	A084566	002		Mar CAHN

ECONAZOLE NITRATE

AEROSOL, FOAM;TOPICAL

ECOZA

+	!	CHEMO RESEARCH SL	1%	N205175	001	Oct 24, 2013	May CAHN
---	---	-------------------	----	---------	-----	--------------	----------

CREAM;TOPICAL

SPECTAZOLE

AB	+	ALVOGEN MALTA	1%	N018751	001	Dec 23, 1982	Sep CMFD
	+	@	1%	N018751	001	Dec 23, 1982	Mar CMS1

EDARAVONE

SOLUTION;IV (INFUSION)

RADICAVA

+	!	MITSUBISHI TANABE	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	May NEWA
---	---	-------------------	-----------------------	---------	-----	--------------	----------

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

TENSILON

+	@	TELIGENT	10MG/ML	N007959	001		Apr CAHN
---	---	----------	---------	---------	-----	--	----------

TENSILON PRESERVATIVE FREE

+	@	TELIGENT	10MG/ML	N007959	002		Apr CAHN
---	---	----------	---------	---------	-----	--	----------

EFAVIRENZ

CAPSULE;ORAL

EFAVIRENZ

>A>	AB	AUROBINDO PHARMA LTD	50MG	A078064	001	Dec 15, 2017	Dec NEWA
>A>			100MG	A078064	002	Dec 15, 2017	Dec NEWA
>A>	AB		200MG	A078064	003	Dec 15, 2017	Dec NEWA
		SUSTIVA					
>D>	+	BRISTOL MYERS SQUIBB	50MG	N020972	001	Sep 17, 1998	Dec CFTG
>A>	AB	+	50MG	N020972	001	Sep 17, 1998	Dec CFTG
>D>	+	!	200MG	N020972	003	Sep 17, 1998	Dec CFTG
>A>	AB	+	200MG	N020972	003	Sep 17, 1998	Dec CFTG

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL

ELETRIPTAN HYDROBROMIDE

AB	AJANTA PHARMA LTD	EQ 20MG BASE	A205186	001	Aug 29, 2017	Aug NEWA
AB		EQ 40MG BASE	A205186	002	Aug 29, 2017	Aug NEWA
AB	MYLAN PHARMS INC	EQ 20MG BASE	A205152	001	Aug 11, 2017	Jul NEWA
AB		EQ 40MG BASE	A205152	002	Aug 11, 2017	Jul NEWA
AB	TEVA PHARMS USA	EQ 20MG BASE	A202040	001	Jun 27, 2017	Jun NEWA
AB		EQ 40MG BASE	A202040	002	Jun 27, 2017	Jun NEWA
AB	ZYDUS PHARMS USA INC	EQ 20MG BASE	A206409	001	Jun 16, 2017	Jun NEWA
AB		EQ 40MG BASE	A206409	002	Jun 16, 2017	Jun NEWA
RELPAK						
AB	+ PFIZER IRELAND	EQ 20MG BASE	N021016	001	Dec 26, 2002	Jun CFTG
AB	+!	EQ 40MG BASE	N021016	002	Dec 26, 2002	Jun CFTG

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	TEVA PHARMS USA	200MG;300MG	A090894	001	Jun 08, 2017	May NEWA
TRUVADA						
AB	+! GILEAD	200MG;300MG	N021752	001	Aug 02, 2004	May CFTG

ENALAPRIL MALEATE

SOLUTION; ORAL

EPANED

+!	SILVERGATE PHARMS	1MG/ML	N208686	001	Sep 20, 2016	Jul CRLD
----	-------------------	--------	---------	-----	--------------	----------

TABLET; ORAL

ENALAPRIL MALEATE

>A> AB	WOCKHARDT LTD	2.5MG	A075483	001	Aug 22, 2000	Dec CAHN
>A> AB		5MG	A075483	002	Aug 22, 2000	Dec CAHN
>A> AB		10MG	A075483	003	Aug 22, 2000	Dec CAHN
>A> AB		20MG	A075483	004	Aug 22, 2000	Dec CAHN
>D> AB	WOCKHARDT USA	2.5MG	A075483	001	Aug 22, 2000	Dec CAHN
>D> AB		5MG	A075483	002	Aug 22, 2000	Dec CAHN
>D> AB		10MG	A075483	003	Aug 22, 2000	Dec CAHN
>D> AB		20MG	A075483	004	Aug 22, 2000	Dec CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

@	UPSHER-SMITH LABS	5MG;12.5MG	A076116	001	Sep 19, 2001	Jun CAHN
@		10MG;25MG	A076116	002	Sep 19, 2001	Jun CAHN

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

AP	! ATHENEX INC	1.25MG/ML	A075634	001	Aug 22, 2000	Mar CAHN
VASOTEC						
	+ @ BIOVAIL LABS INTL	1.25MG/ML	N019309	001	Feb 09, 1988	Mar CRLD

ENASIDENIB MESYLATE

TABLET; ORAL

IDHIFA

+	CELGENE CORP	EQ 50MG BASE	N209606	001	Aug 01, 2017	Aug NEWA
+	!	EQ 100MG BASE	N209606	002	Aug 01, 2017	Aug NEWA

ENTACAPONE

TABLET; ORAL

ENTACAPONE

AB	AJANTA PHARMA LTD	200MG	A205792	001	Aug 31, 2017	Aug NEWA
AB	MACLEODS PHARMS LTD	200MG	A207210	001	Jun 05, 2017	May NEWA
	@ MYLAN PHARMS INC	200MG	A202394	001	May 13, 2013	May DISC

ENTECAVIR

TABLET; ORAL

ENTECAVIR

AB	ACCORD HLTHCARE	0.5MG	A205824	001	Aug 25, 2017	Aug NEWA
AB		1MG	A205824	002	Aug 25, 2017	Aug NEWA
AB	PRINSTON INC	0.5MG	A208782	001	Oct 10, 2017	Sep NEWA
AB		1MG	A208782	002	Oct 10, 2017	Sep NEWA
AB	SANDOZ INC	0.5MG	A206672	001	May 11, 2017	May NEWA

TABLET;ORAL
ENTECAVIR

AB		1MG	A206672	002	May 11, 2017	May NEWA
AB	ZYDUS PHARMS USA INC	0.5MG	A206745	001	Jun 23, 2017	Jun NEWA
AB		1MG	A206745	002	Jun 23, 2017	Jun NEWA

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS
AKOVAZ

AP	+! FLAMEL IRELAND LTD	50MG/ML (50MG/ML)	N208289	001	Apr 29, 2016	Mar CTEC
	EPHEDRINE SULFATE					
AP	AKORN INC	50MG/ML (50MG/ML)	N208609	001	Mar 01, 2017	Mar NEWA
AP	SANDOZ INC	50MG/ML (50MG/ML)	A209784	001	Aug 23, 2017	Aug NEWA
	SOLUTION;IV (INFUSION)					
	CORPHEDRA					
	PAR STERILE PRODUCTS	50MG/ML (50MG/ML)	N208943	001	Jan 27, 2017	Jan NEWA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
EPINASTINE HYDROCHLORIDE

AT	AKORN	0.05%	A204055	001	May 05, 2017	Apr NEWA
AT	SANDOZ INC	0.05%	A203384	001	Dec 07, 2016	Mar CAHN

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
ADRENALIN

BX	+! IMPAX LABS INC	EQ 0.15MG/DELIVERY	N020800	003	Nov 25, 2009	Jun CAHN
BX	+!	EQ 0.3MG/DELIVERY	N020800	004	Nov 25, 2009	Jun CAHN
	TWINJECT 0.15					
	@ IMPAX LABS INC	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004	Jun CAHN
	TWINJECT 0.3					
	@ IMPAX LABS INC	EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003	Jun CAHN
	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS					
	ADRENALIN					
	+! PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Aug CDFR
	+!	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Aug CDFR
	AUVI-Q					
	+ KALEO INC	EQ 0.1MG/DELIVERY	N201739	003	Nov 17, 2017	Nov NEWA
BX	+!	EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012	Nov CDFR
BX	+	EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012	Nov CDFR
	SYMJEPI					
>D>	+! ADAMIS PHARMS CORP	0.3MG/ML (0.3MG/ML)	N207534	001	Jun 15, 2017	Dec CPOT
>A>	+!	0.3MG/0.3ML (0.3MG/0.3ML)	N207534	001	Jun 15, 2017	Dec CPOT
	+!	0.3MG/ML (0.3MG/ML)	N207534	001	Jun 15, 2017	Jun NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

	@ BELMORA LLC	0.01MG/ML;2%	A080504	004	Oct 19, 1983	Feb CAHN
	@	0.02MG/ML;2%	A080504	005	Oct 19, 1983	Feb CAHN
	@ WEST-WARD PHARMS INT	0.01MG/ML;1%	A080406	001		Mar CAHN
	@	0.01MG/ML;2%	A080406	002		Mar CAHN
	XYLOCAINE W/ EPINEPHRINE					
	+! FRESENIUS KABI USA	0.005MG/ML;1%	N006488	018	Nov 13, 1986	Nov CTEC

EPLERENONE

TABLET;ORAL
EPLERENONE

AB	ACCORD HLTHCARE	25MG	A206922	001	Jul 13, 2017	Jul NEWA
AB		50MG	A206922	002	Jul 13, 2017	Jul NEWA
AB	MYLAN PHARMS INC	25MG	A203896	001	Feb 02, 2017	Jan NEWA
AB		50MG	A203896	002	Feb 02, 2017	Jan NEWA

EPTIFIBATIDE

INJECTABLE;INJECTION
EPTIFIBATIDE

AP	ACCORD HLTHCARE	2MG/ML	A205557	001	Nov 06, 2017	Oct NEWA
AP		75MG/100ML	A205557	002	Nov 06, 2017	Oct NEWA
AP	AKORN	2MG/ML	A204589	001	Apr 18, 2017	Apr NEWA
AP		75MG/100ML	A204589	002	Apr 18, 2017	Apr NEWA
AP	AMNEAL PHARMS	2MG/ML	A205581	001	Dec 08, 2016	May CAHN
AP		75MG/100ML	A205581	002	Dec 08, 2016	May CAHN

ERGOLOID MESYLATES

TABLET;ORAL

ERGOLOID MESYLATES

! SUN PHARM INDUSTRIES 1MG
HYDERGINE

A081113 001 Oct 31, 1991 May CHRS

+ @ NOVARTIS 1MG

N017993 001 May DISC

>A> ERTUGLIFLOZIN

>A> TABLET;ORAL

>A> STEGLATRO

>A> + MERCK SHARP DOHME 5MG

N209803 001 Dec 19, 2017 Dec NEWA

>A> +! 15MG

N209803 002 Dec 19, 2017 Dec NEWA

>A> ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE

>A> TABLET;ORAL

>A> SEGLUROMET

>A> + MERCK SHARP DOHME 2.5MG;500MG

N209806 001 Dec 19, 2017 Dec NEWA

>A> + 2.5MG;1GM

N209806 002 Dec 19, 2017 Dec NEWA

>A> + 7.5MG;500MG

N209806 003 Dec 19, 2017 Dec NEWA

>A> +! 7.5MG;1GM

N209806 004 Dec 19, 2017 Dec NEWA

>A> ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

>A> TABLET;ORAL

>A> STELUJAN

>A> + MERCK SHARP DOHME 5MG;EQ 100MG BASE

N209805 001 Dec 19, 2017 Dec NEWA

>A> +! 15MG;EQ 100MG BASE

N209805 002 Dec 19, 2017 Dec NEWA

ERYTHROMYCIN

GEL;TOPICAL

E-GLADES

@ MYLAN PHARMS INC 2%

A065009 001 Mar 18, 2002 Jan CAHN

ERYGEL

AT +! MYLAN PHARMS INC 2%

N050617 001 Oct 21, 1987 Jan CAHN

ERYTHROMYCIN

AT PERRIGO CO 2%

A063211 001 Jan 29, 1993 Apr CAHN

AT TELIGENT PHARMA INC 2%

A208154 001 Jul 19, 2017 Jul NEWA

OINTMENT;TOPICAL

AKNE-MYCIN

+ @ DOW PHARM 2%

N050584 001 Jan 10, 1985 Oct DISC

SOLUTION;TOPICAL

A/T/S

@ TARO 2%

A062405 001 Nov 18, 1982 Apr CAHN

ERYTHRA-DERM

@ SAPTALIS PHARMS 2%

A062687 001 Feb 05, 1988 Oct CAHN

ERYTHROMYCIN

@ FOUGERA PHARMS 2%

A064187 001 Sep 30, 1997 Aug DISC

AT ! PERRIGO NEW YORK 2%

A063038 001 Jan 11, 1991 Aug CHRS

AT TELIGENT PHARMA INC 2%

A208100 001 Nov 20, 2017 Nov NEWA

>D> AT WOCKHARDT 2%

A062825 001 Oct 23, 1987 Dec CAHN

>A> AT WOCKHARDT BIO AG 2%

A062825 001 Oct 23, 1987 Dec CAHN

SWAB;TOPICAL

ERYCETTE

+ @ JOHNSON AND JOHNSON 2%

N050594 001 Feb 15, 1985 Sep CRLD

ERYTHROMYCIN

@ MYLAN PHARMS INC 2%

A064128 001 Jul 03, 1996 Jan CAHN

AT ! PERRIGO CO 2%

A064126 001 Jul 03, 1996 Apr CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

E.E.S.

+ ARBOR PHARMS LLC EQ 200MG BASE/5ML

N050207 001 Oct CTEC

ERYPED

+ ARBOR PHARMS LLC EQ 200MG BASE/5ML

N050207 003 Mar 30, 1987 Oct CTEC

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL

@ BARR EQ 200MG BASE/5ML;EQ 600MG
BASE/5ML

A062759 001 May 20, 1988 Jul DISC

ESCITALOPRAM OXALATE

TABLET; ORAL

ESCITALOPRAM OXALATE

AB	AMNEAL PHARMS	EQ 5MG BASE	A205619	001	May 17, 2017	May	NEWA
AB		EQ 10MG BASE	A205619	002	May 17, 2017	May	NEWA
AB		EQ 20MG BASE	A205619	003	May 17, 2017	May	NEWA
	@ MYLAN PHARMS INC	EQ 5MG BASE	A077550	001	May 14, 2015	Nov	DISC
	@	EQ 10MG BASE	A077550	002	May 14, 2015	Nov	DISC
	@	EQ 20MG BASE	A077550	003	May 14, 2015	Nov	DISC

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

ESOMEPRAZOLE MAGNESIUM

AB	ALKEM LABS LTD	EQ 20MG BASE	A208333	001	Oct 20, 2017	Oct	NEWA
AB		EQ 40MG BASE	A208333	002	Oct 20, 2017	Oct	NEWA
AB	KREMERS URBAN PHARMS	EQ 20MG BASE	A205563	001	Sep 01, 2017	Aug	NEWA
AB		EQ 40MG BASE	A205563	002	Sep 01, 2017	Aug	NEWA

FOR SUSPENSION, DELAYED RELEASE; ORAL

NEXIUM

+	ASTRAZENECA PHARMS	EQ 10MG BASE/PACKET	N022101	001	Feb 27, 2008	May	CRLD
---	--------------------	---------------------	---------	-----	--------------	-----	------

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

ESOMEPRAZOLE SODIUM

>D>	AP	!	AUROBINDO PHARMA LTD	EQ 20MG BASE/VIAL	A204657	001	Aug 10, 2016	Dec	DISC
>A>		@		EQ 20MG BASE/VIAL	A204657	001	Aug 10, 2016	Dec	DISC
	AP	!		EQ 20MG BASE/VIAL	A204657	001	Aug 10, 2016	May	CHRS
>D>	AP			EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Dec	CHRS
>A>	AP	!		EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Dec	CHRS
	AP			EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Aug	CHRS
	AP	!		EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	May	CHRS
	AP		DEVA HOLDING AS	EQ 40MG BASE/VIAL	A207181	001	Mar 06, 2017	Feb	NEWA
>D>	AP		MYLAN LABS LTD	EQ 20MG BASE/VIAL	A202686	001	May 17, 2017	Dec	DISC
>A>		@		EQ 20MG BASE/VIAL	A202686	001	May 17, 2017	Dec	DISC
	AP			EQ 20MG BASE/VIAL	A202686	001	May 17, 2017	May	NEWA
	AP			EQ 40MG BASE/VIAL	A202686	002	May 17, 2017	May	NEWA
>D>	AP		SUN PHARMA GLOBAL	EQ 20MG BASE/VIAL	A200882	001	Mar 18, 2013	Dec	DISC
>A>		@		EQ 20MG BASE/VIAL	A200882	001	Mar 18, 2013	Dec	DISC
			NEXIUM IV						
		+	@ ASTRAZENECA PHARMS	EQ 20MG BASE/VIAL	N021689	001	Mar 31, 2005	May	DISC
AP		+	!	EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005	Aug	CMFD
		+	@	EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005	May	DISC

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE STRONTIUM

>D>	+	R2 PHARMA LLC	24.65MG	N202342	001	Aug 06, 2013	Dec	DISC
>A>	+	@	24.65MG	N202342	001	Aug 06, 2013	Dec	DISC

ESTRADIOL

CREAM; VAGINAL

ESTRACE

>D>	!	ALLERGAN SALES LLC	0.01%	A086069	001	Jan 31, 1984	Dec	CFTG	
>A>	AB	!		A086069	001	Jan 31, 1984	Dec	CFTG	
>A>			ESTRADIOL						
>A>	AB		MYLAN PHARMS INC	0.01%	A208788	001	Dec 29, 2017	Dec	NEWA

FILM, EXTENDED RELEASE; TRANSDERMAL

ESTRADERM

+	@	NOVARTIS	0.05MG/24HR	N019081	002	Sep 10, 1986	May	DISC
+	@		0.1MG/24HR	N019081	003	Sep 10, 1986	May	DISC
		VIVELLE						
	@	NOVARTIS	0.05MG/24HR	N020323	002	Oct 28, 1994	May	DISC
	@		0.1MG/24HR	N020323	004	Oct 28, 1994	May	DISC

GEL, METERED; TRANSDERMAL

ELESTRIN

+	!	MYLAN SPECIALITY LP	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006	Mar	CAHN
		SPRAY; TRANSDERMAL						
		EVAMIST						
+	!	PERRIGO PHARMA INTL	1.53MG/SPRAY	N022014	001	Jul 27, 2007	May	CAHN

TABLET;VAGINAL						
ESTRADIOL						
AB	TEVA PHARMS USA	10MCG	A206388	001	Jul 21, 2017	Jul NEWA

ESTRADIOL ACETATE

TABLET;ORAL
FEMTRACE

+	@ APIL	0.45MG	N021633	001	Aug 20, 2004	Jun DISC
+	@	0.9MG	N021633	002	Aug 20, 2004	Jun DISC
+	@	1.8MG	N021633	003	Aug 20, 2004	Jun DISC

ESTRADIOL VALERATE

INJECTABLE;INJECTION
ESTRADIOL VALERATE

@	SANDOZ INC	10MG/ML	A040628	001	Oct 04, 2007	Apr CAHN
@		20MG/ML	A040628	002	Oct 04, 2007	Apr CAHN
@		40MG/ML	A040628	003	Oct 04, 2007	Apr CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

AB	MYLAN LABS LTD	0.5MG;0.1MG	A207261	001	Feb 10, 2017	Jan NEWA
AB		1MG;0.5MG	A207261	002	Feb 10, 2017	Jan NEWA

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET;ORAL
CENESTIN

+	@ TEVA BRANDED PHARM	0.3MG	N020992	001	Jun 21, 2002	Aug CRLD
+	@	0.45MG	N020992	005	Feb 05, 2004	Aug CRLD
+	@	0.625MG	N020992	002	Mar 24, 1999	Aug CRLD
+	@	0.9MG	N020992	003	Mar 24, 1999	Aug CRLD
+	@	1.25MG	N020992	004	Mar 13, 2000	Aug CRLD

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET;ORAL

ENJUVIA

@	TEVA BRANDED PHARM	0.3MG	N021443	001	Dec 20, 2004	Aug DISC
		0.3MG	N021443	001	Dec 20, 2004	Apr CAHN
@		0.45MG	N021443	002	Dec 20, 2004	Aug DISC
		0.45MG	N021443	002	Dec 20, 2004	Apr CAHN
@		0.625MG	N021443	003	May 10, 2004	Apr CAHN
@		0.9MG	N021443	005	Apr 27, 2007	Aug DISC
		0.9MG	N021443	005	Apr 27, 2007	Apr CAHN
@		1.25MG	N021443	004	May 10, 2004	Apr CAHN

ESTROGENS, ESTERIFIED

TABLET;ORAL

MENEST

	MONARCH PHARMS	0.3MG	A084951	001		Jun CAHN
		0.625MG	A084948	001		Jun CAHN
		1.25MG	A084950	001		Jun CAHN
!		2.5MG	A084949	001		Jun CAHN

ESTRONE

INJECTABLE;INJECTION

ESTRONE

@	WATSON LABS TEVA	5MG/ML	A085239	001		May CAHN
---	------------------	--------	---------	-----	--	----------

ESTROPIPATE

TABLET;ORAL

ESTROPIPATE

>D>	AB	MYLAN	0.75MG	A040359	001	Aug 26, 1999	Dec CTEC
>A>			0.75MG	A040359	001	Aug 26, 1999	Dec CTEC
>D>	AB		1.5MG	A040359	002	Aug 26, 1999	Dec CTEC
>A>			1.5MG	A040359	002	Aug 26, 1999	Dec CTEC
>D>	AB	WATSON LABS	0.75MG	A081213	001	Sep 23, 1993	Dec DISC
>A>		@	0.75MG	A081213	001	Sep 23, 1993	Dec DISC
>D>	AB		1.5MG	A081214	001	Sep 23, 1993	Dec DISC
>A>		@	1.5MG	A081214	001	Sep 23, 1993	Dec DISC
>D>		! WATSON LABS TEVA	3MG	A081215	001	Sep 23, 1993	Dec DISC
>A>		@	3MG	A081215	001	Sep 23, 1993	Dec DISC
		!	3MG	A081215	001	Sep 23, 1993	May CHRS

TABLET;ORAL
ESTROPIPATE

AB		3MG	A081215	001	Sep 23, 1993	Feb CAHN
	OGEN .625					
	@ PHARMACIA AND UPJOHN	0.75MG	A083220	001		May DISC
	OGEN 1.25					
	@ PHARMACIA AND UPJOHN	1.5MG	A083220	002		May DISC
	OGEN 2.5					
	@ PHARMACIA AND UPJOHN	3MG	A083220	003		May DISC

ETELCALCETIDE

SOLUTION;INTRAVENOUS
PARSABIV

+	KAI PHARMS INC	2.5MG/0.5ML (2.5MG/0.5ML)	N208325	001	Feb 07, 2017	Feb NEWA
+		5MG/ML (5MG/ML)	N208325	002	Feb 07, 2017	Feb NEWA
+		10MG/2ML (5MG/ML)	N208325	003	Feb 07, 2017	Feb NEWA

ETHACRYNATE SODIUM

INJECTABLE;INJECTION
ETHACRYNATE SODIUM

AP	ZYDUS PHARMS USA INC	EQ 50MG BASE/VIAL	A207758	001	Nov 17, 2017	Nov NEWA
----	----------------------	-------------------	---------	-----	--------------	----------

ETHACRYNIC ACID

TABLET;ORAL

	ETHACRYNIC ACID					
AB	PAR PHARM INC	25MG	A208501	001	Jul 21, 2017	Jul NEWA
AB	WEST-WARD PHARMS INT	25MG	A207262	001	Feb 23, 2017	Feb NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-21

	ZOVIA 1/35E-21					
	@ WATSON PHARMS TEVA	0.035MG;1MG	A072720	001	Dec 30, 1991	Mar CAHN

ETHINYL ESTRADIOL; ETONOGESTREL

RING;VAGINAL
NUVARING

>A>	+	ORGANON SUB MERCK	0.015MG/24HR;0.12MG/24HR	N021187	001	Oct 03, 2001	Dec CAHN
>D>	+	ORGANON USA INC	0.015MG/24HR;0.12MG/24HR	N021187	001	Oct 03, 2001	Dec CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

INTROVALE

AB	LABS LEON FARMA	0.03MG;0.15MG	A079064	001	Sep 27, 2010	Nov CAHN
>A>	JAIMESS					
>A> AB	LABS LEON FARMA	0.03MG,0.01MG;0.15MG,N/A	A203770	001	Dec 27, 2017	Dec NEWA
	LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL					
>A> AB	LABS LEON FARMA	0.02MG,0.01MG;0.1MG,N/A	A205131	001	Dec 14, 2017	Dec NEWA
	LO SIMPESSE					
AB	AUROBINDO PHARMA LTD	0.02MG,0.01MG;0.01MG,N/A	A206852	001	Apr 28, 2017	Apr NEWA
	SIMPESSE					
AB	AUROBINDO PHARMA LTD	0.03MG,0.01MG;0.15MG,N/A	A206851	001	Apr 07, 2017	Mar NEWA
	TABLET;ORAL-28					
	ALTAVERA					
AB	LABS LEON FARMA	0.03MG;0.15MG	A079102	001	Aug 03, 2010	Nov CAHN
	ELIFEMME					
AB	LABS LEON FARMA	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202507	001	Dec 04, 2015	Feb CAHN
	VIENVA					
AB1	LABS LEON FARMA	0.02MG;0.1MG	A201088	001	May 21, 2015	Nov CAHN

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL
XULANE

!	MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Nov CTEC
AB	!	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Mar CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/35E-21

@ WATSON PHARMS TEVA	0.035MG;1MG	A071480	001	Apr 12, 1988	Mar CAHN
----------------------	-------------	---------	-----	--------------	----------

NORETHINDRONE AND ETHINYL ESTRADIOL

@ WATSON PHARMS TEVA	0.035MG;1MG	A070685	001	Jan 29, 1987	Mar CAHN
----------------------	-------------	---------	-----	--------------	----------

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

@ WATSON LABS TEVA	0.035MG,0.035MG;0.5MG,1MG	A071041	001	Sep 24, 1991	May CAHN
--------------------	---------------------------	---------	-----	--------------	----------

TABLET; ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL

AB	ACCORD HLTHCARE	0.035MG;1MG	A206864	001	Apr 28, 2017	Apr NEWA
----	-----------------	-------------	---------	-----	--------------	----------

@ MYLAN LABS LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A200486	001	Dec 28, 2015	Oct DISC
------------------	--	---------	-----	--------------	----------

@	0.035MG;0.5MG	A200488	001	Oct 21, 2015	Sep DISC
---	---------------	---------	-----	--------------	----------

@	0.035MG;1MG	A200489	001	Oct 21, 2015	Sep DISC
---	-------------	---------	-----	--------------	----------

AB	WATSON LABS TEVA	0.035MG;1MG	A070687	001	Jan 29, 1987	May CAHN
----	------------------	-------------	---------	-----	--------------	----------

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

WATSON LABS TEVA	0.035MG,0.035MG;0.5MG,1MG	A071044	001	Apr 01, 1988	May CAHN
------------------	---------------------------	---------	-----	--------------	----------

TABLET, CHEWABLE; ORAL

NEXESTA FE

AB	AUROBINDO PHARMA LTD	0.035MG;0.4MG	A207535	001	Feb 02, 2017	Jan NEWA
----	----------------------	---------------	---------	-----	--------------	----------

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	ACCORD HLTHCARE	0.035MG;0.4MG	A207066	001	Mar 29, 2017	Mar NEWA
----	-----------------	---------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

AUROVELA 24 FE

AB	AUROBINDO PHARMA LTD	0.02MG;1MG	A207504	001	Jun 15, 2017	Jun NEWA
----	----------------------	------------	---------	-----	--------------	----------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	MYLAN LABS LTD	0.0025MG;0.5MG	A207260	001	Feb 02, 2017	Jan NEWA
----	----------------	----------------	---------	-----	--------------	----------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	GLENMARK PHARMS LTD	0.02MG;1MG	A204847	001	Nov 17, 2017	Nov NEWA
----	---------------------	------------	---------	-----	--------------	----------

TABLET; ORAL-21

AUROVELA 1.5/30

AB	AUROBINDO PHARMA LTD	0.03MG;1.5MG	A207581	001	Jun 26, 2017	Jun NEWA
----	----------------------	--------------	---------	-----	--------------	----------

AUROVELA 1/20

AB	AUROBINDO PHARMA LTD	0.02MG;1MG	A207506	001	Jun 16, 2017	Jun NEWA
----	----------------------	------------	---------	-----	--------------	----------

TABLET; ORAL-28

AUROVELA FE 1.5/30

AB	AUROBINDO PHARMA LTD	0.03MG;1.5MG	A207580	001	Jun 15, 2017	May NEWA
----	----------------------	--------------	---------	-----	--------------	----------

AUROVELA FE 1/20

AB	AUROBINDO PHARMA LTD	0.02MG;1MG	A207505	001	Jun 16, 2017	Jun NEWA
----	----------------------	------------	---------	-----	--------------	----------

HAILEY FE 1/20

AB	GLENMARK PHARMS LTD	0.02MG;1MG	A206597	001	Nov 21, 2017	Nov NEWA
----	---------------------	------------	---------	-----	--------------	----------

LOESTRIN FE 1/20

AB	+ APIL	0.02MG;1MG	N017354	001		Jul CRLD
----	--------	------------	---------	-----	--	----------

TABLET, CHEWABLE; ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	AMNEAL PHARMS	0.02MG;1MG	A207514	001	Sep 11, 2017	Aug NEWA
----	---------------	------------	---------	-----	--------------	----------

>A> AB	GLENMARK PHARMS LTD	0.02MG;1MG	A210369	001	Dec 26, 2017	Dec NEWA
--------	---------------------	------------	---------	-----	--------------	----------

AB	MYLAN LABS LTD	0.02MG;1MG	A206120	001	Sep 12, 2017	Sep NEWA
----	----------------	------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

ESTARYLLA

AB	LABS LEON FARMA	0.035MG;0.25MG	A090794	001	Jan 30, 2013	Nov CAHN
----	-----------------	----------------	---------	-----	--------------	----------

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	AMNEAL PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A203873	001	May 12, 2016	Sep CAHN
----	---------------	---	---------	-----	--------------	----------

TRI-ESTARYLLA

AB	LABS LEON FARMA	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A090793	001	Jan 30, 2013	Nov CAHN
----	-----------------	---	---------	-----	--------------	----------

TRI-LO-ESTARYLLA

AB	LABS LEON FARMA	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A091232	001	Jun 29, 2015	Nov CAHN
----	-----------------	---	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-28						
NORGESTREL AND ETHINYL ESTRADIOL						
AB	@ MYLAN LABS LTD	0.03MG; 0.3MG	A201828	001	Jun 21, 2016	Oct DISC
	@	0.05MG; 0.5MG	A202875	001	May 08, 2017	Oct DISC
		0.05MG; 0.5MG	A202875	001	May 08, 2017	Apr NEWA
	OGESTREL 0.5/50-28					
AB	! WATSON LABS	0.05MG; 0.5MG	A075406	002	Dec 15, 1999	Oct CTEC
	!	0.05MG; 0.5MG	A075406	002	Dec 15, 1999	May CTEC

ETHOSUXIMIDE

	SYRUP; ORAL						
	ETHOSUXIMIDE						
AA	PHARM ASSOC	250MG/5ML	A040253	001	Nov 22, 2000	May	CAHN
	ZARONTIN						
AA	! PARKE-DAVIS	250MG/5ML	A080258	001		Mar	CAHN

ETIDRONATE DISODIUM

TABLET; ORAL					
DIDRONEL					
+	@ APIL	200MG	N017831	001	Jun DISC
+	@	400MG	N017831	002	Jun DISC
ETIDRONATE DISODIUM					
	MYLAN	200MG	A075800	001	Jan 24, 2003 Jun CTEC
!		400MG	A075800	002	Jan 24, 2003 Jun CHRS

ETODOLAC

	CAPSULE;ORAL					
	ETODOLAC					
	@ CHARTWELL MOLECULES	200MG	A074842	001	Jul 17, 1997	Mar CAHN
	@	300MG	A074842	002	Jul 17, 1997	Mar CAHN
	@ CHARTWELL PHARMS LLC	200MG	A074842	001	Jul 17, 1997	Jan CAHN
	@	300MG	A074842	002	Jul 17, 1997	Jan CAHN
	@ ECI PHARMS LLC	300MG	A074929	001	Jan 30, 1998	Apr CAHN
	LODINE					
	+ @ WYETH PHARMS INC	300MG	N018922	003	Jan 31, 1991	Jul CRLD
	TABLET;ORAL					
	ETODOLAC					
	@ CHARTWELL MOLECULES	400MG	A074841	001	Jun 27, 1997	Jan CAHN
	@ MYLAN PHARMS INC	400MG	A075104	001	Feb 06, 1998	May DISC
AB		400MG	A075104	001	Feb 06, 1998	Mar CAHN
	@	500MG	A075104	002	Nov 20, 1998	May DISC
AB		500MG	A075104	002	Nov 20, 1998	Mar CAHN

ETOMIDATE

INJECTABLE; INJECTION						
ETOMIDATE						
AP	AUROBINDO PHARMA LTD	2MG/ML	A206126	001	Feb 24, 2017	Feb NEWA
AP	GLAND PHARMA LTD	2MG/ML	A209058	001	Apr 18, 2017	Apr NEWA
AP	MYLAN LABS LTD	2MG/ML	A201044	001	Feb 07, 2017	Jan NEWA
AP	WEST-WARD PHARMS INT	2MG/ML	A074593	001	Nov 04, 1996	Jan CAHN

ETOPOSIDE

CAPSULE; ORAL						
VEPESID						
	+ @ DAVA PHARMS INC	50MG	N019557	001	Dec 30, 1986	Sep CRLD
	+ @	100MG	N019557	002	Dec 30, 1986	Sep CRLD
INJECTABLE; INJECTION						
ETOPOSIDE						
AP	MYLAN LABS LTD	20MG/ML	A203507	001	Nov 20, 2017	Nov NEWA
AP		20MG/ML	A204927	001	Oct 31, 2017	Oct NEWA

EXAMETAZIME

POWDER; INTRAVENOUS						
DRAX EXAMETAZIME						
AP	JUBILANT DRAXIMAGE	0.5MG/VIAL	N208870	001	Aug 17, 2017	Aug NEWA

EXEMESTANE

TABLET; ORAL
EXEMESTANE

AB	MYLAN PHARMS INC	25MG	A203315	001	Mar 10, 2017	Feb	NEWA
AB	UPSHER-SMITH LABS	25MG	A209208	001	Jul 26, 2017	Aug	CAHN
AB		25MG	A209208	001	Jul 26, 2017	Jul	NEWA

EXENATIDE

SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS
BYDUREON BCISE

+	!	ASTRAZENECA AB	2MG/0.85ML (2MG/0.85ML)	N209210	001	Oct 20, 2017	Oct	NEWA
---	---	----------------	-------------------------	---------	-----	--------------	-----	------

EZETIMIBE

TABLET; ORAL
EZETIMIBE

>A>	AB	ALKEM LABS LTD	10MG	A209234	001	Dec 21, 2017	Dec	NEWA
	AB	AMNEAL PHARMS CO	10MG	A208803	001	Jun 12, 2017	May	NEWA
	AB	APOTEX INC	10MG	A208332	001	Jun 12, 2017	May	NEWA
	AB	AUROBINDO PHARMA LTD	10MG	A209838	001	Aug 25, 2017	Aug	NEWA
	AB	OHM LABS INC	10MG	A207311	001	Jun 12, 2017	May	NEWA
	AB	SANDOZ INC	10MG	A203931	001	Jun 12, 2017	May	NEWA
	AB	TEVA PHARMS USA	10MG	A078724	001	Jun 12, 2017	May	NEWA
	AB	WATSON LABS INC	10MG	A200831	001	Jun 12, 2017	May	NEWA
	AB	ZYDUS PHARMS USA INC	10MG	A204331	001	Jun 12, 2017	May	NEWA

EZETIMIBE; SIMVASTATIN

TABLET; ORAL
EZETIMIBE AND SIMVASTATIN

>A>	AB	ALKEM LABS LTD	10MG; 10MG	A209222	001	Dec 22, 2017	Dec	NEWA	
>A>	AB		10MG; 20MG	A209222	002	Dec 22, 2017	Dec	NEWA	
>A>	AB		10MG; 40MG	A209222	003	Dec 22, 2017	Dec	NEWA	
>A>	AB		10MG; 80MG	A209222	004	Dec 22, 2017	Dec	NEWA	
	AB	AMNEAL PHARMS CO	10MG; 10MG	A208831	001	Nov 21, 2017	Nov	NEWA	
	AB		10MG; 20MG	A208831	002	Nov 21, 2017	Nov	NEWA	
	AB		10MG; 40MG	A208831	003	Nov 21, 2017	Nov	NEWA	
	AB		10MG; 80MG	A208831	004	Nov 21, 2017	Nov	NEWA	
	AB	DR REDDYS LABS INTL	10MG; 10MG	A200909	001	Apr 26, 2017	Apr	NEWA	
	AB		10MG; 20MG	A200909	002	Apr 26, 2017	Apr	NEWA	
	AB		10MG; 40MG	A200909	003	Apr 26, 2017	Apr	NEWA	
	AB		10MG; 80MG	A200909	004	Apr 26, 2017	Apr	NEWA	
	AB	DR REDDYS LABS SA	10MG; 10MG	A200909	001	Apr 26, 2017	May	CAHN	
	AB		10MG; 20MG	A200909	002	Apr 26, 2017	May	CAHN	
	AB		10MG; 40MG	A200909	003	Apr 26, 2017	May	CAHN	
	AB		10MG; 80MG	A200909	004	Apr 26, 2017	May	CAHN	
	AB	IMPAX LABS INC	10MG; 10MG	A201890	001	Apr 26, 2017	Apr	NEWA	
	AB		10MG; 20MG	A201890	002	Apr 26, 2017	Apr	NEWA	
	AB		10MG; 40MG	A201890	003	Apr 26, 2017	Apr	NEWA	
	AB		10MG; 80MG	A201890	004	Apr 26, 2017	Apr	NEWA	
	AB	WATSON LABS INC	10MG; 10MG	A202968	001	Apr 26, 2017	Apr	NEWA	
	AB		10MG; 20MG	A202968	002	Apr 26, 2017	Apr	NEWA	
	AB		10MG; 40MG	A202968	003	Apr 26, 2017	Apr	NEWA	
	AB		10MG; 80MG	A202968	004	Apr 26, 2017	Apr	NEWA	
		VYTORIN							
	AB	+	MSD INTL	10MG; 10MG	N021687	001	Jul 23, 2004	Apr	CFTG
	AB	+		10MG; 20MG	N021687	002	Jul 23, 2004	Apr	CFTG
	AB	+		10MG; 40MG	N021687	003	Jul 23, 2004	Apr	CFTG
	AB	+	!	10MG; 80MG	N021687	004	Jul 23, 2004	Apr	CFTG

FAMCICLOVIR

TABLET; ORAL
FAMCICLOVIR

AB	!	TEVA PHARMS	500MG	A077487	003	Aug 24, 2007	Jan	CHRS	
		FAMVIR							
	+	@	NOVARTIS	125MG	N020363	003	Dec 11, 1995	Jan	DISC
	+	@		250MG	N020363	001	Apr 26, 1996	Jan	DISC
	+	@		500MG	N020363	002	Jun 29, 1994	Jan	DISC

FAMOTIDINEFOR SUSPENSION;ORAL
FAMOTIDINE

AB	NOVEL LABS INC	40MG/5ML	A201695	001	Dec 17, 2012	Nov	CDFR
	INJECTABLE;INJECTION						
	FAMOTIDINE						
AP	ATHENEX INC	10MG/ML	A075651	001	Apr 16, 2001	Mar	CAHN
AP		10MG/ML	A075684	001	Apr 16, 2001	Mar	CAHN
	@ WEST-WARD PHARMS INT	10MG/ML	A075799	001	Apr 30, 2002	Aug	CAHN
	FAMOTIDINE PRESERVATIVE FREE						
AP	ATHENEX INC	10MG/ML	A075622	001	Apr 16, 2001	Mar	CAHN
AP		10MG/ML	A075825	001	Apr 17, 2001	Mar	CAHN
	@ WEST-WARD PHARMS INT	10MG/ML	A075789	001	Apr 30, 2002	Aug	CAHN
	FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER						
	! BAXTER HLTHCARE	0.4MG/ML	A075591	001	May 10, 2001	Nov	CTEC
	TABLET;ORAL						
	FAMOTIDINE						
AB	PERRIGO R AND D	20MG	A077352	002	Jul 27, 2005	Apr	CAHN
AB		40MG	A077352	001	Jul 27, 2005	Apr	CAHN
>D> AB	WOCKHARDT	20MG	A075786	001	Apr 16, 2001	Dec	CAHN
>D> AB		40MG	A075786	002	Apr 16, 2001	Dec	CAHN
>A> AB	WOCKHARDT LTD	20MG	A075786	001	Apr 16, 2001	Dec	CAHN
>A> AB		40MG	A075786	002	Apr 16, 2001	Dec	CAHN

FELBAMATESUSPENSION;ORAL
FELBAMATE

AB	TARO PHARM	600MG/5ML	A206314	001	Jun 16, 2017	Jun	NEWA
	FELBATOL						
AB	+! MYLAN SPECIALITY LP	600MG/5ML	N020189	003	Jul 29, 1993	Mar	CAHN
	TABLET;ORAL						
	FELBAMATE						
AB	IMPAX LABS INC	400MG	A202284	001	Nov 04, 2015	Feb	CAHN
AB		600MG	A202284	002	Nov 04, 2015	Feb	CAHN
AB	TARO PHARM	400MG	A207093	001	Apr 20, 2017	Apr	NEWA
AB		600MG	A207093	002	Apr 20, 2017	Apr	NEWA
AB	ZYDUS PHARMS USA INC	400MG	A208970	001	May 30, 2017	May	NEWA
AB		600MG	A208970	002	May 30, 2017	May	NEWA
	FELBATOL						
AB	+ MYLAN SPECIALITY LP	400MG	N020189	001	Jul 29, 1993	Mar	CAHN
AB	+!	600MG	N020189	002	Jul 29, 1993	Mar	CAHN

FENOFIBRATECAPSULE;ORAL
FENOFIBRATE (MICRONIZED)

AB	CNTY LINE PHARMS	67MG	A207805	001	Nov 16, 2017	Nov	NEWA
AB		134MG	A207805	002	Nov 16, 2017	Nov	NEWA
AB		200MG	A207805	003	Nov 16, 2017	Nov	NEWA
AB	GLENMARK PHARMS LTD	67MG	A205566	001	Apr 07, 2017	Mar	NEWA
AB		134MG	A205566	002	Apr 07, 2017	Mar	NEWA
AB		200MG	A205566	003	Apr 07, 2017	Mar	NEWA
AB	! IMPAX LABS	200MG	A075868	003	Oct 27, 2003	Jun	CHRS
AB	INVAGEN PHARMS	67MG	A207378	001	Mar 28, 2017	Mar	NEWA
AB		134MG	A207378	002	Mar 28, 2017	Mar	NEWA
AB		200MG	A207378	003	Mar 28, 2017	Mar	NEWA
AB	RHODES PHARMS	200MG	A075753	003	Apr 09, 2002	Jun	CHRS
	TABLET;ORAL						
	FENOFIBRATE						
>A> AB	CNTY LINE PHARMS	54MG	A207803	001	Dec 19, 2017	Dec	NEWA
>A> AB		160MG	A207803	002	Dec 19, 2017	Dec	NEWA
AB	! IMPAX LABS	160MG	A076509	002	Mar 26, 2008	Mar	CHRS
AB	RHODES PHARMS	160MG	A076433	002	May 13, 2005	Mar	CHRS
AB	SUN PHARM INDS LTD	48MG	A200884	001	Sep 07, 2017	Aug	NEWA
AB		145MG	A200884	002	Sep 07, 2017	Aug	NEWA
	TRICOR						
	+ @ ABBVIE INC	54MG	N021203	001	Sep 04, 2001	Aug	CAHN
	+ @	160MG	N021203	003	Sep 04, 2001	Aug	CAHN

FENOLDOPAM MESYLATEINJECTABLE; INJECTION
FENOLDOPAM MESYLATE

AP	SANDOZ INC	EQ 10MG BASE/ML	A077155	001	Feb 15, 2005	Mar CAHN
----	------------	-----------------	---------	-----	--------------	----------

FENOPROFEN CALCIUMCAPSULE; ORAL
NALFON

+	! XSPIRE PHARMA	EQ 200MG BASE	N017604	003		Aug CAHN
	@	EQ 300MG BASE	N017604	002		Aug CAHN
+		EQ 400MG BASE	N017604	004	Jul 21, 2009	Aug CAHN

TABLET; ORAL

FENOPROFEN CALCIUM

!	XSPIRE PHARMA	EQ 600MG BASE	A072267	001	Aug 17, 1988	Aug CAHN
---	---------------	---------------	---------	-----	--------------	----------

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

AB	3M DRUG DELIVERY	100MCG/HR	A202097	005	Nov 04, 2016	Mar CAHN
AB	ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007	Mar CAHN
>D>	AB MALLINCKRODT INC	100MCG/HR	A077154	004	Feb 09, 2011	Dec CAHN
AB	MAYNE PHARMA	100MCG/HR	A077062	004	Aug 20, 2007	Mar CAHN
>A>	AB SPECGX LLC	100MCG/HR	A077154	004	Feb 09, 2011	Dec CAHN

FENTANYL-12

AB	3M DRUG DELIVERY	12.5MCG/HR	A202097	001	Nov 04, 2016	Mar CAHN
>D>	AB MALLINCKRODT INC	12.5MCG/HR	A077154	005	Jun 11, 2015	Dec CAHN
>A>	AB SPECGX LLC	12.5MCG/HR	A077154	005	Jun 11, 2015	Dec CAHN

FENTANYL-25

AB	3M DRUG DELIVERY	25MCG/HR	A202097	002	Nov 04, 2016	Mar CAHN
AB	ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007	Mar CAHN
>D>	AB MALLINCKRODT INC	25MCG/HR	A077154	001	Feb 09, 2011	Dec CAHN
AB	MAYNE PHARMA	25MCG/HR	A077062	001	Aug 20, 2007	Mar CAHN
>A>	AB SPECGX LLC	25MCG/HR	A077154	001	Feb 09, 2011	Dec CAHN

FENTANYL-37

AB	AVEVA	37.5MCG/HR	A077449	006	Dec 06, 2017	Nov NEWA
----	-------	------------	---------	-----	--------------	----------

FENTANYL-50

AB	3M DRUG DELIVERY	50MCG/HR	A202097	003	Nov 04, 2016	Mar CAHN
AB	ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007	Mar CAHN
>D>	AB MALLINCKRODT INC	50MCG/HR	A077154	002	Feb 09, 2011	Dec CAHN
AB	MAYNE PHARMA	50MCG/HR	A077062	002	Aug 20, 2007	Mar CAHN
>A>	AB SPECGX LLC	50MCG/HR	A077154	002	Feb 09, 2011	Dec CAHN

FENTANYL-62

AB	AVEVA	62.5MCG/HR	A077449	007	Dec 06, 2017	Nov NEWA
----	-------	------------	---------	-----	--------------	----------

FENTANYL-75

AB	3M DRUG DELIVERY	75MCG/HR	A202097	004	Nov 04, 2016	Mar CAHN
AB	ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007	Mar CAHN
>D>	AB MALLINCKRODT INC	75MCG/HR	A077154	003	Feb 09, 2011	Dec CAHN
AB	MAYNE PHARMA	75MCG/HR	A077062	003	Aug 20, 2007	Mar CAHN
>A>	AB SPECGX LLC	75MCG/HR	A077154	003	Feb 09, 2011	Dec CAHN

FENTANYL-87

AB	AVEVA	87.5MCG/HR	A077449	008	Dec 06, 2017	Nov NEWA
----	-------	------------	---------	-----	--------------	----------

SPRAY; SUBLINGUAL
SUBSYS

+	INSYS DEV CO INC	0.1MG	N202788	001	Jan 04, 2012	May CAHN
+		0.2MG	N202788	002	Jan 04, 2012	May CAHN
+	!	0.4MG	N202788	003	Jan 04, 2012	May CAHN
+		0.6MG	N202788	004	Jan 04, 2012	May CAHN
+		0.8MG	N202788	005	Jan 04, 2012	May CAHN
+		1.2MG	N202788	006	Aug 30, 2012	May CAHN
+		1.6MG	N202788	007	Aug 30, 2012	May CAHN

FENTANYL CITRATESPRAY, METERED; NASAL
LAZANDA

+	ELEFSEE PHARMS INTL	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Nov CAHN
+		EQ 0.3MG BASE	N022569	003	Dec 21, 2015	Nov CAHN
+	!	EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Nov CAHN

TABLET; SUBLINGUAL

ABSTRAL

AB	+	SENTYNL THERAPS INC	EQ 0.1MG BASE	N022510	001	Jan 07, 2011	Nov CFTG
AB	+		EQ 0.2MG BASE	N022510	002	Jan 07, 2011	Nov CFTG

TABLET;SUBLINGUAL
ABSTRAL

AB	+	EQ 0.3MG BASE	N022510	003	Jan 07, 2011	Nov CFTG
AB	+	EQ 0.4MG BASE	N022510	004	Jan 07, 2011	Nov CFTG
AB	+	EQ 0.6MG BASE	N022510	005	Jan 07, 2011	Nov CFTG
AB	+	EQ 0.8MG BASE	N022510	006	Jan 07, 2011	Nov CFTG

FENTANYL CITRATE

AB	ACTAVIS LABS FL INC	EQ 0.1MG BASE	A207338	001	Nov 17, 2017	Nov NEWA
AB		EQ 0.2MG BASE	A207338	002	Nov 17, 2017	Nov NEWA
AB		EQ 0.3MG BASE	A207338	003	Nov 17, 2017	Nov NEWA
AB		EQ 0.4MG BASE	A207338	004	Nov 17, 2017	Nov NEWA
AB		EQ 0.6MG BASE	A207338	005	Nov 17, 2017	Nov NEWA
AB		EQ 0.8MG BASE	A207338	006	Nov 17, 2017	Nov NEWA

TROCHE/LOZENGE;TRANSMUCOSAL

FENTANYL CITRATE

>D>	AB	MALLINCKRODT	EQ 0.2MG BASE	A078907	001	Oct 30, 2009	Dec CAHN
>D>	AB		EQ 0.4MG BASE	A078907	002	Oct 30, 2009	Dec CAHN
>D>	AB		EQ 0.6MG BASE	A078907	003	Oct 30, 2009	Dec CAHN
>D>	AB		EQ 0.8MG BASE	A078907	004	Oct 30, 2009	Dec CAHN
>D>	AB		EQ 1.2MG BASE	A078907	005	Oct 30, 2009	Dec CAHN
>D>	AB		EQ 1.6MG BASE	A078907	006	Oct 30, 2009	Dec CAHN
>A>	AB	SPECGX LLC	EQ 0.2MG BASE	A078907	001	Oct 30, 2009	Dec CAHN
>A>	AB		EQ 0.4MG BASE	A078907	002	Oct 30, 2009	Dec CAHN
>A>	AB		EQ 0.6MG BASE	A078907	003	Oct 30, 2009	Dec CAHN
>A>	AB		EQ 0.8MG BASE	A078907	004	Oct 30, 2009	Dec CAHN
>A>	AB		EQ 1.2MG BASE	A078907	005	Oct 30, 2009	Dec CAHN
>A>	AB		EQ 1.6MG BASE	A078907	006	Oct 30, 2009	Dec CAHN

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE

AB	AUROBINDO PHARMA LTD	4MG	A205007	001	Feb 17, 2017	Feb NEWA
AB		8MG	A205007	002	Feb 17, 2017	Feb NEWA
AB	ZYDUS PHARMS USA INC	4MG	A204946	001	Oct 03, 2017	Sep NEWA
AB		8MG	A204946	002	Oct 03, 2017	Sep NEWA

FINASTERIDE

TABLET;ORAL
FINASTERIDE

AB	ACCORD HLTHCARE	1MG	A091643	001	Nov 05, 2013	Mar CAHN
AB	ACTAVIS TOTOWA TEVA	5MG	A077914	001	Mar 28, 2007	May CAHN

FLECAINIDE ACETATE

TABLET;ORAL
FLECAINIDE ACETATE

AB	AUROBINDO PHARMA LTD	50MG	A202821	001	Nov 03, 2017	Oct NEWA
AB		100MG	A202821	002	Nov 03, 2017	Oct NEWA
AB		150MG	A202821	003	Nov 03, 2017	Oct NEWA

FLOXURIDINE

INJECTABLE;INJECTION
FLOXURIDINE

AP	PHARMAFORCE	500MG/VIAL	A203008	001	Nov 22, 2017	Nov NEWA
----	-------------	------------	---------	-----	--------------	----------

FLUCONAZOLE

FOR SUSPENSION;ORAL
FLUCONAZOLE

AB	AUROBINDO PHARMA LTD	50MG/5ML	A079150	001	Sep 18, 2009	Jan CAHN
AB		200MG/5ML	A079150	002	Sep 18, 2009	Jan CAHN

INJECTABLE;INJECTION

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

+	@ PFIZER	200MG/100ML (2MG/ML)	N019950	003	Sep 29, 1992	Mar DISC
+	@	400MG/200ML (2MG/ML)	N019950	005	Jul 08, 1994	Mar DISC

DIFLUCAN IN SODIUM CHLORIDE 0.9%

+	@ PFIZER	200MG/100ML (2MG/ML)	N019950	001	Jan 29, 1990	Mar DISC
+	@	400MG/200ML (2MG/ML)	N019950	006	Jan 29, 1990	Mar DISC

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	@ PFIZER	200MG/100ML (2MG/ML)	N019950	002	Jan 29, 1990	Mar DISC
+	@	400MG/200ML (2MG/ML)	N019950	004	Jan 29, 1990	Mar DISC

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	!	HOSPIRA	200MG/100ML (2MG/ML)	A076304	001	Jul 29, 2004	Mar CHRS
AP	!		400MG/200ML (2MG/ML)	A076304	002	Jul 29, 2004	Mar CHRS

INJECTABLE;INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	RENAISSANCE SSA LLC	200MG/100ML (2MG/ML)	A077988	001	May 26, 2010	Aug CAHN
AP		400MG/200ML (2MG/ML)	A077988	002	May 26, 2010	Aug CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP	BAXTER HLTHCARE CORP	200MG/100ML (2MG/ML)	A077947	001	May 26, 2010	Aug CAHN
AP		400MG/200ML (2MG/ML)	A077947	002	May 26, 2010	Aug CAHN
	WEST-WARD PHARMS INT	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008	Jan CAHN
AP		200MG/100ML (2MG/ML)	A076087	001	Jul 29, 2004	Jan CAHN
AP		400MG/200ML (2MG/ML)	A076087	003	Jul 29, 2004	Jan CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	! ACS DOBFAR INFO SA	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Mar CHRS
AP	!	400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Mar CHRS
	RENAISSANCE SSA LLC	100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Aug CAHN
AP		200MG/100ML (2MG/ML)	A077909	001	May 26, 2010	Aug CAHN
AP		400MG/200ML (2MG/ML)	A077909	002	May 26, 2010	Aug CAHN
AP	WEST-WARD PHARMS INT	200MG/100ML (2MG/ML)	A078107	001	Jul 30, 2008	Jan CAHN
AP		400MG/200ML (2MG/ML)	A078107	002	Jul 30, 2008	Jan CAHN

TABLET;ORAL

FLUCONAZOLE

AB	UNIQUE PHARM LABS	50MG	A076957	001	Sep 28, 2005	Aug CAHN
AB		100MG	A076957	002	Sep 28, 2005	Aug CAHN
AB		150MG	A076957	004	Feb 27, 2017	Aug CAHN
AB		150MG	A076957	004	Feb 27, 2017	Feb NEWA
AB		200MG	A076957	003	Sep 28, 2005	Aug CAHN
AB	ZYDUS PHARMS USA INC	50MG	A208963	001	Feb 16, 2017	Feb NEWA
AB		100MG	A208963	002	Feb 16, 2017	Feb NEWA
AB		150MG	A208963	003	Feb 16, 2017	Feb NEWA
AB		200MG	A208963	004	Feb 16, 2017	Feb NEWA

FLUCYTOSINE

CAPSULE;ORAL

FLUCYTOSINE

AB	NOVEL LABS INC	250MG	A204652	001	Jul 07, 2017	Jun NEWA
AB		500MG	A204652	002	Jul 07, 2017	Jun NEWA
AB	ROXANE	250MG	A206550	001	Oct 17, 2017	Oct NEWA
AB		500MG	A206550	002	Oct 17, 2017	Oct NEWA
AB	WEST-WARD PHARMS INT	250MG	A206550	001	Oct 17, 2017	Oct CAHN
AB		500MG	A206550	002	Oct 17, 2017	Oct CAHN

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

AP	ACTAVIS LLC	50MG/2ML (25MG/ML)	A203738	001	Feb 28, 2017	Feb NEWA
AP	CUSTOPHARM INC	50MG/VIAL	A076349	001	Aug 28, 2003	Oct CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	JUBILANT DRAXIMAGE	20-300mCi/ML	A203920	001	Jun 23, 2015	Sep CAHN
AP	SOFIE	20-300mCi/ML	A203591	001	Aug 31, 2015	Nov CAHN

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

	@ BAXTER HLTHCARE CORP	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Aug CAHN
	@	1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Aug CAHN
AP	SANDOZ INC	0.5MG/5ML (0.1MG/ML)	A077071	001	May 03, 2005	Apr CAHN
AP		1MG/10ML (0.1MG/ML)	A077071	002	May 03, 2005	Apr CAHN
AP	WEST-WARD PHARMS INT	0.5MG/5ML (0.1MG/ML)	A076256	002	Oct 12, 2004	Jan CAHN
AP		0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jan CAHN
AP		1MG/10ML (0.1MG/ML)	A076256	001	Oct 12, 2004	Jan CAHN
AP		1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jan CAHN

FLUNISOLIDE

AEROSOL, METERED;INHALATION

AEROSPAN HFA

+	! MYLAN SPECIALITY LP	0.078MG/INH	N021247	001	Jan 27, 2006	Mar CAHN
---	-----------------------	-------------	---------	-----	--------------	----------

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL

FLUOCINOLONE ACETONIDE

AT	FOUGERA PHARMS INC	0.01%	A088170	001	Dec 16, 1982	Jan CAHN
AT		0.025%	A088169	001	Dec 16, 1982	Jan CAHN
	@ TARO	0.01%	A040035	001	Oct 31, 1994	Apr CAHN
	@	0.025%	A040042	001	Oct 31, 1994	Apr CAHN

OIL/DROPS;OTIC

FLUOCINOLONE ACETONIDE

AT	PERRIGO ISRAEL	0.01%	A202849	001	Jul 17, 2017	Jul NEWA
----	----------------	-------	---------	-----	--------------	----------

OINTMENT;TOPICAL

FLUOCINOLONE ACETONIDE

AT	FOUGERA PHARMS INC	0.025%	A088168	001	Dec 16, 1982	Jan CAHN
AT	TARO	0.025%	A040041	001	Sep 15, 1994	Apr CAHN

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

AT	FOUGERA PHARMS INC	0.01%	A088167	001	Dec 16, 1982	Jan CAHN
>A> AT	GLASSHOUSE PHARMS	0.01%	A209596	001	Dec 26, 2017	Dec NEWA

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

AB1	FOUGERA PHARMS INC	0.05%	A073030	001	Oct 17, 1994	Jan CAHN
AB	PERRIGO ISRAEL	0.1%	A090256	001	Jan 14, 2014	Apr CAHN
AB1	TARO	0.05%	A071500	001	Jun 10, 1987	Mar CMFD

FLUOCINONIDE EMULSIFIED BASE

AB2	G AND W LABS INC	0.05%	A074204	001	Jun 13, 1995	May CMFD
-----	------------------	-------	---------	-----	--------------	----------

GEL;TOPICAL

FLUOCINONIDE

AB	+ CNTY LINE PHARMS	0.05%	N017373	001		Oct CMFD
AB	FOUGERA PHARMS INC	0.05%	A072933	001	Dec 30, 1994	Jan CAHN
AB	! TARO	0.05%	A074935	001	Jul 29, 1997	Apr CAHN

OINTMENT;TOPICAL

FLUOCINONIDE

AB	NOVEL LABS INC	0.05%	A207538	001	Jul 31, 2017	Jul NEWA
AB	! TARO	0.05%	A075008	001	Jun 30, 1999	Apr CAHN

SOLUTION;TOPICAL

FLUOCINONIDE

AT	FOUGERA PHARMS INC	0.05%	A072934	001	Feb 27, 1995	Nov CAHN
AT	NOVEL LABS INC	0.05%	A206003	001	Jul 21, 2017	Jul NEWA
AT	! TARO	0.05%	A074799	001	Dec 31, 1996	Apr CAHN

LIDEX

AT	+ CNTY LINE PHARMS	0.05%	N018849	001	Apr 06, 1984	Mar CRLD
----	--------------------	-------	---------	-----	--------------	----------

FLUOROURACIL

CREAM;TOPICAL

FLUOROURACIL

AB	MYLAN PHARMS INC	0.5%	A203122	001	Apr 20, 2015	Jun CAHN
----	------------------	------	---------	-----	--------------	----------

INJECTABLE;INJECTION

FLUOROURACIL

AP	GLAND PHARMA LTD	500MG/10ML (50MG/ML)	A210123	001	Oct 27, 2017	Oct NEWA
AP		1GM/20ML (50MG/ML)	A210123	002	Oct 27, 2017	Oct NEWA
>A> AP		2.5GM/50ML (50MG/ML)	A210124	001	Dec 26, 2017	Dec NEWA
>A> AP		5GM/100ML (50MG/ML)	A210124	002	Dec 26, 2017	Dec NEWA
AP	SAGENT PHARMS	500MG/10ML (50MG/ML)	A203608	001	May 11, 2017	May NEWA
AP		1GM/20ML (50MG/ML)	A203608	002	May 11, 2017	May NEWA
	@ SANDOZ	2.5GM/50ML (50MG/ML)	A091299	001	May 02, 2011	Jul DISC
	@	5GM/100ML (50MG/ML)	A091299	002	May 02, 2011	Jul DISC
	+ @ SPECTRUM PHARMS	500MG/10ML (50MG/ML)	N012209	001		Jan CRLD
	+ @	2.5GM/50ML (50MG/ML)	N012209	002	Jul 29, 2016	Aug DISC

SOLUTION;TOPICAL

FLUOROURACIL

AT	TARO PHARM	2%	A076526	001	Nov 05, 2003	Mar CAHN
AT		5%	A076526	002	Nov 05, 2003	Mar CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

>D>	AB1	MALLINCKRODT	EQ 10MG BASE	A075658	001	Jan 29, 2002	Dec CAHN
>D>	AB1		EQ 20MG BASE	A075658	002	Jan 29, 2002	Dec CAHN
		@ MYLAN	EQ 10MG BASE	A075207	001	Jan 30, 2002	Jun DISC
		@	EQ 20MG BASE	A075207	002	Jan 30, 2002	Jun DISC
		@	EQ 40MG BASE	A075207	003	May 25, 2007	Jun DISC
		@ MYLAN PHARMS INC	EQ 10MG BASE	A075577	001	Jan 29, 2002	Nov DISC
		@	EQ 20MG BASE	A075577	002	Jan 29, 2002	Nov DISC
>A>	AB1	SPECGX LLC	EQ 10MG BASE	A075658	001	Jan 29, 2002	Dec CAHN
>A>	AB1		EQ 20MG BASE	A075658	002	Jan 29, 2002	Dec CAHN

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

	AA	AUROBINDO PHARMA LTD	EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009	Jan CAHN
>D>	AA	MALLINCKRODT	EQ 20MG BASE/5ML	A075920	001	Jan 29, 2002	Dec CAHN
	AA	! PHARM ASSOC	EQ 20MG BASE/5ML	A076015	001	Jan 30, 2002	May CAHN
>A>	AA	SPECGX LLC	EQ 20MG BASE/5ML	A075920	001	Jan 29, 2002	Dec CAHN
>D>	AA	WOCKHARDT	EQ 20MG BASE/5ML	A075514	001	Aug 29, 2002	Dec CAHN
>A>	AA	WOCKHARDT BIO AG	EQ 20MG BASE/5ML	A075514	001	Aug 29, 2002	Dec CAHN

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

	AB	ALEMBIC PHARMS LTD	EQ 10MG BASE	A208698	001	Apr 05, 2017	Mar NEWA
	AB		EQ 20MG BASE	A208698	002	Apr 05, 2017	Mar NEWA
	AB	+! ALVOGEN	EQ 60MG BASE	N202133	001	Oct 06, 2011	Oct CTEC
		+!	EQ 60MG BASE	N202133	001	Oct 06, 2011	Jan CAHN
	AB	INVENTIA HLTHCARE	EQ 60MG BASE	A209695	001	Nov 20, 2017	Nov NEWA
	AB	PAR PHARM INC	EQ 60MG BASE	A209419	001	Nov 16, 2017	Oct NEWA

FLUOXYMESTERONE

TABLET;ORAL

FLUOXYMESTERONE

	!	USL PHARMA	10MG	A088342	001	Oct 21, 1983	Jun CAHN
--	---	------------	------	---------	-----	--------------	----------

FLUPHENAZINE DECANOATE

INJECTABLE;INJECTION

FLUPHENAZINE DECANOATE

AO		AUROBINDO PHARMA LTD	25MG/ML	A207739	001	Oct 17, 2017	Oct NEWA
----	--	----------------------	---------	---------	-----	--------------	----------

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

FLUPHENAZINE HYDROCHLORIDE

	@	ANI PHARMS INC	5MG/ML	A073058	001	Aug 30, 1991	Jan CAHN
	!	PHARM ASSOC	5MG/ML	A074725	001	Sep 16, 1996	May CAHN

ELIXIR;ORAL

FLUPHENAZINE HYDROCHLORIDE

	!	PHARM ASSOC	2.5MG/5ML	A040146	001	Aug 21, 1996	May CAHN
--	---	-------------	-----------	---------	-----	--------------	----------

PROLIXIN

	+	@ APOTHECON	2.5MG/5ML	N012145	003		Sep DISC
--	---	-------------	-----------	---------	-----	--	----------

TABLET;ORAL

PROLIXIN

>D>		@ APOTHECON	1MG	N011751	004		Dec CRLD
>A>		+ @	1MG	N011751	004		Dec CRLD
>D>		@	2.5MG	N011751	001		Dec CRLD
>A>		+ @	2.5MG	N011751	001		Dec CRLD
>D>		@	5MG	N011751	003		Dec CRLD
>A>		+ @	5MG	N011751	003		Dec CRLD
>D>		@	10MG	N011751	002		Dec CRLD
>A>		+ @	10MG	N011751	002		Dec CRLD

FLURANDRENOLIDE

CREAM;TOPICAL

FLURANDRENOLIDE

AT		CINTEX SVCS	0.05%	A205342	001	Apr 13, 2016	Jun CAHN
----	--	-------------	-------	---------	-----	--------------	----------

LOTION;TOPICAL

FLURANDRENOLIDE

AT		CINTEX SVCS	0.05%	A205343	001	Dec 22, 2016	Jun CAHN
----	--	-------------	-------	---------	-----	--------------	----------

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL

FLURAZEPAM HYDROCHLORIDE

@ AUROLIFE PHARMA LLC 15MG

A071717 002 Jul 31, 1991 Jan CMS1

FLUTAMIDE

CAPSULE;ORAL

EULEXIN

+ @ SCHERING 125MG

N018554 001 Jan 27, 1989 Sep CRLD

FLUTAMIDE

>A> @ FOSUN PHARMA 125MG

A075818 001 Sep 18, 2001 Dec CAHN

@ MYLAN 125MG

A076224 001 May 09, 2003 Jun DISC

>D> @ SANDOZ 125MG

A075818 001 Sep 18, 2001 Dec CAHN

FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER;INHALATION

TRELEGY ELLIPTA

+! GLAXOSMITHKLINE 0.1MG/INH;EQ 0.0625MG BASE/INH;EQ
0.025MG BASE/INH

N209482 001 Sep 18, 2017 Sep NEWA

FLUTICASONE PROPIONATE

POWDER;INHALATION

ARMONAIR RESPICLICK

+ TEVA PHARM 0.055MG/INH

N208798 001 Jan 27, 2017 Jan NEWA

+ 0.113MG/INH

N208798 002 Jan 27, 2017 Jan NEWA

+! 0.232MG/INH

N208798 003 Jan 27, 2017 Jan NEWA

SPRAY, METERED;NASAL

FLONASE

+ @ GLAXOSMITHKLINE 0.05MG/SPRAY

N020121 001 Oct 19, 1994 Jul CRLD

FLUTICASONE PROPIONATE

AB ! WEST-WARD PHARMS INT 0.05MG/SPRAY

A076504 001 Feb 22, 2006 Jul CHRS

>D> AB WOCKHARDT 0.05MG/SPRAY

A078492 001 Jan 09, 2012 Dec CAHN

>A> AB WOCKHARDT BIO AG 0.05MG/SPRAY

A078492 001 Jan 09, 2012 Dec CAHN

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER;INHALATION

AIRDUO RESPICLICK

+ TEVA PHARM 0.055MG/INH;EQ 0.014MG BASE/INH

N208799 001 Jan 27, 2017 Jan NEWA

+ 0.113MG/INH;EQ 0.014MG BASE/INH

N208799 002 Jan 27, 2017 Jan NEWA

+! 0.232MG/INH;EQ 0.014MG BASE/INH

N208799 003 Jan 27, 2017 Jan NEWA

FLUVASTATIN SODIUM

CAPSULE;ORAL

FLUVASTATIN SODIUM

AB ! MYLAN PHARMS INC EQ 40MG BASE

A090595 002 Apr 11, 2012 May CHRS

LESCOL

+ @ NOVARTIS EQ 20MG BASE

N020261 001 Dec 31, 1993 May DISC

+ @ EQ 40MG BASE

N020261 002 Dec 31, 1993 May DISC

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

AB ! ACTAVIS ELIZABETH 150MG

A091482 002 Nov 18, 2013 Apr CHRS

LUVOX CR

+ @ JAZZ PHARMS 100MG

N022033 001 Feb 28, 2008 Apr DISC

+ @ 150MG

N022033 002 Feb 28, 2008 Apr DISC

TABLET;ORAL

FLUVOXAMINE MALEATE

@ ECI PHARMS LLC 25MG

A075900 001 Feb 23, 2006 May CAHN

@ 50MG

A075900 002 Feb 23, 2006 May CAHN

@ 100MG

A075900 003 Feb 23, 2006 May CAHN

@ UPSHER-SMITH LABS 25MG

A075887 001 Jan 05, 2001 Jun CAHN

AB 25MG

A075888 001 Nov 29, 2000 Jun CAHN

@ 50MG

A075887 002 Jan 05, 2001 Jun CAHN

AB 50MG

A075888 002 Nov 29, 2000 Jun CAHN

@ 100MG

A075887 003 Jan 05, 2001 Jun CAHN

AB ! 100MG

A075888 003 Nov 29, 2000 Jun CAHN

FONDAPARINUX SODIUM

INJECTABLE;SUBCUTANEOUS
FONDAPARINUX SODIUM

>A>	AP	AUROBINDO PHARMA LTD	2.5MG/0.5ML	A206918	001	Dec 26, 2017	Dec NEWA
>A>	AP		5MG/0.4ML	A206918	002	Dec 26, 2017	Dec NEWA
>A>	AP		7.5MG/0.6ML	A206918	003	Dec 26, 2017	Dec NEWA
>A>	AP		10MG/0.8ML	A206918	004	Dec 26, 2017	Dec NEWA

FORMOTEROL FUMARATE

POWDER;INHALATION
FORADIL

+	@	NOVARTIS	0.012MG/INH	N020831	001	Feb 16, 2001	Feb DISC
---	---	----------	-------------	---------	-----	--------------	----------

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED;INHALATION
BEVESPI AEROSPHERE

+	!	ASTRAZENECA PHARMS	0.0048MG/INH;0.0090MG/INH	N208294	001	Apr 25, 2016	Mar CAHN
---	---	--------------------	---------------------------	---------	-----	--------------	----------

FOSCARNET SODIUM

INJECTABLE;INJECTION
FOSCARNET SODIUM

@	HOSPIRA	2.4GM/100ML	A077174	001	May 31, 2005	Sep DISC	
+	!	CLINIGEN HLTHCARE	2.4GM/100ML	N020068	001	Sep 27, 1991	Sep CTEC

FOSINOPRIL SODIUM

TABLET;ORAL
FOSINOPRIL SODIUM

	@	UPSHER-SMITH LABS	10MG	A076188	001	Oct 08, 2004	Jun CAHN
AB			10MG	A076483	001	Apr 23, 2004	Jun CAHN
	@		20MG	A076188	002	Oct 08, 2004	Jun CAHN
AB			20MG	A076483	002	Apr 23, 2004	Jun CAHN
	@		40MG	A076188	003	Oct 08, 2004	Jun CAHN
AB			40MG	A076483	003	Apr 23, 2004	Jun CAHN
		MONOPRIL					
+	@	BRISTOL MYERS SQUIBB	10MG	N019915	002	May 16, 1991	Jan CRLD
+	@		20MG	N019915	003	May 16, 1991	Jan CRLD
+	@		40MG	N019915	004	Mar 28, 1995	Jan CRLD

FOSPHENYTOIN SODIUM

INJECTABLE;INJECTION
FOSPHENYTOIN SODIUM

AP		FRESENIUS KABI USA	EQ 50MG PHENYTOIN NA/ML	A078052	001	Aug 06, 2007	Jun CMFD
AP		WEST-WARD PHARMS INT	EQ 50MG PHENYTOIN NA/ML	A077481	001	Aug 06, 2007	Jan CAHN
AP			EQ 50MG PHENYTOIN NA/ML	A077989	001	Aug 06, 2007	Jan CAHN

FUROSEMIDE

INJECTABLE;INJECTION
FUROSEMIDE

	@	ACCORD HLTHCARE	10MG/ML	A070017	001	Dec 15, 1986	Jun CAHN
AP		BAXTER HLTHCARE CORP	10MG/ML	A022747	001	Jan 27, 2014	Aug CAHN

SOLUTION;ORAL

FUROSEMIDE

>D>	AA	WOCKHARDT	10MG/ML	A070655	001	Oct 02, 1987	Dec CAHN
>A>	AA	WOCKHARDT BIO AG	10MG/ML	A070655	001	Oct 02, 1987	Dec CAHN

TABLET;ORAL

FUROSEMIDE

AB		IPCA LABS LTD	20MG	A078010	001	Sep 18, 2006	Aug CTEC
BX			20MG	A078010	001	Sep 18, 2006	Apr CTEC
AB			40MG	A078010	002	Sep 18, 2006	Aug CTEC
BX			40MG	A078010	002	Sep 18, 2006	Apr CTEC
AB			80MG	A078010	003	Sep 18, 2006	Aug CTEC
BX			80MG	A078010	003	Sep 18, 2006	Apr CTEC
AB		PRINSTON INC	20MG	A076796	001	Mar 26, 2004	Feb CAHN
AB			40MG	A076796	002	Mar 26, 2004	Feb CAHN
AB			80MG	A076796	003	Mar 26, 2004	Feb CAHN
	@	SUN PHARM INDS INC	20MG	A091258	001	Apr 01, 2014	May DISC
	@		40MG	A091258	002	Apr 01, 2014	May DISC
	@		40MG	N018790	001	Nov 29, 1983	Oct CAHN
	@		80MG	A091258	003	Apr 01, 2014	May DISC
AB		WEST-WARD PHARMS INT	20MG	N018823	001	Nov 10, 1983	Jan CAHN

TABLET;ORAL						
FUROSEMIDE						
AB		40MG	N018823	002	Nov 10, 1983	Jan CAHN
<u>GABAPENTIN</u>						
CAPSULE;ORAL						
GABAPENTIN						
AB	AUROBINDO PHARMA LTD	100MG	A078787	001	Jan 31, 2008	Jan CAHN
AB		300MG	A078787	002	Jan 31, 2008	Jan CAHN
AB		400MG	A078787	003	Jan 31, 2008	Jan CAHN
	@ CSPC OUYI PHARM CO	100MG	A075477	001	Mar 23, 2005	Oct CAHN
	@	300MG	A075477	002	Mar 23, 2005	Oct CAHN
	@	400MG	A075477	003	Mar 23, 2005	Oct CAHN
AB	EPIC PHARMA LLC	100MG	A207099	001	Mar 24, 2017	Mar NEWA
AB		300MG	A207099	002	Mar 24, 2017	Mar NEWA
AB		400MG	A207099	003	Mar 24, 2017	Mar NEWA
AB	JIANGSU HENGRUI MED	100MG	A091008	001	Oct 26, 2017	Oct NEWA
AB		300MG	A091008	002	Oct 26, 2017	Oct NEWA
AB		400MG	A091008	003	Oct 26, 2017	Oct NEWA
TABLET;ORAL						
GABAPENTIN						
AB	CSPC OUYI PHARM CO	600MG	A207057	001	Oct 26, 2017	Oct NEWA
AB		800MG	A207057	002	Oct 26, 2017	Oct NEWA
AB	GLENMARK PHARMS LTD	600MG	A077662	001	Aug 18, 2006	May CAHN
AB		800MG	A077662	002	Aug 18, 2006	May CAHN
AB	TEVA PHARMS USA	600MG	A205807	001	Mar 10, 2017	Feb NEWA
AB		800MG	A205807	002	Mar 10, 2017	Feb NEWA
<u>GADOTERATE MEGLUMINE</u>						
SOLUTION;INTRAVENOUS						
DOTAREM						
+	GUERBET	1.8845GM/5ML (376.9MG/ML)	N204781	005	Mar 31, 2017	Sep CMS1
+		1.884GM/5ML (376.9MG/ML)	N204781	005	Mar 31, 2017	Aug NEWA
<u>GALANTAMINE HYDROBROMIDE</u>						
TABLET;ORAL						
GALANTAMINE HYDROBROMIDE						
	@ MYLAN	EQ 4MG BASE	A077603	001	Aug 28, 2008	Oct DISC
	@	EQ 8MG BASE	A077603	002	Aug 28, 2008	Oct DISC
	@	EQ 12MG BASE	A077603	003	Aug 28, 2008	Oct DISC
AB	YABAO PHARM	EQ 4MG BASE	A077604	001	Feb 06, 2009	Jul CMFD
AB		EQ 8MG BASE	A077604	002	Feb 06, 2009	Jul CMFD
AB		EQ 12MG BASE	A077604	003	Feb 06, 2009	Jul CMFD
<u>GANCICLOVIR</u>						
SOLUTION;IV (INFUSION)						
GANCICLOVIR						
+	EXELA PHARMA SCS LLC	500MG/250ML (2MG/ML)	N209347	001	Feb 17, 2017	Feb NEWA
<u>GANCICLOVIR SODIUM</u>						
INJECTABLE;INJECTION						
GANCICLOVIR						
AP	MYLAN LABS LTD	EQ 500MG BASE/VIAL	A204560	001	Nov 17, 2017	Nov NEWA
AP	PHARMASCIENCE INC	EQ 500MG BASE/VIAL	A207645	001	Dec 08, 2017	Nov NEWA
<u>GATIFLOXACIN</u>						
SOLUTION/DROPS;OPHTHALMIC						
GATIFLOXACIN						
AT	SANDOZ INC	0.5%	A204227	001	Jul 11, 2016	Feb CAHN
<u>GEMCITABINE HYDROCHLORIDE</u>						
INJECTABLE;INJECTION						
GEMCITABINE HYDROCHLORIDE						
AP	ACTAVIS TOTOWA	EQ 2GM BASE/VIAL	A079160	003	Jul 28, 2016	Oct NEWA
AP	APOTEX INC	200MG/5.26ML (38MG/ML)	A206776	001	May 23, 2017	May NEWA
AP		1GM/26.3ML (38MG/ML)	A206776	002	May 23, 2017	May NEWA
AP		2GM/52.6ML (38MG/ML)	A206776	003	May 23, 2017	May NEWA
AP	MYLAN LABS LTD	200MG/5.26ML (38MG/ML)	A205242	001	Dec 06, 2017	Nov NEWA
AP		1GM/26.3ML (38MG/ML)	A205242	002	Dec 06, 2017	Nov NEWA
AP		2GM/52.6ML (38MG/ML)	A205242	003	Dec 06, 2017	Nov NEWA
	@ SAGENT PHARMS	EQ 200MG BASE/VIAL	A091597	001	May 07, 2013	Nov DISC

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

@ EQ 1GM BASE/VIAL

A091597 002 May 07, 2013 Nov DISC

SOLUTION;IV (INFUSION)

GEMCITABINE HYDROCHLORIDE

+! ACCORD HLTHCARE 1GM/10ML (100MG/ML)
 +! 1.5GM/15ML (100MG/ML)
 +! 2GM/20ML (100MG/ML)
 +! 200MG/2ML (100MG/ML)

N209604 002 Aug 03, 2017 Aug NEWA
 N209604 003 Aug 03, 2017 Aug NEWA
 N209604 004 Aug 03, 2017 Aug NEWA
 N209604 001 Aug 03, 2017 Aug NEWA

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

AB CARIBE HOLDINGS 600MG
 >A> @ FOSUN PHARMA 600MG
 >D> @ SANDOZ 600MG

A078012 001 Mar 26, 2007 Jan CAHN
 A074615 001 Sep 29, 1995 Dec CAHN
 A074615 001 Sep 29, 1995 Dec CAHN

GEMIFLOXACIN MESYLATE

TABLET;ORAL

FACTIVE

AB +! LG CHEM LTD EQ 320MG BASE

N021158 001 Apr 04, 2003 Mar CAHN

GENTAMICIN SULFATE

CREAM;TOPICAL

GENTAMICIN SULFATE

AT @ FOUGERA PHARMS INC EQ 0.1% BASE
 ! PERRIGO NEW YORK EQ 0.1% BASE
 @ TARO EQ 0.1% BASE

A062531 001 Jul 05, 1984 Jan DISC
 A062307 001 Jan CHRS
 A062427 001 May 26, 1983 Jan DISC

OINTMENT;TOPICAL

GENTAMICIN SULFATE

AT FOUGERA PHARMS INC EQ 0.1% BASE

A062533 001 Oct 05, 1984 Jan CAHN

SOLUTION/DROPS;OPHTHALMIC

GENOPTIC

AT ! ALLERGAN EQ 0.3% BASE

A062452 001 Oct 10, 1984 Oct CHRS

GENTAMICIN SULFATE

>D> @ BAUSCH AND LOMB EQ 0.3% BASE

A064048 001 May 11, 1994 Dec CMFD

>A> AT EQ 0.3% BASE

A064048 001 May 11, 1994 Dec CMFD

@ EQ 0.3% BASE

A064048 001 May 11, 1994 Oct DISC

AT SANDOZ INC EQ 0.3% BASE

A062196 001 Mar CAHN

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS

COPAXONE

AP +! TEVA PHARMS USA 40MG/ML

N020622 003 Jan 28, 2014 Sep CFTG

GLATIRAMER ACETATE

AP MYLAN PHARMS INC 20MG/ML

A091646 001 Oct 03, 2017 Sep NEWA

AP 40MG/ML

A206936 001 Oct 03, 2017 Sep NEWA

GLECAPREVIR; PIBRENTASVIR

TABLET;ORAL

MAVYRET

+! ABBVIE INC 100MG;40MG

N209394 001 Aug 03, 2017 Aug NEWA

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

AB @ EPIC PHARMA LLC 1MG

A077274 001 Oct 06, 2005 May CAHN

@ 2MG

A077274 002 Oct 06, 2005 May CAHN

@ 4MG

A077274 003 Oct 06, 2005 May CAHN

AB PRINSTON INC 1MG

A077370 001 Dec 23, 2005 Feb CAHN

AB 2MG

A077370 002 Dec 23, 2005 Feb CAHN

AB 4MG

A077370 003 Dec 23, 2005 Feb CAHN

AB 8MG

A077370 004 Dec 23, 2005 Feb CAHN

AB VIVA HLTHCARE 1MG

A091220 001 Jun 29, 2012 Nov CAHN

AB 2MG

A091220 002 Jun 29, 2012 Nov CAHN

AB 3MG

A091220 003 Jun 29, 2012 Nov CAHN

AB 4MG

A091220 004 Jun 29, 2012 Nov CAHN

AB 6MG

A091220 005 Jun 29, 2012 Nov CAHN

AB 8MG

A091220 006 Jun 29, 2012 Nov CAHN

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

	@ MYLAN	5MG	A074438	001	Jun 20, 1995	Nov DISC
	@	10MG	A074438	002	Jun 20, 1995	Nov DISC
AB	WATSON LABS TEVA	5MG	A074223	001	Feb 27, 1995	May CAHN
AB		10MG	A074223	002	Feb 27, 1995	May CAHN

TABLET, EXTENDED RELEASE;ORAL

GLIPIZIDE

AB	AUROBINDO PHARMA LTD	2.5MG	A206928	001	May 12, 2017	May NEWA
AB		5MG	A206928	002	May 12, 2017	May NEWA
AB		10MG	A206928	003	May 12, 2017	May NEWA

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB	EPIC PHARMA LLC	2.5MG;250MG	A077507	001	Oct 27, 2005	May CAHN
AB		2.5MG;500MG	A077507	002	Oct 27, 2005	May CAHN
AB		5MG;500MG	A077507	003	Oct 27, 2005	May CAHN

METAGLIP

	+ @ BRISTOL MYERS SQUIBB	2.5MG;250MG	N021460	001	Oct 21, 2002	Jan CRLD
	+ @	2.5MG;500MG	N021460	002	Oct 21, 2002	Jan CRLD
	+ @	5MG;500MG	N021460	003	Oct 21, 2002	Jan CRLD

GLUTETHIMIDE

TABLET;ORAL

GLUTETHIMIDE

	@ UPSHER-SMITH LABS	500MG	A083234	002		Jun CAHN
--	---------------------	-------	---------	-----	--	----------

GLYBURIDE

TABLET;ORAL

GLYBURIDE

AB1	EPIC PHARMA LLC	1.25MG	A076257	001	Jun 27, 2002	May CAHN
AB1		2.5MG	A076257	002	Jun 27, 2002	May CAHN
AB1		5MG	A076257	003	Jun 27, 2002	May CAHN
AB2	IMPAX LABS INC	1.25MG	A206079	001	Sep 30, 2015	Feb CAHN
AB2		2.5MG	A206079	002	Sep 30, 2015	Feb CAHN
AB2		5MG	A206079	003	Sep 30, 2015	Feb CAHN

GLYBURIDE (MICRONIZED)

>A>	@ FOSUN PHARMA	1.5MG	A075174	001	Jun 22, 1998	Dec CAHN
>A>	@	3MG	A075174	002	Jun 22, 1998	Dec CAHN
>D>	@ SANDOZ	1.5MG	A075174	001	Jun 22, 1998	Dec CAHN
>D>	@	3MG	A075174	002	Jun 22, 1998	Dec CAHN

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLUCOVANCE

	+ @ BRISTOL MYERS SQUIBB	2.5MG;500MG	N021178	002	Jul 31, 2000	Aug DISC
	+ @	5MG;500MG	N021178	003	Jul 31, 2000	Aug DISC

GLYBURIDE AND METFORMIN HYDROCHLORIDE

AB	! AUROBINDO PHARMA	2.5MG;500MG	A077870	002	Nov 14, 2007	Aug CHRS
	@ IMPAX LABS INC	1.25MG;250MG	A076731	001	Nov 19, 2004	Feb CAHN
	@	2.5MG;500MG	A076731	002	Nov 19, 2004	Feb CAHN
	@	5MG;500MG	A076731	003	Nov 19, 2004	Feb CAHN

GLYCINE

SOLUTION;IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

AT	ICU MEDICAL INC	1.5GM/100ML	N018315	001		Feb CAHN
----	-----------------	-------------	---------	-----	--	----------

GLYCOPYRROLATE

INJECTABLE;INJECTION

GLYCOPYRROLATE

AP	AMNEAL PHARMS CO	0.2MG/ML	A208973	001	Jun 15, 2017	Jun NEWA
>D>	AA FRESENIUS KABI USA	0.2MG/ML	A209328	001	Oct 27, 2017	Dec CTEC
>A>	AP	0.2MG/ML	A209328	001	Oct 27, 2017	Dec CTEC
	AA	0.2MG/ML	A209328	001	Oct 27, 2017	Oct NEWA
AP	SOMERSET THERAPS LLC	0.2MG/ML	A207639	001	Jun 23, 2017	Jun NEWA

POWDER;INHALATION

SEEBRI

	+! SUNOVION PHARMS INC	15.6MCG/INH	N207923	001	Oct 29, 2015	Jan CAHN
--	------------------------	-------------	---------	-----	--------------	----------

SOLUTION; INHALATION							
>A>	LONHALA MAGNAIR KIT						
>A>	+!	SUNOVION RESP	25MCG/ML	N208437	001	Dec 05, 2017	Dec NEWA
TABLET; ORAL							
GLYCOPYRROLATE							
	@	EPIC PHARMA LLC	1MG	A040568	001	Dec 22, 2004	May CAHN
	@		2MG	A040568	002	Dec 22, 2004	May CAHN
		NEXGEN PHARMA	1.5MG	A091522	001	Mar 12, 2012	Nov CTEC
AA		SANTOS BIOTECH	1MG	A091182	001	Feb 03, 2014	May CAHN
AA			2MG	A091182	002	Feb 03, 2014	May CAHN
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE</u>							
POWDER; INHALATION							
UTIBRON							
	+!	SUNOVION PHARMS INC	15.6MCG/INH; 27.5MCG/INH	N207930	001	Oct 29, 2015	Jan CAHN
<u>GONADORELIN HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
FACTREL							
	@	WEST-WARD PHARMS INT	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982	Mar CAHN
	@		EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982	Mar CAHN
	@		EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982	Mar CAHN
<u>GONADOTROPIN, CHORIONIC</u>							
INJECTABLE; INJECTION							
CHORIONIC GONADOTROPIN							
	+!	FERRING	5,000 UNITS/VIAL	N017016	006		Jan CMFD
<u>GOSERELIN ACETATE</u>							
IMPLANT; IMPLANTATION							
ZOLADEX							
	+!	TERSERA THERAPS LLC	EQ 3.6MG BASE	N019726	001	Dec 29, 1989	May CAHN
	+!		EQ 10.8MG BASE	N020578	001	Jan 11, 1996	May CAHN
<u>GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>							
SOLUTION/DROPS; OPHTHALMIC							
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN							
AT		AMRING PHARMS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A065187	001	Oct 28, 2005	Mar CAHN
NEOSPORIN							
AT	!	MONARCH PHARMS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A060582	001		Apr CAHN
<u>GRANISETRON HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
GRANISETRON HYDROCHLORIDE							
	@	BAXTER HLTHCARE CORP	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007	Aug CAHN
	@		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008	Aug CAHN
	@		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008	Aug CAHN
>A>	AP	MYLAN ASI	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A091137	002	Apr 09, 2010	Dec CAHN
	AP	MYLAN LABS LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A203454	001	Apr 04, 2017	Mar NEWA
	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A203454	002	Apr 04, 2017	Mar NEWA
	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A203453	001	Jan 31, 2017	Jan NEWA
>D>	AP	SAGENT AGILA	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A091137	002	Apr 09, 2010	Dec CAHN
	AP	SANDOZ INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078534	001	Apr 30, 2009	Mar CAHN
	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078531	001	Apr 30, 2009	Mar CAHN
	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078531	002	Apr 30, 2009	Mar CAHN
	AP	WEST-WARD PHARMS INT	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A077913	001	Jun 26, 2008	Jan CAHN
	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077186	001	Jun 30, 2008	Jan CAHN
	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077187	001	Jun 30, 2008	Jan CAHN
	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177	001	Dec 31, 2007	Jan CAHN
TABLET; ORAL							
GRANISETRON HYDROCHLORIDE							
	@	EPIC PHARMA LLC	EQ 1MG BASE	A078260	001	Dec 31, 2007	May CAHN
AB		TARO PHARM	EQ 1MG BASE	A090817	001	May 28, 2010	Mar CAHN

GRISEOFULVIN, MICROCRYSTALLINE

TABLET;ORAL

FULVICIN-U/F

@ CHARTWELL RX	250MG	A 060569	002		Sep CAHN
@	500MG	A 060569	001		Sep CAHN

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL

GRISEOFULVIN

AB	CHARTWELL RX	125MG/5ML	A 065200	001	Mar 02, 2005	Jun CAHN
----	--------------	-----------	----------	-----	--------------	----------

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET;ORAL

FULVICIN P/G

@ CHARTWELL RX	125MG	A 061996	001		Sep CAHN
@	250MG	A 061996	002		Sep CAHN

FULVICIN P/G 165

@ CHARTWELL RX	165MG	A 061996	003	Apr 06, 1982	Sep CAHN
----------------	-------	----------	-----	--------------	----------

FULVICIN P/G 330

@ CHARTWELL RX	330MG	A 061996	004	Apr 06, 1982	Sep CAHN
----------------	-------	----------	-----	--------------	----------

GRISEOFULVIN, ULTRAMICROSIZED

TABLET;ORAL

GRISEOFULVIN, ULTRAMICROSIZED

>A> AB	COREPHARMA	125MG	A 204371	001	Jan 09, 2014	Dec CAHN
>A> AB		250MG	A 204371	002	Jan 09, 2014	Dec CAHN
>D> AB	IMPAX LABS INC	125MG	A 204371	001	Jan 09, 2014	Dec CAHN
AB		125MG	A 204371	001	Jan 09, 2014	Sep CAHN
>D> AB		250MG	A 204371	002	Jan 09, 2014	Dec CAHN
AB		250MG	A 204371	002	Jan 09, 2014	Sep CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

OBREDON

+ @ SOVEREIGN PHARMS	200MG/5ML; 2.5MG/5ML	N 205474	001	Nov 14, 2014	Aug DISC
----------------------	----------------------	----------	-----	--------------	----------

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 1MG BASE	A 205689	001	Nov 16, 2017	Nov NEWA
AB		EQ 2MG BASE	A 205689	002	Nov 16, 2017	Nov NEWA
AB		EQ 3MG BASE	A 205689	003	Nov 16, 2017	Nov NEWA
AB		EQ 4MG BASE	A 205689	004	Nov 16, 2017	Nov NEWA

HALCINONIDE

CREAM;TOPICAL

HALOG-E

@ SUN PHARM INDS INC	0.1%	N 018234	001		Aug CAHN
----------------------	------	----------	-----	--	----------

OINTMENT;TOPICAL

HALOG

+! SUN PHARM INDS INC	0.1%	N 017824	001		Aug CAHN
-----------------------	------	----------	-----	--	----------

SOLUTION;TOPICAL

HALOG

@ SUN PHARM INDS INC	0.1%	N 017823	001		Aug CAHN
----------------------	------	----------	-----	--	----------

HALOBETASOL PROPIONATE

CREAM;TOPICAL

HALOBETASOL PROPIONATE

AB	! G AND W LABS	0.05%	A 078162	001	Apr 24, 2007	Apr CHRS
	ULTRAVATE					
AB	+ SUN PHARM INDS LTD	0.05%	N 019967	001	Dec 27, 1990	Apr CHRS
AB	+!	0.05%	N 019967	001	Dec 27, 1990	Mar CAHN

OINTMENT;TOPICAL

HALOBETASOL PROPIONATE

AB	! G AND W LABS	0.05%	A 077721	001	Sep 07, 2006	Jun CHRS
AB	G AND W LABS INC	0.05%	A 077109	001	Jun 14, 2005	Nov CMFD
AB	PERRIGO ISRAEL	0.05%	A 076872	001	Dec 16, 2004	Apr CAHN
	ULTRAVATE					
AB	+ RANBAXY	0.05%	N 019968	001	Dec 17, 1990	Jun CHRS

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

@	ANDA REPOSITORY	0.5MG	A071156	001	Jan 02, 1987	Sep CAHN
@		1MG	A071157	001	Jan 02, 1987	Sep CAHN
@		2MG	A071172	001	Jan 02, 1987	Sep CAHN
@		5MG	A071212	001	Jan 07, 1988	Sep CAHN
@		10MG	A071173	001	Jan 07, 1988	Sep CAHN
@		20MG	A071177	001	Jan 07, 1988	Sep CAHN
@	FRONTIDA BIOPHARM	20MG	A071177	001	Jan 07, 1988	Feb CAHN

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

AO	GLAND PHARMA LTD	EQ 50MG BASE/ML	A205241	001	May 12, 2017	May NEWA
AO		EQ 100MG BASE/ML	A205241	002	May 12, 2017	May NEWA
@	SANDOZ INC	EQ 50MG BASE/ML	A076463	001	Jun 24, 2005	Mar CAHN
@		EQ 100MG BASE/ML	A076463	002	Jun 24, 2005	Mar CAHN

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

AA	PHARM ASSOC	EQ 2MG BASE/ML	A073037	001	Feb 26, 1993	May CAHN
AP	AKORN	EQ 5MG BASE/ML	A204849	001	Sep 06, 2017	Aug NEWA
@	BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Aug CAHN
@		EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	Aug CAHN
@	SANDOZ INC	EQ 5MG BASE/ML	A076464	001	Sep 29, 2004	Mar CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP	GLAND PHARMA LTD	5,000 UNITS/ML	A205323	001	Feb 06, 2017	Jan NEWA
AP	MYLAN LABS LTD	1,000 UNITS/ML	A203851	001	Nov 30, 2017	Nov NEWA
AP		5,000 UNITS/ML	A203851	002	Nov 30, 2017	Nov NEWA
AP		10,000 UNITS/ML	A203851	003	Nov 30, 2017	Nov NEWA
AP		20,000 UNITS/ML	A203852	001	Nov 30, 2017	Nov NEWA
@	WEST-WARD PHARMS INT	1,000 UNITS/ML	N017007	001		Jul CAHN
@		2,500 UNITS/ML	N017007	007		Jul CAHN
@		5,000 UNITS/ML	N017007	002		Jul CAHN
@		5,000 UNITS/0.5ML	N017007	010		Jul CAHN
@		7,500 UNITS/ML	N017007	003		Jul CAHN
@		10,000 UNITS/ML	N017007	004		Jul CAHN
@		15,000 UNITS/ML	N017007	005		Jul CAHN
@		20,000 UNITS/ML	N017007	006		Jul CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	ABHAI LLC	1.5MG/5ML; 5MG/5ML	A207487	001	Feb 21, 2017	Feb NEWA
AA	BIO-PHARM INC	1.5MG/5ML; 5MG/5ML	A204765	001	Mar 06, 2017	Feb NEWA
AA	NOVEL LABS INC	1.5MG/5ML; 5MG/5ML	A203535	001	Feb 13, 2017	Jan NEWA
AA	PADDOCK LLC	1.5MG/5ML; 5MG/5ML	A205731	001	Feb 15, 2017	Jan NEWA
>D> AA	WOCKHARDT	1.5MG/5ML; 5MG/5ML	A088008	001	Mar 03, 1983	Dec CAHN
>A> AA	WOCKHARDT BIO AG	1.5MG/5ML; 5MG/5ML	A088008	001	Mar 03, 1983	Dec CAHN

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AA	AVANTHI INC	1.5MG; 5MG	A207176	001	Aug 07, 2017	Jul NEWA
AA	! KING PHARMS	1.5MG; 5MG	A088508	001	Jul 30, 1985	Feb CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

@	ANDA REPOSITORY	10MG	A089359	001	Jul 25, 1986	Sep CAHN
@		25MG	A089258	001	May 05, 1986	Sep CAHN
@		50MG	A089259	001	May 05, 1986	Sep CAHN
@		100MG	A088729	001	Apr 11, 1985	Sep CAHN
@	MYLAN	10MG	A090413	001	Dec 08, 2010	Nov DISC
@		25MG	A090413	002	Dec 08, 2010	Nov DISC

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

	@	50MG	A090413	003	Dec 08, 2010	Nov	DISC
	@	100MG	A090413	004	Dec 08, 2010	Nov	DISC
AA	SCIEGEN PHARMS INC	10MG	A205236	001	May 26, 2017	May	NEWA
AA		25MG	A205236	002	May 26, 2017	May	NEWA
AA		50MG	A205236	003	May 26, 2017	May	NEWA
AA		100MG	A205236	004	May 26, 2017	May	NEWA
AA	TECH ORGANIZED	10MG	A205236	001	May 26, 2017	Sep	CAHN
AA		25MG	A205236	002	May 26, 2017	Sep	CAHN
AA		50MG	A205236	003	May 26, 2017	Sep	CAHN
AA		100MG	A205236	004	May 26, 2017	Sep	CAHN
	@ UPSHER-SMITH LABS	10MG	A083241	001		Jun	CAHN
	@	25MG	A083560	001		Jun	CAHN
	@	50MG	A083561	001		Jun	CAHN
	@	50MG	A085088	001		Sep	CAHN

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG	A075907	001	Sep 17, 2002	Feb	CAHN
----	--------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL

HYDROCHLOROTHIAZIDE

>A>	@ FOSUN PHARMA	25MG	A087565	001	Mar 09, 1982	Dec	CAHN
>A>	@	50MG	A084912	001		Dec	CAHN
	@ JUBILANT CADISTA	25MG	A040809	001	Sep 04, 2007	Sep	DISC
	@	50MG	A040809	002	Sep 04, 2007	Sep	DISC
>A> AB	LEADING PHARMA LLC	12.5MG	A040702	003	May 10, 2017	Dec	NEWA
	@ MYLAN PHARMS INC	12.5MG	A040770	001	Jan 23, 2007	Nov	DISC
AB	PRINSTON INC	25MG	A040412	001	Mar 29, 2002	Feb	CAHN
AB		50MG	A040412	002	Mar 29, 2002	Feb	CAHN
>D>	@ SANDOZ	25MG	A087565	001	Mar 09, 1982	Dec	CAHN
>D>	@	50MG	A084912	001		Dec	CAHN
AB	TECH ORGANIZED	25MG	A203018	001	Jul 23, 2014	Sep	CAHN
AB		50MG	A203018	002	Jul 23, 2014	Sep	CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	ATLAS PHARMS LLC	12.5MG;150MG	A203036	001	Jan 15, 2016	Mar	CAHN
AB		12.5MG;300MG	A203036	002	Jan 15, 2016	Mar	CAHN
AB		25MG;300MG	A203036	003	Jan 15, 2016	Mar	CAHN
AB	UNICHEM LABS LTD	12.5MG;150MG	A207018	001	Sep 19, 2017	Sep	NEWA
AB		12.5MG;300MG	A207018	002	Sep 19, 2017	Sep	NEWA
AB	WEST-WARD PHARMS INT	25MG;300MG	A090351	003	Jun 08, 2017	May	NEWA

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET;ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB	INVAGEN PHARMS	12.5MG;10MG	A204058	001	May 23, 2017	May	NEWA
AB		12.5MG;20MG	A204058	002	May 23, 2017	May	NEWA
AB		25MG;20MG	A204058	003	May 23, 2017	May	NEWA
	PRINZIDE						
+	@ MERCK	12.5MG;10MG	N019778	003	Nov 18, 1993	Jan	CRLD
+	@	12.5MG;20MG	N019778	001	Feb 16, 1989	Jan	CRLD

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG;50MG	A204901	001	Nov 06, 2017	Oct	NEWA
AB		12.5MG;100MG	A204901	002	Nov 06, 2017	Oct	NEWA
AB		25MG;100MG	A204901	003	Nov 06, 2017	Oct	NEWA
AB	UNICHEM LABS LTD	12.5MG;50MG	A204832	001	Jul 21, 2017	Jul	NEWA
AB		12.5MG;100MG	A204832	002	Jul 21, 2017	Jul	NEWA
AB		25MG;100MG	A204832	003	Jul 21, 2017	Jul	NEWA

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

>A>	@ FOSUN PHARMA	15MG;250MG	A070182	001	Jan 15, 1986	Dec	CAHN
>A>	@	25MG;250MG	A070183	001	Jan 15, 1986	Dec	CAHN
>A>	@	30MG;500MG	A070543	001	Jan 15, 1986	Dec	CAHN
>D>	@ SANDOZ	15MG;250MG	A070182	001	Jan 15, 1986	Dec	CAHN

TABLET;ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

>D>	@	25MG;250MG	A070183	001	Jan 15, 1986	Dec CAHN
>D>	@	30MG;500MG	A070543	001	Jan 15, 1986	Dec CAHN

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@ CHARTWELL RX	12.5MG;7.5MG	A090096	001	Sep 25, 2008	Mar CAHN
	@	12.5MG;15MG	A090096	002	Sep 25, 2008	Mar CAHN
	@	25MG;15MG	A090096	003	Sep 25, 2008	Mar CAHN
AB	HERITAGE PHARMS INC	12.5MG;7.5MG	A202150	001	Mar 07, 2014	Jan CMS1
AB		12.5MG;15MG	A202150	002	Mar 07, 2014	Jan CMS1
AB		25MG;15MG	A202150	003	Mar 07, 2014	Jan CMS1

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG;20MG	A204233	001	Apr 24, 2017	Apr NEWA
AB		12.5MG;40MG	A204233	002	Apr 24, 2017	Apr NEWA
AB		25MG;40MG	A204233	003	Apr 24, 2017	Apr NEWA
AB	AUROBINDO PHARMA LTD	12.5MG;20MG	A205391	001	Apr 24, 2017	Apr NEWA
AB		12.5MG;40MG	A205391	002	Apr 24, 2017	Apr NEWA
AB		25MG;40MG	A205391	003	Apr 24, 2017	Apr NEWA
AB	PRINSTON INC	12.5MG;20MG	A207804	001	Apr 24, 2017	Apr NEWA
AB		12.5MG;40MG	A207804	002	Apr 24, 2017	Apr NEWA
AB		25MG;40MG	A207804	003	Apr 24, 2017	Apr NEWA
AB	TEVA PHARMS USA	12.5MG;20MG	A200532	001	Apr 24, 2017	Apr NEWA
AB		12.5MG;40MG	A200532	002	Apr 24, 2017	Apr NEWA
AB		25MG;40MG	A200532	003	Apr 24, 2017	Apr NEWA
AB	TORRENT PHARMS LTD	12.5MG;20MG	A206515	001	May 03, 2017	Apr NEWA
AB		12.5MG;40MG	A206515	002	May 03, 2017	Apr NEWA
AB		25MG;40MG	A206515	003	May 03, 2017	Apr NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>A>	@ FOSUN PHARMA	25MG;40MG	A071060	001	Aug 26, 1987	Dec CAHN
>A>	@	25MG;80MG	A071061	001	Aug 26, 1987	Dec CAHN
>D>	@ SANDOZ	25MG;40MG	A071060	001	Aug 26, 1987	Dec CAHN
>D>	@	25MG;80MG	A071061	001	Aug 26, 1987	Dec CAHN

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	INVAGEN PHARMS	12.5MG;EQ 10MG BASE	A201356	001	Apr 20, 2011	Jun CMS1
AB		12.5MG;EQ 20MG BASE	A201356	002	Apr 20, 2011	Jun CMS1
AB		25MG;EQ 20MG BASE	A201356	003	Apr 20, 2011	Jun CMS1

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

>A>	@ FOSUN PHARMA	25MG;25MG	A086881	001		Dec CAHN
>D>	@ SANDOZ	25MG;25MG	A086881	001		Dec CAHN
	SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE					
	@ UPSHER SMITH	25MG;25MG	A087553	001		Jun CAHN

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG;40MG	A209028	001	Nov 06, 2017	Oct NEWA
AB		12.5MG;80MG	A209028	002	Nov 06, 2017	Oct NEWA
AB		25MG;80MG	A209028	003	Nov 06, 2017	Oct NEWA
AB	ZYDUS PHARMS USA INC	12.5MG;40MG	A204221	001	Aug 15, 2017	Jul NEWA
AB		12.5MG;80MG	A204221	002	Aug 15, 2017	Jul NEWA
AB		25MG;80MG	A204221	003	Aug 15, 2017	Jul NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG;80MG	A201662	001	Mar 21, 2013	May CAHN
AB		12.5MG;160MG	A201662	002	Mar 21, 2013	May CAHN
AB		12.5MG;320MG	A201662	003	Mar 21, 2013	May CAHN
AB		25MG;160MG	A201662	004	Mar 21, 2013	May CAHN
AB		25MG;320MG	A201662	005	Mar 21, 2013	May CAHN
AB	WATSON LABS TEVA	12.5MG;80MG	A091519	001	Mar 21, 2013	May CAHN
AB		12.5MG;160MG	A091519	002	Mar 21, 2013	May CAHN
AB		12.5MG;320MG	A091519	003	Mar 21, 2013	May CAHN
AB		25MG;160MG	A091519	004	Mar 21, 2013	May CAHN
AB		25MG;320MG	A091519	005	Mar 21, 2013	May CAHN

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

ZOHYDRO ER

>D>	+!	PERNIX IRELAND PAIN	10MG	N202880	001	Oct 25, 2013	Dec CAHN
>A>	+!		10MG	N202880	001	Oct 25, 2013	Dec CAHN
>D>	+		15MG	N202880	002	Oct 25, 2013	Dec CAHN
>A>	+		15MG	N202880	002	Oct 25, 2013	Dec CAHN
>D>	+		20MG	N202880	003	Oct 25, 2013	Dec CAHN
>A>	+		20MG	N202880	003	Oct 25, 2013	Dec CAHN
>D>	+		30MG	N202880	004	Oct 25, 2013	Dec CAHN
>A>	+		30MG	N202880	004	Oct 25, 2013	Dec CAHN
>D>	+		40MG	N202880	005	Oct 25, 2013	Dec CAHN
>A>	+		40MG	N202880	005	Oct 25, 2013	Dec CAHN
>D>	+		50MG	N202880	006	Oct 25, 2013	Dec CAHN
>A>	+		50MG	N202880	006	Oct 25, 2013	Dec CAHN

TABLET, EXTENDED RELEASE; ORAL

VANTRELA ER

+	TEVA BRANDED PHARM	15MG	N207975	001	Jan 17, 2017	Jan NEWA
+		30MG	N207975	002	Jan 17, 2017	Jan NEWA
+		45MG	N207975	003	Jan 17, 2017	Jan NEWA
+		60MG	N207975	004	Jan 17, 2017	Jan NEWA
+		90MG	N207975	005	Jan 17, 2017	Jan NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB	!	AMNEAL PHARMS NY	7.5MG;200MG	A076642	001	Oct 12, 2004	Sep CHRS
		VICOPROFEN					
	+	@ ABBVIE	7.5MG;200MG	N020716	001	Sep 23, 1997	Sep DISC

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@	TRIS PHARMA INC	5MG/5ML;60MG/5ML	A203839	001	Oct 28, 2014	Sep DISC
---	-----------------	------------------	---------	-----	--------------	----------

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT	!	FOUGERA PHARMS INC	1%	A080693	003		Jan CAHN
AT	!		2.5%	A089414	001	Dec 16, 1986	Jan CAHN
		SYNACORT					
	@	MEDICIS	1%	A087458	001		Jul DISC
	@		2.5%	A087457	001		Jul DISC

LOTION; TOPICAL

STIE-CORT

	@	PERRIGO CO	1%	A089066	001	Nov 25, 1985	Apr CAHN
AT			2.5%	A089074	001	Nov 26, 1985	Apr CAHN

OINTMENT; TOPICAL

HYDROCORTISONE

AT	!	FOUGERA PHARMS INC	2.5%	A081203	001	May 28, 1993	Jan CAHN
		HYDROCORTISONE IN ABSORBASE					
AT		CMP PHARMA INC	1%	A088138	001	Sep 06, 1985	Apr CAHN

TABLET; ORAL

HYDROCORTISONE

AB		PII	5MG	A207029	001	Apr 27, 2017	Apr NEWA
AB			10MG	A207029	002	Apr 27, 2017	Apr NEWA
AB			20MG	A207029	003	Apr 27, 2017	Apr NEWA

HYDROCORTISONE ACETATEAEROSOL, METERED;RECTAL
CORTIFOAM

+!	MYLAN SPECIALITY LP	10%	N017351	001	Feb 10, 1982	Mar CAHN
	CREAM;TOPICAL					
	HYDROCORTISONE ACETATE					
	@ FERNDAL LABS	2.5%	A040259	001	Jul 29, 1999	Sep DISC
	MICORT-HC					
	@ SEBELA IRELAND LTD	2%	A040398	001	Mar 29, 2002	Nov DISC

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATECREAM;TOPICAL
CORTISPORIN

+!	MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050218	001	Aug 09, 1985	Feb CAHN
----	----------------	--	---------	-----	--------------	----------

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDEAEROSOL, METERED;TOPICAL
EPIFOAM

BX	MYLAN SPECIALITY LP	1%;1%	A086457	001		Mar CAHN
	PROCTOFOAM HC					
BX	MYLAN SPECIALITY LP	1%;1%	A086195	001		Mar CAHN

HYDROCORTISONE BUTYRATECREAM;TOPICAL
HYDROCORTISONE BUTYRATE

AB2	ACTAVIS MID ATLANTIC	0.1%	A205134	001	Dec 08, 2017	Nov NEWA
	LOTION;TOPICAL					
	HYDROCORTISONE BUTYRATE					
AB	TELIGENT PHARMA INC	0.1%	A209556	001	Nov 21, 2017	Nov NEWA
	LOCOID					
AB	+! PRECISION DERMAT	0.1%	N022076	001	May 18, 2007	Nov CFTG

HYDROCORTISONE SODIUM SUCCINATEINJECTABLE;INJECTION
A-HYDROCORT

	@ HOSPIRA	EQ 100MG BASE/VIAL	A040666	001	Apr 06, 2006	Sep DISC
	SOLU-CORTEF					
	+! PHARMACIA AND UPJOHN	EQ 100MG BASE/VIAL	N009866	001		Sep CTEC
	+!	EQ 250MG BASE/VIAL	N009866	002		Nov CTEC
	+!	EQ 500MG BASE/VIAL	N009866	003		Nov CTEC
	+!	EQ 1GM BASE/VIAL	N009866	004		Nov CTEC

HYDROCORTISONE VALERATECREAM;TOPICAL
HYDROCORTISONE VALERATE

AB	! TARO	0.2%	A075042	001	Aug 25, 1998	Apr CAHN
	OINTMENT;TOPICAL					
	HYDROCORTISONE VALERATE					
	! TARO	0.2%	A075043	001	Aug 25, 1998	Apr CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATESOLUTION/DROPS;OTIC
CORTISPORIN

AT	+! MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050479	001		Apr CAHN
	NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE					
AT	AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065216	001	Oct 31, 2005	Mar CAHN
AT	SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062423	001	Aug 25, 1983	Feb CAHN
	SUSPENSION/DROPS;OPHTHALMIC					
	CORTISPORIN					
	@ MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050169	001		Apr CAHN
	NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE					
	! SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062874	001	May 11, 1988	Feb CAHN

SUSPENSION/DROPS;OTIC
CASPORYN HC

>A>						
>A> AT	+! CASPER PHARMA LLC	1%;EQ 3.5MG BASE/ML;10,000	N060613	001		Dec CTNA

>A>		SUSPENSION/DROPS;OTIC							
		CASPORYN HC							
>D>				UNITS/ML					
>D>		CORTISPORIN							
>D>	AT	+	CASPER PHARMA LLC	1%;EQ 3.5MG BASE/ML;10,000	N060613	001			Dec CTNA
				UNITS/ML					
		NEOMYCIN AND POLYMYXIN B		SULFATES AND HYDROCORTISONE					
	AT		AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000	A065219	001	May 01, 2006		Mar CAHN
				UNITS/ML					
	AT		SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000	A062488	001	Nov 06, 1985		Feb CAHN
				UNITS/ML					
<u>HYDROFLUMETHIAZIDE</u>									
TABLET;ORAL									
SALURON									
		+	@ SHIRE LLC	50MG	N011949	001			Nov DISC
		+	!	50MG	N011949	001			Sep CTEC
>A>		<u>HYDROGEN PEROXIDE</u>							
>A>		SOLUTION;TOPICAL							
>A>		ESKATA							
>A>		+	!	ACLARIS THERAPS INC	40%	N209305	001	Dec 14, 2017	Dec NEWA
<u>HYDROMORPHONE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
DILAUDID									
	AP	+	!	FRESENIUS KABI USA	1MG/ML	N019034	003	Apr 30, 2009	Jan CAHN
	AP	+	!		2MG/ML	N019034	004	Apr 30, 2009	Jan CAHN
	AP	+	!		4MG/ML	N019034	005	Apr 30, 2009	Jan CAHN
DILAUDID-HP									
	AP	+	!	FRESENIUS KABI USA	10MG/ML	N019034	001	Jan 11, 1984	Jan CAHN
		@			250MG/VIAL	N019034	002	Aug 04, 1994	Jan CAHN
HYDROMORPHONE HYDROCHLORIDE									
		@		HOSPIRA	10MG/ML	A074598	001	Jun 19, 1997	Sep DISC
SOLUTION;ORAL									
DILAUDID									
	AA	+	!	RHODES PHARMS	5MG/5ML	N019891	001	Dec 07, 1992	Jun CAHN
HYDROMORPHONE HYDROCHLORIDE									
	AA			ASCENT PHARMS INC	5MG/5ML	A210176	001	Oct 27, 2017	Oct NEWA
TABLET;ORAL									
DILAUDID									
	AB	+		RHODES PHARMS	2MG	N019892	003	Nov 09, 2007	Jun CAHN
	AB	+			4MG	N019892	002	Nov 09, 2007	Jun CAHN
	AB	+	!		8MG	N019892	001	Dec 07, 1992	Jun CAHN
HYDROMORPHONE HYDROCHLORIDE									
>D>	AB			MALLINCKRODT	2MG	A076855	002	Sep 19, 2007	Dec CAHN
>D>	AB				4MG	A076855	003	Sep 19, 2007	Dec CAHN
>D>	AB				8MG	A076855	001	Dec 23, 2004	Dec CAHN
>A>	AB			SPECGX LLC	2MG	A076855	002	Sep 19, 2007	Dec CAHN
>A>	AB				4MG	A076855	003	Sep 19, 2007	Dec CAHN
>A>	AB				8MG	A076855	001	Dec 23, 2004	Dec CAHN
TABLET, EXTENDED RELEASE;ORAL									
EXALGO									
>D>	AB	+		MALLINCKRODT INC	8MG	N021217	001	Mar 01, 2010	Dec CAHN
>D>	AB	+			12MG	N021217	002	Mar 01, 2010	Dec CAHN
>D>	AB	+			16MG	N021217	003	Mar 01, 2010	Dec CAHN
>D>	AB	+	!		32MG	N021217	004	Aug 24, 2012	Dec CAHN
>A>	AB	+		SPECGX LLC	8MG	N021217	001	Mar 01, 2010	Dec CAHN
>A>	AB	+			12MG	N021217	002	Mar 01, 2010	Dec CAHN
>A>	AB	+			16MG	N021217	003	Mar 01, 2010	Dec CAHN
>A>	AB	+	!		32MG	N021217	004	Aug 24, 2012	Dec CAHN
HYDROMORPHONE HYDROCHLORIDE									
	AB			PADDOCK LLC	32MG	A204278	004	Sep 20, 2017	Sep NEWA
<u>HYDROXOCOBALAMIN</u>									
INJECTABLE;INJECTION									
HYDROXOCOBALAMIN									
		!		ACTAVIS LLC	1MG/ML	A085998	001		Feb CAHN

HYDROXYUREA

>A>	TABLET;ORAL						
>A>	SIKLOS						
>A>	+ ADDMEDICA SAS	100MG	N208843	001	Dec 21, 2017	Dec	NEWA
>A>	+	1GM	N208843	002	Dec 21, 2017	Dec	NEWA

HYDROXYZINE HYDROCHLORIDE

	INJECTABLE;INJECTION						
	VISTARIL						
	+ @ PFIZER	25MG/ML	N011111	001		Jan	CRLD
	+ @	50MG/ML	N011111	002		Jan	CRLD
	SYRUP;ORAL						
	HYDROXYZINE HYDROCHLORIDE						
>D> AA	! WOCKHARDT	10MG/5ML	A087294	001	Apr 12, 1982	Dec	CAHN
>A> AA	! WOCKHARDT BIO AG	10MG/5ML	A087294	001	Apr 12, 1982	Dec	CAHN
	TABLET;ORAL						
	HYDROXYZINE HYDROCHLORIDE						
	@ AUROLIFE PHARMA LLC	10MG	A087871	002	Dec 20, 1982	Jan	CMS1
	@	25MG	A087871	003	Dec 20, 1982	Jan	CMS1
AB	BAYSHORE PHARMS LLC	10MG	A207120	001	Mar 29, 2017	Sep	CAHN
AB		50MG	A207122	001	Mar 29, 2017	Sep	CAHN
AB	NUVO PHARM	10MG	A207120	001	Mar 29, 2017	Nov	CAHN
AB		50MG	A207122	001	Mar 29, 2017	Nov	CAHN
AB	NUVO PHARM INC	10MG	A207120	001	Mar 29, 2017	Mar	NEWA
AB		25MG	A207121	001	Mar 29, 2017	Mar	NEWA
AB		50MG	A207122	001	Mar 29, 2017	Mar	NEWA
AB	PRINSTON INC	10MG	A040579	001	May 27, 2005	Feb	CAHN
AB		25MG	A040574	001	May 27, 2005	Feb	CAHN
AB		50MG	A040580	001	May 27, 2005	Feb	CAHN

IBANDRONATE SODIUM

	TABLET;ORAL						
	IBANDRONATE SODIUM						
AB	MACLEODS PHARMS LTD	EQ 150MG BASE	A206887	001	Oct 31, 2017	Oct	NEWA
	@ MYLAN PHARMS INC	EQ 150MG BASE	A078995	001	Mar 19, 2012	May	DISC
AB	WATSON LABS TEVA	EQ 150MG BASE	A079003	001	Mar 20, 2012	May	CAHN

IBRUTINIB

	CAPSULE;ORAL						
	IMBRUVICA						
>A>	+ PHARMACYCLICS INC	70MG	N205552	002	Dec 20, 2017	Dec	NEWA

IBUPROFEN

	SUSPENSION;ORAL						
	IBUPROFEN						
AB	! ACTAVIS MID ATLANTIC	100MG/5ML	A074978	001	Mar 25, 1998	May	CAHN
AB	TARO	100MG/5ML	A209204	001	Jun 23, 2017	Jun	NEWA
	MOTRIN						
	+ @ MCNEIL CONSUMER	100MG/5ML	N019842	001	Sep 19, 1989	Jan	CRLD
	TABLET;ORAL						
	IBUPROFEN						
	@ MYLAN PHARMS INC	400MG	A070045	001	Sep 24, 1985	Mar	CAHN
	@ PLIVA	400MG	A071666	001	Jun 18, 1987	Aug	CAHN

IBUPROFEN; OXYCODONE HYDROCHLORIDE

	TABLET;ORAL						
	OXYCODONE HYDROCHLORIDE AND IBUPROFEN						
	@ WATSON LABS	400MG;5MG	A078394	001	Nov 26, 2007	Jun	DISC
BX		400MG;5MG	A078394	001	Nov 26, 2007	Apr	CTEC

ICOSAPENT ETHYL

	CAPSULE;ORAL						
	VASCEPA						
	+ AMARIN PHARMS	500MG	N202057	002	Feb 16, 2017	Mar	NEWA

IDOXURIDINESOLUTION/DROPS;OPHTHALMIC
DENDRID

+ @ ALCON 0.1% N014169 001 Jul DISC

IFOSFAMIDEINJECTABLE;INJECTION
IFOSFAMIDE

AP	WEST-WARD PHARMS INT	1GM/20ML (50MG/ML)	A 076619	001	Jun 29, 2011	Nov CMS1
AP		3GM/60ML (50MG/ML)	A 076619	002	Jun 29, 2011	Nov CMS1

IFOSFAMIDE; MESNAINJECTABLE;INTRAVENOUS
IFOSFAMIDE/MESNA KIT

@	TEVA PHARMS USA	1GM/20ML;1GM/10ML (50MG/ML;100MG/ML)	A 075874	001	Feb 26, 2002	Mar DISC
---	-----------------	---	----------	-----	--------------	----------

@		3GM/60ML;1GM/10ML (50MG/ML;100MG/ML)	A 075874	002	Feb 26, 2002	Mar DISC
---	--	---	----------	-----	--------------	----------

IMATINIB MESYLATE

TABLET;ORAL

IMATINIB MESYLATE

AB	MYLAN PHARMS INC	EQ 100MG BASE	A 204644	001	Jun 21, 2017	Jun NEWA
AB		EQ 400MG BASE	A 204644	002	Jun 21, 2017	Jun NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL

IMIPRAMINE HYDROCHLORIDE

>D>	AB	MALLINCKRODT INC	10MG	A 087846	002	May 22, 1984	Dec CAHN
	AB		10MG	A 087846	002	May 22, 1984	Aug CMS1
>D>	AB		25MG	A 087846	003	May 22, 1984	Dec CAHN
	AB		25MG	A 087846	003	May 22, 1984	Aug CMS1
		OXFORD PHARMS	10MG	A 040751	003	Feb 28, 2008	May CMS1
			25MG	A 040751	002	Feb 28, 2008	May CMS1
	@	PAR PHARM	10MG	A 089422	001	Jul 14, 1987	Jul DISC
>A>	AB	SPECGX LLC	10MG	A 087846	002	May 22, 1984	Dec CAHN
>A>	AB		25MG	A 087846	003	May 22, 1984	Dec CAHN
		TOFRANIL					
>D>	AB	! MALLINCKRODT INC	50MG	A 087846	001	May 22, 1984	Dec CAHN
>A>	AB	! SPECGX LLC	50MG	A 087846	001	May 22, 1984	Dec CAHN

IMIPRAMINE PAMOATE

CAPSULE;ORAL

IMIPRAMINE PAMOATE

@	MYLAN PHARMS INC	EQ 75MG HCL	A 202338	001	Jun 28, 2013	Jun DISC
@		EQ 100MG HCL	A 202338	002	Jun 28, 2013	Jun DISC
@		EQ 125MG HCL	A 202338	003	Jun 28, 2013	Jun DISC
@		EQ 150MG HCL	A 202338	004	Jun 28, 2013	Jun DISC

TOFRANIL-PM

>D>	+	@ MALLINCKRODT INC	EQ 75MG HCL	N 017090	001		Dec CAHN
>D>	+	@	EQ 100MG HCL	N 017090	004		Dec CAHN
>D>	+	@	EQ 125MG HCL	N 017090	003		Dec CAHN
>D>	+	@	EQ 150MG HCL	N 017090	002		Dec CAHN
>A>	+	@ SPECGX LLC	EQ 75MG HCL	N 017090	001		Dec CAHN
>A>	+	@	EQ 100MG HCL	N 017090	004		Dec CAHN
>A>	+	@	EQ 125MG HCL	N 017090	003		Dec CAHN
>A>	+	@	EQ 150MG HCL	N 017090	002		Dec CAHN

INDACATEROL MALEATEPOWDER;INHALATION
ARCAPTA NEOHALER

+! SUNOVION PHARMS INC EQ 75MCG BASE N 022383 001 Jul 01, 2011 Jan CAHN

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

>A>	@	FOSUN PHARMA	1.25MG	A 074594	001	May 23, 1996	Dec CAHN
>A>	@		2.5MG	A 074594	002	May 23, 1996	Dec CAHN
	@	MYLAN PHARMS INC	1.25MG	A 075105	001	Jul 23, 1998	Nov DISC
	@		2.5MG	A 075105	002	Jul 23, 1998	Nov DISC
>D>	@	SANDOZ	1.25MG	A 074594	001	May 23, 1996	Dec CAHN
>D>	@		2.5MG	A 074594	002	May 23, 1996	Dec CAHN

INDOMETHACIN

CAPSULE;ORAL							
INDOMETHACIN							
	@ CHARTWELL MOLECULES	25MG	N018829	002	Aug 06, 1984	Feb	CAHN
	@	50MG	A070651	001	Mar 05, 1986	Apr	CAHN
	@	50MG	N018829	001	Aug 06, 1984	Feb	CAHN
AB	JUBILANT GENERICS	25MG	A205215	001	Aug 25, 2017	Aug	NEWA
AB		50MG	A205215	002	Aug 25, 2017	Aug	NEWA
CAPSULE, EXTENDED RELEASE;ORAL							
INDOMETHACIN							
AB	CHARTWELL RX	75MG	A200529	001	Nov 30, 2010	Jun	CAHN
AB	GLENMARK PHARMS LTD	75MG	A203501	001	Jun 22, 2017	Jun	NEWA
AB	NOVAST LABS LTD	75MG	A204853	001	May 08, 2017	Apr	NEWA
	@ WATSON LABS INC	75MG	A202572	001	Dec 09, 2013	Feb	DISC
AB	ZYDUS PHARMS USA INC	75MG	A202711	001	Sep 25, 2017	Sep	NEWA

INDOMETHACIN SODIUM

INJECTABLE;INJECTION							
INDOMETHACIN SODIUM							
AP	NAVINTA LLC	EQ 1MG BASE/VIAL	A206561	001	Jul 19, 2017	Jul	NEWA

>A> INSULIN ASPART

>A>	SOLUTION;IV (INFUSION), SUBCUTANEOUS						
>A>	FIASP						
>A>	+! NOVO NORDISK INC	1000 UNITS/10ML (100 UNITS/ML)	N208751	001	Sep 29, 2017	Dec	CAIN
>A>	SOLUTION;SUBCUTANEOUS						
>A>	FIASP FLEXTouch						
>A>	+! NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N208751	002	Sep 29, 2017	Dec	CAIN

>D> INSULIN ASPART RECOMBINANT

>D>	SOLUTION;IV (INFUSION), SUBCUTANEOUS						
>D>	FIASP						
>D>	+! NOVO NORDISK INC	1000 UNITS/10ML (100 UNITS/ML)	N208751	001	Sep 29, 2017	Dec	CAIN
	+!	1000 UNITS/10ML (100 UNITS/ML)	N208751	001	Sep 29, 2017	Sep	NEWA
>D>	SOLUTION;SUBCUTANEOUS						
>D>	FIASP FLEXTouch						
>D>	+! NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N208751	002	Sep 29, 2017	Dec	CAIN
	+!	300 UNITS/3ML (100 UNITS/ML)	N208751	002	Sep 29, 2017	Sep	NEWA

INSULIN LISPRO

SOLUTION;IV (INFUSION), SUBCUTANEOUS							
>A>	ADMELOG						
>A>	+ SANOFI-AVENTIS US	1000 UNITS/10ML (100 UNITS/ML)	N209196	001	Dec 11, 2017	Dec	NEWA
>A>	ADMELOG SOLOSTAR						
>A>	+ SANOFI-AVENTIS US	300 UNITS/3ML (100 UNITS/ML)	N209196	002	Dec 11, 2017	Dec	NEWA

IODIPAMIDE MEGLUMINE

INJECTABLE;INJECTION							
CHOLOGRAFIN MEGLUMINE							
	+ @ BRACCO	52%	N009321	003		Aug	DISC

IODIXANOL

INJECTABLE;INJECTION							
VISIPAQUE 270							
	@ GE HEALTHCARE	55%	N020808	001	Aug 29, 1997	Aug	DISC

IOPAMIDOL

INJECTABLE;INJECTION							
SCANLUX-300							
AP	MYLAN IRELAND LTD	61%	A090394	001	Jun 18, 2010	Jan	CAHN
AP	SANOCHEMIA CORP USA	61%	A090394	001	Jun 18, 2010	Feb	CAHN
SCANLUX-370							
AP	MYLAN IRELAND LTD	76%	A090394	002	Jun 18, 2010	Jan	CAHN
AP	SANOCHEMIA CORP USA	76%	A090394	002	Jun 18, 2010	Feb	CAHN

IOPROMIDE

INJECTABLE; INJECTION
ULTRAVIST 150

+ @ BAYER HLTHCARE	31.2%	N020220	004	May 10, 1995	Aug DISC
ULTRAVIST 300 IN PLASTIC CONTAINER					
+ @ BAYER HLTHCARE	62.3%	N020220	005	Nov 18, 2008	Aug DISC

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
IPRATROPIUM BROMIDE

@ BAUSCH AND LOMB INC	0.02%	A075835	001	Oct 15, 2001	Jul DISC
-----------------------	-------	---------	-----	--------------	----------

IRBESARTAN

TABLET; ORAL
IRBESARTAN

@ AJANTA PHARMA LTD	75MG	A203685	001	Dec 10, 2015	Oct DISC
@	150MG	A203685	002	Dec 10, 2015	Oct DISC
@	300MG	A203685	003	Dec 10, 2015	Oct DISC
>D> AB MYLAN PHARMS INC	75MG	A200461	001	Sep 27, 2012	Dec DISC
>A> @	75MG	A200461	001	Sep 27, 2012	Dec DISC
>D> AB	150MG	A200461	002	Sep 27, 2012	Dec DISC
>A> @	150MG	A200461	002	Sep 27, 2012	Dec DISC
>D> AB	300MG	A200461	003	Sep 27, 2012	Dec DISC
>A> @	300MG	A200461	003	Sep 27, 2012	Dec DISC

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE

AP INGENUS PHARMS LLC	40MG/2ML (20MG/ML)	A206935	001	May 26, 2017	May NEWA
AP	100MG/5ML (20MG/ML)	A206935	002	May 26, 2017	May NEWA
AP INTAS PHARMS USA	40MG/2ML (20MG/ML)	A203054	001	Aug 31, 2017	Aug NEWA
AP	100MG/5ML (20MG/ML)	A203054	002	Aug 31, 2017	Aug NEWA
@ SANDOZ INC	40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009	Jul DISC
@	100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009	Jul DISC
AP WEST-WARD PHARMS INT	40MG/2ML (20MG/ML)	A078753	001	Dec 24, 2008	Jan CAHN
AP	100MG/5ML (20MG/ML)	A078753	002	Dec 24, 2008	Jan CAHN
INJECTABLE, LIPOSOMAL; IV (INFUSION)					
ONIVYDE					
+! IPSEN INC	EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)	N207793	001	Oct 22, 2015	Apr CAHN

ISONIAZID

INJECTABLE; INJECTION
ISONIAZID

! SANDOZ INC	100MG/ML	A040648	001	Jul 05, 2005	Mar CAHN
SYRUP; ORAL					
ISONIAZID					
! CMP PHARMA INC	50MG/5ML	A088235	001	Nov 10, 1983	Apr CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION
ISOPROTERENOL HYDROCHLORIDE

AP NEXUS PHARMS	0.2MG/ML	A206961	001	Aug 02, 2017	Jul NEWA
ISUPREL					
AP +! HOSPIRA	0.2MG/ML	N010515	001		Jul CTEC

ISOSORBIDE DINITRATE

TABLET; SUBLINGUAL
ISOSORBIDE DINITRATE

@ WATSON LABS TEVA	5MG	A086031	001	Sep 29, 1987	May CAHN
TABLET, EXTENDED RELEASE; ORAL					
ISOSORBIDE DINITRATE					
@ IMPAX LABS INC	40MG	A040723	001	Mar 17, 2008	Feb CAHN

ISOSORBIDE MONONITRATE

TABLET; ORAL
MONOKET

AB + LANNETT CO INC	10MG	N020215	002	Jun 30, 1993	Nov CAHN
AB +!	20MG	N020215	001	Jun 30, 1993	Nov CAHN

TABLET, EXTENDED RELEASE;ORAL							
ISOSORBIDE MONONITRATE							
AB		ACCORD HLTHCARE	30MG	A209684	001	Oct 24, 2017	Oct NEWA
AB			60MG	A209684	002	Oct 24, 2017	Oct NEWA
AB			120MG	A209684	003	Oct 24, 2017	Oct NEWA
<u>ISOTRETINOIN</u>							
CAPSULE;ORAL							
ABSORICA							
BX	+	SUN PHARM INDS INC	10MG	N021951	001	May 25, 2012	Aug CAHN
BX	+		20MG	N021951	002	May 25, 2012	Aug CAHN
	+		25MG	N021951	005	Aug 15, 2014	Aug CAHN
BX	+		30MG	N021951	003	May 25, 2012	Aug CAHN
	+		35MG	N021951	006	Aug 15, 2014	Aug CAHN
BX	+	!	40MG	N021951	004	May 25, 2012	Aug CAHN
ISOTRETINOIN							
AB		AMNEAL PHARMS NY	10MG	A207792	001	Sep 29, 2017	Sep NEWA
AB			20MG	A207792	002	Sep 29, 2017	Sep NEWA
AB			30MG	A207792	003	Sep 29, 2017	Sep NEWA
AB			40MG	A207792	004	Sep 29, 2017	Sep NEWA
<u>ISRADIPINE</u>							
CAPSULE;ORAL							
DYNACIRC							
	+	@ SMITHKLINE BEECHAM	2.5MG	N019546	001	Dec 20, 1990	Sep CRLD
	+	@	5MG	N019546	002	Dec 20, 1990	Sep CRLD
ISRADIPINE							
AB		WATSON LABS TEVA	2.5MG	A077317	001	Jan 05, 2006	May CAHN
AB	!		5MG	A077317	002	Jan 05, 2006	May CAHN
TABLET, EXTENDED RELEASE;ORAL							
ISRADIPINE							
		@ MYLAN PHARMS INC	5MG	A201067	001	Nov 27, 2015	Nov DISC
		@	10MG	A201067	002	Nov 27, 2015	Nov DISC
<u>ITRACONAZOLE</u>							
CAPSULE;ORAL							
ITRACONAZOLE							
AB		ALKEM LABS LTD	100MG	A208591	001	Jun 12, 2017	May NEWA
AB		JUBILANT GENERICS	100MG	A203445	001	Feb 23, 2017	Feb NEWA
AB		ZYDUS PHARMS USA INC	100MG	A204672	001	Sep 19, 2017	Sep NEWA
<u>KANAMYCIN SULFATE</u>							
INJECTABLE;INJECTION							
KANAMYCIN							
		@ WEST-WARD PHARMS INT	EQ 75MG BASE/2ML	A062324	001		Jan CAHN
		@	EQ 500MG BASE/2ML	A062324	002		Jan CAHN
		@	EQ 1GM BASE/3ML	A062324	003		Jan CAHN
<u>KETOCONAZOLE</u>							
AEROSOL, FOAM;TOPICAL							
EXTINA							
AT	+	! MYLAN PHARMS INC	2%	N021738	001	Jun 12, 2007	Jan CAHN
CREAM;TOPICAL							
NIZORAL							
	+	@ JANSSEN PHARMA	2%	N019084	001	Dec 31, 1985	May CRLD
TABLET;ORAL							
NIZORAL							
	+	@ JANSSEN PHARMS	200MG	N018533	001		Oct CRLD
<u>KETOPROFEN</u>							
CAPSULE;ORAL							
KETOPROFEN							
		HERITAGE PHARMS INC	25MG	A074014	001	Jan 29, 1993	Feb CAHN
AB			50MG	A074014	002	Jan 29, 1993	Feb CAHN
AB			75MG	A074014	003	Jan 29, 1993	Feb CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION							
KETOROLAC TROMETHAMINE							
AP	@ BAXTER HLTHCARE CORP	15MG/ML	A075631	002	Jun 29, 2001	Aug	CAHN
	@	30MG/ML	A075631	001	Jun 29, 2001	Aug	CAHN
	CYCLE PHARMS LTD	30MG/ML	A209900	001	Sep 15, 2017	Sep	NEWA
	@ MYLAN LABS LTD	15MG/ML	A078299	001	Jul 16, 2007	Oct	DISC
	@	15MG/ML	A201155	001	Aug 04, 2014	Oct	DISC
	@	30MG/ML	A078299	002	Jul 16, 2007	Oct	DISC
	@	30MG/ML	A201155	002	Aug 04, 2014	Oct	DISC
	@ SANDOZ INC	15MG/ML	A076271	001	Oct 06, 2004	Mar	CAHN
AP		30MG/ML	A076271	002	Oct 06, 2004	Mar	CAHN
SOLUTION/DROPS; OPHTHALMIC							
ACUVAIL							
	+! ALLERGAN	0.45%	N022427	001	Jul 22, 2009	Sep	CTEC
KETOROLAC TROMETHAMINE							
AT	SANDOZ INC	0.5%	A076583	001	Nov 05, 2009	Feb	CAHN

L-GLUTAMINE

FOR SOLUTION; ORAL							
ENDARI							
	+ EMMAUS MEDCL	5GM/PACKET	N208587	001	Jul 07, 2017	Jul	NEWA
NUTRESTORE							
	+! EMMAUS MEDCL	5GM/PACKET	N021667	001	Jun 10, 2004	Jul	CAIN

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION							
LABETALOL HYDROCHLORIDE							
AP	@ BAXTER HLTHCARE CORP	5MG/ML	A076051	001	Jul 05, 2002	Aug	CAHN
	SAGENT AGILA LLC	5MG/ML	A079134	001	Feb 03, 2010	Feb	CAHN
TABLET; ORAL							
LABETALOL HYDROCHLORIDE							
AB	INNOGENIX	100MG	A075215	001	Jul 29, 1999	Sep	CAHN
AB		200MG	A075215	002	Jul 29, 1999	Sep	CAHN
AB		300MG	A075215	003	Jul 29, 1999	Sep	CAHN
AB	ZYDUS PHARMS USA INC	100MG	A207743	001	Sep 19, 2017	Sep	NEWA
AB		200MG	A207743	002	Sep 19, 2017	Sep	NEWA
AB		300MG	A207743	003	Sep 19, 2017	Sep	NEWA

LACOSAMIDE

SOLUTION; ORAL							
VIMPAT							
	+! UCB INC	10MG/ML	N022255	001	Apr 20, 2010	Oct	CTEC
TABLET; ORAL							
VIMPAT							
	+ UCB INC	50MG	N022253	001	Oct 28, 2008	Oct	CTEC
	+	100MG	N022253	002	Oct 28, 2008	Oct	CTEC
	+	150MG	N022253	003	Oct 28, 2008	Oct	CTEC
	+!	200MG	N022253	004	Oct 28, 2008	Oct	CTEC

LACTULOSE

SOLUTION; ORAL							
LACTULOSE							
>D> AA	MORTON GROVE	10GM/15ML	A074602	001	Nov 14, 1996	Dec	CAHN
AA	PHARM ASSOC	10GM/15ML	A074623	001	Jul 30, 1996	May	CAHN
>A> AA	WOCKHARDT BIO AG	10GM/15ML	A074602	001	Nov 14, 1996	Dec	CAHN
SOLUTION; ORAL, RECTAL							
GENERLAC							
>D> AA	MORTON GROVE PHARMS	10GM/15ML	A074603	001	Oct 31, 1996	Dec	CAHN
>A> AA	WOCKHARDT BIO AG	10GM/15ML	A074603	001	Oct 31, 1996	Dec	CAHN

LAMIVUDINE

TABLET; ORAL							
LAMIVUDINE							
AB	CIPLA LTD	150MG	A077221	001	Mar 03, 2017	Feb	NEWA
AB		300MG	A077221	002	Mar 03, 2017	Feb	NEWA
AB	ECI PHARMS LLC	150MG	A203586	001	Nov 21, 2016	Aug	CAHN

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	AUROBINDO PHARMA LTD	150MG;300MG	A077558	001	May 05, 2017	Apr NEWA
BX	PHARMACARE	150MG;300MG	N022018	001	Mar 17, 2017	Mar NEWA

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

@ MYLAN LABS LTD	25MG	A078443	001	Feb 11, 2009	Mar CAHN
@	100MG	A078443	002	Feb 11, 2009	Mar CAHN
@	150MG	A078443	003	Feb 11, 2009	Mar CAHN
@	200MG	A078443	004	Feb 11, 2009	Mar CAHN

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

AB	GLENMARK PHARMS LTD	5MG	A079099	001	Feb 19, 2009	May CAHN
AB		25MG	A079099	002	Feb 19, 2009	May CAHN
@ MYLAN	5MG	A076630	001	Jan 22, 2009	Jun DISC	
@	25MG	A076630	002	Jan 22, 2009	Jun DISC	

TABLET, EXTENDED RELEASE; ORAL

LAMOTRIGINE

AB	ACTAVIS ELIZABETH	250MG	A203733	001	Nov 13, 2013	Apr CAHN
AB	HANDA PHARMS LLC	25MG	A202887	001	Jun 17, 2013	Jan CAHN
AB		50MG	A202887	002	Jun 17, 2013	Jan CAHN
AB		100MG	A202887	003	Jun 17, 2013	Jan CAHN
AB		200MG	A202887	004	Jun 17, 2013	Jan CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

AB	INVENTIA HLTHCARE	15MG	A205868	001	Aug 30, 2017	Aug NEWA
AB		30MG	A205868	002	Aug 30, 2017	Aug NEWA
AB	KREMERS URBAN PHARMS	15MG	A207156	001	Sep 28, 2017	Sep NEWA
AB		30MG	A207156	002	Sep 28, 2017	Sep NEWA

>D> TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

LANSOPRAZOLE

>D>	@ ANI PHARMS INC	15MG	A078730	001	Oct 15, 2010	Dec CDFR
>D>	@	30MG	A078730	002	Oct 15, 2010	Dec CDFR

>D> PREVACID

>D> AB	+ TAKEDA PHARMS USA	15MG	N021428	001	Aug 30, 2002	Dec CDFR
AB	+	15MG	N021428	001	Aug 30, 2002	Sep CTEC
>D> AB	+!	30MG	N021428	002	Aug 30, 2002	Dec CDFR
AB	+	30MG	N021428	002	Aug 30, 2002	Sep CTEC

>A> TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE; ORAL

LANSOPRAZOLE

>A>	@ ANI PHARMS INC	15MG	A078730	001	Oct 15, 2010	Dec CDFR
>A>	@	30MG	A078730	002	Oct 15, 2010	Dec CDFR
AB	TEVA PHARMS USA	15MG	A208784	001	Sep 21, 2017	Sep NEWA
AB		30MG	A208784	002	Sep 21, 2017	Sep NEWA

>A> PREVACID

>A> AB	+ TAKEDA PHARMS USA	15MG	N021428	001	Aug 30, 2002	Dec CDFR
>A> AB	+	30MG	N021428	002	Aug 30, 2002	Dec CDFR

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

FOSRENOL

AB	+ SHIRE LLC	EQ 500MG BASE	N021468	002	Oct 26, 2004	Jul CFTG
AB	+	EQ 750MG BASE	N021468	003	Nov 23, 2005	Jul CFTG
AB	+	EQ 1GM BASE	N021468	004	Nov 23, 2005	Jul CFTG

LANTHANUM CARBONATE

AB	NATCO PHARMA LTD	EQ 500MG BASE	A090978	001	Aug 11, 2017	Jul NEWA
AB		EQ 750MG BASE	A090978	002	Aug 11, 2017	Jul NEWA
AB		EQ 1GM BASE	A090978	003	Aug 11, 2017	Jul NEWA

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

AT	AMRING PHARMS	0.005%	A200925	001	Mar 22, 2011	Mar CAHN
AT	SANDOZ INC	0.005%	A091449	001	Mar 22, 2011	Feb CAHN

LATANOPROSTENE BUNODSOLUTION/DROPS;OPHTHALMIC
VYZULTA

+! BAUSCH AND LOMB 0.024% N207795 001 Nov 02, 2017 Nov NEWA

LETERMOVIRSOLUTION;IV (INFUSION)
PREVIMIS

+! MERCK SHARP DOHME 240MG/12ML (20MG/ML) N209940 001 Nov 08, 2017 Nov NEWA

+! 480MG/24ML (20MG/ML) N209940 002 Nov 08, 2017 Nov NEWA

TABLET;ORAL
PREVIMIS

+ MERCK SHARP DOHME 240MG N209939 001 Nov 08, 2017 Nov NEWA

+! 480MG N209939 002 Nov 08, 2017 Nov NEWA

LETROZOLETABLET;ORAL
LETROZOLE

@ KREMERS URBAN PHARMS 2.5MG A091098 001 Jun 03, 2011 Jun DISC

@ LANNETT HOLDINGS INC 2.5MG A202048 001 Oct 29, 2014 Jun DISC

@ SUN PHARM INDS LTD 2.5MG A091466 001 Jun 03, 2011 Oct DISC

LETROZOLE; RIBOCICLIB SUCCINATETABLET, TABLET;ORAL
KISQALI FEMARA CO-PACK (COPACKAGED)

+! NOVARTIS PHARMS CORP 2.5MG,N/A;N/A,EQ 200MG BASE N209935 001 May 04, 2017 May NEWA

LEUCOVORIN CALCIUMINJECTABLE;INJECTION
LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP ! FRESENIUS KABI USA EQ 500MG BASE/VIAL A040286 001 Feb 26, 1999 Oct CTEC

AP MYLAN LABS LTD EQ 100MG BASE/VIAL A203800 001 May 19, 2017 May NEWA

AP EQ 200MG BASE/VIAL A203800 002 May 19, 2017 May NEWA

AP EQ 350MG BASE/VIAL A203800 003 May 19, 2017 May NEWA

AP SAGENT PHARMS EQ 500MG BASE/VIAL A209110 001 Oct 26, 2017 Oct NEWA

TABLET;ORAL

LEUCOVORIN CALCIUM

@ EPIC PHARMA LLC EQ 5MG BASE A074544 001 Aug 28, 1997 May CAHN

@ EQ 25MG BASE A074544 002 Aug 28, 1997 May CAHN

WELLCOVORIN

+ @ GLAXOSMITHKLINE EQ 5MG BASE N018342 001 Jul 08, 1983 Jun CRLD

+ @ EQ 25MG BASE N018342 002 Jul 08, 1983 Jun CRLD

LEVALBUTEROL HYDROCHLORIDESOLUTION;INHALATION
LEVALBUTEROL HYDROCHLORIDE

AN AUROBINDO PHARMA LTD EQ 0.025% BASE A207628 001 Jan 31, 2017 Jan NEWA

LEVETIRACETAMINJECTABLE;IV (INFUSION)
LEVETIRACETAM

AP JUBILANT GENERICS 500MG/5ML (100MG/ML) A206838 001 Jun 02, 2016 Jul CAHN

LEVETIRACETAM IN SODIUM CHLORIDE

AP GLAND PHARMA LTD 500MG/100ML (5MG/ML) A206880 001 Oct 25, 2017 Oct NEWA

AP 1000MG/100ML (10MG/ML) A206880 002 Oct 25, 2017 Oct NEWA

AP 1500MG/100ML (15MG/ML) A206880 003 Oct 25, 2017 Oct NEWA

SOLUTION;ORAL

LEVETIRACETAM

AA ALLIED PHARMA INC 100MG/ML A078582 001 Jan 15, 2009 Mar CAHN

AA AUROBINDO PHARMA LTD 100MG/ML A079063 001 Jan 15, 2009 Jan CAHN

>D> AA WOCKHARDT 100MG/ML A090028 001 Mar 03, 2010 Dec CAHN

>A> AA WOCKHARDT BIO AG 100MG/ML A090028 001 Mar 03, 2010 Dec CAHN

TABLET;ORAL

LEVETIRACETAM

AB ACI HEALTHCARE LTD 250MG A078042 001 Jan 15, 2009 Jun CAHN

AB 500MG A078042 002 Jan 15, 2009 Jun CAHN

AB 750MG A078042 003 Jan 15, 2009 Jun CAHN

AB 1GM A078042 004 Jan 15, 2009 Jun CAHN

AB ACIC PHARMS 250MG A090767 001 Jul 28, 2010 Sep CAHN

AB 500MG A090767 002 Jul 28, 2010 Sep CAHN

AB 750MG A090767 003 Jul 28, 2010 Sep CAHN

TABLET;ORAL						
LEVETIRACETAM						
AB		1GM	A090767	004	Jul 28, 2010	Sep CAHN
AB	ALLIED PHARMA INC	250MG	A078042	001	Jan 15, 2009	Mar CAHN
AB		500MG	A078042	002	Jan 15, 2009	Mar CAHN
AB		750MG	A078042	003	Jan 15, 2009	Mar CAHN
AB		1GM	A078042	004	Jan 15, 2009	Mar CAHN
ROWEEPRA						
AB	LOTUS PHARM CO LTD	250MG	A090906	002	Oct 31, 2016	Apr NEWA
AB		500MG	A090906	001	Nov 05, 2010	Apr CTNA
AB		750MG	A090906	003	Oct 31, 2016	Apr NEWA
AB		1GM	A090906	004	Oct 31, 2016	Apr NEWA
TABLET, EXTENDED RELEASE;ORAL						
LEVETIRACETAM						
AB	ECI PHARMS LLC	500MG	A204754	001	Aug 26, 2016	Mar CAHN
AB		750MG	A204754	002	Aug 26, 2016	Mar CAHN
	@ MYLAN PHARMS INC	500MG	A200475	001	Dec 19, 2011	Apr DISC
	@	750MG	A200475	002	Dec 19, 2011	Apr DISC
	@	1GM	A200475	003	Dec 07, 2015	Apr DISC
AB	PHARMTAK INC	500MG	A207175	001	Sep 28, 2017	Sep NEWA
AB		750MG	A207175	002	Sep 28, 2017	Sep NEWA
AB	PRINSTON INC	500MG	A202533	001	Jul 20, 2012	Feb CAHN
AB		750MG	A202533	002	Jul 20, 2012	Feb CAHN
AB	VIRTUS PHARMS	500MG	A091291	001	Sep 12, 2011	Feb CAHN
AB		750MG	A091291	002	Sep 12, 2011	Feb CAHN
TABLET, FOR SUSPENSION;ORAL						
SPRITAM						
+	APRECIA PHARMS	250MG	N207958	001	Jul 31, 2015	Nov CAHN
+		500MG	N207958	002	Jul 31, 2015	Nov CAHN
+		750MG	N207958	003	Jul 31, 2015	Nov CAHN
+	!	1GM	N207958	004	Jul 31, 2015	Nov CAHN
<u>LEVOBUNOLOL HYDROCHLORIDE</u>						
SOLUTION/DROPS;OPHTHALMIC						
LEVOBUNOLOL HYDROCHLORIDE						
	@ BAUSCH AND LOMB	0.25%	A074307	001	Mar 04, 1994	Jul DISC
AT	SANDOZ INC	0.5%	A074850	001	Oct 28, 1996	Feb CAHN
<u>LEVOCARNITINE</u>						
INJECTABLE;INJECTION						
CARNITOR						
AP	+! LEADIANT BIOSCI INC	200MG/ML	N020182	001	Dec 16, 1992	Mar CAHN
SOLUTION;ORAL						
CARNITOR						
	@ LEADIANT BIOSCI INC	1GM/10ML	N018948	002	Apr 27, 1988	Mar CAHN
AA	+!	1GM/10ML	N019257	001	Apr 10, 1986	Mar CAHN
CARNITOR SF						
AA	+ LEADIANT BIOSCI INC	1GM/10ML	N019257	002	Mar 28, 2007	Mar CAHN
TABLET;ORAL						
CARNITOR						
AB	+! LEADIANT BIOSCI INC	330MG	N018948	001	Dec 27, 1985	Mar CAHN
LEVOCARNITINE						
AB	IMPAX LABS INC	330MG	A076858	001	Sep 20, 2004	Feb CAHN
AB	RISING PHARMS INC	330MG	A076858	001	Sep 20, 2004	Oct CAHN
<u>LEVOCETIRIZINE DIHYDROCHLORIDE</u>						
SOLUTION;ORAL						
LEVOCETIRIZINE DIHYDROCHLORIDE						
AA	SILARX PHARMS INC	2.5MG/5ML	A204599	001	May 15, 2017	Nov CPOT
AA		2.5MG/ML	A204599	001	May 15, 2017	May NEWA
XYZAL						
AA	+! SANOFI-AVENTIS US	2.5MG/5ML	N022157	001	Jan 28, 2008	Jul CAHN
TABLET;ORAL						
LEVOCETIRIZINE DIHYDROCHLORIDE						
AB	ALLIED PHARMA INC	5MG	A202046	001	Sep 17, 2013	Sep CAHN
AB		5MG	A204323	001	Dec 20, 2016	Apr CAHN
AB	MICRO LABS LTD INDIA	5MG	A202046	001	Sep 17, 2013	Nov CAHN
XYZAL						
AB	+! SANOFI-AVENTIS US	5MG	N022064	001	May 25, 2007	Jul CAHN

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

+ @	JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jan CRLD
+ @		EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jan CRLD
+ @		EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jan CRLD

LEVOFLOXACIN

AP	BAXTER HLTHCARE CORP	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Aug CAHN
AP	SAGENT AGILA LLC	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011	Jun CAHN
AP		EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011	Jun CAHN
AP	ZYDUS PHARMS USA INC	EQ 500MG/20ML (EQ 25MG/ML)	A205968	001	Jun 01, 2017	May NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A205968	002	Jun 01, 2017	May NEWA

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE CORP	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Aug CAHN
AP		EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Aug CAHN
AP		EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Aug CAHN
AP	HIKMA FARMACEUTICA	EQ 500MG/100ML (EQ 5MG/ML)	A091375	002	Sep 16, 2011	Nov CMS1

SOLUTION; ORAL

LEVAQUIN

+ @	JANSSEN PHARMS	250MG/10ML	N021721	001	Oct 21, 2004	Aug DISC
-----	----------------	------------	---------	-----	--------------	----------

LEVOFLOXACIN

!	HI TECH PHARMA	250MG/10ML	A091678	001	Jun 20, 2011	Aug CHRS
---	----------------	------------	---------	-----	--------------	----------

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

AT	MYLAN LABS LTD	0.5%	A204899	001	Dec 08, 2017	Nov NEWA
AT	WATSON LABS TEVA	0.5%	A076826	001	Feb 10, 2011	Feb CAHN

TABLET; ORAL

LEVOFLOXACIN

@	MYLAN	250MG	A076276	001	Jun 20, 2011	Jul DISC
@		500MG	A076276	002	Jun 20, 2011	Jul DISC
@		750MG	A077097	001	Jun 20, 2011	Jun DISC

LEVOLEUCOVORIN CALCIUM

POWDER; IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

AP	ACTAVIS LLC	EQ 50MG BASE/VIAL	A206516	001	Feb 13, 2017	Jan NEWA
+	!	EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016	May CRLD
AP	AMNEAL PHARMS CO	EQ 50MG BASE/VIAL	A207547	001	Feb 13, 2017	Jan NEWA

SOLUTION; IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

AP	AMNEAL PHARMS CO	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A207548	001	Sep 08, 2017	Aug NEWA
----	------------------	--	---------	-----	--------------	----------

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ISOCAINE HYDROCHLORIDE W/ LEVONORDEFIN

@	SEPTODONT INC	0.05MG/ML; 2%	A084697	001		May CAHN
---	---------------	---------------	---------	-----	--	----------

MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFIN

@	BELMORA LLC	0.05MG/ML; 2%	A084850	002	Oct 21, 1983	Feb CAHN
---	-------------	---------------	---------	-----	--------------	----------

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

@	FDN CONSUMER	0.75MG	A078665	001	Aug 28, 2009	Nov CAHN
	PLAN B					
+ @	FDN CONSUMER	0.75MG	N021045	001	Jul 28, 1999	Nov CAHN
+ @		0.75MG	N021045	002	Aug 24, 2006	Nov CAHN

LEVOTHYROXINE SODIUM

CAPSULE; ORAL

TIROSINT

>A>	+	INSTITUT BIOCHIMIQUE	0.013MG	N021924	013	Aug 01, 2007	Dec CMS1
	+		0.175MG	N021924	011	Apr 25, 2017	Sep NEWA
	+		0.200MG	N021924	012	Apr 25, 2017	Sep NEWA

SOLUTION; ORAL

TIROSINT-SOL

+	@	INSTITUT BIOCHIMIQUE	13MCG/ML	N206977	001	Dec 15, 2016	Jun DISC
+	@		25MCG/ML	N206977	002	Dec 15, 2016	Jun DISC
+	@		50MCG/ML	N206977	003	Dec 15, 2016	Jun DISC
+	@		75MCG/ML	N206977	004	Dec 15, 2016	Jun DISC
+	@		88MCG/ML	N206977	005	Dec 15, 2016	Jun DISC

SOLUTION;ORAL
TIROSINT-SOL

+ @	100MCG/ML	N206977	006	Dec 15, 2016	Jun DISC
+ @	112MCG/ML	N206977	007	Dec 15, 2016	Jun DISC
+ @	125MCG/ML	N206977	008	Dec 15, 2016	Jun DISC
+ @	137MCG/ML	N206977	009	Dec 15, 2016	Jun DISC
+ @	150MCG/ML	N206977	010	Dec 15, 2016	Jun DISC
+ @	175MCG/ML	N206977	011	Dec 15, 2016	Jun DISC
+ @	200MCG/ML	N206977	012	Dec 15, 2016	Jun DISC

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVO-T

>D>	AB1, + AB2, AB3	ALARA PHARM	0.025MG	N021342	001	Mar 01, 2002	Dec CAHN
>D>	AB1, + AB2, AB3		0.05MG	N021342	002	Mar 01, 2002	Dec CAHN
>D>	AB1, + AB2, AB3		0.075MG	N021342	003	Mar 01, 2002	Dec CAHN
>D>	AB1, + AB2, AB3		0.088MG	N021342	004	Mar 01, 2002	Dec CAHN
>D>	AB1, + AB2, AB3		0.1MG	N021342	005	Mar 01, 2002	Dec CAHN
>D>	AB1, + AB2, AB3		0.112MG	N021342	006	Mar 01, 2002	Dec CAHN
>D>	AB1, + AB2, AB3		0.125MG	N021342	007	Mar 01, 2002	Dec CAHN
>D>	AB1, + AB2, AB3		0.137MG	N021342	012	Dec 08, 2003	Dec CAHN
>D>	AB1, + AB2, AB3		0.15MG	N021342	008	Mar 01, 2002	Dec CAHN
>D>	AB1, + AB2, AB3		0.175MG	N021342	009	Mar 01, 2002	Dec CAHN
>D>	AB1, + AB2, AB3		0.2MG	N021342	010	Mar 01, 2002	Dec CAHN
>D>	AB1, +! AB2, AB3		0.3MG	N021342	011	Mar 01, 2002	Dec CAHN
>A>	AB1, + AB2, AB3	CEDIPROF INC	0.025MG	N021342	001	Mar 01, 2002	Dec CAHN
>A>	AB1, + AB2, AB3		0.05MG	N021342	002	Mar 01, 2002	Dec CAHN
>A>	AB1, + AB2, AB3		0.075MG	N021342	003	Mar 01, 2002	Dec CAHN
>A>	AB1, + AB2, AB3		0.088MG	N021342	004	Mar 01, 2002	Dec CAHN
>A>	AB1, + AB2, AB3		0.1MG	N021342	005	Mar 01, 2002	Dec CAHN
>A>	AB1, + AB2, AB3		0.112MG	N021342	006	Mar 01, 2002	Dec CAHN
>A>	AB1, + AB2, AB3		0.125MG	N021342	007	Mar 01, 2002	Dec CAHN
>A>	AB1, + AB2, AB3		0.137MG	N021342	012	Dec 08, 2003	Dec CAHN
>A>	AB1, + AB2, AB3		0.15MG	N021342	008	Mar 01, 2002	Dec CAHN
>A>	AB1, + AB2, AB3		0.175MG	N021342	009	Mar 01, 2002	Dec CAHN

TABLET;ORAL
LEVO-T

>A>	AB1, + AB2, AB3	0.2MG	N021342	010	Mar 01, 2002	Dec CAHN
>A>	AB1, +! AB2, AB3	0.3MG	N021342	011	Mar 01, 2002	Dec CAHN

LEVOLET

@ GENUS LIFESCIENCES

	@	0.025MG	N021137	001	Jun 06, 2003	Sep CAHN
	@	0.05MG	N021137	002	Jun 06, 2003	Sep CAHN
	@	0.075MG	N021137	003	Jun 06, 2003	Sep CAHN
	@	0.088MG	N021137	004	Jun 06, 2003	Sep CAHN
	@	0.1MG	N021137	005	Jun 06, 2003	Sep CAHN
	@	0.112MG	N021137	006	Jun 06, 2003	Sep CAHN
	@	0.125MG	N021137	007	Jun 06, 2003	Sep CAHN
	@	0.137MG	N021137	008	Jun 06, 2003	Sep CAHN
	@	0.15MG	N021137	009	Jun 06, 2003	Sep CAHN
	@	0.175MG	N021137	010	Jun 06, 2003	Sep CAHN
	@	0.2MG	N021137	011	Jun 06, 2003	Sep CAHN
	@	0.3MG	N021137	012	Jun 06, 2003	Sep CAHN

LEVOXYL

AB1, +	KING PHARMS	0.025MG	N021301	001	May 25, 2001	May CAHN
AB3						
AB1, +		0.05MG	N021301	002	May 25, 2001	May CAHN
AB3						
AB1, +		0.075MG	N021301	003	May 25, 2001	May CAHN
AB3						
AB1, +		0.088MG	N021301	004	May 25, 2001	May CAHN
AB3						
AB1, +		0.1MG	N021301	005	May 25, 2001	May CAHN
AB3						
AB1, +		0.112MG	N021301	006	May 25, 2001	May CAHN
AB3						
AB1, +		0.125MG	N021301	007	May 25, 2001	May CAHN
AB3						
AB1, +		0.137MG	N021301	008	May 25, 2001	May CAHN
AB3						
AB1, +		0.15MG	N021301	009	May 25, 2001	May CAHN
AB3						
AB1, +		0.175MG	N021301	010	May 25, 2001	May CAHN
AB3						
AB1, +!		0.2MG	N021301	011	May 25, 2001	May CAHN
AB3						
	+ @	0.3MG	N021301	012	May 25, 2001	May CAHN
	THYRO-TABS					
	+ @ LLOYD	0.025MG	N021116	001	Oct 24, 2002	Sep CTNA
	+ @	0.05MG	N021116	002	Oct 24, 2002	Sep CTNA
	+ @	0.075MG	N021116	003	Oct 24, 2002	Sep CTNA
	+ @	0.088MG	N021116	010	Oct 24, 2002	Sep CTNA
	+ @	0.1MG	N021116	004	Oct 24, 2002	Sep CTNA
	+ @	0.112MG	N021116	011	Oct 24, 2002	Sep CTNA
	+ @	0.125MG	N021116	005	Oct 24, 2002	Sep CTNA
	+ @	0.137MG	N021116	012	Dec 07, 2004	Sep CTNA
	+ @	0.15MG	N021116	006	Oct 24, 2002	Sep CTNA
	+ @	0.175MG	N021116	007	Oct 24, 2002	Sep CTNA
	+ @	0.2MG	N021116	008	Oct 24, 2002	Sep CTNA
	+ @	0.3MG	N021116	009	Oct 24, 2002	Sep CTNA

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

AT	ALKEM LABS LTD	5%	A207810	001	Mar 10, 2017	Feb NEWA
AT	! FOUGERA PHARMS INC	5%	A080198	001		Jan CAHN
AT	RICONPHARMA LLC	5%	A208604	001	Sep 20, 2017	Sep NEWA
AT	VITRUVIAS THERAP	5%	A208822	001	Sep 25, 2017	Sep NEWA
	XYLOCAINE					
	+ @ ASTRAZENECA	5%	N008048	001		Jan CRLD

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

AP	AUROBINDO PHARMA LTD	1%	A207182	001	Oct 30, 2017	Oct NEWA
AP		2%	A207182	002	Oct 30, 2017	Oct NEWA
	@ BELMORA LLC	2%	A080504	001		Feb CAHN
	@ MYLAN LABS LTD	0.5%	A091056	001	Dec 08, 2010	Nov DISC

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

@ 0.5%
 @ 1%
 @ 1%
 @ 2%

A091058 001 Sep 30, 2010 Nov DISC
 A091056 002 Dec 08, 2010 Nov DISC
 A091058 002 Sep 30, 2010 Nov DISC
 A202242 001 Apr 11, 2014 Nov DISC

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

@ MYLAN LABS LTD 2%

A090665 001 Sep 27, 2010 Nov DISC

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE

>D> AT WOCKHARDT 2%
 >A> AT WOCKHARDT BIO AG 2%

A087872 001 Nov 18, 1982 Dec CAHN
 A087872 001 Nov 18, 1982 Dec CAHN

SOLUTION; TOPICAL

LIDOCAINE HYDROCHLORIDE

>D> AT WOCKHARDT 4%
 >A> AT WOCKHARDT BIO AG 4%

A087881 001 Nov 18, 1982 Dec CAHN
 A087881 001 Nov 18, 1982 Dec CAHN

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

PLIAGLIS

+! TARO PHARMS 7%; 7%

N021717 001 Jun 29, 2006 May CAHN

LINACLOTIDE

CAPSULE; ORAL

LINZESS

+ FOREST LABS LLC 72MCG

N202811 003 Jan 25, 2017 Jan NEWA

LINDANE

SHAMPOO; TOPICAL

LINDANE

>D> AT ! WOCKHARDT 1%
 >A> AT ! WOCKHARDT BIO AG 1%

A088191 001 Sep 18, 1984 Dec CAHN
 A088191 001 Sep 18, 1984 Dec CAHN

LINEZOLID

SOLUTION; IV (INFUSION)

LINEZOLID

AP HQ SPCLT PHARMA 200MG/100ML (2MG/ML)
 AP 600MG/300ML (2MG/ML)
 AP MYLAN LABS LTD 200MG/100ML (2MG/ML)
 AP 600MG/300ML (2MG/ML)
 AP SAGENT PHARMS 200MG/100ML (2MG/ML)
 AP 600MG/300ML (2MG/ML)

A207001 001 Jul 07, 2017 Jun NEWA
 A207001 002 Jul 07, 2017 Jun NEWA
 A205154 001 Dec 06, 2017 Nov NEWA
 A205154 002 Dec 06, 2017 Nov NEWA
 A204696 001 Mar 02, 2017 Feb NEWA
 A204696 002 Mar 02, 2017 Feb NEWA

TABLET; ORAL

LINEZOLID

AB ZYDUS PHARMS USA INC 600MG

A206097 001 Feb 22, 2017 Feb NEWA

LIOTHYRONINE SODIUM

TABLET; ORAL

CYTOMEL

AB + KING PHARMS EQ 0.005MG BASE
 AB + EQ 0.025MG BASE
 AB +! EQ 0.05MG BASE

N010379 001 Mar CAHN
 N010379 002 Mar CAHN
 N010379 003 Mar CAHN

LISDEXAMFETAMINE DIMESYLATE

TABLET, CHEWABLE; ORAL

VYVANSE

+ SHIRE DEV LLC 10MG
 + 20MG
 + 30MG
 + 40MG
 + 50MG
 +! 60MG
 + 60MG

N208510 001 Jan 28, 2017 Jan NEWA
 N208510 002 Jan 28, 2017 Jan NEWA
 N208510 003 Jan 28, 2017 Jan NEWA
 N208510 004 Jan 28, 2017 Jan NEWA
 N208510 005 Jan 28, 2017 Jan NEWA
 N208510 006 Jan 28, 2017 Apr CHRS
 N208510 006 Jan 28, 2017 Jan NEWA

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB PRINSTON INC 2.5MG
 AB 5MG
 AB 10MG
 AB 20MG
 AB 30MG

A075743 001 Jul 01, 2002 Feb CAHN
 A075743 002 Jul 01, 2002 Feb CAHN
 A075743 003 Jul 01, 2002 Feb CAHN
 A075743 004 Jul 01, 2002 Feb CAHN
 A075743 005 Jul 01, 2002 Feb CAHN

TABLET;ORAL									
LISINOPRIL									
AB		40MG		A075743	006	Jul 01, 2002	Feb	CAHN	
<u>LITHIUM CARBONATE</u>									
CAPSULE;ORAL									
LITHIUM CARBONATE									
AB	MYLAN PHARMS INC	150MG		A076243	002	Feb 24, 2003	Jan	CAHN	
AB		300MG		A076243	001	Jun 27, 2002	Jan	CAHN	
AB		600MG		A078763	001	Apr 15, 2008	Jan	CAHN	
AB	+ WEST-WARD PHARMS INT	150MG		N017812	002	Jan 28, 1987	Jan	CAHN	
AB	+	300MG		N017812	001		Jan	CAHN	
AB	+	600MG		N017812	003	Jan 28, 1987	Jan	CAHN	
TABLET;ORAL									
LITHIUM CARBONATE									
AB	+	WEST-WARD PHARMS INT	300MG	N018558	001	Jan 29, 1982	Jan	CAHN	
TABLET, EXTENDED RELEASE;ORAL									
LITHIUM CARBONATE									
AB	UNIQUE PHARM LABS	450MG		A205663	001	Jun 05, 2017	May	NEWA	
<u>LITHIUM CITRATE</u>									
SYRUP;ORAL									
LITHIUM CITRATE									
AA	+	WEST-WARD PHARMS INT	EQ 300MG CARBONATE/5ML	N018421	001		Jan	CAHN	
>D>	AA	WOCKHARDT	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Dec	CAHN	
>A>	AA	WOCKHARDT BIO AG	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Dec	CAHN	
<u>LOPERAMIDE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
LOPERAMIDE HYDROCHLORIDE									
>A>	@	FOSUN PHARMA	2MG	A072993	001	Aug 28, 1992	Dec	CAHN	
>D>	@	SANDOZ	2MG	A072993	001	Aug 28, 1992	Dec	CAHN	
<u>LORAZEPAM</u>									
CONCENTRATE;ORAL									
LORAZEPAM									
AA	SAPTALIS PHARMS	2MG/ML		A079244	001	Apr 28, 2009	Oct	CAHN	
INJECTABLE;INJECTION									
LORAZEPAM									
>D>	AP	SAGENT AGILA LLC	2MG/ML	A200217	001	Apr 04, 2017	Dec	DISC	
>A>	@		2MG/ML	A200217	001	Apr 04, 2017	Dec	DISC	
	AP		2MG/ML	A200217	001	Apr 04, 2017	Mar	NEWA	
>D>	AP		2MG/ML	A200542	001	Apr 28, 2017	Dec	DISC	
>A>	@		2MG/ML	A200542	001	Apr 28, 2017	Dec	DISC	
	AP		2MG/ML	A200542	001	Apr 28, 2017	Apr	NEWA	
>D>	AP		4MG/ML	A200217	002	Apr 04, 2017	Dec	DISC	
>A>	@		4MG/ML	A200217	002	Apr 04, 2017	Dec	DISC	
	AP		4MG/ML	A200217	002	Apr 04, 2017	Mar	NEWA	
>D>	AP		4MG/ML	A200542	002	Apr 28, 2017	Dec	DISC	
>A>	@		4MG/ML	A200542	002	Apr 28, 2017	Dec	DISC	
	AP		4MG/ML	A200542	002	Apr 28, 2017	Apr	NEWA	
	@	WEST-WARD PHARMS INT	2MG/ML	A074496	001	Sep 28, 1998	Mar	CAHN	
	@		4MG/ML	A074496	002	Sep 28, 1998	Mar	CAHN	
TABLET;ORAL									
LORAZEPAM									
	@	ANDA REPOSITORY	0.5MG	A072553	001	Mar 29, 1991	Sep	CAHN	
	@		1MG	A072554	001	Mar 29, 1991	Sep	CAHN	
	@		2MG	A072555	001	Mar 29, 1991	Sep	CAHN	
>A>	AB	AUROLIFE PHARMA LLC	0.5MG	A203572	001	Dec 22, 2017	Dec	NEWA	
>A>	AB		1MG	A203572	002	Dec 22, 2017	Dec	NEWA	
>A>	AB		2MG	A203572	003	Dec 22, 2017	Dec	NEWA	
	@	MYLAN	2MG	A071591	001	Oct 13, 1987	Nov	DISC	
	AB	SANDOZ	0.5MG	A071141	002	Apr 21, 1987	Nov	CMS1	
	AB		0.5	A071141	002	Apr 21, 1987	Apr	CMS1	
	AB		1MG	A071141	003	Apr 21, 1987	Apr	CMS1	
<u>LOSARTAN POTASSIUM</u>									
TABLET;ORAL									
LOSARTAN POTASSIUM									
AB	HETERO LABS LTD V	25MG		A203835	001	Aug 12, 2015	Jul	CTEC	
AB		50MG		A203835	002	Aug 12, 2015	Jul	CTEC	
AB		100MG		A203835	003	Aug 12, 2015	Jul	CTEC	

TABLET;ORAL

LOSARTAN POTASSIUM

AB	UPSHER-SMITH LABS	25MG	A090544	001	Oct 06, 2010	Jun CAHN
AB		50MG	A090544	002	Oct 06, 2010	Jun CAHN
AB		100MG	A090544	003	Oct 06, 2010	Jun CAHN
AB	VIVA HLTHCARE	25MG	A091541	001	Sep 24, 2012	Sep CAHN
AB		50MG	A091541	002	Sep 24, 2012	Sep CAHN
AB		100MG	A091541	003	Sep 24, 2012	Sep CAHN
AB	VIVIMED GLOBAL	25MG	A090382	001	Oct 06, 2010	Aug CAHN
AB		50MG	A090382	002	Oct 06, 2010	Aug CAHN
AB		100MG	A090382	003	Oct 06, 2010	Aug CAHN

LOVASTATIN

TABLET;ORAL

LOVASTATIN

@ MYLAN

10MG

A075935 001 Dec 17, 2001 Mar DISC

@

20MG

A075935 002 Dec 17, 2001 Mar DISC

@

40MG

A075935 003 Dec 17, 2001 Mar DISC

TABLET, EXTENDED RELEASE;ORAL

ALTOPREV

@ COVIS PHARMA BV

10MG

N021316 001 Jun 26, 2002 Apr CAHN

+

20MG

N021316 002 Jun 26, 2002 Apr CAHN

+

40MG

N021316 003 Jun 26, 2002 Apr CAHN

+!

60MG

N021316 004 Jun 26, 2002 Apr CAHN

LOXAPINE

POWDER; INHALATION

ADASUVE

+! GALEN UK

10MG

N022549 001 Dec 21, 2012 Sep CAHN

>A> MACIMORELIN

>A> SOLUTION;ORAL

>A> MACRILEN

>A> +! AETERNA ZENTARIS

0.5MG/ML

N205598 001 Dec 21, 2017 Dec NEWA

>A> MACIMORELIN ACETATE

>A> FOR SOLUTION;ORAL

>A> MACRILEN

>A> +! AETERNA ZENTARIS

EQ 60MG BASE/POUCH

N205598 001 Dec 21, 2017 Dec NEWA

MAFENIDE ACETATE

FOR SOLUTION;TOPICAL

MAFENIDE ACETATE

AT NOVAST LABS LTD

5%

A206716 001 Jul 31, 2017 Sep CAHN

AT RICONPHARMA LLC

5%

A206716 001 Jul 31, 2017 Jul NEWA

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

NORMOSOL-R IN PLASTIC CONTAINER

ICU MEDICAL INC

30MG/100ML;37MG/100ML;222MG/100ML;

N017586 001

Feb CAHN

526MG/100ML;502MG/100ML

SOLUTION;IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

ICU MEDICAL INC

30MG/100ML;37MG/100ML;222MG/100ML;

N017637 002 Jul 08, 1982

Feb CAHN

526MG/100ML;502MG/100ML

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

AP + HOSPIRA

40GM/1000ML (40MG/ML)

N020309 005 Jan 18, 1995 Nov CMS1

AP HQ SPCLT PHARMA

2GM/50ML (40MG/ML)

A207350 001 Dec 06, 2017 Nov NEWA

AP 4GM/100ML (40MG/ML)

A207350 002 Dec 06, 2017 Nov NEWA

AP 4GM/50ML (80MG/ML)

A207350 003 Dec 06, 2017 Nov NEWA

AP 20GM/500ML (40MG/ML)

A207350 004 Dec 06, 2017 Nov NEWA

AP 40GM/1000ML (40MG/ML)

A207350 005 Dec 06, 2017 Nov NEWA

MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

AA NOVEL LABS INC

1.6GM/BOT;3.13GM/BOT;17.5GM/BOT

A202511 001 Feb 23, 2017 Feb NEWA

SUPREP BOWEL PREP KIT

AA +! BRAINTREE LABS

1.6GM/BOT;3.13GM/BOT;17.5GM/BOT

N022372 001 Aug 05, 2010 Feb CFTG

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

AA	NOVEL LABS INC	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A202511	001	Feb 23, 2017	May CAIN
AA	+	SUPREP BOWEL PREP KIT				
AA	! BRAINTREE LABS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N022372	001	Aug 05, 2010	May CAIN

MALATHIONLOTION;TOPICAL
OVIDE

AT	+	TARO PHARM	0.5%	N018613	001	Aug 02, 1982	May CAHN
----	---	------------	------	---------	-----	--------------	----------

MANGAFODIPIR TRISODIUM

INJECTABLE;INJECTION

TESLASCAN

	@	IC TARGETS	37.9MG/ML	N020652	001	Nov 26, 1997	Nov CAHN
--	---	------------	-----------	---------	-----	--------------	----------

MANNITOL

INJECTABLE;INJECTION

MANNITOL 10% IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	10GM/100ML	N019603	002	Jan 08, 1987	Feb CAHN
AP	MANNITOL 15% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	15GM/100ML	N019603	003	Jan 08, 1990	Feb CAHN
AP	MANNITOL 20% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	20GM/100ML	N019603	004	Jan 08, 1990	Feb CAHN
AP	MANNITOL 5% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	5GM/100ML	N019603	001	Jan 08, 1987	Feb CAHN

MANNITOL; SORBITOL

SOLUTION;IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

	ICU MEDICAL INC	540MG/100ML;2.7GM/100ML	N018316	001		Feb CAHN
--	-----------------	-------------------------	---------	-----	--	----------

MAPROTILINE HYDROCHLORIDE

TABLET;ORAL

MAPROTILINE HYDROCHLORIDE

	@	WATSON LABS TEVA	25MG	A072162	001	Jun 01, 1988	May CAHN
	@		50MG	A072163	001	Jun 01, 1988	May CAHN

MEBENDAZOLE

TABLET, CHEWABLE;ORAL

EMVERM

!	IMPAX LABS INC	100MG	A073580	001	Jan 04, 1995	Jun CAHN
---	----------------	-------	---------	-----	--------------	----------

MECAMYLAMINE HYDROCHLORIDE

TABLET;ORAL

MECAMYLAMINE HYDROCHLORIDE

!	NEXGEN PHARMA	2.5MG	A204054	001	Mar 19, 2013	May CHRS
---	---------------	-------	---------	-----	--------------	----------

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

AA	AMNEAL PHARMS	12.5MG	A201451	001	Feb 23, 2011	May CAHN
AA		25MG	A201451	002	Feb 23, 2011	May CAHN
	@	50MG	A201451	003	Feb 23, 2011	May CAHN
	@ PLIVA	25MG	A088734	001	Dec 11, 1985	Aug CAHN

MECLOFENAMATE SODIUM

CAPSULE;ORAL

MECLOFENAMATE SODIUM

	@	WATSON LABS TEVA	EQ 100MG BASE	A071469	001	Apr 15, 1987	May CAHN
--	---	------------------	---------------	---------	-----	--------------	----------

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION

MEDROXYPROGESTERONE ACETATE

AB	AMPHASTAR PHARMS INC	150MG/ML	A077235	001	Nov 28, 2017	Nov NEWA
AB		150MG/ML	A077334	001	Nov 28, 2017	Nov NEWA
	@ SANDOZ INC	150MG/ML	A078711	001	May 20, 2009	Jun DISC
AB		150MG/ML	A078711	001	May 20, 2009	Mar CAHN
AB	TEVA PHARMS USA	150MG/ML	A076553	001	Jul 28, 2004	Jan CAHN

TABLET;ORAL

MEDROXYPROGESTERONE ACETATE

@ USL PHARMA 10MG

A088484 001 Jul 26, 1984 Jun CAHN

MEFENAMIC ACID

CAPSULE;ORAL

MEFENAMIC ACID

AB VIVA HLTHCARE 250MG

A090562 001 Nov 19, 2010 Sep CAHN

MEFLOQUINE HYDROCHLORIDE

TABLET;ORAL

LARIAM

+ @ ROCHE 250MG

N019591 001 May 02, 1989 Sep CRLD

MEFLOQUINE HYDROCHLORIDE

AB ! BARR 250MG

A076392 001 Dec 29, 2003 Apr CHRS

@ SANDOZ 250MG

A076175 001 Feb 20, 2002 Apr DISC

MEGESTROL ACETATE

SUSPENSION;ORAL

MEGACE

+ @ BRISTOL MYERS SQUIBB 40MG/ML

N020264 001 Sep 10, 1993 Feb DISC

MEGESTROL ACETATE

AB BRECKENRIDGE PHARM 125MG/ML

A204688 001 Dec 01, 2017 Nov NEWA

AB HI-TECH PHARMACAL 40MG/ML

A203960 001 Jun 09, 2017 May NEWA

AB ! WEST-WARD PHARMS INT 40MG/ML

A075997 001 Feb 15, 2002 Feb CHRS

>D> AB WOCKHARDT 40MG/ML

A076721 001 Nov 01, 2004 Dec CAHN

>A> AB WOCKHARDT BIO AG 40MG/ML

A076721 001 Nov 01, 2004 Dec CAHN

MELOXICAM

SUSPENSION;ORAL

MOBIC

+ @ BOEHRINGER INGELHEIM 7.5MG/5ML

N021530 001 Jun 01, 2004 Sep DISC

TABLET;ORAL

MELOXICAM

@ ANDA REPOSITORY 7.5MG

A077935 001 Jul 19, 2006 Sep CAHN

@ 15MG

A077935 002 Jul 19, 2006 Sep CAHN

@ IMPAX LABS INC 7.5MG

A077930 001 Jul 19, 2006 Nov CAHN

@ 15MG

A077930 002 Jul 19, 2006 Nov CAHN

MELPHALAN

TABLET;ORAL

ALKERAN

AB +! APOTEX INC 2MG

N014691 002 Mar CFTG

MELPHALAN

AB ALVOGEN MALTA 2MG

A207809 001 Mar 22, 2017 Mar NEWA

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

ALKERAN

+ @ APOTEX INC EQ 50MG BASE/VIAL

N020207 001 Nov 18, 1992 May DISC

MELPHALAN HYDROCHLORIDE

>D> AP + DR REDDYS LABS LTD EQ 50MG BASE/VIAL

A203655 001 Dec 08, 2017 Dec CRLD

>A> AP EQ 50MG BASE/VIAL

A203655 001 Dec 08, 2017 Dec CRLD

AP + EQ 50MG BASE/VIAL

A203655 001 Dec 08, 2017 Nov NEWA

>A> AP FRESENIUS KABI USA EQ 50MG BASE/VIAL

A203393 001 Dec 22, 2017 Dec NEWA

AP ! MYLAN INSTITUTIONAL EQ 50MG BASE/VIAL

A090270 001 Jun 09, 2009 May CHRS

AP SAGENT PHARMS EQ 50MG BASE/VIAL

A201379 001 Feb 28, 2017 Feb NEWA

POWDER; IV (INFUSION)

EVOMELA

+! SPECTRUM PHARMS EQ 50MG BASE/VIAL

N207155 001 Mar 10, 2016 Aug CRLD

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

AB AMNEAL PHARMS 7MG

A205825 001 Oct 12, 2016 May CAHN

AB 14MG

A205825 002 Oct 12, 2016 May CAHN

AB 21MG

A205825 003 Oct 12, 2016 May CAHN

AB 28MG

A205825 004 Oct 12, 2016 May CAHN

AB ANCHEN PHARMS 7MG

A205784 001 Jun 09, 2017 May NEWA

AB 14MG

A205784 002 Jun 09, 2017 May NEWA

AB 21MG

A205784 003 Jun 09, 2017 May NEWA

AB 28MG

A205784 004 Jun 09, 2017 May NEWA

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	7MG	A203293	001	Aug 03, 2017	Jul NEWA
AB		14MG	A203293	002	Aug 03, 2017	Jul NEWA
AB		21MG	A203293	003	Aug 03, 2017	Jul NEWA
AB		28MG	A203293	004	Aug 03, 2017	Jul NEWA

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

AB	AMNEAL PHARMS	5MG	A090041	001	Apr 10, 2015	May CAHN
AB		10MG	A090041	002	Apr 10, 2015	May CAHN
AB	STRIDES PHARMA	5MG	A202350	001	May 23, 2017	May NEWA
AB		10MG	A202350	002	May 23, 2017	May NEWA
AB	UPSHER-SMITH LABS	5MG	A090043	001	Jul 31, 2015	Jun CAHN
AB		10MG	A090043	002	Jul 31, 2015	Jun CAHN
AB	ZYDUS PHARMS USA INC	5MG	A090961	001	Jul 10, 2017	Jun NEWA
AB		10MG	A090961	002	Jul 10, 2017	Jun NEWA

MEPENZOLATE BROMIDE

TABLET;ORAL

CANTIL

	+ @ SANOFI AVENTIS US	25MG	N010679	003		Aug DISC
--	-----------------------	------	---------	-----	--	----------

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERIDINE HYDROCHLORIDE

AP	WEST-WARD PHARMS INT	25MG/ML	A080445	001		Jan CAHN
AP		25MG/ML	A080455	007		Jan CAHN
AP		50MG/ML	A080445	002		Jan CAHN
AP		50MG/ML	A080455	008		Jan CAHN
AP		75MG/ML	A080445	003		Jan CAHN
AP		75MG/ML	A080455	009		Jan CAHN
AP		100MG/ML	A080445	004		Jan CAHN
AP		100MG/ML	A080455	010		Jan CAHN

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

AP	! ICU MEDICAL INC	10MG/ML	A088432	001	Aug 16, 1984	Apr CAHN
>D>	@ MALLINCKRODT INC	10MG/ML	A040163	001	May 12, 1997	Dec CAHN
	@	10MG/ML	A040163	001	May 12, 1997	Mar CAHN
>A>	@ SPECGX LLC	10MG/ML	A040163	001	May 12, 1997	Dec CAHN
AP	WEST-WARD PHARMS INT	10MG/ML	A081002	001	Jul 30, 1993	Apr CAHN

TABLET;ORAL

MEPERIDINE HYDROCHLORIDE

>D>	AA MALLINCKRODT	50MG	A040352	001	Jun 13, 2000	Dec CAHN
>D>	AA	100MG	A040352	002	Jun 13, 2000	Dec CAHN
>A>	AA SPECGX LLC	50MG	A040352	001	Jun 13, 2000	Dec CAHN
>A>	AA	100MG	A040352	002	Jun 13, 2000	Dec CAHN

MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

ISOCAINE HYDROCHLORIDE

AP	! SEPTODONT INC	3%	A080925	001		May CAHN
	MEPIVACAINE HYDROCHLORIDE					
	@ BELMORA LLC	3%	A083559	001		Feb CAHN

MERCAPTOPURINE

TABLET;ORAL

MERCAPTOPURINE

AB	DR REDDYS LABS SA	50MG	A040461	001	Feb 11, 2004	Jun CAHN
----	-------------------	------	---------	-----	--------------	----------

MEROPENEM

INJECTABLE;INJECTION

MEROPENEM

AP	AUROBINDO PHARMA LTD	500MG/VIAL	A205835	001	Mar 27, 2017	Mar NEWA
AP		1GM/VIAL	A205835	002	Mar 27, 2017	Mar NEWA
	MERREM					
AP	+! PFIZER	500MG/VIAL	N050706	003	Jun 21, 1996	Jun CAHN
AP	+!	1GM/VIAL	N050706	001	Jun 21, 1996	Jun CAHN

MEROPENEM; VABORBACTAMPOWDER; IV (INFUSION)
VABOMERE

+! REMPEX PHARMS MEDCNS 1GM/VIAL; 1GM/VIAL

N209776 001 Aug 29, 2017 Aug NEWA

MESALAMINEENEMA; RECTAL
ROWASAAB +! MYLAN SPECIALITY LP 4GM/60ML
SFROWASA

N019618 001 Dec 24, 1987 Mar CAHN

AB + MYLAN SPECIALITY LP 4GM/60ML
TABLET, DELAYED RELEASE; ORAL
ASACOL HD

N019618 002 Jun 20, 2008 Mar CAHN

AB +! APIL 800MG
LIALDA

N021830 001 May 29, 2008 Jul CFTG

AB +! SHIRE 1.2GM
MESALAMINE

N022000 001 Jan 16, 2007 May CFTG

AB ZYDUS PHARMS USA INC 800MG

A203286 001 Jul 21, 2017 Jul NEWA

AB 1.2GM

A091640 001 Jun 05, 2017 May NEWA

MESNAINJECTABLE; INTRAVENOUS
MESNA>A> AP GLAND PHARMA LTD 100MG/ML
@ MYLAN LABS LTD 100MG/ML

A206992 001 Dec 18, 2017 Dec NEWA

A203364 001 Jul 18, 2014 Oct DISC

METAXALONETABLET; ORAL
METAXALONEAB ACTAVIS LABS FL INC 800MG
>A> COREPHARMA 400MG

A203695 001 Jun 15, 2017 Jun NEWA

A040486 001 Feb 27, 2015 Dec CAHN

@ EPIC PHARMA LLC 640MG

N022503 001 Jun 01, 2015 May CAHN

>D> IMPAX LABS INC 400MG
400MG

A040486 001 Feb 27, 2015 Dec CAHN

A040486 001 Feb 27, 2015 Feb CAHN

AB SCIEGEN PHARMS INC 800MG
SKELAXIN

A207466 001 Aug 31, 2017 Aug NEWA

+ @ KING PHARMS 400MG

N013217 001 May CAHN

AB +! 800MG

N013217 003 Aug 30, 2002 May CAHN

METFORMIN HYDROCHLORIDETABLET; ORAL
METFORMIN HYDROCHLORIDE

AB MACLEODS PHARMS LTD 500MG

A205330 001 Oct 31, 2017 Oct NEWA

AB 850MG

A205330 002 Oct 31, 2017 Oct NEWA

AB 1GM

A205330 003 Oct 31, 2017 Oct NEWA

@ MYLAN PHARMS INC 500MG

A075969 001 Jan 29, 2002 May DISC

@ 850MG

A075969 002 Jan 29, 2002 May DISC

@ 1GM

A075969 003 Jan 29, 2002 May DISC

@ WATSON LABS FLORIDA 500MG

A075961 001 Jan 25, 2002 Mar DISC

@ 850MG

A075961 002 Jan 25, 2002 Mar DISC

@ 1GM

A075961 003 Jan 25, 2002 Mar DISC

TABLET, EXTENDED RELEASE; ORAL
METFORMIN HYDROCHLORIDE

AB1 INTELLIPHARMACEUTICS 500MG

A202306 001 Feb 23, 2017 Feb NEWA

AB 750MG

A202306 002 Feb 23, 2017 Feb NEWA

@ MYLAN 500MG

A076650 001 Sep 13, 2005 Nov DISC

@ 750MG

A077113 001 Sep 08, 2005 Oct DISC

>A> AB2 NOSTRUM LABS INC 500MG

A203832 001 Dec 26, 2017 Dec NEWA

>A> AB2 1GM

A203832 002 Dec 26, 2017 Dec NEWA

AB1 TORRENT PHARMS LTD 500MG

A090014 001 Dec 30, 2009 Apr CAHN

METFORMIN HYDROCHLORIDE; REPAGLINIDETABLET; ORAL
PRANDIMET

+ @ NOVO NORDISK INC 500MG; 1MG

N022386 001 Jun 23, 2008 Oct DISC

+ @ 500MG; 2MG

N022386 002 Jun 23, 2008 Oct DISC

REPAGLINIDE AND METFORMIN HYDROCHLORIDE

LUPIN LTD 500MG; 1MG

A200624 001 Jul 15, 2015 Oct CTEC

! 500MG; 2MG

A200624 002 Jul 15, 2015 Oct CHRS

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

TEVA

500MG;EQ 1MG BASE

A077337 005 May 19, 2017 May NEWA

METHACHOLINE CHLORIDE

FOR SOLUTION; INHALATION

PROVOCHOLINE

+ @ METHAPHARM

1600MG/VIAL

N019193 002 Aug 29, 2016 Sep DISC

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

METHADOSE

>D> AA +! MALLINCKRODT INC 10MG/ML N017116 002 Dec CAHN

AA +! 10MG/ML N017116 002 Apr CAHN

>A> AA +! SPECGX LLC 10MG/ML N017116 002 Dec CAHN

INJECTABLE; INJECTION

METHADONE HYDROCHLORIDE

AP AKORN 10MG/ML A208306 001 Oct 27, 2017 Oct NEWA

AP +! MYLAN INSTITUTIONAL 10MG/ML N021624 001 Oct CFTG

POWDER; FOR RX COMPOUNDING

METHADONE HYDROCHLORIDE

@ MALLINCKRODT INC 50GM/BOT

N006383 002 Oct DISC

50GM/BOT

N006383 002 Apr CAHN

@ 100GM/BOT

N006383 003 Oct DISC

100GM/BOT

N006383 003 Apr CAHN

@ 500GM/BOT

N006383 004 Oct DISC

500GM/BOT

N006383 004 Apr CAHN

SYRUP; ORAL

DOLOPHINE HYDROCHLORIDE

@ WEST-WARD PHARMS INT 10MG/30ML

N006134 004 Jan CAHN

TABLET; ORAL

DOLOPHINE HYDROCHLORIDE

AA +! WEST-WARD PHARMS INT 5MG N006134 002 Jan CAHN

AA +! 10MG N006134 010 Jan CAHN

METHADONE HYDROCHLORIDE

AA EPIC PHARMA LLC 5MG A090065 001 Aug 18, 2015 May CAHN

AA 10MG A090065 002 Aug 18, 2015 May CAHN

>D> AA MALLINCKRODT 5MG A040517 001 Apr 27, 2004 Dec CAHN

>D> AA 10MG A040517 002 Apr 27, 2004 Dec CAHN

>A> AA SPECGX LLC 5MG A040517 001 Apr 27, 2004 Dec CAHN

>A> AA 10MG A040517 002 Apr 27, 2004 Dec CAHN

METHADOSE

>D> AA MALLINCKRODT 5MG A040050 001 Apr 15, 1993 Dec CAHN

>D> AA 10MG A040050 002 Apr 15, 1993 Dec CAHN

>A> AA SPECGX LLC 5MG A040050 001 Apr 15, 1993 Dec CAHN

>A> AA 10MG A040050 002 Apr 15, 1993 Dec CAHN

TABLET, FOR SUSPENSION; ORAL

METHADONE HYDROCHLORIDE

>D> AA MALLINCKRODT INC 40MG A077142 001 Jul 12, 2005 Dec CAHN

>A> AA SPECGX LLC 40MG A077142 001 Jul 12, 2005 Dec CAHN

AA +! WEST-WARD PHARMS INT 40MG N017058 001 Jan CAHN

METHADOSE

>D> AA MALLINCKRODT INC 40MG A074184 001 Apr 29, 1993 Dec CAHN

>A> AA SPECGX LLC 40MG A074184 001 Apr 29, 1993 Dec CAHN

METHENAMINE HIPPURATE

TABLET; ORAL

METHENAMINE HIPPURATE

AB IMPAX LABS INC 1GM A076411 001 Jun 20, 2003 Feb CAHN

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

@ ECI PHARMS LLC 15MG

A040619 003 Jul 12, 2005 May CAHN

TAPAZOLE

AB KING PHARMS LLC 5MG A040320 001 Mar 31, 2000 Feb CAHN

AB 10MG A040320 002 Mar 31, 2000 Feb CAHN

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

AP	LUITPOLD PHARMS INC	1GM/10ML (100MG/ML)	A207496	001	Jun 22, 2017	Jun NEWA
AP	NAVINTA LLC	1GM/10ML (100MG/ML)	A206071	001	Nov 24, 2017	Nov NEWA
AP	RENAISSANCE PHARMA	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Jan NEWA
AP	RENAISSANCE SSA LLC	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Mar CAHN
AP	SAGENT PHARMS	1GM/10ML (100MG/ML)	A205404	001	Jul 18, 2017	Jul NEWA
AP	SOMERSET THERAPS LLC	1GM/10ML (100MG/ML)	A207522	001	Jul 31, 2017	Jul NEWA

TABLET; ORAL

METHOCARBAMOL

AA	ATLAS PHARMS LLC	500MG	A203550	001	Feb 08, 2017	Jan NEWA
AA		750MG	A203550	002	Feb 08, 2017	Jan NEWA
AA	BEXIMCO PHARMS USA	500MG	A208507	001	Jul 21, 2017	Jul NEWA
AA		750MG	A208507	002	Jul 21, 2017	Jul NEWA
	@ UPSHER SMITH	500MG	A087453	001		Jun CAHN
	@	750MG	A087454	001		Jun CAHN

METHOTREXATE

SOLUTION; SUBCUTANEOUS

OTREXUP

>D>	@ ANTARES PHARMA INC	7.5MG/0.4ML (7.5MG/0.4ML)	N204824	005	Nov 07, 2014	Dec CRLD
>A>	+ @	7.5MG/0.4ML (7.5MG/0.4ML)	N204824	005	Nov 07, 2014	Dec CRLD
>D>	+	10MG/0.4ML (10MG/0.4ML)	N204824	001	Oct 11, 2013	Dec CHRS
>A>	+!	10MG/0.4ML (10MG/0.4ML)	N204824	001	Oct 11, 2013	Dec CHRS
>D>	+	12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016	Dec CHRS
>A>	+!	12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016	Dec CHRS
>D>	+	15MG/0.4ML (15MG/0.4ML)	N204824	002	Oct 11, 2013	Dec CHRS
>A>	+!	15MG/0.4ML (15MG/0.4ML)	N204824	002	Oct 11, 2013	Dec CHRS
>D>	+	17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016	Dec CHRS
>A>	+!	17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016	Dec CHRS
>D>	+	20MG/0.4ML (20MG/0.4ML)	N204824	003	Oct 11, 2013	Dec CHRS
>A>	+!	20MG/0.4ML (20MG/0.4ML)	N204824	003	Oct 11, 2013	Dec CHRS
>D>	+	22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016	Dec CHRS
>A>	+!	22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016	Dec CHRS

OTREXUP PFS

+	@ ANTARES PHARMA INC	10MG/0.4ML (10MG/0.4ML)	N204824	009	May 31, 2017	Nov DISC
+		10MG/0.4ML (10MG/0.4ML)	N204824	009	May 31, 2017	Jul NEWA
+	@	15MG/0.6ML (15MG/0.6ML)	N204824	010	May 31, 2017	Nov DISC
+		15MG/0.6ML (15MG/0.6ML)	N204824	010	May 31, 2017	Jul NEWA
+	@	17.5MG/0.7ML (17.5MG/0.7ML)	N204824	011	May 31, 2017	Nov DISC
+		17.5MG/0.7ML (17.5MG/0.7ML)	N204824	011	May 31, 2017	Jul NEWA
+	@	20MG/0.8ML (20MG/0.8ML)	N204824	012	May 31, 2017	Nov DISC
+		20MG/0.8ML (20MG/0.8ML)	N204824	012	May 31, 2017	Jul NEWA
+	@	22.5MG/0.9ML (22.5MG/0.9ML)	N204824	013	May 31, 2017	Nov DISC
+		22.5MG/0.9ML (22.5MG/0.9ML)	N204824	013	May 31, 2017	Jul NEWA
+	@	25MG/ML (25MG/ML)	N204824	014	May 31, 2017	Nov DISC
+		25MG/ML (25MG/ML)	N204824	014	May 31, 2017	Jul NEWA

RASUVO

>D>	MEDAC PHARMA INC	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014	Dec CRLD
>A>	+	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014	Dec CRLD
>D>		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014	Dec CRLD
>A>	+	10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014	Dec CRLD
>D>		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014	Dec CRLD
>A>	+	12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014	Dec CRLD
>D>		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014	Dec CRLD
>A>	+	15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014	Dec CRLD
>D>		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014	Dec CRLD
>A>	+	17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014	Dec CRLD
>D>		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014	Dec CRLD
>A>	+	20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014	Dec CRLD
>D>		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014	Dec CRLD
>A>	+	22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014	Dec CRLD
>D>		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014	Dec CRLD
>A>	+	25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014	Dec CRLD
>D>	@	27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014	Dec CRLD
>A>	+ @	27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014	Dec CRLD
	@	27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014	Jun DISC
>D>		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014	Dec CRLD
>A>	+	30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014	Dec CRLD

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	PHARMACHEMIE BV	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A 040843	002	Jan 11, 2010	Apr CMS1
AP		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A 040843	003	Feb 27, 2012	Apr CMS1
AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A 040843	004	Jan 11, 2010	Apr CMS1

SOLUTION;ORAL

XATMEP

+!	SILVERGATE PHARMS	EQ 2.5MG BASE/ML	N 208400	001	Apr 25, 2017	Apr NEWA
----	-------------------	------------------	----------	-----	--------------	----------

TABLET;ORAL

METHOTREXATE SODIUM

>A>	AB	AMNEAL PHARMS	EQ 2.5MG BASE	A 210040	001	Dec 22, 2017	Dec NEWA
	AB	ORION CORP ORION	EQ 2.5MG BASE	A 201749	001	May 21, 2015	Jul CAHN
	AB	SUN PHARMA GLOBAL	EQ 2.5MG BASE	A 201749	001	May 21, 2015	Oct CAHN
	AB	ZYDUS PHARMS USA INC	EQ 2.5MG BASE	A 207812	001	Jan 13, 2017	Jan NEWA

METHOXSALEN

CAPSULE;ORAL

8-MOP

+	@	VALEANT PHARM INTL	10MG	N 009048	001		Oct DISC
---	---	--------------------	------	----------	-----	--	----------

LOTION;TOPICAL

OXSORALEN

+	@	VALEANT PHARM INTL	1%	N 009048	002		Oct DISC
---	---	--------------------	----	----------	-----	--	----------

METHYCLOTHIAZIDE

TABLET;ORAL

METHYCLOTHIAZIDE

>A>	@	FOSUN PHARMA	2.5MG	A 089835	001	Aug 18, 1988	Dec CAHN
>A>	@		5MG	A 089837	001	Aug 18, 1988	Dec CAHN
>D>	@	SANDOZ	2.5MG	A 089835	001	Aug 18, 1988	Dec CAHN
>D>	@		5MG	A 089837	001	Aug 18, 1988	Dec CAHN

METHYLDOPA

TABLET;ORAL

METHYLDOPA

>A>	@	FOSUN PHARMA	250MG	N 018934	001	Jun 29, 1984	Dec CAHN
>A>	@		500MG	N 018934	002	Jun 29, 1984	Dec CAHN
>D>	@	SANDOZ	250MG	N 018934	001	Jun 29, 1984	Dec CAHN
>D>	@		500MG	N 018934	002	Jun 29, 1984	Dec CAHN

METHYLDOPATE HYDROCHLORIDE

INJECTABLE;INJECTION

METHYLDOPATE HYDROCHLORIDE

!	LUITPOLD	50MG/ML	A 071279	001	Oct 02, 1987	Jan CTEC
---	----------	---------	----------	-----	--------------	----------

METHYLERGONOVINE MALEATE

INJECTABLE;INJECTION

METHYLERGONOVINE MALEATE

AP	BRECKENRIDGE PHARM	0.2MG/ML	A 040889	001	Sep 13, 2010	Sep CAHN
----	--------------------	----------	----------	-----	--------------	----------

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

COTEMPLA XR-ODT

+	NEOS THERAPS INC	8.6MG	N 205489	001	Jun 19, 2017	Jun NEWA
+		17.3MG	N 205489	002	Jun 19, 2017	Jun NEWA
+		25.9MG	N 205489	003	Jun 19, 2017	Jun NEWA

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB2	IMPAX LABS INC	10MG	A 205105	001	Jul 28, 2016	Feb CAHN	
AB2		20MG	A 205105	002	Jul 28, 2016	Feb CAHN	
AB2		30MG	A 205105	003	Jul 28, 2016	Feb CAHN	
AB2		40MG	A 205105	004	Jul 28, 2016	Feb CAHN	
AB2		50MG	A 205105	005	Jul 28, 2016	Feb CAHN	
AB2		60MG	A 205105	006	Jul 28, 2016	Feb CAHN	
>D>	AB2	MALLINCKRODT INC	10MG	A 203583	001	Sep 29, 2015	Dec CAHN
>D>	AB2		20MG	A 203583	002	Sep 29, 2015	Dec CAHN
>D>	AB2		30MG	A 203583	003	Sep 29, 2015	Dec CAHN

CAPSULE, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

>D>	AB2		40MG	A203583	004	Sep 29, 2015	Dec CAHN
>D>	AB2		50MG	A203583	005	Sep 29, 2015	Dec CAHN
>D>	AB2		60MG	A203583	006	Sep 29, 2015	Dec CAHN
	!	MAYNE PHARMA	60MG	A078458	004	Jun 23, 2016	Feb CHRS
>A>	AB2	SPECGX LLC	10MG	A203583	001	Sep 29, 2015	Dec CAHN
>A>	AB2		20MG	A203583	002	Sep 29, 2015	Dec CAHN
>A>	AB2		30MG	A203583	003	Sep 29, 2015	Dec CAHN
>A>	AB2		40MG	A203583	004	Sep 29, 2015	Dec CAHN
>A>	AB2		50MG	A203583	005	Sep 29, 2015	Dec CAHN
>A>	AB2		60MG	A203583	006	Sep 29, 2015	Dec CAHN

SOLUTION;ORAL
METHYLIN

>D>	AA	+!	MALLINCKRODT	5MG/5ML	N021419	001	Dec 19, 2002	Dec CAHN
>D>	AA	+!		10MG/5ML	N021419	002	Dec 19, 2002	Dec CAHN
>A>	AA	+!	SPECGX LLC	5MG/5ML	N021419	001	Dec 19, 2002	Dec CAHN
>A>	AA	+!		10MG/5ML	N021419	002	Dec 19, 2002	Dec CAHN
			METHYLPHENIDATE HYDROCHLORIDE					
	AA		BRECKENRIDGE PHARM	5MG/5ML	A201466	001	Nov 12, 2013	Sep CAHN
	AA			10MG/5ML	A201466	002	Nov 12, 2013	Sep CAHN

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

	AB		ABHAI INC	5MG	A206932	001	May 11, 2017	Apr NEWA
	AB			10MG	A206932	002	May 11, 2017	Apr NEWA
	AB			20MG	A206932	003	May 11, 2017	Apr NEWA
	AB		BRECKENRIDGE PHARM	5MG	A207587	001	Mar 03, 2017	Sep CAHN
	AB			10MG	A207587	002	Mar 03, 2017	Sep CAHN
	AB			20MG	A207587	003	Mar 03, 2017	Sep CAHN
>A>	AB		COREPHARMA	5MG	A091159	001	Mar 12, 2014	Dec CAHN
>A>	AB			10MG	A091159	002	Mar 12, 2014	Dec CAHN
>A>	AB			20MG	A091159	003	Mar 12, 2014	Dec CAHN
>D>	AB		IMPAX LABS INC	5MG	A091159	001	Mar 12, 2014	Dec CAHN
	AB			5MG	A091159	001	Mar 12, 2014	Feb CAHN
>D>	AB			10MG	A091159	002	Mar 12, 2014	Dec CAHN
	AB			10MG	A091159	002	Mar 12, 2014	Feb CAHN
>D>	AB			20MG	A091159	003	Mar 12, 2014	Dec CAHN
	AB			20MG	A091159	003	Mar 12, 2014	Feb CAHN
>D>	AB		MALLINCKRODT	5MG	A040300	001	Nov 27, 1998	Dec CAHN
>D>	AB			10MG	A040300	002	Nov 27, 1998	Dec CAHN
>D>	AB			20MG	A040300	003	Nov 27, 1998	Dec CAHN
	AB		NOSTRUM LABS INC	5MG	A207587	001	Mar 03, 2017	Feb NEWA
	AB			10MG	A207587	002	Mar 03, 2017	Feb NEWA
	AB			20MG	A207587	003	Mar 03, 2017	Feb NEWA
>A>	AB		SPECGX LLC	5MG	A040300	001	Nov 27, 1998	Dec CAHN
>A>	AB			10MG	A040300	002	Nov 27, 1998	Dec CAHN
>A>	AB			20MG	A040300	003	Nov 27, 1998	Dec CAHN

TABLET, CHEWABLE;ORAL
METHYLIN

>D>		+ @	MALLINCKRODT	2.5MG	N021475	001	Apr 15, 2003	Dec CAHN
>D>		+ @		5MG	N021475	002	Apr 15, 2003	Dec CAHN
>D>		+ @		10MG	N021475	003	Apr 15, 2003	Dec CAHN
>A>		+ @	SPECGX LLC	2.5MG	N021475	001	Apr 15, 2003	Dec CAHN
>A>		+ @		5MG	N021475	002	Apr 15, 2003	Dec CAHN
>A>		+ @		10MG	N021475	003	Apr 15, 2003	Dec CAHN

METHYLPHENIDATE HYDROCHLORIDE

>A>	AB		ASCENT PHARMS INC	2.5MG	A210354	001	Dec 29, 2017	Dec NEWA
>A>	AB			5MG	A210354	002	Dec 29, 2017	Dec NEWA
>A>	AB			10MG	A210354	003	Dec 29, 2017	Dec NEWA
	AB		BRECKENRIDGE PHARM	2.5MG	A204954	001	Jan 26, 2017	Sep CAHN
	AB			5MG	A204954	002	Jan 26, 2017	Sep CAHN
	AB			10MG	A204954	003	Jan 26, 2017	Sep CAHN
	AB		NOSTRUM LABS INC	2.5MG	A204954	001	Jan 26, 2017	Jan NEWA
	AB			5MG	A204954	002	Jan 26, 2017	Jan NEWA
	AB			10MG	A204954	003	Jan 26, 2017	Jan NEWA

TABLET, EXTENDED RELEASE;ORAL
METHYLIN ER

>D>	AB		MALLINCKRODT INC	10MG	A075629	001	May 09, 2000	Dec CAHN
>D>	AB			20MG	A075629	002	May 09, 2000	Dec CAHN
>A>	AB		SPECGX LLC	10MG	A075629	001	May 09, 2000	Dec CAHN
>A>	AB			20MG	A075629	002	May 09, 2000	Dec CAHN

TABLET, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

>A>	AB	COREPHARMA	18MG	A208607	001	Jul 14, 2017	Dec CAHN
>A>	AB		27MG	A208607	002	Jul 14, 2017	Dec CAHN
>A>	AB		36MG	A208607	003	Jul 14, 2017	Dec CAHN
>A>	AB		54MG	A208607	004	Jul 14, 2017	Dec CAHN
>D>	AB	IMPAX LABS INC	18MG	A208607	001	Jul 14, 2017	Dec CAHN
	AB		18MG	A208607	001	Jul 14, 2017	Jul NEWA
>D>	AB		27MG	A208607	002	Jul 14, 2017	Dec CAHN
	AB		27MG	A208607	002	Jul 14, 2017	Jul NEWA
>D>	AB		36MG	A208607	003	Jul 14, 2017	Dec CAHN
	AB		36MG	A208607	003	Jul 14, 2017	Jul NEWA
>D>	AB		54MG	A208607	004	Jul 14, 2017	Dec CAHN
	AB		54MG	A208607	004	Jul 14, 2017	Jul NEWA
>D>	BX	MALLINCKRODT INC	27MG	A202608	001	Dec 28, 2012	Dec CAHN
>D>	BX		36MG	A202608	002	Dec 28, 2012	Dec CAHN
>D>	BX		54MG	A202608	003	Dec 28, 2012	Dec CAHN
	AB	OSMOTICA	18MG	A205327	001	Jul 28, 2017	Jul NEWA
	AB		27MG	A205327	002	Jul 28, 2017	Jul NEWA
	AB		36MG	A205327	003	Jul 28, 2017	Jul NEWA
	AB		54MG	A205327	004	Jul 28, 2017	Jul NEWA
			72MG	A205327	005	Jul 28, 2017	Jul NEWA
>A>	BX	SPECGX LLC	27MG	A202608	001	Dec 28, 2012	Dec CAHN
>A>	BX		36MG	A202608	002	Dec 28, 2012	Dec CAHN
>A>	BX		54MG	A202608	003	Dec 28, 2012	Dec CAHN
		RITALIN-SR					
	AB	+ NOVARTIS	20MG	N018029	001	Mar 30, 1982	Feb CRLD

METHYLPREDNISOLONE

TABLET;ORAL
MEDROL

	+	PHARMACIA AND UPJOHN	2MG	N011153	002		Nov CTEC
--	---	----------------------	-----	---------	-----	--	----------

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION
METHYLPREDNISOLONE ACETATE

AB		SANDOZ INC	40MG/ML	A040719	001	Jan 29, 2009	Mar CAHN
AB			40MG/ML	A040794	001	Mar 05, 2009	Jul CAHN
AB			80MG/ML	A040719	002	Jan 29, 2009	Mar CAHN
AB			80MG/ML	A040794	002	Mar 05, 2009	Jul CAHN

METHYLTESTOSTERONE

TABLET;ORAL
ANDROID 10

	@	VALEANT PHARMS NORTH	10MG	A086450	001		May CAHN
--	---	----------------------	------	---------	-----	--	----------

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
METIPRANOLOL

AT		SANDOZ INC	0.3%	A075720	001	Aug 06, 2001	Feb CAHN
----	--	------------	------	---------	-----	--------------	----------

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION;ORAL
METOCLOPRAMIDE HYDROCHLORIDE

AA		PHARM ASSOC	EQ 5MG BASE/5ML	A072744	001	May 28, 1991	May CAHN
>D>	AA	! WOCKHARDT	EQ 5MG BASE/5ML	A074703	001	Oct 31, 1997	Dec CAHN
>A>	AA	! WOCKHARDT BIO AG	EQ 5MG BASE/5ML	A074703	001	Oct 31, 1997	Dec CAHN

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

>A>		@ FOSUN PHARMA	EQ 5MG BASE	A074478	001	Oct 05, 1995	Dec CAHN
>A>		@	EQ 10MG BASE	A072215	001	Jan 30, 1990	Dec CAHN
>A>		@	EQ 10MG BASE	A074478	002	Oct 05, 1995	Dec CAHN
>D>		@ SANDOZ	EQ 5MG BASE	A074478	001	Oct 05, 1995	Dec CAHN
>D>		@	EQ 10MG BASE	A072215	001	Jan 30, 1990	Dec CAHN
>D>		@	EQ 10MG BASE	A074478	002	Oct 05, 1995	Dec CAHN
		@ SUN PHARM INDUSTRIES	EQ 5MG BASE	A071536	002	Jan 16, 1997	May DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
TOPROL-XL

AB	+	ARALEZ PHARMS	EQ 25MG TARTRATE	N019962	004	Feb 05, 2001	Jan CAHN
AB	+	!	EQ 50MG TARTRATE	N019962	001	Jan 10, 1992	Jan CAHN
AB	+		EQ 100MG TARTRATE	N019962	002	Jan 10, 1992	Jan CAHN
AB	+	!	EQ 200MG TARTRATE	N019962	003	Jan 10, 1992	Jan CAHN

METOPROLOL TARTRATE

INJECTABLE;INJECTION
METOPROLOL TARTRATE

AP		BAXTER HLTHCARE CORP	1MG/ML	A078950	001	Apr 29, 2013	Aug CAHN
AP		SANDOZ INC	1MG/ML	A077360	001	Oct 02, 2007	Mar CAHN
AP		WEST-WARD PHARMS INT	1MG/ML	A076495	001	Jul 07, 2003	Jan CAHN

TABLET;ORAL
LOPRESSOR

AB	+	US PHARMS HOLDINGS I	50MG	N017963	001		Sep CRLD
AB	+		100MG	N017963	002		Sep CRLD

METOPROLOL TARTRATE

>A>		@ FOSUN PHARMA	50MG	A073288	001	Mar 25, 1994	Dec CAHN
>A>		@	100MG	A073289	001	Mar 25, 1994	Dec CAHN
>D>		@ SANDOZ	50MG	A073288	001	Mar 25, 1994	Dec CAHN
>D>		@	100MG	A073289	001	Mar 25, 1994	Dec CAHN
AB		SUN PHARM INDUSTRIES	50MG	A073654	003	Dec 21, 1993	Jul CMS1

METRONIDAZOLE

CAPSULE;ORAL

METRONIDAZOLE

AB		ALEMBIC PHARMS LTD	375MG	A079065	001	Jun 23, 2009	May CAHN
----	--	--------------------	-------	---------	-----	--------------	----------

GEL;TOPICAL

METRONIDAZOLE

AB		TARO PHARM	1%	A204651	001	Mar 14, 2017	Feb NEWA
----	--	------------	----	---------	-----	--------------	----------

GEL;VAGINAL

NUVESSA

+	!	CHEMO RESEARCH SL	1.3%	N205223	001	Mar 24, 2014	Aug CAHN
---	---	-------------------	------	---------	-----	--------------	----------

INJECTABLE;INJECTION

METRONIDAZOLE

		@ WEST-WARD PHARMS INT	500MG/100ML	N018907	001	Mar 30, 1984	May CAHN
		METRONIDAZOLE IN PLASTIC CONTAINER					
AP		BAXTER HLTHCARE CORP	500MG/100ML	A078084	001	Mar 31, 2008	Aug CAHN
AP		MYLAN LABS LTD	500MG/100ML	A205531	001	May 09, 2017	Apr NEWA

TABLET;ORAL

METRONIDAZOLE

AB		CADILA PHARMS LTD	250MG	A209794	001	Dec 12, 2017	Nov NEWA
AB			500MG	A209794	002	Dec 12, 2017	Nov NEWA
		@ CHARTWELL MOLECULES	250MG	N018845	001	Aug 18, 1983	Jun CAHN
		@	500MG	N018930	001	Aug 18, 1983	Jun CAHN
AB		INNOGENIX	250MG	A070772	001	Jul 16, 1986	Sep CAHN
>A>	AB		500MG	A070772	002	Jul 16, 1986	Dec CMS1
AB		LUPIN LTD	250MG	A209096	001	Sep 12, 2017	Sep NEWA
AB			500MG	A209096	002	Sep 12, 2017	Sep NEWA
AB		ORIT LABS LLC	250MG	A208681	001	Jun 20, 2017	Jun NEWA
AB			500MG	A208681	002	Jun 20, 2017	Jun NEWA
AB		VIVIMED GLOBAL	250MG	A070040	001	Jan 29, 1985	Aug CAHN
AB			500MG	A070039	001	Jan 29, 1985	Aug CAHN

TABLET, EXTENDED RELEASE;ORAL

METRONIDAZOLE

AB		ALEMBIC PHARMS LTD	750MG	A090222	001	May 05, 2010	May CAHN
----	--	--------------------	-------	---------	-----	--------------	----------

MICONAZOLE NITRATE

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

AB		ACTAVIS PHARMA	200MG	A073508	001	Nov 19, 1993	May CAHN
----	--	----------------	-------	---------	-----	--------------	----------

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT;TOPICAL

VUSION

+	!	MYLAN PHARMS INC	0.25%;81.35%;15%	N021026	001	Feb 16, 2006	Jan CAHN
---	---	------------------	------------------	---------	-----	--------------	----------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

	@ BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Aug CAHN
	@	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Aug CAHN
	FRESENIUS KABI USA	EQ 5MG BASE/ML	A208878	001	Mar 28, 2017	Mar NEWA
AP	WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A075243	001	Jun 20, 2000	Jan CAHN
AP		EQ 1MG BASE/ML	A075247	002	Jun 23, 2000	Jan CAHN
AP		EQ 1MG BASE/ML	A075324	001	Jun 20, 2000	Mar CAHN
AP		EQ 1MG BASE/ML	A075421	002	Jun 20, 2000	Jan CAHN
AP		EQ 5MG BASE/ML	A075243	002	Jun 20, 2000	Jan CAHN
AP		EQ 5MG BASE/ML	A075247	001	Jun 23, 2000	Jan CAHN
AP		EQ 5MG BASE/ML	A075324	002	Jun 20, 2000	Mar CAHN
AP		EQ 5MG BASE/ML	A075421	001	Jun 20, 2000	Jan CAHN
	MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE					
AP	SAGENT AGILA LLC	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	May CAHN
AP		EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	May CAHN

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

	@ SUN PHARM INDS LTD	EQ 2MG BASE/ML	A076058	001	Mar 15, 2002	May DISC
--	----------------------	----------------	---------	-----	--------------	----------

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

BX	APOTEX INC	2.5MG	A077746	001	Sep 12, 2006	Sep CTEC
BX		5MG	A077746	002	Sep 12, 2006	Sep CTEC
BX		10MG	A077746	003	Sep 12, 2006	Sep CTEC
	ORVATEN					
AB	UPSHER-SMITH LABS	2.5MG	A076725	001	Nov 03, 2004	Jun CAHN
AB		5MG	A076725	002	Nov 03, 2004	Jun CAHN
AB		10MG	A076725	003	Nov 03, 2004	Jun CAHN
	PROAMATINE					
+	@ SHIRE LLC	2.5MG	N019815	001	Sep 06, 1996	Feb CRLD
+	@	5MG	N019815	002	Sep 06, 1996	Feb CRLD
+	@	10MG	N019815	003	Mar 20, 2002	Feb CRLD

MIDOSTAURIN

CAPSULE; ORAL

RYDAPT

+	NOVARTIS PHARMS CORP	25MG	N207997	001	Apr 28, 2017	Apr NEWA
---	----------------------	------	---------	-----	--------------	----------

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

MILNACIPRAN HYDROCHLORIDE

	@ WINDLAS HLTHCARE	12.5MG	A205071	001	Jan 27, 2016	Sep CAHN
	@	25MG	A205071	002	Jan 27, 2016	Sep CAHN
	@	50MG	A205071	003	Jan 27, 2016	Sep CAHN
	@	100MG	A205071	004	Jan 27, 2016	Sep CAHN
	SAVELLA					
AB	+ ALLERGAN SALES LLC	12.5MG	N022256	001	Jan 14, 2009	Feb CAHN
AB	+	25MG	N022256	002	Jan 14, 2009	Feb CAHN
AB	+	50MG	N022256	003	Jan 14, 2009	Feb CAHN
AB	+	100MG	N022256	004	Jan 14, 2009	Feb CAHN

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

	@ BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A076427	001	Sep 21, 2004	Aug CAHN
AP	WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Jan CAHN
AP		EQ 1MG BASE/ML	A075660	001	May 28, 2002	Jan CAHN
	@	EQ 1MG BASE/ML	A075852	001	May 28, 2002	Mar CAHN
	MILRINONE LACTATE IN DEXTROSE 5%					
AP	RENAISSANCE SSA LLC	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005	Aug CAHN
	MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
	@ RENAISSANCE SSA LLC	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Aug CAHN
	@ WEST-WARD PHARMS INT	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510	001	May 28, 2002	Mar CAHN
AP		EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008	Jan CAHN
AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008	Jan CAHN

INJECTABLE;INJECTION

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER
BASE/ML)

PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

+ @	SANOFI AVENTIS US	EQ 10MG BASE/100ML	N020343	001	Aug 09, 1994	Jan CRLD
+ @		EQ 15MG BASE/100ML	N020343	002	Aug 09, 1994	Jan CRLD
+ @		EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	N020343	003	Aug 09, 1994	Jan CRLD
+ @		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	N020343	004	Aug 09, 1994	Jan CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL

DYNACIN

AB	CNTY LINE PHARMS	EQ 50MG BASE	A063067	003	Aug 14, 1990	Sep CMFD
	MINOCIN					
AB	+ PRECISION DERMAT	EQ 50MG BASE	N050649	001	May 31, 1990	Nov CRLD
AB	+	EQ 100MG BASE	N050649	002	May 31, 1990	Nov CRLD
	MINOCYCLINE HYDROCHLORIDE					
AB	WATSON LABS TEVA	EQ 50MG BASE	A063181	001	Dec 30, 1991	May CAHN
	CAPSULE, EXTENDED RELEASE;ORAL					
	XIMINO					
	SUN PHARM INDS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	Apr CMFD
		EQ 90MG BASE	N201922	003	Jul 11, 2012	Apr CMFD
		EQ 135MG BASE	N201922	005	Jul 11, 2012	Apr CMFD

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

	@ BARR LABS INC	EQ 80MG BASE	A065485	007	Apr 26, 2017	Apr DISC
		EQ 80MG BASE	A065485	007	Apr 26, 2017	Apr NEWA
	@	EQ 105MG BASE	A065485	008	Apr 26, 2017	Apr DISC
		EQ 105MG BASE	A065485	008	Apr 26, 2017	Apr NEWA
	@ MYLAN PHARMS INC	EQ 45MG BASE	A090911	001	Jul 20, 2010	May DISC
	@	EQ 80MG BASE	A203443	002	Aug 22, 2014	May DISC
	@	EQ 90MG BASE	A090911	002	Jul 20, 2010	May DISC
	@	EQ 105MG BASE	A203443	003	Aug 22, 2014	May DISC
	@	EQ 135MG BASE	A090911	003	Jul 20, 2010	May DISC
AB	ZYDUS PHARMS USA INC	EQ 45MG BASE	A203553	001	Nov 16, 2017	Oct NEWA
AB		EQ 80MG BASE	A203553	004	Nov 16, 2017	Oct NEWA
AB		EQ 90MG BASE	A203553	005	Nov 16, 2017	Oct NEWA
AB		EQ 105MG BASE	A203553	006	Nov 16, 2017	Oct NEWA
AB		EQ 135MG BASE	A203553	008	Nov 16, 2017	Oct NEWA
	MINOLIRA					
	DR REDDYS LABS LTD	EQ 105MG BASE	N209269	001	May 08, 2017	May NEWA
		EQ 135MG BASE	N209269	002	May 08, 2017	May NEWA

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MYRBETRIQ

+!	APGDI	25MG	N202611	001	Jun 28, 2012	Feb CHRS
----	-------	------	---------	-----	--------------	----------

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

	@ MYLAN PHARMS INC	15MG	A076176	001	Jun 19, 2003	Nov DISC
	@	30MG	A076176	002	Jun 19, 2003	Nov DISC
	@	45MG	A076176	003	Jun 19, 2003	Nov DISC
	@ UPSHER-SMITH LABS	15MG	A076189	001	Jun 19, 2003	Jun CAHN
AB		15MG	A076219	001	Jun 19, 2003	Jun CAHN
	@	30MG	A076189	002	Jun 19, 2003	Jun CAHN
AB		30MG	A076219	002	Jun 19, 2003	Jun CAHN
	@	45MG	A076189	003	Jun 19, 2003	Jun CAHN
AB		45MG	A076219	003	Jun 19, 2003	Jun CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

MIRTAZAPINE

AB	AUROBINDO PHARMA LTD	15MG	A077376	002	Dec 08, 2005	Jan CAHN
AB		30MG	A077376	003	Dec 08, 2005	Jan CAHN
AB		45MG	A077376	004	Feb 28, 2006	Jan CAHN
AB	ZYDUS PHARMS USA INC	15MG	A205798	001	Jun 01, 2017	May NEWA
AB		30MG	A205798	002	Jun 01, 2017	May NEWA
AB		45MG	A205798	003	Jun 01, 2017	May NEWA

MITOMYCININJECTABLE; INJECTION
MITOMYCIN

AP	MYLAN LABS LTD	5MG/VIAL	A202670	001	Oct 13, 2017	Oct NEWA
AP		20MG/VIAL	A202670	002	Oct 13, 2017	Oct NEWA
AP		40MG/VIAL	A203386	001	Oct 13, 2017	Oct NEWA
AP	WEST-WARD PHARMS INT	5MG/VIAL	A064117	001	Apr 19, 1995	Jan CAHN
AP		5MG/VIAL	A064180	001	Dec 23, 1999	Jan CAHN
AP		20MG/VIAL	A064117	002	Apr 19, 1995	Jan CAHN
AP		20MG/VIAL	A064180	002	Dec 23, 1999	Jan CAHN
	MUTAMYCIN					
	+ @ BRISTOL	5MG/VIAL	N050450	001		Jan CRLD
	+ @	20MG/VIAL	N050450	002		Jan CRLD

MODAFINILTABLET; ORAL
MODAFINIL

AB	ALEMBIC PHARMS LTD	100MG	A202700	001	Oct 18, 2012	May CAHN
AB		200MG	A202700	002	Oct 18, 2012	May CAHN
AB	APPCO PHARMA LLC	100MG	A207196	001	Aug 16, 2017	Aug NEWA
AB		200MG	A207196	002	Aug 16, 2017	Aug NEWA
AB	ZYDUS PHARMS USA INC	100MG	A209966	001	Sep 14, 2017	Sep NEWA
AB		200MG	A209966	002	Sep 14, 2017	Sep NEWA

MOEXIPRIL HYDROCHLORIDETABLET; ORAL
MOEXIPRIL HYDROCHLORIDE

AB	CHARTWELL RX	7.5MG	A077536	001	Nov 30, 2006	Apr CAHN
AB		15MG	A077536	002	Nov 30, 2006	Apr CAHN

MOLINDONE HYDROCHLORIDETABLET; ORAL
MOLINDONE HYDROCHLORIDE

	EPIC PHARMA LLC	5MG	A090453	001	Mar 20, 2015	May CAHN
		10MG	A090453	002	Mar 20, 2015	May CAHN
	!	25MG	A090453	003	Mar 20, 2015	May CAHN

MOMETASONE FUROATEIMPLANT; IMPLANTATION
SINUVA

>A>						
>A>	+ INTERSECT ENT INC	1.35MG	N209310	001	Dec 08, 2017	Dec NEWA
	LOTION; TOPICAL					
	MOMETASONE FUROATE					
AB	PERRIGO ISRAEL	0.1%	A077180	001	Apr 06, 2005	Apr CAHN
	SPRAY, METERED; NASAL					
	MOMETASONE FUROATE					
AB	AMNEAL PHARMS	EQ 0.05MG BASE/SPRAY	A207989	001	Apr 03, 2017	Mar NEWA

MONTELUKAST SODIUMTABLET; ORAL
MONTELUKAST SODIUM

AB	CSPC OUYI PHARM CO	EQ 10MG BASE	A209012	001	Apr 24, 2017	Apr NEWA
AB	PERRIGO R AND D	EQ 10MG BASE	A206112	001	Apr 26, 2017	Apr NEWA
	SINGULAIR					
AB	+! MSD MERCK CO	EQ 10MG BASE	N020829	002	Feb 20, 1998	Oct CAHN
	TABLET, CHEWABLE; ORAL					
	MONTELUKAST SODIUM					
AB	CSPC OUYI PHARM CO	EQ 4MG BASE	A209011	001	Apr 18, 2017	Apr NEWA
AB		EQ 5MG BASE	A209011	002	Apr 18, 2017	Apr NEWA
	SINGULAIR					
AB	+ MSD MERCK CO	EQ 4MG BASE	N020830	002	Mar 03, 2000	Oct CAHN
AB	+!	EQ 5MG BASE	N020830	001	Feb 20, 1998	Oct CAHN

MORPHINE SULFATECAPSULE, EXTENDED RELEASE; ORAL
MORPHINE SULFATE

	ACTAVIS ELIZABETH	30MG	A079040	001	Jan 16, 2013	Apr CAHN
		45MG	A079040	002	Jan 16, 2013	Apr CAHN
		60MG	A079040	003	Jan 16, 2013	Apr CAHN
		75MG	A079040	004	Jan 16, 2013	Apr CAHN
		90MG	A079040	005	Jan 16, 2013	Apr CAHN

CAPSULE, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

!		120MG	A079040	006	Jan 16, 2013	Apr CAHN
AB	UPSHER-SMITH LABS	10MG	A202104	001	Jun 03, 2013	Jun CAHN
AB		20MG	A202104	002	Jun 03, 2013	Jun CAHN
AB		30MG	A202104	003	Jun 03, 2013	Jun CAHN
AB		50MG	A202104	004	Jun 03, 2013	Jun CAHN
AB		60MG	A202104	005	Jun 03, 2013	Jun CAHN
AB		80MG	A202104	006	Jun 03, 2013	Jun CAHN
AB		100MG	A202104	007	Jun 03, 2013	Jun CAHN

INJECTABLE;INJECTION
MORPHINE SULFATE

	+ @ HOSPIRA INC	15MG/ML	N202515	005	Nov 14, 2011	Aug DISC
	@ ICU MEDICAL INC	0.5MG/ML	N019917	001	Oct 30, 1992	Jun CAHN
AP	+	1MG/ML	N019916	001	Oct 30, 1992	Apr CAHN
	+	5MG/ML	N019916	002	Oct 27, 2006	Apr CAHN
>D>	@ MALLINCKRODT INC	1MG/ML	N020631	001	Jul 03, 1996	Dec CAHN
	@	1MG/ML	N020631	001	Jul 03, 1996	Apr CAHN
>D>	@	2MG/ML	N020631	002	Jul 03, 1996	Dec CAHN
	@	2MG/ML	N020631	002	Jul 03, 1996	Apr CAHN
>A>	@ SPECGX LLC	1MG/ML	N020631	001	Jul 03, 1996	Dec CAHN
>A>	@	2MG/ML	N020631	002	Jul 03, 1996	Dec CAHN

SOLUTION;ORAL

MORPHINE SULFATE

AA	HI-TECH PHARMACAL	100MG/5ML	A208809	001	Jul 06, 2017	Jun NEWA
>D> AA	MALLINCKRODT INC	100MG/5ML	A202348	001	Jul 15, 2011	Dec CAHN
AA	RHODES PHARMS	10MG/5ML	A206308	001	Jun 22, 2017	Jun NEWA
AA		100MG/5ML	A206308	002	Jun 22, 2017	Jun NEWA
>A> AA	SPECGX LLC	100MG/5ML	A202348	001	Jul 15, 2011	Dec CAHN
AA	+ WEST-WARD PHARMS INT	10MG/5ML	N022195	001	Mar 17, 2008	Jan CAHN
AA	+	20MG/5ML	N022195	002	Mar 17, 2008	Jan CAHN
AA	+	100MG/5ML	N022195	003	Jan 25, 2010	Jan CAHN

TABLET;ORAL

MORPHINE SULFATE

+	WEST-WARD PHARMS INT	15MG	N022207	001	Mar 17, 2008	Jan CAHN
+	!	30MG	N022207	002	Mar 17, 2008	Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

ARYMO ER

+	EGALET	15MG	N208603	001	Jan 09, 2017	Jan NEWA
+		30MG	N208603	002	Jan 09, 2017	Jan NEWA
+		60MG	N208603	003	Jan 09, 2017	Jan NEWA

MORPHABOND ER

+	DAIICHI SANKYO INC	15MG	N206544	001	Oct 02, 2015	Jan CTNA
+		30MG	N206544	002	Oct 02, 2015	Jan CTNA
+		60MG	N206544	003	Oct 02, 2015	Jan CTNA
+	!	100MG	N206544	004	Oct 02, 2015	Jan CTNA

MORPHINE SULFATE

AB	ACTAVIS ELIZABETH	15MG	A203849	001	Apr 06, 2015	Apr CAHN
AB		30MG	A203849	002	Apr 06, 2015	Apr CAHN
AB		60MG	A203849	003	Apr 06, 2015	Apr CAHN
AB		100MG	A203849	004	Apr 06, 2015	Apr CAHN
AB		200MG	A203849	005	Apr 06, 2015	Apr CAHN
AB	EPIC PHARMA LLC	15MG	A091357	001	Jun 23, 2016	May CAHN
AB		30MG	A091357	002	Jun 23, 2016	May CAHN
AB		60MG	A091357	003	Jun 23, 2016	May CAHN
AB		100MG	A091357	004	Jun 23, 2016	May CAHN
AB		200MG	A091357	005	Jun 23, 2016	May CAHN
>D> AB	MALLINCKRODT	15MG	A076412	001	Jul 31, 2003	Dec CAHN
>D> AB		30MG	A076412	002	Jul 31, 2003	Dec CAHN
>D> AB		60MG	A076412	003	Jul 31, 2003	Dec CAHN
>D> AB		100MG	A076438	001	Jul 03, 2003	Dec CAHN
>D> AB		200MG	A076438	002	Jul 03, 2003	Dec CAHN
>A> AB	SPECGX LLC	15MG	A076412	001	Jul 31, 2003	Dec CAHN
>A> AB		30MG	A076412	002	Jul 31, 2003	Dec CAHN
>A> AB		60MG	A076412	003	Jul 31, 2003	Dec CAHN
>A> AB		100MG	A076438	001	Jul 03, 2003	Dec CAHN
>A> AB		200MG	A076438	002	Jul 03, 2003	Dec CAHN
AB	SUN PHARM INDUSTRIES	15MG	A205634	001	Aug 25, 2016	Mar CAHN
AB		30MG	A205634	002	Aug 25, 2016	Mar CAHN
AB		60MG	A205634	003	Aug 25, 2016	Mar CAHN
AB		100MG	A205634	004	Aug 25, 2016	Mar CAHN
AB		200MG	A205634	005	Aug 25, 2016	Mar CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;IV (INFUSION)

>D> AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

>D>	AP	+	!	BAYER HLTHCARE	400MG/250ML (1.6MG/ML)	N021277	001	Nov 30, 2001	Dec	DISC
>A>		+	@		400MG/250ML (1.6MG/ML)	N021277	001	Nov 30, 2001	Dec	DISC
	AP	+	!		400MG/250ML (1.6MG/ML)	N021277	001	Nov 30, 2001	Apr	CFTG

MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

>D>	AP			MYLAN LABS LTD	400MG/250ML (1.6MG/ML)	A205833	001	May 05, 2017	Dec	CHRS
>A>			!		400MG/250ML (1.6MG/ML)	A205833	001	May 05, 2017	Dec	CHRS
	AP				400MG/250ML (1.6MG/ML)	A205833	001	May 05, 2017	Apr	NEWA

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

AT1				AKORN	EQ 0.5% BASE	A202916	001	Nov 09, 2017	Oct	NEWA
AT1				APOTEX INC	EQ 0.5% BASE	A090080	001	Jun 30, 2017	Jun	NEWA
AT1				AUROBINDO PHARMA LTD	EQ 0.5% BASE	A206242	001	Oct 04, 2017	Sep	NEWA

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB				MSN LABS PVT LTD	EQ 400MG BASE	A208682	001	Sep 22, 2017	Sep	NEWA
AB				NOVEL LABS INC	EQ 400MG BASE	A207285	001	Feb 13, 2017	Jan	NEWA

MUPIROCIN

OINTMENT;TOPICAL

MUPIROCIN

AB			!	PERRIGO NEW YORK	2%	A065123	001	Nov 07, 2003	May	CHRS
----	--	--	---	------------------	----	---------	-----	--------------	-----	------

MUPIROCIN CALCIUM

CREAM;TOPICAL

MUPIROCIN

AB				GLENMARK PHARMS INC	EQ 2% BASE	A201587	001	Jan 24, 2013	May	CAHN
----	--	--	--	---------------------	------------	---------	-----	--------------	-----	------

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

			@	JUBILANT CADISTA	250MG	A090762	001	Dec 15, 2014	Sep	DISC
AB				ZHEJIANG HISUN PHARM	250MG	A204077	001	Nov 13, 2017	Oct	NEWA

TABLET;ORAL

MYCOPHENOLATE MOFETIL

			@	JUBILANT CADISTA	500MG	A090661	001	Dec 15, 2014	Sep	DISC
AB				ZHEJIANG HISUN PHARM	500MG	A204076	001	Nov 16, 2017	Nov	NEWA

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP				AKORN INC	500MG/VIAL	A204043	001	Feb 28, 2017	Feb	NEWA
AP				MYLAN LABS LTD	500MG/VIAL	A203859	001	Mar 31, 2017	Mar	NEWA
AP				ZYDUS PHARMS USA INC	500MG/VIAL	A204473	001	Aug 31, 2017	Aug	NEWA

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC ACID

AB				ACCORD HLTHCARE	180MG	A202555	001	Aug 23, 2017	Aug	NEWA
AB					360MG	A202555	002	Aug 23, 2017	Aug	NEWA

NABILONE

CAPSULE;ORAL

CESAMET

			+	!	MYLAN SPECIALITY LP	1MG	N018677	001	Dec 26, 1985	Mar	CAHN
--	--	--	---	---	---------------------	-----	---------	-----	--------------	-----	------

NABUMETONE

TABLET;ORAL

NABUMETONE

>D>			@	DR REDDYS LABS LTD	500MG	A078420	001	Sep 24, 2008	Dec	CAHN
>D>			@		750MG	A078420	002	Sep 24, 2008	Dec	CAHN
>A>			@	SCIEGEN PHARMS INC	500MG	A078420	001	Sep 24, 2008	Dec	CAHN
>A>			@		750MG	A078420	002	Sep 24, 2008	Dec	CAHN

NADOLOL

TABLET; ORAL

NADOLOL

AB	AMNEAL PHARMS CO	20MG	A208832	001	Jun 02, 2017	May NEWA
AB		40MG	A208832	002	Jun 02, 2017	May NEWA
AB		80MG	A208832	003	Jun 02, 2017	May NEWA
AB	AUROBINDO PHARMA LTD	40MG	A201893	001	Sep 16, 2015	Nov CAHN
AB		80MG	A201893	002	Sep 16, 2015	Nov CAHN
AB	LUPIN LTD	20MG	A209309	001	Oct 05, 2017	Sep NEWA
AB		40MG	A209309	002	Oct 05, 2017	Sep NEWA
AB		80MG	A209309	003	Oct 05, 2017	Sep NEWA
AB	ZYDUS PHARMS USA INC	20MG	A207761	001	Jul 28, 2017	Jul NEWA
AB		40MG	A207761	002	Jul 28, 2017	Jul NEWA
AB		80MG	A207761	003	Jul 28, 2017	Jul NEWA

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIFINE HYDROCHLORIDE

AB	TOLMAR	2%	A206960	001	Apr 10, 2017	Mar NEWA
----	--------	----	---------	-----	--------------	----------

NALDEMEDINE TOSYLATE

TABLET; ORAL

SYMPROIC

+	!	SHIONOGI INC	EQ 0.2MG BASE	N208854	001	Mar 23, 2017	Mar NEWA
---	---	--------------	---------------	---------	-----	--------------	----------

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION

REVEX

+	@	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML	N020459	001	Apr 17, 1995	Nov CRLD
+	@		EQ 1MG BASE/ML	N020459	002	Apr 17, 1995	Nov CRLD

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

@ WEST-WARD PHARMS INT 0.4MG/ML

@ 0.4MG/ML

NALOXONE HYDROCHLORIDE

AP	AKORN	0.4MG/ML	A208871	001	Feb 28, 2017	Feb NEWA
AP		0.4MG/ML	A208872	001	Mar 14, 2017	Feb NEWA
!	INTL MEDICATION	1MG/ML	A072076	001	Mar 24, 1988	Nov CTEC
AP	SOMERSET THERAPS LLC	0.4MG/ML	A207633	001	Aug 08, 2017	Jul NEWA
AP		0.4MG/ML	A207634	001	Jul 26, 2017	Jul NEWA

SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS

EVZIO

+	@	KALEO INC	0.4MG/0.4ML (0.4MG/0.4ML)	N205787	001	Apr 03, 2014	Aug DISC
---	---	-----------	---------------------------	---------	-----	--------------	----------

SPRAY, METERED; NASAL

NARCAN

+	ADAPT	2MG/SPRAY	N208411	002	Jan 24, 2017	Jan NEWA
---	-------	-----------	---------	-----	--------------	----------

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TARGINIQ

+	@	PURDUE PHARMA LP	5MG; 10MG	N205777	001	Jul 23, 2014	Oct CRLD
+	@		10MG; 20MG	N205777	002	Jul 23, 2014	Oct CRLD
+	@		20MG; 40MG	N205777	003	Jul 23, 2014	Oct CRLD

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

AB	APOTEX INC	50MG	A207905	001	Jul 21, 2017	Jul NEWA
>D>	MALLINCKRODT	25MG	A076264	001	Mar 22, 2002	Dec CAHN
>D> AB	!	50MG	A076264	002	Mar 22, 2002	Dec CAHN
>D>		100MG	A076264	003	Mar 22, 2002	Dec CAHN
>A>	SPECGX LLC	25MG	A076264	001	Mar 22, 2002	Dec CAHN
>A> AB	!	50MG	A076264	002	Mar 22, 2002	Dec CAHN
>A>		100MG	A076264	003	Mar 22, 2002	Dec CAHN

NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
TROXYCA ER

@	PFIZER INC	1.2MG;10MG	N207621	001	Aug 19, 2016	Oct	DISC
@		2.4MG;20MG	N207621	002	Aug 19, 2016	Oct	DISC
@		3.6MG;30MG	N207621	003	Aug 19, 2016	Oct	DISC
@		4.8MG;40MG	N207621	004	Aug 19, 2016	Oct	DISC
@		7.2MG;60MG	N207621	005	Aug 19, 2016	Oct	DISC
@		9.6MG;80MG	N207621	006	Aug 19, 2016	Oct	DISC

NANDROLONE DECANOATEINJECTABLE;INJECTION
NANDROLONE DECANOATE

!	LUITPOLD PHARMS INC	200MG/ML	A091252	001	Aug 30, 2010	Jun	CAHN
---	---------------------	----------	---------	-----	--------------	-----	------

NAPROXENTABLET;ORAL
NAPROXEN

AB	AUROBINDO PHARMA LTD	250MG	A200429	001	Nov 08, 2011	Jan	CAHN
AB		375MG	A200429	002	Nov 08, 2011	Jan	CAHN
AB		500MG	A200429	003	Nov 08, 2011	Jan	CAHN
	@ CHARTWELL MOLECULES	250MG	A074410	001	Apr 28, 1995	May	CAHN
	@	375MG	A074410	002	Apr 28, 1995	May	CAHN
	@	500MG	A074410	003	Apr 28, 1995	May	CAHN
	@ HIKMA INTL PHARMS	250MG	A076494	001	Jan 14, 2004	May	DISC
	@	375MG	A076494	002	Jan 14, 2004	May	DISC
	@	500MG	A076494	003	Jan 14, 2004	May	DISC
	TABLET, DELAYED RELEASE;ORAL						
	NAPROXEN						
	@ MYLAN PHARMS INC	375MG	A075390	001	Apr 19, 2001	Oct	DISC
	@	500MG	A075390	002	Apr 19, 2001	Oct	DISC

NAPROXEN SODIUMTABLET;ORAL
NAPROXEN SODIUM

AB	GLENMARK PHARMS LTD	EQ 250MG BASE	A078314	001	Apr 27, 2007	May	CAHN
AB		EQ 500MG BASE	A078314	002	Apr 27, 2007	May	CAHN

NATAMYCINSUSPENSION;OPHTHALMIC
NATACYN

+	!	NOVARTIS PHARMS CORP	5%	N050514	001		Jan	CAHN
---	---	----------------------	----	---------	-----	--	-----	------

NEBIVOLOL HYDROCHLORIDETABLET;ORAL
NEBIVOLOL HYDROCHLORIDE

	@ GLENMARK PHARMS LTD	EQ 2.5MG BASE	A203821	001	May 25, 2017	May	DISC
AB		EQ 2.5MG BASE	A203821	001	May 25, 2017	May	NEWA
	@	EQ 5MG BASE	A203821	002	May 25, 2017	May	DISC
AB		EQ 5MG BASE	A203821	002	May 25, 2017	May	NEWA
	@	EQ 10MG BASE	A203821	003	May 25, 2017	May	DISC
AB		EQ 10MG BASE	A203821	003	May 25, 2017	May	NEWA
	@	EQ 20MG BASE	A203821	004	May 25, 2017	May	DISC
AB		EQ 20MG BASE	A203821	004	May 25, 2017	May	NEWA

NEBIVOLOL HYDROCHLORIDE; VALSARTANTABLET;ORAL
BYVALSON

+	!	FOREST LABS LLC	EQ 5MG BASE;80MG	N206302	001	Jun 03, 2016	May	CRLD
---	---	-----------------	------------------	---------	-----	--------------	-----	------

NEFAZODONE HYDROCHLORIDETABLET;ORAL
NEFAZODONE HYDROCHLORIDE

@	DR REDDYS LABS INC	50MG	A076309	001	Sep 16, 2003	Nov	DISC
@		100MG	A076309	002	Sep 16, 2003	Nov	DISC
@		150MG	A076309	003	Sep 16, 2003	Nov	DISC
@		200MG	A076309	004	Sep 16, 2003	Nov	DISC
@		250MG	A076309	005	Sep 16, 2003	Nov	DISC
	TEVA	50MG	A076037	001	Sep 16, 2003	Nov	CTEC
		100MG	A076037	002	Sep 16, 2003	Nov	CTEC
		150MG	A076037	003	Sep 16, 2003	Nov	CTEC

TABLET;ORAL
NEFAZODONE HYDROCHLORIDE

	200MG	A076037	004	Sep 16, 2003	Nov CTEC
!	250MG	A076037	005	Sep 16, 2003	Nov CTEC

NELFINAVIR MESYLATE

POWDER;ORAL
VIRACEPT

@ AGOURON PHARMS	EQ 50MG BASE/SCOOPFUL	N020778	001	Mar 14, 1997	Jan CAHN
------------------	-----------------------	---------	-----	--------------	----------

TABLET;ORAL
VIRACEPT

+! AGOURON PHARMS	EQ 250MG BASE	N020779	001	Mar 14, 1997	Jan CAHN
+!	EQ 625MG BASE	N021503	001	Apr 30, 2003	Jan CAHN

NEOMYCIN SULFATE

TABLET;ORAL
NEOMYCIN SULFATE

AA	BRECKENRIDGE PHARM	500MG	A065468	001	Mar 29, 2010	Sep CAHN
----	--------------------	-------	---------	-----	--------------	----------

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION;IRRIGATION
NEOSPORIN G.U. IRRIGANT

AT	!	MONARCH PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	A060707	001		Apr CAHN
----	---	----------------	----------------------------------	---------	-----	--	----------

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS
NEOSTIGMINE METHYLSULFATE

AP	AMPHASTAR PHARMS INC	5MG/10ML (0.5MG/ML)	A209933	001	Sep 25, 2017	Sep NEWA
AP		10MG/10ML (1MG/ML)	A209933	002	Sep 25, 2017	Sep NEWA
AP	PAR STERILE PRODUCTS	5MG/10ML (0.5MG/ML)	A208405	001	Apr 26, 2017	Apr NEWA
AP		10MG/10ML (1MG/ML)	A208405	002	Apr 26, 2017	Apr NEWA

NERATINIB MALEATE

TABLET;ORAL
NERLYNX

+!	PUMA BIOTECH	EQ 40MG BASE	N208051	001	Jul 17, 2017	Jul NEWA
----	--------------	--------------	---------	-----	--------------	----------

>A> NETARSUDIL DIMESYLATE

>A> SOLUTION/DROPS;OPHTHALMIC
>A> RHOPRESSA

>A>	+!	AERIE PHARMS INC	EQ 0.02% BASE	N208254	001	Dec 18, 2017	Dec NEWA
-----	----	------------------	---------------	---------	-----	--------------	----------

NEVIRAPINE

SUSPENSION;ORAL
NEVIRAPINE

AA	CIPLA LTD	50MG/5ML	A207684	001	Aug 03, 2017	Jul NEWA
----	-----------	----------	---------	-----	--------------	----------

TABLET;ORAL
NEVIRAPINE

AB	TECH ORGANIZED	200MG	A203176	001	May 22, 2012	Sep CAHN
----	----------------	-------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL
NEVIRAPINE

AB	AUROBINDO PHARMA LTD	400MG	A207698	001	Feb 28, 2017	Mar CAHN
AB	AUROBINDO PHARMA USA	400MG	A207698	001	Feb 28, 2017	Feb NEWA
AB	MACLEODS PHARMS LTD	400MG	A206879	001	Oct 06, 2017	Sep NEWA
AB	SCIEGEN PHARMS INC	100MG	A207467	001	Jul 31, 2017	Jul NEWA
AB		400MG	A207467	002	Jul 31, 2017	Jul NEWA
AB	TECH ORGANIZED	100MG	A207467	001	Jul 31, 2017	Sep CAHN
AB		400MG	A207467	002	Jul 31, 2017	Sep CAHN

NIACIN

TABLET;ORAL
NIACOR

AA	!	AVONDALE PHARMS	500MG	A040378	001	May 03, 2000	Oct CAHN
AA	!	UPSHER-SMITH LABS	500MG	A040378	001	May 03, 2000	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL
NIACIN

AB	LANNETT CO INC	500MG	A203899	001	Jun 16, 2017	Jun NEWA
AB		1GM	A203899	002	Jun 16, 2017	Jun NEWA

NICARDIPINE HYDROCHLORIDE

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

AP	WEST-WARD PHARMS INT	25MG/10ML (2.5MG/ML)	A078714	001	Dec 28, 2009	Jan CAHN
	INJECTABLE;INTRAVENOUS					
	NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE					
	EXELA PHARMA SCIENCE	20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016	Feb NEWA
		40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016	Feb NEWA

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

AFEDITAB CR

AB1	WATSON LABS TEVA	30MG	A075128	001	Mar 10, 2000	May CAHN
	NIFEDIPINE					
	@ MYLAN LABS LTD	30MG	A090602	001	Sep 13, 2010	May DISC
AB2		30MG	A090602	001	Sep 13, 2010	Mar CAHN
	@	60MG	A090602	002	Sep 13, 2010	May DISC
AB2		60MG	A090602	002	Sep 13, 2010	Mar CAHN
	@	90MG	A090602	003	Sep 13, 2010	May DISC
AB2		90MG	A090602	003	Sep 13, 2010	Mar CAHN
AB2	OSMOTICA PHARM US	90MG	A077410	001	Oct 03, 2007	Jun CAHN
>A> AB2	ZYDUS PHARMS USA INC	30MG	A210012	001	Dec 19, 2017	Dec NEWA
>A> AB2		60MG	A210012	002	Dec 19, 2017	Dec NEWA
>A> AB2		90MG	A210012	003	Dec 19, 2017	Dec NEWA

NIRAPARIB TOSYLATE

CAPSULE;ORAL

ZEJULA

+	TESARO INC	EQ 100MG BASE	N208447	001	Mar 27, 2017	Mar NEWA
---	------------	---------------	---------	-----	--------------	----------

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

SULAR

AB	+	COVIS PHARMA BV	8.5MG	N020356	008	Jan 02, 2008	May CAHN
	+	@	10MG	N020356	001	Feb 02, 1995	May CAHN
AB	+		17MG	N020356	007	Jan 02, 2008	May CAHN
	+	@	20MG	N020356	002	Feb 02, 1995	May CAHN
	+	@	25.5MG	N020356	006	Jan 02, 2008	May CAHN
	+	@	30MG	N020356	003	Feb 02, 1995	May CAHN
AB	+		34MG	N020356	005	Jan 02, 2008	May CAHN
	+	@	40MG	N020356	004	Feb 02, 1995	May CAHN

NITISINONE

CAPSULE;ORAL

ORFADIN

+	SWEDISH ORPHAN	10MG	N021232	003	Jan 18, 2002	Oct CHRS
---	----------------	------	---------	-----	--------------	----------

TABLET;ORAL

NITYR

+	CYCLE PHARMS LTD	2MG	N209449	001	Jul 26, 2017	Jul NEWA
+		5MG	N209449	002	Jul 26, 2017	Jul NEWA
+	+	10MG	N209449	003	Jul 26, 2017	Jul NEWA

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

AB	ZYDUS PHARMS USA INC	50MG	A205005	001	Dec 12, 2017	Nov NEWA
AB		100MG	A205005	002	Dec 12, 2017	Nov NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB	AMNEAL PHARMS	75MG;25MG	A207372	001	May 15, 2017	May NEWA
----	---------------	-----------	---------	-----	--------------	----------

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL

NITRO-DUR

AB1	+	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	Jun CAHN
AB1	+		0.2MG/HR	N020145	002	Apr 04, 1995	Jun CAHN
	+		0.3MG/HR	N020145	003	Apr 04, 1995	Jun CAHN
AB1	+		0.4MG/HR	N020145	004	Apr 04, 1995	Jun CAHN
AB1	+		0.6MG/HR	N020145	005	Apr 04, 1995	Jun CAHN

FILM, EXTENDED RELEASE;TRANSDERMAL
NITRO-DUR

+	!	0.8MG/HR	N020145	006	Apr 04, 1995	Jun CAHN
	OINTMENT;TRANSDERMAL NITROGLYCERIN					
	!	FOUGERA PHARMS INC 2%	A087355	001	Jul 08, 1988	Jan CAHN
	TABLET;SUBLINGUAL NITROGLYCERIN					
AB	ACTAVIS LABS FL INC	0.3MG	A203693	001	Oct 16, 2017	Oct NEWA
AB		0.4MG	A203693	002	Oct 16, 2017	Oct NEWA
AB		0.6MG	A203693	003	Oct 16, 2017	Oct NEWA
AB	GLENMARK PHARMS LTD	0.3MG	A206391	001	Sep 19, 2017	Sep NEWA
AB		0.4MG	A206391	002	Sep 19, 2017	Sep NEWA
AB		0.6MG	A206391	003	Sep 19, 2017	Sep NEWA

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION
NOREPINEPHRINE BITARTRATE

AP	BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A040859	001	Mar 27, 2012	Aug CAHN
AP	WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A040462	001	Oct 31, 2003	Jan CAHN

NORFLOXACIN

TABLET;ORAL
NOROXIN

>D>	@	MERCK	400MG	N019384	002	Oct 31, 1986	Dec CRLD
>A>	+	@	400MG	N019384	002	Oct 31, 1986	Dec CRLD

NORGESTREL

TABLET;ORAL
OPILL

+	@	LABORATOIRE HRA	0.075MG	N017031	001		Oct CTNA
+	@		0.075MG	N017031	001		Oct CRLD

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL
NORTRIPTYLINE HYDROCHLORIDE

	@	MYLAN	EQ 10MG BASE	A074234	001	Jul 26, 1993	Jun DISC
	@		EQ 25MG BASE	A074234	002	Jul 26, 1993	Jun DISC
	@		EQ 50MG BASE	A074234	003	Jul 26, 1993	Jun DISC
	@		EQ 75MG BASE	A074234	004	Jul 26, 1993	Jun DISC
AB		TARO PHARM	EQ 10MG BASE	A075520	004	May 08, 2000	Mar CAHN
AB			EQ 25MG BASE	A075520	003	May 08, 2000	Mar CAHN
AB			EQ 50MG BASE	A075520	001	May 08, 2000	Mar CAHN
AB			EQ 75MG BASE	A075520	002	May 08, 2000	Mar CAHN
		PAMELOR					
>D>	AB	+	MALLINCKRODT LLC	EQ 10MG BASE	N018013	001	Dec CAHN
>D>	AB	+		EQ 25MG BASE	N018013	002	Dec CAHN
>D>	AB	+		EQ 50MG BASE	N018013	004	Dec CAHN
>D>	AB	+	!	EQ 75MG BASE	N018013	003	Dec CAHN
>A>	AB	+	SPECGX LLC	EQ 10MG BASE	N018013	001	Dec CAHN
>A>	AB	+		EQ 25MG BASE	N018013	002	Dec CAHN
>A>	AB	+		EQ 50MG BASE	N018013	004	Dec CAHN
>A>	AB	+	!	EQ 75MG BASE	N018013	003	Dec CAHN

SOLUTION;ORAL
NORTRIPTYLINE HYDROCHLORIDE

AA	!	PHARM ASSOC	EQ 10MG BASE/5ML	A075606	001	Aug 28, 2000	May CAHN
		PAMELOR					
>D>	@	MALLINCKRODT INC	EQ 10MG BASE/5ML	N018012	001		Dec CAHN
>A>	@	SPECGX LLC	EQ 10MG BASE/5ML	N018012	001		Dec CAHN

NYSTATIN

CREAM;TOPICAL
NYSTATIN

AT		CROWN LABS INC	100,000 UNITS/GM	A207733	001	Sep 26, 2017	Sep NEWA
	OINTMENT;TOPICAL NYSTATIN						
AT		G AND W LABS INC	100,000 UNITS/GM	A209114	001	Oct 06, 2017	Sep NEWA
	PASTILLE;ORAL MYCOSTATIN						
	@	DELCOR ASSET CORP	200,000 UNITS	N050619	001	Apr 09, 1987	Jun CAHN

POWDER; TOPICAL									
NYSTATIN									
AT	LYNE	100,000 UNITS/GM	A208838	001	May 30, 2017	May	NEWA		
AT	NESHER PHARMS	100,000 UNITS/GM	A208581	001	Jun 08, 2017	May	NEWA		
AT	UPSHER-SMITH LABS	100,000 UNITS/GM	A065183	001	May 03, 2005	Jun	CAHN		
SUSPENSION; ORAL									
NILSTAT									
>D>	@ GLENMARK GENERICS	100,000 UNITS/ML	N050299	001		Dec	CRLD		
>A>	+ @	100,000 UNITS/ML	N050299	001		Dec	CRLD		
NYSTATIN									
	@ ALLIED PHARMA INC	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Jul	CAHN		
AA	FOUGERA PHARMS INC	100,000 UNITS/ML	A062517	001	Jun 07, 1984	Jan	CAHN		
AA	PHARM ASSOC	100,000 UNITS/ML	A203621	001	Jan 07, 2016	May	CAHN		
AA	TARO PHARM	100,000 UNITS/ML	A062876	001	Feb 29, 1988	Apr	CAHN		
>D> AA	! WOCKHARDT	100,000 UNITS/ML	A062512	001	Oct 29, 1984	Dec	CAHN		
>A> AA	! WOCKHARDT BIO AG	100,000 UNITS/ML	A062512	001	Oct 29, 1984	Dec	CAHN		
TABLET; ORAL									
NYSTATIN									
	@ USL PHARMA	500,000 UNITS	A062524	001	Nov 26, 1985	Jun	CAHN		
<u>NYSTATIN; TRIAMCINOLONE ACETONIDE</u>									
CREAM; TOPICAL									
MYCOLOG-II									
	@ MYLAN PHARMS INC	100,000 UNITS/GM; 0.1%	A062606	001	May 15, 1985	Jan	CAHN		
NYSTATIN AND TRIAMCINOLONE ACETONIDE									
>A> AT	CROWN LABS INC	100,000 UNITS/GM; 0.1%	A207730	001	Dec 26, 2017	Dec	NEWA		
AT	FOUGERA PHARMS INC	100,000 UNITS/GM; 0.1%	A062599	001	Oct 08, 1985	Jan	CAHN		
AT	PERRIGO UK FINCO	100,000 UNITS/GM; 0.1%	A208479	001	Aug 14, 2017	Jul	NEWA		
OINTMENT; TOPICAL									
MYCOLOG-II									
	@ MYLAN PHARMS INC	100,000 UNITS/GM; 0.1%	A060572	001	Jun 28, 1985	Jan	CAHN		
NYSTATIN AND TRIAMCINOLONE ACETONIDE									
AT	AKORN	100,000 UNITS/GM; 0.1%	A207217	001	Aug 04, 2017	Jul	NEWA		
>A> AT	CROWN LABS INC	100,000 UNITS/GM; 0.1%	A207731	001	Dec 26, 2017	Dec	NEWA		
AT	DR REDDYS LABS LTD	100,000 UNITS/GM; 0.1%	A207741	001	Jan 31, 2017	Jan	NEWA		
AT	FOUGERA PHARMS INC	100,000 UNITS/GM; 0.1%	A062602	001	Oct 09, 1985	Jan	CAHN		
<u>OCTREOTIDE ACETATE</u>									
INJECTABLE; INJECTION									
OCTREOTIDE ACETATE									
	@ SUN PHARM INDS	EQ 0.05MG BASE/ML	A077329	001	Mar 04, 2008	Sep	DISC		
	@	EQ 0.1MG BASE/ML	A077329	002	Mar 04, 2008	Sep	DISC		
	@	EQ 0.2MG BASE/ML	A077330	001	Mar 04, 2008	Oct	DISC		
	@	EQ 0.5MG BASE/ML	A077329	003	Mar 04, 2008	Sep	DISC		
	@	EQ 1MG BASE/ML	A077331	001	Mar 04, 2008	Oct	DISC		
<u>OFLOXACIN</u>									
SOLUTION/DROPS; OPHTHALMIC									
OFLOXACIN									
AT	SANDOZ INC	0.3%	A076231	001	May 14, 2004	Feb	CAHN		
SOLUTION/DROPS; OTIC									
OFLOXACIN									
AT	SANDOZ INC	0.3%	A078222	001	Mar 17, 2008	Feb	CAHN		
<u>OLANZAPINE</u>									
TABLET; ORAL									
OLANZAPINE									
	@ AJANTA PHARMA LTD	2.5MG	A206711	001	Aug 30, 2016	Oct	DISC		
	@	5MG	A206711	002	Aug 30, 2016	Oct	DISC		
	@	7.5MG	A206711	003	Aug 30, 2016	Oct	DISC		
	@	10MG	A206711	004	Aug 30, 2016	Oct	DISC		
	@	15MG	A206711	005	Aug 30, 2016	Oct	DISC		
	@	20MG	A206711	006	Aug 30, 2016	Oct	DISC		
AB	HIKMA PHARMS	2.5MG	A204866	001	Jun 16, 2017	Jun	NEWA		
AB		5MG	A204866	002	Jun 16, 2017	Jun	NEWA		
AB		7.5MG	A204866	003	Jun 16, 2017	Jun	NEWA		
AB		10MG	A204866	004	Jun 16, 2017	Jun	NEWA		
AB		15MG	A204866	005	Jun 16, 2017	Jun	NEWA		
AB		20MG	A204866	006	Jun 16, 2017	Jun	NEWA		
	@ MYLAN PHARMS INC	2.5MG	A076866	001	Apr 23, 2012	Jun	DISC		
AB		2.5MG	A076866	001	Apr 23, 2012	Mar	CAHN		
	@	5MG	A076866	002	Apr 23, 2012	Jun	DISC		

TABLET; ORAL							
OLANZAPINE							
AB		5MG	A076866	002	Apr 23, 2012	Mar	CAHN
	@	7.5MG	A076866	003	Apr 23, 2012	Jun	DISC
AB		7.5MG	A076866	003	Apr 23, 2012	Mar	CAHN
	@	10MG	A076866	004	Apr 23, 2012	Jun	DISC
AB		10MG	A076866	004	Apr 23, 2012	Mar	CAHN
	@	15MG	A076866	005	Apr 23, 2012	Jun	DISC
AB		15MG	A076866	005	Apr 23, 2012	Mar	CAHN
	@	20MG	A076866	006	Apr 23, 2012	Jun	DISC
AB		20MG	A076866	006	Apr 23, 2012	Mar	CAHN
TABLET, ORALLY DISINTEGRATING; ORAL							
OLANZAPINE							
AB	AJANTA PHARMA LTD	5MG	A204320	001	May 30, 2017	May	NEWA
AB		10MG	A204320	002	May 30, 2017	May	NEWA
AB		15MG	A204320	003	May 30, 2017	May	NEWA
AB		20MG	A204320	004	May 30, 2017	May	NEWA
<u>OLAPARIB</u>							
CAPSULE; ORAL							
LYNPARZA							
+!	ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014	Mar	CRLD
TABLET; ORAL							
LYNPARZA							
+	ASTRAZENECA PHARMS	100MG	N208558	001	Aug 17, 2017	Aug	NEWA
+!		150MG	N208558	002	Aug 17, 2017	Aug	NEWA
<u>OLIVE OIL; SOYBEAN OIL</u>							
INJECTABLE; INJECTION							
CLINOLIPID 20%							
+	@ BAXTER HLTHCARE CORP	16% (160GM/1000ML); 4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Jul	DISC
<u>OLMESARTAN MEDOXOMIL</u>							
TABLET; ORAL							
OLMESARTAN MEDOXOMIL							
AB	ACCORD HLTHCARE	5MG	A207662	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A207662	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A207662	003	Apr 24, 2017	Apr	NEWA
AB	ALEMBIC PHARMS LTD	5MG	A203012	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A203012	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A203012	003	Apr 24, 2017	Apr	NEWA
AB	ALKEM LABS LTD	5MG	A206763	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A206763	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A206763	003	Apr 24, 2017	Apr	NEWA
AB	AUROBINDO PHARMA LTD	5MG	A204798	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A204798	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A204798	003	Apr 24, 2017	Apr	NEWA
AB	GLENMARK PHARMS LTD	5MG	A203281	001	May 25, 2017	May	NEWA
AB		20MG	A203281	002	May 25, 2017	May	NEWA
AB		40MG	A203281	003	May 25, 2017	May	NEWA
AB	JUBILANT GENERICS	5MG	A205482	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A205482	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A205482	003	Apr 24, 2017	Apr	NEWA
AB	LUPIN LTD	5MG	A206631	001	Apr 27, 2017	Apr	NEWA
AB		20MG	A206631	002	Apr 27, 2017	Apr	NEWA
AB		40MG	A206631	003	Apr 27, 2017	Apr	NEWA
AB	MACLEODS PHARMS LTD	5MG	A204814	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A204814	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A204814	003	Apr 24, 2017	Apr	NEWA
AB	TEVA PHARMS USA	5MG	A091079	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A091079	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A091079	003	Apr 24, 2017	Apr	NEWA
AB	TORRENT PHARMS LTD	5MG	A202375	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A202375	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A202375	003	Apr 24, 2017	Apr	NEWA
AB	ZYDUS PHARMS USA INC	5MG	A205192	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A205192	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A205192	003	Apr 24, 2017	Apr	NEWA

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

AT	AKORN	EQ 0.2% BASE	A204723	001	Dec 05, 2017	Nov NEWA
AT	APOTEX INC	EQ 0.2% BASE	A090918	001	Dec 05, 2017	Nov NEWA
AT	CIPLA LTD	EQ 0.1% BASE	A206046	001	Jul 26, 2017	Jul NEWA
AT		EQ 0.2% BASE	A206087	001	Dec 05, 2017	Nov NEWA
AT	WOCKHARDT LTD	EQ 0.1% BASE	A200810	001	Jun 28, 2017	Jun NEWA
AT	ZAMBON SPA	EQ 0.1% BASE	A204706	001	Dec 07, 2015	Sep CAHN

SPRAY, METERED;NASAL
OLOPATADINE HYDROCHLORIDE

AB	PERRIGO ISRAEL	0.665MG/SPRAY	A202853	001	Jan 31, 2017	Jan NEWA
----	----------------	---------------	---------	-----	--------------	----------

OLSALAZINE SODIUMCAPSULE;ORAL
DIPENTUM

+	MYLAN SPECIALITY LP	250MG	N019715	001	Jul 31, 1990	Mar CAHN
---	---------------------	-------	---------	-----	--------------	----------

OMACETAXINE MEPESUCCINATEPOWDER;SUBCUTANEOUS
SYNRIBO

+	TEVA PHARMS INTL	3.5MG/VIAL	N203585	001	Oct 26, 2012	Apr CAHN
---	------------------	------------	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERSCAPSULE;ORAL
OMEGA-3-ACID ETHYL ESTERS

AB	AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	May CAHN
AB	STRIDES PHARMA	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A203893	001	Sep 19, 2017	Sep NEWA

OMEGA-3-ACID ETHYL ESTERS TYPE ACAPSULE;ORAL
OMTRYG

+	@ OSMOTICA	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Sep DISC
+	!	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Sep CAHN

OMEPRAZOLECAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

AB	AUROBINDO PHARMA LTD	10MG	A203270	001	Aug 19, 2015	Jan CAHN
AB		20MG	A203270	002	Aug 19, 2015	Jan CAHN
AB		40MG	A203270	003	Aug 19, 2015	Jan CAHN
AB	BRECKENRIDGE PHARM	10MG	A203481	001	Jul 03, 2017	Jun NEWA
AB		20MG	A203481	002	Jul 03, 2017	Jun NEWA
AB		40MG	A203481	003	Jul 03, 2017	Jun NEWA
AB	TEVA PHARMS USA	20MG	A204661	001	Jun 13, 2017	May NEWA
AB		40MG	A204661	002	Jun 13, 2017	May NEWA

OMEPRAZOLE MAGNESIUMFOR SUSPENSION, DELAYED RELEASE;ORAL
PRILOSEC

+	COVIS PHARMA BV	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008	May CAHN
+	!	EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008	May CAHN

OMEPRAZOLE; SODIUM BICARBONATEFOR SUSPENSION;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

AB	AJANTA PHARMA LTD	20MG/PACKET;1.68GM/PACKET	A205545	001	Jul 27, 2016	Jan CTEC	
AB		40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Jan CTEC	
AB	PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Jan CMFD	
AB		40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Jan CMFD	
	ZEGERID						
AB	+	SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jan CTEC
AB	+	!	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jan CTEC

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL
ONDANSETRON

@ CHARTWELL MOLECULES	4MG	A076506	001	Dec 26, 2006	Mar CAHN
@	8MG	A076506	002	Dec 26, 2006	Mar CAHN
@	16MG	A077406	001	Dec 26, 2006	Mar CAHN
@	24MG	A077406	002	Dec 26, 2006	Mar CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE

AP	!	BAXTER HLTHCARE CORP	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Aug CAHN
	@	MYLAN LABS LTD	EQ 2MG BASE/ML	A078257	001	Apr 23, 2008	Nov DISC
AP			EQ 2MG BASE/ML	A204906	001	Jul 31, 2017	Jul NEWA
AP		SANDOZ INC	EQ 2MG BASE/ML	A077430	001	Jun 27, 2007	Mar CAHN
	@	SUN PHARM INDS (IN)	EQ 2MG BASE/ML	A077172	001	Dec 26, 2006	Oct DISC
AP		WEST-WARD PHARMS INT	EQ 2MG BASE/ML	A076967	001	Dec 26, 2006	Jan CAHN
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP	!	BAXTER HLTHCARE CORP	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Aug CAHN
	@	MYLAN LABS LTD	EQ 2MG BASE/ML	A078244	001	Apr 23, 2008	Nov DISC
AP		SANDOZ INC	EQ 2MG BASE/ML	A077551	001	Jun 27, 2007	Mar CAHN
AP		WEST-WARD PHARMS INT	EQ 2MG BASE/ML	A077011	001	Dec 26, 2006	Jan CAHN
AP			EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jan CAHN

ORLISTAT

CAPSULE;ORAL
XENICAL

>A>	+	!	CHEPLAPHARM	120MG	N020766	001	Apr 23, 1999	Dec CAHN
>D>	+	!	HOFFMANN LA ROCHE	120MG	N020766	001	Apr 23, 1999	Dec CAHN

ORPHENADRINE CITRATE

INJECTABLE;INJECTION
NORFLEX

@ TELIGENT	30MG/ML	N013055	001		Apr CAHN
------------	---------	---------	-----	--	----------

TABLET, EXTENDED RELEASE;ORAL
NORFLEX

+	@	MEDICIS	100MG	N012157	001		Aug CRLD
---	---	---------	-------	---------	-----	--	----------

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL
OSELTAMIVIR PHOSPHATE

AB		AMNEAL PHARMS	EQ 30MG BASE	A209093	001	May 17, 2017	May NEWA
AB			EQ 45MG BASE	A209093	002	May 17, 2017	May NEWA
AB			EQ 75MG BASE	A209093	003	May 17, 2017	May NEWA
>A>	AB	LUPIN ATLANTIS	EQ 30MG BASE	A208348	001	Jan 09, 2018	Dec NEWA
>A>	AB		EQ 45MG BASE	A208348	002	Jan 09, 2018	Dec NEWA
>A>	AB		EQ 75MG BASE	A208348	003	Jan 09, 2018	Dec NEWA
AB		MACLEODS PHARMS LTD	EQ 30MG BASE	A207211	001	Sep 14, 2017	Sep NEWA
AB			EQ 45MG BASE	A207211	002	Sep 14, 2017	Sep NEWA
AB			EQ 75MG BASE	A207211	003	Sep 14, 2017	Sep NEWA
AB		NESHER PHARMS	EQ 30MG BASE	A208578	001	Feb 24, 2017	Feb NEWA
AB			EQ 45MG BASE	A208578	002	Feb 24, 2017	Feb NEWA
AB			EQ 75MG BASE	A208578	003	Feb 24, 2017	Feb NEWA

FOR SUSPENSION;ORAL
OSELTAMIVIR PHOSPHATE

AB		ALVOGEN PINE BROOK	EQ 6MG BASE/ML	A208823	001	Oct 31, 2017	Oct NEWA	
AB		NESHER PHARMS	EQ 6MG BASE/ML	A209113	001	Sep 14, 2017	Sep NEWA	
		TAMIFLU						
AB	+	!	ROCHE	EQ 6MG BASE/ML	N021246	002	Mar 21, 2011	Sep CFTG

OSPEMIFENE

TABLET;ORAL
OSPHEANA

+	!	DUCHESNAY	60MG	N203505	001	Feb 26, 2013	Mar CAHN
---	---	-----------	------	---------	-----	--------------	----------

OXACILLIN SODIUM

INJECTABLE;INJECTION
OXACILLIN SODIUM

	@	MYLAN LABS LTD	EQ 1GM BASE/VIAL	A091486	001	Aug 25, 2014	Oct DISC
	@		EQ 2GM BASE/VIAL	A091486	002	Aug 25, 2014	Oct DISC
AP		RENAISSANCE SSA LLC	EQ 1GM BASE/VIAL	A206681	001	Sep 11, 2017	Aug NEWA

INJECTABLE; INJECTION
OXACILLIN SODIUM

AP		EQ 2GM BASE/VIAL	A206681	002	Sep 11, 2017	Aug NEWA
AP		EQ 10GM BASE/VIAL	A206760	001	Oct 26, 2017	Oct NEWA
AP	WOCKHARDT BIO AG	EQ 1GM BASE/VIAL	A207147	001	Jul 31, 2017	Jul NEWA
AP		EQ 2GM BASE/VIAL	A207147	002	Jul 31, 2017	Jul NEWA
AP		EQ 10GM BASE/VIAL	A207148	001	Nov 24, 2017	Nov NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)
ELOXATIN

	+ @ SANOFI AVENTIS US	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	Jan CRLD
	OXALIPLATIN					
AP	ACCORD HLTHCARE	50MG/10ML (5MG/ML)	A207474	001	Mar 21, 2017	Mar NEWA
AP		100MG/20ML (5MG/ML)	A207474	002	Mar 21, 2017	Mar NEWA
AP		200MG/40ML (5MG/ML)	A207474	003	Mar 21, 2017	Mar NEWA
AP	CIPLA LTD	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	Jan NEWA
AP		100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	Jan NEWA
AP	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A090030	001	Jan 31, 2017	Jan NEWA
AP		100MG/20ML (5MG/ML)	A090030	002	Jan 31, 2017	Jan NEWA
AP		200MG/40ML (5MG/ML)	A090030	003	Jan 31, 2017	Jan NEWA
AP	GLAND PHARMA LTD	50MG/10ML (5MG/ML)	A207325	001	Feb 10, 2017	Jan NEWA
AP		50MG/VIAL	A207385	001	May 23, 2017	May NEWA
AP		100MG/20ML (5MG/ML)	A207325	002	Feb 10, 2017	Jan NEWA
AP		100MG/VIAL	A207385	002	May 23, 2017	May NEWA
AP		200MG/40ML (5MG/ML)	A207325	003	Oct 18, 2017	Oct NEWA
AP	LUITPOLD PHARMS INC	50MG/10ML (5MG/ML)	A204378	001	May 12, 2017	May NEWA
AP		100MG/20ML (5MG/ML)	A204378	002	May 12, 2017	May NEWA
AP	MYLAN LABS LTD	200MG/40ML (5MG/ML)	A091358	003	Nov 14, 2017	Oct NEWA
AP	! QILU PHARM CO LTD	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Jan CTEC
AP	SANJA PHARMS CO	50MG/10ML (5MG/ML)	A205529	001	Sep 06, 2017	Aug NEWA
AP		100MG/20ML (5MG/ML)	A205529	002	Sep 06, 2017	Aug NEWA

OXANDROLONE

TABLET; ORAL
OXANDROLONE

AB	UPSHER-SMITH LABS	2.5MG	A076761	001	Dec 01, 2006	Jun CAHN
AB		10MG	A078033	001	Mar 22, 2007	Jun CAHN

OXAPROZIN

TABLET; ORAL
OXAPROZIN

AB	AMNEAL PHARMS CO	600MG	A208633	001	May 04, 2017	Apr NEWA
----	------------------	-------	---------	-----	--------------	----------

OXAZEPAM

CAPSULE; ORAL
OXAZEPAM

AB	ACTAVIS ELIZABETH	10MG	A072253	002	Apr 14, 1988	May CMS1
AB		15MG	A072253	003	Apr 14, 1988	May CMS1
	@ ANDA REPOSITORY	10MG	A071026	002	Aug 10, 1987	Sep CAHN
	@	15MG	A071026	003	Aug 10, 1987	Sep CAHN
	@	30MG	A071026	001	Aug 10, 1987	Sep CAHN
	@ WATSON LABS TEVA	10MG	A072952	001	Sep 28, 1990	May CAHN

TABLET; ORAL
OXAZEPAM

	@ SUN PHARM INDUSTRIES	15MG	A070683	001	Jan 16, 1987	Jan CAHN
--	------------------------	------	---------	-----	--------------	----------

OXCARBAZEPINE

TABLET; ORAL
OXCARBAZEPINE

AB	GLENMARK PHARMS LTD	150MG	A077802	001	Oct 09, 2007	May CAHN
AB		300MG	A077802	002	Oct 09, 2007	May CAHN
AB		600MG	A077802	003	Oct 09, 2007	May CAHN
	@ JUBILANT CADISTA	150MG	A090239	001	Jan 25, 2010	Sep DISC
AB		150MG	A090239	001	Jan 25, 2010	Apr CAHN
	@	300MG	A090239	002	Jan 25, 2010	Sep DISC
AB		300MG	A090239	002	Jan 25, 2010	Apr CAHN
	@	600MG	A090239	003	Jan 25, 2010	Sep DISC
AB		600MG	A090239	003	Jan 25, 2010	Apr CAHN

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE;ORAL
CHOLEDYL SA

@ WARNER CHILCOTT LLC 600MG

A086742 001

Sep DISC

OXYBUTYNIN CHLORIDE

SYRUP;ORAL

DITROPAN

+ @ ORTHO MCNEIL JANSSEN 5MG/5ML
OXYBUTYNIN CHLORIDE

N018211 001

Jan CRLD

AA PHARM ASSOC 5MG/5ML

A075137 001

Dec 18, 1998 May CAHN

>D> AA ! WOCKHARDT 5MG/5ML

A074868 001

Feb 12, 1997 Dec CAHN

>A> AA ! WOCKHARDT BIO AG 5MG/5ML

A074868 001

Feb 12, 1997 Dec CAHN

TABLET;ORAL

OXYBUTYNIN CHLORIDE

>A> AB ABHAI LLC 5MG

A209335 001

Dec 22, 2017 Dec NEWA

>A> AB APPCO PHARMA LLC 5MG

A209025 001

Dec 21, 2017 Dec NEWA

AB NOVITIUM PHARMA 5MG

A209823 001

Oct 23, 2017 Oct NEWA

AB UPSHER-SMITH LABS 5MG

A074625 001

Jul 31, 1996 Sep CAHN

AB USL PHARMA 5MG

A074625 001

Jul 31, 1996 Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

OXYBUTYNIN CHLORIDE

AB UNIQUE PHARM LABS 5MG

A206121 001

May 27, 2016 Aug CAHN

AB 10MG

A206121 002

May 27, 2016 Aug CAHN

AB 15MG

A206121 003

May 27, 2016 Aug CAHN

AB ZYDUS PHARMS USA INC 5MG

A202332 001

Jun 26, 2017 Jun NEWA

AB 10MG

A202332 002

Jun 26, 2017 Jun NEWA

AB 15MG

A202332 003

Jun 26, 2017 Jun NEWA

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA ABHAI LLC 5MG/5ML

A208593 001

Jul 21, 2017 Jul NEWA

AA 100MG/5ML

A208593 002

Jul 21, 2017 Jul NEWA

AA ANI PHARMS INC 100MG/5ML

A203447 001

Aug 30, 2017 Aug NEWA

AA ASCENT PHARMS INC 5MG/5ML

A209021 001

Nov 09, 2017 Oct NEWA

AA 100MG/5ML

A209021 002

Nov 09, 2017 Oct NEWA

AA HI-TECH PHARMACAL 5MG/5ML

A208817 001

Aug 10, 2017 Jul NEWA

AA 100MG/5ML

A208795 001

Aug 07, 2017 Jul NEWA

AA PHARM ASSOC 100MG/5ML

A206822 001

Aug 15, 2017 Jul NEWA

AA WES PHARMA INC 100MG/5ML

A209897 001

Sep 06, 2017 Aug NEWA

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

AB ASCENT PHARMS INC 15MG

A207418 001

Aug 07, 2017 Jul NEWA

AB 30MG

A207418 002

Aug 07, 2017 Jul NEWA

AB EPIC PHARMA LLC 5MG

A090895 001

Aug 24, 2009 May CAHN

AB 15MG

A090895 002

Aug 24, 2009 May CAHN

AB 30MG

A090895 003

Aug 24, 2009 May CAHN

>D> AB MALLINCKRODT INC 5MG

A076758 003

Mar 19, 2007 Dec CAHN

>D> AB 15MG

A076758 001

Jun 30, 2004 Dec CAHN

>D> AB 30MG

A076758 002

Jun 30, 2004 Dec CAHN

AB NOVEL LABS INC 5MG

A204021 001

Jun 12, 2017 May NEWA

AB 10MG

A204021 002

Jun 12, 2017 May NEWA

AB 15MG

A204021 003

Jun 12, 2017 May NEWA

AB 20MG

A204021 004

Jun 12, 2017 May NEWA

AB 30MG

A204021 005

Jun 12, 2017 May NEWA

>A> AB SPECGX LLC 5MG

A076758 003

Mar 19, 2007 Dec CAHN

>A> AB 15MG

A076758 001

Jun 30, 2004 Dec CAHN

>A> AB 30MG

A076758 002

Jun 30, 2004 Dec CAHN

ROXICODONE

>D> AB + MALLINCKRODT INC 5MG

N021011 003

May 15, 2009 Dec CAHN

>D> AB +! 15MG

N021011 001

Aug 31, 2000 Dec CAHN

>D> AB + 30MG

N021011 002

Aug 31, 2000 Dec CAHN

>A> AB + SPECGX LLC 5MG

N021011 003

May 15, 2009 Dec CAHN

>A> AB +! 15MG

N021011 001

Aug 31, 2000 Dec CAHN

>A> AB + 30MG

N021011 002

Aug 31, 2000 Dec CAHN

ROXYBOND

DAIICHI SANKYO INC 5MG

N209777 001

Apr 20, 2017 Aug CAHN

15MG

N209777 002

Apr 20, 2017 Aug CAHN

30MG

N209777 003

Apr 20, 2017 Aug CAHN

INSPIRION DELIVERY 5MG

N209777 001

Apr 20, 2017 Apr NEWA

15MG

N209777 002

Apr 20, 2017 Apr NEWA

TABLET;ORAL
ROXYBOND

30MG

N209777 003 Apr 20, 2017 Apr NEWA

OXYMETAZOLINE HYDROCHLORIDE

CREAM;TOPICAL
RHOFADÉ

+! ALLERGAN INC 1%

N208552 001 Jan 18, 2017 Jan NEWA

OXYMETHOLONE

TABLET;ORAL
ANADROL-50

+! MYLAN SPECIALITY LP 50MG

N016848 001 Mar CAHN

OXYMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION
OPANA

+ @ ENDO PHARMS 1MG/ML

N011707 002 Aug DISC

TABLET;ORAL

OXYMORPHONE HYDROCHLORIDE

AB EPIC PHARMA LLC 5MG

A201187 001 Dec 15, 2014 May CAHN

AB 10MG

A201187 002 Dec 15, 2014 May CAHN

>D> AB MALLINCKRODT INC 5MG

A202321 001 Apr 25, 2013 Dec CAHN

>D> AB 10MG

A202321 002 Apr 25, 2013 Dec CAHN

>A> AB SPECGX LLC 5MG

A202321 001 Apr 25, 2013 Dec CAHN

>A> AB 10MG

A202321 002 Apr 25, 2013 Dec CAHN

TABLET, EXTENDED RELEASE;ORAL
OPANA ER

+ @ ENDO PHARMS 5MG

N201655 001 Dec 09, 2011 Aug DISC

+ @ 7.5MG

N201655 002 Dec 09, 2011 Aug DISC

+ @ 10MG

N201655 003 Dec 09, 2011 Aug DISC

+ @ 15MG

N201655 004 Dec 09, 2011 Aug DISC

+ @ 20MG

N201655 005 Dec 09, 2011 Aug DISC

+ @ 30MG

N201655 006 Dec 09, 2011 Aug DISC

+ @ 40MG

N201655 007 Dec 09, 2011 Aug DISC

OXYMORPHONE HYDROCHLORIDE

AB ACTAVIS ELIZABETH 5MG

A079046 003 Jul 11, 2013 Apr CAHN

AB 7.5MG

A079046 001 Dec 13, 2010 Apr CAHN

AB 10MG

A079046 004 Jul 11, 2013 Apr CAHN

AB 15MG

A079046 002 Dec 13, 2010 Apr CAHN

AB 20MG

A079046 005 Jul 11, 2013 Apr CAHN

AB 30MG

A079046 006 Jul 11, 2013 Apr CAHN

AB 40MG

A079046 007 Jul 11, 2013 Apr CAHN

>D> AB MALLINCKRODT INC 5MG

A202946 001 Jun 27, 2014 Dec CAHN

>D> AB 7.5MG

A202946 002 Jun 27, 2014 Dec CAHN

>D> AB 10MG

A202946 003 Jun 27, 2014 Dec CAHN

>D> AB 15MG

A202946 004 Jun 27, 2014 Dec CAHN

>D> AB 20MG

A202946 005 Jun 27, 2014 Dec CAHN

>D> AB 30MG

A202946 006 Jun 27, 2014 Dec CAHN

>D> AB 40MG

A202946 007 Jun 27, 2014 Dec CAHN

@ PAR PHARM

@ 5MG

A200792 001 Oct 24, 2014 May DISC

@ 7.5MG

A200792 002 Oct 24, 2014 May DISC

@ 10MG

A200792 003 Oct 24, 2014 May DISC

@ 15MG

A200792 004 Oct 24, 2014 May DISC

@ 20MG

A200792 005 Oct 24, 2014 May DISC

@ 30MG

A200792 006 Oct 24, 2014 May DISC

@ 40MG

A200792 007 Oct 24, 2014 May DISC

>A> AB SPECGX LLC 5MG

A202946 001 Jun 27, 2014 Dec CAHN

>A> AB 7.5MG

A202946 002 Jun 27, 2014 Dec CAHN

>A> AB 10MG

A202946 003 Jun 27, 2014 Dec CAHN

>A> AB 15MG

A202946 004 Jun 27, 2014 Dec CAHN

>A> AB 20MG

A202946 005 Jun 27, 2014 Dec CAHN

>A> AB 30MG

A202946 006 Jun 27, 2014 Dec CAHN

>A> AB 40MG

A202946 007 Jun 27, 2014 Dec CAHN

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

TERRAMYCIN W/ POLYMYXIN B SULFATE

! CASPER PHARMA LLC EQ 5MG BASE/GM;10,000 UNITS/GM

A061015 001 Jul CAHN

>A>	<u>OZENOXACIN</u>								
>A>	CREAM;TOPICAL								
>A>	XEPI								
>A>	+! FERRER INTERNACIONAL	1%	N208945	001	Dec 11, 2017		Dec	NEWA	
	<u>PALONOSETRON HYDROCHLORIDE</u>								
	SOLUTION;INTRAVENOUS								
	PALONOSETRON HYDROCHLORIDE								
	@ DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016		Sep	DISC	
	@	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016		Sep	DISC	
	+ FRESENIUS KABI USA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N208109	001	Nov 21, 2017		Nov	NEWA	
	<u>PAMIDRONATE DISODIUM</u>								
	INJECTABLE;INJECTION								
	PAMIDRONATE DISODIUM								
	AREVA PHARMS	60MG/VIAL	A077433	002	Nov 26, 2008		Nov	CTEC	
	<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)</u>								
	CAPSULE, DELAYED RELEASE;ORAL								
	PERTZYE								
	+ DIGESTIVE CARE INC	90,750USP UNITS;24,000USP UNITS;86,250USP UNITS	N022175	004	Jul 13, 2017		Sep	NEWA	
	ZENPEP								
>D>	+ FOREST LABS INC	218,000USP UNITS; 40,00USP UNITS; 136,000 USP UNITS	N022210	007	Mar 25, 2014		Dec	CPOT	
>A>	+	168,000USP UNITS;40,000USP UNITS;126,000USP UNITS	N022210	007	Mar 25, 2014		Dec	CPOT	
>D>	+	10,000USP UNITS;16,000USP UNITS;3,000USP UNITS	N022210	005	Jun 15, 2011		Dec	CPOT	
>D>	+	10,000USP UNITS;34,000USP UNITS;55,000USP UNITS	N022210	002	Aug 27, 2009		Dec	CPOT	
>A>	+	14,000USP UNITS;3,000USP UNITS;10,000USP UNITS	N022210	005	Jun 15, 2011		Dec	CPOT	
>D>	+	15,000USP UNITS;51,000USP UNITS;82,000USP UNITS	N022210	003	Aug 27, 2009		Dec	CPOT	
>D>	+	17,000USP UNITS;27,000USP UNITS;5,000USP UNITS	N022210	001	Aug 27, 2009		Dec	CPOT	
>A>	+	24,000USP UNITS;5,000USP UNITS;17,000USP UNITS	N022210	001	Aug 27, 2009		Dec	CPOT	
>A>	+	42,000USP UNITS;10,000USP UNITS;32,000USP UNITS	N022210	002	Aug 27, 2009		Dec	CPOT	
>A>	+	63,000USP UNITS;15,000USP UNITS;47,000USP UNITS	N022210	003	Aug 27, 2009		Dec	CPOT	
>A>	+	84,000USP UNITS;20,000USP UNITS;63,000USP UNITS	N022210	004	Aug 27, 2009		Dec	CPOT	
>A>	+!	105,000USP UNITS;25,000USP UNITS;79,000USP UNITS	N022210	006	Jul 13, 2011		Dec	CPOT	
>D>	+	109,000USP UNITS;20,000USP UNITS;68,000USP UNITS	N022210	004	Aug 27, 2009		Dec	CPOT	
>D>	+!	136,000USP UNITS;25,000USP UNITS;85,000USP UNITS	N022210	006	Jul 13, 2011		Dec	CPOT	
	<u>PANCURONIUM BROMIDE</u>								
	INJECTABLE;INJECTION								
	PANCURONIUM BROMIDE								
	! TEVA PHARMS USA	2MG/ML	A072760	001	Jul 31, 1990		Nov	CTEC	
	PAVULON								
>D>	@ ORGANON USA INC	1MG/ML	N017015	002			Dec	CRLD	
>A>	+ @	1MG/ML	N017015	002			Dec	CRLD	
>D>	@	2MG/ML	N017015	001			Dec	CRLD	
>A>	+ @	2MG/ML	N017015	001			Dec	CRLD	
	<u>PANTOPRAZOLE SODIUM</u>								
	POWDER;IV (INFUSION)								
	PANTOPRAZOLE SODIUM								
	EXELA PHARMA SCS LLC	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017		Jun	NEWA	
	TABLET, DELAYED RELEASE;ORAL								
	PANTOPRAZOLE SODIUM								
	@ SUN PHARM INDS LTD	EQ 20MG BASE	A077058	001	Sep 10, 2007		Sep	DISC	
AB	@	EQ 20MG BASE	A077058	001	Sep 10, 2007		Mar	CAHN	
	@	EQ 40MG BASE	A077058	002	Sep 10, 2007		Sep	DISC	
AB	@	EQ 40MG BASE	A077058	002	Sep 10, 2007		Mar	CAHN	

PARICALCITOL

CAPSULE;ORAL

PARICALCITOL

AB	AMNEAL PHARMS	1MCG	A204327	001	Jan 13, 2016	May CAHN
AB		2MCG	A204327	002	Jan 13, 2016	May CAHN
AB		4MCG	A204327	003	Jan 13, 2016	May CAHN

ZEMPLAR

AB	+ ABBVIE	1MCG	N021606	001	May 26, 2005	Oct CRLD
AB	+	2MCG	N021606	002	May 26, 2005	Oct CRLD
	+ @	4MCG	N021606	003	May 26, 2005	Oct CRLD

SOLUTION;INTRAVENOUS

PARICALCITOL

AP	AKORN	0.005MG/ML (0.005MG/ML)	A207692	001	Oct 16, 2017	Oct NEWA
AP	AMNEAL PHARMS CO	0.002MG/ML (0.002MG/ML)	A206699	001	Mar 09, 2017	Feb NEWA
AP		0.005MG/ML (0.005MG/ML)	A206699	002	Mar 09, 2017	Feb NEWA
AP		0.01MG/2ML (0.005MG/ML)	A206699	003	Mar 09, 2017	Feb NEWA
AP	MYLAN LABS LTD	0.002MG/ML (0.002MG/ML)	A203897	001	Nov 02, 2017	Oct NEWA
AP		0.005MG/ML (0.005MG/ML)	A203897	002	Nov 02, 2017	Oct NEWA
AP		0.01MG/2ML (0.005MG/ML)	A203897	003	Nov 02, 2017	Oct NEWA
AP	SANDOZ INC	0.002MG/ML (0.002MG/ML)	A091108	001	Jul 27, 2011	Apr CAHN
AP		0.005MG/ML (0.005MG/ML)	A091108	002	Jul 27, 2011	Apr CAHN
AP		0.01MG/2ML (0.005MG/ML)	A091108	003	Jul 27, 2011	Apr CAHN

PAROXETINE HYDROCHLORIDE

SUSPENSION;ORAL

PAXIL

+	APOTEX TECHNOLOGIES	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Sep CTEC
---	---------------------	------------------	---------	-----	--------------	----------

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

@	MYLAN PHARMS INC	EQ 10MG BASE	A075716	001	Mar 08, 2004	Apr DISC
---	------------------	--------------	---------	-----	--------------	----------

@		EQ 20MG BASE	A075716	002	Mar 08, 2004	Apr DISC
---	--	--------------	---------	-----	--------------	----------

@		EQ 30MG BASE	A075716	003	Mar 08, 2004	Apr DISC
---	--	--------------	---------	-----	--------------	----------

@		EQ 40MG BASE	A075716	004	Mar 08, 2004	Apr DISC
---	--	--------------	---------	-----	--------------	----------

@	UPSHER-SMITH LABS	EQ 10MG BASE	A075566	001	Mar 08, 2004	Jun CAHN
---	-------------------	--------------	---------	-----	--------------	----------

@		EQ 20MG BASE	A075566	002	Mar 08, 2004	Jun CAHN
---	--	--------------	---------	-----	--------------	----------

@		EQ 30MG BASE	A075566	003	Mar 08, 2004	Jun CAHN
---	--	--------------	---------	-----	--------------	----------

@		EQ 40MG BASE	A075566	004	Mar 08, 2004	Jun CAHN
---	--	--------------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

PAROXETINE HYDROCHLORIDE

AB	LUPIN LTD	EQ 12.5MG BASE	A204134	001	Jan 20, 2017	Jan NEWA
AB		EQ 25MG BASE	A204134	002	Jan 20, 2017	Jan NEWA
AB		EQ 37.5MG BASE	A204134	003	Jan 20, 2017	Jan NEWA

PAROXETINE MESYLATE

CAPSULE;ORAL

BRISDELLE

AB	+	SEBELA IRELAND LTD	EQ 7.5MG BASE	N204516	001	Jun 28, 2013	Jun CFTG
----	---	--------------------	---------------	---------	-----	--------------	----------

PAROXETINE MESYLATE

AB		ACTAVIS LABS FL INC	EQ 7.5MG BASE	A207139	001	Jun 20, 2017	Jun NEWA
----	--	---------------------	---------------	---------	-----	--------------	----------

AB		PRINSTON INC	EQ 7.5MG BASE	A207188	001	Aug 18, 2017	Aug NEWA
----	--	--------------	---------------	---------	-----	--------------	----------

PENCICLOVIR

CREAM;TOPICAL

DENA VIR

+	MYLAN PHARMS INC	1%	N020629	001	Sep 24, 1996	Jan CAHN
---	------------------	----	---------	-----	--------------	----------

PENICILLAMINE

TABLET;ORAL

DEPEN

+	MYLAN SPECIALITY LP	250MG	N019854	001		Mar CAHN
---	---------------------	-------	---------	-----	--	----------

PENICILLIN G BENZATHINE

INJECTABLE;INJECTION

BICILLIN L-A

+	KING PHARMS LLC	300,000 UNITS/ML	N050141	003		May CAHN
---	-----------------	------------------	---------	-----	--	----------

BC	+		600,000 UNITS/ML	N050141	001	May CAHN
----	---	--	------------------	---------	-----	----------

PERMAPEN

BC		CASPER PHARMA LLC	600,000 UNITS/ML	A060014	001	Jul CAHN
----	--	-------------------	------------------	---------	-----	----------

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE;INJECTION

BICILLIN C-R

+	!	KING PHARMS LLC	150,000 UNITS/ML;150,000 UNITS/ML	N050138	002		Apr	CAHN
+	!		300,000 UNITS/ML;300,000 UNITS/ML	N050138	001		Apr	CAHN
		BICILLIN C-R 900/300						
+	!	KING PHARMS LLC	900,000 UNITS/2ML;300,000 UNITS/2ML	N050138	003		Apr	CAHN

PENICILLIN G PROCAINE

INJECTABLE;INJECTION

PENICILLIN G PROCAINE

!		KING PHARMS LLC	300,000 UNITS/ML	A060101	002		Jun	CAHN
!			600,000 UNITS/ML	A060101	001		Jun	CAHN

PENTAMIDINE ISETHIONATE

INJECTABLE;INJECTION

PENTAM

AP	+	!	FRESENIUS KABI USA	300MG/VIAL	N019264	001	Oct 16, 1984	Sep CTEC
			PENTAMIDINE ISETHIONATE					
AP			SETON PHARMS	300MG/VIAL	A206666	001	Sep 28, 2017	Sep NEWA

PENTOBARBITAL SODIUM

INJECTABLE;INJECTION

PENTOBARBITAL SODIUM

AP			CUSTOPHARM INC	50MG/ML	A203619	001	Nov 13, 2017	Oct NEWA
AP			RENAISSANCE SSA LLC	50MG/ML	A206677	001	Nov 27, 2017	Nov NEWA
AP			SAGENT PHARMS	50MG/ML	A206404	001	May 23, 2016	Apr CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL

PENTOXIFYLLINE

			@ PLIVA	400MG	A074874	001	May 25, 1999	Aug CAHN
			PENTOXIL					
AB			UPSHER-SMITH LABS	400MG	A074962	001	Mar 31, 1999	Jun CAHN
			TRENTAL					
	+	@	US PHARM HOLDINGS	400MG	N018631	001	Aug 30, 1984	Jan CRLD

PERINDOPRIL ERBUMINE

TABLET;ORAL

PERINDOPRIL ERBUMINE

AB	!		AUROBINDO PHARMA	2MG	A079070	001	Nov 10, 2009	May CHRS
AB	!			4MG	A079070	002	Nov 10, 2009	May CHRS
AB	!			8MG	A079070	003	Nov 10, 2009	May CHRS

PERMETHRIN

CREAM;TOPICAL

ELIMITE

AB	+	!	MYLAN PHARMS INC	5%	N019855	001	Aug 25, 1989	Jan CAHN
			PERMETHRIN					
AB			ACTAVIS LABS	5%	A074806	001	Jan 23, 1998	May CAHN

PERPHENAZINE

TABLET;ORAL

PERPHENAZINE

AB			MYLAN PHARMS INC	2MG	A206691	001	Apr 14, 2017	Apr NEWA
AB				4MG	A206691	002	Apr 14, 2017	Apr NEWA
AB				8MG	A206691	003	Apr 14, 2017	Apr NEWA
AB				16MG	A206691	004	Apr 14, 2017	Apr NEWA

PHENDIMETRAZINE TARTRATE

TABLET;ORAL

PHENDIMETRAZINE TARTRATE

>A>	AA		ELITE LABS INC	35MG	A203600	001	Dec 27, 2017	Dec NEWA
			@ USL PHARMA	35MG	A084399	001		Jun CAHN

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL

	PHENOXYBENZAMINE HYDROCHLORIDE						
AB	PAR PHARM INC	10MG	A204522	001	Jan 24, 2017	Jan	NEWA

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

	@ ELITE LABS INC	30MG	A040227	001	Jun 18, 1997	May	CAHN
	@	30MG	A040448	001	Jan 22, 2003	May	CAHN
AA		37.5MG	A040228	001	Jun 19, 1997	May	CAHN
	@ UPSHER-SMITH LABS	30MG	A084487	001	Apr 09, 1982	Jun	CAHN
	@	30MG	A088430	001	Mar 27, 1984	Jun	CAHN

TABLET;ORAL

LOMAIRA

AA	! AVANTHI INC	8MG	A203495	001	Sep 12, 2016	Nov	CTEC
	PHENTERMINE HYDROCHLORIDE						
AA	ELITE LABS INC	37.5MG	A040190	001	May 30, 1997	May	CAHN
AA	KVK TECH INC	8MG	A203436	001	Mar 17, 2017	Mar	NEWA
AA	PRINSTON INC	37.5MG	A040377	001	Jan 04, 2002	Feb	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

PHENTERMINE HYDROCHLORIDE

	ZYDUS PHARMS USA INC	15MG	A204663	001	Jun 28, 2017	Jun	NEWA
		30MG	A204663	002	Jun 28, 2017	Jun	NEWA
		37.5MG	A204663	003	Jun 28, 2017	Jun	NEWA

PHENTOLAMINE MESYLATE

INJECTABLE;INJECTION

PHENTOLAMINE MESYLATE

AP	PRECISION DOSE INC	5MG/VIAL	A207686	001	Jul 14, 2017	Jul	NEWA
AP	! WEST-WARD PHARMS INT	5MG/VIAL	A040235	001	Mar 11, 1998	Jul	CTEC
	! REGITINE	5MG/VIAL	A040235	001	Mar 11, 1998	May	CHRS
	+ @ NOVARTIS	5MG/VIAL	N008278	003		May	DISC

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IV (INFUSION)

VAZCULEP

	+ AVADEL LEGACY	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Jan	CAHN
	+	50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Jan	CAHN
	+!	100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Jan	CAHN

PHENYTOIN

SUSPENSION;ORAL

PHENYTOIN

>D>	AB	WOCKHARDT	125MG/5ML	A040420	001	Apr 19, 2002	Dec	CAHN
>A>	AB	WOCKHARDT EU OPERATN	125MG/5ML	A040420	001	Apr 19, 2002	Dec	CAHN

TABLET, CHEWABLE;ORAL

DILANTIN

AB	! PFIZER	50MG	A084427	001		Feb	CAHN
	PHENYTOIN						
AB	EPIC PHARMA LLC	50MG	A040884	001	Nov 28, 2014	May	CAHN

PHENYTOIN SODIUM

CAPSULE;ORAL

DILANTIN

	! PARKE-DAVIS	30MG EXTENDED	A084349	001		Nov	CTEC
AB	!	30MG EXTENDED	A084349	001		Feb	CAHN
AB	!	100MG EXTENDED	A084349	002		Feb	CAHN

INJECTABLE;INJECTION

PHENYTOIN SODIUM

AP	ACELLA PHARMS LLC	50MG/ML	A040573	001	Sep 13, 2006	May	CAHN
----	-------------------	---------	---------	-----	--------------	-----	------

PHYTONADIONE

INJECTABLE;INJECTION

AQUAMEPHYTON

	+ @ TELIGENT	1MG/0.5ML	N012223	002		Apr	CAHN
	+ @	10MG/ML	N012223	001		Apr	CAHN

PILOCARPINE HYDROCHLORIDESOLUTION;OPHTHALMIC
ISOPTO CARPINE

AT	+	NOVARTIS PHARMS CORP	1%	N200890	001	Jun 22, 2010	Sep CFTG
AT	+		2%	N200890	002	Jun 22, 2010	Sep CFTG
AT	+	!	4%	N200890	003	Jun 22, 2010	Sep CFTG

PILOCARPINE HYDROCHLORIDE

AT		AKORN INC	1%	A204398	001	Sep 27, 2017	Sep NEWA
AT			2%	A204398	002	Sep 27, 2017	Sep NEWA
AT			4%	A204398	003	Sep 27, 2017	Sep NEWA

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

AB		ALLIED PHARMA INC	5MG	A076963	001	Dec 22, 2004	Mar CAHN
AB			7.5MG	A076963	002	Feb 27, 2007	Mar CAHN
AB		INNOGENIX	5MG	A076963	001	Dec 22, 2004	Sep CAHN
AB			7.5MG	A076963	002	Feb 27, 2007	Sep CAHN
AB		PERRIGO PHARMA INTL	5MG	A076746	001	Nov 16, 2004	Apr CAHN

PINDOLOL

TABLET;ORAL

PINDOLOL

AB		IDT AUSTRALIA LTD	5MG	A073608	001	Mar 29, 1993	May CMFD
AB			10MG	A073609	001	Mar 29, 1993	May CMFD
AB		ZYDUS PHARMS USA INC	5MG	A209866	001	Aug 18, 2017	Aug NEWA
AB			10MG	A209866	002	Aug 18, 2017	Aug NEWA

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

AB		CIPLA LTD	EQ 15MG BASE	A076798	001	Oct 26, 2012	Jun CAHN
AB			EQ 30MG BASE	A076798	002	Oct 26, 2012	Jun CAHN
AB			EQ 45MG BASE	A076798	003	Oct 26, 2012	Jun CAHN
AB		PURACAP PHARM LLC	EQ 15MG BASE	A206738	001	Oct 06, 2017	Sep NEWA
AB			EQ 30MG BASE	A206738	002	Oct 06, 2017	Sep NEWA
AB			EQ 45MG BASE	A206738	003	Oct 06, 2017	Sep NEWA
AB		WATSON LABS TEVA	EQ 15MG BASE	A076798	001	Oct 26, 2012	May CAHN
AB			EQ 30MG BASE	A076798	002	Oct 26, 2012	May CAHN
AB			EQ 45MG BASE	A076798	003	Oct 26, 2012	May CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP		APOLLO PHARMS INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A207847	001	Jan 13, 2017	Jan NEWA
AP			EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A207847	002	Jan 13, 2017	Jan NEWA
AP			EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207848	002	Jan 13, 2017	Jan NEWA
AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207847	003	Jan 13, 2017	Jan NEWA
AP		WOCKHARDT BIO AG	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A206996	001	Mar 22, 2017	Mar NEWA
AP			EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A206996	002	Mar 22, 2017	Mar NEWA
AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A206996	003	Mar 22, 2017	Mar NEWA
AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207146	001	Mar 17, 2017	Mar NEWA

PIRFENIDONE

TABLET;ORAL

ESBRIET

+	GENENTECH INC	267MG	N208780	001	Jan 11, 2017	Jan NEWA
+	@	534MG	N208780	002	Jan 11, 2017	Jan DISC
+	!	801MG	N208780	003	Jan 11, 2017	Jan NEWA

PIROXICAM

CAPSULE;ORAL

PIROXICAM

AB		HIKMA PHARMS	10MG	A209256	001	Aug 11, 2017	Jul NEWA
AB			20MG	A209256	002	Aug 11, 2017	Jul NEWA
>A>	AB	+	MICRO LABS	A206152	001	Dec 29, 2017	Dec NEWA
>A>	AB	+		A206152	002	Dec 29, 2017	Dec NEWA

CAPSULE;ORAL
PIROXICAM

	@ MYLAN	10MG	A074102	001	Jul 31, 1992	Jul DISC
	@	20MG	A074102	002	Jul 31, 1992	Jul DISC
AB	PII	10MG	A206136	001	Jun 20, 2017	Jun NEWA
AB		20MG	A206136	002	Jun 20, 2017	Jun NEWA
AB	SUN PHARM INDUSTRIES	10MG	A073536	002	Jan 23, 2008	Oct CMS1
AB		20MG	A073536	001	Mar 12, 1993	Oct CMFD
AB	UNICHEM LABS LTD	10MG	A208340	001	Apr 13, 2017	Apr NEWA
AB		20MG	A208340	002	Apr 13, 2017	Apr NEWA

PITAVASTATIN CALCIUM

TABLET;ORAL

PITAVASTATIN CALCIUM

AB	ORIENT PHARMA CO LTD	EQ 1MG BASE	A205932	001	Feb 03, 2017	Jan NEWA
AB		EQ 2MG BASE	A205932	002	Feb 03, 2017	Jan NEWA
AB		EQ 4MG BASE	A205932	003	Feb 03, 2017	Jan NEWA
AB	SAWAI USA	EQ 1MG BASE	A205955	001	Feb 03, 2017	Jan NEWA
AB		EQ 2MG BASE	A205955	002	Feb 03, 2017	Jan NEWA
AB		EQ 4MG BASE	A205955	003	Feb 03, 2017	Jan NEWA

PITAVASTATIN MAGNESIUM

TABLET;ORAL

ZYPITAMAG

+	ZYDUS PHARMS USA INC	EQ 1MG BASE	N208379	001	Jul 14, 2017	Jul NEWA
+		EQ 2MG BASE	N208379	002	Jul 14, 2017	Jul NEWA
+	!	EQ 4MG BASE	N208379	003	Jul 14, 2017	Jul NEWA

PITAVASTATIN SODIUM

TABLET;ORAL

NIKITA

+	@ LUPIN LTD	EQ 1MG BASE	N209875	001	Aug 04, 2017	Sep DISC
+		EQ 1MG BASE	N209875	001	Aug 04, 2017	Aug NEWA
+	@	EQ 2MG BASE	N209875	002	Aug 04, 2017	Sep DISC
+		EQ 2MG BASE	N209875	002	Aug 04, 2017	Aug NEWA
+	@	EQ 4MG BASE	N209875	003	Aug 04, 2017	Sep DISC
+	!	EQ 4MG BASE	N209875	003	Aug 04, 2017	Aug NEWA

PLECANATIDE

TABLET;ORAL

TRULANCE

+	!	SYNERGY PHARMS	3MG	N208745	001	Jan 19, 2017	Jan NEWA
---	---	----------------	-----	---------	-----	--------------	----------

PODOFILOX

SOLUTION;TOPICAL

PODOFILOX

	@ BAUSCH AND LOMB INC	0.5%	A090184	001	Jul 21, 2010	Aug DISC
--	-----------------------	------	---------	-----	--------------	----------

POLIDOCANOL

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

VARITHENA

>A>	+	!	PROVENSIS	77.5MG/7.75ML (10MG/ML)	N205098	002	Dec 21, 2017	Dec NEWA
-----	---	---	-----------	-------------------------	---------	-----	--------------	----------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

	@ MYLAN	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A090409	001	Apr 02, 2010	Apr DISC
AA	STRIDES PHARMA	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A204559	001	Apr 13, 2015	Apr CAHN
		PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE				
AA	BRECKENRIDGE PHARM	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A202060	001	Mar 08, 2017	Mar CAHN
AA	BRECKENRIDGE PHARMS	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A202060	001	Mar 08, 2017	Feb NEWA
		TRILYTE				
AA	MYLAN PHARMS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A076491	001	Feb 05, 2004	Mar CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE

	@ MYLAN SPECIALITY LP	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Mar CAHN
	@	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Mar CAHN
	@	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Mar CAHN
	@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Mar CAHN
	@	360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Mar CAHN
	COLYTE WITH FLAVOR PACKS					
AA	MYLAN SPECIALITY LP	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Mar CAHN
	COLYTE-FLAVORED					
	@ MYLAN SPECIALITY LP	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Mar CAHN
	@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Mar CAHN
	PEG 3350 AND ELECTROLYTES					
	@ MYLAN	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090928	001	Jan 28, 2010	Apr DISC

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	SANDOZ INC	10,000 UNITS/ML;EQ 1MG BASE/ML	A064211	001	Apr 13, 1998	Feb CAHN
----	------------	--------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

KLOR-CON

AB	UPSHER-SMITH LABS	8MEQ	A203106	001	Jul 10, 2015	Jun CAHN
AB		10MEQ	A203106	002	Jul 10, 2015	Jun CAHN
	MICRO-K					
AB	+ NESHER PHARMS	8MEQ	N018238	001		Nov CRLD
	MICRO-K 10					
AB	+ NESHER PHARMS	10MEQ	N018238	002	May 14, 1984	Nov CRLD
	POTASSIUM CHLORIDE					
AB	ADARE PHARMS INC	8MEQ	A208864	001	Mar 17, 2017	Mar NEWA
AB		10MEQ	A208864	002	Mar 17, 2017	Mar NEWA
	FOR SOLUTION;ORAL					
	KLOR-CON					
AA	UPSHER-SMITH LABS	20MEQ	A209662	001	Oct 23, 2017	Oct CAHN
AA		20MEQ	A209662	001	Oct 23, 2017	Oct NEWA
	POTASSIUM CHLORIDE					
AA	+! PHARMA RES SOFTWARE	20MEQ	N208019	001	Aug 19, 2015	Oct CFTG
	INJECTABLE;INJECTION					
	POTASSIUM CHLORIDE					
	@ BAXTER HLTHCARE	2MEQ/ML	A085499	001		Apr DISC
	POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER					
AP	+ ICU MEDICAL INC	14.9MG/ML	N020161	005	Nov 30, 1992	Feb CAHN
AP	+ ICU MEDICAL INC	745MG/100ML	N020161	001	Nov 30, 1992	Feb CAHN
	POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER					
AP	+! ICU MEDICAL INC	29.8MG/ML	N020161	006	Aug 11, 1998	Feb CAHN
AP	+ ICU MEDICAL INC	1.49GM/100ML	N020161	002	Nov 30, 1992	Feb CAHN
	POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER					
AP	+! ICU MEDICAL INC	2.24GM/100ML	N020161	003	Aug 11, 1998	Feb CAHN
	POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER					
AP	+! ICU MEDICAL INC	2.98GM/100ML	N020161	004	Aug 11, 1998	Feb CAHN
	TABLET, EXTENDED RELEASE;ORAL					
	KLOR-CON					
AB2	+ UPSHER-SMITH LABS	8MEQ	N019123	001	Apr 17, 1986	Jun CAHN
AB2	+! UPSHER-SMITH LABS	10MEQ	N019123	002	Apr 17, 1986	Jun CAHN
	KLOR-CON M10					
AB1	UPSHER-SMITH LABS	10MEQ	A074726	002	Aug 09, 2000	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL
KLOR-CON M15

	UPSHER-SMITH LABS	15MEQ	A074726	003	Jun 06, 2003	Jun CAHN
	KLOR-CON M20					
AB1 !	UPSHER-SMITH LABS	20MEQ	A074726	001	Nov 20, 1998	Jun CAHN

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

	POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	149MG/100ML;450MG/100ML	A078446	001	Sep 10, 2008	Feb CAHN
	POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	149MG/100ML;900MG/100ML	N019686	001	Oct 17, 1988	Feb CAHN
	POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC	298MG/100ML;900MG/100ML	N019686	002	Oct 17, 1988	Feb CAHN

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CITRATE

>A>	AB	COREPHARMA	5MEQ	A077440	001	Jun 09, 2006	Dec CAHN
>A>	AB		10MEQ	A077440	002	Jun 09, 2006	Dec CAHN
>D>	AB	IMPAX LABS INC	5MEQ	A077440	001	Jun 09, 2006	Dec CAHN
	AB		5MEQ	A077440	001	Jun 09, 2006	Feb CAHN
>D>	AB		10MEQ	A077440	002	Jun 09, 2006	Dec CAHN
	AB		10MEQ	A077440	002	Jun 09, 2006	Feb CAHN
	AB	STRIDES PHARMA	5MEQ	A206813	001	Sep 11, 2017	Aug NEWA
	AB		10MEQ	A206813	002	Sep 11, 2017	Aug NEWA
	AB		15MEQ	A206813	003	Sep 11, 2017	Aug NEWA

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

	PRAMIPEXOLE DIHYDROCHLORIDE					
	@ ACTAVIS GRP PTC	0.125MG	A091254	001	Nov 30, 2010	Jan DISC
	@	0.25MG	A091254	002	Nov 30, 2010	Jan DISC
	@	0.5MG	A091254	003	Nov 30, 2010	Jan DISC
	@	0.75MG	A091254	004	Nov 30, 2010	Jan DISC
	@	1MG	A091254	005	Nov 30, 2010	Jan DISC
	@	1.5MG	A091254	006	Nov 30, 2010	Jan DISC
AB	ALEMBIC PHARMS LTD	0.125MG	A078894	001	Oct 08, 2010	May CAHN
AB		0.25MG	A078894	002	Oct 08, 2010	May CAHN
AB		0.5MG	A078894	003	Oct 08, 2010	May CAHN
AB		1MG	A078894	004	Oct 08, 2010	May CAHN
AB		1.5MG	A078894	005	Oct 08, 2010	May CAHN

TABLET, EXTENDED RELEASE;ORAL

	PRAMIPEXOLE DIHYDROCHLORIDE					
AB	ACTAVIS ELIZABETH	2.25MG	A203615	001	Oct 14, 2016	Apr CAHN
AB		3.75MG	A203615	002	Jan 03, 2017	Apr CAHN
AB	MACLEODS PHARMS LTD	3.75MG	A206156	007	Jan 23, 2017	Jan NEWA
AB	ZYDUS PHARMS USA INC	0.375MG	A202891	001	Dec 12, 2017	Nov NEWA
AB		0.75MG	A202891	002	Dec 12, 2017	Nov NEWA
AB		1.5MG	A202891	003	Dec 12, 2017	Nov NEWA
AB		2.25MG	A202891	004	Dec 12, 2017	Nov NEWA
AB		3MG	A202891	005	Dec 12, 2017	Nov NEWA
AB		3.75MG	A202891	006	Dec 12, 2017	Nov NEWA
AB		4.5MG	A202891	007	Dec 12, 2017	Nov NEWA

PRASTERONE

INSERT;VAGINAL
INTRAROSA

+!	AMAG PHARMS INC	6.5MG	N208470	001	Nov 16, 2016	May CAHN
----	-----------------	-------	---------	-----	--------------	----------

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

	EFFIENT					
AB	+ ELI LILLY AND CO	EQ 5MG BASE	N022307	001	Jul 10, 2009	Jun CFTG
AB	+!	EQ 10MG BASE	N022307	002	Jul 10, 2009	Jun CFTG
	PRASUGREL					
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A205888	001	Oct 16, 2017	Oct NEWA
AB		EQ 10MG BASE	A205888	002	Oct 16, 2017	Oct NEWA
AB	LIBERTY PHARMA INC	EQ 5MG BASE	A205790	001	Oct 16, 2017	Oct NEWA
AB		EQ 10MG BASE	A205790	002	Oct 16, 2017	Oct NEWA
AB	MYLAN PHARMS INC	EQ 5MG BASE	A205927	001	Jul 12, 2017	Jun NEWA
AB		EQ 10MG BASE	A205927	002	Jul 12, 2017	Jun NEWA

TABLET;ORAL

PRASUGREL

AB	PANACEA BIOTEC LTD	EQ 5MG BASE	A205897	001	Oct 16, 2017	Oct NEWA
AB		EQ 10MG BASE	A205897	002	Oct 16, 2017	Oct NEWA

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

AB	AUROBINDO PHARMA LTD	10MG	A203367	001	Feb 02, 2017	Jan NEWA
AB		20MG	A203367	002	Feb 02, 2017	Jan NEWA
AB		40MG	A203367	003	Feb 02, 2017	Jan NEWA
AB		80MG	A203367	004	Feb 02, 2017	Jan NEWA

PRAZQUANTEL

TABLET;ORAL

BILTRICIDE

AB	+! BAYER HLTHCARE	600MG	N018714	001	Dec 29, 1982	Nov CFTG
AB	PAR PHARM INC	600MG	A208820	001	Nov 27, 2017	Nov NEWA

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

AA	PHARM ASSOC	15MG/5ML	A040399	001	Mar 05, 2003	May CAHN
AA	VISTAPHARM	15MG/5ML	A040323	001	May 13, 1999	Mar CAHN
>D> AA	WOCKHARDT	15MG/5ML	A040313	001	Sep 10, 2003	Dec CAHN
>A> AA	WOCKHARDT BIO AG	15MG/5ML	A040313	001	Sep 10, 2003	Dec CAHN

TABLET;ORAL

PREDNISOLONE

@	CHARTWELL RX	5MG	A084542	001		Apr CAHN
---	--------------	-----	---------	-----	--	----------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

	@ AMNEAL PHARMS	EQ 15MG BASE/5ML	A078345	001	Mar 10, 2009	May DISC
AA	CHARTWELL RX	EQ 5MG BASE/5ML	A075988	001	May 25, 2004	Jun CAHN
	@ PHARM ASSOC	EQ 5MG BASE/5ML	A076123	001	Dec 23, 2002	May CAHN
>D> AA	WOCKHARDT	EQ 5MG BASE/5ML	A075099	001	Jun 28, 2002	Dec CAHN
>A> AA	WOCKHARDT BIO AG	EQ 5MG BASE/5ML	A075099	001	Jun 28, 2002	Dec CAHN

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	! BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995	Feb CAHN
AT	SANDOZ INC	EQ 0.23% PHOSPHATE;10%	A073630	001	May 27, 1993	Feb CAHN

PREDNISON

TABLET;ORAL

PREDNISON

	@ CHARTWELL RX	5MG	A083059	001		Apr CAHN
AB	MYLAN PHARMS INC	5MG	A080292	001		Jan CAHN
AB		10MG	A088832	001	Dec 04, 1985	Jan CAHN
AB		20MG	A083677	001		Jan CAHN
AB	SUN PHARM INDUSTRIES	10MG	A089246	001	Dec 04, 1985	May CAHN
	@ UPSHER SMITH	5MG	A087471	001		Jun CAHN
	@	20MG	A087470	001		Jun CAHN

TABLET, DELAYED RELEASE;ORAL

PREDNISON

AB	ACTAVIS LABS FL INC	1MG	A204867	001	Apr 25, 2017	Apr NEWA
AB		2MG	A204867	002	Apr 25, 2017	Apr NEWA
AB		5MG	A204867	003	Apr 25, 2017	Apr NEWA

RAYOS

AB	+ HORIZON PHARMA	1MG	N202020	001	Jul 26, 2012	Apr CFTG
AB	+	2MG	N202020	002	Jul 26, 2012	Apr CFTG
AB	+!	5MG	N202020	003	Jul 26, 2012	Apr CFTG

PREGABALIN

TABLET, EXTENDED RELEASE;ORAL

LYRICA CR

+	PFIZER INC	82.5MG	N209501	001	Oct 11, 2017	Oct NEWA
+		165MG	N209501	002	Oct 11, 2017	Oct NEWA
+	!	330MG	N209501	003	Oct 11, 2017	Oct NEWA

PRIMIDONETABLET; ORAL
PRIMIDONE

AB	ANDA REPOSITORY	50MG	A040626	001	Sep 29, 2005	Sep CAHN
AB		250MG	A040626	002	Sep 29, 2005	Sep CAHN

PROBENECIDTABLET; ORAL
BENEMID

	+ @ MERCK	500MG	N007898	004		Jan CRLD
AB	WATSON LABS TEVA	500MG	A084442	004	Mar 29, 1983	May CAHN

PROCAINAMIDE HYDROCHLORIDECAPSULE; ORAL
PROCAINAMIDE HYDROCHLORIDE

	@ IDT AUSTRALIA LTD	375MG	A089219	002	Jul 01, 1986	Aug CMS1
	@	500MG	A089219	003	Jul 01, 1986	Aug CMS1

INJECTABLE; INJECTION
PROCAINAMIDE HYDROCHLORIDE

AP	NEXUS PHARMS	100MG/ML	A206332	001	Oct 13, 2017	Oct NEWA
AP		500MG/ML	A206332	002	Oct 13, 2017	Oct NEWA
	@ WEST-WARD PHARMS INT	100MG/ML	A089029	001	Apr 17, 1986	Jan CAHN
	@	500MG/ML	A089030	001	Apr 17, 1986	Mar CAHN

TABLET, EXTENDED RELEASE; ORAL
PROCAINAMIDE HYDROCHLORIDE

	@ IDT AUSTRALIA LTD	500MG	A089369	002	Jan 09, 1987	Oct DISC
		500MG	A089369	002	Jan 09, 1987	Aug CMS1
	@	750MG	A089369	003	Aug 14, 1987	Oct DISC
		750MG	A089369	003	Aug 14, 1987	Aug CMS1

PROCARBAZINE HYDROCHLORIDECAPSULE; ORAL
MATULANE

	+! LEADIANT BIOSCI INC	EQ 50MG BASE	N016785	001		Feb CAHN
--	------------------------	--------------	---------	-----	--	----------

PROCHLORPERAZINE EDISYLATEINJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

	@ ATHENEX INC	EQ 5MG BASE/ML	A040540	001	May 28, 2004	Mar CAHN
	@ WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A089523	001	May 03, 1988	Jan CAHN
AP		EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Jan CAHN

PROCYCLIDINE HYDROCHLORIDETABLET; ORAL
KEMADRIN

	@ MONARCH PHARMS	2MG	N009818	005		Apr CAHN
	@	5MG	N009818	003		Apr CAHN

PROGESTERONECAPSULE; ORAL
PROGESTERONE

AB	AMNEAL PHARMS NY	100MG	A207724	001	Sep 07, 2017	Aug NEWA
AB		200MG	A207724	002	Sep 07, 2017	Aug NEWA
AB	DR REDDYS LABS INC	100MG	A208801	001	Feb 28, 2017	Feb NEWA
AB		200MG	A208801	002	Feb 28, 2017	Feb NEWA
AB	SANDOZ INC	100MG	A205229	001	Oct 20, 2017	Oct NEWA
AB		200MG	A205229	002	Oct 20, 2017	Oct NEWA

INJECTABLE; INJECTION
PROGESTERONE

AO	+! ACTAVIS LABS UT INC	50MG/ML	N017362	002		Feb CAHN
----	------------------------	---------	---------	-----	--	----------

PROMETHAZINE HYDROCHLORIDESUPPOSITORY; RECTAL
PHENERGAN

	+ @ MYLAN PHARMS INC	50MG	N011689	001		Jan CAHN
--	----------------------	------	---------	-----	--	----------

SYRUP; ORAL
PROMETHAZINE PLAIN

>D> AA	!	WOCKHARDT	6.25MG/5ML	A087953	001	Nov 15, 1982	Dec CAHN
>A> AA	!	WOCKHARDT BIO AG	6.25MG/5ML	A087953	001	Nov 15, 1982	Dec CAHN

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

	IMPAX LABS	12.5MG	A040791	002	Feb 12, 2008	Aug CMS1
		25MG	A040791	003	Feb 12, 2008	Aug CMS1
	@ MYLAN	12.5MG	A091054	001	Aug 30, 2011	Nov DISC
	@	25MG	A091054	002	Aug 30, 2011	Nov DISC
	@	50MG	A091054	003	Aug 30, 2011	Nov DISC
AB	PRINSTON INC	12.5MG	A040622	001	Jul 18, 2006	Feb CAHN
AB		25MG	A040622	002	Jul 18, 2006	Feb CAHN
AB		50MG	A040622	003	Jul 18, 2006	Feb CAHN
AB	STRIDES PHARMA	12.5MG	A209177	001	Jun 30, 2017	Jun NEWA
AB		25MG	A209177	002	Jun 30, 2017	Jun NEWA
AB		50MG	A209177	003	Jun 30, 2017	Jun NEWA

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPAFENONE HYDROCHLORIDE

AB	GLENMARK PHARMS LTD	225MG	A205268	001	Sep 08, 2017	Aug NEWA
AB		325MG	A205268	002	Sep 08, 2017	Aug NEWA
AB		425MG	A205268	003	Sep 08, 2017	Aug NEWA

TABLET;ORAL

PROPAFENONE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	150MG	A202445	001	May 11, 2016	Nov CAHN
AB		225MG	A202445	002	May 11, 2016	Nov CAHN
AB		300MG	A202445	003	May 11, 2016	Nov CAHN

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

LARGON

@	WEST-WARD PHARMS INT	20MG/ML	N012382	002		Jan CAHN
---	----------------------	---------	---------	-----	--	----------

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

INNOPRAN XL

BX	ANI PHARMS INC	80MG	N021438	001	Mar 12, 2003	Mar CAHN
BX		120MG	N021438	002	Mar 12, 2003	Mar CAHN

PROPRANOLOL HYDROCHLORIDE

BX	UPSHER SMITH	60MG	A078311	001	Mar 06, 2009	Apr CMFD
	@	60MG	A078311	001	Mar 06, 2009	Feb DISC
BX		80MG	A078311	002	Mar 06, 2009	Apr CMFD
	@	80MG	A078311	002	Mar 06, 2009	Feb DISC
BX		120MG	A078311	003	Mar 06, 2009	Apr CMFD
	@	120MG	A078311	003	Mar 06, 2009	Feb DISC
BX		160MG	A078311	004	Mar 06, 2009	Apr CMFD
	@	160MG	A078311	004	Mar 06, 2009	Feb DISC
	@ UPSHER-SMITH LABS	60MG	A078311	001	Mar 06, 2009	Sep DISC
BX		60MG	A078311	001	Mar 06, 2009	Jun CAHN
	@	80MG	A078311	002	Mar 06, 2009	Sep DISC
BX		80MG	A078311	002	Mar 06, 2009	Jun CAHN
	@	120MG	A078311	003	Mar 06, 2009	Sep DISC
BX		120MG	A078311	003	Mar 06, 2009	Jun CAHN
	@	160MG	A078311	004	Mar 06, 2009	Sep DISC
BX		160MG	A078311	004	Mar 06, 2009	Jun CAHN

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE

AP	ATHENEX INC	1MG/ML	A075792	001	Aug 29, 2000	Mar CAHN
	@ SANDOZ INC	1MG/ML	A076400	001	Feb 26, 2003	Mar CAHN

TABLET;ORAL

INDERAL

+	@ WYETH PHARMS INC	40MG	N016418	002		Jan CRLD
	PROPRANOLOL HYDROCHLORIDE					
	@ ANDA REPOSITORY	10MG	A070319	001	Oct 22, 1985	Sep CAHN
	@	20MG	A070320	001	Oct 22, 1985	Sep CAHN
	@	40MG	A070103	001	Oct 22, 1985	Sep CAHN
	@	60MG	A070321	001	Sep 24, 1986	Sep CAHN
	@	80MG	A070322	001	Aug 04, 1986	Sep CAHN
>A>	AB	VINTAGE PHARMS	A070221	002	Aug 01, 1986	Dec CMS1
>A>	AB		A070221	003	Aug 01, 1986	Dec CMS1
>A>	AB		A070221	004	Aug 01, 1986	Dec CMS1
>A>	AB		A070221	005	Sep 24, 1986	Dec CMS1
	@ WATSON LABS TEVA	10MG	A070548	001	Jul 10, 1986	May CAHN
	@	20MG	A070549	001	Apr 11, 1986	May CAHN

TABLET;ORAL		PROPRANOLOL HYDROCHLORIDE							
	@	40MG		A070550	001	Apr 11, 1986	May	CAHN	
<u>PROPYLTHIOURACIL</u>									
TABLET;ORAL		PROPYLTHIOURACIL							
	@ CHARTWELL RX	50MG		A084543	001		Apr	CAHN	
<u>PROTAMINE SULFATE</u>									
INJECTABLE;INJECTION		PROTAMINE SULFATE							
	@ WEST-WARD PHARMS INT	10MG/ML		A089474	001	Nov 05, 1986	Mar	CAHN	
	@	10MG/ML		A089475	001	Nov 05, 1986	Jan	CAHN	
<u>PYRIDOSTIGMINE BROMIDE</u>									
INJECTABLE;INJECTION		REGONOL							
AP	SANDOZ INC	5MG/ML		N017398	001		May	CAHN	
TABLET;ORAL		PYRIDOSTIGMINE BROMIDE							
	@ IMPAX LABS INC	60MG		A040457	001	Dec 26, 2002	Feb	CAHN	
TABLET, EXTENDED RELEASE;ORAL		PYRIDOSTIGMINE BROMIDE							
AB	KINEDEXE UK	180MG		A205464	001	Aug 15, 2017	Jul	NEWA	
<u>PYRIMETHAMINE</u>									
TABLET;ORAL		DARAPRIM							
	+! TURING PHARMS LLC	25MG		N008578	001		May	CAHN	
<u>QUETIAPINE FUMARATE</u>									
TABLET;ORAL		QUETIAPINE FUMARATE							
	@ MYLAN PHARMS INC	EQ 25MG BASE		A090323	001	Mar 27, 2012	May	DISC	
	SEROQUEL								
AB	+! ASTRAZENECA PHARMS	EQ 25MG BASE		N020639	001	Sep 26, 1997	Sep	CAHN	
AB	+	EQ 50MG BASE		N020639	007	Oct 04, 2005	Sep	CAHN	
AB	+	EQ 100MG BASE		N020639	002	Sep 26, 1997	Sep	CAHN	
	+ @	EQ 150MG BASE		N020639	004	Dec 20, 1998	Sep	CAHN	
AB	+	EQ 200MG BASE		N020639	003	Sep 26, 1997	Sep	CAHN	
AB	+!	EQ 300MG BASE		N020639	005	Jul 26, 2000	Sep	CAHN	
AB	+	EQ 400MG BASE		N020639	006	Oct 04, 2005	Sep	CAHN	
TABLET, EXTENDED RELEASE;ORAL		QUETIAPINE FUMARATE							
AB	ACCORD HLTHCARE	EQ 50MG BASE		A206252	001	Nov 29, 2017	Nov	NEWA	
AB		EQ 150MG BASE		A090681	001	May 09, 2017	Apr	NEWA	
AB		EQ 200MG BASE		A090681	002	May 09, 2017	Apr	NEWA	
AB		EQ 300MG BASE		A090681	003	May 09, 2017	Apr	NEWA	
AB		EQ 400MG BASE		A090681	004	Nov 01, 2016	Mar	CAHN	
AB	ANCHEN PHARMS	EQ 150MG BASE		A090757	001	Dec 01, 2017	Nov	NEWA	
AB		EQ 200MG BASE		A090757	002	Dec 01, 2017	Nov	NEWA	
AB		EQ 300MG BASE		A090757	003	Dec 01, 2017	Nov	NEWA	
AB		EQ 400MG BASE		A090757	004	Dec 01, 2017	Nov	NEWA	
AB	AUROBINDO PHARMA LTD	EQ 50MG BASE		A207655	001	Nov 29, 2017	Nov	NEWA	
AB		EQ 150MG BASE		A207655	002	Nov 29, 2017	Nov	NEWA	
AB		EQ 200MG BASE		A207655	003	Nov 29, 2017	Nov	NEWA	
AB		EQ 300MG BASE		A207655	004	Nov 29, 2017	Nov	NEWA	
AB		EQ 400MG BASE		A207655	005	Nov 29, 2017	Nov	NEWA	
AB	INTELLIPHARMACEUTICS	EQ 50MG BASE		A202939	001	May 09, 2017	Apr	NEWA	
AB		EQ 150MG BASE		A202939	002	May 09, 2017	Apr	NEWA	
AB		EQ 200MG BASE		A202939	003	May 09, 2017	Apr	NEWA	
AB		EQ 300MG BASE		A202939	004	May 09, 2017	Apr	NEWA	
AB		EQ 400MG BASE		A202939	005	May 09, 2017	Apr	NEWA	
AB	LUPIN LTD	EQ 50MG BASE		A204203	001	May 17, 2017	May	NEWA	
AB		EQ 150MG BASE		A204203	002	May 17, 2017	May	NEWA	
AB		EQ 200MG BASE		A204203	003	May 17, 2017	May	NEWA	
AB		EQ 300MG BASE		A204203	004	May 17, 2017	May	NEWA	
AB		EQ 400MG BASE		A204203	005	May 17, 2017	May	NEWA	
AB	MACLEODS PHARMS LTD	EQ 150MG BASE		A204253	001	Nov 29, 2017	Nov	NEWA	
AB		EQ 200MG BASE		A204253	002	Nov 29, 2017	Nov	NEWA	
AB		EQ 300MG BASE		A204253	003	Nov 29, 2017	Nov	NEWA	

TABLET, EXTENDED RELEASE;ORAL
QUETIAPINE FUMARATE

AB		EQ 400MG BASE	A204253	004	Nov 29, 2017	Nov	NEWA
AB	NOVAST LABS LTD	EQ 50MG BASE	A208947	001	Nov 29, 2017	Nov	NEWA
AB		EQ 150MG BASE	A208947	002	Nov 29, 2017	Nov	NEWA
AB		EQ 200MG BASE	A208947	003	Nov 29, 2017	Nov	NEWA
AB		EQ 300MG BASE	A208947	004	Nov 29, 2017	Nov	NEWA
AB		EQ 400MG BASE	A208947	005	Nov 29, 2017	Nov	NEWA
AB	PAR PHARM	EQ 50MG BASE	A090482	001	May 09, 2017	Apr	NEWA
AB		EQ 150MG BASE	A090482	002	May 09, 2017	Apr	NEWA
AB		EQ 200MG BASE	A090482	003	May 09, 2017	Apr	NEWA
AB		EQ 300MG BASE	A090482	004	May 09, 2017	Apr	NEWA
AB		EQ 400MG BASE	A090482	005	May 09, 2017	Apr	NEWA
AB	PHARMADAX INC	EQ 50MG BASE	A206260	001	May 09, 2017	Apr	NEWA
AB		EQ 150MG BASE	A206260	002	May 09, 2017	Apr	NEWA
AB		EQ 200MG BASE	A206260	003	May 09, 2017	Apr	NEWA
AB		EQ 300MG BASE	A206260	004	May 09, 2017	Apr	NEWA
AB		EQ 400MG BASE	A206260	005	May 09, 2017	Apr	NEWA
AB	SCIEGEN PHARMS INC	EQ 150MG BASE	A209635	001	Nov 29, 2017	Nov	NEWA
AB		EQ 200MG BASE	A209635	002	Nov 29, 2017	Nov	NEWA
AB		EQ 300MG BASE	A209635	003	Nov 29, 2017	Nov	NEWA
AB		EQ 400MG BASE	A209635	004	Nov 29, 2017	Nov	NEWA
	SEROQUEL XR						
AB	+ ASTRAZENECA	EQ 50MG BASE	N022047	001	May 17, 2007	Sep	CAHN
AB	+	EQ 50MG BASE	N022047	001	May 17, 2007	Apr	CTEC
AB	+	EQ 150MG BASE	N022047	005	Aug 11, 2008	Sep	CAHN
AB	+	EQ 150MG BASE	N022047	005	Aug 11, 2008	Apr	CTEC
AB	+!	EQ 200MG BASE	N022047	002	May 17, 2007	Sep	CAHN
AB	+!	EQ 200MG BASE	N022047	002	May 17, 2007	Apr	CTEC
AB	+	EQ 300MG BASE	N022047	003	May 17, 2007	Sep	CAHN
AB	+	EQ 300MG BASE	N022047	003	May 17, 2007	Apr	CTEC
AB	+	EQ 400MG BASE	N022047	004	May 17, 2007	Sep	CAHN

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

>A>	@ FOSUN PHARMA	EQ 5MG BASE	A076803	001	Mar 02, 2005	Dec	CAHN
>A>	@	EQ 10MG BASE	A076803	002	Mar 02, 2005	Dec	CAHN
>A>	@	EQ 20MG BASE	A076803	003	Mar 02, 2005	Dec	CAHN
>A>	@	EQ 40MG BASE	A076803	004	Mar 02, 2005	Dec	CAHN
>D>	@ SANDOZ	EQ 5MG BASE	A076803	001	Mar 02, 2005	Dec	CAHN
>D>	@	EQ 10MG BASE	A076803	002	Mar 02, 2005	Dec	CAHN
>D>	@	EQ 20MG BASE	A076803	003	Mar 02, 2005	Dec	CAHN
>D>	@	EQ 40MG BASE	A076803	004	Mar 02, 2005	Dec	CAHN
	@ SUN PHARM INDS LTD	EQ 5MG BASE	A090800	001	Jun 18, 2009	Sep	DISC
	@	EQ 10MG BASE	A090800	002	Jun 18, 2009	Sep	DISC
	@	EQ 20MG BASE	A090800	003	Jun 18, 2009	Sep	DISC
	@	EQ 40MG BASE	A090800	004	Jun 18, 2009	Sep	DISC

QUINIDINE GLUCONATE

INJECTABLE;INJECTION

QUINIDINE GLUCONATE

+	@ LILLY	80MG/ML	N007529	002	Feb 10, 1989	Nov	DISC
---	---------	---------	---------	-----	--------------	-----	------

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE;ORAL

ACIPHEX SPRINKLE

+	AVADEL PHARMS	5MG	N204736	001	Mar 26, 2013	Aug	CAHN
+	!	10MG	N204736	002	Mar 26, 2013	Aug	CAHN

TABLET, DELAYED RELEASE;ORAL

RABEPRAZOLE SODIUM

AB	AUROBINDO PHARMA LTD	20MG	A205761	001	Feb 17, 2017	Feb	NEWA
AB	KREMERS URBAN PHARMS	20MG	A090678	001	Nov 08, 2013	Jan	CAHN

RALTEGRAVIR POTASSIUM

TABLET;ORAL

ISENTRESS HD

+	MERCK SHARP DOHME	EQ 600MG BASE	N022145	002	May 26, 2017	May	NEWA
---	-------------------	---------------	---------	-----	--------------	-----	------

RAMIPRILCAPSULE;ORAL
ALTACE

AB	+	KING PHARMS LLC	1.25MG	N019901	001	Jan 28, 1991	Jul CAHN
AB	+		2.5MG	N019901	002	Jan 28, 1991	Jul CAHN
AB	+		5MG	N019901	003	Jan 28, 1991	Jul CAHN
AB	+		10MG	N019901	004	Jan 28, 1991	Jul CAHN

RAMIPRIL

AB		ACCORD HLTHCARE	1.25MG	A202392	001	Apr 15, 2014	Mar CAHN
AB			2.5MG	A202392	002	Apr 15, 2014	Mar CAHN
AB			5MG	A202392	003	Apr 15, 2014	Mar CAHN
AB			10MG	A202392	004	Apr 15, 2014	Mar CAHN

>A>	@	FOSUN PHARMA	1.25MG	A077514	001	Jun 18, 2008	Dec CAHN
>A>	@		2.5MG	A077514	002	Jun 18, 2008	Dec CAHN
>A>	@		5MG	A077514	003	Jun 18, 2008	Dec CAHN
>A>	@		10MG	A077514	004	Jun 18, 2008	Dec CAHN
>D>	@	SANDOZ	1.25MG	A077514	001	Jun 18, 2008	Dec CAHN
>D>	@		2.5MG	A077514	002	Jun 18, 2008	Dec CAHN
>D>	@		5MG	A077514	003	Jun 18, 2008	Dec CAHN
>D>	@		10MG	A077514	004	Jun 18, 2008	Dec CAHN

RANITIDINE HYDROCHLORIDEINJECTABLE;INJECTION
ZANTAC

AP	+	TELIGENT	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Apr CAHN
AP	+	TELIGENT PHARMA INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jan CAHN
		ZANTAC IN PLASTIC CONTAINER					
		@ TELIGENT	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	May CAHN
		@	EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	May CAHN

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

AA		AUROBINDO PHARMA LTD	EQ 15MG BASE/ML	A090623	001	Jul 28, 2010	Jan CAHN
AA		PHARM ASSOC	EQ 15MG BASE/ML	A077405	001	Sep 21, 2007	May CAHN

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

AB		ACIC PHARMS	EQ 150MG BASE	A203694	001	Nov 30, 2017	Nov NEWA
AB			EQ 300MG BASE	A203694	002	Nov 30, 2017	Nov NEWA
AB		GLENMARK PHARMS INC	EQ 150MG BASE	A078542	001	Nov 19, 2008	May CAHN
AB			EQ 300MG BASE	A078542	002	Nov 19, 2008	May CAHN
>D>	AB	WOCKHARDT	EQ 150MG BASE	A075208	001	Dec 17, 1998	Dec CAHN
>D>	AB		EQ 300MG BASE	A075208	002	Dec 17, 1998	Dec CAHN
>A>	AB	WOCKHARDT LTD	EQ 150MG BASE	A075208	001	Dec 17, 1998	Dec CAHN
>A>	AB		EQ 300MG BASE	A075208	002	Dec 17, 1998	Dec CAHN

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANEXA

+	GILEAD	500MG	N021526	002	Jan 27, 2006	Feb CTEC	
+	+	1GM	N021526	001	Feb 12, 2007	Feb CTEC	
		RANOLAZINE					
	@	LUPIN LTD	500MG	A201046	001	Jul 29, 2013	Feb DISC
	@		1GM	A201046	002	Jul 29, 2013	Feb DISC

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

AB		ALKEM LABS LTD	EQ 0.5MG BASE	A201889	001	Oct 30, 2017	Oct NEWA
AB			EQ 1MG BASE	A201889	002	Oct 30, 2017	Oct NEWA
AB		MYLAN PHARMS INC	EQ 0.5MG BASE	A201971	001	May 15, 2017	Jul CMFD
	@		EQ 0.5MG BASE	A201971	001	May 15, 2017	Jun DISC
AB			EQ 0.5MG BASE	A201971	001	May 15, 2017	May NEWA
AB			EQ 1MG BASE	A201971	002	May 15, 2017	Jul CMFD
	@		EQ 1MG BASE	A201971	002	May 15, 2017	Jun DISC
AB			EQ 1MG BASE	A201971	002	May 15, 2017	May NEWA

REPAGLINIDE

TABLET;ORAL

PRANDIN

AB	+	GEMINI LABS LLC	0.5MG	N020741	001	Dec 22, 1997	Feb CAHN
AB	+		1MG	N020741	002	Dec 22, 1997	Feb CAHN
AB	+		2MG	N020741	003	Dec 22, 1997	Feb CAHN

TABLET;ORAL
REPAGLINIDE

AB	BOSCOGEN	0.5MG	A091517	001	Apr 24, 2015	Jun CAHN
AB		1MG	A091517	002	Apr 24, 2015	Jun CAHN
AB		2MG	A091517	003	Apr 24, 2015	Jun CAHN

RESERPINE

TABLET;ORAL
RESERPINE

	+ @ SANDOZ	0.1MG	N009838	001		Apr DISC
	+ @	0.25MG	N009838	002		Apr DISC

RIBAVIRIN

CAPSULE;ORAL
RIBASPHERE

AB	KADMON PHARMS LLC	200MG	A076203	001	Apr 06, 2004	Jan CAHN
----	-------------------	-------	---------	-----	--------------	----------

TABLET;ORAL
RIBAVIRIN

AB	KADMON PHARMS LLC	200MG	A077456	001	Dec 05, 2005	Jan CAHN
AB		400MG	A077456	002	Dec 05, 2005	Jan CAHN
AB	!	600MG	A077456	003	Dec 05, 2005	Jan CAHN

RIBOCICLIB SUCCINATE

TABLET;ORAL
KISQALI

	+! NOVARTIS PHARMS CORP	EQ 200MG BASE	N209092	001	Mar 13, 2017	Mar NEWA
--	-------------------------	---------------	---------	-----	--------------	----------

RIFAMPIN

INJECTABLE;INJECTION
RIFAMPIN

AP	WATSON PHARMS TEVA	600MG/VIAL	A206736	001	Jan 19, 2016	Feb CAHN
AP	WEST-WARD PHARMS INT	600MG/VIAL	A064217	001	Oct 29, 1999	Jan CAHN

RILUZOLE

TABLET;ORAL
RILUTEK

AB	+! COVIS PHARMA BV	50MG	N020599	001	Dec 12, 1995	Aug CAHN
----	--------------------	------	---------	-----	--------------	----------

RILUZOLE

AB	GLENMARK PHARMS LTD	50MG	A091394	001	Jun 18, 2013	May CAHN
----	---------------------	------	---------	-----	--------------	----------

RIMANTADINE HYDROCHLORIDE

TABLET;ORAL
FLUMADINE

AB	+! SUN PHARM INDS INC	100MG	N019649	001	Sep 17, 1993	Oct CAHN
	RIMANTADINE HYDROCHLORIDE					
	@ IMPAX LABS INC	100MG	A075916	001	Nov 02, 2001	Feb CAHN

RISPERIDONE

TABLET;ORAL
RISPERIDONE

	@ JUBILANT CADISTA	0.25MG	A078828	001	Mar 23, 2009	Apr CAHN
	@	0.5MG	A078828	002	Mar 23, 2009	Apr CAHN
	@	1MG	A078828	003	Mar 23, 2009	Apr CAHN
	@	2MG	A078828	004	Mar 23, 2009	Apr CAHN
	@	3MG	A078828	005	Mar 23, 2009	Apr CAHN
	@	4MG	A078828	006	Mar 23, 2009	Apr CAHN
AB	PRINSTON INC	0.25MG	A078707	001	Dec 29, 2008	Feb CAHN
AB		0.5MG	A078707	002	Dec 29, 2008	Feb CAHN
AB		1MG	A078707	003	Dec 29, 2008	Feb CAHN
AB		2MG	A078707	004	Dec 29, 2008	Feb CAHN
AB		3MG	A078707	005	Dec 29, 2008	Feb CAHN
AB		4MG	A078707	006	Dec 29, 2008	Feb CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
RISPERIDONE

>D>	AB	MYLAN PHARMS INC	0.25MG	A091537	006	Feb 12, 2013	Dec DISC
>A>		@	0.25MG	A091537	006	Feb 12, 2013	Dec DISC
>D>	AB		0.5MG	A091537	001	Mar 30, 2011	Dec DISC
>A>		@	0.5MG	A091537	001	Mar 30, 2011	Dec DISC
>D>	AB		1MG	A091537	002	Mar 30, 2011	Dec DISC
>A>		@	1MG	A091537	002	Mar 30, 2011	Dec DISC
>D>	AB		2MG	A091537	003	Mar 30, 2011	Dec DISC
>A>		@	2MG	A091537	003	Mar 30, 2011	Dec DISC

TABLET, ORALLY DISINTEGRATING;ORAL
RISPERIDONE

>D>	AB		3MG	A091537	004	Mar 30, 2011	Dec	DISC
>A>	@		3MG	A091537	004	Mar 30, 2011	Dec	DISC
>D>	AB		4MG	A091537	005	Mar 30, 2011	Dec	DISC
>A>	@		4MG	A091537	005	Mar 30, 2011	Dec	DISC
>D>	AB	PAR PHARM	0.25MG	A077494	001	Apr 30, 2009	Dec	CTEC
>A>			0.25MG	A077494	001	Apr 30, 2009	Dec	CTEC

RITONAVIR

POWDER;ORAL
NORVIR

+	!	ABBVIE INC	100MG/PACKET	N209512	001	Jun 07, 2017	Jun	NEWA
---	---	------------	--------------	---------	-----	--------------	-----	------

RIVASTIGMINE TARTRATE

CAPSULE;ORAL
RIVASTIGMINE TARTRATE

AB	AJANTA PHARMA LTD	EQ 1.5MG BASE	A207797	001	Sep 28, 2017	Sep	NEWA
AB		EQ 3MG BASE	A207797	002	Sep 28, 2017	Sep	NEWA
AB		EQ 4.5MG BASE	A207797	003	Sep 28, 2017	Sep	NEWA
AB		EQ 6MG BASE	A207797	004	Sep 28, 2017	Sep	NEWA
AB	CADILA PHARMS LTD	EQ 1.5MG BASE	A203844	001	Feb 13, 2017	Jan	NEWA
AB		EQ 3MG BASE	A203844	002	Feb 13, 2017	Jan	NEWA
AB		EQ 4.5MG BASE	A203844	003	Feb 13, 2017	Jan	NEWA
AB		EQ 6MG BASE	A203844	004	Feb 13, 2017	Jan	NEWA
AB	SUN PHARM INDS LTD	EQ 1.5MG BASE	A077131	001	Oct 22, 2007	Mar	CAHN
AB		EQ 3MG BASE	A077131	002	Oct 22, 2007	Mar	CAHN
AB		EQ 4.5MG BASE	A077131	003	Oct 22, 2007	Mar	CAHN
AB		EQ 6MG BASE	A077131	004	Oct 22, 2007	Mar	CAHN

RIZATRIPTAN BENZOATE

TABLET;ORAL
RIZATRIPTAN BENZOATE

AB	ECI PHARMS LLC	EQ 5MG BASE	A202047	001	Dec 31, 2012	Mar	CAHN
AB		EQ 10MG BASE	A202047	002	Dec 31, 2012	Mar	CAHN
AB	UNICHEM LABS LTD	EQ 5MG BASE	A207836	001	Mar 07, 2017	Feb	NEWA
AB		EQ 10MG BASE	A207836	002	Mar 07, 2017	Feb	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
RIZATRIPTAN BENZOATE

AB	GLENMARK PHARMS LTD	EQ 5MG BASE	A201914	001	Jul 01, 2013	May	CAHN
AB		EQ 10MG BASE	A201914	002	Jul 01, 2013	May	CAHN
AB	PANACEA BIOTEC LTD	EQ 5MG BASE	A204722	001	Jan 11, 2017	Jan	NEWA
AB		EQ 10MG BASE	A204722	002	Jan 11, 2017	Jan	NEWA
AB	UNICHEM LABS LTD	EQ 5MG BASE	A207835	001	Mar 07, 2017	Feb	NEWA
AB		EQ 10MG BASE	A207835	002	Mar 07, 2017	Feb	NEWA

ROCURONIUM BROMIDE

INJECTABLE;INJECTION
ROCURONIUM BROMIDE

AP	AUROBINDO PHARMA LTD	50MG/5ML (10MG/ML)	A206206	001	Apr 12, 2017	Mar	NEWA	
AP		100MG/10ML (10MG/ML)	A206206	002	Apr 12, 2017	Mar	NEWA	
AP	!	SANDOZ INC	50MG/5ML (10MG/ML)	A079195	001	Dec 05, 2008	Mar	CAHN
AP	!		100MG/10ML (10MG/ML)	A079195	002	Dec 05, 2008	Mar	CAHN
AP	WEST WARD PHARM CORP	50MG/5ML (10MG/ML)	A204679	001	Feb 28, 2017	Feb	NEWA	
AP		100MG/10ML (10MG/ML)	A204679	002	Feb 28, 2017	Feb	NEWA	

ROLAPITANT HYDROCHLORIDE

EMULSION;IV (INFUSION)
VARUBI

+	!	TESARO INC	EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)	N208399	001	Oct 25, 2017	Oct	NEWA
---	---	------------	---	---------	-----	--------------	-----	------

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL
ROPINIROLE HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ 0.25MG BASE	A204022	001	Feb 28, 2017	Apr	CAHN
AB		EQ 0.5MG BASE	A204022	002	Feb 28, 2017	Apr	CAHN
AB		EQ 1MG BASE	A204022	003	Feb 28, 2017	Apr	CAHN
AB		EQ 2MG BASE	A204022	004	Feb 28, 2017	Apr	CAHN
AB		EQ 3MG BASE	A204022	005	Feb 28, 2017	Apr	CAHN
AB		EQ 4MG BASE	A204022	006	Feb 28, 2017	Apr	CAHN
AB		EQ 5MG BASE	A204022	007	Feb 28, 2017	Apr	CAHN
AB	ACCORD HLTHCARE INC	EQ 0.25MG BASE	A204022	001	Feb 28, 2017	Feb	NEWA

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB		EQ 0.5MG BASE	A204022	002	Feb 28, 2017	Feb NEWA
AB		EQ 1MG BASE	A204022	003	Feb 28, 2017	Feb NEWA
AB		EQ 2MG BASE	A204022	004	Feb 28, 2017	Feb NEWA
AB		EQ 3MG BASE	A204022	005	Feb 28, 2017	Feb NEWA
AB		EQ 4MG BASE	A204022	006	Feb 28, 2017	Feb NEWA
AB		EQ 5MG BASE	A204022	007	Feb 28, 2017	Feb NEWA
	@ EPIC PHARMA LLC	EQ 0.25MG BASE	A078230	001	May 20, 2008	May CAHN
	@	EQ 0.5MG BASE	A078230	002	May 20, 2008	May CAHN
	@	EQ 1MG BASE	A078230	003	May 20, 2008	May CAHN
	@	EQ 2MG BASE	A078230	004	May 20, 2008	May CAHN
	@	EQ 3MG BASE	A078230	005	May 20, 2008	May CAHN
	@	EQ 4MG BASE	A078230	006	May 20, 2008	May CAHN
	@	EQ 5MG BASE	A078230	007	May 20, 2008	May CAHN

TABLET, EXTENDED RELEASE;ORAL

ROPINIROLE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 2MG BASE	A202786	001	Apr 22, 2013	May CAHN
AB		EQ 4MG BASE	A202786	002	Apr 22, 2013	May CAHN
AB		EQ 6MG BASE	A202786	003	Apr 22, 2013	May CAHN
AB		EQ 8MG BASE	A202786	004	Apr 22, 2013	May CAHN
AB		EQ 12MG BASE	A202786	005	Apr 22, 2013	May CAHN
	@ MYLAN PHARMS INC	EQ 3MG BASE	A200462	002	Oct 15, 2012	Apr DISC

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

ROPIVACAINE HYDROCHLORIDE

AP	AKORN INC	150MG/30ML (5MG/ML)	A203955	001	Apr 11, 2016	Jun CDFR
----	-----------	---------------------	---------	-----	--------------	----------

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

AB	ACCORD HLTHCARE	5MG	A206434	001	Oct 31, 2016	Mar CAHN
AB		10MG	A206434	002	Oct 31, 2016	Mar CAHN
AB		20MG	A206434	003	Oct 31, 2016	Mar CAHN
AB		40MG	A206434	004	Oct 31, 2016	Mar CAHN
AB	ALKEM LABS LTD	5MG	A206465	001	Mar 21, 2017	Mar NEWA
AB		10MG	A206465	002	Mar 21, 2017	Mar NEWA
AB		20MG	A206465	003	Mar 21, 2017	Mar NEWA
AB		40MG	A206465	004	Mar 21, 2017	Mar NEWA
AB	LUPIN LTD	5MG	A205587	001	Jul 31, 2017	Jul NEWA
AB		10MG	A205587	002	Jul 31, 2017	Jul NEWA
AB		20MG	A205587	003	Jul 31, 2017	Jul NEWA
AB		40MG	A205587	004	Jul 31, 2017	Jul NEWA
AB	MSN LABS PVT LTD	5MG	A208898	001	Nov 22, 2017	Nov NEWA
AB		10MG	A208898	002	Nov 22, 2017	Nov NEWA
AB		20MG	A208898	003	Nov 22, 2017	Nov NEWA
AB		40MG	A208898	004	Nov 22, 2017	Nov NEWA
AB	TORRENT PHARMS LTD	5MG	A201619	001	Oct 31, 2016	Apr CAHN
AB		10MG	A201619	002	Oct 31, 2016	Apr CAHN
AB		20MG	A201619	003	Oct 31, 2016	Apr CAHN
AB		40MG	A201619	004	Oct 31, 2016	Apr CAHN

RUCAPARIB CAMSYLATE

TABLET;ORAL

RUBRACA

+	CLOVIS ONCOLOGY INC	EQ 250MG BASE	N209115	003	May 01, 2017	May NEWA
---	---------------------	---------------	---------	-----	--------------	----------

SAFINAMIDE MESYLATE

TABLET;ORAL

XADAGO

+	NEWRON PHARMS US INC	50MG	N207145	001	Mar 21, 2017	Mar NEWA
+	!	100MG	N207145	002	Mar 21, 2017	Mar NEWA
+	US WORLDMEDS LLC	50MG	N207145	001	Mar 21, 2017	Apr CAHN
+	!	100MG	N207145	002	Mar 21, 2017	Apr CAHN

SECNIDAZOLE

GRANULE;ORAL

SOLOSEC

+	!	LUPIN	2GM/PACKET	N209363	001	Sep 15, 2017	Oct CAHN
+	!	SYMBIOMIX THERAP	2GM/PACKET	N209363	001	Sep 15, 2017	Sep NEWA

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

AB	BOSCOGEN	5MG	A074912	001	Apr 30, 1998	May CAHN
	@ CHARTWELL MOLECULES	5MG	A074565	001	Aug 02, 1996	Jan CAHN
	@	5MG	A074641	001	Aug 02, 1996	Jan CAHN

SELENIUM SULFIDE

LOTION/SHAMPOO;TOPICAL

SELENIUM SULFIDE

>D>	AT	WOCKHARDT	2.5%	A088228	001	Sep 01, 1983	Dec CAHN
>A>	AT	WOCKHARDT BIO AG	2.5%	A088228	001	Sep 01, 1983	Dec CAHN

>A> SEMAGLUTIDE

>A> SOLUTION;SUBCUTANEOUS

>A> OZEMPIC

>A>	+	NOVO NORDISK INC	2MG/1.5ML (1.34MG/ML)	N209637	001	Dec 05, 2017	Dec NEWA
-----	---	------------------	-----------------------	---------	-----	--------------	----------

SERTRALINE HYDROCHLORIDE

CONCENTRATE;ORAL

SERTRALINE HYDROCHLORIDE

@ ALLIED PHARMA INC EQ 20MG BASE/ML

A076934 001 Jun 30, 2006 Mar CAHN

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

	@	ACI HEALTHCARE LTD	EQ 25MG BASE	A076881	001	Feb 06, 2007	Jun CAHN
	@		EQ 50MG BASE	A076881	002	Feb 06, 2007	Jun CAHN
	@		EQ 100MG BASE	A076881	003	Feb 06, 2007	Jun CAHN
	@	ALLIED PHARMA INC	EQ 25MG BASE	A076881	001	Feb 06, 2007	Mar CAHN
	@		EQ 50MG BASE	A076881	002	Feb 06, 2007	Mar CAHN
	@		EQ 100MG BASE	A076881	003	Feb 06, 2007	Mar CAHN
	@	ANDA REPOSITORY	EQ 25MG BASE	A077818	001	Feb 06, 2007	Sep CAHN
	@		EQ 50MG BASE	A077818	002	Feb 06, 2007	Sep CAHN
	@		EQ 100MG BASE	A077818	003	Feb 06, 2007	Sep CAHN
>D>	@	DR REDDYS LABS LTD	EQ 25MG BASE	A076442	001	Apr 30, 2007	Dec CAHN
>D>	@		EQ 50MG BASE	A076442	002	Apr 30, 2007	Dec CAHN
>D>	@		EQ 100MG BASE	A076442	003	Apr 30, 2007	Dec CAHN
	@	MYLAN	EQ 25MG BASE	A076671	001	Feb 06, 2007	Mar DISC
	@		EQ 50MG BASE	A076671	002	Feb 06, 2007	Mar DISC
	@		EQ 100MG BASE	A076671	003	Feb 06, 2007	Mar DISC
>A>	@	SCIEGEN PHARMS INC	EQ 25MG BASE	A076442	001	Apr 30, 2007	Dec CAHN
>A>	@		EQ 50MG BASE	A076442	002	Apr 30, 2007	Dec CAHN
>A>	@		EQ 100MG BASE	A076442	003	Apr 30, 2007	Dec CAHN
	@	SUN PHARM INDS (IN)	EQ 25MG BASE	A078108	001	Feb 06, 2007	Oct DISC
	@		EQ 50MG BASE	A078108	002	Feb 06, 2007	Oct DISC
	@		EQ 100MG BASE	A078108	003	Feb 06, 2007	Oct DISC
	@	WATSON LABS TEVA	EQ 25MG BASE	A077663	001	Feb 06, 2007	May CAHN
	@		EQ 50MG BASE	A077663	002	Feb 06, 2007	May CAHN
	@		EQ 100MG BASE	A077663	003	Feb 06, 2007	May CAHN

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

RENEVELA

AB	+	GENZYME	800MG/PACKET	N022318	001	Aug 12, 2009	May CFTG
AB	+		2.4GM/PACKET	N022318	002	Feb 18, 2009	May CFTG

SEVELAMER CARBONATE

AB	AUROBINDO PHARMA LTD	800MG/PACKET	A207624	001	Jun 13, 2017	May NEWA
AB		2.4GM/PACKET	A207624	002	Jun 13, 2017	May NEWA

TABLET;ORAL

RENEVELA

AB	+	GENZYME	800MG	N022127	001	Oct 19, 2007	Jul CFTG
----	---	---------	-------	---------	-----	--------------	----------

SEVELAMER CARBONATE

AB	AMNEAL PHARMS CO	800MG	A207288	001	Nov 28, 2017	Nov NEWA
AB	AUROBINDO PHARMA LTD	800MG	A207179	001	Jul 17, 2017	Jul NEWA
AB	DR REDDYS LABS LTD	800MG	A206094	001	Sep 29, 2017	Sep NEWA
AB	IMPAX LABS INC	800MG	A090975	001	Oct 23, 2017	Oct NEWA
AB	INVAGEN PHARMS	800MG	A203860	001	Oct 26, 2017	Oct NEWA

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

AB	TEVA	EQ 25MG BASE	A077342	001	Mar 09, 2016	Nov	CMFD
AB		EQ 50MG BASE	A077342	002	Mar 09, 2016	Nov	CMFD
AB		EQ 100MG BASE	A077342	003	Mar 09, 2016	Nov	CMFD

VIAGRA

AB	+	PFIZER INC	EQ 25MG BASE	N020895	001	Mar 27, 1998	Nov	CTEC
	+		EQ 25MG BASE	N020895	001	Mar 27, 1998	May	CAHN
AB	+		EQ 50MG BASE	N020895	002	Mar 27, 1998	Nov	CTEC
	+		EQ 50MG BASE	N020895	002	Mar 27, 1998	May	CAHN
AB	+	!	EQ 100MG BASE	N020895	003	Mar 27, 1998	Nov	CTEC
	+	!	EQ 100MG BASE	N020895	003	Mar 27, 1998	May	CAHN

SILODOSIN

CAPSULE;ORAL

RAPAFLO

AB	+	!	ALLERGAN SALES LLC	4MG	N022206	001	Oct 08, 2008	Mar	CFTG
AB	+			8MG	N022206	002	Oct 08, 2008	Mar	CFTG

SILODOSIN

AB		SANDOZ INC	4MG	A204726	001	Mar 31, 2017	Mar	NEWA
AB			8MG	A204726	002	Mar 31, 2017	Mar	NEWA

SILVER SULFADIAZINE

CREAM;TOPICAL

SILVADENE

AB	+	!	KING PHARMS LLC	1%	N017381	001		Aug	CAHN
----	---	---	-----------------	----	---------	-----	--	-----	------

SIMVASTATIN

SUSPENSION;ORAL

FLOLIPID

	+	TCG FLUENT PHARMA	20MG/5ML	N206679	001	Apr 21, 2016	Oct	CTNA
	+	!	40MG/5ML	N206679	002	Apr 21, 2016	Oct	CTNA

TABLET;ORAL

SIMVASTATIN

>A>	@	FOSUN PHARMA	5MG	A077766	001	Dec 20, 2006	Dec	CAHN
>A>	@		10MG	A077766	002	Dec 20, 2006	Dec	CAHN
>A>	@		20MG	A077766	003	Dec 20, 2006	Dec	CAHN
>A>	@		40MG	A077766	004	Dec 20, 2006	Dec	CAHN
>A>	@		80MG	A077766	005	Dec 20, 2006	Dec	CAHN
AB		HISUN PHARM HANGZHOU	10MG	A206557	001	Nov 13, 2017	Oct	NEWA
AB			20MG	A206557	002	Nov 13, 2017	Oct	NEWA
AB			40MG	A206557	003	Nov 13, 2017	Oct	NEWA
AB			80MG	A206557	004	Nov 13, 2017	Oct	NEWA
	@	MYLAN PHARMS INC	5MG	A090868	001	Jun 08, 2010	May	DISC
	@		10MG	A090868	002	Jun 08, 2010	May	DISC
	@		20MG	A090868	003	Jun 08, 2010	May	DISC
	@		40MG	A090868	004	Jun 08, 2010	May	DISC
	@		80MG	A090868	005	Jun 08, 2010	May	DISC
>D>	@	SANDOZ INC	5MG	A077766	001	Dec 20, 2006	Dec	CAHN
>D>	@		10MG	A077766	002	Dec 20, 2006	Dec	CAHN
>D>	@		20MG	A077766	003	Dec 20, 2006	Dec	CAHN
>D>	@		40MG	A077766	004	Dec 20, 2006	Dec	CAHN
>D>	@		80MG	A077766	005	Dec 20, 2006	Dec	CAHN
AB		VIVA HLTHCARE	5MG	A090383	001	Sep 16, 2011	Sep	CAHN
AB			10MG	A090383	002	Sep 16, 2011	Sep	CAHN
AB			20MG	A090383	003	Sep 16, 2011	Sep	CAHN
AB			40MG	A090383	004	Sep 16, 2011	Sep	CAHN
AB			80MG	A090383	005	Sep 16, 2011	Sep	CAHN
AB		WATSON LABS TEVA	5MG	A076685	001	Dec 20, 2006	May	CAHN
AB			10MG	A076685	002	Dec 20, 2006	May	CAHN
AB			20MG	A076685	003	Dec 20, 2006	May	CAHN
AB			40MG	A076685	004	Dec 20, 2006	May	CAHN
AB			80MG	A076685	005	Dec 20, 2006	May	CAHN
		ZOCOR						
AB	+	MSD MERCK CO	5MG	N019766	001	Dec 23, 1991	Oct	CAHN
AB	+		10MG	N019766	002	Dec 23, 1991	Oct	CAHN
AB	+		20MG	N019766	003	Dec 23, 1991	Oct	CAHN
AB	+		40MG	N019766	004	Dec 23, 1991	Oct	CAHN
AB	+	!	80MG	N019766	005	Jul 10, 1998	Oct	CAHN

SODIUM ACETATE

INJECTABLE;INJECTION

SODIUM ACETATE

	FRESENIUS KABI USA	4MEQ/ML	A206687	001	Oct 30, 2017	Oct NEWA
+	HOSPIRA	2MEQ/ML	N018893	001	May 04, 1983	Nov CTNA

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION;IV (INFUSION)

SODIUM PHENYLACETATE AND SODIUM BENZOATE

AP	AILEX PHARMS LLC	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Jul CAHN
----	------------------	-----------------------------	---------	-----	--------------	----------

SODIUM BICARBONATE

INJECTABLE;INJECTION

SODIUM BICARBONATE

AP	!	HOSPIRA	0.9MEQ/ML	A077394	001	Nov 09, 2005	Feb CTEC
AP	!		1MEQ/ML	A077394	002	Nov 09, 2005	Feb CTEC
		HOSPIRA INC	0.5MEQ/ML	A202679	001	Mar 07, 2017	Feb NEWA
AP			0.9MEQ/ML	A202494	001	Mar 06, 2017	Feb NEWA
AP			1MEQ/ML	A202432	001	Sep 26, 2017	Sep NEWA
			1MEQ/ML	A202495	001	Mar 06, 2017	Feb NEWA
AP			1MEQ/ML	A202494	002	Mar 06, 2017	Feb NEWA
AP		INTL MEDICATION SYS	1MEQ/ML	A203449	001	Sep 19, 2017	Sep NEWA

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	+	ICU MEDICAL INC	450MG/100ML	N018090	001		Feb CAHN
----	---	-----------------	-------------	---------	-----	--	----------

SODIUM CHLORIDE 0.9%

AP		SPECTRA MDCL DEVICES	9MG/ML	A206171	001	Jul 21, 2017	Jul NEWA
AP		WEST-WARD PHARMS INT	9MG/ML	A201850	001	Jan 20, 2012	Jan CAHN

SODIUM CHLORIDE 0.9%

		WEST-WARD PHARMS INT	9MG/ML	A201833	001	Sep 24, 2013	Jan CAHN
--	--	----------------------	--------	---------	-----	--------------	----------

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	900MG/100ML	A207310	001	Sep 19, 2017	Sep NEWA
AP	+	ICU MEDICAL INC	900MG/100ML	N016366	001		Feb CAHN
AP		LABORATORIOS GRIFOLS	900MG/100ML	A207956	001	May 25, 2017	May NEWA
AP	!	TARO	9MG/ML	A077407	001	Aug 11, 2006	Apr CAHN

SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER

	+	@ ABRAXIS PHARM	234MG/ML	N019329	001	Apr 22, 1987	Jan CRLD
--	---	-----------------	----------	---------	-----	--------------	----------

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

AP		B BRAUN	3GM/100ML	N019635	003	Mar 09, 1988	Jul CMFD
AP	+	BAXTER HLTHCARE	3GM/100ML	N019022	001	Nov 01, 1983	Jul CTEC

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

AP		B BRAUN	5GM/100ML	N019635	004	Mar 09, 1988	Jul CMFD
AP	+	BAXTER HLTHCARE	5GM/100ML	N019022	002	Nov 01, 1983	Jul CTEC

SODIUM CHLORIDE IN PLASTIC CONTAINER

	+	HOSPIRA	2.5MEQ/ML	N018897	001	Jul 20, 1984	Mar CRLD
--	---	---------	-----------	---------	-----	--------------	----------

SOLUTION;IRRIGATION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AT		ICU MEDICAL INC	900MG/100ML	N017514	001		Feb CAHN
AT			900MG/100ML	N018314	001		Feb CAHN

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

AP		JUBILANT DRAXIMAGE	10-200mCi/ML	A203968	001	Oct 23, 2015	Sep CAHN
>D>	AP	UIHC PET IMAGING	10-200mCi/ML	A204462	001	Nov 17, 2015	Dec DISC
>A>		@	10-200mCi/ML	A204462	001	Nov 17, 2015	Dec DISC

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

SODIUM NITROPRUSSIDE

AP		AKORN	25MG/ML	A208635	001	May 04, 2017	Apr NEWA
AP		AMNEAL PHARMS CO	25MG/ML	A209493	001	Nov 07, 2017	Oct NEWA
>A>	AP	AMPHASTAR PHARMS INC	25MG/ML	A209832	001	Dec 18, 2017	Dec NEWA
AP		MICRO LABS	25MG/ML	A209352	001	Dec 08, 2017	Nov NEWA
AP		NEXUS PHARMS	25MG/ML	A207499	001	May 25, 2017	May NEWA

SOLUTION;IV (INFUSION)

NIPRIDE RTU IN SODIUM CHLORIDE 0.9%

>A>	+	EXELA PHARMA SCS LLC	10MG/50ML (0.2MG/ML)	N209387	002	Dec 07, 2017	Dec NEWA
	+		50MG/100ML (0.5MG/ML)	N209387	001	Mar 08, 2017	Mar NEWA

SODIUM OXYBATESOLUTION;ORAL
SODIUM OXYBATE

AA	WEST-WARD PHARMS INT	500MG/ML	A202090	001	Jan 17, 2017	Jan NEWA
----	----------------------	----------	---------	-----	--------------	----------

SODIUM PHENYLBUTYRATETABLET;ORAL
SODIUM PHENYLBUTYRATE

AB	ALVOGEN MALTA	500MG	A090910	001	Nov 18, 2011	Apr CAHN
----	---------------	-------	---------	-----	--------------	----------

SODIUM POLYSTYRENE SULFONATEPOWDER;ORAL, RECTAL
KALEXATE

AA	! KVK TECH	454GM/BOT	A040905	001	Mar 30, 2009	Sep CHRS
----	------------	-----------	---------	-----	--------------	----------

KAYEXALATE

	+ @ CONCORDIA PHARMS INC	453.6GM/BOT	N011287	001		Sep DISC
--	--------------------------	-------------	---------	-----	--	----------

SODIUM POLYSTYRENE SULFONATE

AA	AILEX PHARMS LLC	454GM/BOT	A206815	001	Feb 18, 2016	Sep CAHN
----	------------------	-----------	---------	-----	--------------	----------

AA	CMP PHARMA INC	454GM/BOT	A089910	001	Jan 19, 1989	Apr CAHN
----	----------------	-----------	---------	-----	--------------	----------

AA	ECI PHARMS LLC	453.6GM/BOT	A090313	001	Dec 21, 2011	Mar CAHN
----	----------------	-------------	---------	-----	--------------	----------

SUSPENSION;ORAL, RECTAL
SPS

AA	! CMP PHARMA INC	15GM/60ML	A087859	001	Dec 08, 1982	Apr CAHN
----	------------------	-----------	---------	-----	--------------	----------

SOFOBUVIR; VELPATASVIR; VOXILAPREVIRTABLET;ORAL
VOSEVI

	+! GILEAD SCIENCES INC	400MG;100MG;100MG	N209195	001	Jul 18, 2017	Jul NEWA
--	------------------------	-------------------	---------	-----	--------------	----------

SOMATROPIN RECOMBINANTINJECTABLE;INJECTION
SEROSTIM

EMD SERONO 4MG/VIAL

N020604	003	Jul 25, 1997	Nov CTEC
---------	-----	--------------	----------

VALTROPIN

BX	LG CHEM LTD	5MG/VIAL	N021905	001	Apr 19, 2007	Jun CAHN
----	-------------	----------	---------	-----	--------------	----------

ZOMACTON

	+ FERRING	10MG/VIAL	N019774	003	Mar 07, 2012	Nov CTEC
--	-----------	-----------	---------	-----	--------------	----------

SONIDEGIB PHOSPHATECAPSULE;ORAL
ODOMZO

	+! SUN PHARM INDS INC	EQ 200MG BASE	N205266	001	Jul 24, 2015	Mar CAHN
--	-----------------------	---------------	---------	-----	--------------	----------

	+! SUN PHARMA GLOBAL	EQ 200MG BASE	N205266	001	Jul 24, 2015	May CAHN
--	----------------------	---------------	---------	-----	--------------	----------

SOTALOL HYDROCHLORIDETABLET;ORAL
BETAPACE

AB1	+ COVIS PHARMA BV	80MG	N019865	001	Oct 30, 1992	May CAHN
-----	-------------------	------	---------	-----	--------------	----------

AB1	+	120MG	N019865	005	Apr 20, 1994	May CAHN
-----	---	-------	---------	-----	--------------	----------

AB1	+!	160MG	N019865	002	Oct 30, 1992	May CAHN
-----	----	-------	---------	-----	--------------	----------

AB1	+	240MG	N019865	003	Oct 30, 1992	May CAHN
-----	---	-------	---------	-----	--------------	----------

@ 320MG

N019865	004	Oct 30, 1992	May CAHN
---------	-----	--------------	----------

BETAPACE AF

@ COVIS PHARMA BV 40MG

N021151	006	Apr 02, 2003	May CAHN
---------	-----	--------------	----------

@ 60MG

N021151	007	Apr 02, 2003	May CAHN
---------	-----	--------------	----------

AB2	+	80MG	N021151	001	Feb 22, 2000	May CAHN
-----	---	------	---------	-----	--------------	----------

	@	100MG	N021151	005	Mar 14, 2003	May CAHN
--	---	-------	---------	-----	--------------	----------

AB2	+	120MG	N021151	002	Feb 22, 2000	May CAHN
-----	---	-------	---------	-----	--------------	----------

AB2	+!	160MG	N021151	003	Feb 22, 2000	May CAHN
-----	----	-------	---------	-----	--------------	----------

SORINE

AB1	UPSHER-SMITH LABS	80MG	A075500	001	Apr 27, 2001	Jun CAHN
-----	-------------------	------	---------	-----	--------------	----------

AB1		120MG	A075500	004	Apr 27, 2001	Jun CAHN
-----	--	-------	---------	-----	--------------	----------

AB1		160MG	A075500	002	Apr 27, 2001	Jun CAHN
-----	--	-------	---------	-----	--------------	----------

AB1		240MG	A075500	003	Apr 27, 2001	Jun CAHN
-----	--	-------	---------	-----	--------------	----------

SOTALOL HYDROCHLORIDE

@ MYLAN 80MG

A075237	001	May 01, 2000	Jun DISC
---------	-----	--------------	----------

@ 80MG

A075725	001	Dec 19, 2000	Jun DISC
---------	-----	--------------	----------

@ 120MG

A075237	002	May 01, 2000	Jun DISC
---------	-----	--------------	----------

@ 120MG

A075725	002	Dec 19, 2000	Jun DISC
---------	-----	--------------	----------

@ 160MG

A075237	003	May 01, 2000	Jun DISC
---------	-----	--------------	----------

@ 160MG

A075725	003	Dec 19, 2000	Jun DISC
---------	-----	--------------	----------

TABLET;ORAL				
SOTALOL HYDROCHLORIDE				
	@	240MG	A075237	004 May 01, 2000 Jun DISC
	@	240MG	A075725	004 Dec 19, 2000 Jun DISC
AB1	UPSHER-SMITH LABS	80MG	A075366	001 May 01, 2000 Jun CAHN
AB1		120MG	A075366	002 May 01, 2000 Jun CAHN
AB1		160MG	A075366	003 May 01, 2000 Jun CAHN
AB1		240MG	A075366	004 May 01, 2000 Jun CAHN
<u>SOYBEAN OIL</u>				
INJECTABLE;INJECTION				
INTRALIPID 30%				
+	FRESENIUS	30%	N019942	001 Dec 30, 1993 Sep CTEC
<u>SPIRONOLACTONE</u>				
SUSPENSION;ORAL				
CAROSPIR				
+	CMP DEV LLC	25MG/5ML	N209478	001 Aug 04, 2017 Sep CAHN
+	CMP PHARMA INC	25MG/5ML	N209478	001 Aug 04, 2017 Aug NEWA
TABLET;ORAL				
SPIRONOLACTONE				
AB	ACCORD HLTHCARE	25MG	A203512	001 Sep 19, 2016 Mar CAHN
AB		50MG	A203512	002 Sep 19, 2016 Mar CAHN
AB		100MG	A203512	003 Sep 19, 2016 Mar CAHN
AB	AMNEAL PHARMS	25MG	A091426	001 Jul 02, 2010 May CAHN
AB		25MG	A091426	001 Jul 02, 2010 May CMS1
AB		50MG	A091426	002 Jul 02, 2010 May CAHN
AB		50MG	A091426	002 Jul 02, 2010 May CMS1
AB		100MG	A091426	003 Jul 02, 2010 May CAHN
AB		100MG	A091426	003 Jul 02, 2010 May CMS1
AB	AUROBINDO PHARMA LTD	25MG	A202187	001 Mar 06, 2014 Nov CAHN
AB		50MG	A202187	002 Mar 06, 2014 Nov CAHN
AB		100MG	A202187	003 Mar 06, 2014 Nov CAHN
	@ UPSHER SMITH	25MG	A087554	001 Jun CAHN
<u>STAVUDINE</u>				
CAPSULE;ORAL				
STAVUDINE				
	@ MYLAN LABS LTD	30MG	A078775	001 Jan 05, 2009 May DISC
AB		30MG	A078775	001 Jan 05, 2009 Mar CAHN
	@	40MG	A078775	002 Jan 05, 2009 May DISC
AB		40MG	A078775	002 Jan 05, 2009 Mar CAHN
FOR SOLUTION;ORAL				
STAVUDINE				
	@ AUROBINDO PHARMA	1MG/ML	A077774	001 Dec 29, 2008 Jul DISC
<u>STERILE WATER FOR INJECTION</u>				
LIQUID;N/A				
STERILE WATER FOR INJECTION				
AP	FRESENIUS KABI USA	100%	A209689	001 Nov 24, 2017 Nov NEWA
AP	WEST-WARD PHARMS INT	100%	A206369	001 Sep 02, 2015 Jan CAHN
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER				
AP	+	ICU MEDICAL INC	100%	N018233 001 Feb CAHN
AP	+		100%	N019869 001 Dec 26, 1989 Apr CAHN
AP		TARO	100%	A077393 001 Aug 11, 2006 Apr CAHN
<u>STERILE WATER FOR IRRIGATION</u>				
LIQUID;IRRIGATION				
STERILE WATER IN PLASTIC CONTAINER				
AT	ICU MEDICAL INC	100%	N017513	001 Feb CAHN
AT		100%	N018313	001 Feb CAHN
<u>SUCCINYLCHOLINE CHLORIDE</u>				
INJECTABLE;INJECTION				
ANECTINE				
AP	+	SANDOZ INC	20MG/ML	N008453 002 May CAHN
	@		50MG/ML	N008453 003 May CAHN
	@		500MG/VIAL	N008453 001 May CAHN
	@		1GM/VIAL	N008453 004 May CAHN

SULCONAZOLE NITRATECREAM;TOPICAL
EXELDERM

+! SUN PHARM INDS INC 1% N018737 001 Feb 28, 1989 Aug CAHN

SOLUTION;TOPICAL
EXELDERM

+! SUN PHARM INDS INC 1% N018738 001 Aug 30, 1985 Aug CAHN

SULFACETAMIDE SODIUMSOLUTION/DROPS;OPHTHALMIC
SULFACETAMIDE SODIUM

AT SANDOZ INC 10% A089560 001 Oct 18, 1988 Feb CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIMINJECTABLE;INJECTION
BACTRIM

+ @ MUTUAL PHARM 80MG/ML;16MG/ML N018374 001 Sep CRLD

+ @ SUN PHARM INDS INC 80MG/ML;16MG/ML N018374 001 Oct CAHN

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP MYLAN LABS LTD 80MG/ML;16MG/ML A206607 001 Aug 30, 2017 Aug NEWA

AP ! TEVA PHARMS USA 80MG/ML;16MG/ML A073303 001 Oct 31, 1991 Aug CTEC

TABLET;ORAL

SEPTRA

AB MONARCH PHARMS 400MG;80MG N017376 001 May CAHN

SEPTRA DS

AB MONARCH PHARMS 800MG;160MG N017376 002 May CAHN

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB CHARTWELL MOLECULES 400MG;80MG A078060 002 Jan 25, 2007 Mar CAHN

AB 800MG;160MG A078060 001 Jan 25, 2007 Mar CAHN

AB CHARTWELL PHARMS LLC 400MG;80MG A078060 002 Jan 25, 2007 Jan CAHN

AB 800MG;160MG A078060 001 Jan 25, 2007 Jan CAHN

SUN PHARM INDUSTRIES 400MG;80MG A071017 002 Aug 25, 1986 Oct CMS1

SULFANILAMIDECREAM;VAGINAL
AVC

+! MYLAN SPECIALITY LP 15% N006530 003 Jan 27, 1987 Mar CAHN

SUPPOSITORY;VAGINAL
AVC

@ MYLAN SPECIALITY LP 1.05GM N006530 004 Jan 27, 1987 Mar CAHN

SULINDACTABLET;ORAL
SULINDAC

AB EPIC PHARMA LLC 150MG A073262 002 Sep 06, 1991 Aug CAHN

AB 200MG A073262 001 Sep 06, 1991 Aug CAHN

SUMATRIPTAN SUCCINATEINJECTABLE;SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

AP SAGENT AGILA LLC EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A090314 001 Jun 10, 2010 Nov CAHN

@ SANDOZ INC EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) A078067 002 Feb 06, 2009 Mar CAHN

@ EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A078067 001 Feb 06, 2009 Mar CAHN

AP WEST-WARD PHARMS INT EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A079123 001 Feb 06, 2009 Jan CAHN

SYSTEM;IONTOPHORESIS
ZECUITY

+ @ TEVA BRANDED PHARM EQ 6.5MG BASE/4HR N202278 001 Jan 17, 2013 Jan DISC

SUNITINIB MALATECAPSULE;ORAL
SUTENT

+ CPPI CV EQ 12.5MG BASE N021938 001 Jan 26, 2006 Mar CTEC

+ EQ 25MG BASE N021938 002 Jan 26, 2006 Mar CTEC

+ EQ 37.5MG BASE N021938 004 Mar 31, 2009 Mar CTEC

+! EQ 50MG BASE N021938 003 Jan 26, 2006 Mar CTEC

TACROLIMUSCAPSULE;ORAL
TACROLIMUS

AB	BELCHER PHARMS LLC	EQ 0.5MG BASE	A206651	001	Nov 30, 2017	Nov NEWA
AB		EQ 1MG BASE	A206651	002	Nov 30, 2017	Nov NEWA
AB		EQ 5MG BASE	A206651	003	Nov 30, 2017	Nov NEWA

INJECTABLE;INJECTION
PROGRAF

AP	+! ASTELLAS	EQ 5MG BASE/ML	N050709	001	Apr 08, 1994	Aug CFTG
	TACROLIMUS					
AP	HOSPIRA INC	EQ 5MG BASE/ML	A203900	001	Aug 25, 2017	Aug NEWA

TALCPOWDER;INTRAPLEURAL
STERITALC

+	NOVATECH SA	2GM/VIAL	N205555	001	May 01, 2017	Apr NEWA
+		3GM/VIAL	N205555	002	May 01, 2017	Apr NEWA
+	!	4GM/VIAL	N205555	003	May 01, 2017	Apr NEWA

TAMOXIFEN CITRATETABLET;ORAL
TAMOXIFEN CITRATE

AB	!	MAYNE PHARMA	EQ 20MG BASE	A075797	002	Feb 20, 2003	Sep CMS1
AB		ZYDUS PHARMS USA INC	EQ 10MG BASE	A206694	001	Oct 27, 2017	Oct NEWA
AB			EQ 20MG BASE	A206694	002	Oct 27, 2017	Oct NEWA

TAMSULOSIN HYDROCHLORIDECAPSULE;ORAL
TAMSULOSIN HYDROCHLORIDE

AB		MACLEODS PHARMS LTD	0.4MG	A204645	001	Jan 20, 2017	Jan NEWA
		TAMSULOSIN HYDROCHLORIDE					
AB		ALKEM LABS LTD	0.4MG	A207405	001	Aug 11, 2017	Jul NEWA

TAZAROTENEAEROSOL, FOAM;TOPICAL
FABIOR

+	!	MAYNE PHARMA	0.1%	N202428	001	May 11, 2012	Jan CAHN
---	---	--------------	------	---------	-----	--------------	----------

CREAM;TOPICAL
AVAGE

AB	+	!	ALLERGAN	0.1%	N021184	003	Sep 30, 2002	Mar CFTG
			TAZAROTENE					

>A>	AB		G AND W LABS INC	0.1%	A208662	001	Dec 22, 2017	Dec NEWA	
	AB		TARO	0.1%	A208258	001	Apr 03, 2017	Mar NEWA	
			TAZORAC						
	AB	+	!	ALLERGAN	0.1%	N021184	002	Sep 29, 2000	Mar CFTG

TECHNETIUM TC-99M ALBUMIN AGGREGATED KITINJECTABLE;INJECTION
PULMOLITE

BS	+	!	JUBILANT DRAXIMAGE	N/A	N017776	001		Nov CRLD
			TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT					
BS	+	!	DRAXIMAGE	N/A	N017881	001	Dec 30, 1987	Nov CRLD

TECHNETIUM TC-99M BICISATE KITINJECTABLE;INJECTION
NEUROLITE

+	!	LANTHEUS MEDCL	N/A	N020256	001	Nov 23, 1994	Nov CRLD
---	---	----------------	-----	---------	-----	--------------	----------

TECHNETIUM TC-99M EXAMETAZIME KITPOWDER;INTRAVENOUS
DRAX EXAMETAZIME
JUBILANT DRAXIMAGE N/A

N208870	001	Aug 17, 2017	Aug NEWA
---------	-----	--------------	----------

TECHNETIUM TC-99M MEDRONATE KITINJECTABLE;INJECTION
MDP-BRACCO

AP		CARDINAL HEALTH 414	N/A	N018107	001		Apr CAHN
----	--	---------------------	-----	---------	-----	--	----------

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE;INJECTION

AN-DTPA

@ JUBILANT DRAXIMAGE N/A

DTPA

+! DRAXIMAGE N/A

N/A

N017714 001

Aug DISC

N018511 001 Dec 29, 1989

Nov CRLD

N018511 001 Dec 29, 1989

Aug CTEC

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE;INJECTION

ULTRATAG

+! MALLINKRODT NUCLEAR N/A

N019981 001

Jun 10, 1991

Nov CRLD

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE;INJECTION

TECHNETIUM TC 99M SESTAMIBI

AP CARDINAL HEALTH 414 N/A

A078809 001

Apr 28, 2009

Sep CAHN

AP JUBILANT DRAXIMAGE N/A

A078806 001

Apr 29, 2009

Jun CAHN

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE;INJECTION

MYOVUE

+ @ GE HEALTHCARE N/A

N020372 001

Feb 09, 1996

Jul DISC

MYOVUE 30ML

+! GE HEALTHCARE N/A

N020372 002

Jul 07, 2005

Aug CMFD

+ @ N/A

N020372 002

Jul 07, 2005

Jul DISC

TECHNETIUM TC-99M TILMANOCEPT

INJECTABLE;INJECTION

LYMPHOSEEK KIT

+! CARDINAL HEALTH 414 N/A

N202207 001

Mar 13, 2013

Sep CAHN

+! CARDINAL HLTH 414 N/A

N202207 001

Mar 13, 2013

Mar CAHN

TELAVANCIN HYDROCHLORIDE

POWDER;IV (INFUSION)

VIBATIV

+ @ THERAVANCE BIOPHARMA EQ 250MG BASE/VIAL

N022110 001

Sep 11, 2009

Aug DISC

+ EQ 250MG BASE/VIAL

N022110 001

Sep 11, 2009

May CAHN

+! EQ 750MG BASE/VIAL

N022110 002

Sep 11, 2009

May CAHN

>D> TELBIVUDINE

>D> TABLET;ORAL

>D> TYZEKA

>D> +! NOVARTIS 600MG

N022011 001

Oct 25, 2006

Dec DISC

>A> + @ 600MG

N022011 001

Oct 25, 2006

Dec DISC

TELMISARTAN

TABLET;ORAL

TELMISARTAN

AB CADILA PHARMS LTD 20MG

A208605 001

Jul 25, 2017

Jul NEWA

AB 40MG

A208605 002

Jul 25, 2017

Jul NEWA

AB 80MG

A208605 003

Jul 25, 2017

Jul NEWA

AB GLENMARK PHARMS LTD 20MG

A090032 001

Jul 07, 2014

May CAHN

AB 40MG

A090032 002

Jul 07, 2014

May CAHN

AB 80MG

A090032 003

Jul 07, 2014

May CAHN

AB MICRO LABS 20MG

A207016 001

Oct 03, 2017

Sep NEWA

AB 40MG

A207016 002

Oct 03, 2017

Sep NEWA

AB 80MG

A207016 003

Oct 03, 2017

Sep NEWA

AB PRINSTON INC 20MG

A207882 001

May 03, 2017

Apr NEWA

AB 40MG

A207882 002

May 03, 2017

Apr NEWA

AB 80MG

A207882 003

May 03, 2017

Apr NEWA

TELOTTRISTAT ETIPRATE

TABLET;ORAL

XERMELO

+! LEXICON PHARMS INC EQ 250MG BASE

N208794 001

Feb 28, 2017

Feb NEWA

TEMAZEPAMCAPSULE; ORAL
RESTORIL

>D>	AB	+	MALLINCKRODT INC	7.5MG	N018163	003	Oct 25, 1991	Dec CAHN
>D>	AB	+		15MG	N018163	001		Dec CAHN
>D>	AB	+		22.5MG	N018163	004	Nov 02, 2004	Dec CAHN
>D>	AB	+		30MG	N018163	002		Dec CAHN
>A>	AB	+	SPECGX LLC	7.5MG	N018163	003	Oct 25, 1991	Dec CAHN
>A>	AB	+		15MG	N018163	001		Dec CAHN
>A>	AB	+		22.5MG	N018163	004	Nov 02, 2004	Dec CAHN
>A>	AB	+		30MG	N018163	002		Dec CAHN

TEMAZEPAM

AB	ACTAVIS ELIZABETH	15MG	A071620	002	Aug 07, 1987	May CMS1
AB	PRINSTON INC	7.5MG	A201781	001	Jun 04, 2015	Feb CAHN
AB		15MG	A201781	002	Jun 04, 2015	Feb CAHN
AB		22.5MG	A201781	003	Jun 04, 2015	Feb CAHN
AB		30MG	A201781	004	Jun 04, 2015	Feb CAHN

TEMOZOLOMIDECAPSULE; ORAL
TEMOZOLOMIDE

AB	ACCORD HLTHCARE	5MG	A201528	001	Feb 27, 2017	Feb NEWA
AB		20MG	A201528	002	Feb 27, 2017	Feb NEWA
AB		100MG	A201528	003	Feb 27, 2017	Feb NEWA
AB		140MG	A201528	004	Feb 27, 2017	Feb NEWA
AB		180MG	A201528	005	Feb 27, 2017	Feb NEWA
AB		250MG	A201528	006	Feb 27, 2017	Feb NEWA
AB	DEVA HOLDING AS	5MG	A207658	001	Apr 26, 2017	Apr NEWA
AB		20MG	A207658	002	Apr 26, 2017	Apr NEWA
AB		100MG	A207658	003	Apr 26, 2017	Apr NEWA
AB		140MG	A207658	004	Apr 26, 2017	Apr NEWA
AB		180MG	A207658	005	Apr 26, 2017	Apr NEWA
AB		250MG	A207658	006	Apr 26, 2017	Apr NEWA
AB	WATSON LABS TEVA	5MG	A203959	001	Apr 18, 2017	Apr NEWA
AB		20MG	A203959	002	Apr 18, 2017	Apr NEWA
AB		100MG	A203959	003	Apr 18, 2017	Apr NEWA
AB		140MG	A203959	004	Apr 18, 2017	Apr NEWA
AB		250MG	A203959	005	Apr 18, 2017	Apr NEWA
AB	ZYDUS PHARMS USA INC	5MG	A206750	001	Jul 31, 2017	Jul NEWA
AB		20MG	A206750	002	Jul 31, 2017	Jul NEWA
AB		100MG	A206750	003	Jul 31, 2017	Jul NEWA
AB		140MG	A206750	004	Jul 31, 2017	Jul NEWA
AB		180MG	A206750	005	Jul 31, 2017	Jul NEWA
AB		250MG	A206750	006	Jul 31, 2017	Jul NEWA

TENIPOSIDEINJECTABLE; INJECTION
VUMON

+	@ HQ SPECIT PHARMA	10MG/ML	N020119	001	Jul 14, 1992	Aug DISC
---	--------------------	---------	---------	-----	--------------	----------

TERAZOSIN HYDROCHLORIDECAPSULE; ORAL
TERAZOSIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 1MG BASE	A075140	002	Feb 11, 2000	Mar CAHN
AB		EQ 2MG BASE	A075140	003	Feb 11, 2000	Mar CAHN
AB		EQ 5MG BASE	A075140	001	Feb 11, 2000	Mar CAHN
AB		EQ 10MG BASE	A075140	004	Feb 11, 2000	Mar CAHN

TERBINAFINE HYDROCHLORIDEGRANULE; ORAL
LAMISIL

+	@ NOVARTIS	EQ 125MG BASE/PACKET	N022071	001	Sep 28, 2007	Aug DISC
+	@	EQ 187.5MG BASE/PACKET	N022071	002	Sep 28, 2007	Aug DISC

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

@ MYLAN	EQ 250MG BASE	A077195	001	Jul 02, 2007	Aug DISC
---------	---------------	---------	-----	--------------	----------

TERBUTALINE SULFATEINJECTABLE; INJECTION
TERBUTALINE SULFATE

AP	!	ATHENEX INC	1MG/ML	A076770	001	Apr 23, 2004	Mar CAHN
		TABLET; ORAL					
		BRETHINE					
	+	@ ANI PHARMS INC	2.5MG	N017849	001		Feb CAHN
	+	@	5MG	N017849	002		Feb CAHN
		TERBUTALINE SULFATE					
>D>		@ IMPAX LABS	2.5MG	A075877	001	Jun 26, 2001	Dec CMFD
>A>	AB		2.5MG	A075877	001	Jun 26, 2001	Dec CMFD
>D>		@	5MG	A075877	002	Jun 26, 2001	Dec CMFD
>A>	AB		5MG	A075877	002	Jun 26, 2001	Dec CMFD
>D>		LANNETT	2.5MG	A077152	001	Mar 25, 2005	Dec CTEC
>A>	AB		2.5MG	A077152	001	Mar 25, 2005	Dec CTEC
>D>	!		5MG	A077152	002	Mar 25, 2005	Dec CTEC
>A>	AB	!	5MG	A077152	002	Mar 25, 2005	Dec CTEC
		!	5MG	A077152	002	Mar 25, 2005	Jan CHRS

TERCONAZOLE

CREAM; VAGINAL

>D>		TERAZOL 3					
>D>	AB	+!	JANSSEN PHARMS	0.8%	N019964	001	Feb 21, 1991
>A>		+	@	0.8%	N019964	001	Feb 21, 1991
		TERCONAZOLE					
>D>	AB		TARO	0.8%	A075953	001	Apr 06, 2004
>A>	BX	!		0.8%	A075953	001	Apr 06, 2004

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

AB2	+	ABBVIE	1.62% (20.25MG/1.25GM PACKET)	N022309	002	Sep 07, 2012	Jun CFTG
AB2	+	!	1.62% (40.5MG/2.5GM PACKET)	N022309	003	Sep 07, 2012	Jun CFTG
		TESTIM					
AB2	+	!	AUXILIUM PHARMS LLC	50MG/5GM PACKET	N021454	001	Oct 31, 2002
		TESTOSTERONE					
AB2		ACTAVIS LABS UT INC	50MG/5GM PACKET	A091073	001	Sep 18, 2017	Sep NEWA
AB2		PERRIGO UK FINCO	1.62% (20.25MG/1.25GM PACKET)	A205781	001	Jul 12, 2017	Jun NEWA
AB2			1.62% (40.5MG/2.5GM PACKET)	A205781	002	Jul 12, 2017	Jun NEWA
		VOGELXO					
AB2		UPSHER-SMITH LABS	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jun CAHN
		GEL, METERED; TRANSDERMAL					
		TESTOSTERONE					
AB		ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Mar CAHN
		VOGELXO					
BX		UPSHER-SMITH LABS	12.5MG/1.25GM ACTUATION	N204399	003	Jun 04, 2014	Jun CAHN
		SOLUTION, METERED; TRANSDERMAL					
		AXIRON					
	+	@ ELI LILLY AND CO	30MG/1.5ML ACTUATION	N022504	001	Nov 23, 2010	Sep DISC
AT	+	!	30MG/1.5ML ACTUATION	N022504	001	Nov 23, 2010	Feb CFTG
		TESTOSTERONE					
AT		ACTAVIS LABS UT INC	30MG/1.5ML ACTUATION	A205328	001	Aug 07, 2017	Jul NEWA
AT		LUPIN LTD	30MG/1.5ML ACTUATION	A208061	001	Oct 23, 2017	Oct NEWA
AT	!	PERRIGO ISRAEL	30MG/1.5ML ACTUATION	A204255	001	Feb 28, 2017	Sep CHRS
AT			30MG/1.5ML ACTUATION	A204255	001	Feb 28, 2017	Feb NEWA
		TABLET, EXTENDED RELEASE; BUCCAL					
		STRIANT					
	+	!	AUXILIUM PHARMS LLC	30MG	N021543	001	Jun 19, 2003

TESTOSTERONE CYPIONATEINJECTABLE; INJECTION
TESTOSTERONE CYPIONATE

AO		LUITPOLD PHARMS INC	200MG/ML	A207742	001	Jun 16, 2017	Jun NEWA
AO		SANDOZ INC	100MG/ML	A040615	001	Aug 10, 2006	Mar CAHN
AO			200MG/ML	A040615	002	Aug 10, 2006	Mar CAHN
AO		WATSON PHARMS INC	200MG/ML	A086030	001		Feb CAHN
AO		WEST-WARD PHARMS INT	100MG/ML	A090387	001	Jul 15, 2010	Jan CAHN
AO			200MG/ML	A090387	002	Jul 15, 2010	Jan CAHN

TESTOSTERONE ENANTHATEINJECTABLE; INJECTION
TESTOSTERONE ENANTHATE

AO	WATSON PHARMS INC	200MG/ML	A085598	001		Feb	CAHN
----	-------------------	----------	---------	-----	--	-----	------

TETRABENAZINETABLET; ORAL
TETRABENAZINE

AB	ACTAVIS LABS FL INC	25MG	A206686	001	Jul 07, 2017	Jun	NEWA
AB	APICORE US	12.5MG	A207682	001	Jan 31, 2017	Jan	NEWA
AB		25MG	A207682	002	Jan 31, 2017	Jan	NEWA
>A>	BIONPHARMA INC	12.5MG	A208826	001	Dec 18, 2017	Dec	NEWA
>A>		25MG	A208826	002	Dec 18, 2017	Dec	NEWA
>A>	DR REDDYS LABS LTD	12.5MG	A209284	001	Jan 08, 2018	Dec	NEWA
>A>		25MG	A209284	002	Jan 08, 2018	Dec	NEWA

TETRACYCLINE HYDROCHLORIDECAPSULE; ORAL
ACHROMYCIN V

AB	+ HERITAGE PHARMA	250MG	N050278	003		Jan	CAHN
AB	+!	500MG	N050278	001		Jan	CAHN

TETRACYCLINE HYDROCHLORIDE

AB	CHARTWELL TETRA	250MG	A062752	001	Aug 12, 1988	Apr	CAHN
AB		500MG	A062752	002	Aug 12, 1988	Apr	CAHN
	@ IMPAX LABS	100MG	A060469	002		Jul	DISC
	@	250MG	A060469	001		Jul	DISC
	@	500MG	A060469	003		Jul	DISC

THEOPHYLLINEELIXIR; ORAL
THEOPHYLLINE

@	CHARTWELL RX	80MG/15ML
@	PHARM ASSOC	80MG/15ML

A085952	001		Apr	CAHN
A086720	001		May	CAHN

INJECTABLE; INJECTION

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

+! B BRAUN 80MG/100ML

N019826	002	Aug 14, 1992	Nov	CTEC
---------	-----	--------------	-----	------

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

+! HOSPIRA INC 4MG/ML

N019211	007	Dec 14, 1984	Nov	CTEC
---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

THEOCHRON

>A>	NOSTRUM PHARMS LLC	100MG	A087400	003	Feb 21, 1985	Dec	CMS1
>A>		200MG	A087400	004	Feb 21, 1985	Dec	CMS1
	@	300MG	A087400	002	Jan 11, 1983	May	CAHN
	! ALEMBIC LTD	450MG	A090430	002	Oct 27, 2010	Apr	CHRS
AB	ALEMBIC PHARMS LTD	300MG	A090430	001	Oct 27, 2010	May	CAHN
	!	450MG	A090430	002	Oct 27, 2010	May	CAHN

THIAMINE HYDROCHLORIDEINJECTABLE; INJECTION
THIAMINE HYDROCHLORIDE

AP	SAGENT PHARMS	100MG/ML	A206106	001	Dec 01, 2017	Nov	NEWA
	@ WEST-WARD PHARMS INT	100MG/ML	A080575	001		Jan	CAHN

THIORIDAZINE HYDROCHLORIDECONCENTRATE; ORAL
THIORIDAZINE HYDROCHLORIDE

@	ANI PHARMS INC	30MG/ML
@	PHARM ASSOC	30MG/ML
@		100MG/ML

A089602	001	Nov 09, 1987	Jan	CAHN
A040187	001	Aug 28, 1997	May	CAHN
A040213	001	May 29, 1998	May	CAHN

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

@	WATSON LABS TEVA	15MG
@		25MG
@		200MG

A088477	001	Nov 08, 1983	May	CAHN
A088567	001	May 11, 1984	May	CAHN
A088872	001	Apr 26, 1985	May	CAHN

THIOTEPAPOWDER;IV (INFUSION)
TEPADINA

+	!	ADIENNE SA	15MG/VIAL	N208264	001	Jan 26, 2017	Jan NEWA
+	!		100MG/VIAL	N208264	002	Jan 26, 2017	Jan NEWA

TIAGABINE HYDROCHLORIDETABLET;ORAL
GABITRIL

AB	+	CEPHALON	12MG	N020646	002	Sep 30, 1997	Oct CFTG
AB	+		16MG	N020646	003	Sep 30, 1997	Oct CFTG
TIAGABINE HYDROCHLORIDE							
AB		AMNEAL PHARMS CO	2MG	A208181	001	Dec 08, 2017	Nov NEWA
AB			4MG	A208181	002	Dec 08, 2017	Nov NEWA
AB			12MG	A208181	003	Dec 08, 2017	Nov NEWA
AB			16MG	A208181	004	Dec 08, 2017	Nov NEWA
AB		WILSHIRE PHARMS INC	2MG	A206857	001	Oct 13, 2017	Oct NEWA
AB			4MG	A206857	002	Oct 13, 2017	Oct NEWA
AB			12MG	A206857	003	Oct 13, 2017	Oct NEWA
AB			16MG	A206857	004	Oct 13, 2017	Oct NEWA

TICAGRELORTABLET;ORAL
BRILINTA

+		ASTRAZENECA PHARMS	60MG	N022433	002	Sep 03, 2015	Jan CAHN
+	!		90MG	N022433	001	Jul 20, 2011	Jan CAHN

TICLOPIDINE HYDROCHLORIDETABLET;ORAL
TICLOPIDINE HYDROCHLORIDE

>A>	@	FOSUN PHARMA	250MG	A075318	001	Aug 20, 1999	Dec CAHN
>A>	@		250MG	A075326	001	Aug 20, 1999	Dec CAHN
>D>	@	SANDOZ	250MG	A075318	001	Aug 20, 1999	Dec CAHN
>D>	@		250MG	A075326	001	Aug 20, 1999	Dec CAHN

TIGECYCLINEPOWDER;IV (INFUSION)
TIGECYCLINE

AP		SANDOZ INC	50MG/VIAL	A091620	001	May 27, 2015	Feb CDFR
TYGACIL							
AP	+	PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005	Feb CDFR

TIMOLOL MALEATESOLUTION, GEL FORMING/DROPS;OPHTHALMIC
TIMOLOL MALEATE

AB		SANDOZ INC	EQ 0.25% BASE	N020963	001	Oct 21, 1998	Feb CAHN
AB			EQ 0.5% BASE	N020963	002	Oct 21, 1998	Feb CAHN

SOLUTION/DROPS;OPHTHALMIC
TIMOLOL MALEATE

AT	!	SANDOZ INC	EQ 0.25% BASE	A074261	001	Apr 28, 1995	Feb CAHN
AT1	!		EQ 0.5% BASE	A074262	001	Apr 28, 1995	Feb CAHN

TABLET;ORAL

TIMOLOL MALEATE

>A>	@	FOSUN PHARMA	5MG	A072550	001	Apr 13, 1989	Dec CAHN
>A>	@		10MG	A072551	001	Apr 13, 1989	Dec CAHN
>A>	@		20MG	A072552	001	Apr 13, 1989	Dec CAHN
>D>	@	SANDOZ	5MG	A072550	001	Apr 13, 1989	Dec CAHN
>D>	@		10MG	A072551	001	Apr 13, 1989	Dec CAHN
>D>	@		20MG	A072552	001	Apr 13, 1989	Dec CAHN

TINIDAZOLETABLET;ORAL
TINIDAZOLE

AB		UNIQUE PHARM LABS	250MG	A202489	001	Oct 09, 2013	Jan CTEC
AB			500MG	A202489	002	Oct 09, 2013	Jan CTEC

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

AB	JUBILANT GENERICS	EQ 2MG BASE	A209605	001	Aug 04, 2017	Jul	NEWA
AB		EQ 4MG BASE	A209605	002	Aug 04, 2017	Jul	NEWA
AB		EQ 6MG BASE	A209605	003	Aug 04, 2017	Jul	NEWA
AB	PAR PHARM INC	EQ 2MG BASE	A207199	001	Mar 14, 2017	Feb	NEWA
AB		EQ 4MG BASE	A207199	002	Mar 14, 2017	Feb	NEWA
AB		EQ 6MG BASE	A207199	003	Mar 14, 2017	Feb	NEWA
AB	ZYDUS PHARMS USA INC	EQ 2MG BASE	A208622	001	Mar 03, 2017	Feb	NEWA
AB		EQ 4MG BASE	A208622	002	Mar 03, 2017	Feb	NEWA
AB		EQ 6MG BASE	A208622	003	Mar 03, 2017	Feb	NEWA

ZANAFLEX

AB	+ COVIS PHARMA BV	EQ 2MG BASE	N021447	001	Aug 29, 2002	Nov	CAHN
AB	+	EQ 4MG BASE	N021447	002	Aug 29, 2002	Nov	CAHN
AB	+	EQ 6MG BASE	N021447	003	Aug 29, 2002	Nov	CAHN

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

AB	EPIC PHARMA LLC	EQ 2MG BASE	A076347	001	Oct 11, 2002	May	CAHN
AB		EQ 4MG BASE	A076347	002	Oct 11, 2002	May	CAHN
AB	PAR PHARM INC	EQ 2MG BASE	A207170	001	Jan 26, 2017	Jan	NEWA
AB		EQ 4MG BASE	A207170	002	Jan 26, 2017	Jan	NEWA

ZANAFLEX

	+ @ COVIS PHARMA BV	EQ 2MG BASE	N020397	002	Feb 04, 2000	Nov	CAHN
AB	+	EQ 4MG BASE	N020397	001	Nov 27, 1996	Nov	CAHN

TOBRAMYCIN

SOLUTION;INHALATION

TOBRAMYCIN

AN	AMNEAL PHARMS	300MG/5ML	A205501	001	Jul 13, 2015	May	CAHN
AN	LUPIN ATLANTIS	300MG/5ML	A208964	001	Mar 22, 2017	Mar	NEWA
AN	MYLAN PHARMS INC	300MG/5ML	A209554	001	Oct 13, 2017	Oct	NEWA

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

AT	SOMERSET THERAPS LLC	0.3%	A207444	001	Jun 28, 2017	Jun	NEWA
	TOBREX						
AT	SANDOZ INC	0.3%	A062535	001	Dec 13, 1984	Feb	CAHN

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

AP	BAXTER HLTHCARE CORP	EQ 40MG BASE/ML	A206965	001	Jul 01, 2016	Aug	CAHN
----	----------------------	-----------------	---------	-----	--------------	-----	------

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

>A>	@ FOSUN PHARMA	250MG	A070289	001	Mar 13, 1986	Dec	CAHN
>A>	@	500MG	A070290	001	Mar 13, 1986	Dec	CAHN
>D>	@ SANDOZ	250MG	A070289	001	Mar 13, 1986	Dec	CAHN
>D>	@	500MG	A070290	001	Mar 13, 1986	Dec	CAHN

TOLMETIN SODIUM

TABLET;ORAL

TOLMETIN SODIUM

!	MYLAN	EQ 600MG BASE	A074473	001	Aug 30, 1994	Nov	CTEC
---	-------	---------------	---------	-----	--------------	-----	------

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

TOLTERODINE TARTRATE

AB	HETERO LABS LTD III	2MG	A206419	001	Dec 12, 2017	Nov	NEWA
AB		4MG	A206419	002	Dec 12, 2017	Nov	NEWA

TOPIRAMATE

CAPSULE;ORAL

TOPIRAMATE

	@ MYLAN	15MG	A078418	001	Oct 14, 2009	Nov	DISC
	@	25MG	A078418	002	Oct 14, 2009	Nov	DISC

CAPSULE, EXTENDED RELEASE;ORAL

QUDEXY XR

+	UPSHER-SMITH LABS	25MG	N205122	001	Mar 11, 2014	Jun	CAHN
+		50MG	N205122	002	Mar 11, 2014	Jun	CAHN

CAPSULE, EXTENDED RELEASE;ORAL
QUDEXY XR

	+	100MG	N205122	003	Mar 11, 2014	Jun CAHN
	+	150MG	N205122	004	Mar 11, 2014	Jun CAHN
	+	200MG	N205122	005	Mar 11, 2014	Jun CAHN

TOPIRAMATE

AB		ZYDUS PHARMS USA INC	25MG	A207382	001	Nov 24, 2017	Nov NEWA
AB			50MG	A207382	002	Nov 24, 2017	Nov NEWA
AB			100MG	A207382	003	Nov 24, 2017	Nov NEWA

TROKENDI XR

AB	+	SUPERMUS PHARMS	25MG	N201635	001	Aug 16, 2013	Nov CFTG
AB	+		50MG	N201635	002	Aug 16, 2013	Nov CFTG
AB	+		100MG	N201635	003	Aug 16, 2013	Nov CFTG

TABLET;ORAL

TOPIRAMATE

	@	MYLAN	25MG	A076314	001	Mar 27, 2009	May DISC
	@		50MG	A076314	002	Mar 27, 2009	May DISC
	@		100MG	A076314	003	Mar 27, 2009	May DISC
	@		200MG	A076314	004	Mar 27, 2009	May DISC
AB		UPSHER-SMITH LABS	25MG	A078499	001	Jan 07, 2010	Jun CAHN
AB			50MG	A078499	002	Jan 07, 2010	Jun CAHN
AB			100MG	A078499	003	Jan 07, 2010	Jun CAHN
AB			200MG	A078499	004	Jan 07, 2010	Jun CAHN

TOPOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

TOPOTECAN HYDROCHLORIDE

AP		HONG KONG	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	Sep CAHN
AP		NOVAST LABS LTD	EQ 4MG BASE/VIAL	A206962	001	Nov 30, 2016	Sep CAHN
	@	SUN PHARM INDS LTD	EQ 4MG BASE/VIAL	A202203	001	Aug 29, 2013	Sep DISC

SOLUTION;INTRAVENOUS

TOPOTECAN HYDROCHLORIDE

		ACCORD HLTHCARE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204406	001	Jul 06, 2017	Nov CTEC
AP			EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204406	001	Jul 06, 2017	Jun NEWA
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A204406	002	Jul 06, 2017	Jun NEWA
AP		MYLAN LABS LTD	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A206074	001	Nov 24, 2017	Nov NEWA

TORSEMIFENE CITRATE

TABLET;ORAL

FARESTON

	+	KYOWA KIRIN	EQ 60MG BASE	N020497	001	May 29, 1997	Jan CAHN
--	---	-------------	--------------	---------	-----	--------------	----------

TORSEMIDE

TABLET;ORAL

DEMADEX

AB	+	MYLAN SPECIALITY LP	5MG	N020136	001	Aug 23, 1993	Mar CAHN
AB	+		10MG	N020136	002	Aug 23, 1993	Mar CAHN
AB	+		20MG	N020136	003	Aug 23, 1993	Mar CAHN
AB	+		100MG	N020136	004	Aug 23, 1993	Mar CAHN

TORSEMIDE

@ SUN PHARM INDS

@

@

@

@

			5MG	A078478	001	Feb 26, 2008	Sep DISC
			10MG	A078478	002	Feb 26, 2008	Sep DISC
			20MG	A078478	003	Feb 26, 2008	Sep DISC
			100MG	A078478	004	Feb 26, 2008	Sep DISC

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

@ ACCORD HLTHCARE

			50MG	A202390	001	May 16, 2013	Oct DISC
AB			50MG	A202390	001	May 16, 2013	Mar CAHN
AB		AMNEAL PHARMS	50MG	A076003	001	Jun 20, 2002	May CAHN
>D> AB		MALLINCKRODT	50MG	A075983	001	Jun 25, 2002	Dec CAHN
	@	MYLAN PHARMS INC	50MG	A075980	001	Nov 21, 2002	Nov DISC
>A> AB		SPECGX LLC	50MG	A075983	001	Jun 25, 2002	Dec CAHN

TABLET, EXTENDED RELEASE;ORAL

ULTRAM ER

	+	@ VALEANT PHARMS	100MG	N021692	001	Sep 08, 2005	Mar CRLD
	+	@	200MG	N021692	002	Sep 08, 2005	Mar CRLD
	+	@	300MG	N021692	003	Sep 08, 2005	Mar CRLD

TRAMETINIB DIMETHYL SULFOXIDETABLET;ORAL
MEKINIST

+ @ NOVARTIS PHARMS CORP EQ 1MG N204114 002 May 29, 2013 Jul DISC

TRANDOLAPRILTABLET;ORAL
TRANDOLAPRIL

	@ EPIC PHARMA LLC	1MG	A 077256	001	Jun 12, 2007	May CAHN
	@	2MG	A 077256	002	Jun 12, 2007	May CAHN
	@	4MG	A 077256	003	Jun 12, 2007	May CAHN
	@ INVAGEN PHARMS	1MG	A 078320	001	Jun 12, 2007	Jun DISC
BX		1MG	A 078320	001	Jun 12, 2007	Apr CTEC
	@	2MG	A 078320	002	Jun 12, 2007	Jun DISC
BX		2MG	A 078320	002	Jun 12, 2007	Apr CTEC
	@	4MG	A 078320	003	Jun 12, 2007	Jun DISC
BX		4MG	A 078320	003	Jun 12, 2007	Apr CTEC
	@ MYLAN	1MG	A 078346	001	Apr 28, 2008	May DISC
	@	2MG	A 078346	002	Apr 28, 2008	May DISC
	@	4MG	A 078346	003	Apr 28, 2008	May DISC

TRANEXAMIC ACIDINJECTABLE;INJECTION
TRANEXAMIC ACID

AP	AKORN	100MG/ML	A 206594	001	Sep 28, 2017	Sep NEWA
AP	AMNEAL PHARMS CO	100MG/ML	A 208840	001	Feb 28, 2017	Feb NEWA
AP	GLAND PHARMA LTD	100MG/ML	A 207239	001	Feb 13, 2017	Jan NEWA
AP	MICRO LABS	100MG/ML	A 206713	001	Jun 27, 2017	Jun NEWA
AP	VIRTUS PHARMS	100MG/ML	A 202755	001	Feb 25, 2016	Sep CAHN
AP	VIVA HLTHCARE	100MG/ML	A 206713	001	Jun 27, 2017	Sep CAHN
AP	ZYDUS PHARMS USA INC	100MG/ML	A 205228	001	Jul 17, 2017	Jul NEWA

TABLET;ORAL
LYSTEDA

AB +! FERRING PHARMS INC 650MG N022430 001 Nov 13, 2009 Nov CAHN

TRAVOPROSTSOLUTION/DROPS;OPHTHALMIC
TRAVOPROST

AT MYLAN PHARMS INC 0.004% A 205050 001 Jul 07, 2017 Jun NEWA

TRAZODONE HYDROCHLORIDETABLET;ORAL
TRAZODONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	50MG	A 206923	001	Sep 08, 2017	Aug NEWA
AB		100MG	A 206923	002	Sep 08, 2017	Aug NEWA
AB		150MG	A 206923	003	Sep 08, 2017	Aug NEWA
AB		300MG	A 206923	004	Sep 08, 2017	Aug NEWA
	@ MYLAN PHARMS INC	50MG	A 090514	001	Jun 02, 2009	May DISC
	@	100MG	A 090514	002	Jun 02, 2009	May DISC
	@	150MG	A 090514	003	Jun 02, 2009	May DISC
	@	300MG	A 090514	004	Jun 02, 2009	May DISC
AB	ZYDUS PHARMS USA INC	50MG	A 205253	001	Oct 10, 2017	Sep NEWA
AB		100MG	A 205253	002	Oct 10, 2017	Sep NEWA
AB		150MG	A 205253	003	Oct 10, 2017	Sep NEWA
AB		300MG	A 205253	004	Oct 10, 2017	Sep NEWA

TREPROSTINILINJECTABLE;IV (INFUSION), SUBCUTANEOUS
REMODULIN

AP	+! UNITED THERAP	1MG/ML	N 021272	001	May 21, 2002	Nov CFTG
AP	+!	2.5MG/ML	N 021272	002	May 21, 2002	Nov CFTG
AP	+!	5MG/ML	N 021272	003	May 21, 2002	Nov CFTG
AP	+!	10MG/ML	N 021272	004	May 21, 2002	Nov CFTG

TREPROSTINIL

AP	SANDOZ INC	1MG/ML	A 203649	001	Nov 30, 2017	Nov NEWA
AP		2.5MG/ML	A 203649	002	Nov 30, 2017	Nov NEWA
AP		5MG/ML	A 203649	003	Nov 30, 2017	Nov NEWA
AP		10MG/ML	A 203649	004	Nov 30, 2017	Nov NEWA

TRETINOIN

CAPSULE;ORAL							
TRETINOIN							
AB	GLENMARK PHARMS LTD	10MG	A208279	001	Dec 23, 2016	Jun	CAHN
VESANOID							
	+ @ CHEPLAPHARM	10MG	N020438	001	Nov 22, 1995	May	CAHN
CREAM;TOPICAL							
TRETINOIN							
AB2	ZO SKIN HEALTH	0.05%	A076498	001	Sep 15, 2005	Feb	CAHN
GEL;TOPICAL							
RETIN-A-MICRO							
	+! VALEANT INTL	0.06%	N020475	004	Oct 23, 2017	Oct	NEWA
TRETINOIN							
AB	MYLAN PHARMS INC	0.04%	A202567	001	Jul 17, 2013	Jun	CAHN
AB		0.05%	A207955	001	Aug 13, 2015	Jun	CAHN
AB		0.1%	A202026	001	Jul 17, 2013	Jun	CAHN
SOLUTION;TOPICAL							
RETIN-A							
	+ @ VALEANT INTL	0.05%	N016921	001		Oct	DISC

TRIAMCINOLONE ACETONIDE

		CREAM;TOPICAL									
		TRIAMCINOLONE ACETONIDE									
>A>	AT	ALKEM LABS LTD	0.025%	A207651	001	Dec 26, 2017	Dec	NEWA			
>A>	AT		0.1%	A207651	002	Dec 26, 2017	Dec	NEWA			
>A>	AT		0.5%	A207651	003	Dec 26, 2017	Dec	NEWA			
	AT	LUPIN ATLANTIS	0.025%	A208763	001	Feb 01, 2017	Jan	NEWA			
	AT		0.1%	A208763	002	Feb 01, 2017	Jan	NEWA			
	AT		0.5%	A208763	003	Feb 01, 2017	Jan	NEWA			
	AT	+ MYLAN PHARMS INC	0.025%	N011601	003		Jan	CAHN			
	AT	+	0.1%	N011601	006		Jan	CAHN			
		@ TARO	0.025%	A040038	001	Oct 26, 1994	Apr	CAHN			
	AT		0.1%	A040039	001	Nov 26, 1997	Apr	CAHN			
	AT		0.1%	A040039	001	Nov 26, 1997	Mar	CAHN			
	AT	TELIGENT PHARMA INC	0.1%	A208848	001	Sep 18, 2017	Sep	NEWA			
		FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR									
		ZILRETTA									
	+	FLEXION THERAPS INC	32MG/VIAL	N208845	001	Oct 06, 2017	Oct	NEWA			
		INJECTABLE;INJECTION									
		KENALOG-10									
	+	APOTHECON	10MG/ML	N012041	001		Jun	CRLD			
		KENALOG-40									
AP	+	APOTHECON	40MG/ML	N014901	001		Nov	CTEC			
		TRIAMCINOLONE ACETONIDE									
AP		AMNEAL PHARMS CO	40MG/ML	A207550	001	Dec 11, 2017	Nov	NEWA			
		@ SANDOZ INC	10MG/ML	A090166	001	May 27, 2009	Apr	CAHN			
		@	40MG/ML	A090164	001	Jun 01, 2009	Apr	CAHN			
		LOTION;TOPICAL									
		TRIAMCINOLONE ACETONIDE									
>D>	AT	! WOCKHARDT	0.1%	A088451	001	Apr 03, 1985	Dec	CAHN			
>A>	AT	! WOCKHARDT BIO AG	0.025%	A088450	001	Apr 01, 1985	Dec	CAHN			
>A>	AT	!	0.1%	A088451	001	Apr 03, 1985	Dec	CAHN			
>D>	AT	! WOCKHARDT EU OPERATN	0.025%	A088450	001	Apr 01, 1985	Dec	CAHN			
		OINTMENT;TOPICAL									
		KENALOG									
	+	@ MYLAN PHARMS INC	0.025%	N011600	003		Sep	CRLD			
		@	0.025%	N011600	003		Aug	DISC			
	AT		0.025%	N011600	003		Jan	CAHN			
	+	@	0.1%	N011600	001		Sep	CRLD			
		@	0.1%	N011600	001		Aug	DISC			
	AT		0.1%	N011600	001		Jan	CAHN			
		TRIAMCINOLONE ACETONIDE									
AT		G AND W LABS INC	0.5%	A208925	001	Oct 06, 2017	Sep	NEWA			
AT		GLENMARK PHARMS	0.1%	A208320	001	Aug 22, 2017	Aug	NEWA			
		@ TARO	0.025%	A040040	001	Sep 30, 1994	Apr	CAHN			
	AT		0.1%	A040037	001	Sep 30, 1994	Apr	CAHN			
	AT	TELIGENT PHARMA INC	0.5%	A208590	001	Mar 03, 2017	Feb	NEWA			
		TRIAMCINOLONE ACETONIDE IN ABSORBASE									
	!	CMP PHARMA INC	0.05%	A089595	001	Mar 23, 1995	Apr	CAHN			

PASTE;DENTAL							
TRIAMCINOLONE ACETONIDE							
AT	G AND W LABS INC	0.1%	A205592	001	Jan 12, 2017	Jan	NEWA
SPRAY;TOPICAL							
TRIAMCINOLONE ACETONIDE							
AT	RICONPHARMA LLC	0.147MG/GM	A206786	001	Sep 08, 2017	Aug	NEWA
SPRAY, METERED;NASAL							
TRIAMCINOLONE ACETONIDE							
	@ PERRIGO ISRAEL	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Jan	CAHN
<u>TRIAMCINOLONE DIACETATE</u>							
INJECTABLE;INJECTION							
ARISTOCORT							
>A>	@ FOSUN PHARMA	25MG/ML	N011685	003		Dec	CAHN
>A>	+ @	40MG/ML	N012802	001		Dec	CAHN
>D>	@ SANDOZ INC	25MG/ML	N011685	003		Dec	CAHN
	@	25MG/ML	N011685	003		Jun	CAHN
>D>	+ @	40MG/ML	N012802	001		Dec	CAHN
	+ @	40MG/ML	N012802	001		Jun	CAHN
<u>TRIAMCINOLONE HEXACETONIDE</u>							
INJECTABLE;INJECTION							
ARISTOSPAN							
	+! SANDOZ INC	5MG/ML	N016466	001		Jun	CAHN
	+!	20MG/ML	N016466	002		Jun	CAHN
<u>TRIFLURIDINE</u>							
SOLUTION/DROPS;OPHTHALMIC							
TRIFLURIDINE							
AT	HI-TECH PHARMACAL	1%	A205438	001	Jul 28, 2017	Jul	NEWA
AT	SANDOZ INC	1%	A074311	001	Oct 06, 1995	Feb	CAHN
VIOPTIC							
AT	+! MONARCH PHARMS	1%	N018299	001		Feb	CAHN
<u>TRIHEXYPHENIDYL HYDROCHLORIDE</u>							
ELIXIR;ORAL							
TRIHEXYPHENIDYL HYDROCHLORIDE							
AA	! PHARM ASSOC	2MG/5ML	A040177	001	Apr 17, 1997	May	CAHN
TABLET;ORAL							
TRIHEXYPHENIDYL HYDROCHLORIDE							
AA	VINTAGE PHARMS LLC	2MG	A040254	001	Dec 24, 1998	Mar	CAHN
AA		5MG	A040254	002	Dec 24, 1998	Mar	CAHN
<u>TRIMETHOBENZAMIDE HYDROCHLORIDE</u>							
CAPSULE;ORAL							
TIGAN							
AB	+! KING PHARMS LLC	300MG	N017531	006	Dec 13, 2001	May	CAHN
<u>TRIMETHOPRIM HYDROCHLORIDE</u>							
SOLUTION;ORAL							
PRIMSOL							
>A>	@ ALLEGIS	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995	Dec	CAHN
	+!	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Oct	CAHN
>D>	@ AYTU PHARMS	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995	Dec	CAHN
<u>TRIMIPRAMINE MALEATE</u>							
CAPSULE;ORAL							
TRIMIPRAMINE MALEATE							
AB	ELITE LABS INC	EQ 25MG BASE	A077361	001	Aug 02, 2006	May	CAHN
AB		EQ 50MG BASE	A077361	002	Aug 02, 2006	May	CAHN
AB		EQ 100MG BASE	A077361	003	Aug 02, 2006	May	CAHN
<u>TRIPTORELIN PAMOATE</u>							
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR							
TRIPTODUR KIT							
	+! ARBOR PHARMS LLC	EQ 22.5MG BASE/VIAL	N208956	001	Jun 29, 2017	Jun	NEWA

TROPICAMIDESOLUTION/DROPS;OPHTHALMIC
MYDRIACYL

AT	!	SANDOZ INC	0.5%	A084305	001		Feb	CAHN
----	---	------------	------	---------	-----	--	-----	------

TROSPIMUM CHLORIDECAPSULE, EXTENDED RELEASE;ORAL
TROSPIMUM CHLORIDE

	@	UPSHER-SMITH LABS	60MG	A091635	001	Apr 29, 2015	Jun	CAHN
--	---	-------------------	------	---------	-----	--------------	-----	------

ULIPRISTAL ACETATETABLET;ORAL
ELLA

AB	+	LAB HRA PHARMA	30MG	N022474	001	Aug 13, 2010	Jan	CFTG
----	---	----------------	------	---------	-----	--------------	-----	------

LOGILIA

AB		TEVA PHARMS USA	30MG	A207952	001	Feb 13, 2017	Jan	NEWA
----	--	-----------------	------	---------	-----	--------------	-----	------

URSODIOLCAPSULE;ORAL
URSODIOL

	@	IMPAX LABS INC	300MG	A077895	001	Jul 27, 2006	May	DISC
BX			300MG	A077895	001	Jul 27, 2006	Apr	CTEC
AB			300MG	A077895	001	Jul 27, 2006	Feb	CAHN

VALACYCLOVIR HYDROCHLORIDETABLET;ORAL
VALACYCLOVIR HYDROCHLORIDE

@ MYLAN EQ 500MG BASE

A078070	001	May 24, 2010	Jun	DISC
---------	-----	--------------	-----	------

@ EQ 1GM BASE

A078070	002	May 24, 2010	Jun	DISC
---------	-----	--------------	-----	------

>A>	AB		ZYDUS PHARMS USA INC	EQ 500MG BASE	A079137	001	Dec 29, 2017	Dec	NEWA
-----	----	--	----------------------	---------------	---------	-----	--------------	-----	------

>A>	AB			EQ 1GM BASE	A079137	002	Dec 29, 2017	Dec	NEWA
-----	----	--	--	-------------	---------	-----	--------------	-----	------

VALBENAZINE TOSYLATECAPSULE;ORAL
INGREZZA

+! NEUROCRINE 40MG

N209241	001	Apr 11, 2017	Apr	NEWA
---------	-----	--------------	-----	------

+ 80MG

N209241	002	Oct 04, 2017	Oct	NEWA
---------	-----	--------------	-----	------

VALGANCICLOVIR HYDROCHLORIDETABLET;ORAL
VALGANCICLOVIR HYDROCHLORIDE

AB		DR REDDYS LABS LTD	EQ 450MG BASE	A206876	001	Dec 12, 2017	Nov	NEWA
----	--	--------------------	---------------	---------	-----	--------------	-----	------

VALPROATE SODIUMINJECTABLE;INJECTION
VALPROATE SODIUM

AP		ATHENEX INC	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Mar	CAHN
----	--	-------------	------------------	---------	-----	--------------	-----	------

VALPROIC ACIDCAPSULE;ORAL
VALPROIC ACID

@ USL PHARMA 250MG

A070631	001	Jun 11, 1987	Jun	CAHN
---------	-----	--------------	-----	------

SYRUP;ORAL

VALPROIC ACID

AA		ECI PHARMS LLC	250MG/5ML	A090517	001	May 28, 2010	Mar	CAHN
----	--	----------------	-----------	---------	-----	--------------	-----	------

AA		PHARM ASSOC	250MG/5ML	A075379	001	Dec 15, 2000	May	CAHN
----	--	-------------	-----------	---------	-----	--------------	-----	------

AA		VISTAPHARM	250MG/5ML	A075782	001	Dec 22, 2000	Feb	CAHN
----	--	------------	-----------	---------	-----	--------------	-----	------

>D>	AA		WOCKHARDT	250MG/5ML	A070868	001	Jul 01, 1986	Dec	CAHN
-----	----	--	-----------	-----------	---------	-----	--------------	-----	------

>A>	AA		WOCKHARDT BIO AG	250MG/5ML	A070868	001	Jul 01, 1986	Dec	CAHN
-----	----	--	------------------	-----------	---------	-----	--------------	-----	------

VALSARTAN

>A> SOLUTION;ORAL

>A> PREXXARTAN

>A>		+	CARMEL BIOSCIENCES	20MG/5ML	N209139	001	Dec 19, 2017	Dec	NEWA
-----	--	---	--------------------	----------	---------	-----	--------------	-----	------

>A>		+		80MG/20ML	N209139	002	Dec 19, 2017	Dec	NEWA
-----	--	---	--	-----------	---------	-----	--------------	-----	------

TABLET;ORAL

VALSARTAN

AB		AMNEAL PHARMS	40MG	A204011	001	Jan 11, 2016	May	CAHN
----	--	---------------	------	---------	-----	--------------	-----	------

AB			80MG	A204011	002	Jan 11, 2016	May	CAHN
----	--	--	------	---------	-----	--------------	-----	------

AB			160MG	A204011	003	Jan 11, 2016	May	CAHN
----	--	--	-------	---------	-----	--------------	-----	------

AB			320MG	A204011	004	Jan 11, 2016	May	CAHN
----	--	--	-------	---------	-----	--------------	-----	------

TABLET;ORAL							
VALSARTAN							
AB	MYLAN PHARMS INC	40MG	A090866	001	Jan 05, 2015	Feb	CAHN
AB		80MG	A090866	002	Jan 05, 2015	Feb	CAHN
AB		160MG	A090866	003	Jan 05, 2015	Feb	CAHN
AB		320MG	A090866	004	Jan 05, 2015	Feb	CAHN
<u>VANCOMYCIN HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
VANCOMYCIN HYDROCHLORIDE							
AP	MUSTAFA NEVZAT ILAC	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Aug	CAHN
AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Aug	CAHN
	@ TEVA PHARMS USA	EQ 500MG BASE/VIAL	A201251	001	Dec 23, 2015	Oct	DISC
	@	EQ 1GM BASE/VIAL	A201251	002	Dec 23, 2015	Oct	DISC
	@	EQ 5GM BASE/VIAL	A201250	001	Dec 23, 2015	Oct	DISC
	@	EQ 10GM BASE/VIAL	A201250	002	Dec 23, 2015	Oct	DISC
<u>VARDENAFIL HYDROCHLORIDE</u>							
TABLET;ORAL							
LEVITRA							
+	BAYER HLTHCARE	2.5MG	N021400	003	Aug 19, 2003	Nov	CTEC
+		5MG	N021400	001	Aug 19, 2003	Nov	CTEC
+		10MG	N021400	002	Aug 19, 2003	Nov	CTEC
+	!	20MG	N021400	004	Aug 19, 2003	Nov	CTEC
VARDENAFIL HYDROCHLORIDE							
	@ TEVA PHARMS	2.5MG	A091347	001	May 03, 2012	Sep	DISC
	@	5MG	A091347	002	May 03, 2012	Sep	DISC
	@	10MG	A091347	003	May 03, 2012	Sep	DISC
	@	20MG	A091347	004	May 03, 2012	Sep	DISC
TABLET, ORALLY DISINTEGRATING;ORAL							
STAXYN							
+	! BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010	Jun	CTEC
<u>VASOPRESSIN</u>							
SOLUTION;IV (INFUSION)							
VASOSTRICT							
+	! PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	May	CMFD
+	@	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	Apr	DISC
+	!	20UNITS/ML (20UNITS/ML)	N204485	002	Mar 18, 2016	Apr	NEWA
+	!	200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016	May	NEWA
<u>VECURONIUM BROMIDE</u>							
INJECTABLE;INJECTION							
VECURONIUM BROMIDE							
	@ WEST-WARD PHARMS INT	10MG/VIAL	A075218	001	Aug 23, 1999	Mar	CAHN
AP		10MG/VIAL	A075549	001	Jun 13, 2000	Jan	CAHN
	@	20MG/VIAL	A075218	002	Aug 23, 1999	Mar	CAHN
AP		20MG/VIAL	A075549	002	Jun 13, 2000	Jan	CAHN
<u>VENLAFAXINE HYDROCHLORIDE</u>							
CAPSULE, EXTENDED RELEASE;ORAL							
VENLAFAXINE HYDROCHLORIDE							
AB	MACLEODS PHARMS LTD	EQ 37.5MG BASE	A204889	001	Oct 05, 2017	Sep	NEWA
AB		EQ 75MG BASE	A204889	002	Oct 05, 2017	Sep	NEWA
AB		EQ 150MG BASE	A204889	003	Oct 05, 2017	Sep	NEWA
	@ MYLAN	EQ 37.5MG BASE	A078789	001	Jun 01, 2011	Aug	DISC
	@	EQ 75MG BASE	A078789	002	Jun 01, 2011	Aug	DISC
	@	EQ 150MG BASE	A078789	003	Jun 01, 2011	Aug	DISC
TABLET;ORAL							
VENLAFAXINE HYDROCHLORIDE							
AB	PRINSTON INC	EQ 25MG BASE	A090027	001	Aug 04, 2010	Feb	CAHN
AB		EQ 37.5MG BASE	A090027	002	Aug 04, 2010	Feb	CAHN
AB		EQ 50MG BASE	A090027	003	Aug 04, 2010	Feb	CAHN
AB		EQ 75MG BASE	A090027	004	Aug 04, 2010	Feb	CAHN
AB		EQ 100MG BASE	A090027	005	Aug 04, 2010	Feb	CAHN
TABLET, EXTENDED RELEASE;ORAL							
VENLAFAXINE HYDROCHLORIDE							
AB	NOSTRUM LABS INC	EQ 150MG BASE	A205468	002	Mar 24, 2017	Mar	NEWA
AB		EQ 225MG BASE	A205468	003	Mar 24, 2017	Mar	NEWA
AB	+	OSMOTICA PHARM	N022104	004	May 20, 2008	Mar	CFTG

VERAPAMIL HYDROCHLORIDE

TABLET;ORAL

VERAPAMIL HYDROCHLORIDE

>A>	@ FOSUN PHARMA	40MG	A073168	001	Jul 31, 1992	Dec CAHN
>A>	@	80MG	A071423	001	May 24, 1988	Dec CAHN
>A>	@	120MG	A071424	001	May 25, 1988	Dec CAHN
>A> AB	HERITAGE PHARMS INC	80MG	A071881	003	Apr 05, 1988	Dec CMS1
>D>	@ SANDOZ	40MG	A073168	001	Jul 31, 1992	Dec CAHN
>D>	@	80MG	A071423	001	May 24, 1988	Dec CAHN
>D>	@	120MG	A071424	001	May 25, 1988	Dec CAHN

TABLET, EXTENDED RELEASE;ORAL

CALAN SR

+	@ PFIZER	180MG	N019152	002	Dec 15, 1989	Jan CRLD
	COVERA-HS					
	@ GD SEARLE LLC	180MG	N020552	001	Feb 26, 1996	Jan DISC
	@	240MG	N020552	002	Feb 26, 1996	Jan DISC
	VERAPAMIL HYDROCHLORIDE					
AB	CADILA PHARMS LTD	180MG	A206173	001	May 05, 2017	Apr NEWA
AB		240MG	A206173	002	May 05, 2017	Apr NEWA

VIGABATRIN

FOR SOLUTION;ORAL

SABRIL

AA	+! LUNDBECK PHARMS LLC	500MG/PACKET	N022006	001	Aug 21, 2009	Apr CFTG
	+!	500MG/PACKET	N022006	001	Aug 21, 2009	Jan CAHN
	VIGABATRIN					
AA	PAR PHARM INC	500MG/PACKET	A208218	001	Apr 27, 2017	Apr NEWA
	TABLET;ORAL					
	SABRIL					
	+! LUNDBECK PHARMS LLC	500MG	N020427	001	Aug 21, 2009	Jan CAHN

VINORELBINE TARTRATE

INJECTABLE;INJECTION

VINORELBINE TARTRATE

	@ MYLAN LABS LTD	EQ 10MG BASE/ML	A200148	001	Aug 31, 2012	Oct DISC
AP	WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A075992	001	Jun 10, 2003	Mar CAHN
AP		EQ 10MG BASE/ML	A076461	001	Dec 11, 2003	Jan CAHN

VORICONAZOLE

POWDER;IV (INFUSION)

VORICONAZOLE

	XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	Mar NEWA
--	-------------------	------------	---------	-----	--------------	----------

WARFARIN SODIUM

TABLET;ORAL

JANTOVEN

AB	USL PHARMA	1MG	A040416	001	Oct 02, 2003	Jun CAHN
AB		2MG	A040416	002	Oct 02, 2003	Jun CAHN
AB		2.5MG	A040416	003	Oct 02, 2003	Jun CAHN
AB		3MG	A040416	004	Oct 02, 2003	Jun CAHN
AB		4MG	A040416	005	Oct 02, 2003	Jun CAHN
AB		5MG	A040416	006	Oct 02, 2003	Jun CAHN
AB		6MG	A040416	007	Oct 02, 2003	Jun CAHN
AB		7.5MG	A040416	008	Oct 02, 2003	Jun CAHN
AB		10MG	A040416	009	Oct 02, 2003	Jun CAHN

WARFARIN SODIUM

>A>	@ FOSUN PHARMA	1MG	A040196	001	Sep 30, 1997	Dec CAHN
>A>	@	2MG	A040196	002	Sep 30, 1997	Dec CAHN
>A>	@	2.5MG	A040196	003	Sep 30, 1997	Dec CAHN
>A>	@	3MG	A040196	008	Jul 26, 2000	Dec CAHN
>A>	@	4MG	A040196	004	Sep 30, 1997	Dec CAHN
>A>	@	5MG	A040196	005	Sep 30, 1997	Dec CAHN
>A>	@	6MG	A040196	009	Jul 26, 2000	Dec CAHN
>A>	@	7.5MG	A040196	006	Sep 30, 1997	Dec CAHN
>A>	@	10MG	A040196	007	Sep 30, 1997	Dec CAHN
	@ MYLAN	1MG	A040415	001	Sep 27, 2004	Apr DISC
	@	2MG	A040415	002	Sep 27, 2004	Apr DISC
	@	2.5MG	A040415	003	Sep 29, 2004	Apr DISC
	@	3MG	A040415	004	Sep 27, 2004	Apr DISC
	@	4MG	A040415	005	Sep 27, 2004	Apr DISC
	@	5MG	A040415	006	Sep 27, 2004	Apr DISC

TABLET;ORAL

WARFARIN SODIUM

	@	6MG	A040415	007	Sep 27, 2004	Apr	DISC
	@	7.5MG	A040415	008	Sep 27, 2004	Apr	DISC
	@	10MG	A040415	009	Sep 27, 2004	Apr	DISC
>D>	@ SANDOZ	1MG	A040196	001	Sep 30, 1997	Dec	CAHN
>D>	@	2MG	A040196	002	Sep 30, 1997	Dec	CAHN
>D>	@	2.5MG	A040196	003	Sep 30, 1997	Dec	CAHN
>D>	@	3MG	A040196	008	Jul 26, 2000	Dec	CAHN
>D>	@	4MG	A040196	004	Sep 30, 1997	Dec	CAHN
>D>	@	5MG	A040196	005	Sep 30, 1997	Dec	CAHN
>D>	@	6MG	A040196	009	Jul 26, 2000	Dec	CAHN
>D>	@	7.5MG	A040196	006	Sep 30, 1997	Dec	CAHN
>D>	@	10MG	A040196	007	Sep 30, 1997	Dec	CAHN
AB	TARO PHARM	1MG	A040301	002	Jul 15, 1999	Mar	CAHN
AB		2MG	A040301	003	Jul 15, 1999	Mar	CAHN
AB		2.5MG	A040301	004	Jul 15, 1999	Mar	CAHN
AB		3MG	A040301	005	Jul 15, 1999	Mar	CAHN
AB		4MG	A040301	006	Jul 15, 1999	Mar	CAHN
AB		5MG	A040301	007	Jul 15, 1999	Mar	CAHN
AB		6MG	A040301	008	Jul 15, 1999	Mar	CAHN
AB		7.5MG	A040301	009	Jul 15, 1999	Mar	CAHN
AB		10MG	A040301	001	Jul 15, 1999	Mar	CAHN

ZALEPLON

CAPSULE;ORAL

ZALEPLON

@ MYLAN	5MG	A077238	001	Jun 06, 2008	Jul	DISC
@	10MG	A077238	002	Jun 06, 2008	Jul	DISC
@ UPSHER-SMITH LABS	5MG	A078095	001	Jun 06, 2008	Jun	CAHN
@	10MG	A078095	002	Jun 06, 2008	Jun	CAHN

ZIDOVUDINE

TABLET;ORAL

ZIDOVUDINE

@ HEC PHARM USA INC	300MG	A202058	001	Oct 07, 2011	May	CAHN
---------------------	-------	---------	-----	--------------	-----	------

ZILEUTON

TABLET, EXTENDED RELEASE;ORAL

ZILEUTON

AB	PACK PHARMS LLC	600MG	A204929	001	Mar 17, 2017	Mar	NEWA
AB	RISING PHARMS INC	600MG	A204929	001	Mar 17, 2017	Mar	CAHN
	ZYFLO CR						
AB	+! CHIESI USA INC	600MG	N022052	001	May 30, 2007	Mar	CFTG

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

ZIPRASIDONE HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A204375	001	Feb 17, 2017	Feb	NEWA
AB		EQ 40MG BASE	A204375	002	Feb 17, 2017	Feb	NEWA
AB		EQ 60MG BASE	A204375	003	Feb 17, 2017	Feb	NEWA
AB		EQ 80MG BASE	A204375	004	Feb 17, 2017	Feb	NEWA
AB	ZYDUS PHARMS USA INC	EQ 20MG BASE	A208988	001	Aug 22, 2017	Aug	NEWA
AB		EQ 40MG BASE	A208988	002	Aug 22, 2017	Aug	NEWA
AB		EQ 60MG BASE	A208988	003	Aug 22, 2017	Aug	NEWA
AB		EQ 80MG BASE	A208988	004	Aug 22, 2017	Aug	NEWA

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)

ZOLEDRONIC ACID

AP	AUROBINDO PHARMA LTD	EQ 5MG BASE/100ML	A209125	001	Dec 08, 2017	Nov	NEWA
>A>	BPI LABS LLC	EQ 4MG BASE/5ML	A207341	001	Dec 29, 2017	Dec	NEWA
AP	BRECKENRIDGE PHARM	EQ 4MG BASE/5ML	A091170	001	Mar 04, 2013	Sep	CAHN
AP		EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Sep	CAHN
AP		EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Sep	CAHN
AP	CIPLA LTD	EQ 4MG BASE/100ML	A210174	001	Oct 27, 2017	Oct	NEWA
AP	MYLAN LABS LTD	EQ 5MG BASE/100ML	A203841	001	Feb 14, 2017	Jan	NEWA
AP		EQ 5MG BASE/100ML	A205254	001	Oct 27, 2017	Oct	NEWA
AP	PII	EQ 4MG BASE/5ML	A202571	001	May 07, 2013	May	CAHN
	@ SUN PHARMA GLOBAL	EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013	Oct	DISC

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

AB	APPCO PHARMA LLC	2.5MG	A206973	001	Jun 30, 2017	Jun NEWA
AB		5MG	A206973	002	Jun 30, 2017	Jun NEWA
AB	PLD ACQUISITIONS LLC	2.5MG	A207867	001	Feb 27, 2017	Feb NEWA
AB		5MG	A207867	002	Feb 27, 2017	Feb NEWA
	@ SUN PHARMA GLOBAL	2.5MG	A203476	001	Nov 13, 2014	Oct DISC
	@	5MG	A203476	002	Nov 13, 2014	Oct DISC

ZOLPIDEM TARTRATE

SPRAY, METERED;ORAL

ZOLPIMIST

+!	MAGNA PHARMS	5MG/SPRAY	N022196	001	Dec 19, 2008	Aug CAHN
----	--------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

ZOLPIDEM TARTRATE

>A>	AB	ACME LABS	5MG	A077214	001	Apr 23, 2007	Dec CAHN
>A>	AB		10MG	A077214	002	Apr 23, 2007	Dec CAHN
>D>	AB	ALLIED PHARMA INC	5MG	A077214	001	Apr 23, 2007	Dec CAHN
	AB		5MG	A077214	001	Apr 23, 2007	Mar CAHN
>D>	AB		10MG	A077214	002	Apr 23, 2007	Dec CAHN
	AB		10MG	A077214	002	Apr 23, 2007	Mar CAHN
		@ VIVIMED GLOBAL	5MG	A076062	001	Apr 23, 2007	Aug CAHN
		@	10MG	A076062	002	Apr 23, 2007	Aug CAHN

TABLET;SUBLINGUAL

EDLUAR

AB	+	MYLAN SPECIALITY LP	5MG	N021997	001	Mar 13, 2009	Mar CAHN
AB	+		10MG	N021997	002	Mar 13, 2009	Mar CAHN
		ZOLPIDEM TARTRATE					
AB		PAR PHARM INC	1.75MG	A204229	001	Sep 11, 2017	Aug NEWA
AB			3.5MG	A204229	002	Sep 11, 2017	Aug NEWA

TABLET, EXTENDED RELEASE;ORAL

ZOLPIDEM TARTRATE

AB		SUN PHARMA GLOBAL	6.25MG	A204170	001	Jan 24, 2017	Jan NEWA
AB			12.5MG	A204170	002	Jan 24, 2017	Jan NEWA

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

@	EPIC PHARMA LLC	25MG	A077876	001	Feb 21, 2007	May CAHN
@		50MG	A077876	002	Feb 21, 2007	May CAHN
@		100MG	A077876	003	Feb 21, 2007	May CAHN
@	MYLAN PHARMS INC	25MG	A077647	001	Dec 22, 2005	Jun DISC
@		50MG	A077647	002	Dec 22, 2005	Jun DISC
@		100MG	A077647	003	Dec 22, 2005	Jun DISC
@	UPSHER-SMITH LABS	25MG	A077644	001	Dec 22, 2005	Jun CAHN
@		50MG	A077644	002	Dec 22, 2005	Jun CAHN
@		100MG	A077644	003	Dec 22, 2005	Jun CAHN

ACETAMINOPHENSUPPOSITORY;RECTAL
ACETAMINOPHEN@ ACINO PRODS 120MG
@ 650MGA071010 001 May 12, 1987 Oct CAHN
A071011 001 May 12, 1987 Oct CAHNALUMINUM HYDROXIDE; MAGNESIUM TRISILICATETABLET, CHEWABLE;ORAL
FOAMCOAT

@ GUARDIAN DRUG 80MG;20MG

A071793 001 Sep 04, 1987 Sep DISC

AVOBENZONE; OCTINOXATE; OXYBENZONELOTION;TOPICAL
SHADE UVAGUARD

+ @ BAYER HEALTHCARE LLC 3%;7.5%;3%

N020045 001 Dec 07, 1992 Jun DISC

BRIMONIDINE TARTRATESOLUTION/DROPS;OPHTHALMIC
LUMIFY>A> +! BAUSCH AND LOMB INC 0.025%
>A>

N208144 001 Dec 22, 2017 Dec NEWA

BUTENAFINE HYDROCHLORIDECREAM;TOPICAL
BUTENAFINE HYDROCHLORIDE
TARO 1%

A205181 001 Nov 16, 2017 Oct NEWA

BUTOCONAZOLE NITRATECREAM;VAGINAL
FEMSTAT 3

+ @ BAYER 2%

N020421 001 Dec 21, 1995 Aug DISC

CETIRIZINE HYDROCHLORIDECAPSULE;ORAL
CETIRIZINE HYDROCHLORIDE ALLERGY
STRIDES PHARMA 10MG

A205291 001 Jul 21, 2017 Jul NEWA

SYRUP;ORAL
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY
ALLIED PHARMA INC 5MG/5ML

A091327 001 Oct 17, 2011 Apr CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF
ALLIED PHARMA INC 5MG/5ML

A091327 002 Oct 17, 2011 Apr CAHN

TABLET;ORAL
CETIRIZINE HYDROCHLORIDE ALLERGYGRANULES INDIA LTD 10MG
JUBILANT CADISTA 5MGA209274 001 Dec 22, 2017 Dec NEWA
A078933 001 Jun 15, 2010 Apr CAHN10MG
UNIQUE PHARM LABS 5MG
10MGA078933 002 Jun 15, 2010 Apr CAHN
A077829 001 Aug 26, 2009 Aug CAHN
A077829 004 Aug 26, 2009 Aug CAHNCETIRIZINE HYDROCHLORIDE HIVES
JUBILANT CADISTA 5MG

A078933 003 Jun 15, 2010 Apr CAHN

10MG
UNIQUE PHARM LABS 5MG
10MGA078933 004 Jun 15, 2010 Apr CAHN
A077829 003 Aug 26, 2009 Aug CAHN
A077829 002 Aug 26, 2009 Aug CAHNTABLET, ORALLY DISINTEGRATING;ORAL
CETIRIZINE HYDROCHLORIDE ALLERGY
PERRIGO R AND D 10MG

A205490 001 Sep 02, 2015 Aug CAHN

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDETABLET;ORAL
ADVIL MULTI-SYMPTOM COLD & FLU

+! PFIZER 4MG;200MG;10MG

N022113 002 Apr 28, 2017 Apr NEWA

CIMETIDINETABLET;ORAL
CIMETIDINE@ CONTRACT PHARMACAL 200MG
@ 200MG
L PERRIGO CO 200MG
@ SANDOZ INC 100MG
@ 200MGA074961 001 Jun 19, 1998 Oct DISC
A074963 001 Jun 19, 1998 Oct DISC
A075285 001 Oct 29, 1998 Apr CAHN
A075122 001 Jun 19, 1998 Mar CAHN
A075122 002 Jun 19, 1998 Mar CAHN

TABLET;ORAL							
CIMETIDINE							
@ WATSON LABS TEVA	200MG	A075425	001	Jul 29, 1999	May	CAHN	
<u>CLEMASTINE FUMARATE</u>							
TABLET;ORAL							
CLEMASTINE FUMARATE							
L PERRIGO CO	1.34MG	A074512	001	Nov 22, 1995	Apr	CAHN	
TAVIST-1							
+! GLAXOSMITHKLINE CONS	1.34MG	N020925	001	Aug 21, 1992	Apr	CAHN	
<u>CLOTRIMAZOLE</u>							
CREAM;VAGINAL							
CLOTRIMAZOLE							
! ACTAVIS MID ATLANTIC	1%	A074165	001	Jul 16, 1993	Jun	CHRS	
TARO	1%	A072641	001	Dec 04, 1995	Apr	CAHN	
GYNE-LOTRIMIN							
+ @ BAYER HEALTHCARE LLC	1%	N018052	002	Nov 30, 1990	Jun	DISC	
GYNE-LOTRIMIN 3							
+ @ BAYER HEALTHCARE LLC	2%	N020574	001	Nov 24, 1998	Jun	DISC	
CREAM, TABLET;TOPICAL, VAGINAL							
GYNE-LOTRIMIN 3 COMBINATION PACK							
+ @ BAYER HEALTHCARE LLC	1%,200MG	N020526	002	Jul 29, 1996	Jun	DISC	
GYNE-LOTRIMIN COMBINATION PACK							
+ @ BAYER HEALTHCARE LLC	1%,100MG	N020289	002	Apr 26, 1993	Jun	DISC	
TABLET;VAGINAL							
GYNE-LOTRIMIN							
+ @ BAYER HEALTHCARE LLC	100MG	N017717	002	Nov 30, 1990	Jun	DISC	
GYNE-LOTRIMIN 3							
+ @ BAYER HEALTHCARE LLC	200MG	N020525	001	Jul 29, 1996	Jun	DISC	
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN</u>							
TABLET, EXTENDED RELEASE;ORAL							
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE							
ACTAVIS LABS FL	30MG;600MG	A091070	001	Aug 31, 2015	Mar	CAHN	
	60MG;1.2GM	A091070	002	Aug 31, 2015	Mar	CAHN	
AUROBINDO PHARMA LTD	30MG;600MG	A206941	001	Mar 17, 2017	Mar	NEWA	
	60MG;1.2GM	A206941	002	Mar 17, 2017	Mar	NEWA	
<u>DEXTROMETHORPHAN POLISTIREX</u>							
SUSPENSION, EXTENDED RELEASE;ORAL							
DEXTROMETHORPHAN POLISTIREX							
AMNEAL PHARMS LLC	EQ 30MG HBR/5ML	A203133	001	Jul 28, 2017	Jul	NEWA	
<u>ESOMEPRAZOLE MAGNESIUM</u>							
CAPSULE, DELAYED RELEASE;ORAL							
ESOMEPRAZOLE MAGNESIUM							
AUROBINDO PHARMA LTD	EQ 20MG BASE	A209339	001	Oct 16, 2017	Oct	NEWA	
PERRIGO R AND D	EQ 20MG BASE	A207193	001	Aug 18, 2017	Aug	NEWA	
<u>FAMOTIDINE</u>							
TABLET;ORAL							
FAMOTIDINE							
PERRIGO R AND D	20MG	A077351	001	Sep 25, 2006	Apr	CAHN	
<u>FEXOFENADINE HYDROCHLORIDE</u>							
SUSPENSION;ORAL							
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY							
TARO PHARM	30MG/5ML	A208123	001	Nov 09, 2017	Oct	NEWA	
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES							
TARO PHARM	30MG/5ML	A208123	002	Nov 09, 2017	Oct	NEWA	
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>							
TABLET, EXTENDED RELEASE;ORAL							
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE							
AUROBINDO PHARMA LTD	60MG;120MG	A209116	001	Oct 30, 2017	Oct	NEWA	

FLUTICASONE FUROATE

SPRAY, METERED;NASAL

FLONASE SENSIMIST ALLERGY RELIEF

+! GLAXOSMITHKLINE CONS 0.0275MG/SPRAY

N022051 002 Aug 02, 2016 Jun CAHN

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

ACTAVIS LABS FL 1.2GM

A091009 002 Sep 03, 2015 Mar CAHN

GUARDIAN PHARMS 600MG

A209215 001 Sep 06, 2017 Aug NEWA

1.2GM

A209215 002 Sep 06, 2017 Aug NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

ACTAVIS LABS FL 600MG;60MG

A091071 001 May 27, 2015 Mar CAHN

1.2GM;120MG

A091071 002 May 27, 2015 Mar CAHN

>A> DR REDDYS LABS LTD 600MG;60MG

A208369 001 Dec 29, 2017 Dec NEWA

>A> 1.2GM;120MG

A208369 002 Dec 29, 2017 Dec NEWA

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

AMNEAL PHARMS EQ 200MG FREE ACID AND POTASSIUM SALT

A202300 001 Dec 23, 2011 May CAHN

>A> ASCENT PHARMS INC EQ 200MG FREE ACID AND POTASSIUM SALT

A206999 001 Dec 21, 2017 Dec NEWA

@ CONTRACT PHARMACAL 200MG

A074782 001 Jul 06, 1998 Oct DISC

SUSPENSION;ORAL

IBUPROFEN

ARISE PHARMS 100MG/5ML

A200457 001 Aug 18, 2011 Oct CAHN

TARO 100MG/5ML

A209207 001 Jun 27, 2017 Jun NEWA

SUSPENSION/DROPS;ORAL

IBUPROFEN

L PERRIGO CO 40MG/ML

A075217 001 Dec 16, 1998 Apr CAHN

TABLET;ORAL

IBUPROFEN

AIPING PHARM INC 200MG

A207095 001 May 05, 2017 Apr NEWA

AMNEAL PHARMS 200MG

A079233 001 Mar 18, 2014 Apr CAHN

AUROBINDO PHARMA LTD 200MG

A208865 001 Nov 08, 2017 Oct NEWA

@ CONTRACT PHARMACAL 200MG

A071735 001 Sep 10, 1987 Oct DISC

@ 200MG

A074931 001 Jul 20, 1998 Oct DISC

STRIDES PHARMA 200MG

A207052 001 May 30, 2017 Jun CMS2

200MG

A207052 001 May 30, 2017 May NEWA

JUNIOR STRENGTH IBUPROFEN

L PERRIGO CO 100MG

A075367 001 Apr 22, 1999 Apr CAHN

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD EQ 200MG FREE ACID AND POTASSIUM SALT;30MG

A209235 001 Dec 01, 2017 Nov NEWA

TABLET;ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ CONTRACT PHARMACAL 200MG;30MG

A075588 001 Apr 08, 2002 Oct DISC

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

KREMERS URBAN PHARMS 15MG

A207157 001 Sep 29, 2017 Sep NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

XYZAL ALLERGY 24HR

+ SANOFI-AVENTIS US 2.5MG/5ML (0.5MG/ML)

N209090 001 Jan 31, 2017 Feb CAHN

+ UCB INC 2.5MG/5ML (0.5MG/ML)

N209090 001 Jan 31, 2017 Jan NEWA

TABLET;ORAL

XYZAL ALLERGY 24HR

+ SANOFI-AVENTIS US 5MG

N209089 001 Jan 31, 2017 Feb CAHN

+ UCB INC 5MG

N209089 001 Jan 31, 2017 Jan NEWA

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

@ FDN CONSUMER	0.75MG	A078665	001	Aug 28, 2009	Nov CAHN
	1.5MG	A200670	001	Jul 12, 2012	Nov CAHN
RECKITT BENCKISER	1.5MG	A202246	001	Jun 05, 2015	Apr CAHN
PLAN B					
+ @ FDN CONSUMER	0.75MG	N021045	002	Aug 24, 2006	Nov CAHN
PLAN B ONE-STEP					
+! FDN CONSUMER	1.5MG	N021998	001	Jul 10, 2009	Nov CAHN

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

LOPERAMIDE HYDROCHLORIDE

>D>	ALLIED PHARMA INC	1MG/5ML	A073079	001	Apr 30, 1992	Mar CAHN
>A>	WOCKHARDT	1MG/5ML	A074730	001	Aug 28, 1997	Dec CAHN
	WOCKHARDT BIO AG	1MG/5ML	A074730	001	Aug 28, 1997	Dec CAHN

TABLET; ORAL

LOPERAMIDE HYDROCHLORIDE

@ CONTRACT PHARMACAL	2MG	A073254	001	Jul 30, 1993	Oct DISC
L PERRIGO CO	2MG	A075232	001	Jan 06, 2000	Apr CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE; ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

! PERRIGO	2MG;125MG	A076029	001	Aug 30, 2002	Jan CHRS
-----------	-----------	---------	-----	--------------	----------

LORATADINE

SYRUP; ORAL

LORATADINE

>D>	TARO PHARM	1MG/ML	A201865	001	Jul 31, 2015	Mar CAHN
>A>	WOCKHARDT	1MG/ML	A075815	001	Aug 20, 2004	Dec CAHN
	WOCKHARDT BIO AG	1MG/ML	A075815	001	Aug 20, 2004	Dec CAHN

MICONAZOLE NITRATE

CREAM; VAGINAL

MICONAZOLE NITRATE

TARO	2%	A074444	001	Jan 13, 1997	Apr CAHN
------	----	---------	-----	--------------	----------

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

ACTAVIS MID ATLANTIC	2%,200MG	A074926	001	Apr 16, 1999	Jun CAHN
----------------------	----------	---------	-----	--------------	----------

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE

ACTAVIS PHARMA	100MG	A073507	001	Nov 19, 1993	May CAHN
----------------	-------	---------	-----	--------------	----------

MINOXIDIL

AEROSOL, FOAM; TOPICAL

MINOXIDIL (FOR MEN)

WATSON LABS INC	5%	A208092	001	Feb 17, 2017	Feb NEWA
-----------------	----	---------	-----	--------------	----------

MINOXIDIL (FOR WOMEN)

WATSON LABS INC	5%	A208092	002	Jul 27, 2017	Jul NEWA
-----------------	----	---------	-----	--------------	----------

SOLUTION; TOPICAL

MINOXIDIL (FOR MEN)

>D>	L PERRIGO CO	2%	A075357	001	Jul 30, 1999	Apr CAHN
>A>	WOCKHARDT	2%	A074767	001	Feb 28, 1997	Dec CAHN
	WOCKHARDT BIO AG	2%	A074767	001	Feb 28, 1997	Dec CAHN

MINOXIDIL (FOR WOMEN)

L PERRIGO CO	2%	A075357	002	Jul 30, 1999	Apr CAHN
--------------	----	---------	-----	--------------	----------

MINOXIDIL EXTRA STRENGTH (FOR MEN)

>D>	WOCKHARDT	5%	A075438	001	Feb 27, 2003	Dec CAHN
>A>	WOCKHARDT BIO AG	5%	A075438	001	Feb 27, 2003	Dec CAHN

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

@ CONTRACT PHARMACAL	EQ 200MG BASE	A074789	001	Feb 27, 1997	Oct DISC
LNK INTL INC	EQ 200MG BASE	A204872	001	Jan 23, 2017	Jan NEWA

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL
HABITROL

+	DR REDDYS LABS SA	7MG/24HR	N020076	004	Nov 12, 1999	Jun CAHN
+		14MG/24HR	N020076	005	Nov 12, 1999	Jun CAHN
+	!	21MG/24HR	N020076	006	Nov 12, 1999	Jun CAHN

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL
NICORETTE

+	GLAXOSMITHKLINE	EQ 2MG BASE	N018612	002	Feb 09, 1996	Nov CHRS
	NICOTINE POLACRILEX					
	L PERRIGO CO	EQ 2MG BASE	A076775	001	Sep 16, 2004	Apr CAHN
		EQ 2MG BASE	A076776	001	Sep 16, 2004	Apr CAHN
		EQ 2MG BASE	A076777	001	Sep 16, 2004	Apr CAHN
		EQ 4MG BASE	A076778	001	Sep 16, 2004	Apr CAHN
		EQ 4MG BASE	A076779	001	Sep 16, 2004	Apr CAHN
		EQ 4MG BASE	A076789	001	Sep 16, 2004	Apr CAHN

OMEPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
OMEPRAZOLE

+	DEXCEL PHARMA	20MG	N209400	001	Jul 05, 2017	Jul NEWA
---	---------------	------	---------	-----	--------------	----------

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OCUCLEAR

@	BAYER HEALTHCARE LLC	0.025%	N018471	001	May 30, 1986	May DISC
---	----------------------	--------	---------	-----	--------------	----------

PERMETHRIN

LOTION;TOPICAL
PERMETHRIN

	ACTAVIS MID ATLANTIC	1%	A075014	001	Mar 28, 2000	May CAHN
--	----------------------	----	---------	-----	--------------	----------

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL
POLYETHYLENE GLYCOL 3350

	AILEX PHARMS LLC	17GM/SCOOPFUL	A202071	001	Dec 28, 2012	Sep CAHN
--	------------------	---------------	---------	-----	--------------	----------

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
PSEUDOEPHEDRINE HYDROCHLORIDE

	AUROBINDO PHARMA LTD	120MG	A209008	001	Jun 09, 2017	May NEWA
	L PERRIGO CO	120MG	A075153	001	Feb 26, 1999	Apr CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL
RANITIDINE HYDROCHLORIDE

	AUROBINDO PHARMA LTD	EQ 75MG BASE	A207579	001	Nov 13, 2017	Oct NEWA
		EQ 150MG BASE	A207578	001	Nov 13, 2017	Oct NEWA
@	CONTRACT PHARMACAL	EQ 75MG BASE	A075094	001	Jun 21, 1999	Oct DISC
	STRIDES PHARMA	EQ 150MG BASE	A200536	001	Jun 28, 2011	Jan CAHN
	ZANTAC 150					
+	SANOFI US	EQ 150MG BASE	N021698	001	Aug 31, 2004	Mar CAHN
+		EQ 150MG BASE	N021698	002	Mar 13, 2007	Mar CAHN
	ZANTAC 75					
+	SANOFI US	EQ 75MG BASE	N020520	001	Dec 19, 1995	Nov CRLD
		EQ 75MG BASE	N020520	001	Dec 19, 1995	Mar CAHN

TERBINAFINE HYDROCHLORIDE

CREAM;TOPICAL
LAMISIL

+	GLAXOSMITHKLINE	1%	N020980	001	Mar 09, 1999	Jul CAHN
---	-----------------	----	---------	-----	--------------	----------

TIOCONAZOLE

OINTMENT;VAGINAL
VAGISTAT-1

+	COMBE	6.5%	N020676	001	Feb 11, 1997	Jul CAHN
---	-------	------	---------	-----	--------------	----------

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

TRIAMCINOLONE ACETONIDE

PERRIGO ISRAEL 0.055MG/SPRAY

A078104 002 Nov 14, 2014 Jan CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 12 DECEMBER 2017

NO DECEMBER 2017 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO DECEMBER 2017 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ABACAVIR SULFATE</u>						
A 201107 001					PC	Mar 14, 2018
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001					D-147	Mar 23, 2018
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	7803770	Mar 26, 2028	U-2009		NCE	Apr 28, 2022
	8148333	Nov 08, 2027	DP			
	8748382	Oct 03, 2027	U-2009			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	7855211	Dec 15, 2029	DS DP U-2132		NCE	Sep 28, 2022
	7855211	Dec 15, 2029	DS DP U-2135			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	7855211	Dec 15, 2029	DS DP U-2132		NCE	Sep 28, 2022
	7855211	Dec 15, 2029	DS DP U-2135			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	7855211	Dec 15, 2029	DS DP U-2132		NCE	Sep 28, 2022
	7855211	Dec 15, 2029	DS DP U-2135			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 004	7855211	Dec 15, 2029	DS DP U-2132		NCE	Sep 28, 2022
	7855211	Dec 15, 2029	DS DP U-2135			
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 002	8822438	Aug 24, 2027	U-1579			
	8822438	Aug 24, 2027	U-1580			
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	9290504	Jul 11, 2032	DS DP		NCE	Oct 31, 2022
	9758524	Jul 11, 2032	U-2145			
	9796721	Jul 01, 2036	DS DP U-2145			
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	9610265	Nov 13, 2028	U-2000		M-196 PED	Jan 27, 2020 Jul 27, 2020
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	9561204	May 08, 2032	U-1373			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	9561204	May 08, 2032	U-1373			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	RE46417	Sep 05, 2020	DS DP U-1263			
<u>ADAPALENE; BENZOYL PEROXIDE - ADAPALENE AND BENZOYL PEROXIDE</u>						
A 203790 001					PC	Jan 23, 2018
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8445543	Dec 23, 2022	U-1078			
	9814690	Dec 23, 2022	DP U-1078			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	9539258	Nov 09, 2026	U-1950			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AFATINIB DIMALEATE - GILOTREF</u>						
N 201292 002	9539258	Nov 09, 2026	U-1950			
<u>AFATINIB DIMALEATE - GILOTREF</u>						
N 201292 003	9539258	Nov 09, 2026	U-1950			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001	9808587	May 18, 2031	DP			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	9731087	May 18, 2031	DP			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	8733341	Oct 16, 2030	DP			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001					I-756 >A> ODE	Nov 06, 2020 Nov 06, 2024
<u>ALISKIREN HEMIFUMARATE - TEKTURNIA</u>						
N 021985 001	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	8617595	Feb 19, 2026	DP			
	8617595*PED	Aug 19, 2026				
<u>ALISKIREN HEMIFUMARATE - TEKTURNIA</u>						
N 021985 002	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	8617595	Feb 19, 2026	DP			
	8617595*PED	Aug 19, 2026				
<u>ALISKIREN HEMIFUMARATE - TEKTURNIA</u>						
N 210709 001					>A> NP >A> PED	Nov 14, 2020 May 14, 2021
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNIA HCT</u>						
N 022107 001	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	9023893	Mar 03, 2022	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNIA HCT</u>						
N 022107 002	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	9023893	Mar 03, 2022	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNIA HCT</u>						
N 022107 003	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	9023893	Mar 03, 2022	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNIA HCT</u>						
N 022107 004	5559111	Jul 21, 2018	DS DP U-3			
	5559111*PED	Jan 21, 2019				
	9023893	Mar 03, 2022	DP			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 001	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029			U-2104	
	8283369	Nov 26, 2028			U-2104	
	8357713	Nov 26, 2028	DP		U-2104	
	8546436	Feb 29, 2032	DS			
	8546437	Apr 29, 2029			U-2104	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 001	9216179	Aug 01, 2031	U-2104			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 002	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029	U-2104			
	8283369	Nov 26, 2028	U-2104			
	8357713	Nov 26, 2028	DP U-2104			
	8546436	Feb 29, 2032	DS			
	8546437	Apr 29, 2029	U-2104			
	9216179	Aug 01, 2031	U-2104			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	8173663	Dec 02, 2025	U-1338			
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	8173663	Dec 02, 2025	U-1338			
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	8173663	Dec 02, 2025	U-1338			
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001	8288539	Jun 24, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002	8288539	Jun 24, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	6329404	Jun 19, 2021	DP U-1334			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8112290	Jul 31, 2030	U-1443	Y		
	8645160	Jun 18, 2029	U-1485	Y		
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	8389578	Jan 22, 2028	U-2105		NP	Aug 24, 2020
	8741343	Dec 02, 2030	U-2106		ODE	Aug 24, 2024
	8796337	Nov 23, 2025	U-2106			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-2106			
	8895616	Nov 23, 2025	U-2106			
	8895617	Nov 23, 2025	U-2106			
	8895618	Nov 23, 2025	DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	8389578	Jan 22, 2028	U-2105		NP	Aug 24, 2020
	8741343	Dec 02, 2030	U-2106		ODE	Aug 24, 2024
	8796337	Nov 23, 2025	U-2106			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-2106			
	8895616	Nov 23, 2025	U-2106			
	8895617	Nov 23, 2025	U-2106			
	8895618	Nov 23, 2025	DP			
<u>AMBRISSENTAN - LETAIRIS</u>						
N 022081 001	9549926	Oct 14, 2031	U-1965			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 002	9549926	Oct 14, 2031	U-1965			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - GLEOLAN</u>						
N 208630 001					ODE	Jun 06, 2024
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 001					NP	Jan 21, 2018
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 002					NP	Jan 21, 2018
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 003					NP	Jan 21, 2018
<u>AMPHETAMINE - ADZENYS ER</u>						
N 204325 001	8709491	Jun 28, 2032	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - DYANAVEL XR</u>						
N 208147 001	9675703	Mar 15, 2027	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 001	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 002	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 003	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 004	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6967208	Nov 21, 2026	DS DP U-1167			
	6967208	Nov 21, 2026	DS DP U-1200			
	6967208	Nov 21, 2026	DS DP U-1301			
	6967208	Nov 21, 2026	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1323			
	6967208	Nov 21, 2026	DS DP U-1501			
	6967208	Nov 21, 2026	DS DP U-1502			
	6967208	Nov 21, 2026	DS DP U-1729			
	6967208	Nov 21, 2026	DS DP U-1730			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6967208	Nov 21, 2026	DS DP U-1200			
	6967208	Nov 21, 2026	DS DP U-1301			
	6967208	Nov 21, 2026	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1323			
<u>APREPITANT - CINVANTI</u>						
N 209296 001	9561229	Sep 18, 2035	DP U-2161			
	9808465	Sep 18, 2035	U-2161			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001					I-746	Jul 27, 2020
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002					I-746	Jul 27, 2020
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003					I-746	Jul 27, 2020
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004					I-746	Jul 27, 2020
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001	>A> 7053092	Jan 28, 2022	U-1529		I-746	Jul 27, 2020
	>A> 7978064	Sep 14, 2026	DP		M-150	Dec 05, 2017
	>A> 8017615	Jun 16, 2024	DP			
	>A> 8114021	Nov 02, 2026	DP			
	>A> 8258962	Nov 25, 2030	DP			
	>A> 8545402	Apr 27, 2030	DP			
	>A> 8547248	Dec 18, 2030	DP U-2167			
	>A> 8580796	Sep 25, 2022	DS			
	>A> 8642760	Sep 25, 2022	DS			
	>A> 8674825	Apr 09, 2029	DP U-2170			
	>A> 8718193	Dec 05, 2029	DP			
	>A> 8759350	Mar 02, 2027	U-1529			
	>A> 8847766	Mar 29, 2030	DP U-2167			
	>A> 8945005	Aug 19, 2029	DP U-2167			
	>A> 8956288	Jul 06, 2029	DP U-2167			
	>A> 8961412	Nov 17, 2030	DP			
	>A> 9060708	Mar 05, 2029	DP			
	>A> 9089567	Jan 28, 2022	U-543			
	>A> 9119554	Dec 16, 2028	DP			
	>A> 9125939	Jul 28, 2026	U-1749			
	>A> 9149577	Dec 15, 2029	DP			
	>A> 9258035	Mar 05, 2029	DP			
	>A> 9268909	Oct 15, 2033	DP U-2168			
	>A> 9270503	Sep 19, 2034	DP U-2169			
	>A> 9320455	Dec 15, 2031	DP			
	>A> 9359302	Sep 25, 2022	DS DP U-543			
	>A> 9359302	Sep 25, 2022	DS DP U-1529			
	>A> 9359302	Sep 25, 2022	DS DP U-1749			
	>A> 9387182	Dec 25, 2023	U-1529			
	>A> 9433371	Sep 15, 2029	DP			
	>A> 9444503	Nov 19, 2027	DP U-2169			
	>A> 9577864	Oct 03, 2033	DP U-2169			
	>A> 9787511	Sep 19, 2034	DP U-2169			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	>A> 7053092	Jan 28, 2022	U-1529		I-746	Jul 27, 2020
	>A> 7978064	Sep 14, 2026	DP		M-150	Dec 05, 2017
	>A> 8017615	Jun 16, 2024	DP			
	>A> 8114021	Nov 02, 2026	DP			
	>A> 8258962	Nov 25, 2030	DP			
	>A> 8545402	Apr 27, 2030	DP			
	>A> 8547248	Dec 18, 2030	DP U-2167			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	>A> 8580796	Sep 25, 2022	DS			
	>A> 8642760	Sep 25, 2022	DS			
	>A> 8674825	Apr 09, 2029	DP U-2170			
	>A> 8718193	Dec 05, 2029	DP			
	>A> 8759350	Mar 02, 2027	U-1529			
	>A> 8847766	Mar 29, 2030	DP U-2167			
	>A> 8945005	Aug 19, 2029	DP U-2167			
	>A> 8956288	Jul 06, 2029	DP U-2167			
	>A> 8961412	Nov 17, 2030	DP			
	>A> 9060708	Mar 05, 2029	DP			
	>A> 9089567	Jan 28, 2022	U-543			
	>A> 9119554	Dec 16, 2028	DP			
	>A> 9125939	Jul 28, 2026	U-1749			
	>A> 9149577	Dec 15, 2029	DP			
	>A> 9258035	Mar 05, 2029	DP			
	>A> 9268909	Oct 15, 2033	DP U-2168			
	>A> 9270503	Sep 19, 2034	DP U-2169			
	>A> 9320455	Dec 15, 2031	DP			
	>A> 9359302	Sep 25, 2022	DS DP U-543			
	>A> 9359302	Sep 25, 2022	DS DP U-1529			
	>A> 9359302	Sep 25, 2022	DS DP U-1749			
	>A> 9387182	Dec 25, 2023	U-1529			
	>A> 9433371	Sep 15, 2029	DP			
	>A> 9444503	Nov 19, 2027	DP U-2169			
	>A> 9577864	Oct 03, 2033	DP U-2169			
	>A> 9787511	Sep 19, 2034	DP U-2169			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	>A> 7053092	Jan 28, 2022	U-1529		I-746	Jul 27, 2020
	>A> 7978064	Sep 14, 2026	DP		M-150	Dec 05, 2017
	>A> 8017615	Jun 16, 2024	DP			
	>A> 8114021	Nov 02, 2026	DP			
	>A> 8258962	Nov 25, 2030	DP			
	>A> 8545402	Apr 27, 2030	DP			
	>A> 8547248	Dec 18, 2030	DP U-2167			
	>A> 8580796	Sep 25, 2022	DS			
	>A> 8642760	Sep 25, 2022	DS			
	>A> 8674825	Apr 09, 2029	DP U-2170			
	>A> 8718193	Dec 05, 2029	DP			
	>A> 8759350	Mar 02, 2027	U-1529			
	>A> 8847766	Mar 29, 2030	DP U-2167			
	>A> 8945005	Aug 19, 2029	DP U-2167			
	>A> 8956288	Jul 06, 2029	DP U-2167			
	>A> 8961412	Nov 17, 2030	DP			
	>A> 9060708	Mar 05, 2029	DP			
	>A> 9089567	Jan 28, 2022	U-543			
	>A> 9119554	Dec 16, 2028	DP			
	>A> 9125939	Jul 28, 2026	U-1749			
	>A> 9149577	Dec 15, 2029	DP			
	>A> 9258035	Mar 05, 2029	DP			
	>A> 9268909	Oct 15, 2033	DP U-2168			
	>A> 9270503	Sep 19, 2034	DP U-2169			
	>A> 9320455	Dec 15, 2031	DP			
	>A> 9359302	Sep 25, 2022	DS DP U-543			
	>A> 9359302	Sep 25, 2022	DS DP U-1529			
	>A> 9359302	Sep 25, 2022	DS DP U-1749			
	>A> 9387182	Dec 25, 2023	U-1529			
	>A> 9433371	Sep 15, 2029	DP			
	>A> 9444503	Nov 19, 2027	DP U-2169			
	>A> 9577864	Oct 03, 2033	DP U-2169			
	>A> 9787511	Sep 19, 2034	DP U-2169			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	>A> 7053092	Jan 28, 2022	U-1529		I-746	Jul 27, 2020
	>A> 7978064	Sep 14, 2026	DP		M-150	Dec 05, 2017
	>A> 8017615	Jun 16, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	>A> 8114021	Nov 02, 2026	DP			
	>A> 8258962	Nov 25, 2030	DP			
	>A> 8545402	Apr 27, 2030	DP			
	>A> 8547248	Dec 18, 2030	DP U-2167			
	>A> 8580796	Sep 25, 2022	DS			
	>A> 8642760	Sep 25, 2022	DS			
	>A> 8674825	Apr 09, 2029	DP U-2170			
	>A> 8718193	Dec 05, 2029	DP			
	>A> 8759350	Mar 02, 2027	U-1529			
	>A> 8847766	Mar 29, 2030	DP U-2167			
	>A> 8945005	Aug 19, 2029	DP U-2167			
	>A> 8956288	Jul 06, 2029	DP U-2167			
	>A> 8961412	Nov 17, 2030	DP			
	>A> 9060708	Mar 05, 2029	DP			
	>A> 9089567	Jan 28, 2022	U-543			
	>A> 9119554	Dec 16, 2028	DP			
	>A> 9125939	Jul 28, 2026	U-1749			
	>A> 9149577	Dec 15, 2029	DP			
	>A> 9258035	Mar 05, 2029	DP			
	>A> 9268909	Oct 15, 2033	DP U-2168			
	>A> 9270503	Sep 19, 2034	DP U-2169			
	>A> 9320455	Dec 15, 2031	DP			
	>A> 9359302	Sep 25, 2022	DS DP U-543			
	>A> 9359302	Sep 25, 2022	DS DP U-1529			
	>A> 9359302	Sep 25, 2022	DS DP U-1749			
	>A> 9387182	Dec 25, 2023	U-1529			
	>A> 9433371	Sep 15, 2029	DP			
	>A> 9444503	Nov 19, 2027	DP U-2169			
	>A> 9577864	Oct 03, 2033	DP U-2169			
	>A> 9787511	Sep 19, 2034	DP U-2169			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	>A> 7053092	Jan 28, 2022	U-1529		I-746	Jul 27, 2020
	>A> 7978064	Sep 14, 2026	DP		M-150	Dec 05, 2017
	>A> 8017615	Jun 16, 2024	DP			
	>A> 8114021	Nov 02, 2026	DP			
	>A> 8258962	Nov 25, 2030	DP			
	>A> 8545402	Apr 27, 2030	DP			
	>A> 8547248	Dec 18, 2030	DP U-2167			
	>A> 8580796	Sep 25, 2022	DS			
	>A> 8642760	Sep 25, 2022	DS			
	>A> 8674825	Apr 09, 2029	DP U-2170			
	>A> 8718193	Dec 05, 2029	DP			
	>A> 8759350	Mar 02, 2027	U-1529			
	>A> 8847766	Mar 29, 2030	DP U-2167			
	>A> 8945005	Aug 19, 2029	DP U-2167			
	>A> 8956288	Jul 06, 2029	DP U-2167			
	>A> 8961412	Nov 17, 2030	DP			
	>A> 9060708	Mar 05, 2029	DP			
	>A> 9089567	Jan 28, 2022	U-543			
	>A> 9119554	Dec 16, 2028	DP			
	>A> 9125939	Jul 28, 2026	U-1749			
	>A> 9149577	Dec 15, 2029	DP			
	>A> 9258035	Mar 05, 2029	DP			
	>A> 9268909	Oct 15, 2033	DP U-2168			
	>A> 9270503	Sep 19, 2034	DP U-2169			
	>A> 9320455	Dec 15, 2031	DP			
	>A> 9359302	Sep 25, 2022	DS DP U-543			
	>A> 9359302	Sep 25, 2022	DS DP U-1529			
	>A> 9359302	Sep 25, 2022	DS DP U-1749			
	>A> 9387182	Dec 25, 2023	U-1529			
	>A> 9433371	Sep 15, 2029	DP			
	>A> 9444503	Nov 19, 2027	DP U-2169			
	>A> 9577864	Oct 03, 2033	DP U-2169			
	>A> 9787511	Sep 19, 2034	DP U-2169			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	>A> 7053092	Jan 28, 2022	U-1529		I-746	Jul 27, 2020
	>A> 7978064	Sep 14, 2026	DP		M-150	Dec 05, 2017
	>A> 8017615	Jun 16, 2024	DP			
	>A> 8114021	Nov 02, 2026	DP			
	>A> 8258962	Nov 25, 2030	DP			
	>A> 8545402	Apr 27, 2030	DP			
	>A> 8547248	Dec 18, 2030	DP U-2167			
	>A> 8580796	Sep 25, 2022	DS			
	>A> 8642760	Sep 25, 2022	DS			
	>A> 8674825	Apr 09, 2029	DP U-2170			
	>A> 8718193	Dec 05, 2029	DP			
	>A> 8759350	Mar 02, 2027	U-1529			
	>A> 8847766	Mar 29, 2030	DP U-2167			
	>A> 8945005	Aug 19, 2029	DP U-2167			
	>A> 8956288	Jul 06, 2029	DP U-2167			
	>A> 8961412	Nov 17, 2030	DP			
	>A> 9060708	Mar 05, 2029	DP			
	>A> 9089567	Jan 28, 2022	U-543			
	>A> 9119554	Dec 16, 2028	DP			
	>A> 9125939	Jul 28, 2026	U-1749			
	>A> 9149577	Dec 15, 2029	DP			
	>A> 9258035	Mar 05, 2029	DP			
	>A> 9268909	Oct 15, 2033	DP U-2168			
	>A> 9270503	Sep 19, 2034	DP U-2169			
	>A> 9320455	Dec 15, 2031	DP			
	>A> 9359302	Sep 25, 2022	DS DP U-543			
	>A> 9359302	Sep 25, 2022	DS DP U-1529			
	>A> 9359302	Sep 25, 2022	DS DP U-1749			
	>A> 9387182	Dec 25, 2023	U-1529			
	>A> 9433371	Sep 15, 2029	DP			
	>A> 9444503	Nov 19, 2027	DP U-2169			
	>A> 9577864	Oct 03, 2033	DP U-2169			
	>A> 9787511	Sep 19, 2034	DP U-2169			
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	9526726	Mar 19, 2035	DP			
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	9526726	Mar 19, 2035	DP			
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	9526726	Mar 19, 2035	DP			
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	8431576	Oct 26, 2030	DS		NCE	Oct 05, 2020
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-543			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 002	>A> 6723351	Nov 10, 2018	U-2204			
	>A> 6855339	Nov 10, 2018	U-2204			
	>A> 6861076	Nov 10, 2018	U-2204			
	>A> 6884439	Nov 10, 2018	U-2204			
	>A> 6982096	Nov 10, 2018	U-2204			
	>A> 8273379	Nov 10, 2018	U-2204			
<u>ASCORBIC ACID - ASCOR</u>						
N 209112 001					ODE	Oct 02, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1960		I-597	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1961			
	5763476	Jun 09, 2020	DP U-1962			
	5763476	Jun 09, 2020	DP U-1963			
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1064			
	7741358	Apr 06, 2026	DS DP U-1960			
	7741358	Apr 06, 2026	DS DP U-1961			
	7741358	Apr 06, 2026	DS DP U-1962			
	7741358	Apr 06, 2026	DS DP U-1963			
	7741358*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1960		I-597	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1961			
	5763476	Jun 09, 2020	DP U-1962			
	5763476	Jun 09, 2020	DP U-1963			
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1064			
	7741358	Apr 06, 2026	DS DP U-1960			
	7741358	Apr 06, 2026	DS DP U-1961			
	7741358	Apr 06, 2026	DS DP U-1962			
	7741358	Apr 06, 2026	DS DP U-1963			
	7741358*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 003	5763476	Jun 09, 2020	DP U-1893		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1966		I-597	Jan 13, 2020
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1893			
	7741358	Apr 06, 2026	DS DP U-1966			
	7741358*PED	Oct 06, 2026				
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 001	9539214	Mar 13, 2033	U-1902			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 002	9539214	Mar 13, 2033	U-1902			
<u>ATAZANAVIR SULFATE - ATAZANAVIR SULFATE</u>						
A 091673 001					>A> PC	Jun 25, 2018
<u>ATAZANAVIR SULFATE - ATAZANAVIR SULFATE</u>						
A 091673 002					>A> PC	Jun 25, 2018
<u>ATAZANAVIR SULFATE - ATAZANAVIR SULFATE</u>						
A 091673 003					>A> PC	Jun 25, 2018
<u>ATAZANAVIR SULFATE - ATAZANAVIR SULFATE</u>						
A 091673 004					>A> PC	Jun 25, 2018
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353 001					NCE	Aug 27, 2017
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 001					M-204	Jun 23, 2020
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 002					M-204	Jun 23, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	9284314	Jun 15, 2032	DS			
	9695122	Jun 15, 2032	DS			
<u>AXITINIB - INLYTA</u>						
N 202324 001	8791140	Dec 14, 2030	DS			
<u>AXITINIB - INLYTA</u>						
N 202324 002	8791140	Dec 14, 2030	DS			
<u>AZITHROMYCIN - AZITHROMYCIN</u>						
A 065488 001					PC	Mar 26, 2018
<u>AZITHROMYCIN - AZITHROMYCIN</u>						
A 065488 002					PC	Mar 26, 2018
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	5998402	Apr 04, 2018	DS DP U-594		NCE	Oct 13, 2018
<u>BECLOMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911 001	9808587	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 40</u>						
N 020911 002	9808587	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	6446627	Dec 18, 2017	DP			
	7637260	Aug 25, 2020	DP			
	8132712	Sep 07, 2028	DP			
	8931476	Jul 17, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	6446627	Dec 18, 2017	DP			
	7637260	Aug 25, 2020	DP			
	8132712	Sep 07, 2028	DP			
	8931476	Jul 17, 2031	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	7498343	Dec 01, 2026	DS DP U-1321			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9572796	Jan 28, 2031	DP U-1971			
	9572796	Jan 28, 2031	DP U-1972			
	9572797	Jan 28, 2031	U-1971			
	9572797	Jan 28, 2031	U-1972			
	9572887	Mar 15, 2033	U-1971			
	9572887	Mar 15, 2033	U-1972			
	9579384	Mar 15, 2033	U-1971			
	9579384	Mar 15, 2033	U-1972			
	9597397	Mar 15, 2033	U-1971			
	9597397	Mar 15, 2033	U-1972			
	9597398	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1972			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9572796	Jan 28, 2031	DP U-1971			
	9572796	Jan 28, 2031	DP U-1972			
	9572797	Jan 28, 2031	U-1971			
	9572797	Jan 28, 2031	U-1972			
	9572887	Mar 15, 2033	U-1971			
	9572887	Mar 15, 2033	U-1972			
	9579384	Mar 15, 2033	U-1971			
	9579384	Mar 15, 2033	U-1972			
	9597397	Mar 15, 2033	U-1971			
	9597397	Mar 15, 2033	U-1972			
	9597398	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1972			
<u>BENZNIDAZOLE - BENZNIDAZOLE</u>						
N 209570 001					NCE ODE	Aug 29, 2022 Aug 29, 2024
<u>BENZNIDAZOLE - BENZNIDAZOLE</u>						
N 209570 002					NCE ODE	Aug 29, 2022 Aug 29, 2024
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	9561208	Jun 03, 2029	DP U-916			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	9655907	Aug 31, 2030	DP U-1858			
	9775851	Aug 31, 2030	DP U-1858			
<u>BETRIXABAN - BEVYXXA</u>						
N 208383 001	6376515	Sep 15, 2020	DS DP U-1167		NCE	Jun 23, 2022
	6376515	Sep 15, 2020	DS DP U-1502			
	6376515	Sep 15, 2020	DS DP U-2029			
	6376515	Sep 15, 2020	DS DP U-2030			
	6835739	Sep 15, 2020	DS DP			
	7598276	Nov 08, 2026	DS			
	8404724	Mar 29, 2031	DP U-2034			
	8518977	Sep 15, 2020	DS			
	8557852	Sep 08, 2028	U-1167			
	8557852	Sep 08, 2028	U-2030			
	8691847	Sep 15, 2020	DS DP U-2029			
	8691847	Sep 15, 2020	DS DP U-2035			
	8987463	Dec 28, 2030	DP			
	9555023	Nov 07, 2026	U-1502			
	9629831	Sep 15, 2020	U-1167			
	9629831	Sep 15, 2020	U-1502			
	9629831	Sep 15, 2020	U-2030			
	9629831	Sep 15, 2020	U-2035			
<u>BETRIXABAN - BEVYXXA</u>						
N 208383 002	6376515	Sep 15, 2020	DS DP U-1167		NCE	Jun 23, 2022
	6376515	Sep 15, 2020	DS DP U-1502			
	6376515	Sep 15, 2020	DS DP U-2029			
	6376515	Sep 15, 2020	DS DP U-2030			
	6835739	Sep 15, 2020	DS DP			
	7598276	Nov 08, 2026	DS			
	8404724	Mar 29, 2031	DP U-2034			
	8518977	Sep 15, 2020	DS			
	8557852	Sep 08, 2028	U-1167			
	8557852	Sep 08, 2028	U-2030			
	8691847	Sep 15, 2020	DS DP U-2029			
	8691847	Sep 15, 2020	DS DP U-2035			
	8987463	Dec 28, 2030	DP			
	9555023	Nov 07, 2026	U-1502			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BETRIXABAN - BEVYXXA</u>						
N 208383 002	9629831	Sep 15, 2020	U-1167			
	9629831	Sep 15, 2020	U-1502			
	9629831	Sep 15, 2020	U-2030			
	9629831	Sep 15, 2020	U-2035			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	9579270	Jan 31, 2021	U-1975			
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 205004 001	8962572	Nov 03, 2032	DP			
<u>BOSENTAN - TRACLEER</u>						
N 021290 001					NPP	Sep 05, 2020
<u>BOSENTAN - TRACLEER</u>						
N 021290 002					NPP	Sep 05, 2020
<u>BOSENTAN - TRACLEER</u>						
N 209279 001	7959945	Dec 28, 2027	DP		NP	Sep 05, 2020
	8309126	May 15, 2026	DP		ODE	Sep 05, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 001					>A> I-759	Dec 19, 2020
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 002					>A> I-759	Dec 19, 2020
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003	6002008	Mar 27, 2018	DS DP U-1284		>A> I-759	Dec 19, 2020
	7417148	Jan 23, 2026	U-1283		ODE	Sep 04, 2019
	7767678	Nov 23, 2026	DS DP			
	7919625	Dec 11, 2025	DP			
	RE42376	Apr 13, 2024	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	>A> 9839637	Apr 12, 2026	DP U-543			
	>A> 9839637	Apr 12, 2026	DP U-1529			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	>A> 9839637	Apr 12, 2026	DP U-543			
	>A> 9839637	Apr 12, 2026	DP U-1529			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	>A> 9839637	Apr 12, 2026	DP U-543			
	>A> 9839637	Apr 12, 2026	DP U-1529			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	>A> 9839637	Apr 12, 2026	DP U-543			
	>A> 9839637	Apr 12, 2026	DP U-1529			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	>A> 9839637	Apr 12, 2026	DP U-543			
	>A> 9839637	Apr 12, 2026	DP U-1529			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	>A> 9839637	Apr 12, 2026	DP U-543			
	>A> 9839637	Apr 12, 2026	DP U-1529			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029	U-1927		ODE	Apr 28, 2024
	9611283	Apr 10, 2034	U-1927			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029	U-1927		ODE	Apr 28, 2024
	9611283	Apr 10, 2034	U-1927			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029	U-1927		ODE	Apr 28, 2024
	9611283	Apr 10, 2034	U-1927			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	9687443	Jul 10, 2021	DP			
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144 001					>A> NP	Dec 22, 2020
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	9770453	Apr 19, 2022	DP U-2131			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	6784197	Feb 21, 2021	DS DP U-1815			
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	6784197	Feb 21, 2021	DS DP U-1815			
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-1815			
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-1815			
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-1815			
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-1815			
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001	6784197	Feb 21, 2021	DS DP U-1815			
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-1815			
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	9517220	Nov 11, 2033	U-1933			
	9561277	Jan 16, 2024	U-1933			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9352025	Jun 07, 2030	U-2111			
	9352025	Jun 07, 2030	U-2112			
	9352025	Jun 07, 2030	U-2113			
	9352025	Jun 07, 2030	U-2114			
	9352025	Jun 07, 2030	U-2115			
	9352025	Jun 07, 2030	U-2116			
	9352025	Jun 07, 2030	U-2117			
	9352025	Jun 07, 2030	U-2118			
	9352025	Jun 07, 2030	U-2119			
	9522117	Apr 30, 2032	DP U-976			
	9522117	Apr 30, 2032	DP U-1939			
	>A> 9700555	Apr 30, 2032	DP U-2183			
	>A> 9700555	Apr 30, 2032	DP U-2184			
	>A> 9700555	Apr 30, 2032	DP U-2185			
	>A> 9700555	Apr 30, 2032	DP U-2186			
	>A> 9700555	Apr 30, 2032	DP U-2187			
	>A> 9700555	Apr 30, 2032	DP U-2188			
	>A> 9700555	Apr 30, 2032	DP U-2189			
	>A> 9700555	Apr 30, 2032	DP U-2190			
	>A> 9700555	Apr 30, 2032	DP U-2191			
	>A> 9700555	Apr 30, 2032	DP U-2192			
	>A> 9700555	Apr 30, 2032	DP U-2193			
	>A> 9700555	Apr 30, 2032	DP U-2194			
	>A> 9700555	Apr 30, 2032	DP U-2195			
	>A> 9700555	Apr 30, 2032	DP U-2196			
	>A> 9700555	Apr 30, 2032	DP U-2197			
	>A> 9700555	Apr 30, 2032	DP U-2198			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9532954	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	6123924	Sep 26, 2017	DP		M-210	Sep 11, 2020
	7367333	Nov 11, 2018	DP		>A> M-214	Dec 20, 2020
	7367333*PED	May 11, 2019			NPP	Jan 27, 2020
	7587988	Apr 10, 2026	DP		PED	Jul 27, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-2001			
	7759328	Jan 29, 2023	DP U-2002			
	7759328	Jan 29, 2023	DP U-2122			
	7759328*PED	Jul 29, 2023				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-2001			
	8143239	Jan 29, 2023	DP U-2002			
	8143239	Jan 29, 2023	DP U-2122			
	8143239*PED	Jul 29, 2023				
	8387615	Nov 10, 2024	DP			
	8387615*PED	May 10, 2025				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-2001			
	8575137	Jan 29, 2023	DP U-2002			
	8575137	Jan 29, 2023	DP U-2122			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	6123924	Sep 26, 2017	DP		M-210	Sep 11, 2020
	7367333	Nov 11, 2018	DP		>A> M-214	Dec 20, 2020
	7367333*PED	May 11, 2019				
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-2001			
	7759328	Jan 29, 2023	DP U-2002			
	7759328	Jan 29, 2023	DP U-2122			
	7759328*PED	Jul 29, 2023				
	7897646	Sep 09, 2018	U-2002			
	7897646	Sep 09, 2018	U-2122			
	7897646*PED	Mar 09, 2019				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-2001			
	8143239	Jan 29, 2023	DP U-2002			
	8143239	Jan 29, 2023	DP U-2122			
	8143239*PED	Jul 29, 2023				
	8387615	Nov 10, 2024	DP			
	8387615*PED	May 10, 2025				
	8461211	Sep 09, 2018	U-2002			
	8461211	Sep 09, 2018	U-2122			
	8461211*PED	Mar 09, 2019				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-2001			
	8575137	Jan 29, 2023	DP U-2002			
	8575137	Jan 29, 2023	DP U-2122			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	9585838	Dec 24, 2021	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	9585838	Dec 24, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 001	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 002	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 003	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 004	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 005	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	>A> 8921387	Jan 06, 2032	DP U-2173			
	>A> 8921387	Jan 06, 2032	DP U-2174			
	>A> 8975270	Sep 05, 2031	DP U-2175			
	>A> 8975270	Sep 05, 2031	DP U-2206			
	>A> 9272044	Jun 06, 2031	U-2176			
	>A> 9272044	Jun 06, 2031	U-2177			
	>A> 9272044	Jun 06, 2031	U-2178			
	>A> 9272044	Jun 06, 2031	U-2209			
	>A> 9498432	Jun 06, 2031	DP U-2179			
	>A> 9782402	Jun 06, 2031	DP U-2176			
	>A> 9782402	Jun 06, 2031	DP U-2180			
	>A> 9782402	Jun 06, 2031	DP U-2207			
	>A> 9782402	Jun 06, 2031	DP U-2208			
	>A> 9827241	Jun 06, 2031	DP U-2174			
	>A> 9827241	Jun 06, 2031	DP U-2181			
	>A> 9827241	Jun 06, 2031	DP U-2206			
	>A> 9827241	Jun 06, 2031	DP U-2210			
	>A> 9827241	Jun 06, 2031	DP U-2211			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	>A> 8921387	Jan 06, 2032	DP U-2173			
	>A> 8921387	Jan 06, 2032	DP U-2174			
	>A> 8975270	Sep 05, 2031	DP U-2175			
	>A> 8975270	Sep 05, 2031	DP U-2206			
	>A> 9272044	Jun 06, 2031	U-2176			
	>A> 9272044	Jun 06, 2031	U-2177			
	>A> 9272044	Jun 06, 2031	U-2178			
	>A> 9272044	Jun 06, 2031	U-2209			
	>A> 9498432	Jun 06, 2031	DP U-2179			
	>A> 9782402	Jun 06, 2031	DP U-2176			
	>A> 9782402	Jun 06, 2031	DP U-2180			
	>A> 9782402	Jun 06, 2031	DP U-2207			
	>A> 9782402	Jun 06, 2031	DP U-2208			
	>A> 9827241	Jun 06, 2031	DP U-2174			
	>A> 9827241	Jun 06, 2031	DP U-2181			
	>A> 9827241	Jun 06, 2031	DP U-2206			
	>A> 9827241	Jun 06, 2031	DP U-2210			
	>A> 9827241	Jun 06, 2031	DP U-2211			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 001	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 002	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003	9655843	Jul 23, 2027	DP U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	9687454	Aug 07, 2029	DP U-1464			
	>A> 9855221	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	9687454	Aug 07, 2029	DP U-1464			
	>A> 9855221	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	9687454	Aug 07, 2029	DP U-1464			
	>A> 9855221	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	9687454	Aug 07, 2029	DP U-1464			
	>A> 9855221	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 001	9655843	Jul 23, 2027	DP U-2017			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 002	9655843	Jul 23, 2027	DP U-2017			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 003	9655843	Jul 23, 2027	DP U-2017			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	5847170	Mar 26, 2021	DS DP		M-201	May 17, 2020
	5847170*PED	Sep 26, 2021			M-209	Sep 14, 2020
	7241907	Dec 10, 2025	DS		PED	Nov 17, 2020
	7241907*PED	Jun 10, 2026				
	8927592	Oct 27, 2030	U-1630			
	8927592*PED	Apr 27, 2031				
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 001	9717720	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 002	9717720	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	9724342	Jul 09, 2033	DP		>A> I-760	Dec 19, 2020
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	9724342	Jul 09, 2033	DP		>A> I-760	Dec 19, 2020
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	9724342	Jul 09, 2033	DP		>A> I-760	Dec 19, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003					M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004					M-197	Feb 01, 2020
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	9700575	Jul 10, 2035	DP			
<u>CAPSAICIN - OUTENZA</u>						
N 022395 001	6239180	Jun 04, 2021	DP			
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030 001	9493582	Feb 27, 2033	DP			
	9629797	Nov 10, 2028		U-2004		
	9629797	Nov 10, 2028		U-2005		
	9629797	Nov 10, 2028		U-2006		
	9750822	Mar 13, 2029	DP			
	9770407	Nov 10, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	9533046	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	9533046	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	9533046	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	9533046	Dec 26, 2028	DP U-219			
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556 001	9522191	Jun 15, 2027	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	9493582	Feb 27, 2033	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 002	9493582	Feb 27, 2033	DP			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001					M-213	Nov 09, 2020
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002					M-213	Nov 09, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003					M-213	Nov 09, 2020
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004					M-213	Nov 09, 2020
<u>CARVEDILOL PHOSPHATE - CARVEDILOL PHOSPHATE</u>						
A 090132 001					PC	May 07, 2018
<u>CARVEDILOL PHOSPHATE - CARVEDILOL PHOSPHATE</u>						
A 090132 002					PC	May 07, 2018
<u>CARVEDILOL PHOSPHATE - CARVEDILOL PHOSPHATE</u>						
A 090132 003					PC	May 07, 2018
<u>CARVEDILOL PHOSPHATE - CARVEDILOL PHOSPHATE</u>						
A 090132 004					PC	May 07, 2018
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110 001	9636407	Dec 21, 2032	DP			
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110 002	9636407	Dec 21, 2032	DP			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001	9629861	Sep 21, 2030	DP			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002	9629861	Sep 21, 2030	DP			
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	8188276	Jan 31, 2023	DS DP		M-199	May 26, 2020
	8399450	Nov 20, 2027	DS DP		ODE	May 26, 2024
	8835430	Jan 31, 2023	DS DP			
	9018204	Jan 31, 2023	DS DP			
	9416112	Jan 31, 2023	DS DP			
<u>CETIRIZINE HYDROCHLORIDE - ZERVIA</u>						
N 208694 001	8829005	Mar 15, 2030		U-1680	NDF	May 30, 2020
	8829005*PED	Sep 15, 2030			PED	Nov 30, 2020
	9254286	Jul 09, 2032	DP			
	9254286*PED	Jan 09, 2033				
	9750684	Mar 15, 2030	DP			
<u>CHLOROPROCAINE HYDROCHLORIDE - CLOROTEKAL</u>						
N 208791 001					NP	Sep 26, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 001					M-200	May 23, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 002					M-200	May 23, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 003					M-200	May 23, 2020
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589 001	9827231	Jun 23, 2034	DP U-2162			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLINDAMYCIN PHOSPHATE - CLINDESSE</u>						
N 050793 001	>A> 9789057	Dec 02, 2026	DP U-137			
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483 001	>A> 9855334	Mar 11, 2035	DP		NP	Nov 28, 2020
<u>CLOFARABINE - CLOFARABINE</u>						
A 204029 001					PC	Nov 05, 2017
<u>COBICISTAT - TYBOST</u>						
N 203094 001					NCE	Aug 27, 2017
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001					NCE	Aug 27, 2017
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	7176220	Aug 27, 2026	DS DP U-257		NCE NPP	Aug 27, 2017 Sep 25, 2020
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
	9744181	Jan 13, 2024	DP U-257		NPP	Jan 27, 2020
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	9555029	Aug 22, 2033	U-1020			
	9675613	Aug 22, 2033	U-1020			
	9789108	Aug 22, 2033	U-1020			
<u>COPANLISIB DIHYDROCHLORIDE - ALIQOPA</u>						
N 209936 001	7511041	May 13, 2024	DS DP		NCE	Sep 14, 2022
	8466283	Oct 22, 2029	DS DP U-2124		ODE	Sep 14, 2024
	9636344	Mar 29, 2032	U-2124			
<u>CRISABOROLE - EUCRISA</u>						
N 207695 001	8039451	Jun 11, 2026	DS DP		NCE	Dec 14, 2021
	8168614	Jan 20, 2030	U-1932			
	8501712	Feb 16, 2027	U-1932			
	9682092	Feb 16, 2027	U-1932			
<u>CROFELEMER - FULYZAO</u>						
N 202292 001	9585868	Oct 31, 2031	DS U-1319			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8292129	Feb 25, 2031	DP			
	8561859	Apr 16, 2032	DP			
	9669974	May 11, 2034	DP			
	9676525	Feb 07, 2034	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	>A> 8026284	Sep 22, 2027	U-1399		>A> M-216	Dec 22, 2020
	>A> 8026284*PED	Mar 22, 2028			>A> ODE	Apr 30, 2020
	>A> 9173851	Jun 17, 2034	DP		>A> ODE	Aug 14, 2022
	>A> 9173851*PED	Dec 17, 2034			>A> PED	Oct 30, 2020
	>A> 9192590	Jan 26, 2027	U-1399		>A> PED	Jun 22, 2021
	>A> 9192590*PED	Jul 26, 2027			>A> PED	Feb 14, 2023
	>A> 9198882	Jan 26, 2027	U-1399			
	>A> 9198882*PED	Jul 26, 2027				
	>A> 9233077	Jun 17, 2034	DP			
	>A> 9233077*PED	Dec 17, 2034				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	>A> 8026284	Sep 22, 2027	U-1399		>A> M-216	Dec 22, 2020
	>A> 8026284*PED	Mar 22, 2028			>A> ODE	Apr 30, 2020
	>A> 9173851	Jun 17, 2034	DP		>A> ODE	Aug 14, 2022
	>A> 9173851*PED	Dec 17, 2034			>A> PED	Oct 30, 2020
	>A> 9192590	Jan 26, 2027	U-1399		>A> PED	Jun 22, 2021
	>A> 9192590*PED	Jul 26, 2027			>A> PED	Feb 14, 2023
	>A> 9198882	Jan 26, 2027	U-1399			
	>A> 9198882*PED	Jul 26, 2027				
	>A> 9233077	Jun 17, 2034	DP			
	>A> 9233077*PED	Dec 17, 2034				
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	7850990	Jan 23, 2027	DP U-2090		NP	Aug 03, 2020
	8022279	Sep 14, 2027	DP U-2090			
	8092828	Apr 01, 2029	U-2090			
	8431806	Apr 22, 2025	DP U-2090			
	8518437	Jun 07, 2026	DP			
	9271931	Jan 23, 2027	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	7994185	Jan 20, 2030	DS DP U-1406		I-745	Jun 22, 2020
	7994185	Jan 20, 2030	DS DP U-2031		ODE	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8835443	Sep 13, 2025	U-2026			
	8835443	Sep 13, 2025	U-2027			
	8952018	Oct 15, 2030	U-2027			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	7994185	Jan 20, 2030	DS DP U-1406		I-745	Jun 22, 2020
	7994185	Jan 20, 2030	DS DP U-2031		ODE	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8835443	Sep 13, 2025	U-2026			
	8835443	Sep 13, 2025	U-2027			
	8952018	Oct 15, 2030	U-2027			
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 001	6414126	Oct 04, 2020	DS DP U-493		M-212	Oct 20, 2020
	6414126	Oct 04, 2020	DS DP U-2139			
	>A> 6479065	Aug 10, 2020	DP	Y		
	>A> 6495164	May 25, 2020	DP	Y		
	6515117	Oct 04, 2020	DS DP U-493			
	6515117	Oct 04, 2020	DS DP U-2139			
	>A> 6667061	May 25, 2020	DP	Y		
	>A> 6824822	Oct 09, 2022	DP	Y		
	>A> 6872700	Jan 14, 2020	U-654	Y		
	>A> 6956026	Jan 07, 2018	U-687	Y		
	>A> 7223440	Aug 31, 2021	DP	Y		
	>A> 7456254	Jun 30, 2025	DP U-1223			
	>A> 7456254	Jun 30, 2025	DP U-2139			
	>A> 7563871	Apr 15, 2024	DP	Y		
	>A> 7612176	Apr 13, 2025	DP U-1223	Y		
	>A> 7741269	Jan 07, 2018	U-1224	Y		
	>A> 8216180	Jan 11, 2028	DP	Y		
	>A> 8329648	Aug 18, 2026	U-1313			
	>A> 8329648	Aug 18, 2026	U-2139			
	>A> 8329648	Aug 18, 2026	U-2153			
	>A> 8329648	Aug 18, 2026	U-2155			
	>A> 8329648	Aug 18, 2026	U-2156			
	>A> 8329648	Aug 18, 2026	U-2212			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 001	>A> 8329648	Aug 18, 2026	U-2213			
	8361972	Mar 21, 2028	U-493			
	8361972	Mar 21, 2028	U-2139			
	>A> 8431685	Apr 13, 2025	DP U-412			
	>A> 8431685	Apr 13, 2025	DP U-2139			
	>A> 8439864	Mar 25, 2028	DP	Y		
	>A> 8461105	Apr 13, 2025	DP U-412			
	>A> 8461105	Apr 13, 2025	DP U-2139			
	>A> 8690837	May 19, 2029	DP	Y		
	>A> 8721615	Jan 18, 2030	DP			
	>A> 8758292	Nov 12, 2027	DP	Y		
	>A> 8827963	Feb 04, 2029	DP	Y		
	>A> 8906851	Aug 18, 2026	U-1313			
	>A> 8906851	Aug 18, 2026	U-2139			
	>A> 8998876	Jan 07, 2030	DP	Y		
	9198925	Oct 04, 2020	U-493			
	9198925	Oct 04, 2020	U-2139			
	>A> 9238076	Apr 15, 2024	DP U-412			
	>A> 9238076	Apr 15, 2024	DP U-2139			
	>A> 9320853	Mar 25, 2028	DP	Y		
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 002	6414126	Oct 04, 2020	DS DP U-493		M-212	Oct 20, 2020
	6414126	Oct 04, 2020	DS DP U-2139			
	>A> 6479065	Aug 10, 2020	DP	Y		
	>A> 6495164	May 25, 2020	DP	Y		
	6515117	Oct 04, 2020	DS DP U-493			
	6515117	Oct 04, 2020	DS DP U-2139			
	>A> 6667061	May 25, 2020	DP	Y		
	>A> 6824822	Oct 09, 2022	DP	Y		
	>A> 6872700	Jan 14, 2020	U-654	Y		
	>A> 6956026	Jan 07, 2018	U-687	Y		
	>A> 7223440	Aug 31, 2021	DP	Y		
	>A> 7456254	Jun 30, 2025	DP U-1223			
	>A> 7456254	Jun 30, 2025	DP U-2139			
	>A> 7563871	Apr 15, 2024	DP	Y		
	>A> 7612176	Apr 13, 2025	DP U-1223	Y		
	>A> 7741269	Jan 07, 2018	U-1224	Y		
	>A> 8216180	Jan 11, 2028	DP	Y		
	>A> 8329648	Aug 18, 2026	U-1313			
	>A> 8329648	Aug 18, 2026	U-2139			
	>A> 8329648	Aug 18, 2026	U-2153			
	>A> 8329648	Aug 18, 2026	U-2155			
	>A> 8329648	Aug 18, 2026	U-2156			
	>A> 8329648	Aug 18, 2026	U-2212			
	>A> 8329648	Aug 18, 2026	U-2213			
	8361972	Mar 21, 2028	U-493			
	8361972	Mar 21, 2028	U-2139			
	>A> 8431685	Apr 13, 2025	DP U-412			
	>A> 8431685	Apr 13, 2025	DP U-2139			
	>A> 8439864	Mar 25, 2028	DP	Y		
	>A> 8461105	Apr 13, 2025	DP U-412			
	>A> 8461105	Apr 13, 2025	DP U-2139			
	>A> 8690837	May 19, 2029	DP	Y		
	>A> 8721615	Jan 18, 2030	DP			
	>A> 8758292	Nov 12, 2027	DP	Y		
	>A> 8827963	Feb 04, 2029	DP	Y		
	>A> 8906851	Aug 18, 2026	U-1313			
	>A> 8906851	Aug 18, 2026	U-2139			
	>A> 8998876	Jan 07, 2030	DP	Y		
	9198925	Oct 04, 2020	U-493			
	9198925	Oct 04, 2020	U-2139			
	>A> 9238076	Apr 15, 2024	DP U-412			
	>A> 9238076	Apr 15, 2024	DP U-2139			
	>A> 9320853	Mar 25, 2028	DP	Y		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 005	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 001	6414126	Oct 04, 2020	DS DP U-1976		M-175	Apr 05, 2019
	6414126	Oct 04, 2020	DS DP U-1977		NC	Feb 27, 2020
	6515117	Oct 04, 2020	DS DP U-1976		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-1977			
	6936590	Oct 04, 2020	U-1976			
	6936590	Oct 04, 2020	U-1977			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-1976			
	8361972	Mar 21, 2028	U-1977			
	8501698	Jun 20, 2027	DP U-1976			
	8501698	Jun 20, 2027	DP U-1977			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-1976			
	9198925	Oct 04, 2020	U-1977			
	RE44186	Jul 31, 2023	DS DP U-1976			
	RE44186	Jul 31, 2023	DS DP U-1977			
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572 002					M-211	Sep 01, 2020
					NPP	Mar 29, 2020
<u>DAPTOMYCIN - CUBICIN RF</u>						
N 021572 003					M-211	Sep 01, 2020
					NPP	Mar 29, 2020
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	9629841	Oct 18, 2033	DP U-1753			
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	9744170	Jan 02, 2035	DP U-1889			
<u>DASATINIB - SPRYCEL</u>						
N 021986 001					NPP	Nov 09, 2020
<u>DASATINIB - SPRYCEL</u>						
N 021986 002					NPP	Nov 09, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>						
N 021986 003					NPP	Nov 09, 2020
<u>DASATINIB - SPRYCEL</u>						
N 021986 004					NPP	Nov 09, 2020
<u>DASATINIB - SPRYCEL</u>						
N 021986 005					NPP	Nov 09, 2020
<u>DASATINIB - SPRYCEL</u>						
N 021986 006					NPP	Nov 09, 2020
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 001	6465504	Apr 05, 2019	DS DP			
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 002	6465504	Apr 05, 2019	DS DP			
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 003	6465504	Apr 05, 2019	DS DP			
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 001					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 002					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 003					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 004					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208685 001					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	9579359	Feb 10, 2029	U-1978			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	9579359	Feb 10, 2029	U-1978			
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208610 001	7728143	Nov 20, 2027	DS		NCE	Jun 19, 2022
	8252813	Oct 02, 2026	DP U-2028		GAIN	Jun 19, 2027
	8273892	Aug 06, 2026	DS			
	8497378	Dec 28, 2029	DS			
	8648093	Oct 07, 2025	DP U-2028			
	8871938	Sep 23, 2029	DS			
	8969569	Oct 07, 2025	DP U-2028			
	9539250	Oct 07, 2025	DS DP U-2028			
>A>	RE46617	Dec 28, 2029	DS			
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	>A> 7635773	Mar 13, 2029	DP		NCE	Jun 19, 2022
	7728143	Nov 20, 2027	DS		GAIN	Jun 19, 2027
	8252813	Oct 02, 2026	DP U-2028			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DELAFLORACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	8273892	Aug 06, 2026	DS			
	>A> 8410077	Mar 13, 2029	DP			
	8497378	Dec 28, 2029	DS			
	8648093	Oct 07, 2025	DP U-2028			
	8871938	Sep 23, 2029	DS			
	>A> 9200088	Mar 13, 2029	DP			
	>A> 9493582	Feb 27, 2033	DP			
	9539250	Oct 07, 2025	DS DP U-2028			
	>A> 9750822	Mar 13, 2029	DP			
	>A> RE46617	Dec 28, 2029	DS			
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	9522155	Feb 21, 2028	DP U-1940			
	9636349	Feb 21, 2028	U-1940			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 001	7405203	May 06, 2023	U-1980		NP	Mar 03, 2020
	7579321	May 06, 2023	U-1980			
	7799761	Sep 26, 2024	DP			
	9539302	Jun 15, 2030	DP			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 002	7405203	May 06, 2023	U-1980		NP	Mar 03, 2020
	7579321	May 06, 2023	U-1980			
	9539302	Jun 15, 2030	DP			
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204003 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204003 002					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204028 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204028 002					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204065 001					PC	Jan 25, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204065 002					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204065 003					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204082 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204083 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204095 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204095 002					PC	Aug 28, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204172 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204172 002					PC	Aug 28, 2017
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	8524733	Mar 27, 2031	DS DP		I-751	Aug 30, 2020
	9233959	Sep 18, 2033	DP		NCE	Apr 03, 2022
	9296739	Sep 18, 2033	DP		ODE	Apr 03, 2024
	9550780	Sep 18, 2033	DS DP U-1846			
	9550780	Sep 18, 2033	DS DP U-1995			
	9814708	Sep 18, 2033	DP			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	8524733	Mar 27, 2031	DS DP		I-751	Aug 30, 2020
	9233959	Sep 18, 2033	DP		NCE	Apr 03, 2022
	9296739	Sep 18, 2033	DP		ODE	Apr 03, 2024
	9550780	Sep 18, 2033	DS DP U-1846			
	9550780	Sep 18, 2033	DS DP U-1995			
	9814708	Sep 18, 2033	DP			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	8524733	Mar 27, 2031	DS DP		I-751	Aug 30, 2020
	9233959	Sep 18, 2033	DP		NCE	Apr 03, 2022
	9296739	Sep 18, 2033	DP		ODE	Apr 03, 2024
	9550780	Sep 18, 2033	DS DP U-1846			
	9550780	Sep 18, 2033	DS DP U-1995			
	9814708	Sep 18, 2033	DP			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	9592242	Oct 20, 2020	U-1989			
	9592242	Oct 20, 2020	U-1990			
	9775849	Oct 20, 2020	U-1989			
	9775849	Oct 20, 2020	U-1990			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	9616049	Jan 04, 2032	DP			
	9616049*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	9616049	Jan 04, 2032	DP			
	9616049*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	9616049	Jan 04, 2032	DP			
	9616049*PED	Jul 04, 2032				
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165 001	9827197	Jun 16, 2026	DP			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001	9561200	Feb 24, 2029	U-1482			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9539335	Oct 17, 2027	U-1614			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001					I-758	Nov 21, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790	002				I-758	Nov 21, 2020
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790	003				I-758	Nov 21, 2020
<u>DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA</u>						
N 210192	001	>A> 6838464	Feb 26, 2021	DS DP	NC	Nov 21, 2020
		>A> 7067522	Dec 20, 2019	DS DP	NCE	Aug 12, 2018
		>A> 7125879	Apr 21, 2025	DS DP U-257		
		>A> 8080551	Apr 11, 2023	DS DP		
		>A> 8101629	Aug 09, 2022	DP		
		>A> 8129385	Oct 05, 2027	DS DP		
		>A> 9242986	Dec 08, 2029	DS DP		
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036	001	9532971	Jun 01, 2029	DP		
		9572814	Jul 20, 2027	U-620		
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036	002	9532971	Jun 01, 2029	DP		
		9572814	Jul 20, 2027	U-620		
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA</u>						
N 209661	001	7560122	Jan 25, 2019	DP		
		9089489	Feb 18, 2033	DP U-1382		
		9375404	Feb 18, 2033	DP U-1382		
		9526703	Feb 18, 2033	DP U-1382		
<u>DRONABINOL - SYNDROS</u>						
N 205525	001	8222292	Aug 06, 2028	DS DP		
		9345771	Aug 06, 2028	DS DP		
<u>EDARAVONE - RADICAVA</u>						
N 209176	001	6933310	Nov 13, 2020	U-2013	NCE ODE	May 05, 2022 May 05, 2024
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937	001	8598185	Apr 28, 2029	DP		
		9545414	Jun 13, 2026	DP U-750		
		9545414	Jun 13, 2026	DP U-1170		
		9744181	Jan 13, 2024	DP U-257		
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567	001	9566272	Jan 03, 2028	U-1969		
		9662394	Oct 02, 2034	DP		
	>A>	9861698	Jul 08, 2030	DP		
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291	003	8062665	Aug 01, 2027	DP U-930		
		8062665	Aug 01, 2027	DP U-1306		
		8062665	Aug 01, 2027	DP U-1575		
		8062665	Aug 01, 2027	DP U-1714		
		8062665*PED	Feb 01, 2028			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 207027	001	6280959	Oct 30, 2018	DS DP U-1736	ODE PED	Aug 26, 2021 Feb 26, 2022
		6280959*PED	Apr 30, 2019			
		7160870	Nov 20, 2022	DS DP U-1736		
		7160870*PED	May 20, 2023			
		7332481	May 24, 2021	U-1736		
		7332481*PED	Nov 24, 2021			
		7452874	May 24, 2021	DS DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 207027 001	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1736			
	7790704*PED	Nov 24, 2021				
	7795293	May 24, 2023	U-1736			
	7795293*PED	Nov 24, 2023				
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	8772325	Mar 14, 2025	U-1709			
	9675587	Mar 14, 2033	DP			
	9700542	Mar 14, 2025	DP			
	9789125	Jul 07, 2028	DP U-1709			
	9789125	Jul 07, 2028	DP U-2152			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	8772325	Mar 14, 2025	U-1709			
	9675587	Mar 14, 2033	DP			
	9700542	Mar 14, 2025	DP			
	9789125	Jul 07, 2028	DP U-1709			
	9789125	Jul 07, 2028	DP U-2152			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	8673927	May 04, 2027	U-1652			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	8673927	May 04, 2027	U-1652			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001					M-206 M-207	Aug 21, 2020 Aug 21, 2020
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	9744181	Jan 13, 2024	DP U-257			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001					NPP	Sep 25, 2020
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	9744181	Jan 13, 2024	DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245*PED	May 04, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	6642245	Nov 04, 2020	U-1170			
	6642245*PED	May 04, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245*PED	May 04, 2021				
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001 >A>	9855214	Nov 06, 2032	DP			
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686 001	9669008	Mar 25, 2036	DP			
	9808442	Mar 25, 2036	U-3			
	9808442	Mar 25, 2036	U-71			
	9808442	Mar 25, 2036	U-185			
	9808442	Mar 25, 2036	U-1723			
	9808442	Mar 25, 2036	U-1892			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 001	9512107	Jan 07, 2033	DS DP U-2087		NCE	Aug 01, 2022
	9732062	Sep 16, 2034	DS		ODE	Aug 01, 2024
	9738625	Aug 01, 2034	DS			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 002	9512107	Jan 07, 2033	DS DP U-2087		NCE	Aug 01, 2022
	9732062	Sep 16, 2034	DS		ODE	Aug 01, 2024
	9738625	Aug 01, 2034	DS			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	8183274	Aug 24, 2026	U-1281			
	8183274	Aug 24, 2026	U-1588			
<u>EPINEPHRINE - EPIPEN</u>						
N 019430 001	9586010	Sep 11, 2025	DP			
<u>EPINEPHRINE - EPIPEN JR.</u>						
N 019430 002	9586010	Sep 11, 2025	DP			
<u>EPINEPHRINE - ADRENALCLIK</u>						
N 020800 003	7905352	Apr 12, 2027	DP			
<u>EPINEPHRINE - ADRENALCLIK</u>						
N 020800 004	7905352	Apr 12, 2027	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003 >A>	7731686	Jun 01, 2026	DP			
	>A> 7731690	Jan 15, 2025	DP			
	>A> 7749194	Oct 30, 2028	DP			
	>A> 7918823	Nov 23, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003	>A> 7947017	Mar 12, 2028	DP			
	>A> 8016788	Mar 21, 2025	DP			
	>A> 8021344	Nov 02, 2029	DP			
	>A> 8206360	Feb 27, 2027	DP			
	>A> 8226610	Apr 10, 2029	DP			
	>A> 8231573	Nov 25, 2028	DP			
	>A> 8313466	Nov 23, 2024	DP			
	>A> 8361029	Nov 23, 2024	DP			
	>A> 8425462	Nov 23, 2024	DP			
	>A> 8608698	Nov 23, 2024	DP			
	>A> 8920377	Nov 23, 2024	DP			
	>A> 8926594	Mar 31, 2026	DP			
	>A> 9056170	Nov 23, 2024	DP			
	>A> 9149579	Jul 19, 2025	U-1758			
	>A> 9238108	Feb 20, 2027	DP			
	>A> 9259539	Feb 01, 2026	DP			
	>A> 9278182	Feb 01, 2026	DP			
	>A> 9724471	May 23, 2027	DP U-2092			
	>A> 9737669	Nov 23, 2024	DP			
	9833573	Nov 23, 2024	U-2172			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	9295657	Mar 13, 2035	U-1829			
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 001				>A> NCE		Dec 19, 2022
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 002				>A> NCE		Dec 19, 2022
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 001				>A> NCE		Dec 19, 2022
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 002				>A> NCE		Dec 19, 2022
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 003				>A> NCE		Dec 19, 2022
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 004				>A> NCE		Dec 19, 2022
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STELUJAN</u>						
N 209805 001				>A> NCE		Dec 19, 2022
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STELUJAN</u>						
N 209805 002				>A> NCE		Dec 19, 2022
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2021	DS DP U-2041			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2021	DS DP U-2041			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2021	DS DP U-2041			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2021	DS DP U-2041			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	9707181	May 31, 2022	DP		NPP	Jul 06, 2020
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	9707181	May 31, 2022	DP		NPP	Jul 06, 2020
<u>ESTRADIOL - ESTRADIOL</u>						
A 205256 001					PC	Apr 15, 2017
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 001	9730900	Jul 10, 2028	U-2086			
>A>	9833419	Jul 10, 2028	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 002	9730900	Jul 10, 2028	U-2086			
>A>	9833419	Jul 10, 2028	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 003	9730900	Jul 10, 2028	U-2086			
>A>	9833419	Jul 10, 2028	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 004	9730900	Jul 10, 2028	U-2086			
>A>	9833419	Jul 10, 2028	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 005	9724310	Jul 10, 2028	DS DP			
	9730900	Jul 10, 2028	DP U-2086			
>A>	9833419	Jul 10, 2028	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
	9820938	Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
	9820938	Jun 27, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
	9820938	Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
	9820938	Jun 27, 2034	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	8486907	Jun 28, 2025	U-1904	Y		
	9243245	Oct 27, 2028	DS U-2097			
	9243245	Oct 27, 2028	DS U-2098			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	8486907	Jun 28, 2025	U-1904	Y		
	9243245	Oct 27, 2028	DS U-2097			
	9243245	Oct 27, 2028	DS U-2098			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - FAYOSIM</u>						
A 205943 001					PC	Sep 30, 2017
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MIBELAS 24 FE</u>						
A 206287 001					PC	Sep 11, 2017
<u>ETONOGESTREL - IMPLANON</u>						
N 021529 001	9757552	Jul 28, 2030	DP U-1			
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529 002	9757552	Jul 28, 2030	DP U-1			
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 001	6239124	Jul 29, 2017	U-1049			
	6239124*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 002	6239124	Jul 29, 2017	U-1049			
	6239124*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 003	6239124	Jul 29, 2017	U-1049			
	6239124*PED	Jan 29, 2018				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001					ODE	Feb 26, 2023
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002					ODE	Feb 26, 2023
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003					ODE	Feb 26, 2023
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004					ODE	Feb 26, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	6479065	Aug 10, 2020	DP		NP	Oct 20, 2020
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
	8329648	Aug 18, 2026	U-1313			
	8329648	Aug 18, 2026	U-2154			
	8329648	Aug 18, 2026	U-2155			
	8329648	Aug 18, 2026	U-2156			
	8431685	Apr 13, 2025	DP U-412			
	8461105	Apr 13, 2025	DP U-412			
	8895033	Oct 04, 2030	DP U-1313			
	8895033	Oct 04, 2030	DP U-2157			
	8895033	Oct 04, 2030	DP U-2158			
	8906851	Aug 18, 2026	U-1313			
	9238076	Apr 15, 2024	DP U-412			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6414126	Oct 04, 2020	DS DP U-493		M-212	Oct 20, 2020
	6414126	Oct 04, 2020	DS DP U-2139			
	6515117	Oct 04, 2020	DS DP U-493			
	6515117	Oct 04, 2020	DS DP U-2139			
	6936590	Oct 04, 2020	U-493			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8361972	Mar 21, 2028	U-2139			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	9198925	Oct 04, 2020	U-2139			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6414126	Oct 04, 2020	DS DP U-493			
	6414126	Oct 04, 2020	DS DP U-2139			
	6515117	Oct 04, 2020	DS DP U-493			
	6515117	Oct 04, 2020	DS DP U-2139			
	6936590	Oct 04, 2020	U-493			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8361972	Mar 21, 2028	U-2139			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8690837	May 19, 2029	DP			
	8716251	Mar 21, 2028	DP			
	8721615	Jan 18, 2030	DP			
	8758292	Nov 12, 2027	DP			
	8827963	Feb 04, 2029	DP			
	8998876	Jan 07, 2030	DP			
	9198925	Oct 04, 2020	U-493			
	9198925	Oct 04, 2020	U-2139			
	9320853	Mar 25, 2028	DP			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 001					M-205	Aug 15, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 002					M-205	Aug 15, 2020
<u>FENTANYL - SUBSYS</u>						
N 202788 001	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 001	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 002	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 003	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 004	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 005	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	9731869	Jan 26, 2032	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	9731869	Jan 26, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 003	9731869	Jan 26, 2032	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	9731121	Oct 17, 2031	DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	9757416	Feb 18, 2024	DS DP U-1577			
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 001					NCE	Jul 13, 2021
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 002					NCE	Jul 13, 2021
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 003					NCE	Jul 13, 2021
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	5808146	Nov 09, 2018	DS			
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482 001	6537983	Aug 03, 2021	DP U-2125		NCE	May 10, 2018
	6759398	Aug 03, 2021	DP U-2125		NCE	Dec 18, 2018
	6878698	Aug 03, 2021	U-2134			
	7101866	Aug 03, 2021	DS DP U-2126			
	7439393	May 21, 2025	DS DP U-2127			
	7488827	Dec 18, 2027	DS DP			
	7498440	Apr 27, 2025	DS DP			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-2128			
	8309572	Apr 27, 2025	U-2129			
	8511304	Jun 14, 2027	DP			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
	9750762	Nov 29, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-2127			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	7439393	May 21, 2025	DS DP U-1401		M-202	May 15, 2020
	7439393	May 21, 2025	DS DP U-1691		NCE	May 10, 2018
	7439393	May 21, 2025	DS DP U-2099			
	7439393	May 21, 2025	DS DP U-2100			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	7439393	May 21, 2025	DS DP U-1691		M-202	May 15, 2020
	7439393	May 21, 2025	DS DP U-2099		NCE	May 10, 2018
	7439393	May 21, 2025	DS DP U-2100			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	6715485	Mar 03, 2020	DP		NP	Sep 18, 2020
	7975690	Dec 29, 2025	U-2133			
	8327844	Oct 08, 2023	U-2133			
	8522778	May 11, 2022	DP			
	8550073	Oct 22, 2029	DP			
	8555878	Mar 20, 2020	DP			
	8978647	Aug 06, 2030	DP			
	9072857	Apr 10, 2021	DP			
	9468727	Jul 30, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50</u>						
N 021077 001					>A> M-214	Dec 20, 2020
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50</u>						
N 021077 002					>A> M-214	Dec 20, 2020
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50</u>						
N 021077 003					>A> M-214	Dec 20, 2020
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9415008	Oct 06, 2034	DP U-645			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 001				>A> M-214		Dec 20, 2020
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 002				>A> M-214		Dec 20, 2020
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	6774122	Jan 09, 2021	U-596		I-749	Aug 25, 2020
	6774122	Jan 09, 2021	U-1826			
	6774122	Jan 09, 2021	U-2108			
	6774122	Jan 09, 2021	U-2163			
	6774122*PED	Jul 09, 2021				
	7456160	Jan 09, 2021	U-596			
	7456160	Jan 09, 2021	U-1826			
	7456160	Jan 09, 2021	U-2108			
	7456160	Jan 09, 2021	U-2163			
	7456160*PED	Jul 09, 2021				
	8329680	Jan 09, 2021	U-596			
	8329680	Jan 09, 2021	U-1826			
	8329680	Jan 09, 2021	U-2108			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	8329680	Jan 09, 2021	U-2163			
	8329680*PED	Jul 09, 2021				
	8466139	Jan 09, 2021	U-596			
	8466139	Jan 09, 2021	U-1826			
	8466139	Jan 09, 2021	U-2108			
	8466139	Jan 09, 2021	U-2163			
	8466139*PED	Jul 09, 2021				
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 001					NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 002					NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 003					NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 004					NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 005					NCE NPP	Mar 20, 2018 Aug 25, 2020
<u>GANCICLOVIR - GANCICLOVIR</u>						
N 209347 001	9486530	Sep 02, 2034	DP			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	8648037	Jan 19, 2032	DS DP U-2141		NCE	Aug 03, 2022
	8937150	May 18, 2032	DS DP			
	9321807	Jun 05, 2035	DS			
	9586978	Jun 10, 2030	U-2141			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	9561197	Sep 22, 2030	U-1383		NPP >A> ODE	Apr 28, 2020 Apr 28, 2024
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437 001	>A> 6962151	Oct 27, 2020	DP		>A> NP	Dec 05, 2020
	>A> 7316067	Sep 06, 2022	DP			
	>A> 7458372	Nov 18, 2024	DP			
	>A> 7931212	Nov 25, 2025	DP			
	>A> 8511581	Nov 08, 2023	DP			
	>A> 9168556	Sep 01, 2032	DP			
	>A> 9265900	Dec 07, 2028	DP			
	>A> 9604018	May 16, 2033	DP			
	>A> 9789270	Oct 30, 2030	DP			
<u>GUAIFENESIN; HYDROCODONE BITARTRATE - OBREDON</u>						
N 205474 001	9549907	Nov 13, 2035	DS DP U-2023			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	>A> 9861584	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	>A> 9861584	Dec 21, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	>A> 9861584	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	>A> 9861584	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	>A> 9861584	Dec 21, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020		U-1556		
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027		U-1556		
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020		U-1556		
	9682077	Oct 30, 2020		U-1556		
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
>A>	9861584	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020		U-1556		
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027		U-1556		
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2021	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020		U-1556		
	9682077	Oct 30, 2020		U-1556		
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
>A>	9861584	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 001	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 002	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 003	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 004	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 005	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 005	9572803	Sep 13, 2027	DP			
<u>HYDROGEN PEROXIDE - ESKATA</u>						
N 209305 001	>A> 7381427	Jun 08, 2022	U-2205		>A> NP	Dec 14, 2020
	>A> 9675639	Jul 04, 2035	DP U-2205			
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA PRESERVATIVE FREE</u>						
N 021945 002					ODE	Feb 03, 2018
<u>HYDROXYUREA - SIKLOS</u>						
N 208843 001					>A> NP	Dec 21, 2020
<u>HYDROXYUREA - SIKLOS</u>						
N 208843 002					>A> NP	Dec 21, 2020
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8476284	Dec 28, 2026	U-1456		I-741	Jan 18, 2020
	8476284	Dec 28, 2026	U-1650		I-753	Aug 02, 2020
	8476284	Dec 28, 2026	U-1946		ODE	Jan 18, 2024
	8476284	Dec 28, 2026	U-1947		ODE	Aug 02, 2024
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9713617	Jun 03, 2033	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801883	Jun 03, 2031	U-2159			
	9814721	Jun 03, 2031	U-1947			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	9649284	Sep 30, 2029	U-2018			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	8188146	Jan 27, 2020	DS DP		NCE	Jul 26, 2017
	8293727	Feb 09, 2030	U-1287			
	8293728	Feb 09, 2030	U-1287			
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030	U-1287			
	8318715	Feb 09, 2030	U-1287			
	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8501225	Apr 29, 2030	U-1287			
	8518929	Apr 29, 2030	U-1287			
	8524698	Apr 29, 2030	U-1287			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	8546372	Apr 29, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1287			
	8617594	Apr 29, 2030	U-1287			
	8623406	Apr 29, 2030	U-1287			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	9789078	May 15, 2033	U-2138			
	9820959	Dec 18, 2026	DP U-1440			
	9833428	Dec 18, 2026	DP			
	9833429	Dec 18, 2026	DP			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	9820959	Dec 18, 2026	DP U-1440			
	9833428	Dec 18, 2026	DP			
	9833429	Dec 18, 2026	DP			
<u>INSULIN ASPART - FIASP</u>						
N 208751 001	8324157	Jun 25, 2030	DP		NP	Sep 29, 2020
<u>INSULIN ASPART - FIASP FLEXTOUCH</u>						
N 208751 002	6899699	Jan 02, 2022	DP		NP	Sep 29, 2020
	7686786	Aug 03, 2026	DP			
	8324157	Jun 25, 2030	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Jan 20, 2026	DP			
	9486588	Jan 02, 2022	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 02, 2024	DP U-2146			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 02, 2024	DP U-2146			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	9526764	Oct 09, 2029	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9707176	Nov 11, 2030	DP			
	9775954	Mar 02, 2024	DP			
	>A> 9821032	May 09, 2032	U-2182			
	9827379	Mar 02, 2024	DP U-2146			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 02, 2024	DP U-2146			
<u>INSULIN LISPRO - ADMELOG</u>						
N 209196 001				>A> NP		Dec 11, 2020
<u>INSULIN LISPRO - ADMELOG SOLOSTAR</u>						
N 209196 002				>A> NP		Dec 11, 2020
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	6444226	Jun 29, 2020	DP U-1534			
	6652885	Jun 29, 2020	U-1535			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP U-1621			
	8623817	Sep 18, 2029	U-1537			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
	8912193	Jun 12, 2029	DP U-1538			
	9192675	Jun 12, 2029	DP U-1788			
	9358352	Feb 15, 2031	DP U-1861			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	9446133	Jun 12, 2029	DP U-1861			
	9597374	Oct 08, 2031	U-1987			
	9662461	Jun 12, 2029	DP U-2019			
	9717689	Sep 14, 2026	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	6444226	Jun 29, 2020	DP U-1534			
	6652885	Jun 29, 2020	U-1535			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP U-1621			
	8623817	Sep 18, 2029	U-1537			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
	8912193	Jun 12, 2029	DP U-1538			
	9192675	Jun 12, 2029	DP U-1788			
	9358352	Feb 15, 2031	DP U-1861			
	9446133	Jun 12, 2029	DP U-1861			
	9597374	Oct 08, 2031	U-1987			
	9662461	Jun 12, 2029	DP U-2019			
	9717689	Sep 14, 2026	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	6444226	Jun 29, 2020	DP U-1534			
	6652885	Jun 29, 2020	U-1535			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP U-1621			
	8623817	Sep 18, 2029	U-1537			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
	8912193	Jun 12, 2029	DP U-1538			
	9192675	Jun 12, 2029	DP U-1788			
	9358352	Feb 15, 2031	DP U-1861			
	9446133	Jun 12, 2029	DP U-1861			
	9597374	Oct 08, 2031	U-1987			
	9662461	Jun 12, 2029	DP U-2019			
	9717689	Sep 14, 2026	DP			
<u>IODIXANOL - VISIPAQUE 320</u>						
N 020351 002					I-752	Apr 05, 2020
<u>IODIXANOL - VISIPAQUE 320</u>						
N 020808 002					I-752	Apr 05, 2020
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	9717724	Jun 12, 2033	U-1848			
	9717724	Jun 12, 2033	U-2091			
	9724303	May 02, 2025	DS DP			
	9730891	May 02, 2025	U-1848			
	9782349	May 02, 2025	DS DP			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	9670163	Dec 28, 2026	DP U-1311		NPP	Jul 31, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	9670163	Dec 28, 2026	DP U-1311		NPP	Jul 31, 2020
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	9670163	Dec 28, 2026	DP U-1311		NPP	Jul 31, 2020
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	7973038	Nov 08, 2026	U-1973			
	9670163	Dec 28, 2026	DP U-1911			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	7973038	Nov 08, 2026	U-1973			
	9670163	Dec 28, 2026	DP U-1911			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	>A> 9782425	Mar 13, 2034	U-1631			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - Omidria</u>						
N 205388 001	8173707	Jul 30, 2023	U-1518		>A> NPP	Dec 08, 2020
	8173707*PED	Jan 30, 2024			>A> PED	Jun 08, 2021
	8586633	Jul 30, 2023	DP			
	8586633*PED	Jan 30, 2024				
	9066856	Oct 23, 2033	DP			
	9066856*PED	Apr 23, 2034				
	9278101	Jul 30, 2023	U-1518			
	9278101*PED	Jan 30, 2024				
	9399040	Jul 30, 2023	DP			
	9399040*PED	Jan 30, 2024				
	9486406	Oct 23, 2033	DP			
	9486406*PED	Apr 23, 2034				
	>A> 9855246	Oct 23, 2033	DP			
<u>L-GLUTAMINE - ENDARI</u>						
N 208587 001					I-748 ODE	Jul 07, 2020 Jul 07, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 001	RE38551	Mar 17, 2022	DS U-1567		>A> NPP	Nov 03, 2020
	RE38551	Mar 17, 2022	DS U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 002	RE38551	Mar 17, 2022	DS U-1567		>A> NPP	Nov 03, 2020
	RE38551	Mar 17, 2022	DS U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 003	RE38551	Mar 17, 2022	DS U-1567		>A> NPP	Nov 03, 2020
	RE38551	Mar 17, 2022	DS U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 004	RE38551	Mar 17, 2022	DS U-1567		>A> NPP	Nov 03, 2020
	RE38551	Mar 17, 2022	DS U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022254 001					>A> M-217	Nov 03, 2020
<u>LACOSAMIDE - VIMPAT</u>						
N 022255 001	RE38551	Mar 17, 2022	DS U-1567		>A> NPP	Nov 03, 2020
	RE38551	Mar 17, 2022	DS U-2140			
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510 001	7169780	Oct 03, 2023	DS DP			
	7169780*PED	Apr 03, 2024				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510 001	7217713	Oct 21, 2022	U-1663			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-1663			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-1663			
	7754731*PED	Sep 11, 2029				
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 001					I-754 ODE	Sep 15, 2020 Sep 15, 2024
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 002					I-754 ODE	Sep 15, 2020 Sep 15, 2024
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 003					I-754 ODE	Sep 15, 2020 Sep 15, 2024
<u>LATANOPROSTENE BUNOD - VYZULTA</u>						
N 207795 001	6211233	Jun 17, 2018	DS DP			
	7273946	Oct 03, 2025	DS DP U-2144			
	7629345	Jan 05, 2025	DP U-2144			
	7910767	Jan 05, 2025	DS DP U-2144			
	8058467	Jan 05, 2025	DS U-2144			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001					NPP ODE	Apr 07, 2020 Apr 07, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 001	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
	8513255	May 22, 2024	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
	8513255	May 22, 2024	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
	8513255	May 22, 2024	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
	8513255	May 22, 2024	DS DP			
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	8324225	Jun 17, 2028	DS DP		NCE	Mar 13, 2022
	8415355	Feb 19, 2031	DS DP			
	8685980	May 25, 2030	DS DP			
	8962630	Dec 09, 2029	U-1981			
	9193732	Nov 09, 2031	DS DP			
	9416136	Aug 20, 2029	U-1981			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021343 001	9254307	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEVETIRACETAM - ROWEEPR</u>						
A 090906 003					>A> PC	Sep 13, 2017
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 001	9339489	Mar 14, 2034	DP U-1850			
	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL ALLERGY 24HR</u>						
N 209090 001	8633194	Oct 16, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	9708371	Aug 16, 2033	DP U-1515			
	9708371	Aug 16, 2033	DP U-1516			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	9708371	Aug 16, 2033	DP U-1515			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	7304036	Aug 30, 2026	DS DP U-1516		NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS		NS	Jan 25, 2020
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1516			
	8933030	Feb 17, 2031	DP U-1516			
	9708371	Aug 16, 2033	DP U-1516			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8846695	Jun 04, 2030	U-1503	Y		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8846695	Jun 04, 2030	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8846695	Jun 04, 2030	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8846695	Jun 04, 2030	U-1503	Y		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001					I-750	Aug 25, 2020
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023			U-727	
	7671030	Feb 24, 2023	DP		U-727	
	7671031	Feb 24, 2023			U-727	
	7674774	Feb 24, 2023	DP		U-727	
	7678770	Feb 24, 2023			U-727	
	7678771	Feb 24, 2023	DP		U-727	
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP		U-727	
	7713936	Feb 24, 2023			U-727	
	7718619	Feb 24, 2023	DP		U-727	
	7723305	Feb 24, 2023	DP		U-727	
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 002	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP		U-727	
	7659254	Feb 24, 2023			U-727	
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023			U-727	
	7671030	Feb 24, 2023	DP		U-727	
	7671031	Feb 24, 2023			U-727	
	7674774	Feb 24, 2023	DP		U-727	
	7678770	Feb 24, 2023			U-727	
	7678771	Feb 24, 2023	DP		U-727	
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP		U-727	
	7713936	Feb 24, 2023			U-727	
	7718619	Feb 24, 2023	DP		U-727	
	7723305	Feb 24, 2023	DP		U-727	
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 003	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP		U-727	
	7659254	Feb 24, 2023			U-727	
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023			U-727	
	7671030	Feb 24, 2023	DP		U-727	
	7671031	Feb 24, 2023			U-727	
	7674774	Feb 24, 2023	DP		U-727	
	7678770	Feb 24, 2023			U-727	
	7678771	Feb 24, 2023	DP		U-727	
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP		U-727	
	7713936	Feb 24, 2023			U-727	
	7718619	Feb 24, 2023	DP		U-727	
	7723305	Feb 24, 2023	DP		U-727	
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP		U-727	
	7659254	Feb 24, 2023			U-727	
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023			U-727	
	7671030	Feb 24, 2023	DP		U-727	
	7671031	Feb 24, 2023			U-727	
	7674774	Feb 24, 2023	DP		U-727	
	7678770	Feb 24, 2023			U-727	
	7678771	Feb 24, 2023	DP		U-727	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 005	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 006	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001	9616096	Nov 06, 2035	U-3			
	9616096	Nov 06, 2035	U-8			
	9616096	Nov 06, 2035	U-71			
	9616096	Nov 06, 2035	U-185			
	9616096	Nov 06, 2035	U-1723			
	9616096	Nov 06, 2035	U-1864			
	9616096	Nov 06, 2035	U-1991			
	9814751	Nov 06, 2035	DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	9707176	Nov 11, 2030	DP			
>A>	9821032	May 09, 2032	U-2200			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	9707176	Nov 11, 2030	DP			
>A>	9821032	May 09, 2032	U-2200			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	9770455	Aug 31, 2031	U-2110			
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	9770455	Aug 31, 2031	U-2110			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	9687487	Oct 26, 2021	DS DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	5900488	Jan 18, 2020	DS DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9555027	May 26, 2026	DP U-543		M-195	Jan 27, 2020
	9815827	Feb 20, 2024	U-543		NPP	Jan 27, 2020
	9815827	Feb 20, 2024	U-2166		PED	Jul 27, 2020
	>A> 9827242	May 23, 2031	U-2199		PED	Jul 27, 2020
	>A> 9827242	May 23, 2031	U-2201			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9555027	May 26, 2026	DP U-543		NPP	Jan 27, 2020
	9815827	Feb 20, 2024	U-543		PED	Jul 27, 2020
	9815827	Feb 20, 2024	U-2166			
	>A> 9827242	May 23, 2031	U-2199			
	>A> 9827242	May 23, 2031	U-2201			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9555027	May 26, 2026	DP U-543		M-195	Jan 27, 2020
	9815827	Feb 20, 2024	U-543		NPP	Jan 27, 2020
	9815827	Feb 20, 2024	U-2166		PED	Jul 27, 2020
	>A> 9827242	May 23, 2031	U-2199		PED	Jul 27, 2020
	>A> 9827242	May 23, 2031	U-2201			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9555027	May 26, 2026	DP U-543			
	9815827	Feb 20, 2024	U-543			
	9815827	Feb 20, 2024	U-2166			
	>A> 9827242	May 23, 2031	U-2199			
	>A> 9827242	May 23, 2031	U-2201			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9555027	May 26, 2026	DP U-543		M-195	Jan 27, 2020
	9815827	Feb 20, 2024	U-543		NPP	Jan 27, 2020
	9815827	Feb 20, 2024	U-2166		PED	Jul 27, 2020
	>A> 9827242	May 23, 2031	U-2199		PED	Jul 27, 2020
	>A> 9827242	May 23, 2031	U-2201			
<u>MACIMORELIN ACETATE - MACRILEN</u>						
N 205598 001					>A> NCE	Dec 20, 2022
<u>MARAVIROC - SELZENTRY</u>						
N 022128 001					NPP	Nov 04, 2019
					NS	Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 022128 002					NPP	Nov 04, 2019
					NS	Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 022128 003	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
	6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MARAVIROC - SELZENTRY</u>						
N 022128 003	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
	6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 022128 004	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
	6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 208984 001					NP	Nov 04, 2019
<u>MELOXICAM - VIVLODEX</u>						
N 207233 001	9649318	Mar 31, 2035	DP			
<u>MELOXICAM - VIVLODEX</u>						
N 207233 002	9649318	Mar 31, 2035	DP			
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	9493582	Feb 27, 2033	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	8680136	Aug 17, 2031	DS DP			
	9694025	Aug 08, 2031	U-2120			
<u>MESALAMINE - MESALAMINE</u>						
A 091640 001					PC	Jan 14, 2018
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001					M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	9339472	Jul 13, 2025	DP		M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	9339472	Jul 13, 2025	DP		M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	9259427	Jan 02, 2033	DP		ODE	Apr 25, 2024
					ODE	Apr 25, 2024
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	9492445	Sep 30, 2029	DP U-1185			
	9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	9492445	Sep 30, 2029	DP U-1185			
	9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	9492445	Sep 30, 2029	DP U-1185			
	9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271 001	9492445	Sep 30, 2029	DP U-1185			
	9724343	Sep 30, 2029	DP U-1185			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 001	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 002	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 003	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	9801823	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	9545399	Aug 14, 2033	DP U-1827			
	>A> 9844544	Aug 14, 2033	DP U-2203			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	9545399	Aug 14, 2033	DP U-1827			
	>A> 9844544	Aug 14, 2033	DP U-2203			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	9545399	Aug 14, 2033	DP U-1827			
	>A> 9844544	Aug 14, 2033	DP U-2203			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIDOSTAURIN - RYDAPT</u>						
N 207997 001	7973031	Oct 17, 2024	U-2007		NCE	Apr 28, 2022
	8222244	Oct 29, 2022	U-2007		ODE	Apr 28, 2024
	8575146	Dec 02, 2030	U-2008		ODE	Apr 28, 2024
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	9829495	Aug 15, 2036	U-1643			
<u>MITOMYCIN - MITOSOL</u>						
N 022572 001	9539241	Jan 02, 2028	DS DP U-2095			
	9649428	May 21, 2029	U-2095			
<u>MOMETASONE FUROATE - SINUVA</u>						
N 209310 001					>A> NP	Dec 08, 2020
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 001	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 002	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 003	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>NALDEMEDINE TOSYLATE - SYMPROIC</u>						
N 208854 001	9108975	Nov 11, 2031	DS DP		NCE	Mar 23, 2022
	RE46365	Jan 11, 2028	DS DP			
	RE46375	Oct 05, 2026	DS DP U-1185			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 001	9211253	Mar 16, 2035	DP			
	9561177	Mar 16, 2035	DP U-1903			
	9629965	Mar 16, 2035	DP U-1903			
	9775838	Mar 16, 2035	U-1903			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 002	9480644	Mar 16, 2035	DP U-1903			
	9707226	Mar 16, 2035	DP U-1903			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 209862 001	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9555000	Apr 04, 2023	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9555000	Apr 04, 2023	DP U-1556			
<u>NAPROXEN SODIUM - NAPROXEN SODIUM</u>						
N 021920 001	9693978	Mar 03, 2026	DP			
	9693979	Mar 03, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	9662398	Dec 01, 2030	DP			
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001	6288082	Sep 24, 2019	DS DP U-2043		NCE	Jul 17, 2022
	7399865	Dec 29, 2025	DS DP			
	7982043	Oct 08, 2025	U-2043			
	8518446	Nov 20, 2030	DP U-2043			
	8790708	Nov 05, 2030	DP U-2043			
	9139558	Oct 15, 2028	U-2043			
	9211291	Mar 24, 2030	U-2043			
	9630946	Oct 15, 2028	U-2043			
<u>NETARSUDIL DIMESYLATE - RHOPRESSA</u>						
N 208254 001	>A> 8394826	Nov 10, 2030	DS DP U-1524		>A> NCE	Dec 18, 2022
	>A> 8450344	Jul 11, 2026	DS DP U-1524			
	>A> 9096569	Jul 11, 2026	DS DP U-1524			
	>A> 9415043	Mar 14, 2034	DS			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001	8071623	Mar 22, 2030	DS DP		NCE	Mar 27, 2022
	8436185	Apr 24, 2029	DS		ODE	Mar 27, 2024
<u>NITISINONE - ORFADIN</u>						
N 021232 001					D-169	Sep 01, 2020
<u>NITISINONE - ORFADIN</u>						
N 021232 002					D-169	Sep 01, 2020
<u>NITISINONE - ORFADIN</u>						
N 021232 003					D-169	Sep 01, 2020
<u>NITISINONE - ORFADIN</u>						
N 021232 004					D-169	Sep 01, 2020
<u>NITISINONE - ORFADIN</u>						
N 206356 001					D-169	Sep 01, 2020
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	9770570	May 03, 2036	U-2148		M-167	Oct 09, 2018
	9770570*PED	Nov 03, 2036				
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	6166197	Dec 26, 2017	DS		ODE	Dec 23, 2023
	6210892	Oct 07, 2018	U-1942			
	7101993	Sep 05, 2023	DS			
	7838657	Jul 11, 2027	DS			
	8110560	Dec 05, 2025	U-1942			
	8110560	Dec 05, 2025	U-1943			
	8110560	Dec 05, 2025	U-1944			
	8361977	May 27, 2030	DS DP			
	8980853	Nov 24, 2030	U-1941			
	9717750	Jun 17, 2030	U-1942			
	9717750	Jun 17, 2030	U-1943			
	9717750	Jun 17, 2030	U-2093			
	9717750	Jun 17, 2030	U-2094			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	7151102	Apr 29, 2022	DS DP		NCE	Dec 19, 2019
	7449464	Oct 11, 2024	DS DP		NP	Aug 17, 2020
	7981889	Oct 11, 2024	DS DP		ODE	Dec 19, 2021
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2102			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8143241	Aug 12, 2027	U-2103			
	8475842	Dec 31, 2029	DP			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2102			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2102			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	7151102	Apr 29, 2022	DS DP		NCE	Dec 19, 2019
	7449464	Oct 11, 2024	DS DP		NP	Aug 17, 2020
	7981889	Oct 11, 2024	DS DP		ODE	Dec 19, 2021
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2102			
	8143241	Aug 12, 2027	U-2103			
	8475842	Dec 31, 2029	DP			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2102			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2102			
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108 001	8733341	Oct 16, 2030	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	6149054	Dec 19, 2016	DP			
	6149054*PED	Jun 19, 2017				
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	8733341	Oct 16, 2030	DP			
<u>OLOPATADINE HYDROCHLORIDE - OLOPATADINE HYDROCHLORIDE</u>						
A 090848 001					PC	Dec 05, 2017
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276 001	9533053	May 19, 2032	DP			
<u>OMACETAXINE MEPESUCCINATE - SYNRIBO</u>						
N 203585 001	6987103	Oct 26, 2026	U-1300			
<u>OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE</u>						
N 207931 001					I-743	Jul 24, 2018
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2018	DP			
	5948818	May 13, 2018	DP			
<u>OMEPRazole MAGNESIUM - OMEPRazole MAGNESIUM</u>						
A 204152 001					PC	May 30, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	9649352	Jul 16, 2035	DP			
	9682061	Apr 26, 2030	U-1569			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	9732058	Jul 25, 2032	DS DP U-1777			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	9732058	Jul 25, 2032	DS DP U-1777			
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2025	U-1370			
	9566252	Jul 21, 2020	U-1370			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001 >A>	9855278	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002 >A>	9855278	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003 >A>	9855278	Apr 13, 2027	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 001	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 002	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 001	7955619	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 002	7955619	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 003	7955619	Aug 12, 2028	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFAD</u>						
N 208552 001	7812049	May 02, 2028	U-1959		NP	Jan 18, 2020
	8420688	Aug 02, 2024	U-1959			
	8883838	Dec 01, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OZENOXACIN - XEPI</u>						
N 208945 001					>A> NCE	Dec 11, 2022
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	9393318	Mar 04, 2032	U-1290			
	9511046	Jan 12, 2034	U-1434			
	9597409	Mar 04, 2032	U-1290			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1998			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1998			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1998			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 001					>A> M-215	Dec 20, 2020
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 002					>A> M-215	Dec 20, 2020
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 003					>A> M-215	Dec 20, 2020
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004					>A> M-215	Dec 20, 2020
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 005					>A> M-215	Dec 20, 2020
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N 022523 005	>A> 8221747	Feb 20, 2028	DP			
	>A> 8562978	Feb 20, 2028	DP			
	>A> 8562979	Feb 20, 2028	DP U-1274			
	>A> 8562980	Feb 20, 2028	DP U-1274			
	>A> 8562981	Feb 20, 2028	DP U-1274			
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677 001	7473761	Dec 14, 2026	DS DP			
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677 002	7473761	Dec 14, 2026	DS DP			
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677 003	7473761	Dec 14, 2026	DS DP			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255 001	7473761	Dec 14, 2026	DS DP			
	9351923	May 23, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255 002	7473761	Dec 14, 2026	DS DP			
	9351923	May 23, 2028	DP			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255 003	7473761	Dec 14, 2026	DS DP			
	9351923	May 23, 2028	DP			
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001					NPP	Sep 20, 2020
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	9545457	Jan 13, 2019	U-665			
	9789210	Mar 16, 2037	U-665			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	9566271	Jan 15, 2024	U-1974			
	9765053	Jul 27, 2022	U-1974			
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001					NCE	Oct 15, 2019
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	7566729	Apr 22, 2029	U-2077		NCE	Oct 15, 2019
	7566729	Apr 22, 2029	U-2078		ODE	Oct 15, 2021
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2052			
	8084475	Jan 08, 2030	U-2054			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	Sep 22, 2026	DP U-1607			
	8420674	Dec 18, 2017	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002					NCE ODE	Oct 15, 2019 Oct 15, 2021
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	7566729	Apr 22, 2029	U-2077		NCE	Oct 15, 2019
	7566729	Apr 22, 2029	U-2078		ODE	Oct 15, 2021
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2052			
	8084475	Jan 08, 2030	U-2054			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	Sep 22, 2026	DP U-1607			
	8420674	Dec 18, 2017	U-2079			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
<u>PITAVASTATIN MAGNESIUM - ZYPITAMAG</u>						
N 208379 001 >A>	8829186	Jan 19, 2031	DS DP			
<u>PITAVASTATIN MAGNESIUM - ZYPITAMAG</u>						
N 208379 002 >A>	8829186	Jan 19, 2031	DS DP			
<u>PITAVASTATIN MAGNESIUM - ZYPITAMAG</u>						
N 208379 003 >A>	8829186	Jan 19, 2031	DS DP			
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	7041786	Mar 25, 2023	DS		NCE	Jan 19, 2022
	7799897	Jun 09, 2022	DS			
	8637451	Mar 28, 2022	U-1964			
	9610321	Sep 11, 2031	U-1999			
	9616097	Jul 02, 2032	DP			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	8114874	Dec 22, 2026	DS DP			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9750822	Mar 13, 2029	DP			
<u>PRASUGREL HYDROCHLORIDE - PRASUGREL</u>						
A 205927 001					PC	Feb 11, 2018
<u>PRASUGREL HYDROCHLORIDE - PRASUGREL</u>						
A 205927 002					PC	Feb 11, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PREDNISONE - RAYOS</u>						
N 202020 001	9504699	Aug 03, 2027	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 002	9504699	Aug 03, 2027	U-1362			
<u>PREGABALIN - LYRICA CR</u>						
N 209501 001	6197819	Dec 30, 2018	DS DP		NP	Oct 11, 2020
	8945620	Nov 02, 2026	DP U-2136			
	8945620	Nov 02, 2026	DP U-2137			
	9144559	Nov 02, 2026	DP			
	RE41920	Dec 30, 2018	U-2136			
	RE41920	Dec 30, 2018	U-2137			
<u>PREGABALIN - LYRICA CR</u>						
N 209501 002	6197819	Dec 30, 2018	DS DP		NP	Oct 11, 2020
	8945620	Nov 02, 2026	DP U-2136			
	8945620	Nov 02, 2026	DP U-2137			
	9144559	Nov 02, 2026	DP			
	RE41920	Dec 30, 2018	U-2136			
	RE41920	Dec 30, 2018	U-2137			
<u>PREGABALIN - LYRICA CR</u>						
N 209501 003	6197819	Dec 30, 2018	DS DP		NP	Oct 11, 2020
	8945620	Nov 02, 2026	DP U-2136			
	8945620	Nov 02, 2026	DP U-2137			
	9144559	Nov 02, 2026	DP			
	RE41920	Dec 30, 2018	U-2136			
	RE41920	Dec 30, 2018	U-2137			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 022145 001	7169780	Oct 03, 2023	DS DP		D-167	May 26, 2020
	7169780*PED	Apr 03, 2024			NPP	Nov 22, 2020
	7217713	Oct 21, 2022	U-257		PED	Nov 26, 2020
	7217713*PED	Apr 21, 2023			PED	May 22, 2021
	7435734	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-900			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS HD</u>						
N 022145 002	7169780	Oct 03, 2023	DS DP		NPP	Nov 22, 2020
	7169780*PED	Apr 03, 2024			NS	May 26, 2020
	7217713	Oct 21, 2022	U-257		PED	Nov 26, 2020
	7217713*PED	Apr 21, 2023			PED	May 22, 2021
	7435734	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-900			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
	9649311	Oct 21, 2030	DP			
	9649311*PED	Apr 21, 2031				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 001	7169780	Oct 03, 2023	DS DP		NPP	Nov 22, 2020
	7169780*PED	Apr 03, 2024			PED	May 22, 2021
	7217713	Oct 21, 2022	U-257			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-257			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 002	7169780	Oct 03, 2023	DS DP		NPP	Nov 22, 2020
	7169780*PED	Apr 03, 2024			PED	May 22, 2021
	7217713	Oct 21, 2022	U-257			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-257			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786 001	7169780	Oct 03, 2023	DS DP		NPP	Nov 22, 2020
	7169780*PED	Apr 03, 2024			PED	May 22, 2021
	7217713	Oct 21, 2022	U-257			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-257			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823 001					PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823 002					PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950 001					PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950 002					PC	Jul 01, 2017
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001					M-194	Jan 17, 2020
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	7351834	Jun 28, 2022	DS		I-744 ODE	Apr 27, 2020 Apr 27, 2024
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	8324225	Jun 17, 2028	DS DP		NCE	Mar 13, 2022
	8415355	Feb 19, 2031	DS DP			
	8685980	May 25, 2030	DS DP			
	8962630	Dec 09, 2029	U-1981			
	9193732	Nov 09, 2031	DS DP			
	9416136	Aug 20, 2029	U-1981			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	9629828	Jul 24, 2029	U-1994			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	7592339	Dec 11, 2020	U-1167		D-168	Oct 27, 2020
	7592339	Dec 11, 2020	U-1200			
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
	7592339	Dec 11, 2020	U-2142			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
	9415053	Nov 13, 2024	DP U-2142			
	9539218	Feb 17, 2034	U-1953			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1956			
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1956			
	9539218	Feb 17, 2034	U-1957			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7592339	Dec 11, 2020	U-1167	Y		
	7592339	Dec 11, 2020	U-1200	Y		
	7592339	Dec 11, 2020	U-1301	Y		
	7592339	Dec 11, 2020	U-1302	Y		
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1957			
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001					M-208	Aug 31, 2020
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500 001	8404702	Apr 04, 2027	U-1741			
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 208399 001	7049320	Dec 08, 2023	DS DP U-1741		NCE	Sep 01, 2020
	7981905	Apr 04, 2027	U-1741			
	8178550	Apr 04, 2027	DS DP			
	8404702	Apr 04, 2027	U-1741			
	8470842	Jan 18, 2029	U-1741			
	8796299	Dec 17, 2022	U-1741			
	9101615	Jul 14, 2032	U-1741			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 001					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 002					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 003					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 004					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 005					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 006					M-203	Mar 23, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	7351701	Jul 23, 2024	U-2012		ODE	Dec 19, 2023
	7531530	Jul 23, 2024	U-2012			
	8071579	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2012			
	8859562	Aug 04, 2031	U-2012			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	7351701	Jul 23, 2024	U-2012		ODE	Dec 19, 2023
	7531530	Jul 23, 2024	U-2012			
	8071579	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2012			
	8859562	Aug 04, 2031	U-2012			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	6495541	Jan 10, 2020	DS DP		NCE	Dec 19, 2021
	7351701	Jul 23, 2024	U-2012		ODE	Dec 19, 2023
	7531530	Jul 23, 2024	U-2012			
	8071579	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2012			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-2012			
	9045487	Feb 10, 2031	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	9662335	Dec 12, 2026	DS			
<u>SACROSIDASE - SUCRAID</u>						
N 020772 001	9469847	Feb 07, 2034	DS DP			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 001	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS U-1993			
	8283380	Sep 01, 2027	U-1993			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 002	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS U-1993			
	8283380	Sep 01, 2027	U-1993			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001					M-198	Feb 27, 2020
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002					M-198	Feb 27, 2020
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001					NCE GAIN	Sep 15, 2022 Sep 15, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	>A> 6899699	Jan 02, 2022	DP		>A> NCE	Dec 05, 2022
	>A> 7762994	May 23, 2024	DP			
	>A> 8114833	Aug 13, 2025	DP			
	>A> 8129343	Jan 29, 2029	DS DP U-2202			
	>A> 8536122	Mar 20, 2026	DS DP U-2202			
	>A> 8579869	Jun 30, 2023	DP			
	>A> 8672898	Jan 02, 2022	DP			
	>A> 8684969	Oct 20, 2025	DP			
	>A> 8920383	Jul 17, 2026	DP			
	>A> 9108002	Jan 20, 2026	DP			
	>A> 9132239	Feb 01, 2032	DP			
	>A> 9457154	Sep 27, 2027	DP			
	>A> 9486588	Jan 02, 2022	DP			
	>A> 9687611	Feb 27, 2027	DP			
	>A> 9775953	Jul 17, 2026	DP			
	>A> RE46363	Aug 03, 2026	DP			
<u>SILDENAFIL CITRATE - SILDENAFIL CITRATE</u>						
A 077342 001					>A> PC	Jun 09, 2018
<u>SILDENAFIL CITRATE - SILDENAFIL CITRATE</u>						
A 077342 002					>A> PC	Jun 09, 2018
<u>SILDENAFIL CITRATE - SILDENAFIL CITRATE</u>						
A 077342 003					>A> PC	Jun 09, 2018
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9623022	Jul 28, 2026	U-1467			
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679 001	9597289	Feb 23, 2030	DP			
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679 002	9597289	Feb 23, 2030	DP			
<u>SINECATECHINS - VEREGEN</u>						
N 021902 001	9770406	Jul 12, 2025	DP U-172			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	9345724	Mar 29, 2031	DS DP U-2015			
	9585912	Mar 29, 2031	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	9539330	Dec 22, 2019	DP			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	9345724	Mar 29, 2031	DS DP U-2015			
	9585912	Mar 29, 2031	DS DP			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9549941	Mar 26, 2029	U-1958		NPP ODE	Apr 07, 2020 Apr 07, 2024
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	9757406	Jan 30, 2034	DP		NCE NPP	Dec 06, 2018 Aug 01, 2020
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	7964580	Mar 26, 2029	DS DP U-2039		NCE	Jul 18, 2022
	7964580	Mar 26, 2029	DS DP U-2040			
	8334270	Mar 21, 2028	DS DP U-2039			
	8334270	Mar 21, 2028	DS DP U-2040			
	8575135	Nov 05, 2033	DS DP U-2039			
	8575135	Nov 05, 2033	DS DP U-2040			
	8580765	Mar 21, 2028	DS DP U-2039			
	8580765	Mar 21, 2028	DS DP U-2040			
	8618076	Dec 11, 2030	DS DP U-2039			
	8618076	Dec 11, 2030	DS DP U-2040			
	8633309	Mar 26, 2029	DS DP U-2039			
	8633309	Mar 26, 2029	DS DP U-2040			
	8735372	Mar 21, 2028	DS DP U-2039			
	8735372	Mar 21, 2028	DS DP U-2040			
	8889159	Mar 26, 2029	DS DP U-2039			
	8889159	Mar 26, 2029	DS DP U-2040			
	8921341	Nov 16, 2032	DS DP U-2039			
	8921341	Nov 16, 2032	DS DP U-2040			
	8940718	Nov 16, 2032	DS DP U-2039			
	8940718	Nov 16, 2032	DS DP U-2040			
	9085573	Mar 21, 2028	DS DP U-2039			
	9085573	Mar 21, 2028	DS DP U-2040			
	9284342	Sep 13, 2030	DS DP U-2039			
	9284342	Sep 13, 2030	DS DP U-2040			
	9296782	Jul 17, 2034	DS DP			
	9585906	Mar 21, 2028	DS DP U-2039			
	9585906	Mar 21, 2028	DS DP U-2040			
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N 021518 001	6017927	Nov 19, 2018	DS DP			
	6017927*PED	May 19, 2019				
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N 021518 002	6017927	Nov 19, 2018	DS DP			
	6017927*PED	May 19, 2019				
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 011	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	9737488	Sep 10, 2028	DP U-1480			
	9737488	Sep 10, 2028	DP U-1696			
	9737488	Sep 10, 2028	DP U-2107			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	9724297	Aug 31, 2035	DP U-2096			
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478 001	9757394	Oct 28, 2036	DP U-2109			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	6174442	Dec 19, 2018	DS U-1468			
	9561251	Jan 23, 2030	DP U-1468			
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001	5686060	Nov 11, 2019	DS DP			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	9649456	Oct 21, 2030	DP U-1719			
	9649456	Oct 21, 2030	DP U-2010			
	9649456	Oct 21, 2030	DP U-2011			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 001	>A> 6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	>A> 6573293	Feb 15, 2021	DS DP U-2171			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 002	>A> 6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	>A> 6573293	Feb 15, 2021	DS DP U-2171			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 003	>A> 6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	>A> 6573293	Feb 15, 2021	DS DP U-2171			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 004	>A> 6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	>A> 6573293	Feb 15, 2021	DS DP U-2171			
<u>TACROLIMUS - ENVARISUS XR</u>						
N 206406 001	9549918	May 30, 2028	DP			
	>A> 9757362	Aug 30, 2024	DP			
	>A> 9763920	Aug 30, 2024	DP			
<u>TACROLIMUS - ENVARISUS XR</u>						
N 206406 002	9549918	May 30, 2028	DP			
	>A> 9757362	Aug 30, 2024	DP			
	>A> 9763920	Aug 30, 2024	DP			
<u>TACROLIMUS - ENVARISUS XR</u>						
N 206406 003	9549918	May 30, 2028	DP			
	>A> 9757362	Aug 30, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 003 >A>	9763920	Aug 30, 2024	DP			
<u>TADALAFIL - CIALIS</u>						
N 021368 001	5859006	Nov 21, 2017	DS DP	Y		
	5859006*PED	May 21, 2018				
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6821975	Nov 19, 2020	DS DP U-1184			
	6821975*PED	May 19, 2021				
	6943166	Apr 26, 2020	U-155			
	6943166	Apr 26, 2020	U-614			
	6943166	Apr 26, 2020	U-1184			
	6943166*PED	Oct 26, 2020				
	7182958	Apr 26, 2020	DP U-155			
	7182958	Apr 26, 2020	DP U-1184			
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 002	5859006	Nov 21, 2017	DS DP			
	5859006*PED	May 21, 2018				
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6821975*PED	May 19, 2021				
	6943166	Apr 26, 2020	U-155			
	6943166	Apr 26, 2020	U-614			
	6943166*PED	Oct 26, 2020				
	7182958	Apr 26, 2020	DP U-155			
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 003	5859006	Nov 21, 2017	DS DP			
	5859006*PED	May 21, 2018				
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6821975*PED	May 19, 2021				
	6943166	Apr 26, 2020	U-614			
	6943166*PED	Oct 26, 2020				
	7182958	Apr 26, 2020	DP U-155			
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 004	5859006	Nov 21, 2017	DS DP			
	5859006*PED	May 21, 2018				
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6821975*PED	May 19, 2021				
	6943166	Apr 26, 2020	U-155			
	6943166*PED	Oct 26, 2020				
	7182958	Apr 26, 2020	DP U-155			
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - ADCIRCA</u>						
N 022332 001	5859006	Nov 21, 2017	DS DP U-975			
	5859006*PED	May 21, 2018				
	6821975	Nov 19, 2020	DS DP			
	6821975*PED	May 19, 2021				
	7182958	Apr 26, 2020	DP			
	7182958*PED	Oct 26, 2020				
<u>TALC - STERITALC</u>						
N 205555 001					ODE	May 01, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TALC - STERITALC</u>						
N 205555 002					ODE	May 01, 2024
<u>TALC - STERITALC</u>						
N 205555 003					ODE	May 01, 2024
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	5856529	Dec 09, 2018	DS DP U-2149			
	9539234	Jan 25, 2033	U-1934			
	9549913	Jan 25, 2033	U-1486			
	9730910	May 17, 2034	U-2085			
	RE46604	Jan 25, 2033	U-2147			
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001	7582621	May 26, 2027	U-2016			
	9549938	Feb 16, 2026	U-1951			
	9566289	Feb 16, 2026	DP			
	9566290	Feb 16, 2026	U-1970			
	9572823	Feb 16, 2026	U-1970			
<u>TECHNETIUM TC-99M TETROFOSMIN KIT - MYOVUE 30ML</u>						
N 020372 002	9549999	Mar 10, 2030	DP			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	9539310	Nov 01, 2025	U-1320			
	9545434	Nov 01, 2025	U-1320			
	9545435	Nov 01, 2025	U-1320			
	9555079	Nov 01, 2025	U-1320			
	9572867	Nov 01, 2025	U-1320			
	9592273	Nov 01, 2025	U-1320			
	9592274	Nov 01, 2025	U-1320			
<u>TELOTTRISTAT ETIPRATE - XERMELO</u>						
N 208794 001	7553840	Dec 11, 2027	DS		NCE	Feb 28, 2022
	7709493	Dec 11, 2027	DS	U-1979	ODE	Feb 28, 2024
	7968559	Dec 11, 2027		U-1979		
	8193204	Feb 27, 2031	DS			
	8653094	Dec 19, 2028		U-1979		
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	9662340	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	9662340	Feb 11, 2034	DP U-1531			
<u>THIOTEPA - TEPADINA</u>						
N 208264 001					I-747 ODE	Jan 26, 2020 Jan 26, 2024
<u>THIOTEPA - TEPADINA</u>						
N 208264 002					I-747 ODE	Jan 26, 2020 Jan 26, 2024
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6525060	Dec 02, 2019	DS DP U-1171	Y		
	6525060	Dec 02, 2019	DS DP U-1860	Y		
	6525060	Dec 02, 2019	DS DP U-1862	Y		
	6525060	Dec 02, 2019	DS DP U-1863	Y		
	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	6525060	Dec 02, 2019	DS DP U-1171	Y		
	6525060	Dec 02, 2019	DS DP U-1860	Y		
	6525060	Dec 02, 2019	DS DP U-1862	Y		
	6525060	Dec 02, 2019	DS DP U-1863	Y		
	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	9694078	Mar 13, 2026	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395 001	6777423	Sep 24, 2021	DS DP			
	6777423*PED	Mar 24, 2022				
	6908928	Sep 24, 2021	DS DP U-566			
	6908928	Sep 24, 2021	DS DP U-762			
	6908928*PED	Mar 24, 2022				
	7070800	Jan 22, 2022	DP U-566			
	7070800*PED	Jul 22, 2022				
	7309707	Sep 24, 2021	DS DP			
	7309707*PED	Mar 24, 2022				
	7642268	Sep 24, 2021	DS DP			
	7642268*PED	Mar 24, 2022				
	7694676	Mar 12, 2027	DP			
	7694676*PED	Sep 12, 2027				
	8022082	Jan 19, 2026	DP U-1186			
	8022082*PED	Jul 19, 2026				
	9010323	Apr 19, 2030	DP			
	RE38912	Oct 11, 2021	DP			
	RE38912*PED	Apr 11, 2022				
	RE39820	Jan 30, 2018	DS DP U-566			
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	5964416	Oct 04, 2016	DP		NPP	Feb 15, 2020
	5964416*PED	Apr 04, 2017			PED	Aug 15, 2020
	6149054	Dec 16, 2016	DP			
	6149054*PED	Jun 16, 2017				
	6176442*PED	Dec 01, 2016				
	6453795	Dec 05, 2016	DP			
	6453795*PED	Jun 05, 2017				
	6726124	Oct 04, 2016	DP			
	6726124*PED	Apr 04, 2017				
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7104470	Oct 04, 2016	DP			
	7104470*PED	Apr 04, 2017				
	7246615*PED	Dec 01, 2016				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	RE39820	Jan 30, 2018	DS DP U-1593			
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	5964416	Oct 04, 2016	DP		NPP	Feb 15, 2020
	6149054	Dec 16, 2016	DP		PED	Aug 15, 2020
	6149054*PED	Jun 16, 2017				
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7104470	Oct 04, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				
	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	RE39820	Jan 30, 2018	DS DP			
	RE39820*PED	Jul 30, 2018				
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	9527833	Jun 17, 2034	DS DP			
	RE46284	Dec 16, 2026			U-1751	
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	9527833	Jun 17, 2034	DS DP			
	RE46284	Dec 16, 2026			U-1751	
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001	RE41783	Dec 08, 2025	DS		>A> I-761	Dec 14, 2020
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	RE41783	Dec 08, 2025	DS		>A> I-761	Dec 14, 2020
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	9555005	Mar 19, 2033	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	8703781	Oct 15, 2030	DS DP U-1712		I-745	Jun 22, 2020
	8703781	Oct 15, 2030	DS DP U-2033		ODE	Jun 22, 2024
	8835443	Sep 13, 2025	U-1581			
	8835443	Sep 13, 2025	U-1582			
	8835443	Sep 13, 2025	U-2020			
	8835443	Sep 13, 2025	U-2037			
	8952018	Oct 15, 2030	U-2020			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	8703781	Oct 15, 2030	DS DP U-1712		I-745	Jun 22, 2020
	8703781	Oct 15, 2030	DS DP U-2033		ODE	Jun 22, 2024
	8835443	Sep 13, 2025	U-1581			
	8835443	Sep 13, 2025	U-1582			
	8835443	Sep 13, 2025	U-2020			
	8835443	Sep 13, 2025	U-2037			
	8952018	Oct 15, 2030	U-2020			
	9155706	Jan 28, 2032	DP			
	9271941	Jan 28, 2032	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	8703781	Oct 15, 2030	DS DP U-1712		I-745	Jun 22, 2020
	8703781	Oct 15, 2030	DS DP U-2033		ODE	Jun 22, 2024
	8835443	Sep 13, 2025	U-1581			
	8835443	Sep 13, 2025	U-1582			
	8835443	Sep 13, 2025	U-2020			
	8835443	Sep 13, 2025	U-2037			
	8952018	Oct 15, 2030	U-2020			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024		U-2036		
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	6765117	Oct 24, 2017	DS		D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		D-157	Jan 28, 2019
	7544713	Jul 14, 2024		U-1475		
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026	DP	U-1877		
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TRIAMCINOLONE ACETONIDE - ZILRETTA</u>						
N 208845 001	8828440	Aug 04, 2031	DP		NP	Oct 06, 2020
	9555048	Aug 04, 2031		U-2151		
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001					NP ODE	Jun 29, 2020 Jun 29, 2024
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	7488827	Dec 18, 2027	DS DP		NCE	Dec 18, 2018
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	7439393	May 21, 2025	DS DP	U-1476	NCE	May 10, 2018
	7488827	Dec 18, 2027	DS DP		NCE	Dec 18, 2018
	9750726	Nov 29, 2030	DP			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	8039627	Oct 06, 2029	DS DP		NCE	Apr 11, 2022
	8357697	Nov 08, 2027		U-1995		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 002	8039627	Oct 06, 2029	DS DP		NCE	Apr 11, 2022
	8357697	Nov 08, 2027	U-1995			
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257 001	8889109	Dec 11, 2027	DP			
	9642911	Dec 11, 2027	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 001	9687526	Jan 30, 2035	U-1857			
	9744209	Jan 30, 2035	U-1857			
	9744239	Jan 30, 2035	U-1857			
	9750785	Jan 30, 2035	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 002	9375478	Jan 30, 2035	U-1857			
	9687526	Jan 30, 2035	U-1857			
	9744209	Jan 30, 2035	U-1857			
	9744239	Jan 30, 2035	U-1857			
	9750785	Jan 30, 2035	DP			
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429 001	8470818	Aug 02, 2026	U-1418		I-757	Nov 06, 2020
	8470818	Aug 02, 2026	U-2164		>A> ODE	Nov 06, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	7144884	Oct 02, 2022	DS DP U-1439			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	7144884	Oct 02, 2022	DS DP U-1439			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	7144884	Oct 02, 2022	DS DP U-1439			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	7144884	Oct 02, 2022	DS DP U-1439			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 001	9707270	Oct 01, 2024	U-2084			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 002	9707270	Oct 01, 2024	U-2084			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 003	9707270	Oct 01, 2024	U-2084			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 004	9707270	Oct 01, 2024	U-2084			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	9265720	Feb 25, 2031	U-674			
	9597281	Apr 06, 2027	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	9265720	Feb 25, 2031	U-674			
	9597281	Apr 06, 2027	U-674			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 37th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm